10-Q

0000882104-15-000079.txt : 20151104 0000882104-15-000079.hdr.sgml : 20151104 20151104160309 ACCESSION NUMBER: 0000882104-15-000079 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151104 DATE AS OF CHANGE: 20151104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 151196876 BUSINESS ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 932 SOUTHWOOD BLVD CITY: INCLINE VILLAGE STATE: NV ZIP: 89451 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 10-Q 1 pdli-201593010qdoc.htm 10-Q 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)



ý	Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For the quarterly period ended September 30, 2015



¨	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
	For transition period from to

Commission File Number: 000-19756

PDL BIOPHARMA, INC.

(Exact name of registrant as specified in its charter)



Delaware	94-3023969
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

932 Southwood Boulevard

Incline Village, Nevada 89451

(Address of principal executive offices and Zip Code)

(775) 832-8500

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ý No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer ý	Accelerated filer ¨	Non-accelerated filer ¨	Smaller reporting company ¨
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ¨ No ý

As of October 26, 2015, there were 163,575,319 shares of the registrant’s Common Stock outstanding.

PDL BIOPHARMA, INC.

2015 Form 10-Q

Table of Contents



		Page
GLOSSARY OF TERMS AND ABBREVIATIONS (as used in this document)		3

PART I - FINANCIAL INFORMATION

ITEM 1.	FINANCIAL STATEMENTS	5

	Condensed Consolidated Statements of Income for the Three and Nine Months Ended September 30, 2015 and 2014	5

	Condensed Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2015 and 2014	6

	Condensed Consolidated Balance Sheets at September 30, 2015, and December 31, 2014	7

	Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2015 and 2014	8

	Notes to the Condensed Consolidated Financial Statements	9

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	36

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	58

ITEM 4.	CONTROLS AND PROCEDURES	60

PART II - OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	61

ITEM 1A.	RISK FACTORS	61

ITEM 6.	EXHIBITS	61

SIGNATURES		62

We own or have rights to certain trademarks, trade names, copyrights and other intellectual property used in our business, including PDL BioPharma and the PDL logo, each of which is considered a trademark. All other company names, product names, trade names and trademarks included in this Quarterly Report on Form 10-Q are trademarks, registered trademarks or trade names of their respective owners.

GLOSSARY OF TERMS AND ABBREVIATIONS



Abbreviation/term		Definition

'216B Patent		European Patent No. 0 451 216B
'761 Patent		U.S. Patent No. 5,693,761
AbbVie		AbbVie Biotherapeutics, Inc.
Accel 300		Accel 300, LLC, a wholly-owned subsidiary of kaléo, Inc.
AcelRx		AcelRx Pharmaceuticals, Inc.
AcelRx Royalty Agreement		Royalty Interest Assignment Agreement, dated September 18, 2015, between PDL and AcelRx
APIC		Additional paid-in-capital
ARIAD		ARIAD Pharmaceuticals, Inc.
ARIAD Royalty Agreement		Royalty Interest Assignment Agreement, dated July 28, 2015, between PDL and ARIAD
ARIAD Royalty Rights		The right to receive specified royalties on ARIAD’s Net Revenues (as defined in the ARIAD Royalty Agreement) generated by the sale, distribution or other use of ARIAD’s product Iclusig^® (ponatinib)
ASC		Accounting Standards Codification
ASU		Accounting Standards Update
Avinger		Avinger, Inc.
Avinger Credit and Royalty Agreement		Credit Agreement, dated April 18, 2013, between PDL and Avinger
AxoGen		AxoGen, Inc.
AxoGen Royalty Agreement		Revenue Interests Purchase Agreement, dated as of October 5, 2012, between PDL and AxoGen
Biogen		Biogen, Inc.
CareView		CareView Communications, Inc.
Chugai		Chugai Pharmaceutical Co., Ltd.
Depo DR Sub		Depo DR Sub, LLC, a wholly-owned subsidiary of Depomed
Depomed		Depomed, Inc.
Depomed Royalty Agreement		Royalty Purchase and Sale Agreement, dated as of October 18, 2013, among Depomed, Depo DR Sub and PDL
Direct Flow Medical		Direct Flow Medical, Inc.
Durata		Durata Therapeutics Holding C.V., Durata Therapeutics International B.V. and Durata Therapeutics, Inc. (parent company)
EBITDA		Earnings before interest, taxes, depreciation and amortization
Elan		Elan Corporation, PLC
EPO		European Patent Office
ex-U.S.-based Manufacturing and Sales		Products that are both manufactured and sold outside of the United States
ex-U.S.-based Sales		Products that are manufactured in the United States and sold outside of the United States
Facet		Facet Biotech Corporation. In April 2010, Abbott Laboratories acquired Facet and later renamed the company Abbott Biotherapeutics Corp., and in January 2013, Abbott Biotherapeutics Corp. was renamed AbbVie Biotherapeutics, Inc. and spun off from Abbott Laboratories as a subsidiary of AbbVie Inc.
FASB		Financial Accounting Standards Board
FDA		U.S. Food and Drug Administration
February 2015 Notes		2.875% Convertible Senior Notes due February 15, 2015, fully retired at September 30, 2013
February 2018 Notes		4.0% Convertible Senior Notes due February 1, 2018
GAAP		U.S. Generally Accepted Accounting Principles
Genentech		Genentech, Inc.
Genentech Products		Avastin^®, Herceptin^®, Lucentis^®, Xolair^®, Perjeta^® and Kadcyla^®
Genzyme		Genzyme Corporation (a Sanofi company)
Hyperion		Hyperion Catalysis International, Inc.
IRS		Internal Revenue Service
kaléo		kaléo, Inc. (formerly known as Intelliject, Inc.)



kaléo Revenue Interests		100% of the royalties from kaléo’s first approved product, Auvi-Q™ (epinephrine auto-injection, USP) (known as Allerject in Canada) and 10% of net sales of kaléo’s second proprietary auto-injector based product, EVZIO (naloxone hydrochloride injection), collectively
KMPG		KPMG, LLP
LENSAR		LENSAR, Inc.
Lilly		Eli Lilly and Company
March 2015 Term Loan		Term Loan borrowed under the Credit Agreement, dated as of March 30, 2015, among PDL, the Royal Bank of Canada and lenders thereto
May 2015 Notes		3.75% Senior Convertible Notes due May 2015
Merck		Merck & Co., Inc.
Michigan Royalty Agreement		Royalty Purchase and Sale Agreement, dated as of November 6, 2014, between The Regents of the University of Michigan and PDL
Novartis		Novartis AG
OCI		Other Comprehensive Income (Loss)
October 2013 Term Loan		Term Loan borrowed under the Credit Agreement, dated October 28, 2013, among PDL, the Royal Bank of Canada and lenders thereto, as amended
Paradigm Spine		Paradigm Spine, LLC
Paradigm Spine Credit Agreement		Paradigm Spine Credit Agreement, dated February 14, 2014, between Paradigm Spine and the Company
PDL, we, us, our, the Company		PDL BioPharma, Inc.
Queen et al. patents		PDL's patents in the United States and elsewhere covering the humanization of antibodies
Roche		F. Hoffman LaRoche, Ltd.
Salix		Salix Pharmaceuticals, Inc.
Santarus		Santarus, Inc.
SDK		Showa Denka K.K.
SEC		Securities and Exchange Commission
Series 2012 Notes		2.875% Series 2012 Convertible Senior Notes, fully retired on February 15, 2015
Settlement Agreement		Settlement Agreement between and among PDL, Genentech and Roche, dated January 31, 2014
SPCs		Supplementary Protection Certificates
SPC Products		Avastin, Herceptin, Lucentis, Xolair and Tysabri
Spin-Off		The spin-off by PDL of Facet
Takeda		Takeda Pharmaceuticals America, Inc.
U-M		University of Michigan
Valeant Pharmaceuticals		Valeant Pharmaceuticals International, Inc.
VB		Viscogliosi Brothers, LLC
VB Royalty Agreement		Royalty Purchase and Sale Agreement, dated as of June 26, 2014, between Viscogliosi Brothers, LLC and PDL
VWAP		Volume-weighted average share price
Wellstat Diagnostics		Wellstat Diagnostics, LLC
Wellstat Diagnostics Borrower Notice		A notice of default to Wellstat Diagnostics, due to, inter alia, its ongoing failure to pay its debts as they became due and Wellstat Diagnostics' failure to comply with certain covenants included in the first amendment to amended and restated credit agreement by the deadlines to which the parties had agreed
Wellstat Diagnostics Guarantor Notice		A notice to each of the guarantors of Wellstat Diagnostics' obligations to the Company under the credit agreement
Wellstat Diagnostics Guarantors		Some or all of: Samuel J. Wohlstadter; Nadine H. Wohlstadter; Duck Farm, Inc.; Hebron Valley Farms, Inc.; HVF, Inc.; Hyperion Catalysis EU Limited; Hyperion Catalysis International, Inc.; NHW, LLC; Wellstat AVT Investment, LLC; Wellstat Biocatalysis, LLC; Wellstat Biologics Corporation; Wellstat Diagnostics, LLC; Wellstat Immunotherapeutics, LLC; Wellstat Management Company, LLC; Wellstate Opthalmics Corporation; Wellstat Therapeutics Corporation; Wellstat Therapeutics EU Limited; Wellstat Vaccines, LLC; and SJW Properties, Inc.
Wellstat Diagnostics Note Receivable and Credit Agreement		Senior Secured Note receivable among the Company and the holders of the equity interests in Wellstat Diagnostics, as amended, and Credit Agreement between Wellstat Diagnostics and the Company, dated November 2, 2012, as amended
Wellstat Diagnostics Petition		An Ex Parte Petition for Appointment of Receiver with the Circuit Court of Montgomery County, Maryland

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

(In thousands, except per share amounts)



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2015			2014			2015			2014
Revenues
Royalties from Queen et al. patents	$	119,222		$	123,916		$	363,916		$	355,008
Royalty rights - change in fair value	(4,280		)	27,602			19,298			73,807
Interest revenue	9,096			13,076			28,596			34,760
License and other	580			—			580			575
Total revenues	124,618			164,594			412,390			464,150

Operating expenses
General and administrative	8,450			5,686			23,545			17,188
Operating income	116,168			158,908			388,845			446,962

Non-operating expense, net
Interest and other income, net	87			75			294			207
Interest expense	(5,901		)	(9,387		)	(21,710		)	(29,770		)
Loss on extinguishment of debt	—			—			—			(6,143		)
Total non-operating expense, net	(5,814		)	(9,312		)	(21,416		)	(35,706		)

Income before income taxes	110,354			149,596			367,429			411,256
Income tax expense	40,895			47,361			135,208			144,083
Net income	$	69,459		$	102,235		$	232,221		$	267,173

Net income per share
Basic	$	0.42		$	0.64		$	1.42		$	1.70
Diluted	$	0.42		$	0.61		$	1.42		$	1.62

Weighted average shares outstanding
Basic	163,560			160,268			163,314			157,274
Diluted	163,742			166,894			163,899			165,141

Cash dividends declared per common share	$	—		$	—		$	0.60		$	0.60

See accompanying notes.

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(In thousands)



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2015			2014			2015			2014

Net income	$	69,459		$	102,235		$	232,221		$	267,173

Other comprehensive income (loss), net of tax
Change in unrealized gains on investments in available-for-sale securities:
Change in fair value of investments in available-for-sale securities, net of tax	634			(258		)	445			(1,554		)
Adjustment for net (gains) losses realized and included in net income, net of tax	(406		)	—			(406		)	—
Total change in unrealized gains on investments in available-for-sale securities, net of tax^(a)	228			(258		)	39			(1,554		)
Change in unrealized gains (losses) on cash flow hedges:
Change in fair value of cash flow hedges, net of tax	(57		)	1,974			4,306			2,305
Adjustment to royalties from Queen et al. patents for net (gains) losses realized and included in net income, net of tax	(1,495		)	989			(3,903		)	3,744
Total change in unrealized losses on cash flow hedges, net of tax^(b)	(1,552		)	2,963			403			6,049
Total other comprehensive income (loss), net of tax	(1,324		)	2,705			442			4,495
Comprehensive income	$	68,135		$	104,940		$	232,663		$	271,668

______________________________________________

^(a) Net of tax of $123 and ($139) for the three months ended September 30, 2015 and 2014, respectively, and $21 and ($837) for the nine months ended September 30, 2015 and 2014, respectively.

^(b) Net of tax of ($836) and $1,595 for the three months ended September 30, 2015 and 2014, respectively, and $217 and $3,257 for the nine months ended September 30, 2015 and 2014, respectively.

See accompanying notes.

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share amounts)



	September 30,			December 31,
	2015			2014
	(unaudited)			(Note 1)
Assets
Current assets:
Cash and cash equivalents	$	227,855		$	291,377
Short-term investments	1,827			2,310
Receivables from licensees and other	594			300
Deferred tax assets	—			375
Notes receivable	67,246			57,597
Prepaid and other current assets	9,166			3,938
Total current assets	306,688			355,897

Property and equipment, net	42			62
Royalty rights - at fair value	384,572			259,244
Notes and other receivables, long-term	286,160			305,615
Long-term deferred tax assets	36,499			33,799
Other assets	6,640			7,733
Total assets	$	1,020,601		$	962,350

Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$	421		$	318
Accrued liabilities	32,711			8,876
Accrued income taxes	—			3,293
Deferred tax liabilities	11,615			—
Term loan payable	49,842			—
Convertible notes payable	—			175,496
Total current liabilities	94,589			187,983

Convertible notes payable	281,581			276,228
Other long-term liabilities	48,474			37,702
Total liabilities	424,644			501,913

Commitments and contingencies (Note 8)

Stockholders' equity:
Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding	—			—
Common stock, par value $0.01 per share, 350,000 shares authorized; 163,573 and 162,186 shares issued and outstanding at September 30, 2015, and December 31, 2014, respectively	1,636			1,622
Additional paid-in capital	(118,540		)	(119,874		)
Accumulated other comprehensive income	3,391			2,949
Retained earnings	709,470			575,740
Total stockholders' equity	595,957			460,437
Total liabilities and stockholders' equity	$	1,020,601		$	962,350

See accompanying notes.

PDL BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)



	Nine Months Ended September 30,
	2015			2014
Cash flows from operating activities
Net income	$	232,221		$	267,173
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization of convertible notes and term loan offering costs	9,744			13,473
Change in fair value of royalty rights - at fair value	(19,298		)	(72,992		)
Loss on extinguishment of convertible notes	—			6,143
Other amortization, depreciation and accretion of embedded derivative	29			(144		)
Gain on sale of available-for-sale securities	(580		)	—
Hedge ineffectiveness on foreign exchange contracts	—			(5		)
Stock-based compensation expense	1,348			1,026
Deferred income taxes	9,143			(6,493		)
Changes in assets and liabilities:
Receivables from licensees and other	(294		)	50
Prepaid and other current assets	(4,434		)	1,959
Accrued interest on notes receivable	(3,076		)	(8,367		)
Other assets	35			(29		)
Accounts payable	103			792
Accrued liabilities	(861		)	3,325
Accrued income taxes	(3,293		)	6,494
Other long-term liabilities	10,599			10,834
Net cash provided by operating activities	231,386			223,239
Cash flows from investing activities
Proceeds from sales of available-for-sale securities	1,124			—
Purchase of royalty rights - at fair value	(115,000		)	(15,500		)
Proceeds from royalty rights - at fair value	8,970			81,717
Purchase of notes receivable	(8,976		)	(215,000		)
Repayment of notes receivable	20,600			—
Purchase of property and equipment	(9		)	(49		)
Net cash used in investing activities	(93,291		)	(148,832		)
Cash flows from financing activities
Proceeds from term loan	100,000			—
Repurchase of convertible notes	(177,387		)	(29,906		)
Payment of debt issuance costs	(607		)	(9,287		)
Proceeds from the issuance of convertible notes	—			300,000
Purchase of call options	—			(30,951		)
Proceeds from the issuance of warrants	—			11,427
Repayment of term loan	(50,000		)	(56,250		)
Cash dividends paid	(73,623		)	(72,135		)
Net cash provided by/(used in) financing activities	(201,617		)	112,898
Net increase/(decrease) in cash and cash equivalents	(63,522		)	187,305
Cash and cash equivalents at beginning of the period	291,377			94,302
Cash and cash equivalents at end of period	$	227,855		$	281,607


Supplemental cash flow information
Cash paid for income taxes	$	125,000		$	134,000
Cash paid for interest	$	16,045		$	15,217
Stock issued to settle debt	$	9,794		$	157,591
Warrant received for issuance of notes receivable	$	(1,258	)	$	—

See accompanying notes.

PDL BIOPHARMA, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2015

(Unaudited)

1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with GAAP for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of PDL believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.

The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with our audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2014, included in our Annual Report on Form 10-K, as amended, filed with the SEC. The Condensed Consolidated Balance Sheet at December 31, 2014, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.

Principles of Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of PDL and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Our accompanying unaudited Condensed Consolidated Financial Statements are prepared in accordance with GAAP and the rules and regulations of the SEC.

Management Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Notes Receivable and Other Long-Term Receivables

We account for our notes receivable at both amortized cost, net of unamortized origination fees, if any, and as dependent on collateral when the loan for which repayment is expected to be provided solely by the underlying collateral. For loans accounted for at their amortized cost, related fees and costs are recorded net of any amounts reimbursed. Interest is accreted or accrued to "Interest revenue" using the interest method. When and if supplemental royalties are received from certain of these notes and other long-term receivables, an adjustment to the estimated effective interest rate is affected prospectively.

We evaluate the collectability of both interest and principal for each note receivable and loan to determine whether it is impaired. A note receivable or loan is considered to be impaired when, based on current information and events, we determine it is probable that we will be unable to collect amounts due according to the existing contractual terms. When a note receivable or loan is considered to be impaired, the amount of loss is calculated by comparing the carrying value of the financial asset to the value determined by discounting the expected future cash flows at the loan's effective interest rate or to the estimated fair value of the underlying collateral, less costs to sell, if the loan is collateralized and we expect repayment to be provided solely by the collateral. Impairment assessments require significant judgments and are based on significant assumptions related to the borrower's credit risk, financial performance, expected sales, and estimated fair value of the collateral.

Convertible Notes

We issued our Series 2012 Notes, May 2015 Notes and February 2018 Notes with a net share settlement feature, meaning that upon any conversion, the principal amount will be settled in cash and the remaining amount, if any, will be settled in shares of our common stock. In accordance with accounting guidance for convertible debt instruments that may be settled in cash or other assets upon conversion, we separated the principal balance between the fair value of the liability component and the common stock conversion feature using a market interest rate for a similar nonconvertible instrument at the date of issuance.

Queen et al. Royalty Revenues

Under our Queen Patent license agreements, we receive royalty payments based upon our licensees’ net sales of covered products. Generally, under these agreements we receive royalty reports from our licensees approximately one quarter in arrears, that is, generally in the second month of the quarter after the licensee has sold the royalty-bearing product. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the quarter reported to us by our licensees, that is, royalty revenues are generally recognized one quarter following the quarter in which sales by our licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees.

We also received annual maintenance fees from licensees of our Queen et al. patents prior to patent expiry as well as periodic milestone payments. We have no performance obligations with respect to such fees. Maintenance fees were recognized as they became due and when payment was reasonably assured. Total annual maintenance and milestone payments in each of the last several years have been less than 1% of total revenue.

Although the last of our Queen et al. patents expired in December 2014, we expect to receive royalties beyond expiration based on the terms of our licenses and our legal settlements. We do not expect to receive any meaningful revenue from our Queen et al. patents beyond the first quarter of 2016. We believe that cash from future revenues from the Queen et al. patent royalties through the first quarter of 2016 and from acquired revenue generating assets, net of operating expenses, debt service and income taxes, plus cash on hand, will be sufficient to fund our operations over the next several years. However, we do not expect that our acquired revenue generating assets will, in the near term, replace the revenues we generate from our license agreements related to the Queen et al. patents. In the second quarter of 2016, our revenues are likely to materially decrease after we stop receiving payments from these Queen et al. patents license agreements, which currently account for 88% of our year to date revenue. The continued success of the Company will become more dependent on the timing and our ability to acquire new income generating assets in order to provide recurring revenues going forward and to support our business model and ability to pay dividends.

Royalty Rights - At Fair Value

Currently, we have elected to account for our investments in royalty rights at fair value with changes in fair value presented in earnings. The fair value of the investments in royalty rights is determined by using a discounted cash flow analysis related to the expected future cash flows to be received. These assets are classified as Level 3 assets within the fair value hierarchy as our valuation estimates utilize significant unobservable inputs, including estimates as to the probability and timing of future sales of the related products. Transaction-related fees and costs are expensed as incurred.

The changes in the estimated fair value from investments in royalty rights along with cash receipts each reporting period are presented together on our Condensed Consolidated Statements of Income as a component of revenue under the caption, “Royalty rights - change in fair value.”

Customer Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of our total revenues, was as follows:



		Three Months Ended September 30,				Nine Months Ended September 30,
Licensee	Product Name	2015		2014		2015		2014
Genentech	Avastin	32	%	24	%	28	%	25	%
	Herceptin	32	%	24	%	28	%	25	%
	Xolair	10	%	6	%	8	%	6	%

Biogen	Tysabri^®	11	%	10	%	10	%	9	%

Depomed	Glumetza^®	(10	)%	14	%	—	%	13	%

Foreign Currency Hedging

We enter into foreign currency hedges to manage exposures arising in the normal course of business and not for speculative purposes.

We hedge certain Euro-denominated currency exposures related to royalties associated with our licensees’ product sales with Euro forward contracts. In general, these contracts are intended to offset the underlying Euro market risk in our royalty revenues. The last of these contracts expires in the first quarter of 2016. We designate foreign currency exchange contracts used to hedge royalty revenues based on underlying Euro-denominated licensee product sales as cash flow hedges.

At the inception of each hedging relationship and on a quarterly basis, we assess the hedge effectiveness. The fair value of the Euro contracts is estimated using pricing models with readily observable inputs from actively quoted markets and is disclosed on a gross basis. The aggregate unrealized gains or losses, net of tax, on the effective component of the hedge is recorded in stockholders’ equity as "Accumulated other comprehensive income." Realized gains or losses on cash flow hedges are recognized as an adjustment to royalty revenue in the same period that the hedged transaction impacts earnings as royalty revenue. Any gain or loss on the ineffective portion of our hedge contracts is reported in "Interest and other income, net" in the period the ineffectiveness occurs.

Income Taxes

The provision for income taxes is determined using the asset and liability approach. Tax laws require items to be included in tax filings at different times than the items are reflected in the financial statements. A current liability is recognized for the estimated taxes payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are adjusted for enacted changes in tax rates and tax laws. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.

The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

Comprehensive Income

Comprehensive income comprises net income adjusted for other comprehensive income (loss), using the specific identification method, which includes the changes in unrealized gains and losses on cash flow hedges and changes in unrealized gains and losses on our investments in available-for-sale securities, all net of tax, which are excluded from our net income.

Recently Issued Accounting Pronouncements

In April 2015, the FASB issued ASU 2015-03 – Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for the Company beginning in the first quarter of 2016. The adoption of this ASU is not expected to have a significant impact on the Company's consolidated financial position or results of operations.

2. Net Income per Share



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
Net Income per Basic and Diluted Share:	2015		2014		2015		2014
(in thousands except per share amounts)
Numerator
Net income used to compute net income per basic and diluted share	$	69,459	$	102,235	$	232,221	$	267,173

Denominator
Weighted average shares used to compute net income per basic share	163,560		160,268		163,314		157,274
Restricted stock outstanding	167		96		131		113
Effect of dilutive stock options	15		22		18		22
Assumed conversion of Series 2012 Notes	—		2,247		33		3,301
Assumed conversion of warrants	—		—		403		—
Assumed conversion of May 2015 Notes	—		4,261		—		4,431
Weighted average shares used to compute net income per diluted share	163,742		166,894		163,899		165,141

Net income per share - basic	$	0.42	$	0.64	$	1.42	$	1.70
Net income per share - diluted	$	0.42	$	0.61	$	1.42	$	1.62

We compute diluted net income per share using the sum of the weighted average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of diluted net income per share include shares that may be issued under our stock options and restricted stock awards, our February 2018 Notes, our Series 2012 Notes and our May 2015 Notes on a weighted average basis for the period that the notes were outstanding, including the effect of adding back interest expense and the underlying shares using the if-converted method. In the third quarter of 2013, $1.0 million aggregate principal of our February 2015 Notes was exchanged for our Series 2012 Notes and the February 2015 Notes were retired, in the first quarter of 2014, $131.7 million aggregate principal of our Series 2012 Notes was retired in a privately negotiated exchange and purchase agreements, in the fourth quarter of 2014, the Company entered into a privately negotiated exchange agreement by which it retired approximately $26.0 million in principal of the outstanding Series 2012 Notes, and, in the first quarter of 2015, the Company completed the retirement of the remaining $22.3 million of aggregate principal of its Series 2012 Notes.

In the second quarter of 2015, the Company completed the retirement of the remaining $155.1 million of aggregate principal of its May 2015 Notes. Concurrently with the retirement of the May 2015 Notes, we exercised our purchased call options and received 5.2 million of PDL's common shares, which was the amount equal to the number of shares required to be delivered by us to the note holders for the excess conversion value (see Note 9).

In May 2011, we issued our May 2015 Notes, in January and February 2012, we issued our Series 2012 Notes, and in February 2014, we issued our February 2018 Notes. The Series 2012 Notes and May 2015 Notes were net share settled, with the principal amount settled in cash and the excess settled in our common stock. The weighted average share adjustments related to our Series 2012 Notes, May 2015 Notes and February 2018 Notes, shown in the table above, include the shares issuable in respect of such excess.

May 2015 Notes Purchased Call Option and Warrant Potential Dilution

The warrants are dilutive for the three and nine months ended September 30, 2015, as the exercise price of the warrants was lower than the average market price of our common stock. We excluded from our calculations of net income per diluted share 18.1 million and 22.2 million shares for the three months ended September 30, 2015 and 2014, respectively, and zero and 22.2 million shares for the nine months ended September 30, 2015 and 2014, respectively, for warrants issued in 2011, because the exercise price of the warrants was higher than the average market price of our common stock and thus, for the three and nine months ended September 30, 2014, no stock was issuable upon conversion. Our purchased call options, issued in 2011, will always be anti-dilutive and therefore zero and 26.1 million shares were excluded from our calculations of net income per

diluted share for the three months ended September 30, 2015 and 2014, respectively, and zero and 26.1 million shares were excluded from our calculation of diluted net income per share for the nine months ended September 30, 2015 and 2014, respectively, because they have no effect on diluted net income per share. For information related to the conversion rates on our convertible debt, see Note 9.

February 2018 Notes Purchased Call Option and Warrant Potential Dilution

We excluded from our calculation of net income per diluted share 29.0 million shares for the three and nine months ended September 30, 2015 and 2014, for warrants issued in February 2014, because the exercise price of the warrants exceeded the VWAP of our common stock and conversion of the underlying February 2018 Notes is not assumed, therefore no stock would be issuable upon conversion. These securities could be dilutive in future periods. Our purchased call options, issued in February 2014, will always be anti-dilutive and therefore 32.7 million shares were excluded from our calculation of net income per diluted share for the three and nine months ended September 30, 2015 and 2014, because they have no effect on diluted net income per share. For information related to the conversion rates on our convertible debt, see Note 9.

Anti-Dilutive Effect of Stock Options and Restricted Stock Awards

For the three months ended September 30, 2015 and 2014, we excluded approximately 42,000 and 4,000 shares underlying outstanding stock options, respectively, and for the nine months ended September 30, 2015 and 2014, we excluded approximately 39,000 and 4,000 shares underlying outstanding stock options, respectively. For the three months ended September 30, 2015 and 2014, we excluded approximately 475,000 and zero shares underlying restricted stock awards, respectively, and for the nine months ended September 30, 2015 and 2014, we excluded approximately 437,000 and zero shares underlying restricted stock awards, respectively, calculated on a weighted average basis, from our net income per diluted share calculations because their effect was anti-dilutive.

3. Fair Value Measurements

The fair value of our financial instruments are estimates of the amounts that would be received if we were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:

Level 1 – based on quoted market prices in active markets for identical assets and liabilities;

Level 2 – based on quoted market prices for similar assets and liabilities, using observable market-based inputs or unobservable market-based inputs corroborated by market data; and

Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable.

The following tables present the fair value of our financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy.



	September 30, 2015								December 31, 2014
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
(In thousands)
Financial assets:
Money market funds	$	139,850	$	—	$	—	$	139,850	$	221,792	$	—	$	—	$	221,792
Corporate securities	—		1,827		—		1,827		—		2,310		—		2,310
Foreign currency hedge contracts	—		4,597		—		4,597		—		4,069		—		4,069
Warrants	—		1,258		—		1,258		—		—		—		—
Royalty rights - at fair value	—		—		384,572		384,572		—		—		259,244		259,244
Total	$	139,850	$	7,682	$	384,572	$	532,104	$	221,792	$	6,379	$	259,244	$	487,415

There have been no transfers between levels during each of the three-month periods ended September 30, 2015, and December 31, 2014. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.

Corporate Securities

Corporate securities consist primarily of U.S. corporate equity holdings. The fair value of corporate securities is estimated using recently executed transactions or market quoted prices, where observable. Independent pricing sources are also used for valuation.

Royalty Rights - At Fair Value

Depomed Royalty Agreement

On October 18, 2013, PDL entered into the Depomed Royalty Agreement, whereby the Company acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a $240.5 million cash payment. Total arrangement consideration was $241.3 million, which was comprised of the $240.5 million cash payment to Depomed and $0.8 million in transaction costs.

The rights acquired include Depomed’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus (which was subsequently acquired by Salix, which itself was recently acquired by Valeant Pharmaceuticals) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck with respect to sales of Janumet^® XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica with respect to potential future development milestones and sales of its investigational fixed-dose combination of Invokana^® (canagliflozin) and extended-release metformin tablets; (d) from Boehringer Ingelheim with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Depomed’s license agreement with Boehringer Ingelheim; and (e) from LG Life Sciences and Valeant Pharmaceuticals for sales of extended-release metformin tablets in Korea and Canada, respectively.

Under the terms of the Depomed Royalty Agreement, the Company will receive all royalty and milestone payments due under license agreements between Depomed and its licensees until the Company has received payments equal to two times the cash payment it made to Depomed, after which all net payments received by Depomed will be shared evenly between the Company and Depomed.

The Depomed Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.

As of September 30, 2015, and December 31, 2014, the Company determined that its royalty purchase interest in Depo DR Sub represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Depo DR Sub that most significantly impact Depo DR Sub's economic performance and is not the primary beneficiary of Depo DR Sub; therefore, Depo DR Sub is not subject to consolidation by the Company.

The asset acquired represents a single unit of accounting. The fair value of the asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. This asset is classified as a Level 3 asset within the fair value hierarchy, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by the FDA or other regulatory agencies. The discounted cash flows are based upon expected royalties from sales of licensed products over a eight-year period. The discount rates utilized range from approximately 21% to 25%. Significant judgment is required in selecting appropriate discount rates. At September 30, 2015, an evaluation was performed to assess those rates and general market conditions potentially affecting the fair market value. Should these discount rates increase or decrease by 5%, the fair value of the asset could decrease by $18.3 million or increase by $23.2 million, respectively. A third-party expert was engaged to help management develop its original estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. We periodically assess the expected future cash flows and to the extent such payments are greater or less than our initial estimates, or the timing of such payments is materially different than our original estimates, we will adjust the estimated fair value of the asset. Certain manufacturers of generic equivalents to Glumetza will be permitted to enter the market starting in February and August 2016. Our current expected future cash flows anticipate a reduction in future cash flows of Glumetza as result of the generic competition in 2016. Should the expected

royalties increase or decrease by 5%, the fair value of the asset could increase by $7.1 million or decrease by $7.7 million, respectively.

When PDL acquired the Depomed royalties, Glumetza was marketed by Santarus. In January 2014, Salix acquired Santarus and assumed responsibility for commercializing Glumetza, which was generally perceived to be a positive development because of Salix's larger sales force and track record in the successful commercialization of therapies. In late 2014, Salix made a number of disclosures relating to an excess of supply at the distribution level of Glumetza and other drugs that it commercialized, the practices leading to this excess of supply which were under review by Salix's audit committee in relation to the related accounting practices. Because of these disclosures and PDL's lack of direct access to information as to the levels of inventory of Glumetza in the distribution channels, PDL reviewed of all public statements by Salix, publicly available historical third-party prescription data, analyst reports and other relevant data sources. PDL also engaged a third-party expert to specifically assess estimated inventory levels of Glumetza in the distribution channel and to ascertain the potential effects those inventory levels may have on expected future cash flows. We have received no royalties from Glumetza sales in 2015. Salix was acquired by Valeant Pharmaceuticals in early April 2015. On June 18, 2015, Valeant Pharmaceuticals implemented a price increase on Glumetza and implemented an additional price increase on July 31, 2015. As of September 30, 2015, our discounted cash flow analysis reflects our expectations as to the amount and timing of future cash flows up to the valuation date. We will monitor whether the acquisition or price increase by Valeant Pharmaceuticals has any effect on sales of Glumetza and thus royalties on such sales paid to PDL. Due to the uncertainty around Valeant's marketing and pricing strategy, as well as the near-term generic competition, we may be unable to fully assess the impact of the acquisition or price increase on sales of Glumetza and thus royalties on such sales paid to PDL. PDL expects to exercise its royalty audit right for Glumetza in the near future.

As of September 30, 2015, and December 31, 2014, the carrying value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was approximately $178.2 million and $176.2 million, respectively. As of September 30, 2015, the maximum loss exposure was $178.2 million.

VB Royalty Agreement

On June 26, 2014, PDL entered into the VB Royalty Agreement, whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA, in exchange for a $15.5 million cash payment, less fees.

The acquired royalties include royalty amounts accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company will receive all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to two and three tenths times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB may repurchase the royalty right at any time on or before June 26, 2018, for a specified amount. The acting chief executive officer of Paradigm Spine is one of the owners of VB. The Paradigm Spine Credit Agreement and the VB Royalty Agreement were negotiated separately.

The fair value of the VB Royalty Agreement royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a nine-year period. The discount rate utilized was approximately 17.5%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $2.4 million or increase by $3.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $0.8 million or decrease by $0.8 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. At each reporting period, an evaluation is performed to assess those estimates, discount rates utilized and general market conditions affecting fair market value.

As of September 30, 2015, and December 31, 2014, the carrying value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was $16.9 million and $16.1 million, respectively. As of September 30, 2015, the maximum loss exposure was $16.9 million.

University of Michigan Royalty Agreement

extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States on August 19, 2014, in the European Union on January 22, 2015, and in Japan on March 25, 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities.

The fair value of the royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a seven-year period. The discount rate utilized was approximately 12.8%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $11.1 million or increase by $14.5 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.6 million or decrease by $3.6 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of September 30, 2015, and December 31, 2014, the fair value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was $71.6 million and $66.9 million. As of September 30, 2015, the maximum loss exposure was $71.6 million.

ARIAD Royalty Agreement

On July 28, 2015, PDL entered into the ARIAD Royalty Agreement, whereby the Company acquired the rights to receive royalties payable from ARIAD's net revenues generated by the sale, distribution or other use of Iclusig^® (ponatinib), a cancer medicine for the treatment of adult patients with chronic myeloid leukemia, in exchange for up to $200.0 million in cash payments. The purchase price of $100.0 million is payable in two tranches of $50.0 million each, with the first tranche funded on the closing date and the second tranche to be funded on the 12-month anniversary of the closing date. The ARIAD Royalty Agreement provides ARIAD with an option to draw up to an additional $100.0 million in up to two draws at any time between the six- and 12-month anniversaries of the closing date. ARIAD may repurchase the royalty rights at any time for a specified amount. Upon the occurrence of certain events, PDL has the right to require ARIAD to repurchase the royalty rights for a specified amount. Under the ARIAD Royalty Agreement, the Company has the right to a make-whole payment from ARIAD if the Company does not receive payments equal to or greater than the amounts funded on or prior to the fifth anniversary of each of the respective fundings. In such case, ARIAD will pay to the Company the difference between the amounts paid to such date by ARIAD (excluding any delinquent fee payments) and the amounts funded by the Company. PDL has elected the fair value option to account for the hybrid instrument in its entirety. Any embedded derivative shall not be separated from the host contract.

Under the terms of the ARIAD Royalty Agreement, the Company will receive royalty payments at a royalty rate ranging from 2.5% to 7.5% of Iclusig revenue until the first to occur of (i) repurchase of the royalty rights by ARIAD or (ii) December 31, 2033. The annual royalty payments shall not exceed $20.0 million is any fiscal year for the years ended December 31, 2015 through December 31, 2018. If Iclusig revenue does not meet certain agreed-upon projections on an annual basis, PDL is entitled to certain royalty payments from net revenue of another ARIAD product, brigatinib, up to the amount of the shortfall from the projections for the applicable year.

The asset acquired pursuant to the ARIAD Royalty Agreement represents a single unit of accounting. The fair value of the royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a seven-year period. The discount rate utilized was approximately 10.0%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $15.1 million or increase by $20.0 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $2.5 million or decrease by $2.5 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of September 30, 2015, and December 31, 2014, the fair value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was $49.9 million and zero. As of September 30, 2015, the maximum loss exposure was $49.9 million.

AcelRx Royalty Agreement

As of September 30, 2015, and December 31, 2014, the Company determined that its royalty rights under the agreement with ARPI LLC represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of ARPI LLC that most significantly impact ARPI LLC's economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.

The fair value of the royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a sixteen-year period. The discount rate utilized was approximately 13.4%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $18.4 million or increase by $29.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.3 million or decrease by $3.3 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of September 30, 2015, and December 31, 2014, the fair value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was $65.3 million and zero. As of September 30, 2015, the maximum loss exposure was $65.3 million.

Avinger Credit and Royalty Agreement

On April 18, 2013, PDL entered into the Avinger Credit and Royalty Agreement, under which we made available to Avinger up to $40.0 million (of which only $20.0 million was funded) to be used by Avinger in connection with the commercialization of its lumivascular catheter devices and the development of Avinger's lumivascular atherectomy device. On September 22, 2015, Avinger elected to prepay the note receivable in whole for a payment of $21.4 million in cash (see Note 6).

Under the terms of the Avinger Credit and Royalty Agreement, the Company is entitled to receive royalties at a rate of 1.8% on Avinger's net revenues. As Avinger repaid the note receivable prior to its maturity date in April 2018, the royalty rate was reduced to 0.9% and will be subject to certain minimum payments from the prepayment date until April 2018. PDL has accounted for the royalty rights in accordance with the fair value option. The fair value of the royalty rights at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a three-year period. The discount rate utilized was approximately 15.0%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5.0%, the fair value of this asset could decrease by $158,000 or increase by $179,000, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $137,000 or decrease by $137,000, respectively. Management considered the contractual minimum payments when developing its estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of September 30, 2015, and December 31, 2014, the fair value of the royalty asset as reported in our Condensed Consolidated Balance Sheets was $2.7 million and zero. As of September 30, 2015, the maximum loss exposure was $2.7 million.

The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the nine months ended September 30, 2015:



Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)				Royalty Rights - At Fair Value
Beginning Balance at December 31, 2014							$	259,244

	Total net change in fair value for the period
		Change in fair value of royalty rights - at fair value		$	19,298
		Proceeds from royalty rights - at fair value		$	(8,970	)
			Total net change in fair value for the period				10,328
	Purchases, issues, sales, and settlements
		Purchases					115,000

Ending Balance at September 30, 2015							$	384,572

The changes in the estimated fair value included in earnings for each period are presented in "Royalty rights - change in fair value" as follows:



	Three Months Ended					Nine Months Ended
	September 30,					September 30,
(in thousands)	2015			2014		2015		2014

Total change in fair value for the period included in earnings for assets held at the end of the reporting period	$	(4,280	)	$	26,787	$	19,298	$	72,992

Foreign Currency Hedge Contracts

The fair value of the foreign currency hedge contracts is estimated based on pricing models using readily observable inputs from actively quoted markets and are disclosed on a gross basis.

Warrants

Warrants consist primarily of purchased call options to buy U.S. corporate equity holdings and derivative assets acquired as part of note receivable investments. The fair value of the warrants is estimated using recently quoted market prices and the Black-Scholes model.

The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:



	September 30, 2015						December 31, 2014
	Carrying Value		Fair Value Level 2		Fair Value Level 3		Carrying Value		Fair Value Level 2		Fair Value Level 3
(In thousands)
Assets:
Wellstat Diagnostics note receivable	$	50,191	$	—	$	50,191	$	50,191	$	—	$	50,191
Hyperion note receivable	1,200		—		1,200		1,200		—		1,200
Avinger note receivable	—		—		—		20,611		—		20,760
LENSAR note receivable	50,266		—		50,266		39,668		—		40,451
Direct Flow Medical note receivable	51,772		—		52,052		50,397		—		49,940
Paradigm Spine note receivable	49,909		—		51,071		49,571		—		50,125
kaléo note receivable	151,496		—		151,476		151,574		—		151,073
Total¹	$	354,834	$	—	$	356,256	$	363,212	$	—	$	363,740

Liabilities:
Series 2012 Notes	$	—	$	—	$	—	$	22,261	$	33,506	$	—
May 2015 Notes	—		—		—		153,235		205,534		—
February 2018 Notes	281,581		262,313		—		276,228		289,665		—
March 2015 Term Loan	49,842		50,000		—		—		—		—
Total	$	331,423	$	312,313	$	—	$	451,724	$	528,705	$	—

___________________

¹ The carrying amount of notes receivable excludes the debt discount of $1.4 million arisen from the CareView transaction (Note 6).

As of September 30, 2015 and December 31, 2014, the estimated fair values of our Paradigm Spine note receivable, kaléo note receivable, Hyperion note receivable, Avinger note receivable and Direct Flow Medical note receivable, were determined using one or more discounted cash flow models, incorporating expected payments and the interest rate extended on the notes receivable, with fixed interest rates and incorporating expected payments for notes receivable with a variable rate of return. In some instances the carrying values of certain notes receivable differed from their estimated fair market values. This is generally the result of discount rates used when performing a discounted cash flow for fair value valuation purposes.

When deemed necessary we engage a third-party valuation expert to assist in evaluating our investments and the related inputs needed for us to estimate the fair value of certain investments. We determined our notes receivable assets are Level 3 assets as our valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values and required yield. To provide support for the estimated fair value measurements, we considered forward-looking performance related to the investment and current measures associated with high yield indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in similar sectors.

The Wellstat Diagnostics Note Receivable and Credit Agreement, as amended and restated, is secured by all assets and equity interests in Wellstat Diagnostics. The estimated fair value of the collateral was determined by using an asset approach related to the underlying collateral and was adjusted to consider estimated costs to sell the assets.

The loans under the credit agreement with LENSAR are secured by substantially all of the assets of LENSAR. The estimated fair value of the collateral was determined by using an asset approach related to the underlying collateral and was adjusted to consider estimated costs to sell the assets.

On September 30, 2015, the carrying values of several of our notes receivable differed from their fair value. This is the result of discount rates used when performing a discounted cash flow for fair value valuation purposes. We determined these notes

receivable to be Level 3 assets, as our valuations utilized significant unobservable inputs, estimates of future revenues, expectations about settlement and required yield. To provide support for the fair value measurements, we considered forward-looking performance, and current measures associated with high yield and published indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in a similar sector.

The fair values of our convertible notes were determined using quoted market pricing or dealer quotes.

4. Cash Equivalents and Short-Term Investments

As of September 30, 2015, and December 31, 2014, we had invested our excess cash balances primarily in money market funds, and a corporate equity security. Our securities are classified as available-for-sale and are carried at estimated fair value, with unrealized gains and losses reported in "Accumulated other comprehensive income" in stockholders’ equity, net of estimated taxes. See Note 3 for fair value measurement information. The cost of securities sold is based on the specific identification method. To date, we have not experienced credit losses on investments in these instruments, and we do not require collateral for our investment activities.



Summary of Cash and Available-For-Sale Securities	Adjusted Cost		Unrealized Gains		Unrealized Losses		Estimated Fair Value		Cash and Cash Equivalents		Short-Term Investments
(In thousands)
September 30, 2015
Cash	$	88,005	$	—	$	—	$	88,005	$	88,005	$	—
Money market funds	139,850		—		—		139,850		139,850		—
Corporate securities	1,206		621		—		1,827		—		1,827
Total	$	229,061	$	621	$	—	$	229,682	$	227,855	$	1,827

December 31, 2014
Cash	$	69,585	$	—	$	—	$	69,585	$	69,585	$	—
Money market funds	221,792		—		—		221,792		221,792		—
Corporate securities	1,750		560		—		2,310		—		2,310
Total	$	293,127	$	560	$	—	$	293,687	$	291,377	$	2,310

For the three and nine months ended September 30, 2015, recognized realized gains of available-for-sale securities was $580,000. There were no gains or losses on sales of available-for-sale securities recognized for the three and nine months ended September 31, 2014.

The unrealized gains on investments included in "Other comprehensive income (loss), net of tax" was approximately $404,000 and $364,000 as of September 30, 2015, and December 31, 2014, respectively.

5. Foreign Currency Hedging

We designate the foreign currency exchange contracts used to hedge our royalty revenues based on underlying Euro-denominated sales as cash flow hedges. Euro forward contracts are presented on a net basis on our Condensed Consolidated Balance Sheets as we have entered into a netting arrangement with the counterparty. As of September 30, 2015, and December 31, 2014, all outstanding Euro forward contracts were classified as cash flow hedges.

In October 2014, we entered into a series of Euro forward contracts covering the quarters in which our licensees' sales occurred through December 2015.

The notional amounts, Euro exchange rates and fair values of our Euro forward contracts designated as cash flow hedges were as follows:



Euro Forward Contracts			September 30, 2015				December 31, 2014
			(In thousands)				(In thousands)
Currency	Settlement Price ($ per Euro)	Type	Notional Amount		Fair Value		Notional Amount		Fair Value
Euro	1.256	Sell Euro	$	—	$	—	$	6,000	$	241
Euro	1.257	Sell Euro	—		—		15,750		728
Euro	1.259	Sell Euro	—		—		16,125		752
Euro	1.260	Sell Euro	33,000		4,597		33,000		1,468
Euro	1.270	Sell Euro	—		—		7,000		377
Euro	1.281	Sell Euro	—		—		8,000		503
Total			$	33,000	$	4,597	$	85,875	$	4,069

The location and fair values of our Euro contracts in our Condensed Consolidated Balance Sheets were as follows:



Cash Flow Hedge	Location	September 30, 2015		December 31, 2014
(In thousands)
Euro contracts	Prepaid and other current assets	$	4,597	$	3,352
Euro contracts	Other assets	$	—	$	717

The effect of our derivative instruments in our Condensed Consolidated Statements of Income and our Condensed Consolidated Statements of Comprehensive Income was as follows:



	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2015			2014			2015		2014
(In thousands)
Net gain (loss) recognized in OCI, net of tax ⁽¹⁾	$	(57	)	$	1,974		$	4,306	$	2,305
Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax ⁽²⁾	$	1,495		$	(989	)	$	3,903	$	(3,744	)
Net gain (loss) recognized in interest and other income, net - cash flow hedges ⁽³⁾	$	—		$	2		$	—	$	5

_______________________________

(1) Change in the fair value of cash flow hedges, net of tax.

(2) Effective portion classified as royalty revenue.

(3) Ineffectiveness from excess hedge was approximately zero and ($2) for the three months ended September 30, 2015 and 2014, respectively, and zero and ($5) for the nine months ended September 30, 2015 and 2014, respectively.

6. Notes Receivable and Other Long-Term Receivables

Notes receivable and other long-term receivables included the following significant agreements:

Wellstat Diagnostics Note Receivable and Credit Agreement

In March 2012, the Company executed a $7.5 million two-year senior secured note receivable with the holders of the equity interests in Wellstat Diagnostics. In addition to bearing interest at 10% per annum, the note receivable gave PDL certain rights to negotiate for certain future financing transactions. In August 2012, PDL and Wellstat Diagnostics amended the note receivable, providing a senior secured note receivable of $10.0 million, bearing interest at 12% per annum, to replace the

original $7.5 million note receivable. This $10.0 million note receivable was repaid on November 2, 2012, using the proceeds of the $40.0 million credit facility entered into with the Company on the same date.

On November 2, 2012, the Company and Wellstat Diagnostics entered into a $40.0 million credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, PDL was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics' net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics' products, if any, commencing upon the commercialization of its products.

In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. PDL sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, PDL exercised one of its available remedies and transferred approximately $8.1 million of available cash from a bank account of Wellstat Diagnostics to PDL and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby PDL agreed to refrain from exercising additional remedies for 120 days while Wellstat Diagnostics raised funds to capitalize the business and the parties attempted to negotiate a revised credit agreement. PDL agreed to provide up to $7.9 million to Wellstat Diagnostics to fund the business for the 120-day forbearance period under the terms of the forbearance agreement. Following the conclusion of the forbearance period that ended on June 28, 2013, the Company agreed to forbear its exercise of remedies for additional periods of time to allow the owners and affiliates of Wellstat Diagnostics to complete a pending financing transaction. During such forbearance period, the Company provided approximately $1.3 million to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately $8.7 million was advanced pursuant to the forbearance agreement.

On August 15, 2013, the owners and affiliates of Wellstat Diagnostics completed a financing transaction to fulfill Wellstat Diagnostics' obligations under the forbearance agreement. On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement.

Except as otherwise described here, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, PDL was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics' net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately $44.1 million, which was comprised of approximately $33.7 million original loan principal and interest, $1.3 million term loan principal and interest and $9.1 million forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics' obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).

When the principal amount was reset, a $2.5 million reduction of the carrying value was recorded as a financing cost as a component of "Interest and other income, net". The new carrying value is lower as a function of the variable nature of the internal rate of return to be realized by the Company based on when the note was to be repaid. The internal rate of return calculation, although increased, was reset when the credit agreement was amended and restated.

In June of 2014, the Company received information from Wellstat Diagnostics that showed that it was generally unable to pay its debts as they became due. This constituted an event of default under the amended and restated credit agreement. Wellstat Diagnostics entered into a transaction involving another lender, pursuant to which Wellstat Diagnostics obtained additional short-term funding for its operations. At the same time, the Company entered into the first amendment to amended and restated credit agreement with Wellstat Diagnostics. The material terms of the amendment included the following: (1) Wellstat Diagnostics acknowledged that an event of default had occurred; (2) the Company agreed to forbear from immediately enforcing its rights for up to 60 days, so long as the other lender provided agreed levels of interim funding to Wellstat Diagnostics; and (3) the Company obtained specified additional information rights with regard to Wellstat Diagnostics’ financial matters and investment banking activities.

Wellstat Diagnostics Borrower Notice accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately $53.9 million, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations. On August 7, 2014, the Company delivered the Wellstat Diagnostics Guarantor Notice. The Wellstat Diagnostics Guarantor Notice included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders.

On September 24, 2014, the Company filed the Wellstat Diagnostics Petition, which was granted on the same day. The order granting the Wellstat Diagnostics Petition authorizes the receiver to take immediate possession of the physical assets of Wellstat Diagnostics, with the purpose of holding, protecting, insuring, managing and preserving the business of Wellstat Diagnostics and the value of the Company’s collateral. Wellstat Diagnostics has remained in operation during the period of the receivership with incremental additional funding from the Company. The Company continues to assess its options with respect to collecting on the loan, including determining whether and when it will foreclose on the collateral and proceed with a sale of Wellstat Diagnostics’ assets, whether providing further capital to the receiver to fund Wellstat Diagnostics’ operations for a period of time prior to sale will best position Wellstat Diagnostics’ assets for sale, and assessing the value of the guarantees obtained by the Company from Wellstat Diagnostics’ guarantors, including Wellstat Diagnostics’ stockholders and Wellstat Therapeutics.

On November 4, 2014, the Company entered into the third amendment to the amended and restated credit agreement with Wellstat Diagnostics. The amendment provides that additional funding, if any, to be made by the Company is conditioned upon the agreement by Wellstat Diagnostics to make certain operational changes within Wellstat Diagnostics, which the Company believes will allow the receiver to more efficiently optimize the value of the collateral.

During the second quarter of 2015, the receiver initiated a process for a public sale of the assets of Wellstat Diagnostics and retained the investment banking firm of Duff & Phelps to organize and manage the sale process. The receiver filed a "Motion For Approval of Sale Procedures" with the Circuit Court for Montgomery County, Maryland, which is the court having jurisdiction over the receivership and a hearing was held on July 22, 2015 at which time arguments were heard from interested parties regarding the sale procedures. No significant substantive disagreements between the parties regarding the sale procedures remained after the hearing and a decision approving the receiver’s sale procedures is expected shortly. The sale process is ongoing and Duff & Phelps is actively contacting and holding discussions with interested third parties who may be willing to bid on the assets. In addition, depending on the nature and value of the bids received from third parties, it is possible that PDL will credit bid for the assets at a value corresponding to some portion of the outstanding amount due under the amended and restated credit agreement. We anticipate that the sale process will be completed during the fourth quarter of 2015.

On September 4, 2015, PDL filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, PDL filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantors' assets. At a hearing on September 24, 2015, regarding the Company’s request for a temporary restraining order, the court ordered that the Company’s request for attachment and for summary judgment would be heard at a hearing on November 5, 2015. Although the court denied the Company’s request for a temporary restraining order at the hearing on September 24, it ordered that assets of the Wellstat Diagnostics Guarantors should be held in status quo ante and only used in the normal course of business pending the outcome of the hearing.

On October 22, 2015, the Wellstat Diagnostics Guarantors filed a complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect.

Through the period ended September 30, 2015, PDL has advanced to Wellstat Diagnostics $11.1 million to fund the ongoing operations of the business and other associated costs. This funding has been expensed as incurred.

Effective April 1, 2014, and as a result of the event of default, we determined the loan to be impaired and we ceased to accrue interest revenue. At that time and as of September 30, 2015 it has been determined that an allowance on the carrying value of the note was not necessary as the Company believes the value of the collateral securing Wellstat Diagnostics’ obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of $50.2 million. There can be no assurance that this will be true in the event of the Company’s foreclosure on the collateral, nor can

there be any assurance of the timing in realizing value from such collateral, whether from the sale process currently underway or a subsequent monetization event if PDL makes a successful credit bid for the assets.

Hyperion Agreement

On January 27, 2012, PDL and Hyperion entered into an agreement whereby Hyperion sold to PDL the royalty streams due from SDK related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. The agreement assigned the patent license agreement royalty stream accruing from January 1, 2012, through December 31, 2013, to PDL in exchange for the lump sum payment to Hyperion of $2.3 million. In exchange for the lump sum payment, PDL was to receive two equal payments of $1.2 million on both March 5, 2013 and 2014. The first payment of $1.2 million was paid on March 5, 2013, but Hyperion has not made the payment that was due on March 5, 2014. The Company completed an impairment analysis as of September 30, 2015. Effective with this date and as a result of the event of default, we ceased to accrue interest revenue. As of September 30, 2015, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance that this will be true in the event of the Company's foreclosure on the collateral, nor can there be any assurance of realizing value from such collateral. Hyperion is considering other sources of financing and strategic alternatives, including selling the company.

AxoGen Note Receivable and AxoGen Royalty Agreement

In October 2012, PDL entered into the AxoGen Royalty Agreement with AxoGen pursuant to which the Company would receive specified royalties on AxoGen’s net revenues (as defined in the AxoGen Royalty Agreement) generated by the sale, distribution or other use of AxoGen’s products. The AxoGen Royalty Agreement had an eight-year term and provided PDL with royalties of 9.95% based on AxoGen's net revenues, subject to agreed-upon guaranteed quarterly minimum payments of approximately $1.3 million to $2.5 million, which were to begin in the fourth quarter of 2014, and the right to require AxoGen to repurchase the royalties under the AxoGen Royalty Agreement at the end of the fourth year. AxoGen was granted certain rights to call the contract in years five through eight. The total consideration PDL paid to AxoGen for the royalty rights was $20.8 million, including an interim funding of $1.8 million in August 2012. AxoGen was required to use a portion of the proceeds from the AxoGen Royalty Agreement to pay the outstanding balance under its existing credit facility. The royalty rights were secured by the cash and accounts receivable of AxoGen.

On August 14, 2013, PDL purchased 1,166,666 shares of registered common stock of AxoGen (AXGN) at $3.00 per share, totaling $3.5 million. On December 22, 2014, PDL sold these shares at $3.03 per share, totaling approximately $3.5 million.

On November 13, 2014, the Company agreed to terminate the AxoGen Royalty Agreement in consideration for a payment of $30.3 million in cash, which was the sum of the outstanding principal, interest and embedded derivative.

Subsequent to the pay-off, the Company acquired 643,382 shares of registered common stock of AxoGen for approximately $1.7 million at a public offering price of $2.72 per share. The shares are classified as available for sale securities and recorded as short-term investments on the Condensed Consolidated Balance Sheets. On September 15, 2015, PDL sold 200,000 shares at $5.62 per share, totaling approximately $1.1 million. As of September 30, 2015, the remaining shares were valued at $1.8 million, which resulted in an unrealized gain of $0.6 million and is recorded in "Other comprehensive income (loss), net of tax."

Avinger Credit and Royalty Agreement

On April 18, 2013, PDL entered into the Avinger Credit and Royalty Agreement, under which we made available to Avinger up to $40.0 million to be used by Avinger in connection with the commercialization of its lumivascular catheter devices and the development of Avinger's lumivascular atherectomy device. Of the $40.0 million initially available to Avinger, we funded an initial $20.0 million, net of fees, at the close of the transaction. Outstanding borrowings under the initial loan bore interest at a stated rate of 12% per annum.

On September 22, 2015, Avinger elected as per the voluntary prepayment provision under the Avinger Credit and Royalty Agreement to prepay the notes receivable in whole for a payment of $21.4 million in cash, which was the sum of the outstanding principal, interest and a prepayment fee.

Under the terms of the Avinger Credit and Royalty Agreement, the Company will receive a low, single-digit royalty on Avinger's net revenues until April 2018. Avinger repaid the note receivable prior to its maturity date in April 2018, which resulted in the royalty on Avinger's net revenues being reduced by 50% and subject to certain minimum payments from the

prepayment date until April 2018. PDL has accounted for the royalty rights in accordance with the fair value option (see Note 3).

LENSAR Credit Agreement

On October 1, 2013, PDL entered into a credit agreement with LENSAR, under which PDL made available to LENSAR up to $60.0 million to be used by LENSAR in connection with the commercialization of its currently marketed LENSAR™ Laser System. Of the $60.0 million available to LENSAR, an initial $40.0 million, net of fees, was funded by the Company at the close of the transaction. The additional $20.0 million in the form of a second tranche is no longer available to LENSAR under the terms of the credit agreement. Outstanding borrowings under the loans bear interest at the rate of 15.5% per annum, payable quarterly in arrears.

Principal repayment will commence on the thirteenth interest payment date or December 31, 2016. The principal amount outstanding at the commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on October 1, 2018. LENSAR may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The loans are secured by all of the assets of LENSAR.

On May 12, 2015, PDL entered into a forbearance agreement with LENSAR under which PDL agreed to refrain from exercising certain remedies available to it resulting from the failure of LENSAR to comply with a liquidity covenant and make interest payments due under the credit agreement. Under the forbearance agreement, PDL has agreed to provide LENSAR with up to an aggregate of $8.5 million in weekly increments through the period ending September 30, 2015 plus employee retention amounts of approximately $0.5 million in the form of additional loans subject to LENSAR meeting certain milestones related to LENSAR obtaining additional capital to fund the business or selling itself and repaying outstanding amounts under the credit agreement. As of September 30, 2015, PDL has funded an additional $9.0 million of principal under the forbearance agreement. In exchange for the forbearance, LENSAR agreed to additional reporting covenants, the engagement of a chief restructuring officer and an increase on the interest rate to 18.5%, applicable to all outstanding amounts under the credit agreement. On September 30, 2015, PDL agreed to extend the forbearance agreement until October 9, 2015 and provide for up to an additional $0.8 million in funding while LENSAR negotiated a potential sale of its assets. On October 9, 2015, the forbearance agreement expired, but PDL has agreed to fund LENSAR's operations while LENSAR continues to negotiate a potential sale of its assets.

The Company completed an impairment analysis as of September 30, 2015. Effective April 1, 2015 and as a result of the forbearance, we determined the loan to be impaired and we ceased to accrue interest revenue.

Durata Credit Agreement

On October 31, 2013, PDL entered into a credit agreement with Durata, under which the Company made available to Durata up to $70.0 million. Of the $70.0 million available to Durata, an initial $25.0 million (tranche one), net of fees, was funded by the Company at the close of the transaction. On May 27, 2014, the Company funded Durata an additional $15.0 million (tranche two) as a result of Durata's marketing approval of dalbavancin in the United States, which occurred on May 23, 2014, and was the milestone needed to receive the tranche two funding. Until the occurrence of the tranche two milestone, outstanding borrowings under tranche one bore interest at the rate of 14.0% per annum, payable quarterly in arrears. Upon occurrence of the tranche two milestone, the interest rate of the loans decreased to 12.75%.

On November 17, 2014, the Company received a payment of approximately $42.7 million constituting repayment in full of the outstanding principal amount of loans plus accrued interest and fees under the credit agreement. The repayment was made in connection with the acquisition of Durata by Actavis plc.

Direct Flow Medical Credit Agreement

On November 5, 2013, PDL entered into a credit agreement with Direct Flow Medical, under which PDL agreed to provide up to $50.0 million to Direct Flow Medical. Of the $50.0 million available to Direct Flow Medical, an initial $35.0 million (tranche one), net of fees, was funded by the Company at the close of the transaction. Pursuant to the original terms of the credit agreement the Company agreed to provide Direct Flow Medical an additional $15.0 million tranche, net of fees, upon the attainment of a specified revenue milestone to be accomplished no later than December 31, 2014 (the tranche two milestone). Until the occurrence of the tranche two milestone, outstanding borrowings under tranche one bore interest at the rate of 15.5% per annum, payable quarterly in arrears.

proceeds from an equity offering prior to December 31, 2014. In exchange, the parties amended the credit agreement to provide for additional fees associated with certain liquidity events, such as a change of control or the consummation of an initial public offering, and granted PDL certain board of director observation rights. On November 19, 2014, upon Direct Flow Medical satisfying the amended tranche two milestone, the Company funded the $15.0 million second tranche to Direct Flow Medical, net of fees. Upon occurrence of the borrowing of the second tranche, the interest rate applicable to all loans under the credit agreement was decreased to 13.5% per annum, payable quarterly in arrears.

Principal repayment will commence on the twelfth interest payment date, September 30, 2016. The principal amount outstanding at commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on November 5, 2018. Direct Flow Medical may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The obligations under the credit agreement are secured by a pledge of substantially all of the assets of Direct Flow Medical and any of its subsidiaries.

Paradigm Spine Credit Agreement

On February 14, 2014, the Company entered into the Paradigm Spine Credit Agreement, under which it made available to Paradigm Spine up to $75.0 million to be used by Paradigm Spine to refinance its existing credit facility and expand its domestic commercial operations. Of the $75.0 million available to Paradigm Spine, an initial $50.0 million, net of fees, was funded by the Company at the close of the transaction. The second and third tranches of up to an additional $25.0 million in the aggregate, net of fees, are no longer available under the terms of the Paradigm Spine Credit Agreement. Borrowings under the credit agreement bear interest at the rate of 13.0% per annum, payable quarterly in arrears.

Principal repayment will commence on the twelfth interest payment date, December 31, 2016. The principal amount outstanding at commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on February 14, 2019. Paradigm Spine may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The obligations under the Paradigm Spine Credit Agreement are secured by a pledge of substantially all of the assets of Paradigm Spine and its domestic subsidiaries and, initially, certain assets of Paradigm Spine’s German subsidiaries.

On October 27, 2015, PDL and Paradigm Spine entered into an amendment to the Paradigm Spine Credit Agreement to provide additional term loan commitments of up to $7.0 million payable in two tranches of $4.0 million and $3.0 million, of which the first tranche was drawn on the closing date of the amendment, net of fees, and the second tranche is to be funded at the option of Paradigm Spine prior to June 30, 2016.

kaléo Note Purchase Agreement

On April 1, 2014, PDL entered into a note purchase agreement with Accel 300, a wholly-owned subsidiary of kaléo, pursuant to which the Company acquired $150.0 million of secured notes due 2029. The secured notes were issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and are secured by the kaléo Revenue Interests, and a pledge of kaléo’s equity ownership in Accel 300.

The secured notes bear interest at 13% per annum, paid quarterly in arrears on principal outstanding. The principal balance of the secured notes is repaid to the extent that the kaléo Revenue Interests exceed the quarterly interest payment, as limited by a quarterly payment cap. The final maturity of the secured notes is June 2029. kaléo may redeem the secured notes at any time, subject to a redemption premium.

As of September 30, 2015, the Company determined that its royalty purchase interest in Accel 300 represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Accel 300 that most significantly impact Accel 300's economic performance and is not the primary beneficiary of Accel 300; therefore, Accel 300 is not subject to consolidation by the Company.

On October 28, 2015, Sanofi US initiated a voluntary nationwide recall of all Auvi-Q^® units effectively immediately. Sanofi is the exclusive licensee of kaléo for the manufacturing and commercialization of Auvi-Q. While Sanofi has not identified the reason for the recall, press reports indicate that a small number of units have failed to activate or delivered inadequate doses of epinephrine. It is not known at this time when Sanofi will reintroduce Auvi-Q in the U.S.

owed to PDL. As of this date, despite the recall of Auvi-Q, it is projected that the interest reserve account alone is sufficient to cover possible interest shortfalls until at least through the first quarter of 2016. PDL will monitor the recall situation and how it may impact the ability of kaléo to meet its obligations under the Notes, but at this point it has been determined that there is no impairment.

CareView Credit Agreement

On June 26, 2015, PDL entered into a credit agreement with CareView, under which the Company made available to CareView up to $40.0 million in two tranches of $20.0 million each. Under the terms of the credit agreement, the first tranche of $20.0 million was to be funded by the Company upon CareView’s attainment of a specified milestone relating to the placement of CareView Systems^®, to be accomplished no later than October 31, 2015. The Company expects to fund CareView an additional $20.0 million upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA (as defined in the credit agreement), to be accomplished no later than June 30, 2017. Outstanding borrowings under the credit agreement will bear interest at the rate of 13.5% per annum and are payable quarterly in arrears.

As part of the transaction, the Company received a warrant to purchase approximately 4.4 million shares of common stock of CareView at the exercise price of $0.45 per share. We have accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.

On October 7, 2015, PDL and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. On this date, PDL also funded the first tranche of $20.0 million, net of fees, upon attainment of the modified first tranche milestone relating to the placement of CareView Systems. The additional $20.0 million in the form of a second tranche continues to be available upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA, to be accomplished no later than June 30, 2017 under the terms of the amended credit agreement.

In connection with the amendment of the credit agreement, PDL and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant's exercise price from $0.45 to $0.40 per share. At September 30, 2015, we determined an estimated fair value of the warrant of approximately $1.3 million.

For carrying value and fair value measurement information related to our notes receivable and other long-term receivables, see Note 3.

7. Accrued Liabilities



	September 30, 2015		December 31, 2014
(In thousands)
Compensation	$	3,588	$	1,332
Interest	2,000		6,210
Dividend payable	24,735		90
Legal	1,139		296
Other	1,249		948
Total	$	32,711	$	8,876

8. Commitments and Contingencies

Legal Proceedings

From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.

PDL BioPharma, Inc. v Merck Sharp & Dohme, Corp.

On October 28, 2015, the Company filed a Complaint against Merck Sharp & Dohme, Corp (“Merck”) for patent infringement. In the Complaint, the Company alleges that manufacture and sales of certain of Merck’s Keytruda product infringes one or more claims of the Company’s '761 Patent. The Company has requested judgment that Merck has infringed the ‘761 Patent, an award of damages due to the infringement, a finding that such infringement was willful and deliberate and trebling of damages therefore, and a declaration that the case is exceptional and warrants an award of attorney’s fees and costs. Although the ‘761 Patent expired on December 2, 2014, the Company believes that Merck infringed the patent through, e.g., manufacture and/or sale of Keytruda prior to the expiration of the ‘761 Patent.

Wellstat Litigation

On September 4, 2015, PDL filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics’ Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, PDL filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics’ Guarantors assets. At a hearing on September 24, 2015, regarding the Company’s request for a temporary restraining order, the court ordered that the Company’s request for attachment and for summary judgment would be heard at a hearing on November 5, 2015. Although the court denied the Company’s request for a temporary restraining order at the hearing on September 24, it ordered that assets of the Wellstat Diagnostics Guarantors should be held in status quo ante and only used in the normal course of business pending the outcome of the hearing.

Lease Guarantee

In connection with the Spin-Off, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. Should Facet default under its lease obligations, we could be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of September 30, 2015, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $70.5 million. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie. If AbbVie were to default, we could also be responsible for lease-related costs including utilities, property taxes and common area maintenance, which may be as much as the actual lease payments.

We have recorded a liability of $10.7 million on our Condensed Consolidated Balance Sheets as of September 30, 2015, and December 31, 2014, related to this guarantee. In future periods, we may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.

9. Convertible Notes and Term Loans



		Principal Balance Outstanding		Carrying Value
		September 30,		September 30,		December 31,
Description	Maturity Date	2015		2015		2014
(In thousands)
Convertible Notes
Series 2012 Notes	February 15, 2015	$	—	$	—	$	22,261
May 2015 Notes	May 1, 2015	$	—	—		153,235
February 2018 Notes	February 1, 2018	$	300,000	281,581		276,228
March 2015 Term Loan	February 15, 2016	$	50,000	49,842		—
Total				$	331,423	$	451,724

As of September 30, 2015, PDL was in compliance with all applicable debt covenants, and embedded features of all debt agreements were evaluated and did not need to be accounted for separately.

Series 2012 Notes

In January 2012, we exchanged $169.0 million aggregate principal of Series 2012 Notes for an identical principal amount of our then existing February 2015 Notes, plus a cash payment of $5.00 for each $1,000 principal amount tendered, totaling approximately $845,000. The cash incentive payment was allocated to deferred issue costs of $765,000, additional paid-in capital of $52,000 and deferred tax assets of $28,000. The deferred issue costs will be recognized over the life of the Series 2012 Notes as interest expense. In February 2012, we entered into separate privately negotiated exchange agreements under which we exchanged an additional $10.0 million aggregate principal amount of the Series 2012 Notes for an identical principal amount of our then existing February 2015 Notes. In August 2013, the Company entered into a separate privately negotiated exchange agreement under which it retired the final $1.0 million aggregate principal amount of the Company's outstanding February 2015 Notes. Pursuant to the exchange agreement, the holder of the February 2015 Notes received $1.0 million aggregate principal amount of the Company's Series 2012 Notes. Immediately following the exchange, no principal amount of the February 2015 Notes remained outstanding and $180.0 million principal amount of the Series 2012 Notes was outstanding.

On February 6, 2014, the Company entered into exchange and purchase agreements with certain holders of approximately $131.7 million aggregate principal amount of outstanding Series 2012 Notes. The exchange agreement provided for the issuance by the Company of shares of common stock and a cash payment for the Series 2012 Notes being exchanged, and the purchase agreement provided for a cash payment for the Series 2012 Notes being repurchased. The total consideration given was approximately $191.8 million. The Company issued to the participating holders of the February 2015 Notes a total of approximately 20.3 million shares of its common stock with a fair value of approximately $157.6 million and made an aggregate cash payment of approximately $34.2 million pursuant to the exchange and purchase agreements. Of the $34.2 million cash payment, $2.5 million is attributable to an inducement fee, $1.8 million is attributable to interest accrued through the date of settlement and $29.9 million is attributable to the repurchase of the Series 2012 Notes. It was determined that the exchange and purchase agreement represented an extinguishment of the related notes. As a result, a loss on extinguishment of $6.1 million was recorded. The $6.1 million loss on extinguishment included the derecognition of the original issuance discount of $5.8 million and a $0.3 million charge resulting from the difference of the face value of the notes and the fair value of the notes. Immediately following the exchange, $48.3 million principal amount of the Series 2012 Notes was outstanding with approximately $2.1 million of remaining original issuance discount to be amortized over the remaining life of the Series 2012 Notes.

On October 20, 2014, the Company entered into a privately negotiated exchange agreement under which it retired approximately $26.0 million in principal of the outstanding Series 2012 Notes. The exchange agreement provided for the issuance, by the Company, of shares of common stock and a cash payment for the Series 2012 Notes being exchanged. The Company issued approximately 1.8 million shares of its common stock and made a cash payment of approximately $26.2 million. Immediately following the exchange, $22.3 million principal amount of the Series 2012 Notes was outstanding with approximately $0.1 million of remaining original issuance discount to be amortized over the remaining life of the Series 2012 Notes.

The Series 2012 Notes were due February 15, 2015, and bore interest at a rate of 2.875% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On February 17, 2015, the Company completed the retirement of the remaining $22.3 million of aggregate principal of its Series 2012 notes at their stated maturity for $22.3 million, plus approximately 1.34 million shares of its common stock.

The principal amount, carrying value and unamortized discount of our Series 2012 Notes were as follows:



(In thousands)	September 30, 2015		December 31, 2014
Principal amount of the Series 2012 Notes	$	—	$	22,337
Unamortized discount of liability component	—		(76		)
Total	$	—	$	22,261

Interest expense for our Series 2012 Notes on our Condensed Consolidated Statements of Income was as follows:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2015		2014		2015		2014
Contractual coupon interest	$	—	$	347	$	80	$	1,455
Amortization of debt issuance costs	—		64		13		996
Amortization of debt discount	—		404		76		1,783
Total	$	—	$	815	$	169	$	4,234

May 2015 Notes

On May 16, 2011, we issued $155.3 million in aggregate principal amount, at par, of our May 2015 Notes in an underwritten public offering, for net proceeds of $149.7 million. Our May 2015 Notes were due May 1, 2015, and we paid interest at 3.75% on our May 2015 Notes semiannually in arrears on May 1 and November 1 of each year, beginning November 1, 2011. Proceeds from our May 2015 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem a portion of our Series 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders had the option to require PDL to redeem the May 2015 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

On May 1, 2015, the Company completed the retirement of the remaining $155.1 million of aggregate principal of its May 2015 Notes at their stated maturity for $155.1 million, plus approximately 5.2 million shares of its common stock for the excess conversion value.

The carrying value and unamortized discount of our May 2015 Notes were as follows:



(In thousands)	September 30, 2015		December 31, 2014
Principal amount of the May 2015 Notes	$	—	$	155,050
Unamortized discount of liability component	—		(1,815		)
Total	$	—	$	153,235

Interest expense for our May 2015 Notes on our Condensed Consolidated Statements of Income was as follows:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2015		2014		2015		2014
Contractual coupon interest	$	—	$	1,455	$	1,938	$	4,366
Amortization of debt issuance costs	—		320		435		952
Amortization of debt discount	—		1,308		1,815		3,852
Total	$	—	$	3,083	$	4,188	$	9,170

Purchased Call Options and Warrants

In connection with the issuance of our May 2015 Notes, we entered into purchased call option transactions with two hedge counterparties. We paid an aggregate amount of $20.8 million, plus legal fees, for the purchased call options with terms substantially similar to the embedded conversion options in our May 2015 Notes. We exercised the purchased call options upon conversion of our May 2015 Notes on May 1, 2015, which required the hedge counterparties to deliver shares to the Company. The hedge counterparties delivered to us approximately 5.2 million of PDL common shares, which was the amount equal to the shares required to be delivered by us to the note holders for the excess conversion value.

the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates through the 120 scheduled trading days beginning on July 30, 2015 and ending on January 20, 2016. If the VWAP of our common stock, as defined in the warrant agreement, exceeds the strike price of the warrants on the date of conversion, we will deliver to the warrant counterparties shares of our common stock equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.

The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of our May 2015 Notes. The strike price is approximately $6.40, subject to further adjustment upon certain events including dividend payments, for the warrants.

Because the share price was above $5.44, but below $6.40, upon conversion of our May 2015 Notes, the purchased call options offset the share dilution, and the Company received shares on exercise of the purchased call options equal to the shares that the Company delivered to the note holders. If the share price is above $6.40, upon exercise of the warrants, the Company will deliver shares to the counterparties in an amount equal to the excess of the share price over $6.40. For example, a 10% increase in the share price above $6.40 would result in the issuance of 2.1 million incremental shares upon exercise of the warrants. If our share price continues to increase, additional dilution would occur.

While the purchased call options reduced the potential equity dilution upon conversion of our May 2015 Notes, prior to the conversion or exercise, our May 2015 Notes and the warrants had a dilutive effect on the Company’s earnings per share to the extent that the price of the Company’s common stock during a given measurement period exceeds the respective exercise prices of those instruments. As of September 30, 2015, and December 31, 2014, there were no related warrants exercised.

The warrants are considered indexed to PDL stock, require net-share settlement and met all criteria for equity classification at inception and at September 30, 2015, and December 31, 2014. The purchased call options cost, including legal fees, of $20.8 million, less deferred taxes of $7.2 million, and the $10.9 million received for the warrant issuance, was recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the warrants continue to meet all criteria for equity classification.

February 2018 Notes

On February 12, 2014, we issued $300.0 million in aggregate principal amount, at par, of our February 2018 Notes in an underwritten public offering, for net proceeds of $290.2 million. Our February 2018 Notes are due February 1, 2018, and we pay interest at 4.0% on our February 2018 Notes semiannually in arrears on February 1 and August 1 of each year, beginning August 1, 2014. A portion of the proceeds from our February 2018 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem $131.7 million of our Series 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require PDL to redeem the February 2018 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

Our February 2018 Notes are convertible under any of the following circumstances:


•	During any fiscal quarter ending after the quarter ended June 30, 2014, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on the last day of such preceding fiscal quarter;


•	During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;


•	Upon the occurrence of specified corporate events as described further in the indenture; or


•	At any time on or after August 1, 2017.

The initial conversion rate for the February 2018 Notes is 109.1048 shares of the Company's common stock per $1,000 principal amount of February 2018 Notes, which is equivalent to an initial conversion price of approximately $9.17 per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the indenture. Upon conversion, the Company will be required to pay cash and, if applicable, deliver shares of the Company's common stock as described in the indenture.

In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, we were required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, we separated the principal balance of our February 2018 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 7.0%, which represents the estimated market interest rate for a similar nonconvertible instrument available to us on the date of issuance, we recorded a total debt discount of $29.7 million, allocated $19.3 million to additional paid-in capital and allocated $10.4 million to deferred tax liability. The discount is being amortized to interest expense over the term of our February 2018 Notes and increases interest expense during the term of our February 2018 Notes from the 4.0% cash coupon interest rate to an effective interest rate of 6.9%. As of September 30, 2015, the remaining discount amortization period is 2.3 years.

The carrying value and unamortized discount of our February 2018 Notes were as follows:



(In thousands)	September 30, 2015			December 31, 2014
Principal amount of the February 2018 Notes	$	300,000		$	300,000
Unamortized discount of liability component	(18,419		)	(23,772		)
Total	$	281,581		$	276,228

Interest expense for our February 2018 Notes on our Condensed Consolidated Statements of Income was as follows:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
(In thousands)	2015		2014		2015		2014
Contractual coupon interest	$	3,000	$	3,000	$	9,000	$	7,633
Amortization of debt issuance costs	510		536		1,599		1,358
Amortization of debt discount	1,830		1,688		5,353		4,238
Total	$	5,340	$	5,224	$	15,952	$	13,229

As of September 30, 2015, our February 2018 Notes are not convertible. At September 30, 2015, the if-converted value of our February 2018 Notes did not exceed the principal amount.

Purchased Call Options and Warrants

In connection with the issuance of our February 2018 Notes, we entered into purchased call option transactions with two hedge counterparties. We paid an aggregate amount of $31.0 million for the purchased call options with terms substantially similar to the embedded conversion options in our February 2018 Notes. The purchased call options cover, subject to anti-dilution and certain other customary adjustments substantially similar to those in our February 2018 Notes, approximately 32.7 million shares of our common stock. We may exercise the purchased call options upon conversion of our February 2018 Notes and require the hedge counterparty to deliver shares to the Company in an amount equal to the shares required to be delivered by the Company to the note holder for the excess conversion value. The purchased call options expire on February 1, 2018, or the last day any of our February 2018 Notes remain outstanding.

In addition, we sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive shares of common stock that will initially underlie our February 2018 Notes at a strike price of $10.3610 per share, which represents a premium of approximately 30% over the last reported sale price of the Company's common stock of $7.97 on February 6, 2014. The warrant transactions could have a dilutive effect to the extent that the market price of the Company's common stock exceeds the applicable strike price of the warrants on the date of conversion. We received an aggregate amount of $11.4 million for the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates that occur over a period of time. If the VWAP of our common stock, as defined in the warrant agreement, exceeds the strike price of the warrants, we will deliver to the warrant counterparties shares equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.

The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of our February 2018 Notes. The strike price is subject to further adjustment in the event that future quarterly dividends exceed $0.15 per share.

The purchased call options and warrants are considered indexed to PDL stock, require net-share settlement, and met all criteria for equity classification at inception and at September 30, 2015. The purchased call options cost of $31.0 million, less deferred taxes of $10.8 million, and the $11.4 million received for the warrants, was recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the purchased call options and warrants continue to meet all criteria for equity classification.

March 2015 Term Loan

On March 30, 2015, PDL entered into a credit agreement among the Company, the lenders party thereto and the Royal Bank of Canada, as administrative agent. The credit agreement consists of a term loan of $100.0 million.

The interest rates per annum applicable to amounts outstanding under the term loan are, at the Company’s option, either (a) the alternate base rate (as defined in the credit agreement) plus 0.75%, or (b) the adjusted Eurodollar rate (as defined in the credit agreement) plus 1.75% per annum. As of September 30, 2015, the interest rate, based upon the adjusted Eurodollar rate, was 2.09%. Interest payments under the credit agreement are due on the interest payment dates specified in the credit agreement.

The term loan requires amortization in the form of scheduled principal payments on June 15, September 15 and December 15 of 2015, with the remaining outstanding balance due on February 15, 2016.

Any future material domestic subsidiaries of the Company are required to guarantee the obligations of the Company under the credit agreement, except as otherwise provided by the credit agreement. The Company’s obligations under the credit agreement are secured by a lien on a substantial portion of its assets.

The credit agreement contains affirmative and negative covenants that the Company believes are usual and customary for a senior secured credit agreement. The credit agreement also requires compliance with certain financial covenants, including a maximum total leverage ratio, a debt service coverage ratio and a minimum liquidity covenant, in each case calculated as set forth in the credit agreement and compliance with which may be necessary to take certain corporate actions.

The credit agreement contains events of default that the Company believes are usual and customary for a senior secured credit agreement.

October 2013 Term Loan

On October 28, 2013, PDL entered into a credit agreement among the Company, the lenders party thereto and the Royal Bank of Canada, as administrative agent. The October 2013 Term Loan amount was for $75 million, with a term of one year.

The interest rates per annum applicable to amounts outstanding under the October 2013 Term Loan were, at the Company’s option, either (a) the base rate plus 1.00%, or (b) the Eurodollar rate plus 2.00% per annum. As of the final payment date, the interest rate was 2.22%. This principal balance and outstanding interest was paid in full on October 28, 2014.

10. Other Long-Term Liabilities



	September 30,		December 31,
	2015		2014
(In thousands)
Accrued lease liability	$	10,700	$	10,700
Long-term incentive accrual	2,446		578
Uncertain tax positions	35,035		26,356
Dividend payable	293		68
Total	$	48,474	$	37,702

In connection with the Spin-Off, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. Should Facet default under its lease obligations, we could be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of September 30, 2015, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $70.5 million. If Facet were to default, we could also be responsible for lease-related costs including utilities, property taxes and common area maintenance that may be as much as the actual lease payments. We have recorded a liability of $10.7 million on our Condensed Consolidated Balance Sheets as of September 30, 2015, and December 31, 2014, related to this guarantee.

11. Stock-Based Compensation

The Company grants stock options and restricted stock awards pursuant to a stockholder approved stock-based incentive plan. This incentive plan is described in further detail in Note 13, Stock-Based Compensation, of Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended.

The following table summarizes the Company’s stock option and restricted stock award activity during the nine months ended September 30, 2015:



			Stock Options			Restricted Stock Awards
(In thousands except per share amounts)	Shares Available for Grant		Number of Shares Outstanding	Weighted Average Exercise Price		Number of Shares Outstanding		Weighted Average Grant-date Fair Value Per Share
Balance at December 31, 2014	4,166		58	$	5.41	277		$	8.39
Granted	(522	)	—			522		6.40
Shares released	—		—			(46	)	8.58
Forfeited or canceled	40		—			(40	)	6.46
Balance at September 30, 2015	3,684		58	$	5.41	713		$	7.36

12. Cash Dividends

13. Income Taxes

Income tax expense for the three months ended September 30, 2015 and 2014, was $40.9 million and $47.4 million, respectively, and for the nine months ended September 30, 2015 and 2014, was $135.2 million and $144.1 million, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes.

The uncertain tax positions increased during the three and nine months ended September 30, 2015, by $2.4 million and $7.0 million, respectively, resulting from an increase in tax uncertainties and estimated tax liabilities.

In general, our income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 1996 forward. In May 2012, PDL received a “no-change” letter from the IRS upon completion of an examination of the Company's 2008 federal tax return. We are currently under income tax examination in the state of California for tax years 2009 and 2010. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, we do not anticipate any material change to the amount of our unrecognized tax benefit over the next 12 months.

14. Accumulated Other Comprehensive Income

Comprehensive income is comprised of net income and other comprehensive income (loss). We include unrealized net gains (losses) on investments held in our available-for-sale securities and unrealized gains (losses) on our cash flow hedges in other comprehensive income (loss), and present the amounts net of tax. Our other comprehensive income (loss) is included in our Condensed Consolidated Statements of Comprehensive Income.

The balance of accumulated other comprehensive income, net of tax, was as follows:



	Unrealized gains (losses) on available-for-sale securities		Unrealized gains on cash flow hedges		Total Accumulated Other Comprehensive Income
(In thousands)
Beginning Balance at December 31, 2014	$	364	$	2,585	$	2,949
Activity for the nine months ended September 30, 2015	39		403		442
Ending Balance at September 30, 2015	$	403	$	2,988	$	3,391

15. Subsequent Event

CareView

Paradigm Spine

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues or other financial items, any statements of the plans and objectives of management for future operations, including any statements concerning new licensing, any statements regarding future economic conditions or performance, and any statement of assumptions underlying any of the foregoing. In some cases, forward-looking statements can be identified by the use of terminology such as “may,” “will,” “intends,” “plans,” “believes,” “anticipates,” “expects,” “estimates,” “predicts,” “potential,” “continue” or “opportunity,” or the negative thereof or other comparable terminology. Although we believe that the expectations presented in the forward-looking statements contained herein are reasonable at the time they were made, there can be no assurance that such expectations or any of the forward-looking statements will prove to be correct, and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to inherent risks and uncertainties, including but not limited to the risk factors set forth below or incorporated by reference herein, and for the reasons described elsewhere in this Quarterly Report on Form 10-Q. All forward-looking statements and reasons why results may differ included in this Quarterly Report on Form 10-Q are made as of the date hereof, and we assume no obligation to update these forward-looking statements or reasons why actual results might differ.

OVERVIEW

PDL manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. To acquire new income generating assets, PDL provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. PDL has committed over $1 billion and funded approximately $919 million in these investments to date. PDL evaluates its investments based on the quality of the income generating assets and potential returns on investment. PDL is currently focused on acquiring new income generating assets, the management of its intellectual property and income generating assets, and maximizing value for its stockholders.

The Company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL was founded in 1986 and is headquartered in Incline Village, Nevada. PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases for which it receives significant royalty revenue.

Intellectual Property

Patents

We have been issued patents in the United States and elsewhere, covering the humanization of antibodies, which we refer to as our Queen et al. patents. Our Queen et al. patents, for which final patent expiry was in December 2014, covered, among other things, humanized antibodies, methods for humanizing antibodies, polynucleotide encoding in humanized antibodies and methods of producing humanized antibodies.

Our '761 Patent, which expired on December 2, 2014, covered methods and materials used in the manufacture of humanized antibodies. In addition to covering methods and materials used in the manufacture of humanized antibodies, coverage under our ‘761 Patent typically extended to the use or sale of compositions made with those methods and/or materials.

Our '216B Patent expired in Europe in December 2009. We have been granted SPCs for the Avastin^®, Herceptin^®, Lucentis^®, Xolair^® and Tysabri^® products in many of the jurisdictions in the European Union in connection with the ‘216B Patent. The SPCs effectively extended our patent protection with respect to Avastin, Herceptin, Lucentis, Xolair and Tysabri generally until December 2014, except that the SPCs for Herceptin expired in July 2014. Because SPCs are granted on a jurisdiction-by-jurisdiction basis, the duration of the extension varies slightly in certain jurisdictions. We expect to receive royalties beyond expiration of our patents and SPCs based on the terms of our licenses and our legal settlements. We do not expect to receive any meaningful revenue from our Queen et al. patents or the related license and settlement agreements beyond the first quarter of 2016.

Licensing Agreements

We have entered into licensing agreements under our Queen et al. patents with numerous entities that are independently developing or have developed humanized antibodies. Although the Queen et al. patents and related rights have expired, we are entitled under our license agreements to continue to receive royalties in certain instances based on net sales of products that were made prior to but sold after patent expiry. In addition, in one instance we are entitled to royalties based on know-how provided to a licensee, noted below with respect to Lilly. In general, these agreements cover antibodies targeting antigens specified in the license agreements. Under our licensing agreements, we are entitled to receive a flat-rate based upon our licensees’ net sales of covered antibodies.

Our total revenues from licensees under our Queen et al. patents were $119.2 million and $123.9 million, net of rebates and foreign exchange hedge adjustments, for the three months ended September 30, 2015 and 2014, respectively, and $363.9 million and $355.0 million for the nine months ended September 30, 2015 and 2014, respectively.

Licensing Agreements for Marketed Products

In the nine months ended September 30, 2015, we received royalties on sales of the ten humanized antibody products listed below, all of which are currently approved for use by the FDA and other regulatory agencies outside the United States.



Licensee		Product Names
Genentech		Avastin
		Herceptin
		Xolair
		Lucentis
		Perjeta^®
		Kadcyla^®

Biogen		Tysabri

Chugai		Actemra^®

Roche		Gazyva™

Takeda		Entyvio^®

Genentech

We entered into a master patent license agreement, effective September 25, 1998, under which we granted Genentech a license under our Queen et al. patents to make, use and sell certain antibody products.

On January 31, 2014, we entered into the Settlement Agreement with Genentech and Roche that resolved all then existing legal disputes between the parties.

Under the terms of the Settlement Agreement, Genentech pays a fixed royalty rate of 2.125% on worldwide sales of Avastin, Herceptin, Xolair, Perjeta and Kadcyla occurring on or before December 31, 2015. Pursuant to the agreement, Genentech and Roche confirmed that Avastin, Herceptin, Lucentis, Xolair and Perjeta are licensed products as defined in the relevant license agreements between the parties, and further agreed that Kadcyla and Gazyva are licensed products. With respect to Lucentis, Genentech owes no royalties on U.S. sales occurring after June 30, 2013, and paid a royalty of 2.125% on all ex-U.S.-based Sales occurring on or before December 28, 2014. The royalty term for Gazyva remains unchanged from the existing license agreement pertaining thereto.

The Settlement Agreement precludes Genentech and Roche from challenging the validity of PDL’s patents, including its SPCs in Europe, from contesting their obligation to pay royalties, from contesting patent coverage for Avastin, Herceptin, Lucentis, Xolair, Perjeta, Kadcyla and Gazyva and from assisting or encouraging any third party in challenging PDL’s patents and SPCs. The Settlement Agreement further outlines the conduct of any audits initiated by PDL of the books and records of Genentech in an effort to ensure a full and fair audit procedure. Finally, the Settlement Agreement clarifies that the sales amounts from which the royalties are calculated does not include certain taxes and discounts.

Biogen

We entered into a patent license agreement, effective April 24, 1998, under which we granted to Elan a license under our Queen et al. patents to make, use and sell antibodies that bind to the cellular adhesion molecule α4 in patients with multiple sclerosis. Under the agreement, we are entitled to receive a flat royalty rate in the low, single digits based on Elan’s net sales of the Tysabri product. Our license agreement with Elan entitles us to royalties following the expiration of our patents with respect to sales of licensed product manufactured prior to patent expiry in jurisdictions providing patent protection. In April 2013, Biogen completed its purchase of Elan's interest in Tysabri. All obligations under our original patent license agreement with Elan were assumed by Biogen.

Chugai

We entered into a patent license agreement, effective May 18, 2000, with Chugai, a majority owned subsidiary of Roche, under which we granted to Chugai a license under our Queen et al. patents to make, use and sell antibodies that bind to interleukin-6 receptors to prevent inflammatory cascades involving multiple cell types for the treatment of rheumatoid arthritis. Under the agreement, we are entitled to receive a flat royalty rate in the low, single digits based on net sales of the Actemra product manufactured in the United States prior to patent expiry. The agreement continued until the expiration of the last to expire of our Queen et al. patents. Chugai is obligated to pay us royalties on sales occurring prior to the expiration of any Queen et al. patent which covers the manufacture, use or sale of Actemra. Because the relevant patent rights expired in the fourth quarter of 2014, we did not receive any revenues from Actemra after the first quarter of 2015.

Licensing Agreements for Non-Marketed Products

Solanezumab is the Lilly-licensed antibody for the treatment of Alzheimer's disease. If Lilly’s antibody for Alzheimer’s disease is approved, we would be entitled to receive a royalty based on a "know-how" license for technology provided in the design of this antibody. The 2% royalty payable for "know-how" runs for 12.5 years after the product's initial commercialization. It is currently in Phase 3 testing with results expected in late 2016.

Protection of our Intellectual Property

Our intellectual property, namely our Queen et al. patents and related license agreements, are integral to our business and generate the majority of our revenues. Protection of our intellectual property is key to our success.

Genentech - Roche Matter

Settlement Agreement

On January 31, 2014, we entered into the Settlement Agreement with Genentech and Roche that resolved all then existing legal disputes between the parties.

Economic and Industry-wide Factors

Various economic and industry-wide factors are relevant to us and could affect our business, including changes to laws and interpretation of those laws that protect our intellectual property rights, our licensees ability to obtain or retain regulatory approval for products licensed under our patents, fluctuations in foreign currency exchange rates, the ability to attract, retain and integrate qualified personnel, as well as overall global economic conditions. We actively monitor economic, industry and market factors affecting our business; however, we cannot predict the impact such factors may have on our future results of operations, liquidity and cash flows. See also the “Risk Factors” section of this Quarter Report on Form 10-Q for additional factors that may impact our business and results of operations.

Dividend Payment

On January 27, 2015, our board of directors declared that the regular quarterly dividends to be paid to our stockholders in 2015 will be $0.15 per share of common stock, payable on March 12, June 12, September 11 and December 11 of 2015 to stockholders of record on March 5, June 5, September 4 and December 4 of 2015, the record dates for each of the dividend payments, respectively. On September 11, 2015, we paid the regular quarterly dividend to our stockholders totaling $24.5 million using earnings generated in the three months ended September 30, 2015.

Subsequent Event

CareView

Paradigm Spine

Critical Accounting Policies and Uses of Estimates

During the nine months ended September 30, 2015, there have been no significant changes to our critical accounting policies since those presented in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended.

Operating Results

Three and nine months ended September 30, 2015, compared to three and nine months ended September 30, 2014

Revenues



	Three Months Ended					Change from Prior	Nine Months Ended				Change from Prior
	September 30,					Change from Prior	September 30,				Change from Prior
	2015			2014		Year %	2015		2014		Year %
(Dollars in thousands)
Revenues
Royalties from Queen et al. patents	$	119,222		$	123,916	(4%)	$	363,916	$	355,008	3%
Royalty rights - change in fair value	(4,280		)	27,602		(116%)	19,298		73,807		(74%)
Interest revenue	9,096			13,076		(30%)	28,596		34,760		(18%)
License and other	580			—		100%	580		575		1%
Total revenues	$	124,618		$	164,594	(24%)	$	412,390	$	464,150	(11%)

Total revenues were $124.6 million and $164.6 million for the three months ended September 30, 2015 and 2014, respectively, and $412.4 million and $464.2 million for the nine months ended September 30, 2015 and 2014, respectively. During the three and nine months ended September 30, 2015 and 2014, our Queen et al. royalty revenues consisted of royalties and maintenance fees earned on sales of products under license agreements associated with our Queen et al. patents. During the three and nine months ended September 30, 2015 and 2014, royalty rights - change in fair value consisted of revenues associated with the change in fair value of our royalty right assets, Depomed, U-M, VB, ARIAD, Avinger and AcelRx. Revenues for the nine months ended September 30, 2015 and three and nine months ended September 30, 2014, are net of the payments made under the February 2011 settlement agreement with Novartis, which is based on a portion of the royalties that the Company receives from Lucentis sales made by Novartis outside the United States. No royalties were received on Lucentis sales in the second and third quarters of 2015 and consequently no payments were made to Novartis.

Total revenues decreased by 24% and 11%, respectively, for the three and nine months ended September 30, 2015, when compared to the same periods in 2014. The decrease is primarily driven by the decrease in the Depomed royalty rights cash proceeds related to the Salix (recently acquired by Valeant Pharmaceuticals) excess supply of inventory of Glumetza at the distribution level, decreased interest revenues due to the early payoff of the AxoGen and Durata notes receivables, and the conclusion of the Actemra and Lucentis license agreements, partially offset by increased royalties from sales of Perjeta, Xolair and Kadcyla and the conclusion of the Novartis rebate payments on sales of Lucentis.

The following table summarizes the percentage of our total revenues earned from our licensees’ net product sales that individually accounted for 10% or more of our total revenues for the three and nine months ended September 30, 2015 and 2014:



		Three Months Ended				Nine Months Ended
		September 30,				September 30,
Licensee	Product Name	2015		2014		2015		2014
Genentech	Avastin	32	%	24	%	28	%	25	%
	Herceptin	32	%	24	%	28	%	25	%
	Xolair	10	%	6	%	8	%	6	%

Biogen	Tysabri	11	%	10	%	10	%	9	%

Depomed	Glumetza	(10	)%	14	%	—	%	13	%

Foreign currency exchange rates also impact our reported revenues. More than 50% of our Queen et al. patent licensees’ product sales are in currencies other than U.S. dollars; as such, our revenues may fluctuate due to changes in foreign currency exchange rates and are subject to foreign currency exchange risk. While foreign currency conversion terms vary by license agreement, generally most agreements require that royalties first be calculated in the currency of sale and then converted into U.S. dollars using the average daily exchange rates for that currency for a specified period at the end of the calendar quarter. Accordingly, when the U.S. dollar weakens against other currencies, the converted amount is greater than it would have been had the U.S. dollar not weakened. For example, in a quarter in which we generate $70 million in royalty revenues, and when approximately $35 million is based on sales in currencies other than U.S. dollar, if the U.S. dollar strengthens across all currencies by 10% during the reporting period for that quarter, when compared to the same amount of local currency royalties for the prior year, U.S. dollar converted royalties will be approximately $3.5 million less in the current quarter than in the prior year's quarter.

For the three and nine months ended September 30, 2015 and 2014, we hedged certain Euro-denominated currency exposures related to our licensees’ product sales with Euro forward contracts. We designate foreign currency exchange contracts used to hedge royalty revenues based on underlying Euro-denominated sales as cash flow hedges. The aggregate unrealized gain or loss, net of tax, on the effective portion of the hedge is recorded in stockholders’ equity as "Accumulated other comprehensive income". Realized gains or losses on cash flow hedges are recognized as an adjustment to royalty revenue in the same period that the hedged transaction impacts earnings. For the three months ended September 30, 2015 and 2014, we recognized $2.3 million and ($1.5) million as additions/(reductions) in royalty revenues from our Euro contracts, respectively, and for the nine months ended September 30, 2015 and 2014, we recognized $6.0 million and ($5.8) million as additions/(reductions) in royalty revenues from our Euro contracts, respectively.

Operating Expenses



	Three Months Ended						Change from Prior	Nine Months Ended						Change from Prior
	September 30,						Change from Prior	September 30,						Change from Prior
	2015			2014			Year %	2015			2014			Year %
(In thousands)
General and administrative	$	8,450		$	5,686		49%	$	23,545		$	17,188		37%
Percentage of total revenues	7		%	3		%		6		%	4		%

The increase in operating expenses for the three months ended September 30, 2015, as compared to the same period in 2014, was a result of an increase in general and administrative expenses of $1.1 million for professional service expenses mostly related to the asset management of Wellstat Diagnostics, $0.8 million for compensation and $0.6 million for legal services.

The increase in operating expenses for the nine months ended September 30, 2015, as compared to the same period in 2014, was a result of an increase in general and administrative expenses of $3.9 million for professional service expenses mostly related to the asset management of Wellstat Diagnostics, $1.7 million for compensation and $0.3 million for legal services.

Non-operating Expense, Net

Non-operating expense, net, decreased, in part, primarily due to the decrease in interest expense from the expiration of the Series 2012 Notes and May 2015 Notes during the nine months ended September 30, 2015. The decrease in interest expense for the three and nine months ended September 30, 2015, as compared to the same period in 2014, consisted primarily of non-cash interest expense as we are required to compute interest expense using the interest rate for similar nonconvertible instruments in accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion.

Income Taxes

In general, our income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 1996 forward. In May 2012, PDL received a “no-change” letter from the IRS upon completion of an examination of the Company's 2008 federal tax return. We are currently under income tax examination in the state of California for tax years 2009 and 2010. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, except as noted above, we do not anticipate any material change to the amount of our unrecognized tax benefit over the next 12 months.

Net Income per Share

Net income per share for the three and nine months ended September 30, 2015 and 2014, is presented below:



	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2015		2014		2015		2014
Net income per share - basic	$	0.42	$	0.64	$	1.42	$	1.70
Net income per share - diluted	$	0.42	$	0.61	$	1.42	$	1.62

The decrease in net income per diluted share is primarily due to the increase in outstanding shares, as well as due to decreased revenues and the resulting decrease in net income for the period.

Liquidity and Capital Resources

We finance our operations primarily through royalty and other license-related revenues, public and private placements of debt and equity securities and interest income on invested capital. We currently have ten full-time employees managing our intellectual property, our asset acquisitions and other corporate activities as well as providing for certain essential reporting and management functions of a public company.

We had cash, cash equivalents and short-term investments in the aggregate of $229.7 million and $293.7 million at September 30, 2015, and December 31, 2014, respectively. The decrease was primarily attributable to retirement of the Series 2012 Notes and May 2015 Notes for $177.4 million, the purchase of royalty right assets for $115.0 million, payment of dividends of $73.6 million, repayment of a portion of the March 2015 Term Loan for $50.0 million, additional note receivable purchases of $9.0 million, and the payment of $0.6 million for debt issuance costs related to the March 2015 Term Loan, offset in part by net cash provided by the proceeds from the March 2015 Term Loan of $100.0 million, repayment of notes receivables of $20.6 million, proceeds from royalty rights of $9.0 million, and cash generated by operating activities of $231.4 million.

al. patents beyond the first quarter of 2016. We believe that cash from future revenues from the Queen et al. patent royalties through the first quarter of 2016 and from acquired revenue generating assets, net of operating expenses, debt service and income taxes, plus cash on hand, will be sufficient to fund our operations over the next several years. However, we do not expect that our acquired revenue generating assets will, in the near term, replace the revenues we generate from our license agreements related to the Queen et al. patents. In the second quarter of 2016, our revenues are likely to materially decrease after we stop receiving payments from these Queen et al. patents license agreements, which currently account for 88% of our year to date revenue. The continued success of the Company will become more dependent on the timing and our ability to acquire new income generating assets in order to provide recurring revenues going forward and to support our business model and ability to pay dividends.

We continuously evaluate alternatives to increase return for our stockholders by, for example, purchasing income generating assets, selling discreet assets, buying back our convertible notes, repurchasing our common stock, paying dividends and selling the Company. On January 27, 2015, our board of directors declared regular quarterly dividends of $0.15 per share of common stock, payable on March 12, June 12, September 11 and December 11 of 2015 to stockholders of record on March 5, June 5, September 4 and December 4 of 2015, the record dates for each of the dividend payments, respectively.

Notes and Other Long-Term Receivables

Wellstat Diagnostics Note Receivable and Credit Agreement

certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).

On August 5, 2014, the Company received notice that the short-term funding being provided pursuant to the agreement with the other lender entered into during June 2014, was being terminated. Wellstat Diagnostics remained in default because it was still unable to pay its debts as they became due. Accordingly, the Company delivered the Wellstat Diagnostics Borrower Notice. The Wellstat Diagnostics Borrower Notice accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately $53.9 million, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations. On August 7, 2014, the Company delivered the Wellstat Diagnostics Guarantor Notice. The Wellstat Diagnostics Guarantor Notice included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders.

Hyperion Agreement

AxoGen Note Receivable and AxoGen Royalty Agreement

Avinger Credit and Royalty Agreement

LENSAR Credit Agreement

Durata Credit Agreement

borrowings under tranche one bore interest at the rate of 14.0% per annum, payable quarterly in arrears. Upon occurrence of the tranche two milestone, the interest rate of the loans decreased to 12.75%.

Direct Flow Medical Credit Agreement

On November 10, 2014, PDL and Direct Flow Medical agreed to an amendment to the credit agreement to permit Direct Flow Medical to borrow the $15.0 million second tranche upon receipt by Direct Flow Medical of a specified minimum amount of proceeds from an equity offering prior to December 31, 2014. In exchange, the parties amended the credit agreement to provide for additional fees associated with certain liquidity events, such as a change of control or the consummation of an initial public offering, and granted PDL certain board of director observation rights. On November 19, 2014, upon Direct Flow Medical satisfying the amended tranche two milestone, the Company funded the $15.0 million second tranche to Direct Flow Medical, net of fees. Upon occurrence of the borrowing of the second tranche, the interest rate applicable to all loans under the credit agreement was decreased to 13.5% per annum, payable quarterly in arrears.

Paradigm Spine Credit Agreement

kaléo Note Purchase Agreement

As part of our financing transaction, kaléo was required to establish an interest reserve account of $20 million from the $150 million provided by PDL. The purpose of this interest reserve account is to cover any possible shortfalls in interest payments owed to PDL. As of this date, despite the recall of Auvi-Q, it is projected that the interest reserve account alone is sufficient to cover possible interest shortfalls until at least through the first quarter of 2016. PDL will monitor the recall situation and how it may impact the ability of kaléo to meet its obligations under the Notes, but at this point it has been determined that there is no impairment.

CareView Credit Agreement

On June 26, 2015, PDL entered into a credit agreement with CareView, under which the Company made available to CareView up to $40.0 million in two tranches of $20.0 million each. Under the terms of the credit agreement, the first tranche of $20 million was to be funded by the Company upon CareView’s attainment of a specified milestone relating to the placement of CareView Systems^®, to be accomplished no later than October 31, 2015. The Company expects to fund CareView an additional $20.0 million upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA (as defined in the credit agreement), to be accomplished no later than June 30, 2017. Outstanding borrowings under the credit agreement will bear interest at the rate of 13.5% per annum and are payable quarterly in arrears.

Royalty Rights - At Fair Value

Depomed Royalty Agreement

When PDL acquired the Depomed royalties, Glumetza was marketed by Santarus. In January 2014, Salix acquired Santarus and assumed responsibility for commercializing Glumetza, which was generally perceived to be a positive development because of Salix's larger sales force and track record in the successful commercialization of therapies. In late 2014, Salix made a number of disclosures relating to an excess of supply at the distribution level of Glumetza and other drugs that it commercialized, the practices leading to this excess of supply which were under review by Salix's audit committee in relation to the related accounting practices. Because of these disclosures and PDL's lack of direct access to information as to the levels of inventory of Glumetza in the distribution channels, PDL commenced a review of all public statements by Salix, publicly available historical third-party prescription data, analyst reports and other relevant data sources. PDL also engaged a third-party expert to specifically assess estimated inventory levels of Glumetza in the distribution channel and to ascertain the potential effects those inventory levels may have on expected future cash flows. We have received no royalties from Glumetza sales in 2015. Salix was acquired by Valeant Pharmaceuticals in early April 2015. On June 18, 2015, Valeant Pharmaceuticals implemented a price increase on Glumetza and implemented an additional price increase on July 31, 2015. As of September 30, 2015, our discounted cash flow analysis reflects our expectations as to the amount and timing of future cash flows up to the valuation date. We will monitor whether the acquisition or price increase by Valeant Pharmaceuticals has any effect on sales of Glumetza and thus royalties on such sales paid to PDL. Due to the uncertainty around Valeant's marketing and pricing strategy, as well as the near-term generic competition, we maybe unable to fully assess the impact of the acquisition or price increase on sales of

Glumetza and thus royalties on such sales paid to PDL. PDL expects to exercise its royalty audit right for Glumetza in the near future.

VB Royalty Agreement

University of Michigan Royalty Agreement

On November 6, 2014, PDL acquired a portion of all royalty payments of U-M’s worldwide royalty interest in Cerdelga (Eliglustat) for $65.6 million. Under the terms of the Michigan Royalty Agreement, PDL will receive 75% of all royalty payments due under U-M’s license agreement with Genzyme until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States on August 19, 2014, in the European Union on January 22, 2015, and in Japan on March 25, 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities.

ARIAD Royalty Agreement

specified amount. Under the ARIAD Royalty Agreement, the Company has the right to a make-whole payment from ARIAD if the Company does not receive payments equal to or greater than the amounts funded on or prior to the fifth anniversary of each of the respective fundings. In such case, ARIAD will pay to the Company the difference between the amounts paid to such date by ARIAD (excluding any delinquent fee payments) and the amounts funded by the Company. PDL has elected the fair value option to account for the hybrid instrument in its entirety. Any embedded derivative shall not be separated from the host contract.

AcelRx Royalty Agreement

On September 18, 2015, PDL entered into the AcelRx Royalty Agreement with ARPI LLC, a wholly owned subsidiary of AcelRx, whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso^™ (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx's commercial partner, Grünenthal, in exchange for a $65.0 million cash payment. Under the terms of the AcelRx Royalty Agreement, the Company will receive 75% of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx's license agreement with Grünenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and (ii) the expiration of the licensed patents. Dr. Stephen Hoffman is the President of 10x Capital, Inc., a third-party consultant to the Company, and is also a member of the board of directors of AcelRx. Dr. Hoffman recused himself from the AcelRx board of directors with respect to the entirety of its discussions and considerations of the transaction. Dr. Hoffman is being compensated for his contribution to consummate this transaction by PDL as part of his consulting agreement. PDL concluded Dr. Hoffman is not considered a related party in accordance with FASB ASC 850, Related Party Disclosures and SEC Regulation S-X, Related Party Transactions Which Affect the Financial Statements.

The fair value of the royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a sixteen-year period. The discount rate utilized was approximately 13.4%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $18.4 million or increase by $29.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.3 million or decrease by $3.3 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

Avinger Credit and Royalty Agreement

Under the terms of the Avinger Credit and Royalty Agreement, the Company is entitled to receive royalties at a rate of 1.8% on Avinger's net revenues. As Avinger repaid the note receivable prior to its maturity date in April 2018, the royalty rate was reduced to 0.9% and will be subject to certain minimum payments from the prepayment date until April 2018. PDL has accounted for the royalty rights in accordance with the fair value option. The fair value of the royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a seven-year period. The discount rate utilized was approximately 15.0%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5.0%, the fair value of this asset could decrease by $158,000 or increase by $179,000, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $137,000 or decrease by $137,000, respectively. Management considered the contractual minimum payments when developing its estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

Convertible Notes

Series 2012 Notes

Company issued approximately 1.8 million shares of its common stock and made a cash payment of approximately $26.2 million. Immediately following the exchange, $22.3 million principal amount of the Series 2012 Notes was outstanding with approximately $0.1 million of remaining original issuance discount to be amortized over the remaining life of the Series 2012 Notes.

May 2015 Notes

On May 16, 2011, we issued $155.3 million in aggregate principal amount, at par, of our May 2015 Notes in an underwritten public offering, for net proceeds of $149.7 million. Our May 2015 Notes were due May 1, 2015, and we paid interest at 3.75% on our May 2015 Notes semiannually in arrears on May 1 and November 1 of each year, beginning November 1, 2011. Proceeds from our May 2015 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem a portion of our 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders had the option to require PDL to Redeem the May 2015 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

Purchased Call Options and Warrants

In addition, we sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive up to 27.5 million shares of common stock underlying our May 2015 Notes. We received an aggregate amount of $10.9 million for the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates through the 120 scheduled trading days beginning on July 30, 2015 and ending on January 20, 2016. If the VWAP of our common stock, as defined in the warrant agreement, exceeds the strike price of the warrants on the date of conversion, we will deliver to the warrant counterparties shares of our common stock equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.

February 2018 Notes

Our February 2018 Notes are convertible under any of the following circumstances:


•	During any fiscal quarter ending after the quarter ended June 30, 2014, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on the last day of such preceding fiscal quarter;


•	During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;


•	Upon the occurrence of specified corporate events as described further in the indenture; or


•	At any time on or after August 1, 2017.

As of September 30, 2015, our February 2018 Notes are not convertible. At September 30, 2015, the if-converted value of our February 2018 Notes did not exceed the principal amount.

Purchased Call Options and Warrants

the Company to the note holder for the excess conversion value. The purchased call options expire on February 1, 2018, or the last day any of our February 2018 Notes remain outstanding.

March 2015 Term Loan

The term loan requires amortization in the form of scheduled principal payments on June 15, September 15 and December 15 of 2015, with the remaining outstanding balance due on February 15, 2016.

The credit agreement contains events of default that the Company believes are usual and customary for a senior secured credit agreement.

October 2013 Term Loan

Off-Balance Sheet Arrangements

As of September 30, 2015, we did not have any off-balance sheet arrangements, as defined under SEC Regulation S-K Item 303(a)(4)(ii).

Contractual Obligations

Convertible Notes and Term Loans

As of September 30, 2015, our convertible notes and term loan contractual obligations consisted primarily of our February 2018 Notes and March 2015 Term Loan, which in the aggregate totaled $350.0 million in principal.

We expect that our debt service obligations over the next several years will consist of interest payments and repayment of our February 2018 Notes and March 2015 Term Loan. We may further seek to exchange, repurchase or otherwise acquire the convertible notes in the open market in the future, which could adversely affect the amount or timing of any distributions to our stockholders. We would make such exchanges or repurchases only if we deemed it to be in our stockholders’ best interest. We may finance such repurchases with cash on hand and/or with public or private equity or debt financings if we deem such financings to be available on favorable terms.

Notes Receivable and Other Long-Term Receivables

On June 26, 2015, PDL entered into a credit agreement with CareView, under which the Company made available to CareView up to $40.0 million in two tranches of $20.0 million each. The first tranche of $20 million was to be funded by the Company upon CareView’s attainment of a specified milestone relating to the placement of CareView Systems, to be accomplished no later than October 31, 2015. The Company will fund CareView an additional $20.0 million upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and EBITDA, to be accomplished no later than June 30, 2017.

On October 7, 2015, PDL and CareView agreed to an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. On this date, the Company funded the first tranche of $20.0 million, net of fees, upon attainment of the modified first tranche milestone relating to the placement of CareView Systems. The additional $20.0 million in the form of a second tranche continues to be available upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA, to be accomplished no later than June 30, 2017 under the terms of the amended credit agreement.

Royalty Rights - At Fair Value

On July 28, 2015, PDL entered into a revenue interests assignment agreement with ARIAD pursuant to which ARIAD sold to the Company the right to receive specified royalties on ARIAD’s Net Revenues (as defined in the ARIAD Royalty Agreement) generated by the sale, distribution or other use of ARIAD’s product Iclusig (ponatinib). In exchange for the ARIAD Royalty Rights, the ARIAD Royalty Agreement provides for the funding of up to $200.0 million in cash to ARIAD. Funding of the first $100.0 million will be made in two tranches of $50.0 million each, with the initial amount funded on the closing date of the ARIAD Royalty Agreement and an additional $50.0 million to be funded on the 12-month anniversary of the closing date. In addition, ARIAD has an option to draw up to an additional $100.0 million in up to two draws at any time between the six- and 12-month anniversaries of the closing date.

Lease Guarantee

We recorded a liability of $10.7 million on our Condensed Consolidated Balance Sheets as of September 30, 2015, and December 31, 2014, for the estimated liability resulting from this guarantee. We prepared a discounted, probability-weighted cash flow analysis to calculate the estimated fair value of the lease guarantee as of the Spin-Off. We were required to make assumptions regarding the probability of Facet’s default on the lease payment, the likelihood of a sublease being executed and the times at which these events could occur. These assumptions are based on information that we received from real estate brokers and the then-current economic conditions, as well as expectations of future economic conditions. The fair value of this lease guarantee was charged to additional paid-in capital upon the Spin-Off and any future adjustments to the carrying value of the obligation will also be recorded in additional paid-in capital. In future periods, we may increase the recorded liability for this obligation if we conclude that a loss, which is larger than the amount recorded, is both probable and estimable.

Indemnification

As permitted under Delaware law and under the terms of our bylaws, the Company has entered into indemnification agreements with its directors and executive officers. Under these agreements, the Company has agreed to indemnify such individuals for certain events or occurrences, subject to certain limits, against liabilities that arise by reason of their status as directors or officers and to advance expense incurred by such individuals in connection with related legal proceedings. While the maximum amount of potential future indemnification is unlimited, we have a director and officer insurance policy that limits our exposure and may enable us to recover a portion of any future amounts paid.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Foreign Currency Risk

The underlying sales of our licensees’ products are conducted in multiple countries and in multiple currencies throughout the world. While foreign currency conversion terms vary by license agreement, generally most agreements require that royalties first be calculated in the currency of sale and then converted into U.S. dollars using the average daily exchange rates for that currency for a specified period at the end of the calendar quarter. Accordingly, when the U.S. dollar weakens in relation to other currencies, the converted amount is greater than it would have been had the U.S. dollar not weakened. More than 50% of our licensees’ product sales are in currencies other than U.S. dollars; as such, our revenues may fluctuate due to changes in foreign currency exchange rates and are subject to foreign currency exchange risk. For example, in a quarter in which we generate $70 million in royalty revenues, and when approximately $35 million is based on sales in currencies other than the U.S. dollar, if the U.S. dollar strengthens across all currencies by 10% during the reporting period for that quarter, when compared to the same amount of local currency royalties for the prior year, U.S. dollar converted royalties will be approximately $3.5 million less in that current quarter sales, assuming that the currency risk in such forecasted sales was not hedged.

We hedge Euro-denominated risk exposures related to our licensees’ product sales with Euro forward contracts. In general, these contracts are intended to offset the underlying Euro market risk in our royalty revenues. Our current contracts extend through the first quarter of 2016 and are all classified for accounting purposes as cash flow hedges. We continue to monitor the change in the Euro exchange rate and regularly purchase additional forward contracts to achieve hedged rates that approximate the average exchange rate of the Euro over the year, which we anticipate will better offset potential changes in exchange rates than simply entering into larger contracts at a single point in time.

During the third quarter of 2012, we reduced our forecasted exposure to the Euro for 2013 royalties. In August 2012, we de-designated and terminated certain forward contracts, recording a gain of approximately $391,000 in "Interest and other income, net". The termination of these contracts was effected through a reduction in the notional amount of the original hedge contracts that was then exchanged for new hedges of 2014 Euro-denominated royalties. These 2014 hedges were entered into at a rate more favorable than the market rate as of the date of the exchange.

Gains or losses on our cash flow hedges are recognized in the same period that the hedged transaction impacts earnings as an adjustment to royalty revenue. Ineffectiveness, if any, resulting from the change in fair value of the modified 2012 hedge or lower than forecasted Euro-based royalties will be reclassified from "Other comprehensive income (loss), net of tax" and recorded as "Interest and other income, net", in the period it occurs. The following table summarizes the notional amounts, Euro exchange rates and fair values of our outstanding Euro contracts designated as hedges at September 30, 2015, and December 31, 2014:



Euro Forward Contracts			September 30, 2015				December 31, 2014
			(In thousands)				(In thousands)
Currency	Settlement Price	Type	Notional Amount		Fair Value		Notional Amount		Fair Value
Currency	($ per Euro)	Type	Notional Amount		Fair Value		Notional Amount		Fair Value
Euro	1.256	Sell Euro	$	—	$	—	$	6,000	$	241
Euro	1.257	Sell Euro	—		—		15,750		728
Euro	1.259	Sell Euro	—		—		16,125		752
Euro	1.260	Sell Euro	33,000		4,597		33,000		1,468
Euro	1.270	Sell Euro	—		—		7,000		377
Euro	1.281	Sell Euro	—		—		8,000		503
Total			$	33,000	$	4,597	$	85,875	$	4,069

Interest Rate Risk

Our investment portfolio was approximately $141.7 million at September 30, 2015, and $224.1 million at December 31, 2014, and consisted of investments in Rule 2a-7 money market funds and a corporate security. If market interest rates were to have increased by 1% in either of these years, there would have been no material impact on the fair value of our portfolio.

The aggregate fair value of our convertible notes was estimated to be $312.3 million at September 30, 2015, and $528.7 million at December 31, 2014, based on available pricing information. At September 30, 2015, and December 31, 2014, our convertible note consisted of our February 2018 Notes, with a fixed interest rate of 4.0%. At December 31, 2014, our convertible notes also consisted of our Series 2012 Notes, with a fixed interest rate of 2.875%, and our May 2015 Notes, with a fixed interest rate of 3.75%. These obligations are subject to interest rate risk because the fixed interest rates under these obligations may exceed current market interest rates.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2015, our disclosure controls and procedures were effective to ensure the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure and recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Changes in Internal Controls

There were no changes in our internal controls over financial reporting during the quarter ended September 30, 2015, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Limitations on the Effectiveness of Controls

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. We continue to improve and refine our internal controls and our compliance with existing controls is an ongoing process.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Reference is hereby made to our disclosures in “Legal Proceedings” under Note 8 to our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q and the information under the heading “Legal Proceedings” is incorporated by reference herein.

ITEM 1A. RISK FACTORS

During the nine months ended September 30, 2015, there were no material changes to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended. Please carefully consider the information set forth in this Quarterly Report on Form 10-Q and the risk factors discussed in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended, which could materially affect our business, financial condition or future results. The risks described in our Annual Report on Form 10-K for the year ended December 31, 2014, as amended, as well as other risks and uncertainties, could materially and adversely affect our business, results of operations and financial condition, which in turn could materially and adversely affect the trading price of shares of our common stock. Additional risks not currently known or currently material to us may also harm our business.

ITEM 6. EXHIBITS

The exhibits listed in the exhibit index following the signature page are filed or furnished as part of this report.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



Dated:	November 4, 2015
PDL BIOPHARMA, INC. (REGISTRANT)


/s/ John P. McLaughlin
John P. McLaughlin
President and Chief Executive Officer (Principal Executive Officer)



/s/ Peter S. Garcia
Peter S. Garcia
Vice President and Chief Financial Officer (Principal Financial Officer)



/s/ Steffen Pietzke
Steffen Pietzke
Controller and Chief Accounting Officer (Principal Accounting Officer)



EXHIBIT INDEX
Exhibit Number	Exhibit Title

3.1	Restated Certificate of Incorporation effective March 23, 1993 (incorporated by reference to Exhibit 3.1 to Annual Report on Form 10-K filed March 31, 1993)

3.2	Certificate of Amendment of Certificate of Incorporation effective August 21, 2001 (incorporated by reference to Exhibit 3.3 to Annual Report on Form 10-K filed March 14, 2002)

3.3	Certificate of Amendment of Certificate of Incorporation effective January 9, 2006 (incorporated by reference to Exhibit 99.1 to Current Report on Form 8-K filed January 10, 2006)

3.4	Certificate of Designation, Preferences and Rights of the Terms effective August 25, 2006 (incorporated by reference to Exhibit 3.4 to Registration Statement on Form 8-A filed September 6, 2006)

3.5	Third Amended and Restated Bylaws effective December 4, 2014 (incorporated by reference to Exhibit 99.1 to Current Report on Form 8-K filed December 9, 2014)

3.6	Certificate of Amendment of Restated Certificate of Incorporation effective May 22, 2013 (incorporated by reference to Exhibit 4.4 to Registration Statement on Form S-3 filed June 21, 2013)

4.6	Indenture between the Company and The Bank of New York Mellon Trust Company, N.A., dated February 12, 2014 (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed February 12, 2014)

4.7	Supplemental Indenture between the Company and The Bank of New York Mellon Trust Company, N.A., dated February 12, 2014 (incorporated by reference to Exhibit 4.1 to Current Report on Form 8-K filed February 12, 2014)

4.8	Second Supplemental Indenture between the Company and The Bank of New York Mellon Trust Company, N.A., dated February 28, 2014 (incorporated by reference to Exhibit 4.9 to Annual Report on Form 10-K filed March 3, 2014)

10.1*#	Amended and Restated 2015 Annual Bonus Plan

10.2*#	Amended and Restated 2015/19 Long-Term Incentive Plan

10.3#	Revenue Interest Assignment Agreement, dated as of July 28, 2015, between ARIAD Pharmaceuticals, Inc. and the Company†

12.1#	Ratio of Earnings to Fixed Charges

31.1#	Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended

31.2#	Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended

32.1**#	Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema
101.CAL	XBRL Taxonomy Extension Calculation Linkbase
101.DEF	XBRL Taxonomy Extension Definition Linkbase
101.LAB	XBRL Taxonomy Extension Label Linkbase
101.PRE	XBRL Taxonomy Extension Presentation Linkbase


#	Filed herewith.


*	Management contract or compensatory plan or arrangement


**	This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the registrant under

the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing.


†	Certain information in this exhibit has been omitted and filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request under 17 C.F.R. Sections 200.80(b)(4) and 24b-2.

EX-10.1 2 pdli-201593010qex101.htm AMENDED AND RESTATED 2015 ANNUAL BONUS PLAN Exhibit

Exhibit 10.1

PDL BIOPHARMA, INC.

Amended and Restated 2015 Annual Bonus Plan

This Amended and Restated 2015 Annual Bonus Plan (the “Plan”) is intended to enhance stockholder value by promoting a connection between the performance of PDL BioPharma, Inc. (the “Company”) and the compensation of personnel of the Company and to promote retention of high performing personnel. The Plan is being implemented under the Company’s 2005 Equity Incentive Plan (as amended, the “2005 Equity Plan”), which was approved by the Company’s stockholders. The annual bonuses will be granted as a Cash-Based Award pursuant to the 2005 Equity Plan.

1.All employees of the Company working 30 hours per week or more (each, a “Participant”) are eligible to receive annual bonuses for 2015 according to this Plan. The Plan will be administered by the Compensation Committee of the Board of Directors of the Company (the “Committee”). The Committee shall have all powers and discretion necessary to administer the Plan and to control its operation and may delegate responsibilities to Company officers as it deems appropriate. Participants are eligible to receive bonuses upon the achievement of the threshold goal specified in Section 2. A Participant who does not demonstrate satisfactory individual performance (50% or higher), however, will not be eligible for any portion of his or her bonus, including the portion based on Company performance.

2.For the purpose of payments under the Plan qualifying as Performance-Based Compensation under the 2005 Equity Plan, the threshold goal shall be the consummation of corporate transactions resulting in the acquisition of income generating assets with an aggregate value of not less than $100 million on or prior to December 31, 2015.

3.The determination of the amount of payments under the plan shall be based on the performance of the 2015 Corporate Goals and the 2015 Individual Goals as well as the other factors set forth in this Section 3. Company performance shall be determined by the Committee based on the Company’s ability to meet or exceed corporate goals (“2015 Corporate Goals”) as approved by the Board of Directors and set forth in Exhibit A. Additionally, the Committee may adjust or modify the 2015 Corporate Goals to reflect changed Company objectives. Individual performance of the Company’s officers shall be reviewed and recommended to the Committee by the Chief Executive Officer, except for the performance of the Chief Executive Officer, which shall be determined by the Committee based on the Company’s achievement of established Corporate Goals. Individual performance of employees shall be reviewed by the appropriate manager and approved by the Chief Executive Officer. In all cases, individual performance shall be based on the 2015 Individual Goals that have been approved by the Chief Executive Officer and set forth as Exhibit B (the “2015 Individual Goals”).

The Committee shall have the sole discretion on the basis of individual or corporate performance metrics to determine that the actual amount paid with respect to a Participant’s award will be equal to or less than (but not greater than) the

maximum payout calculated. For clarification, the Committee may determine, in its sole discretion on the basis of individual or corporate performance metrics, that a reduced bonus, or no bonus, shall be paid to individual, regardless of achievement of the 2015 Corporate Goals or the 2015 Individual Goals.

4.To be eligible for a bonus, a Participant must be on payroll prior to October 1, 2015, and must be employed by the Company as of the date of payment of the bonus. A Participant hired after April 1, 2015, shall be eligible for a pro-rated bonus.

5.A Participant who has taken an approved leave of absence pursuant to the Company’s policies during 2015 shall receive a pro-rated bonus, at the Compensation Committee's discretion.

6.The amount of a Participant’s bonus is based on a target percentage of such Participant’s annual average base salary throughout the 2015 calendar year. The target percentage for executives has been determined by the Committee and for employees has been determined by the manager at the beginning of the Plan Year. The target percentage shall then be adjusted based on the attainment of 2015 Corporate Goals and Individual Goals over the course of the Plan Year to arrive at a final performance percentage. For each person, the target percentage and ratio of attainment of 2015 Corporate Goals and 2015 Individual Goals is set forth as Exhibit C.

7.The Company performance percentage and/or the individual performance percentage may exceed 100% in the event the Company or the individual Participant exceeds expected goals, provided that neither percentage may exceed 200%. For example, assuming the Company has met 100% of its 2015 Corporate Goals, a Participant, who has met 150% of his or her 2015 Individual Goals, has a target percentage of 25%, has a corporate-to-individual goal ratio of 50%/50% and a base pay rate of $100,000 will receive a bonus of $31,250 (100% x 0.5 + 150% x 0.5 = 125%; and 125% x 25% = 31.25%; and 31.25% of Participant’s base pay rate of $100,000 = $31,250). All determinations and decisions made by the Committee shall be final, conclusive and binding on all persons and shall be given the maximum deference permitted by law.

8.This Plan is effective for the Company’s 2015 calendar year beginning January 1, 2015, through December 31, 2015 (the “Plan Year”), and will expire automatically on December 31, 2015. Bonus payments will be made no later than February 15^th, 2016.

9.The Company shall withhold all applicable taxes from any bonus payment, including any federal, state and local taxes.

10.Nothing in this Plan shall interfere with or limit in any way the right of the Company to terminate any Participant’s employment or service at any time, with or without cause. Nothing in these guidelines should be construed as an employment agreement or an entitlement to any Participant for any incentive payment hereunder.

11.This Plan and all awards shall be construed in accordance with and governed by the laws of the State of Nevada, without regard to its conflict of law provisions.

12.Payments under this Plan shall be unsecured, unfunded obligations of the Company. To the extent a Participant has any rights under this Plan, the Participant’s rights shall be those of a general unsecured creditor of the Company.

13.It is the intent of the Company that the Plan, and all payments made hereunder, satisfy and be interpreted in a manner that, in the case of Participants who are persons whose compensation is subject to Section 162(m), qualify as Performance-Based Compensation under Section 162(m). Any provision, application or interpretation of the Plan inconsistent with this intent to satisfy the requirements of Section 162(m) shall be disregarded. However, notwithstanding anything to the contrary in the Plan, the provisions of the Plan may at any time be bifurcated by the Committee in any manner so that certain provisions of the Plan or any payment intended (or required in order) to satisfy the applicable requirements of Section 162(m) are only applicable to persons whose compensation is subject to the limitations on deductibility of compensation provided under Section 162(m).



Name	Title	Target Bonus	Ratio of 2015 Corporate Goals/2015 Individual Goals
John McLaughlin	President & CEO	100%	100%/0%
Peter Garcia	VP & CFO	75%	75%/25%
Christopher Stone	VP, General Counsel & Secretary	75%	75%/25%
Danny Hart	Vice President, Business Development	75%	75%/25%
Steffen Pietzke	Controller and Chief Accounting Officer	45%	75%/25%
Nathan Kryszak	Senior Counsel & Assistant Secretary	45%	75%/25%

EX-10.2 3 pdli-201593010qex102.htm AMENDED AND RESTATED 2015/19 LONG-TERM INCENTIVE PLAN Exhibit

Exhibit 10.2

PDL BIOPHARMA, INC.

Amended and Restated 2015/19 Long-Term Incentive Plan

This Amended and Restated 2015/19 Long-Term Incentive Plan (the “Plan”) is intended to enhance stockholder value by promoting a connection between the performance of PDL BioPharma, Inc. (the “Company”) and the compensation of personnel of the Company and retaining high performing personnel. This Plan is the fifth long-term incentive plan in a series of long-term incentive plans, each plan overlapping the previous plan and having a subsequent vesting date to provide maximum continuity and retention effects. The Plan is being implemented under the Company’s 2005 Equity Incentive Plan, as amended (the “Equity Plan”), which was approved by the Company’s stockholders. The Plan will be administered by the Compensation Committee of the Board of Directors of the Company (the “Committee”). The Committee shall have all powers and discretion necessary to administer the Plan and to control its operation, and may delegate any and all such powers and discretion to any officer of the Company. The Plan is effective as of January 1, 2015 (the “Effective Date”), and will 50% vest and be payable on December 12, 2016 (the “Initial Vesting Period Date”) and will 16.667% vest and be payable on each of December 12 of 2017, 2018 and 2019 (each a “Subsequent Vesting Period Date”) upon attainment of specified goals. The Plan will terminate when all payments and benefits under the Plan have been made.


1.	Eligibility

The employees of the Company set forth in Exhibit A and any other employee approved by the Committee after the adoption of the Plan (each, a “Participant”) are eligible to receive a long-term incentive under this Plan. To be eligible for payment, a Participant must be employed by the Company as of the applicable vesting period date or otherwise eligible because of separation from the Company entitling such Participant to acceleration, vesting and payment of the Plan under any outstanding severance agreement.


2.	Performance Goals

Long-term incentives under this Plan will vest and are payable on the Initial Vesting Period Date and on applicable Subsequent Vesting Period Dates upon attainment of the Initial Performance Goal or a Subsequent Performance Goal, as applicable on such date. Failure to accomplish a Subsequent Performance Goal shall not affect any payments awarded on the Initial Vesting Period Date. Failure to achieve the Initial Performance Goal will eliminate a Participant’s eligibility under the Subsequent Performance Goals.

The Initial Performance Goal is: deployment of $500 million or more in the aggregate in income-generating assets in the two calendar-year period of 2015 and 2016. Upon

-1-

attainment of the Initial Performance Goal, 50% of the long-term incentives of cash and restricted stock will vest and be payable on the Initial Vesting Period Date.

Each of the Subsequent Performance Goals is: the basket of income-generating assets acquired during the two calendar-year period of 2015 and 2016 generates at least 80% of the projected cash flow for such basket in the calendar year of the applicable Subsequent Vesting Period Date. Upon attainment of a Subsequent Performance Goal, 16.667% of the long-term incentive set forth on Exhibit A will vest and be payable as of the applicable Subsequent Vesting Period Date. In the event that a Subsequent Performance Goal is not obtained in any calendar year, such long-term incentive may vest and be payable on the final Subsequent Vesting Period Date if the basket of income-generating assets acquired during the two calendar-year period of 2015 and 2016 generates at least 80% of the total projected cash flow for such basket during the combined calendar years of 2017-19.


3.	Incentive

The long-term incentive consists of: (i) a cash payment and (ii) a grant of restricted stock, in each case awarded pursuant to the Company’s 2005 Equity Incentive Plan, as amended. All incentives shall vest and pay on the Initial Vesting Period Date and Subsequent Vesting Period Date, as applicable, subject to compliance with Section 409A of the Internal Revenue Code and except as accelerated by a Change in Control. The number of shares underlying the initial Restricted Stock Award shall be determined based on the closing price of the Company’s common stock on January 28, 2015 and the number of shares underlying the additional Restricted Stock Award shall be determined based on the closing price of the Company’s common stock on September 29, 2015.

Each Participant’s incentive as of the Effective Date is set forth in Exhibit A.


4.	Adjustments

There are circumstances in which adjustments to the Plan may be necessary. The following are examples and are not intended to be an exhaustive list of such circumstances.

Early repayment of debt or buy out of a royalty: PDL acquires an income-generating asset from Company A in early 2015 which is structured as debt requiring repayment of principal and interest in 2016 through 2019. It is part of the basket of 2015-16 income-generating assets against which the Initial and Subsequent Performance Goals under this Plan are measured. Company A is acquired and the debt is fully repaid in June 2016. For purposes of measuring the attainment of the Initial Performance Goal and Subsequent Performance Goals, the income-generating asset of Company A shall be treated as if it generated 100% of the projected income for purposes of attainment of the Initial and Subsequent Performance Goals even though the debt is no longer outstanding during the applicable measurement periods.

Positive or Neutral restructuring of an income-generating asset: PDL provides a loan of $50 million to Company A in 2015. In 2016, PDL modifies the terms of the loan to provide an additional tranche of cash upon attainment of a sales milestone. The restructuring is beneficial to PDL because the asset is performing and the additional amount of the loan

-2-

allows PDL to deploy more cash into an income-generating asset. Attainment of the Initial and Subsequent Performance Goals is measured against the restructured deal.

Negative restructuring of an income-generating asset: Whether facts or circumstances warrant using a revised projection of cash flow based on the restructuring (as compared to the original projected cash flow) is solely within the discretion of the Committee.


5.	Change in Control

Notwithstanding the foregoing, in the event of a Change in Control, (i) the vesting of the restricted stock award, (ii) the payment of any accrued but unpaid dividends or other distributions, plus interest (at the rate set forth above), and (iii) the payment of cash, will accelerate and pay in connection with the Change in Control.

For purposes of this Plan, “Change in Control” shall be deemed to have occurred as of the first day after the Effective Date that any one or more of the following conditions is satisfied:

(a) any “person” (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), other than a trustee or other fiduciary holding securities of the Company under an employee benefit plan of the Company, becomes the “beneficial owner” (as defined in Rule 13d-3 promulgated under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of (i) the outstanding shares of common stock of the Company or (ii) the combined voting power of the Company’s then-outstanding securities entitled to vote generally in the election of directors; or

(b) the Company (i) is party to a merger, consolidation or exchange of securities which results in the holders of voting securities of the Company outstanding immediately prior thereto failing to continue to hold at least 50% of the combined voting power of the voting securities of the Company, the surviving entity or a parent of the surviving entity outstanding immediately after such merger, consolidation or exchange, or (ii) sells or disposes of all or substantially all of the Company’s assets (or any transaction or combination of transactions having similar effect is consummated), or (iii) the individuals constituting the Board of Directors immediately prior to such merger, consolidation, exchange, sale or disposition shall cease to constitute at least 50% of the Board of Directors, unless the election of each director who was not a director prior to such merger, consolidation, exchange, sale or disposition was approved by a vote of at least two-thirds of the directors then in office who were directors prior to such merger, consolidation, exchange, sale or disposition.

Notwithstanding the foregoing, a transaction will not be considered a Change in Control unless the transaction qualifies as a “change in control” as defined in Treasury Regulation Section 1.409A-3(i)(5)(i).


6.	409A

This Plan is intended to be exempt from the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), pursuant to the short term deferral exemption of Code Section 409A, so that none of the payments or benefits under this Plan, or shares of Company common stock issuable pursuant to this Plan, will be subject

-3-

to the additional tax, penalties or other sanctions imposed under Code Section 409A and this Plan shall in all respects be administered, and any ambiguities herein will be interpreted, to be so exempt. For purposes of Code Section 409A, each payment under this Plan shall be treated as a separate payment. In no event may a Participant, directly or indirectly, designate the calendar year of any payment to be made under this Plan.


7.	162(m)

It is the intent of the Company that the Plan, and all payments made hereunder, satisfy and be interpreted in a manner that, in the case of Participants who are persons whose compensation is subject to Section 162(m), qualify as Performance-Based Compensation under Section 162(m). Any provision, application or interpretation of the Plan inconsistent with this intent to satisfy the requirements of Section 162(m) shall be disregarded. However, notwithstanding anything to the contrary in the Plan, the provisions of the Plan may at any time be bifurcated by the Committee in any manner so that certain provisions of the Plan or any payment intended (or required in order) to satisfy the applicable requirements of Section 162(m) are only applicable to persons whose compensation is subject to the limitations on deductibility of compensation provided under Section 162(m).


8.	Miscellaneous

The Company shall withhold all applicable taxes from any payment paid or benefit provided under the Plan, including any federal, state and local taxes.

Nothing in this Plan shall interfere with or limit in any way the right of the Company to terminate any Participant’s employment or service at any time, with or without cause. Nothing in this Plan should be construed as an employment agreement or create any entitlement to any Participant for any incentive payment or benefit hereunder.

This Plan and all awards shall be construed in accordance with and governed by the laws of the State of Nevada, without regard to its conflict of law provisions.

Payments under this Plan shall be unsecured, unfunded obligations of the Company. To the extent a Participant has any rights under this Plan, the Participant’s rights shall be those of a general unsecured creditor of the Company.

-4-

Exhibit A

Participant Incentive



Name	Title	Target Cash Payment	Value of Restricted Stock Award
John P. McLaughlin	President and Chief Executive Officer	$2,297,190	$984,510
Peter Garcia	Vice President, Chief Financial Officer	$759,229	$325,384
Christopher L. Stone	Vice President, General Counsel and Secretary	$765,310	$327,990
Danny Hart	Vice President, Business Development	$710,500	$304,500
Steffen Pietzke	Controller & Chief Accounting Officer	$233,920	$100,254
Nathan Kryszak	Senior Counsel and Assistant Secretary	$328,020	$140,580

-5-

EX-10.3 4 pdli-201593010qex103.htm REVENUE INTEREST ASSIGNMENT AGREEMENT Exhibit

Exhibit 10.3

Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* * *” and has been filed separately with the Securities and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission.

REVENUE INTEREST ASSIGNMENT AGREEMENT

Dated as of July 28, 2015

between

ARIAD PHARMACEUTICALS, INC.

and

PDL BIOPHARMA, INC.

Table of Contents


ARTICLE I DEFINITIONS	1


Section 1.01	Definitions. 1


ARTICLE II PURCHASE OF ASSIGNED INTERESTS	15


Section 2.01	Purchase. 15


Section 2.02	Payments by the Company. 15


Section 2.03	Closing; Payment of Closing Purchase Price; Closing Deliveries; Payment of Additional Purchase Price. 16


Section 2.04	Make Whole Payments. 17


Section 2.05	No Assumed Obligations. 18


ARTICLE III REPRESENTATIONS AND WARRANTIES OF COMPANY	19


Section 3.01	Organization. 19


Section 3.02	Authorization. 19


Section 3.03	Governmental Authorization. 19


Section 3.04	Ownership. 19


Section 3.05	Financial Statements. 20


Section 3.06	No Undisclosed Liabilities. 20


Section 3.07	Solvency. 21


Section 3.08	Litigation. 21


Section 3.09	Compliance with Laws. 21


Section 3.10	Conflicts. 21


Section 3.11	Subordination. 22


Section 3.12	Intellectual Property. 22


Section 3.13	Regulatory Approval. 24


Section 3.14	Material Contracts. 25


Section 3.15	Place of Business. 25


Section 3.16	Broker’s Fees. 25


Section 3.17	Other Information. 25


Section 3.18	Taxes. 25


ARTICLE IV REPRESENTATIONS AND WARRANTIES OF PURCHASER	26


Section 4.01	Organization. 26


Section 4.02	Authorization. 26


Section 4.03	Broker’s Fees. 26


Section 4.04	Conflicts. 26


ARTICLE V COVENANTS	27


Section 5.01	Consents and Waivers. 27


Section 5.02	Access; Information. 27


Section 5.03	Material Contracts. 28


Section 5.04	Confidentiality; Public Announcement. 29


Section 5.05	Security Agreement. 29


Section 5.06	Efforts; Further Assurance. 30


Section 5.07	Put Option; Call Option. 30


Section 5.08	[Remittance to Deposit Account]. 31


Section 5.09	Intellectual Property. 35


Section 5.10	Protective Covenants. 36


Section 5.11	Insurance. 37


Section 5.12	Notice. 38


Section 5.13	Use of Proceeds. 38


ARTICLE VI TERMINATION	40


Section 6.01	Termination Date. 40


Section 6.02	Effect of Termination. 40


ARTICLE VII MISCELLANEOUS	40


Section 7.01	Survival. 40


Section 7.02	Specific Performance; Limitations on Damages. 41


Section 7.03	Notices. 41


Section 7.04	Successors and Assigns. 42


Section 7.05	Indemnification. 43


Section 7.06	No Implied Representations and Warranties. 44


Section 7.07	Independent Nature of Relationship. 44


Section 7.08	Tax Treatment. 45


Section 7.09	Entire Agreement. 45


Section 7.10	Amendments; No Waivers. 45


Section 7.11	Interpretation. 46


Section 7.12	Headings and Captions. 46


Section 7.13	Counterparts; Effectiveness. 46


Section 7.14	Severability. 46


Section 7.15	Expenses. 46


Section 7.16	Governing Law; Jurisdiction. 46


Section 7.17	Waiver of Jury Trial. 47

EXHIBITS



Exhibit A	–	Form of Security Agreement
Exhibit B	–	Form of Assignment of Interests
Exhibit C		Form of Legal Opinion (Mintz Levin)

REVENUE INTEREST ASSIGNMENT AGREEMENT

This REVENUE INTEREST ASSIGNMENT AGREEMENT (as amended, supplemented or otherwise modified from time to time, this “Agreement”) is made and entered into as of July 28, 2015, by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (“ARIAD” or the “Company”), and PDL BioPharma, Inc., a Delaware corporation (“Purchaser”).

WHEREAS, the Company wishes to obtain financing in respect of the development of its pipeline product Brigatinib and the commercialization of the Product (as hereinafter defined);

WHEREAS, the Company wishes to sell, assign, convey and transfer to Purchaser the Assigned Interests in consideration for its payment of the Purchase Price (as hereinafter defined) to raise such financing;

WHEREAS, the Purchaser wishes to purchase from the Company, the Assigned Interests (as hereinafter defined), all upon and subject to the terms and conditions hereinafter set forth;

NOW, THEREFORE, in consideration of the mutual covenants, agreements representations and warranties set forth herein, the parties hereto agree as follows:

ARTICLE I

DEFINITIONS

Section 1.01 Definitions.

The following terms, as used herein, shall have the following meanings:

“Accounts” shall mean, collectively, the Deposit Account, the Joint Concentration Account, the Company Concentration Account, the Purchaser Concentration Account, and, if applicable, the Brigatinib Divestiture Account, each established and maintained pursuant to the Deposit Agreement.

“Additional Purchase Price” shall mean $50,000,000.

“Additional Product Financing Trigger Event” shall mean the first date on which the Net Revenue for the Product for the immediately preceding four fiscal quarters of the Company and its Subsidiaries, calculated as of the end of any fiscal quarter, exceeds $* * *.

“Additional Purchase Price Closing Date” shall have the meaning set forth in Section 2.03(d).

“Affiliate” shall mean any Person that controls, is controlled by, or is under common control with another Person. For purposes of this definition, “control” shall mean (i) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares having the right to vote for the election of directors, and (ii) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest with the power to direct the management and policies of such non-corporate entities.

“Agreement” shall have the meaning set forth in the first paragraph hereof.

“Allowable Additional Product Financing” shall mean, after the occurrence of an Additional Product Financing Trigger Event, (a) any Indebtedness secured by Liens granted on the Shared Assigned Interest Collateral that is incurred by the Company or any Subsidiary of the Company to any Third Party (other than Purchaser) and (b) any sale of Revenue Interests other than the Assigned Interests by the Company or any Subsidiary of the Company to any Third Party not to exceed * * * percent (* * *%) of the total Revenue Interest; provided, however, that (i) in the case of any such Indebtedness, any such Liens must be granted pari passu with, or junior to, but not senior to, the Liens on the Shared Assigned Interests Collateral granted by the Company to the Purchaser pursuant to this Agreement and the Security Agreement, (ii) the terms of any such Indebtedness or sale shall not conflict in any respect with the terms of the Transaction Documents (including, without limitation, Section 5.08(c)), (iii) the sum of the aggregate principal amount of any such Indebtedness and the aggregate amount of any payments on account of the acceleration of all or a substantial portion of payments, mandatory redemption or repurchase, put or sinking fund or similar payment of any such sale (not including payment of the Revenue Interest itself) shall not exceed $* * *, (iv) in the case of any such Indebtedness, such Indebtedness has a maturity date that is a date (such date, the “Outside Date”) at least 91 days after the latest of (X) the * * * anniversary of the Closing Date, (Y) the * * * anniversary of the payment of the Additional Purchase Price by Purchaser to the Company and (Z) the * * * anniversary of the payment of the final Second Tranche Purchase Price by Purchaser to the Company (and the terms of such Indebtedness shall not provide for any scheduled repayment, mandatory redemption, put or sinking fund obligations prior to the Outside Date (other than customary offers to, or put right to require, repurchase upon a change of control, asset sale or casualty event and customary acceleration rights after an event of default)), (v) in the case of any such sale, (1) such sale shall not provide for any acceleration of all or a substantial portion of payments, mandatory redemption or repurchase, put or sinking fund or similar payment obligation prior to the Outside Date and (2) the Third Party purchaser in any such sale shall have entered into one or more inter-creditor agreements with respect to its rights in the portion of the Revenue Interests it purchased in form and substance reasonably satisfactory to Purchaser, whose consent shall not be unreasonably withheld or delayed and (vi) after giving effect to all such Allowable Additional Product Financings and any working capital revolving loans and equipment financings described in clause (iii) of the definition of Permitted Secured Financings, at least * * *% of the Revenue Interests shall remain unsold and subject to no Liens other than (1) any Lien or agreements in favor of Purchaser granted under or pursuant to this Agreement and the other Transaction Documents; and (2) liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable.

“Allowable Back-up Product Financing” shall mean the incurrence of any Indebtedness secured by Liens granted on the Net Revenue of the Back-up Product that is incurred by the Company or any Subsidiary of the Company to any Third Party; provided, however, that such Indebtedness has a maturity date that is not earlier than the Outside Date (as defined above in the definition of “Allowable Additional Product Financing”) (and the terms of such Indebtedness shall not provide for any scheduled repayment, mandatory redemption, put or sinking fund obligations prior to the Outside Date (other than customary offers to, or put right to require,

repurchase upon a change of control, asset sale or casualty event and customary acceleration rights after an event of default)).

“Applicable Percentage” shall mean, as of any date of determination (i) from the Closing through the Second Drawdown Date, 2.5%, (ii) from the Second Drawdown Date through and including December 31, 2018, 5.0% and (iii) thereafter, 6.5%; provided, however, that Applicable Percentage pursuant to this clause (iii) shall increase to 7.5% if the aggregate Purchase Price paid by the Purchaser exceeds $150,000,000.

“Assigned Interests” shall mean Purchaser’s right to receive amounts equal to the product of the Applicable Percentage multiplied by the worldwide Net Revenues of the Product during the Revenue Interest Period, subject to the Yearly Payment Cap, pursuant to the terms and conditions of this Agreement.

“Assigned Interests Collateral” shall mean the property included in the definition of “Collateral” in the Security Agreement.

“Assignment of Interests” shall mean the Assignment of Interests pursuant to which the Company shall assign to Purchaser all of its rights and interests in and to the Assigned Interests purchased hereunder, which Assignment of Interests shall be substantially in the form of Exhibit B.

“Audit Costs” shall mean, with respect to any audit of the books and records of the Company or its Subsidiaries with respect to amounts payable or paid under this Agreement, the reasonable out-of-pocket cost of such audit, including all fees, costs and expenses incurred in connection therewith.

“Back-up Product” shall mean Brigatinib.

“Back-up Product True-Up Amount” shall have the meaning set forth in Section 5.08(f)(iv).

“Back-up Product True-Up Cap” shall have the meaning set forth in Section 5.08(f)(v).

“Bankruptcy Event” shall mean the occurrence of any of the following:

(a) the Company shall commence any case, proceeding or other action (i) under any existing or future law of any jurisdiction, domestic or foreign, relating to bankruptcy, insolvency, reorganization, relief of debtors or the like, seeking to have an order for relief entered with respect to it, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, winding-up, liquidation, dissolution, composition or other relief with respect to it or its debts, or (ii) seeking appointment of a receiver, trustee, custodian or other similar official for it or for all or any portion of its assets, or the Company shall make a general assignment for the benefit of its creditors;

(b) there shall be commenced against the Company any case, proceeding or other action of a nature referred to in clause (a) above which remains un-dismissed, undischarged or un-bonded for a period of sixty (60) days;

(c) there shall be commenced against the Company any case, proceeding or other action seeking issuance of a warrant of attachment, execution, restraint or similar process against (i) all or a substantial portion of its assets and/or (ii) the Product or a substantial portion of the Intellectual Property related to the Product, which results in the entry of an order for any such relief which shall not have been vacated, discharged, stayed, satisfied or bonded pending appeal within sixty (60) days from the entry thereof;

(d) the failure of the Company to take action to object to any of the acts set forth in clause (b) or (c) above within ten (10) days of the Company receiving written notice of such act;

(e) the Company shall generally not, or shall be unable to, or shall admit in writing its inability to, pay its respective debts as they become due; or

(f) an affirmative vote by the Board to commence any case, proceeding or other action described in clause (a) above.

“Board” shall mean the Board of Directors of the Company.

“Brigatinib” means the compound currently known as brigatinib, also known as AP26113, which is an inhibitor of anaplastic lymphoma kinase and is currently under investigation as a potential treatment for non-small cell lung cancer, regardless of the drug formulation or dosage form that is made with brigatinib and regardless of the indication or purpose for which the drug incorporating brigatinib is ultimately marketed or sold.

“Brigatinib Divestiture Account” shall have the meaning set forth in Section 5.17.

“Brigatinib Divestiture Collateral Amount” shall have the meaning set forth in Section 5.17.

“Brigatinib Divestiture Event” shall have the meaning set forth in Section 5.17.

“Business Day” shall mean any day other than a Saturday, a Sunday, any day which is a legal holiday under the laws of the State of New York, or any day on which banking institutions located in the State of New York are required by law or other governmental action to close.

“Call Closing Date” shall have the meaning set forth in Section 5.07(b).

“Call Option” shall have the meaning set forth in Section 5.07(b).

“Change of Control” shall mean:

(a) the acquisition by any Person or group (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended) of beneficial ownership of any capital stock of the Company, if after such acquisition, such Person or group would be the “beneficial owner” (as defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended), directly or indirectly, of securities of the Company representing more than fifty percent (50%) of the combined voting power of the Company’s then outstanding securities entitled to vote generally in the election of directors;

(b) a merger or consolidation of the Company, with any other Person, other than a merger or consolidation which would result in the Company’s voting securities outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity) more than fifty percent (50%) of the combined voting power of the Company’s voting securities or such surviving entity’s voting securities outstanding immediately after such merger or consolidation; or

(c) the bona fide sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Company or any of its Subsidiaries of all or substantially all the assets of the Company and its Subsidiaries, taken as a whole, or the sale or disposition (whether by merger or otherwise) of one or more Subsidiaries of the Company if substantially all of the assets of the Company and its Subsidiaries, taken as a whole, are held by such Subsidiary or Subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned (direct or indirect) Subsidiary of the Company.

“Closing” shall have the meaning set forth in Section 2.03(a).

“Closing Date” shall have the meaning set forth in Section 2.03(a).

“Closing Purchase Price” shall mean $50,000,000.

“Company” shall have the meaning set forth in the first paragraph hereof.

“Company Concentration Account” shall mean a segregated account established and maintained at the Deposit Bank pursuant to the terms of the Deposit Agreement and this Agreement. The Company Concentration Account shall be the account into which the funds remaining in the Joint Concentration Account after payment therefrom of the amounts payable to Purchaser pursuant to this Agreement are swept in accordance with the terms of this Agreement and the Deposit Agreement.

“Company Indemnified Party” shall have the meaning set forth in Section 7.05(b).

“Confidential Information” shall mean, as it relates to the Company and its Affiliates and the Product, the Intellectual Property, confidential business information, financial data and other like information (including ideas, research and development, know-how, formulas, schematics, compositions, technical data, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals), inventory, ideas, algorithms, processes, computer software programs or applications (in both source code and object code form), client lists and tangible or intangible proprietary information or material, or such other information that either party identifies to the other as confidential or the nature of which or the circumstances of the disclosure of which would reasonably indicate that such information is confidential. Notwithstanding the foregoing definition, Confidential Information shall not include information that (a) is already in the public domain at the time the information is disclosed, (b) thereafter becomes lawfully obtainable from other sources who, to the knowledge of the recipient, have no obligation of confidentiality, (c) can be shown to have been independently developed by the recipient or its representatives without reference to any Confidential Information of the other party, or (d) is required to be disclosed under laws, rules and regulations of any Governmental Authority applicable to the

Company or its Affiliates or the Purchaser or its Affiliates, as the case may be, or pursuant to the rules and regulations of any securities exchange or trading system or pursuant to any other laws, rules or regulations of any Governmental Authority having jurisdiction over the Company and its Affiliates or Purchaser and its Affiliates.

“Daily Amount” shall have the meaning set forth in Section 2.02(b).

“Delinquent Assigned Interests Payment” shall mean, with respect to any Assigned Interests payment and, if owed by the Company to Purchaser, any payment due under Section 5.08(f)(iii) that is not paid when due, an amount equal to the product of the amount so owed multiplied by the lower of (i) the highest rate permitted by applicable law, and (ii) * * * percent (* * *%) per year, compounded annually; provided, however, if Purchaser has Knowledge of a delinquent payment and fails to give notice to the Company of such delinquency, then no interest shall accrue in respect of such delinquent payment until notice is given to the Company or the Company otherwise becomes of aware of such delinquency.

“Deposit Account” shall mean collectively, any deposit and segregated deposit account established and maintained at the Deposit Bank pursuant to a Deposit Agreement and this Agreement. The Deposit Account shall be the account into which all payments made to the Company in respect of the sale of the Product are to be remitted, regardless of whether or not any Allowable Additional Product Financings have been entered into by the Company or any Subsidiary.

“Deposit Agreement” shall mean the agreement to be entered into by a Deposit Bank, ARIAD and Purchaser in accordance with Section 5.08, pursuant to which, among other things, the Deposit Account, the Joint Concentration Account, the Purchaser Concentration Account, the Company Concentration Account and, upon the occurrence of a Brigatinib Divestiture Event, the Brigatinib Divestiture Account shall be established and maintained.

“Deposit Bank” shall mean the bank or financial institution approved by each of Purchaser and the Company in accordance with Section 5.08 that is a party to any Deposit Agreement.

“Dispute” shall have the meaning set forth in Section 3.12(e).

“European Subsidiaries” shall mean ARIAD Pharmaceuticals (Luxembourg) S.a.r.l, ARIAD Pharmaceuticals (Europe) S.a.r.l, ARIAD Pharmaceuticals (Denmark) ApS, ARIAD Pharmaceuticals (Finland) Oy, ARIAD Pharmaceuticals (Germany) GmbH, ARIAD Pharmaceuticals (Benelux) B.V., ARIAD Pharmaceuticals (Spain) S.L.U., ARIAD Pharma (UK) Ltd., ARIAD Pharmaceuticals (Austria) GmbH, ARIAD Pharmaceuticals (France), ARIAD Pharmaceuticals (Italy) S.R.L., ARIAD Pharmaceuticals (Norway) AS, ARIAD Pharma S.A. (Greece), and ARIAD Pharmaceuticals (Nordic) AB.

“Excluded Liabilities and Obligations” shall have the meaning set forth in Section 2.05.

“FDA” shall mean the United States Food and Drug Administration or any successor federal agency thereto.

“Financial Statements” shall mean (a) the audited consolidated balance sheets of the Company and its Subsidiaries as of December 31, 2014, and December 31, 2013, and the related

audited consolidated statements of operations, cash flows and shareholders’ equity for the Fiscal Years then ended and (b) the unaudited consolidated balance sheet of the Company and its Subsidiaries as of March 31, 2015, and the related unaudited consolidated statements of operations, cash flows and shareholders’ equity for the three (3) month period then ended.

“Fiscal Quarter” shall mean each three (3) month period commencing January 1, April 1, July 1 or October 1, provided however that (a) the first Fiscal Quarter of the Term shall extend from the Closing Date to the end of the first full Fiscal Quarter thereafter, and (b) the last Fiscal Quarter of the Term shall end upon the expiration or termination of this Agreement.

“Fiscal Year” shall mean the calendar year.

“GAAP” shall mean generally accepted accounting principles in the United States in effect from time to time.

“Governmental Authority” shall mean any government, court, regulatory or administrative agency or commission, or other governmental authority, agency or instrumentality, whether foreign, federal, state or local (domestic or foreign), including the United States Patent and Trademark Office, the FDA, or the United States National Institutes of Health.

“Gross Product Revenues” means, for any period of determination during the Revenue Interest Period, the amount equal to the sum of the following for such period: (a) the amounts invoiced and recognized as revenue in accordance with GAAP by the Company or its Affiliates with respect to the sale by the Company or its Affiliates of Product to a Third Party (including distributors), (b) to the extent not covered by (a) above, any amounts invoiced and recognized as revenue in accordance with GAAP by the Company or its Affiliates from a Third Party solely with respect to the sale, distribution or other use of the Product by such Third Party (including any royalties received by the Company, but excluding (i) * * *, (ii) * * *, or (iii) * * *), and (c) any collections in respect of write-offs or allowances for bad debts in respect of items described in the preceding clauses (a) and (b); provided, however, that with respect to the use of this definition in the definition of “Quarterly Report” and Section 5.02(f) only, “Gross Product Revenue” shall include revenue with respect to the sale of both the Product and, when and as relevant, the Back-up Product.

“Gross Back-up Product Revenues” shall have the same meaning as “Gross Product Revenues” except shall be determined with respect to the Back-up Product.

“Gross Product Revenues of the Company” shall mean Gross Product Revenues that are owned, invoiced, and recognized as revenue in accordance with GAAP by the Company and its Subsidiaries (other than the European Subsidiaries), which correspond to the Revenue Interest (excluding the European Subsidiaries).

“Indebtedness” shall mean all indebtedness for borrowed money and all obligations issued, undertaken or assumed as the deferred purchase price of property or services.

“Intellectual Property” shall mean all proprietary information; technical data; laboratory notebooks; clinical data; priority rights; trade secrets; know-how; confidential information; inventions (whether patentable or unpatentable and whether or not reduced to practice or claimed in a pending patent application); Patents; registered or unregistered trademarks, trade names, service

marks, including all goodwill associated therewith; registered and unregistered copyrights and all applications thereof; in each case that are owned, controlled by, generated by, issued to, licensed to, licensed by or hereafter acquired by or licensed by the Company or its Subsidiaries, in each case solely relating to the manufacture and sale of the Product.

“IRR” shall mean the internal rate of return calculated on a quarterly basis utilizing the same methodology utilized by the XIRR function in Microsoft Excel.

“Joint Concentration Account” shall mean a segregated account, subject to a control agreement in favor of Purchaser, which shall only be exercisable by Purchaser during the occurrence and continuation of the Security Agreement Remedies Period (as defined in the Security Agreement), established for the benefit of the Company and Purchaser and maintained at the Deposit Bank pursuant to the terms of the Deposit Agreement and this Agreement. The Joint Concentration Account shall be the account into which the Deposit Bank sweeps the funds held in the Deposit Account.

“Knowledge of the Company” shall mean the * * *.

“Knowledge of Purchaser” shall mean the actual knowledge of Purchaser’s * * *, relating to a particular matter.

“License Agreement” shall mean any existing or future license, commercialization, co-promotion, collaboration, distribution, marketing or partnering agreement entered into before or during the Revenue Interest Period by the Company or any of its Affiliates that grants a license to a Third Party under the Intellectual Property covering the Product.

“Licensees” shall mean, collectively, the licensees and any sublicensees under the License Agreements; each a “Licensee”.

“Liens” shall mean all liens, encumbrances, security interests, mortgages, rights to preferential payments or charges of any kind, but excluding any License Agreements.

“Losses” shall mean collectively, any and all claims, damages, losses, judgments, awards, penalties, liabilities, costs and expenses (including reasonable expenses and reasonable attorneys’ fees) incurred in connection with defending any action, suit or proceeding.

“Major Countries” shall mean the United States, Germany, France, Great Britain, Spain, Italy and Japan.

“Make Whole Payment” shall have the meaning set forth in Section 2.04.

“Material Adverse Change” shall mean, with respect to the Company and its Subsidiaries, any event, change, circumstance, occurrence, effect or state of facts that has caused or is reasonably likely to cause a material adverse change in the business, operations, assets or financial condition of the Company and its Subsidiaries, taken as a whole.

“Material Adverse Effect” shall mean (a) the effect of a Material Adverse Change, (b) a material adverse effect on the validity or enforceability of any of the Transaction Documents,

(c) material adverse effect on the ability of the Company to perform any of its material obligations under the Transaction Documents, (d) the inability or failure of the Company to make payment of the Assigned Interests in violation of this Agreement, (e) any material adverse effect on the Product or the ability of the Company and its Subsidiaries to distribute, market and/or sell the Product or (f) any material adverse effect on the Revenue Interests.

“Material Contract” shall mean: (a) any marketing agreement, co-promotion agreement or partnering agreement related to the manufacture, sale or distribution of the Product in any of the Major Countries; or (b) any agreement relating to any material Patent, including any license, assignment, or agreement related to control of such material Patent, in each case, for which breach, non-performance or failure to renew by the Company or its Subsidiaries could reasonably be expected to have a Material Adverse Effect.

“Material Patents” means U.S. Patent Nos. * * *; * * * and * * *; EPO Patent Nos. * * * and EPO Application No. * * *.

“Net Back-up Product Revenues” shall have the same meaning as “Net Revenues” except shall be determined with respect to the Back-up Product.

“Net Revenues” shall mean, for any period of determination, the amount equal to the difference of

(a) Gross Product Revenues for such period, less

(b) The sum, with respect to the items described in clauses (a) and (b) of the definition of Gross Product Revenues, of

(i) * * *;

(ii) * * *,

(iii) * * *,

(iv) * * *,

(v) * * *,

(vi) * * *, and

(vii) * * *.

Net Revenues shall be determined in accordance with GAAP as applied by the Company during the Term; provided that if there is any change in GAAP or its application by the Company during the Term that would reasonably be expected to result in an adverse effect on the Assigned Interests, the Company and Purchaser shall negotiate in good faith to make such adjustments as may be reasonably necessary to compensate PDL based on how such Net Revenues would have been calculated using GAAP as applied by the Company on the date of this Agreement. In

calculating Net Revenues, any transfer from the Company to an Affiliate shall be disregarded and the calculation shall instead be based on the first transfer to a Third Party.

“Net Revenues of the Company” shall mean the Net Revenues of the Product that are invoiced and recognized as revenue in accordance with GAAP by the Company and its Subsidiaries (other than the European Subsidiaries) and shall be calculated based on Gross Product Revenues of the Company and its Subsidiaries (other than the European Subsidiaries).

“Obligations” shall mean any and all obligations of the Company under the Transaction Documents.

“Officer’s Certificate” shall mean the duly executed Officer’s Certificate, dated as of the Closing Date, in form and substance reasonably satisfactory to Purchaser, (W) attaching certified copies of the Company’s organizational documents (together with any and all amendments thereto); (X) attaching certified copies of the resolutions adopted by the Board authorizing and approving the execution, delivery and performance by the Company of this Agreement and the other Transaction Documents and the transactions contemplated herein and therein; (Y) setting forth the incumbency of the officer or officers of the Company who have executed and delivered the Agreement and the Assignment of Interests; and (Z) attaching copies, certified by such officer as true and complete, of a certificate of the appropriate Governmental Authority of the Company’s jurisdiction of formation, stating that the Company is in good standing under the laws of the State of Delaware.

“Outside Date” shall have the meaning set forth in the definition of “Allowable Additional Product Financing”.

“Patents” shall mean all patents, patent rights, patent applications, patent disclosures and invention disclosures issued or filed, together with all reissues, divisions, continuations, revisions, term extensions, substitutes, supplementary protection certificates and reexaminations, including the inventions claimed in any of the foregoing and any priority rights arising therefrom, covering or related to the manufacture, use and sale of the Product that are issued or filed as of the date hereof or during the Term, including, without limitation, those identified in Schedule 3.12(a) in each case, which are owned by the Company, its Subsidiaries or any of its Affiliates.

“Permitted Liens” shall mean (i) Liens created in favor of Purchaser on or after the Closing pursuant to the Security Agreement, the Assignment of Interests, and any other Transaction Document; (ii) liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable, and (iii) any other Liens permitted pursuant to any Permitted Secured Financing.

“Permitted Secured Financings” shall mean, as of any date of determination, (i) the Allowable Additional Product Financing, (ii) the Allowable Back-up Product Financing, (iii) working capital revolving loans and equipment financings secured by the Shared Assigned Interests Collateral in an aggregate principal amount not to exceed $* * *; and (iv) secured financings that are not secured by the Product or Back-up Product or any of the assets or collateral included in the Shared Assigned Interest Collateral; provided that with respect to any of the foregoing set forth in item (i) above that are secured by a security interest in the Shared Assigned Interests Collateral,

Purchaser and all other providers (or any designated agent thereof) of any such Permitted Secured Financing shall have entered into one or more inter-creditor agreements with respect to the Shared Assigned Interests Collateral in form and substance reasonably satisfactory to Purchaser, whose consent shall not be unreasonably withheld or delayed; and provided, further, that with respect to any of the foregoing set forth in item (iv) above, such Indebtedness has a maturity date that is not earlier than the Outside Date (and the terms of such Indebtedness shall not provide for any scheduled repayment, mandatory redemption, put or sinking fund obligations prior to the Outside Date (other than customary offers to, or put right to require, repurchase upon a change of control, asset sale or casualty event and customary acceleration rights after an event of default)).

“Person” shall mean an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, but not including a government or political subdivision or any agency or instrumentality of such government or political subdivision.

“Prior Fiscal Quarter” shall mean the most recent prior Fiscal Quarter for which the Net Revenues of the Product were calculated and reported in a True-Up Statement in accordance with this Agreement.

“Product” shall mean the product currently known as Iclusig, also known as ponatinib hydrochloride, the chemical name for which is 3-(imidazo[1,2-b]pyridazin-3ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide hydrochloride having molecular formula C₂₉H₂₈ClF₃N₆O and marketed and sold by the Company, regardless of the formulation or dosage form of such product and regardless of the indication or purpose for which such product is marketed or sold, and any and all future drug formulations and dosage forms incorporating ponatinib hydrochloride that are developed or licensed by the Company or its Subsidiaries.

“Projected Net Product Revenues” shall mean the projected annual Net Revenues of the Product as listed on Schedule A hereto.

“Purchase Price” shall mean the Closing Purchase Price, the Additional Purchase Price and any Second Tranche Purchase Price.

“Purchaser” shall have the meaning set forth in the first paragraph hereof.

“Purchaser Concentration Account” shall mean a segregated account established for the benefit of Purchaser and maintained at a bank specified in writing by Purchaser pursuant to the terms of the Deposit Agreement and this Agreement. The Purchaser Concentration Account shall be the account into which the funds held in the Joint Concentration Account which are payable to Purchaser pursuant to this Agreement are swept by the Deposit Bank in accordance with the terms of this Agreement and the Deposit Agreement.

“Purchaser Indemnified Party” shall have the meaning set forth in Section 7.05(a).

“Put Option” shall have the meaning set forth in Section 5.07(a).

“Put Option Closing Date” shall have the meaning set forth in Section 5.07(a).

“Put Option Event” shall mean any one of the following events:

(a) any Bankruptcy Event;

(b) any Change of Control of the Company;

(c) any Transfer to a Third Party by the Company or its Subsidiaries of its interest in the Revenue Interests or all or substantially all of its interest in the Product, in each case that results in a reduction of the amount of the Assigned Interests other than in connection with a Permitted Secured Financing or a License Agreement; or

(d) any failure by the Company to pay any amounts due and owing from the Company to Purchaser under this Agreement within * * * days of receipt of written notice from Purchaser of the failure by the Company to make payment of any such amounts, unless such amounts have been validly disputed (and remain in dispute) in the good faith determination of the Company and the Company has delivered written notice to Purchaser within such * * * period detailing such amounts in dispute.

“Put/Call Price” shall mean, as of any date of determination, the greater of (i) (X) an amount that, when paid to Purchaser, would generate an IRR to Purchaser of 10.0% after taking into account the amount and timing of all payments made by Purchaser to the Company pursuant to this Agreement as of the date of payment of the Put/Call Price, and taking into account the amount and timing of all payments made by the Company to Purchaser (and retained by Purchaser) pursuant to this Agreement plus (Y) any Delinquent Assigned Interest Payment owed; and (ii) the multiple of all payments made by Purchaser to the Company as of the date of determination pursuant to this Agreement as set forth below with respect to the period in which such date falls, less the amount of payments already received by Purchaser from the Company pursuant to this Agreement as of such date of determination (excluding any amounts attributable to Delinquent Assigned Interest Payments.)



Period	Multiple
On or prior to the first anniversary of the Closing Date	1.15x
After the first anniversary of the Closing Date through and including the second anniversary of the Closing Date	1.20x
After the second anniversary of the Closing Date and thereafter	1.30x

“Quarterly Report” shall mean, with respect to the relevant Fiscal Quarter of the Company, (a) a report showing Gross Product Revenues for both the Product and the Back-Up Product for such quarter and the adjustments and other reconciliations used to arrive at Net Revenues for such

quarter, reconciled, in each case, to the most applicable line item in the Company’s consolidated statements of operations as most recently filed or to be filed with the Securities and Exchange Commission or furnished to Purchaser pursuant to Section 5.02(f) and (b) a reconciliation of all payments made by the Company to Purchaser pursuant to this Agreement during such quarter, including all amounts deposited into the Purchaser Concentration Account during such quarter.

“Regulatory Agency” shall mean a Governmental Authority with responsibility for the approval of the marketing and sale of pharmaceuticals or other regulation of pharmaceuticals in any Major Country.

“Regulatory Approval” shall mean all approvals (including, without limitation, where applicable, pricing and reimbursement approval and schedule classifications), product and/or establishment licenses, registrations or authorizations of any Governmental Authority necessary for the manufacture, use, storage, import, export, transport, offer for sale, or sale of the Product in a Major Country.

“Revenue Interest Period” shall mean the period from and including the Closing Date through and including December 31, 2033, unless earlier terminated upon (i) Purchaser’s exercise of the Put Option in accordance with Section 5.07(a) or the Company’s exercise of the Call Option in accordance with Section 5.07(b), in each case upon the payment of the Put/Call Price, or (ii) Company’s termination pursuant to Section 6.01.

“Revenue Interests” shall mean all of the interest of the Company and its Subsidiaries in the Gross Product Revenues.

“Second Drawdown Date” shall mean the one-year anniversary of the date hereof.

“Second Tranche Purchase Price” shall have the meaning set forth in Section 2.03(e).

“Second Tranche Purchase Price Closing Date” shall have the meaning set forth in Section 2.03(e).

“Security Agreement” shall mean the Security Agreement between the Company and Purchaser providing for, among other things, the grant by the Company in favor of Purchaser of a valid continuing, perfected lien on and security interest in, the Assigned Interests and the other Assigned Interests Collateral described therein, which Security Agreement shall be substantially in the form of Exhibit A.

“Shared Assigned Interests Collateral” shall mean the Assigned Interests Collateral in which Purchaser and, as applicable, the purchaser or provider of any Permitted Secured Financing has been granted a Lien. For the avoidance of doubt, the Shared Assigned Interests Collateral shall not include the Assigned Interests.

“Subsidiary” shall mean, with respect to any Person, any other Person controlled by such first Person, directly or indirectly, through one or more intermediaries.

“Sweep Percentage” shall mean (i) for the period from the Closing Date through the date of the delivery by the Company to the Purchaser of the first True-Up Statement, * * *%, and (ii)

for any given Fiscal Quarter thereafter, the percentage equal to (i) the Applicable Percentage multiplied by worldwide Net Revenues of the Product for the Prior Fiscal Quarter, divided by (ii) the Net Revenues of the Company with respect to the Product for the Prior Fiscal Quarter. The Sweep Percentage shall be calculated on a quarterly basis and shall be set forth in the True-Up Statement for each Fiscal Quarter.

“Tax” or “Taxes” shall mean any federal, state, local or foreign tax, levy, impost, duty, assessment, fee, deduction or withholding or other charge, including all excise, sales, use, value added, transfer, stamp, documentary, filing, recordation and other fees imposed by any taxing authority (and interest, fines, penalties and additions related thereto).

“Tax Return” shall mean any report, return, form (including elections, declarations, statements, amendments, claims for refund, schedules, information returns or attachments thereto) or other information supplied or required to be supplied to a Governmental Authority with respect to Taxes.

“Term” shall have the meaning set forth in Section 6.01.

“Term Sheet” shall mean the Term Sheet discussed between the Company and Purchaser, on or around June 12, 2015.

“Third Party” shall mean any Person other than the Purchaser or the Company and its Subsidiaries.

“Transaction Documents” shall mean, collectively, this Agreement, the Assignment of Interests, the Security Agreement, the Deposit Agreement, and the Officer’s Certificate.

“Transfer” shall mean any sale, conveyance, assignment, disposition, pledge, hypothecation or transfer.

“True-Up Statement” shall have the meaning set forth in Section 5.08(f)(i).

“UCC” shall mean the Uniform Commercial Code (or any similar or equivalent legislation) as in effect in any applicable jurisdiction.

“UCC Financing Statements” shall mean the UCC-1 financing statements, in form and substance reasonably satisfactory to Purchaser, that shall be filed by Purchaser, with the assistance of the Company as reasonably requested by the Purchaser, at or promptly following the Closing, as well as any additional UCC-1 financing statements or amendments thereto as reasonably requested from time to time, to perfect Purchaser’s security interest in the Assigned Interests Collateral.

“United States” shall mean the United States of America.

“Year-to-Date Applicable Net Revenues” shall have the meaning set forth in Section 5.08(f)(i).

“Yearly Payment Cap” shall have the meaning set forth in Section 2.02(a).

ARTICLE II

PURCHASE OF ASSIGNED INTERESTS

Section 2.01 Purchase.

(a) Upon the terms and subject to the conditions set forth in this Agreement, the Company agrees to sell, assign, transfer and convey to Purchaser, and Purchaser agrees to purchase from the Company, free and clear of all Liens (except Permitted Liens), all of the Company’s rights and interests in and to the Assigned Interests on the Closing Date. Purchaser’s ownership interest in the Assigned Interests so acquired shall vest immediately upon the Company’s receipt of payment of the Closing Purchase Price for such Assigned Interests pursuant to Section 2.03(b), subject to the termination provisions of Section 6.01.

(b) The Company hereby consents to Purchaser recording and filing, at Purchaser’s sole responsibility, cost and expense, the UCC Financing Statements and other financing statements in the appropriate filing offices under the UCC (and continuation statements with respect to such financing statements when applicable) meeting the requirements of applicable law in such manner and in such jurisdictions as are necessary or appropriate to perfect the purchase by Purchaser of the Assigned Interests.

Section 2.02 Payments by the Company.

(a) Payments in Respect of the Applicable Percentage of Net Revenues. In connection with the assignment of the Assigned Interests, Purchaser shall be entitled to receive (i) the Applicable Percentage of worldwide Net Revenues of the Product earned during the Revenue Interest Period; provided however, that the yearly amount required to be paid to Purchaser pursuant to this Section 2.02(a)(i) and Section 2.02(a)(ii) below shall not exceed $20,000,000 in any Fiscal Year for the years ended December 31, 2015, December 31, 2016, December 31, 2017 and December 31, 2018 (in each case, the “Yearly Payment Cap”); (ii) payments in respect of the Back-up Product True-Up Amount as provided in Section 5.08(f) (subject to the Yearly Payment Cap); and (iii) without giving effect to any Yearly Payment Cap, any Delinquent Assigned Interests Payment, as and when due. Except with respect to any Delinquent Assigned Interests Payment, any amounts in excess of the Yearly Payment Cap shall be retained by the Company and shall not be part of the Assigned Interest for that year or any prior or subsequent year(s).

(b) Payments into Deposit Accounts. Commencing on the effective date of the Deposit Agreement, the applicable Sweep Percentage of the cash and cash equivalents deposited into the Deposit Account (subject to the Yearly Payment Cap) shall be swept from the Joint Concentration Account into the Purchaser Concentration Account on a daily basis (the “Daily Amount”) pursuant to Section 5.08. Prior to the establishment of the Deposit Account and Purchaser Concentration Account as contemplated by Section 5.08(a), the Company shall promptly pay to Purchaser upon demand the aggregate Daily Amount.

(c) Payment Procedure. All payments required to be made by the Company under this Agreement (including pursuant to this Section 2.02) shall be the obligations of the Company; provided, however, that the Company will use its best efforts to obtain payment from its Subsidiaries

to the extent necessary for the Company to satisfy all of its monetary Obligations hereunder. Other than payments made pursuant to the Deposit Agreement, any payments to be made by the Company to Purchaser hereunder or under any other Transaction Document shall be made by wire transfer of immediately available funds.

Section 2.03 Closing; Payment of Closing Purchase Price; Closing Deliveries; Payment of Additional Purchase Price.

(a) Closing. The closing of the purchase of the Assigned Interests pursuant to this Agreement (the “Closing”) will take place concurrently with the execution of this Agreement on the date hereof (the “Closing Date”) and will be held at the offices of Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, PC, The Chrysler Center, 666 Third Avenue, New York, NY 10017.

(b) Payment of Closing Purchase Price. At the Closing, Purchaser shall pay to the Company the Closing Purchase Price by wire transfer of immediately available funds to the account designated by the Company prior to the date hereof.

(i) At the Closing, the Company will deliver to Purchaser:

A.Its duly executed counterpart to each of this Agreement, the Assignment of Interests, and the Security Agreement;

B.a duly executed Officer’s Certificate, dated as of the Closing Date; and

C. a legal opinion, including certain customary qualifications, exceptions, limitations and assumptions, reasonably satisfactory to Purchaser from Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC addressing such matters with respect to the Transaction Documents as set forth on Exhibit C hereto.

(ii) At the Closing, the Purchaser will deliver to the Company:

A.Payment of the Purchase Price consistent with Section 2.03(b); and

B.Its duly executed counterpart to each of this Agreement, the Assignment of Interests, and the Security Agreement.

(d) Payment of Additional Purchase Price. On the twelve-month anniversary of the Closing Date (or the first Business Day following such date if such date is not a Business Day) (the “Additional Purchase Price Closing Date”), Purchaser shall pay to the Company the Additional Purchase Price by wire transfer of immediately available funds to the account designated by the Company prior to the date thereof. Such additional purchase price payment shall have no contingencies. The failure by Purchaser to pay the Additional Purchase Price when due in accordance with this Section 2.03(d) shall constitute a material breach of this Agreement and shall give rise to the immediate right of the Company to terminate this Agreement in accordance with Section 6.01.

(e) Payment of Second Tranche Purchase Price. At any time from the six month anniversary to the twelve-month anniversary of the Closing Date (or the first Business Day following such date if such date is not a Business Day), at the election of the Company, Purchaser shall pay to the Company up to $100,000,000 in the aggregate (the “Second Tranche Purchase Price”) in no more than two payments (the first of such payments, the “Initial Second Tranche Payment,” and the last of such payments, the “Final Second Tranche Payment”) on dates specified by the Company within such period (with the first such payment date, the “Initial Second Tranche Closing Date,” the second such payment date, the “Final Second Tranche Closing Date” and either such date, a “Second Tranche Purchase Price Closing Date”) by wire transfer of immediately available funds to the account designated by the Company prior to the date thereof; provided, the Company shall provide a written request to Purchaser for any such payment of the Second Tranche Purchase Price at least 30 days prior to any Second Tranche Purchase Price Closing Date. Any such payment of the Second Tranche Purchase Price shall have no contingencies. The failure by Purchaser to pay Second Tranche Purchase Price when due in accordance with this Section 2.03(e) shall constitute a material breach of this Agreement and shall give rise to the immediate right of the Company to terminate this Agreement in accordance with Section 6.01.

Section 2.04 Make Whole Payments.

Notwithstanding any provision in this Agreement or any other writing to the contrary, in the event the Purchaser has not received (i) payments pursuant to this Agreement (excluding any payments attributable to Delinquent Assigned Interest Payments) equal to or greater than the Closing Purchase Price by the fifth anniversary of the Closing Date, (ii) if the Initial Second Tranche Closing Date occurred prior to the Additional Purchase Price Closing Date, payments pursuant to this Agreement (excluding any payments attributable to Delinquent Assigned Interest Payments) equal to or greater than the Closing Purchase Price plus the Initial Second Tranche Payment by the fifth anniversary of the Initial Second Tranche Closing Date, (iii) if the Final Second Tranche Closing Date occurred prior to the Additional Purchase Price Closing Date, payments pursuant to this Agreement (excluding any payments attributable to Delinquent Assigned Interest Payments) equal to or greater than the Closing Purchase Price, plus the Initial Second Tranche Payment, plus the Final Second Tranche Payment by the fifth anniversary of the Final Second Tranche Closing Date, or (iv) payments pursuant to this Agreement (excluding any payments attributable to Delinquent Assigned Interest Payments) equal to or greater than the Closing Purchase Price, plus the Initial Second Tranche Payment (if any), plus the Final Second Tranche Payment (if any), plus the Additional Purchase Price by the fifth anniversary of the Additional Purchase Price Closing Date, the Company shall pay, (A) in the case of item (i), the difference between (X) the Closing Purchase Price, less (Y) the aggregate amount of all proceeds Purchaser has received pursuant to this Agreement (excluding any amounts attributable to Delinquent Assigned Interest Payments) on or prior to the last day of the fifth anniversary of the

Closing Date in payments from the Company under Section 2.02(a) and Section 5.08 in respect of such five year period for which Net Revenues is calculated, (B) in the case of item (ii), the difference between (X) the Closing Purchase Price plus the Initial Second Tranche Payment, less (Y) the aggregate amount of all proceeds Purchaser has received pursuant to this Agreement (excluding any amounts attributable to Delinquent Assigned Interest Payments) on or prior to the last day of the fifth anniversary of the Initial Second Tranche Closing Date in payments from the Company under Section 2.02(a), Section 2.04(A) and Section 5.08, (C) in the case of item (iii), the difference between (X) the Closing Purchase Price plus the Initial Second Tranche Payment plus the Final Second Tranche Payment, less (Y) the aggregate amount of all proceeds Purchaser has received pursuant to this Agreement (excluding any amounts attributable to Delinquent Assigned Interest Payments) on or prior to the last day of the fifth anniversary of the Final Second Tranche Closing Date in payments from the Company under Section 2.02(a), Section 2.04(A), Section 2.04(B) and Section 5.08, and (D) in the case of item (iv), the difference between (X) the Closing Purchase Price plus each additional Second Tranche Purchase Price (if any) plus the Additional Purchase Price, less (Y) the aggregate amount of all proceeds Purchaser has received pursuant to this Agreement on or prior to the last day of the fifth anniversary of the Additional Purchase Price Closing Date in payments from the Company under Section 2.02(a), Section 2.04(A), Section 2.04(B), Section 2.04(C) and Section 5.08, in each case within twenty (20) Business Days of the receipt by Purchaser of the True-Up Statement for the Fiscal Year in which such five year anniversary falls.

Section 2.05 No Assumed Obligations.

Notwithstanding any provision in this Agreement or any other writing to the contrary, Purchaser is acquiring only the Assigned Interests and is not assuming any liability or obligation of the Company or any of its Affiliates of whatever nature, whether presently in existence or arising or asserted hereafter, whether under any Transaction Document or otherwise. All such liabilities and obligations shall be retained by and remain obligations and liabilities of the Company or its Affiliates (the “Excluded Liabilities and Obligations”).

ARTICLE III

REPRESENTATIONS AND WARRANTIES OF COMPANY

For purposes of all the representations and warranties contained in Article III, the term “Product” shall mean the Product and the Back-up Product, as such products currently exist and are marketed (or in the case of the Back-up Product, as currently being developed) in any jurisdiction, and no broader definition shall be implied. The Company hereby represents and warrants to Purchaser, as of the Closing Date, the following:

Section 3.01 Organization.

Each of the Company and its Subsidiaries is a corporation duly incorporated, validly existing and in good standing under the laws of its respective jurisdiction of formation and has all corporate

powers and all licenses, authorizations, consents and approvals required to carry on its respective business as now conducted and as proposed to be conducted in connection with the transactions contemplated by the Transaction Documents. Each of the Company and its Subsidiaries is duly qualified to do business as a foreign corporation and is in good standing in every jurisdiction in which the failure to do so would have a Material Adverse Effect. The Company has no direct or indirect Subsidiaries, other than those set forth on Exhibit 21.1 of the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission.

Section 3.02 Authorization.

The Company has all necessary power and authority to enter into, execute and deliver the Transaction Documents and to perform all of the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder. The Transaction Documents have been duly authorized, executed and delivered by the Company and each Transaction Document constitutes the valid and binding obligation of the Company, enforceable against the Company in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or general equitable principles.

Section 3.03 Governmental Authorization.

The execution and delivery by the Company of the Transaction Documents, and the performance by the Company of its obligations hereunder and thereunder, does not require any notice to, action or consent by, or in respect of, or filing with, any Governmental Authority, except for the filing of the UCC Financing Statements, which are the responsibility of Purchaser.

Section 3.04 Ownership.

(a) The Company owns or holds a valid license under, all of the Intellectual Property and the Regulatory Approvals which it currently purports to own related to the Product free and clear of all Liens (except those Liens created in favor of Purchaser pursuant to the Security Agreement and any liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable), and no license or covenant not to sue under any Intellectual Property has been granted by the Company or any of its Subsidiaries to any Third Party, except as set forth on Schedule 3.04(a). Neither the Company nor any of its Subsidiaries has granted, nor does there exist, any Lien on the Revenue Interests or the Assigned Interests (except those Liens created in favor of Purchaser pursuant to the Security Agreement and any liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable).

(b) The Company and its Subsidiaries, immediately prior to the purchase of the Assigned Interests, owns, and is the sole holder of, all the Revenue Interests and, except as provided in the Material Contracts, owns, and is the sole holder of, and/or has and holds a valid, enforceable and subsisting license to, all of those other assets that are required to produce or receive any payments from any Licensee or payor under and pursuant to, and subject to the terms of any Material Agreement to which they are a Party, in each case free and clear of any and all Liens (other than those Liens created in favor of Purchaser pursuant to the Security Agreement and any liens for taxes or other

governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable). The Company and its Subsidiaries have not transferred, sold, or otherwise disposed of, or agreed to transfer, sell, or otherwise dispose of any portion of the Revenue Interests other than as contemplated by this Agreement. No Person other than the Company and its Subsidiaries has any right to receive the payments payable to the Company or such Subsidiaries on account of the Revenue Interests pursuant to the terms of any License Agreement, other than Purchaser’s rights with respect to the Assigned Interests. The Company has the full right to sell, transfer, convey and assign to Purchaser all of the Company’s rights and interests in and to the Assigned Interests being sold, transferred, conveyed and assigned to Purchaser pursuant to this Agreement without any requirement to obtain the consent of any Person. By the delivery to Purchaser of the executed Assignment of Interests, the Company shall transfer, convey and assign to Purchaser all of the Company’s rights and interests in and to the Assigned Interests being sold, transferred, conveyed and assigned to Purchaser pursuant to this Agreement, free and clear of any Liens (other than those Liens created in favor of Purchaser pursuant to the Security Agreement and any liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable). At the Closing, and upon the delivery of the Assignment of Interests to Purchaser by the Company, Purchaser shall have acquired good and valid rights and interests of the Company in and to the Assigned Interests being sold, transferred, conveyed and assigned to Purchaser pursuant to this Agreement, free and clear of any and all Liens (other than those Liens created in favor of Purchaser pursuant to the Security Agreement).

Section 3.05 Financial Statements.

The Financial Statements are complete and accurate in all material respects, were prepared in conformity with GAAP and present fairly in all material respects the financial position and the financial results of the Company and its Subsidiaries as of the dates and for the periods covered thereby, subject in the case of the unaudited financial statements to the absence of footnotes, year-end adjustments and other supplementary information required by GAAP.

Section 3.06 No Undisclosed Liabilities.

Except for those liabilities (a) identified in the Financial Statements (including the notes thereto) and/or in any current or periodic filing made by the Company with the Securities and Exchange Commission, (b) incurred by the Company in the ordinary course of business since March 31, 2015, or (c) in connection with the Obligations under the Transaction Documents, there are no material liabilities of the Company or its Subsidiaries related to the Product, of any kind whatsoever, whether accrued, contingent, absolute, determined or determinable.

Section 3.07 Solvency.

The Company and its Subsidiaries, taken as a whole, are not insolvent as defined in any statute of the United States Bankruptcy Code or in the fraudulent conveyance or fraudulent transfer statutes of the State of Delaware. Assuming consummation of the transactions contemplated by the Transaction Documents, (a) the present fair saleable value of the Company’s and its Subsidiaries’ assets, taken as a whole, is greater than the total amount of liabilities of the Company and its Subsidiaries as such liabilities mature, (b) the Company and its Subsidiaries, taken as a whole, do not have unreasonably small capital with which to engage in its business, and (c) the Company and

its Subsidiaries, taken as a whole, have not incurred, nor do they have present plans to or intend to incur, debts or liabilities beyond their ability to pay such debts or liabilities as they become absolute and matured.

Section 3.08 Litigation.

Other than as disclosed in any current or periodic filing made by the Company with the Securities and Exchange Commission, there is no (a) action, suit, arbitration proceeding, claim, investigation or other proceeding pending or, to the Knowledge of the Company, threatened against the Company or its Subsidiaries or (b) any governmental inquiry pending or, to the Knowledge of the Company, threatened against the Company or its Subsidiaries, in each case with respect to clauses (a) and (b) above, which, if adversely determined, would question the validity of, or could adversely affect the transactions contemplated by any of the Transaction Documents or could reasonably be expected to have a Material Adverse Effect. There is no action, suit, arbitration proceeding, claim, investigation or other proceeding pending or, to the Knowledge of the Company, threatened against the Company, its Subsidiaries or any other Person relating to the Product, the Intellectual Property, the Regulatory Approvals, the Revenue Interests or the Assigned Interests.

Section 3.09 Compliance with Laws.

Neither the Company nor any of its Subsidiaries (a) is in violation of, has violated, or to the Knowledge of the Company, is under investigation with respect to, and, (b) has been threatened to be charged with or been given notice of any violation of, any law, rule, ordinance or regulation of, or any judgment, order, writ, decree, permit or license entered by any Governmental Authority applicable to the Company, the Assigned Interests or the Revenue Interests which would reasonably be expected to have a Material Adverse Effect.

Section 3.10 Conflicts.

Neither the execution and delivery of any of this Agreement or the other Transaction Documents to which the Company is a party nor the performance or consummation of the transactions contemplated hereby or thereby will: (a) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of: (i) any law, rule, ordinance or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which the Company or its Subsidiaries or any of their respective assets or properties may be subject or bound; or (ii) any contract, agreement, commitment or instrument to which the Company or its Subsidiaries is a party or by which the Company or its Subsidiaries or any of their respective assets or properties is bound or committed; (b) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the articles or certificate of incorporation or bylaws (or other organizational or constitutional documents) of the Company or its Subsidiaries; (c) except for the filing of the UCC Financing Statements required hereunder and filings with the United States Patent and Trademark Office, require any notification to, filing with, or consent of, any Person or Governmental Authority, except such consents that are obtained at or prior to Closing; (d) give rise to any right of termination, cancellation or acceleration of any right or obligation of the Company, its Subsidiaries or any other Person or to a loss of any right to receive the Revenue Interests or the Assigned Interests; or (e) other than

pursuant to the Security Agreement, the Assignment of Interests, or any other Transaction Document, result in the creation or imposition of any Lien on (i) the assets or properties of the Company or its Subsidiaries or (ii) the Assigned Interests, the Revenue Interests, or any other Assigned Interests Collateral, except, in the case of the foregoing clauses (a), (c), (d) or (e), for any such breaches, defaults or other occurrences that would not, individually or in the aggregate, have a Material Adverse Effect.

Section 3.11 Subordination.

The claims and rights of Purchaser created by any Transaction Document in and to the Assigned Interests, the Revenue Interests and any other Assigned Interests Collateral are not subordinated to any creditor of the Company or any other Person.

Section 3.12 Intellectual Property.

(a) For purposes of this Section 3.12 only, the use of the term “Product” shall refer to both the Product and Back-up Product. Schedule 3.12(a) sets forth an accurate, true and complete list of all (i) Patents and utility models, (ii) trade names, registered trademarks, registered service marks, and applications for trademark registration or service mark registration, (iii) registered copyrights and (iv) domain name registrations and websites, in each case with respect to clauses (i), (ii), (iii) and (iv) above in this subsection (a) that the Company owns or licenses and that cover or are or would be used to make, have made, use, sell, have sold, offer for sale, import, develop, promote, market, distribute, manufacture, commercialize or otherwise exploit the Product, including all Material Patents. For each item of Intellectual Property listed on Schedule 3.12(a), the Company has identified (x) the owner and, if licensed from a Third Party, whether the license is exclusive or non-exclusive, (y) the countries in which such listed item is patented or registered or in which an application for Patent or registration is pending and (z) the application number, the Patent number or registration number and the expiration date. The Intellectual Property listed in Schedule 3.12(a) as owned by the Company is exclusively owned by the Company free and clear of any Liens, except for Permitted Liens. The Intellectual Property listed in Schedule 3.12(a) as licensed to the Company is subject to a valid and enforceable license in favor of the Company, free and clear of any Liens, except for Permitted Liens. Each issued Patent and registered trademark listed on Schedule 3.12(a) is subsisting and has not lapsed, expired, been cancelled or become abandoned and, to the Company’s Knowledge, is valid and enforceable. The Patent applications listed in Schedule 3.12(a) have been prosecuted by competent patent counsel in a diligent manner. To the Knowledge of the Company, all Persons relevant to the prosecution of any of the Material Patents or applications related thereto filed in the U.S. have complied with the duty to disclose information and/or the duty of candor owed to the United States Patent and Trademark Office. To the Knowledge of the Company, each of the Material Patents correctly identifies each and every inventor of the claims thereof as determined in accordance with the laws of the jurisdiction in which such Material Patent is issued or pending, and the Company has performed appropriate reasonable inquiry with respect to such inventorship. Each Person who has or has had any rights in or to the Material Patents has executed an agreement assigning his, her or its entire right, title and interest in and to such Material Patents, and the inventions embodied, described and/or claimed therein, to the Company, and to the Knowledge of the Company, no such Person has any contractual or other obligation that would preclude or conflict with any such assignment or otherwise conflict with the obligations of such Person to the Company.

(b) Except for Intellectual Property licensed to or owned by the Company and set forth on Schedule 3.12(a), to the Knowledge of the Company, no other Intellectual Property is necessary to make, have made, offer to sell, sell, have sold, use, import, distribute, commercialize or market the Product in the Major Countries. To the Knowledge of the Company, the use, manufacture, import, export, offer for sale, distribution, marketing and sale of the Product by the Company does not infringe any Patents that are owned by a Third Party in the Major Countries.

(c) The Company has the full right, power and authority to grant all of the rights and interests granted to Purchaser in this Agreement.

(d) There are no unpaid maintenance, annuity or renewal fees currently overdue for any of the issued Patents included in the Material Patents.

(e) There is, and has been, no pending, decided or settled opposition, interference proceeding, reexamination proceeding, cancellation proceeding, injunction, claim, lawsuit, declaratory judgment, administrative post-grant review proceeding, other administrative or judicial proceeding, hearing, investigation, complaint, arbitration, mediation, International Trade Commission investigation, decree, or any other filed claim (other than routine prosecution before the U.S. Patent and Trademark Office) (collectively referred to hereinafter as “Disputes”) related to any of the Material Patents of which the Company has received written notice, nor, to the Knowledge of the Company, has any such Dispute been threatened challenging the legality, validity, enforceability or ownership of any Material Patents. There are no Disputes by any Person or Third Party against the Company, its Licensees or its licensor, and the Company has not received any written notice or claim of any such Dispute as pertaining to the Product. Neither the Company nor its Subsidiaries has sent any notice of any such Dispute to a Third Party. The Company is not subject to any outstanding injunction, judgment, order, decree, ruling, charge, settlement or other disposition of Dispute which relates to the Product or the Material Patents.

(f) There is no pending, or to the Knowledge of the Company threatened, action, suit, or proceeding, or any investigation or claim by any Governmental Authority to which the Company is a party or is the subject (i) that would be the subject of a claim for indemnification by any Person or Third Party under any agreement, or (ii) that the marketing, sale or distribution of the Product worldwide by the Company or its Licensees pursuant to any related License Agreement, as applicable, does or will infringe on any Patent of any other Person.

(g) The Company has taken commercially reasonable measures and precautions to protect and maintain (i) the confidentiality of all trade secret Intellectual Property that it owns and (ii) the value of all Intellectual Property related to the Product, except where such failure to take action would not reasonably be expected to have a Material Adverse Effect.

(h) No material trade secret of the Company has been published or disclosed to any Person except pursuant to a written agreement requiring such Person to keep such trade secret confidential, except where such disclosure would not reasonably be expected to have a Material Adverse Effect.

(i) The Product, or its manufacture or use, is covered by one or more valid and enforceable claims of an issued Patent in the United States.

Section 3.13 Regulatory Approval.

(a) The Company and its Subsidiaries have made available to Purchaser any written reports or other written communications received from a Governmental Authority that would indicate that any Regulatory Agency (A) is likely to revise or revoke any current Regulatory Approval granted by any Regulatory Agency with respect to the Product, or (B) is likely to pursue any material compliance actions against the Company.

(b) The Company and its Subsidiaries possess all Regulatory Approvals issued or required by the appropriate Regulatory Agencies, which Regulatory Approvals are necessary to conduct the current clinical trials relating to the Product, and neither the Company nor its Subsidiaries has received any notice of proceedings relating to the revocation, suspension, termination or modification of any such Regulatory Approvals.

(c) The Company and its Subsidiaries are in compliance with, and has complied with, all applicable federal, state, local and foreign laws, rules, regulations, standards, orders and decrees governing its business, including all regulations promulgated by each Regulatory Agency, the failure of compliance with which could reasonably be expected to result in a Material Adverse Effect; the Company and its Subsidiaries have not received any notice citing action or inaction by any of them that would constitute any non-compliance with any applicable federal, state, local and foreign laws, rules, regulations, or standards, which could reasonably be expected to result in a Material Adverse Effect; and to the Company’s Knowledge, no prospective change in any applicable federal, state, local or foreign laws, rules, regulations or standards has been adopted which, when made effective, would reasonably be expected to result in a Material Adverse Effect.

(d) Preclinical and clinical trials conducted on behalf of the Company or its Subsidiaries relating to the Product were conducted in all material respects in compliance with applicable laws and, in all material respects, in accordance with experimental protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards; the descriptions of the results of such trials provided to Purchaser are complete and accurate in all material respects. Neither the Company nor its Subsidiaries has received any notices or correspondence from any Regulatory Agency or comparable authority requiring the termination, suspension, or material modification or clinical hold of any clinical trials conducted by or on behalf of the Company or its Subsidiaries with respect to the Product, which termination, suspension, material modification or clinical hold could reasonably be expected to result in a Material Adverse Effect.

Section 3.14 Material Contracts.

Schedule 3.14 sets forth all Material Contracts. Neither the Company nor its Subsidiaries is in breach of or in default under any Material Contract, which default, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect. To the Knowledge of the Company, nothing has occurred and no condition exists that would permit any other party thereto to terminate any Material Contract. Neither the Company nor its Subsidiaries has received any notice or, to the Knowledge of the Company, any threat of termination of any such Material Contract. To the Knowledge of the Company, no other party to a Material Contract is in breach of or in default under such Material Contract. All Material Contracts are valid and binding on the

Company or its Subsidiaries and, to the Knowledge of the Company, on each other party thereto, and are in full force and effect.

Section 3.15 Place of Business.

The Company’s principal place of business and chief executive office are set forth on Schedule 3.15.

Section 3.16 Broker’s Fees.

The Company and its Subsidiaries have not taken any action that would entitle any Person to any commission or broker’s fee in connection with this Agreement except fees, commissions and expenses to be paid to Houlihan Lokey Capital, Inc., all of which will be paid by the Company.

Section 3.17 Other Information.

No written statement, information, report or materials prepared by or on behalf of the Company or its Subsidiaries and furnished to Purchaser by or on behalf of the Company or its Subsidiaries in connection with any Transaction Document or any transaction contemplated hereby or thereby, and no written representation, warranty or statement made by the Company or its Subsidiaries in any Transaction Document, and no Schedule or Exhibit hereto or thereto, in each case taken in the aggregate, contains any untrue statement of a material fact or omits any statement of material fact necessary in order to make the statements made therein in light of the circumstances under which they were made not misleading.

Section 3.18 Taxes.

Each of the Company and its Subsidiaries has timely filed (taking into account all extensions of due dates) all material Tax Returns required to be filed by, or on behalf of, it and has timely paid all Taxes required to be paid with such returns. All Tax Returns filed by the Company or its Subsidiaries (or on any of their behalves) have been true, correct and complete in all material respects. Except as set forth on Schedule 3.18, there is no outstanding or, to the Company’s Knowledge, threatened action, claim or other examination or proceeding with respect to Taxes of the Company or any of its Subsidiaries or their assets (including with respect to the Assigned Interests and the Revenue Interests). Except as set forth on Schedule 3.18, there are no Taxes of the Company or any of its Subsidiaries that form or could form, individually or in the aggregate, the basis for a material encumbrance (other than encumbrances for current taxes not yet past due or Permitted Liens) on any of its assets (including the Assigned Interests and the Revenue Interests).

ARTICLE IV

REPRESENTATIONS AND WARRANTIES OF PURCHASER

Purchaser represents and warrants to the Company the following:

Section 4.01 Organization.

Purchaser is a corporation duly incorporated and validly existing under the laws of the State of Delaware.

Section 4.02 Authorization.

Purchaser has all necessary power and authority to enter into, execute and deliver the Transaction Documents and to perform all of the obligations to be performed by it hereunder and thereunder and to consummate the transactions contemplated hereunder and thereunder. The Transaction Documents have been duly authorized, executed and delivered by Purchaser and each Transaction Document constitutes the valid and binding obligation of Purchaser, enforceable against Purchaser in accordance with their respective terms, subject, as to enforcement of remedies, to bankruptcy, insolvency, reorganization, moratorium or similar laws affecting creditors’ rights generally or general equitable principles.

Section 4.03 Broker’s Fees.

Purchaser has not taken any action that would entitle any Person to any commission or broker’s fee in connection with the transactions contemplated by the Transaction Documents.

Section 4.04 Conflicts.

Neither the execution and delivery of this Agreement or any other Transaction Document to which Purchaser is a party nor the performance or consummation of the transactions contemplated hereby or thereby will: (a) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, in any material respects any provisions of: (i) any law, rule or regulation of any Governmental Authority, or any judgment, order, writ, decree, permit or license of any Governmental Authority, to which Purchaser or any of its assets or properties may be subject or bound; or (ii) any contract, agreement, commitment or instrument to which Purchaser is a party or by which Purchaser or any of its assets or properties is bound or committed; (b) contravene, conflict with, result in a breach or violation of, constitute a default under, or accelerate the performance provided by, any provisions of the organizational or constitutional documents of Purchaser; or (c) require any notification to, filing with, or consent of, any Person or Governmental Authority, except, in the case of the foregoing clauses (a) or (c), for any such breaches, defaults or other occurrences that would not, individually or in the aggregate, have a material adverse effect on the ability of Purchaser to perform any of its obligations under the Transaction Documents.

ARTICLE V

COVENANTS

From the date hereof through and including the end of the Revenue Interest Period, the following covenants shall apply:

Section 5.01 Consents and Waivers.

The Company shall use its commercially reasonable efforts to obtain and maintain any required consents, acknowledgements, certificates or waivers so that the transactions contemplated by this Agreement or any other Transaction Document may be consummated and shall not result in any default or breach or termination of any of the Material Contracts.

Section 5.02 Access; Information.

(a) License Notices. Subject to any applicable confidentiality restrictions, the Company shall promptly provide Purchaser with copies of any material written notices received or given by the Company or any of its Subsidiaries under any Material Contract, and to the extent the Company is barred from providing Purchaser with copies of such notices due to any applicable confidentiality restrictions, the Company shall (i) inform Purchaser of the existence of such notice accompanied by a written description of the substance contained in such notice and (ii) promptly use commercially reasonable efforts to seek the removal or waiver of any such confidentiality restrictions so as to permit a free exchange of information with the Purchaser regarding the substance of such notice. The Company shall promptly notify Purchaser of any breaches or alleged breaches under any Material Contracts and of any other events with respect to any Material Contract or the subject matter thereof which could reasonably be expected to have a Material Adverse Effect.

(b) Litigation or Investigations. The Company shall promptly notify Purchaser of (i) any action, demand, suit, claim, cause of action, proceeding or investigation pending or, to the Knowledge of the Company, threatened by or against the Company or any of its Subsidiaries, or (ii) proceeding or inquiry of any Governmental Authority pending or, to the Knowledge of the Company, threatened against the Company or any of its Subsidiaries, related to any Material Contract, the Product, the Material Patents or any Transaction Document.

(c) Maintenance of Books and Records. During the Term, the Company shall keep and maintain, or cause to be kept and maintained, at all times full and accurate books of account and records adequate to correctly reflect all payments paid and/or payable with respect to the Revenue Interests and Assigned Interests and all deposits made into the applicable deposit accounts.

(d) Inspection Rights. Purchaser shall have the right, once a year, to designate a Third Party independent public accounting firm (the “Purchaser Representative”) to visit the Company and its Subsidiaries’ offices and properties where the Company and its Subsidiaries keep and maintain their books and records relating or pertaining to the Revenue Interests, the Assigned Interests and the other Assigned Interests Collateral for purposes of conducting an audit of such books and records, and to inspect and audit such books and records, during normal business hours, and, upon five (5) Business Days’ written notice given by Purchaser to the Company, the Company will provide such Purchaser’s Representative reasonable access to such books and records, and shall permit the Purchaser Representatives to discuss the business, operations, properties and financial and other condition of the Company or any of its Affiliates including, but not limited to, matters relating or pertaining to the Revenue Interests, the Assigned Interests and the other Assigned Interests Collateral with officers of the Company and with the Company’s independent certified public accountants.

(e) Audit Costs. In the event any audit of the books and records of the Company and its Subsidiaries relating to the Revenue Interests, Assigned Interests, and the other Assigned Interests Collateral by Purchaser and/or any of Purchaser’s representatives reveals that the amounts paid to Purchaser hereunder for the period of such audit have been understated by more than five percent (5%) of the amounts determined to be due for the period subject to such audit, then the Audit Costs in respect of such audit shall be borne by the Company; and in all other cases, such Audit Costs shall be borne by Purchaser.

(f) Quarterly Reports. During the Term, the Company shall, promptly after the end of each Fiscal Quarter of the Company (but in no event later than forty-five (45) days following the end of such quarter), produce and deliver to Purchaser a Quarterly Report for such quarter, together with a certificate of the Company, certifying that to the Knowledge of the Company (i) such Quarterly Report is a true and complete copy and (ii) any statements and any data and information therein prepared by the Company are true, correct and accurate in all material respects.

(g) Periodic Reports. In the event that the Company is not subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, the Company shall deliver to Purchaser the following financial statements:

(i) Within forty-five (45) days after the end of each Fiscal Quarter, copies of the unaudited consolidated financial statements of the Company and its Subsidiaries for such Fiscal Quarter; and

(ii) Within ninety (90) days after the end of each Fiscal Year, copies of the audited consolidated financial statements of the Company and its Subsidiaries for such Fiscal Year.

Section 5.03 Material Contracts.

The Company shall comply, and shall cause each of its Subsidiaries to comply, with all terms and conditions of and fulfill all of its obligations under all the Material Contracts to which it is a Party, except for such noncompliance which would not reasonably be expected to give rise to a Material Adverse Effect. The Company shall not, and shall cause its Subsidiaries not to, amend the payment rate or payment amount that it is entitled to receive under any Material Contract or issue any consents or other approvals under any Material Contract that would change the payment rate or alter the timing of the payment amount or otherwise affect the Revenue Interests payable to Purchaser hereunder without the prior written consent of Purchaser (not to be unreasonably withheld, conditioned, or delayed), except where such amendment or consent would not reasonably be expected to give rise to a Material Adverse Effect.

Section 5.04 Confidentiality; Public Announcement.

(a) All Confidential Information furnished by Purchaser to the Company or by the Company to Purchaser in connection with this Agreement and any other Transaction Document and the transactions contemplated hereby and thereby, as well as the terms, conditions and provisions of this Agreement and any other Transaction Document, shall be kept confidential by the Company and Purchaser. Notwithstanding the foregoing, the Company and Purchaser may disclose such Confidential Information to their partners, directors, employees, managers, officers, investors, bankers, advisors, trustees and representatives, provided that such Persons shall be informed of the confidential nature of such information and shall be obligated to keep such information confidential pursuant to the terms of this Section 5.04(a), or as may otherwise be required by applicable law. The Company will consult with Purchaser, and Purchaser will consult with the Company, on the form, content and timing of any such disclosures of Confidential Information, including, without limitation, any disclosures made pursuant to applicable securities laws or made to investment or other analysts.

(b) Each Party is a publicly traded company and has certain disclosure obligations under the U.S. securities laws and the rules and regulations of the U.S. Securities Exchange Commission. In addition to any disclosures required by applicable law, each Party may issue a press release announcing the transactions set forth in the Transaction Documents. Prior to issuing any such press release, each Party shall provide the other Party with an advance copy of press release and provide a reasonable opportunity (not to exceed two Business days) for the other Party to comment thereon. The Party issuing the press release shall give reasonable consideration in good faith to any reasonable comments provided by the other Party. Except as required by applicable law or by the rules and regulations of any securities exchange or trading system or the FDA, taxing authority or any Governmental Authority with similar regulatory authority, or except with the prior written consent of the other party (which consent shall not be unreasonably withheld), no party shall issue any other press release or make any other public disclosure containing Confidential Information with respect to the transactions contemplated by this Agreement or any other Transaction Document.

Section 5.05 Security Agreement.

During the Revenue Interest Period, except as permitted by Section 7.18, the Company shall, at all times until the Obligations are paid and performed in full, grant in favor of Purchaser a valid, continuing, first perfected lien on and security interest in the Assigned Interests and the other Assigned Interests Collateral described in the Security Agreement.

Section 5.06 Efforts; Further Assurance.

(a) Subject to the terms and conditions of this Agreement, each of Purchaser and the Company will use its commercially reasonable efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary under applicable laws and regulations to consummate the transactions contemplated by this Agreement and any other Transaction Document. Purchaser and the Company agree to execute and deliver such other documents, certificates, agreements and other writings (including any financing statement filings requested by Purchaser) and to take such other actions as may be reasonably necessary in order to consummate or implement expeditiously the transactions contemplated by this Agreement and any other Transaction Document and to vest in Purchaser good, valid and marketable rights and interests in and to the Assigned Interests, which are, as of the Closing, free and clear of all Liens, except for (i) Liens created in favor of Purchaser on or after the Closing pursuant to the Security Agreement, the Assignment of Interests, and any other Transaction Document, and (ii) liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable.

(b) Purchaser and the Company shall execute and deliver such additional documents, certificates and instruments, and perform such additional acts, as may be reasonably requested and necessary or appropriate to carry out and effectuate all of the provisions of this Agreement and any other Transaction Document and to consummate all of the transactions contemplated by this Agreement and any other Transaction Document. In the event that the Company or any of its Affiliates enters into any license, commercialization, co-promotion, collaboration, distribution, marketing or partnering agreement before or during the Revenue Interest Period that grants a license with respect to the Intellectual Property covering the Product to any Subsidiary of the Company that is incorporated or organized under the laws of the United States, any state thereof or the District of Columbia, at least 10 Business Days prior to the consummation of any such transaction, the

Company shall give Purchaser written notice thereof and will prior to such consummation cause any such Subsidiary to execute and deliver to Purchaser a joinder agreement and other documents reasonably requested and satisfactory to Purchaser in order to cause such Subsidiary to become a party to the applicable Transaction Documents as if such Subsidiary was a party thereto as of the date hereof.

(c) Purchaser and the Company shall cooperate and provide assistance as reasonably requested by the other party in connection with any Third Party litigation, arbitration or other Third Party proceeding (whether threatened, existing, initiated, or contemplated prior to, on or after the date hereof) to which any party hereto or any of its officers, directors, shareholders, agents or employees is or may become a party or is or may become otherwise directly or indirectly affected or as to which any such Persons have a direct or indirect interests, in each case relating to this Agreement, any other Transaction Document, the Assigned Interests or any other Assigned Interests Collateral, or the transactions described herein or therein.

Section 5.07 Put Option; Call Option.

(a) Put Option. In the event that a Put Option Event shall occur during the Term, Purchaser shall have the right, but not the obligation (the “Put Option”), exercisable within sixty (60) days of the later of (i) Purchaser’s receipt of written notice from the Company of the Put Option Event or (ii) Purchaser’s discovery that a Put Option Event has occurred (other than, in either case, with respect to a Bankruptcy Event or a Put Option Event pursuant to clause (d) of said definition, which shall be exercisable immediately by the Purchaser), to require the Company to repurchase from Purchaser the Assigned Interests at the Put/Call Price. In the event Purchaser elects to exercise its Put Option, Purchaser shall deliver written notice to the Company specifying the closing date which date shall be forty-five (45) days from such notice date (the “Put Option Closing Date”), which notice must be given within sixty (60) days of Purchaser’s receipt of written notice from the Company of a Put Option Event. Failure to provide notice by such times will be deemed an irrevocable waiver of the right to exercise the Put Option. On the Put Option Closing Date, the Company shall repurchase from Purchaser the Assigned Interests at the Put/Call Price in cash, the payment of which shall be made by wire transfer of immediately available funds to the account designated by Purchaser. Notwithstanding anything to the contrary contained herein, immediately upon the occurrence of a Bankruptcy Event, Purchaser shall be deemed to have automatically and simultaneously elected to have the Company repurchase from Purchaser the Assigned Interests for the Put/Call Price in cash and the Put/Call Price shall be immediately due and payable without any further action or notice by any party. Immediately upon exercise by Purchaser of the Put Option and the payment by the Company to Purchaser of the Put/Call Price, Purchaser shall be deemed to have automatically assigned to the Company all right, title, and interest in and to the Assigned Interest.

(b) Call Option. At any time after the Closing Date, the Company shall have the right, but not the obligation (the “Call Option”), exercisable upon ten (10) days’ written notice to

Purchaser, to repurchase the Assigned Interests from Purchaser at a repurchase price equal to the Put/Call Price. In order to exercise the Call Option, the Company shall deliver written notice to Purchaser of its election to so repurchase the Assigned Interests not less than ten (10) days prior to the proposed closing date (the “Call Closing Date”). On the Call Closing Date, the Company shall repurchase from Purchaser the Assigned Interests at the Put/Call Price, the payment of which shall be made by wire transfer of immediately available funds to the account designated by Purchaser. Immediately upon exercise by the Company of the Call Option and the payment by the Company to Purchaser of the Put/Call Price, Purchaser shall be deemed to have automatically assigned to the Company all right, title, and interest in and to the Assigned Interest.

(c) Obligations of Purchaser. In connection with the consummation of a repurchase of the Assigned Interests pursuant to the Put Option or Call Option, Purchaser agrees that it will (i) promptly but no later than three (3) Business Days execute and deliver to the Company such UCC termination statements and other documents as may be necessary to release Purchaser’s Lien on the Assigned Interests Collateral and otherwise give effect to such repurchase and (ii) take such other actions or provide such other assistance as may be necessary to give effect to such repurchase.

Section 5.08 Remittance to Deposit Account.

(a) Within sixty (60) days after the date of this Agreement, the parties hereto shall enter into a deposit agreement in form and substance reasonably satisfactory to the parties hereto and the Deposit Bank (the “Deposit Agreement”), which Deposit Agreement will provide for, among other things, the establishment and maintenance of a Deposit Account, a Joint Concentration Account, a Company Concentration Account and a Purchaser Concentration Account in accordance with the terms herein and therein. Any Purchaser Concentration Account shall be held solely for the benefit of Purchaser, but shall be subject to the terms and conditions of this Agreement, the Security Agreement and the other Transaction Documents. Funds deposited into the Deposit Account shall be swept by the Deposit Bank on a daily basis into the Joint Concentration Account and subsequent thereto on a daily basis, the Daily Amount shall be swept into the Purchaser Concentration Account; provided that once the amount of cash swept into the Purchaser Concentration Account during any of the Fiscal Years ended December 31, 2015, December 31, 2016, December 31, 2017 and December 31, 2018, reaches the Yearly Payment Cap, Deposit Bank shall not make any further sweeps from the Deposit Account into the Joint Concentration Account during the remainder of such Fiscal Year, and shall instead sweep the entirety of funds deposited into the Deposit Account for the balance of such Fiscal Year directly into the Company Concentration Account for immediate and full access by the Company. Purchaser shall have immediate and full access to any funds held in the Purchaser Concentration Account and such funds shall not be subject to any conditions or restrictions whatsoever, subject to Purchaser’s obligations under Section 5.08(f). After the Daily Amount is swept into the Purchaser Concentration Account, the amounts remaining in the Joint Concentration Account shall then be swept, automatically or as otherwise directed by the Company, into the Company Concentration Account. The Company shall have immediate and full access to any funds held in the Company Concentration Account and such funds shall not be subject to any conditions or restrictions whatsoever other than those of the Deposit Bank; provided, however, that nothing herein shall (i) affect or reduce the Company’s obligations to pay in full all amounts due to Purchaser under this Agreement, or (ii) in any manner limit the recourse of Purchaser to the Assigned Interests Collateral in accordance with the Security Agreement.

(b) The Company shall pay all fees, expenses and charges of the Deposit Bank.

(c) Commencing on the Closing Date and thereafter, any and all payments in respect of sales of the Product received by the Company or its Subsidiaries (other than the European Subsidiaries) on account of Gross Product Revenues of the Company shall be deposited into the Deposit Account within two (2) Business Days of the Company’s receipt thereof, regardless of whether or not any Allowable Additional Product Financings have been entered into by the Company or any Subsidiary. In the event (i) the True-Up Statement for the second Fiscal Quarter in any Fiscal Year indicates that the Year-to-Date Net Revenues of the Product are less that * * * percent (* * *%) of the Projected Net Product Revenues set forth on Schedule A for that Fiscal Year or (ii) the True-Up Statement for the third Fiscal Quarter in any Fiscal Year indicates that the Year-to-Date Net Revenues of the Product are less that * * * percent (* * *%) of the Projected Net Product Revenues set forth on Schedule A for that Fiscal Year, the Applicable Percentage of any and all payments in respect of Net Back-up Product Revenues received by the Company (including the Applicable Percentage of any amounts held in the Brigatinib Divestiture Account pursuant to Section 5.17) shall be deposited into the Purchaser Concentration Account within two (2) Business Days of the Company’s receipt of such True-Up Statement, but only until, and to the extent necessary such that, the Back-up Product True-Up Amount due and payable under Section 5.08(f) for that Fiscal Year is paid in full.

(d) With respect to any License Agreement existing on the date hereof (other than License Agreements to which a European Subsidiary is a party and License Agreements that do not call for direct payment to the Company or any Subsidiary of the Company), promptly following the entering into the Deposit Agreement, the Company shall or shall instruct such Subsidiary to instruct any party thereto under such agreement to remit to the Deposit Account when due all applicable payments in respect of Gross Product Revenues of the Company that are due and payable to the Company or such Subsidiary during the Revenue Interest Period, and the Company shall deliver to Purchaser evidence of such instruction and of such applicable party’s agreement thereto. With respect to any License Agreement (other than License Agreements to which a European Subsidiary is a party and License Agreements that do not call for direct payment to the Company or any Subsidiary of the Company) entered into by the Company or any Subsidiary after the Closing Date, the Company shall or shall instruct such Subsidiary to (i) at the time of the execution and delivery of such agreement, instruct any party thereto under such agreement to remit to the Deposit Account when due all applicable payments in respect of Gross Product Revenues of the Company that are due and payable to the Company or such Subsidiary during the Revenue Interest Period, and (ii) deliver to Purchaser evidence of such instruction and of such applicable party’s agreement thereto.

(e) During the Revenue Interest Period and prior to the termination of this Agreement, the Company shall not have any right to terminate the Deposit Agreement without Purchaser’s prior written consent. Any such consent, which Purchaser may grant or withhold in its sole and absolute discretion, shall be subject to the satisfaction of each of the following conditions to the satisfaction of Purchaser:

(i) the successor Deposit Bank shall be acceptable to Purchaser;

(ii) Purchaser, the Company and the successor Deposit Bank shall have entered into a deposit agreement substantially in the form of the Deposit Agreement initially entered into;

(iii) all funds and items in the accounts subject to the Deposit Agreement to be terminated shall be transferred to the new accounts held at the successor Deposit Bank prior to the termination of the then existing Deposit Bank; and

(iv) Purchaser shall have received evidence that all of the applicable parties making payments in respect of sales of the Product have been instructed to remit all future payments in respect of sales of the Product to the new accounts held at the successor Deposit Bank.

(f) True-Up.

(i)Following the end of each Fiscal Quarter, as soon as the Company shall have determined the Applicable Percentage of Net Revenues of the Product for such Fiscal Quarter and for each other Fiscal Quarter in the Fiscal Year in which the then most recently ended Fiscal Quarter occurred (the “Year-to-Date Applicable Net Revenues”) and in any event no later than forty-five (45) days after the end of such Fiscal Quarter (unless such Fiscal Quarter is the last Fiscal Quarter of a Fiscal Year in which case no later than ninety (90) days after the end of such Fiscal Quarter), the Company shall present to Purchaser a certificate of an officer of the Company, in reasonable detail with supporting calculations and information, detailing the Year-to-Date Applicable Net Revenues of the Product (broken down by U.S., Europe, and the rest of world (i.e., global Net Revenues of the Product other than in the U.S. or Europe) (the “True-Up Statement”). The True-Up Statement shall include a calculation of the Net Revenues of the Product for such Fiscal Quarter and for each other Fiscal Quarter in the Fiscal Year in which the then most recently ended Fiscal Quarter occurred, with a reconciliation of such calculation to the Year-to-Date Applicable Net Revenues and the Applicable Percentage of Net Revenues of the Product for such Fiscal Quarter. For purposes of this Section 5.08(f), the first Fiscal Quarter shall comprise the period from the Closing Date through September 30, 2015. The True-Up Statement shall also include the Sweep Percentage that will be applicable to the next successive Fiscal Quarter.

(ii)If Purchaser has received, on or prior to the last day of the most recently ended Fiscal Quarter, payments from the Company under Section 2.02 or this Section 5.08 in respect of the Fiscal Year for which Year-to-Date Applicable Net Revenues is calculated under clause (i) above which are in excess of the Applicable Percentage of Year-to-Date Net Revenues of the Product (after giving effect to the full Yearly Payment Cap (i.e., no quarterly proration)), Purchaser shall pay such excess to the Company within twenty (20) Business Days of receipt by Purchaser of the True-Up Statement.

(iii)If the Applicable Percentage of Year-to-Date Net Revenues of the Product (after giving effect to the full Yearly Payment Cap (i.e., no quarterly proration)) is in excess of the amounts Purchaser has received on or prior to the last day of the most recently ended Fiscal Quarter in respect of the Fiscal Year for which Year-to-Date Applicable Net Revenues is calculated under clause (i) above under Section 2.02 or this Section 5.08, the Company shall pay such excess to Purchaser within twenty (20) Business Days of the receipt by Purchaser of the True-Up Statement.

(iv)Following the end of each Fiscal Year, the True-Up Statement for such Fiscal Year shall also include a calculation of the difference between (A) the Projected Net Product Revenues for that Fiscal Year multiplied by the Applicable Percentage for that Fiscal Year (after giving effect to the full Yearly Payment Cap), and (B) the actual revenues received by Purchaser on account of the Applicable Percentage of the Net Revenues as of the end of Fiscal Year (including any payments received by Purchaser on account of the Back-up Product), after taking into account any true-up adjustments made pursuant to Sections 5.08(f)(ii) or (iii) above, plus any Make-Whole Payment under Section 2.04 received by Purchaser in such Fiscal Year (the “Back-Up Product True-Up Amount”). The Back-up Product True-up Statement shall also include a reconciliation against any remaining amounts held in the Brigatinib Divestiture Account (if applicable) and any debits or sweeps made to or out of such Account.

(v)If the Back-Up Product True-Up Amount calculated pursuant to clause (iv) above is positive for a Fiscal Year, the Company shall pay to Purchaser such Back-up Product True-Up Amount solely to the extent such amount does not exceed the greater of (X) the Applicable Percentage of Net Revenues of Back-up Product for that Fiscal Year and (Y) * * *% of all worldwide Net Sales of the Back-up Product for such Fiscal Year generated by the Company or any of its Affiliates as well as any Third Party, pursuant to any license, commercialization, co-promotion, collaboration, distribution, marketing or partnering agreement (the greater of (X) and (Y) being referred to herein as the “Back-up Product True-Up Cap”). The payment of such Back-up Product True-Up Amount due and owing under Section 5.08(f) shall be satisfied exclusively out of the Net Revenue of the Back-up Product, or in the event of Brigatinib Divestiture Event, exclusively out of the Net Revenue of the Back-up Product and/or the available amounts held in the Brigatinib Divestiture Collateral Account established in accordance with Section 5.17.

(vi)In the event the Net Revenues of the Back-Up Product received by the Company for that Fiscal Year are not sufficient to satisfy payment of the Back-up Product True-Up Amount required to be paid under Section 5.08(f) for that Fiscal Year (taking into account any available amounts then held in the Brigatinib Divestiture Collateral Account), no further amounts shall be due and owing by the Company to Purchaser on account of the Back-up Product True-Up Amount for that Fiscal Year. Any shortfall resulting from the failure of the Net Revenue of the Back-Up Product received by the Company for that Fiscal Year (or the funds available in the Brigatinib Divestiture Account, if applicable) to satisfy payment of the Back-up Product True-Up Amount required to be paid under Section 5.08(f) for that Fiscal Year shall impose no obligation on the Company to make any additional

payment to the Purchaser pursuant to this clause (v), and such deficiency shall not carry over to any subsequent Fiscal Year. Payment of the Back-up Product True-Up Amount required to be paid hereunder shall be made by the Company to Purchaser within fifteen (15) Business Days of receipt by Purchaser of the True-Up Statement for that Fiscal Year.

(vii)If the Back-up Product True-Up Amount calculated pursuant to clause (iv) above is negative, no further payments need be made by the Company to the Purchaser for that Fiscal Year, and any excess payments made by Company to Purchaser in accordance with Section 5.08(c) based on Net Back-up Product Revenues shall be reimbursed to Company by Purchaser within fifteen (15) Business Days of receipt by Purchaser of the True-Up Statement for that Fiscal Year.

Section 5.09 Intellectual Property.

(a) The Company shall, at its sole expense, either directly or by causing any Licensee to do so, take such actions (including taking legal action to specifically enforce the applicable terms of any License Agreement), and prepare, execute, deliver and file any and all agreements, documents or instruments which are necessary to diligently maintain the Material Patents. The Company shall ensure that all patent applications corresponding to the Material Patents are diligently prosecuted with the intent to protect the Product. In the exercise of its reasonable business discretion, the Company shall use commercially reasonable efforts to diligently defend or assert such Intellectual Property and such Material Patents against infringement or interference by any other Persons, and against any claims of invalidity or unenforceability, in the Major Countries (including, without limitation, by bringing any legal action for infringement or defending any counterclaim of invalidity or action of a Third Party for declaratory judgment of non-infringement or non-interference, including timely bringing an action in response to a certification made by an applicant under paragraph IV of clause (vii) of 21 U.S.C. §355(j)(2)(A) with respect to an Abbreviated New Drug Application). The Company shall not, and shall use its commercially reasonable efforts to cause any Licensee not to, disclaim or abandon, or fail to take any action necessary to prevent the disclaimer or abandonment of, the Material Patents, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect.

(b) In the event that the Company becomes aware that the Product infringes or violates any Third Party’s Intellectual Property, the Company shall, in the exercise of its reasonable business discretion, use commercially reasonable efforts to attempt to secure the right to use such Intellectual Property on behalf of itself and any affected Licensee, as applicable, except where the failure to do so would not reasonably be expected to result in a Material Adverse Effect and shall pay all reasonable costs and amounts associated with obtaining any such license, without any reduction in the Assigned Interests.

(c) The Company shall directly, or through a Licensee, take any and all actions and prepare, execute, deliver and file any and all agreements, documents or instruments that are necessary to secure and maintain, all Regulatory Approvals in the Major Countries.

Section 5.10 Protective Covenants.

(a) The Company shall not, without the prior written consent of the Purchaser:

(i)Forgive, release or compromise any amount owed to the Company or its Subsidiaries and relating to the Assigned Interests outside the ordinary course of business in a manner which would reasonably be expected to result in a Material Adverse Effect on the Assigned Interests;

(ii)Waive, amend, cancel or terminate, exercise or fail to exercise, any of its material rights constituting or relating to the Revenue Interests (including any rights under any License Agreement) outside the ordinary course of business, except where such failure would not reasonably be expected to result in a Material Adverse Effect on the Revenue Interest;

(iii)Amend, modify, restate, cancel, supplement, terminate or waive any material provision relating to the payment rate or payment amount the Company or its Subsidiaries are entitled to receive under any Material Contract, or grant any related consent thereunder, or agree to do any of the foregoing, including, without limitation, entering into any agreement with any Person under the provisions of such Material Contract, (in each case) if such action would result in a reduction of any royalty rate, distribution split or other sales-based payments, up-front payment or milestone payment to the Company thereunder;

(iv)Create, incur, assume or suffer to exist any new Indebtedness (not including Indebtedness incurred for the purpose of paying to Purchaser the Put/Call Price in connection with an exercise of the Put Option or Call Option), other than (i) any Permitted Secured Financings, (ii) unsecured indebtedness so long as it remains unsecured, in an aggregate incremental principal amount not to exceed $* * * at any time outstanding (not including any financings in (iii) below); provided that such Indebtedness has a maturity date that is not earlier than the Outside Date (and the terms of such Indebtedness shall not provide for any scheduled repayment, mandatory redemption, put or sinking fund obligations prior to the Outside Date (other than customary offers to repurchase upon a change of control, asset sale or casualty event and customary acceleration rights after an event of default)) and (iii) any Indebtedness incurred to refinance the Company’s existing 3.625% Convertible Senior Notes due 2019 issued pursuant to the Indenture dated as of June 17, 2014, between the Company and Wells Fargo Bank, National Association, as Trustee; provided that any such refinancing Indebtedness is unsecured and has a maturity date that is not earlier than the Outside Date (and the terms of such Indebtedness shall not provide for any scheduled repayment, mandatory redemption, put or sinking fund obligations prior to the Outside Date (other than customary conversion rights, offers to, or put option to require, repurchase upon a fundamental change, change of control, asset sale or casualty event and customary acceleration rights after an event of default));

(v)Create, incur, assume or suffer to exist any Lien, or exercise any right of rescission, offset, counterclaim or defense, upon or with respect to the Deposit Account, the Joint Concentration Account or the Assigned Interests, or agree to do any of the foregoing, except for (i) any Lien or agreements in favor of Purchaser granted under or pursuant to this Agreement and the other Transaction Documents; and (ii) liens for taxes or other governmental charges arising by operation of law in the ordinary course of business for sums which are not yet due and payable;

(vi)Create, incur, assume or suffer to exist any Lien, or exercise any right of rescission, offset, counterclaim or defense, upon or with respect to the Shared Assigned Interests Collateral, or agree to do any of the foregoing, except for (i) any Lien or agreements in favor of Purchaser granted under or pursuant to this Agreement and the other Transaction Documents; and (ii) any Permitted Liens permitted by clause (ii) and clause (iv) of the definition of Permitted Liens (but, with respect to such clause (iv), only with respect to

Permitted Secured Financings described in clause (i) and clause (iii) of the definition of Permitted Secured Financings); or

(vii)Transfer to any European Subsidiary any additional rights in the Product, the Gross Product Revenues or the Collateral; provided that the Company may transfer to ARIAD Europe, via amendment of the Territory of the ARIAD Europe Buy-in License or similar transaction, Product rights in Israel, Saudi Arabia, and other countries that will be managed by ARIAD Europe, as long as the chronic myelogenous leukemia market in those countries transferred in aggregate (as measured by IMS data) does not exceed * * *% of the global chronic myelogenous leukemia market (measured in U.S. dollars).

Section 5.11 Insurance.

The Company shall (i) maintain the current insurance policies with its current insurance companies or with companies having at the least the same rating from A.M. Best Company, Inc. and (ii) maintain Purchaser as an additional insured party with respect to its general liability and product liability insurance policies.

Section 5.12 Notice.

The Company shall provide Purchaser with written notice as promptly as practicable (and in any event within three (3) Business Days) after becoming aware of any of the following:

(a) any material breach or default by the Company of any covenant, agreement or other provision of this Agreement, or any other Transaction Document;

(b) any representation or warranty made by the Company in any of the Transaction Documents or in any certificate delivered to Purchaser pursuant hereto shall prove to be untrue, inaccurate or incomplete in any material respect on the date as of which made;

(d) the occurrence of a Put Option Event.

Section 5.13 Use of Proceeds.

The Company shall use proceeds received from Purchaser in support of the development of the Back-up Product and development and commercialization of the Product.

Section 5.14 Taxes.

(a) The Company shall timely file (taking into account all extensions of due dates) all Tax Returns required to be filed by it and will pay all Taxes required to be paid with such returns.

(b) Purchaser shall deliver to the Company and the Deposit Bank a properly completed IRS Form W-9 at Closing. The Company shall provide the Purchaser any reasonable assistance it may seek in obtaining an exemption or reduced rate from, or refund of, any U.S. federal withholding tax, if applicable. Neither party shall have any obligation to gross-up or otherwise pay the other party (including any assignee) any amounts with respect to source withholding. The parties

furthermore agree to provide the Deposit Bank or any other party that is a withholding agent for tax purposes any requested documentation necessary to establish an exemption from or reduction of applicable withholding taxes with respect to payments under the Deposit Agreement or this Agreement to the extent it is entitled to do so under the applicable law; and in the event the failure to provide such documentation results in the imposition of withholding, then such withholding shall be attributed to the party responsible for such failure.

Section 5.15 Right of First Negotiation with respect to Allowable Additional Product Financing.

In the event the Company intends, at any time and from time to time after the occurrence of an Allowable Additional Product Financing Trigger Event, to seek to obtain Allowable Additional Product Financing, the Company shall provide to Purchaser written notice (the “Financing Notice”) of such intention prior to engaging in any discussions with any Third Party with respect thereto, which Financing Notice shall include the proposed terms of such Allowable Additional Product Financing. Purchaser shall have two (2) Business Days following receipt of the Financing Notice to provide the Company written notice that it desires to enter into good faith negotiations with the Company regarding providing the Allowable Additional Product Financing. If Purchaser does not provide such written notice, the Company shall be free to negotiate and enter into an Allowable Additional Product Financing with a Third Party. If Purchaser provides such written notice, the Company shall negotiate exclusively, reasonably and in good faith with Purchaser concerning the terms of the Allowable Additional Product Financing for a period of * * * days. In the event the Parties have not executed a binding term sheet for such Allowable Additional Product Financing within such * * *-day period, the Company shall be free to pursue an Allowable Additional Product Financing with one or more Third Parties on any terms, whether or not more favorable, without first coming back to Purchaser.

Section 5.16 Right of First Negotiation with respect to Allowable Back-up Product Financing.

In the event the Company intends, at any time and from time to time after the occurrence of an Allowable Additional Product Financing Trigger Event, to seek to obtain Allowable Back-up Product Financing, the Company shall provide to Purchaser written notice (the “Backup Financing Notice”) of such intention prior to engaging in any discussions with any Third Party with respect thereto, which Backup Financing Notice shall include the proposed terms of such Allowable Back-up Product Financing. Purchaser shall have two (2) Business Days following receipt of the Backup Financing Notice to provide the Company written notice that it desires to enter into good faith negotiations with the Company regarding providing the Allowable Back-up Product Financing. If Purchaser does not provide such written notice, the Company shall be free to negotiate and enter into an Allowable Back-up Product Financing with a Third Party. If Purchaser provides such written notice, the Company shall negotiate exclusively, reasonably and in good faith with Purchaser concerning the terms of the Allowable Back-up Product Financing for a period of * * * days. In the event the Parties have not executed a binding term sheet for such Allowable Back-up Product Financing within such * * *-day period, the Company shall be free to pursue an Allowable Back-up Product Financing with one or more Third Parties on any terms, whether or not more favorable, without first coming back to Purchaser.

Section 5.17 Disposition of Back-up Product.

If, during the Revenue Interest Period, the Company Transfers any of its interest in the Back-up Product to a Third Party (other than in connection with a Permitted Secured Financing or a License Agreement (as defined above, except relating to Brigatinib) (a “Brigatinib Divestiture”), the Company shall, within 30 days of the closing of such Brigatinib Divestiture, create a separate account at the Deposit Bank (the “Brigatinib Divestiture Account”) and deposit into such Brigatinib Divestiture Account an amount equal to * * * percent (* * *%) of the net proceeds received by the Company on account of such Brigatinib Divestiture, subject to a maximum amount equal to the product of (a) the lesser of (i) such percent of the Company’s interest in the Backup Product subject to such Brigatinib Divestiture and (ii) * * *% (provided this percentage shall be * * *%, if the FDA suspends or prohibits sales of the Product), multiplied by (b) the Put/Call Price calculated as of the closing date of such Brigatinib Divestiture. At the end of each Fiscal Quarter thereafter, the Company shall include in the True-up Statement for such Fiscal Quarter a calculation of the Put/Call Price calculated as of the end of such Fiscal Quarter (the “Brigatinib Divestiture Collateral Amount”). Any amounts remaining in the Brigatinib Divestiture Account at the end of such Fiscal Quarter in excess of the Brigatinib Divestiture Collateral Amount shall be swept into the Company Concentration Account as soon as reasonable practicable, but in no event later than two (2) Business Days of Purchaser’s receipt of the True-Up Statement for such Fiscal Quarter.

ARTICLE VI

TERM AND TERMINATION

Section 6.01 Term and Termination Date.

Except as provided in this Section 6.01 and in Section 6.02, this Agreement shall terminate upon expiration of the Revenue Interest Period (the “Term”). If any payments are accrued hereunder on or prior to that date and are required to be made by one of the Parties hereunder, this Agreement shall remain in full force and effect until any and all such payments have been made in full, and (except as provided in Section 6.02) solely for that purpose. In addition, this Agreement shall sooner terminate if the Purchaser shall have exercised the Put Option in accordance with Section 5.07(a) or the Company shall have exercised the Call Option in accordance with Section 5.07(b), in each case upon the payment of the Put/Call Price. In addition, the Company may terminate this Agreement immediately upon Purchaser’s failure to pay the Additional Purchase Price on the Additional Purchase Price Closing Date or the Second Tranche Purchase Price on the Second Tranche Purchase Price Closing Date in accordance with Section 2.03(d) and Section 2.03(e), respectively. Upon expiration or termination of this Agreement in accordance with its terms, all right, title, and interest in and to the Assigned Interest shall automatically revert to Company, and Purchaser will have no further rights in the Assigned Interest, the Back-up Product True-Up Funds, or the Assigned Interest Collateral.

Section 6.02 Effect of Termination.

In the event of the termination of this Agreement pursuant to Section 6.01, this Agreement shall forthwith become void and have no effect without any liability on the part of any party hereto or its Affiliates, directors, officers, stockholders, partners, managers or members other than the provisions of this Section 6.02, Section 5.04, Section 5.05 (provided the Security Agreement and the Deposit Agreement shall each terminate as provided in those respective agreements), and Article VII hereof, which shall survive any termination as set forth in Section 6.01. Nothing contained in this Section 6.02 shall relieve any party from liability for any breach of this Agreement.

ARTICLE VII

MISCELLANEOUS

Section 7.01 Survival.

All representations and warranties made herein and in any other Transaction Document, any certificates or in any other writing delivered pursuant hereto or thereto shall survive the execution and delivery of this Agreement and shall continue to survive until the expiration or termination of this Agreement in accordance with Article VI.

Section 7.02 Specific Performance; Limitations on Damages.

(c) Each of the parties hereto acknowledges that the other party will have no adequate remedy at law if it fails to perform any of its obligations under any of the Transaction Documents. In such event, each of the parties agrees that the other party shall have the right, in addition to any other rights it may have (whether at law or in equity), to specific performance of this Agreement.

(d) Notwithstanding anything to the contrary in this Agreement, in no event shall either party be liable for special, indirect, incidental, punitive or consequential damages of the other party, whether or not caused by or resulting from the actions of such party or the breach of its covenants, agreements, representations or warranties hereunder, even if such party has been advised of the possibility of such damages.

Section 7.03 Notices.

All notices, consents, waivers and communications hereunder given by any party to the other shall be in writing (including facsimile transmission) and delivered personally, by telegraph, telecopy, telex or facsimile, by a recognized overnight courier, or by dispatching the same by certified or registered mail, return receipt requested, with postage prepaid, in each case addressed (with a copy by email):

If to Purchaser to:

PDL BioPharma, Inc.

932 Southwood Blvd.

Incline Village, NV 89451

Attention: General Counsel

Facsimile No.: (775) 832-8501
Email: * * *

with a copy to:

Gibson, Dunn & Crutcher LLP
333 South Grand Avenue
Los Angeles, CA 90071-3197
Attention: Karen Bertero
Facsimile No.: (213) 229-7888
Email: kbertero@gibsondunn.com

If to the Company to:

ARIAD Pharmaceuticals, Inc.

26 Landsdowne Street

Cambridge, MA 02139

Attention: General Counsel

Facsimile No.: (617) 494-8144

with a copy to:

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC

666 Third Avenue

New York, New York 10017

Attention: Richard Gervase, Esq.

Fax: (212) 983-3115

Email: RGervase@Mintz.com

with a copy to:

Houlihan Lokey Capital, Inc.

245 Park Avenue, 17^th Floor

New York, New York 10167

Attention: Lionel Leventhal

Fax: * * *

Email: * * *

or to such other address or addresses as Purchaser or the Company may from time to time designate by notice as provided herein, except that notices of changes of address shall be effective only upon receipt. All such notices, consents, waivers and communications shall: (a) when posted by certified or registered mail, postage prepaid, return receipt requested, be effective three (3) Business Days after dispatch, unless such communication is sent trans-Atlantic, in which case they shall be deemed effective five (5) Business Days after dispatch, (b) when telegraphed, telecopied, telexed or facsimiled, be effective upon receipt by the transmitting party of confirmation of complete transmission, or (c) when delivered by a recognized overnight courier or in person, be effective upon receipt when hand delivered.

Section 7.04 Successors and Assigns.

The provisions of this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns. The Company shall not be entitled to assign any of its obligations and rights under the Transaction Documents without the prior written consent of Purchaser. Solely upon the consent of the Company (which consent may not be unreasonably withheld, delayed or conditioned), Purchaser may assign any of its obligations or rights under the Transaction Documents without restriction other than to another pharmaceutical company; provided, however, that, notwithstanding the foregoing, Purchaser may assign any of its obligations or rights under the Transaction Documents to a pharmaceutical company in connection with a change of control of Purchaser by virtue of a merger, sale or issuance of stock or the sale of all or substantially all of Purchaser’s assets; provided, further, that Purchaser, notwithstanding such assignment, will remain liable under Section 5.08(f) (solely to the extent of any amount subject thereto during the Fiscal Year as of the date of such assignment) and Section 7.05.

Section 7.05 Indemnification.

(a) The Company hereby indemnifies and holds Purchaser and its Affiliates and any of their respective partners, directors, managers, members, officers, employees and agents (each, a “Purchaser Indemnified Party”) harmless from and against any and all Losses (including all Losses in connection with any product liability claims or claims of infringement or misappropriation of any Intellectual Property rights of any Third Parties) incurred or suffered by any Purchaser Indemnified Party arising out of any breach of any representation, warranty or certification made by the Company in any of the Transaction Documents or the True-Up Statement or any breach of or default under any covenant or agreement by the Company pursuant to any Transaction Document or the True-Up Statement, including any failure by the Company to satisfy any of the Excluded Liabilities and Obligations.

(b) Purchaser hereby indemnifies and holds the Company, its Affiliates and any of their respective partners, directors, managers, officers, employees and agents (each, a “Company Indemnified Party”) harmless from and against any and all Losses incurred or suffered by a Company Indemnified Party arising out of any breach of any representation, warranty or certification made by Purchaser in any of the Transaction Documents or any breach of or default under any covenant or agreement by Purchaser pursuant to any Transaction Document.

(c) If any claim, demand, action or proceeding (including any investigation by any Governmental Authority) shall be brought or alleged against an indemnified party in respect of which indemnity is to be sought against an indemnifying party pursuant to the preceding paragraphs, the indemnified party shall, promptly after receipt of notice of the commencement of any such claim, demand, action or proceeding, notify the indemnifying party in writing of the commencement of such claim, demand, action or proceeding, enclosing a copy of all papers served, if any; provided, that the omission to so notify such indemnifying party will not relieve the indemnifying party from any liability that it may have to any indemnified party under the foregoing provisions of this Section 7.05 unless, and only to the extent that, such omission results in the forfeiture of, or has a material adverse effect on the exercise or prosecution of, substantive rights or defenses by the indemnifying party. In case any such action is brought against an indemnified party and it notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled to

participate therein and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, to assume the defense thereof, with counsel reasonably satisfactory to such indemnified party (who shall not, except with the consent of the indemnified party, be counsel to the indemnifying party), and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this Section 7.05 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation. In any such proceeding, an indemnified party shall have the right to retain its own counsel, but the reasonable fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel, (ii) the indemnifying party has assumed the defense of such proceeding and has failed within a reasonable time to retain counsel reasonably satisfactory to such indemnified party or (iii) the named parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interests between them based on the advice of such counsel. It is agreed that the indemnifying party shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the reasonable fees and expenses of more than one separate law firm (in addition to local counsel where necessary) for all such indemnified parties. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding.

(d) Purchaser’s sole remedy shall be to recover any monetary damages associated with a breach, subject to the other terms and provisions contained in this Agreement.

Section 7.06 No Implied Representations and Warranties.

Each party acknowledges and agrees that, other than the representations and warranties specifically contained in any of the Transaction Documents, there are no representations or warranties of either party or any other Person either expressed or implied with respect to the Assigned Interests or the transactions contemplated hereby. Without limiting the foregoing, Purchaser acknowledges and agrees that (a) Purchaser and its Affiliates, together with its and its Affiliates’ representatives, have made their own investigation of the Product and the Intellectual Property and are not relying on any implied warranties or upon any representation or warranty whatsoever as to the future amount or potential amount of the Assigned Interests or as to the creditworthiness of Company and (b) except as expressly set forth in any representation or warranty in a Transaction Document, Purchaser shall have no claim or right to indemnification pursuant to Section 7.05 (or otherwise) with respect to any information, documents or materials furnished to Purchaser, any of its Affiliates, or any of its or its Affiliates’ representatives, including any information, documents or material made available to Purchaser and its Affiliates and its Affiliates’ representatives in any data room, presentation, interview or any other form relating to the transactions contemplated hereby.

Section 7.07 Independent Nature of Relationship.

(a) The relationship between the Company and Purchaser is solely that of seller and purchaser, and neither Purchaser nor the Company has any fiduciary or other special relationship with the other or any of their respective Affiliates. Nothing contained herein or in any other Transaction Document shall be deemed to constitute the Company and Purchaser as a partnership, an association, a joint venture or other kind of entity or legal form for any purposes, including any Tax purposes.

(b) No officer or employee or agent of Purchaser will be located at the premises of the Company or any of its Affiliates, except in connection with an audit performed pursuant to Section 5.02. No officer, manager or employee of Purchaser shall engage in any commercial activity with the Company or any of its Affiliates other than as contemplated herein and in the other Transaction Documents.

(c) The Company and/or any of its Affiliates shall not at any time obligate Purchaser, or impose on Purchaser any obligation, in any manner or respect to any Person not a party hereto.

Section 7.08 Tax Treatment.

The Purchaser and the Company acknowledge (a) that, for U.S. federal income tax purposes, they agree to treat the rights and interests in and to the Assigned Interests that are transferred pursuant to this Agreement as indebtedness subject to the U.S. Treasury Regulations Section 1.1275-4 governing contingent payment debt instruments, (b) that the rights in respect of the Closing Purchase Price, the Additional Purchase Price, and each Second Tranche Purchase Price (if any) represent separate debt instruments for U.S. federal income tax purposes; and (c) that the Purchaser will report original issue discount and interest on each such debt instrument in accordance with the Company’s determination of both the “comparable yield” and the “projected payment schedule” for such debt instrument, which determination shall be subject to the prior good faith consultation by the Company with the Purchaser. For this purpose, the “comparable yield” and the “projected payment schedule” relating to the Assigned Interests may be obtained by contacting the Company at the address set forth in Section 7.03. The parties hereto agree not to take any position that is inconsistent with the provisions of this Section 7.08 on any tax return or in any audit or other administrative or judicial proceeding unless (i) the other parties to this Agreement have consented in writing to such actions, which consent shall not be unreasonably withheld or delayed, or (ii) the party that contemplates taking such an inconsistent position has been advised by nationally recognized counsel or tax advisors in writing that it is more likely than not that there is no "reasonable basis" (within the meaning of Treasury Regulation Section 1.6662- 3(b)(3)) for the position specified in this Section 7.08.

Section 7.09 Entire Agreement.

This Agreement, together with the Exhibits and Schedules hereto (which are incorporated herein by reference), and the other Transaction Documents constitute the entire agreement between the parties with respect to the subject matter hereof and supersede all prior agreements (including the Term Sheet), understandings and negotiations, both written and oral, between the parties with respect to the subject matter of this Agreement. No representation, inducement, promise, understanding, condition or warranty not set forth herein (or in the Exhibits, Schedules or other Transaction Documents) has been made or relied upon by either party hereto. None of this Agreement, nor any provision hereof, is intended to confer upon any Person other than the parties hereto any rights or remedies hereunder.

Section 7.10 Amendments; No Waivers.

(a) This Agreement or any term or provision hereof may not be amended, changed or modified except with the written consent of the parties hereto. No waiver of any right hereunder shall be effective unless such waiver is signed in writing by the party against whom such waiver is sought to be enforced.

(b) No failure or delay by either party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The rights and remedies herein provided shall be cumulative and not exclusive of any rights or remedies provided by law.

Section 7.11 Interpretation.

When a reference is made in this Agreement to Articles, Sections, Schedules or Exhibits, such reference shall be to an Article, Section, Schedule or Exhibit to this Agreement unless otherwise indicated. The words “include”, “includes” and “including” when used herein shall be deemed in each case to be followed by the words “without limitation”. Neither party hereto shall be or be deemed to be the drafter of this Agreement for the purposes of construing this Agreement against one party or the other.

Section 7.12 Headings and Captions.

The headings and captions in this Agreement are for convenience and reference purposes only and shall not be considered a part of or affect the construction or interpretation of any provision of this Agreement.

Section 7.13 Counterparts; Effectiveness.

This Agreement may be executed in two or more counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument. This Agreement shall become effective when each party hereto shall have received a counterpart hereof signed by the other parties hereto. Any counterpart may be executed by facsimile or pdf signature and such facsimile or pdf signature shall be deemed an original.

Section 7.14 Severability.

If any provision of this Agreement is held to be invalid or unenforceable, the remaining provisions shall nevertheless be given full force and effect.

Section 7.15 Expenses.

The Company will pay all of its own fees and expenses in connection with entering into and consummating the transactions contemplated by this Agreement.

Section 7.16 Governing Law; Jurisdiction.

(a) This Agreement shall be governed by, and construed, interpreted and enforced in accordance with, the laws of the state of New York, without giving effect to the principles of conflicts of law thereof.

(b) Any legal action or proceeding with respect to this Agreement or any other Transaction Document may be brought in any state or federal court of competent jurisdiction in the State of New York, County of New York. By execution and delivery of this Agreement, each party hereto hereby irrevocably consents to and accepts, for itself and in respect of its property, generally and unconditionally the non-exclusive jurisdiction of such courts. Each party hereto hereby further irrevocably waives any objection, including any objection to the laying of venue or based on the grounds of forum non conveniens, which it may now or hereafter have to the bringing of any action or proceeding in such jurisdiction in respect of any Transaction Document.

(c) Each party hereto hereby irrevocably consents to the service of process out of any of the courts referred to in subsection (b) of this Section 7.16 in any such suit, action or proceeding by the mailing of copies thereof by registered or certified mail, postage prepaid, to it at its address set forth in this Agreement. Each party hereto hereby irrevocably waives any objection to such service of process and further irrevocably waives and agrees not to plead or claim in any suit, action or proceeding commenced hereunder or under any other Transaction Document that service of process was in any way invalid or ineffective. Nothing herein shall affect the right of a party to serve process on the other party in any other manner permitted by law.

Section 7.17 Waiver of Jury Trial.

Each party hereto hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any action, proceeding, claim or counterclaim arising out of or relating to any Transaction Document or the transactions contemplated under any Transaction Document. This waiver shall apply to any subsequent amendments, renewals, supplements or modifications to any Transaction Document.

Section 7.18 Release of Liens upon Certain Allowable Additional Product Financings.

Upon any sale by the Company or any of its Subsidiaries of Revenue Interests that constitutes an Allowable Additional Product Financing, the security interest granted to Purchaser with respect to the portion of the Revenue Interests sold pursuant thereto shall automatically terminate concurrently with the consummation of such Allowable Additional Product Financing; provided,

however, that such security interest shall be automatically reinstated for the benefit of Purchaser upon the termination of such Allowable Additional Product Financing. In connection therewith, Purchaser agrees, at the request of the Company, and at the sole expense of the Company, to execute and deliver such documents as the Company may reasonably request to evidence such release.

[SIGNATURE PAGE FOLLOWS]

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized officers as of the date first above written.




COMPANY:	ARIAD PHARMACEUTICALS, INC.

		By: /s/ Harvey J. Berger, M.D.
		Name: Harvey J. Berger, M.D. Title: Chairman and Chief Executive Officer


PURCHASER:	PDL BIOPHARMA, INC.

		By: /s/ John P. McLaughlin
		Name: John P. McLaughlin Title: Chief Executive Officer

[Signature Page to Revenue Interest Assignment Agreement]

DISCLOSURE SCHEDULES

The following schedules constitute the disclosure schedules of ARIAD Pharmaceuticals, Inc. (the “Company”) with respect to the Revenue Interest Assignment Agreement (the “Revenue Interest Assignment Agreement”), dated as of July 28, 2015, by and between the Company and PDL BioPharma, Inc. (“Purchaser”). Unless otherwise defined in these disclosure schedules, all capitalized terms used herein have the meanings ascribed to them in the Revenue Interest Assignment Agreement. Nothing in these disclosure schedules, including any attachments hereto, is intended to change the scope of the representations or warranties of the Company contained in the Revenue Interest Assignment Agreement or to create any covenant on the part of the Company. Other than expressly set forth herein, all descriptions of documents herein do not purport to be complete and are qualified by reference to the documents themselves. In no event shall any disclosure schedule hereunder be deemed to constitute an acknowledgement that such disclosure schedule is material to the business or financial condition of the Company unless the representation, warranty or covenant to which such disclosure schedule relates expressly calls for the Company to disclose information that is material to the business or financial condition of the Company, pursuant to Article III of the Revenue Interest Assignment Agreement.

Schedule 1.01

* * *

Schedule 3.04(a)

Licenses to Intellectual Property

* * *

Schedule 3.12(a)

Intellectual Property

The following intellectual property is all owned by the Company:


(i)	PATENTS AND PENDING APPLICATIONS

* * *


(ii)	TRADEMARKS

* * *


(iii)	COPYRIGHTS

None


(iv)	DOMAIN NAMES AND WEBSITES

Domain Names

* * *

Website

* * *

Schedule 3.14

Material Contracts

* * *

Schedule 3.15

Principal Place of Business

26 Landsdowne Street, Cambridge, Massachusetts 02139

Schedule 3.18

Matters Involving Taxes

None.

Exhibit A

Form of Security Agreement

[See attached.]

Exhibit B

Form of Assignment of Interests

[See attached.]

FORM OF ASSIGNMENT OF INTERESTS

ASSIGNMENT OF INTERESTS

This ASSIGNMENT OF INTERESTS (this “Assignment”), dated as of July 28, 2015, is made and entered into by and between ARIAD Pharmaceuticals, Inc., a Delaware corporation (the “Assignor”), and PDL BioPharma, Inc., a Delaware corporation (the “Assignee”).

WHEREAS, the Assignor and the Assignee are parties to that certain Revenue Interest Assignment Agreement, dated even date herewith (the “Revenue Interest Assignment Agreement”), pursuant to which, among other things, the Assignor agrees to sell, assign, transfer and convey to the Assignee, and the Assignee agrees to purchase, acquire and accept from the Assignor, all of the Assignor’s right, title and interest in and to the Assigned Interests, as that term is defined in the Revenue Interest Assignment Agreement, for consideration in the amount and on the terms and conditions provided therein;

WHEREAS, the parties now desire to carry out the purposes of the Revenue Interest Assignment Agreement by the execution and delivery of this instrument evidencing the Assignor’s sale, assignment, transfer and conveyance, and Assignee’s purchase, acquisition and acceptance, of the Assigned Interests; and

WHEREAS, capitalized terms used and not defined herein have the meanings given to them in the Revenue Interest Assignment Agreement.

NOW, THEREFORE, in consideration of the foregoing premises and of other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1.Assignment of Assigned Rights. The Assignor hereby sells, assigns, transfers and conveys to the Assignee free and clear of all Liens (other than Permitted Liens), and the Assignee hereby purchases, acquires and accepts, all of the Assignor’s rights and interest in and to the Assigned Interests on the Closing Date.

2.No Assumption of Obligations. The parties hereto acknowledge that the Assignee is acquiring only the Assigned Interests and is not assuming any debt, liability or other obligation of the Assignor or any of its Affiliates of whatever nature, whether presently existing or hereafter arising or asserted, known or unknown, or fixed or contingent, including, without limitation, the Excluded Liabilities and Obligations.

3.Further Assurances. Each party hereto shall execute, acknowledge and deliver to the other party any and all documents or instruments, and shall take any and all actions, reasonably required by such other party from time to time, to confirm or effect the matters set forth herein, or otherwise to carry out the purposes of the Revenue Interest Assignment Agreement and this Assignment and the transactions contemplated thereby and hereby.

4.Revenue Interest Assignment Agreement. This Assignment is entered into pursuant to, and is subject in all respects to all of the terms, provisions and conditions of, the Revenue Interest Assignment Agreement, and nothing herein shall be deemed to modify any of the representations, warranties, covenants and obligations of the parties thereunder.

5.Interpretation. In the event of any conflict or inconsistency between the terms, provisions and conditions of this Assignment and the Revenue Interest Assignment Agreement, the terms, provisions and conditions of the Revenue Interest Assignment Agreement shall govern.

6.Counterparts; Effectiveness. This Assignment may be executed in counterparts, each of which shall be an original, but all of which together shall constitute one and the same instrument. This Assignment shall become effective when each party hereto shall have received a counterpart hereof signed by the other party hereto. Any counterpart may be executed by facsimile or pdf signature and such facsimile or pdf signature shall be deemed an original.

7.Successors and Assigns. This Assignment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and permitted assigns.

8.Governing Law; Jurisdiction; Service of Process; Waiver of Jury Trial. This Assignment shall be subject to the terms set forth in Section 7.16 and Section 7.17 of the Revenue Interest Assignment Agreement with respect to governing law, jurisdiction, service of process and waiver of trial by jury.

[Signature Page to Follow]

IN WITNESS WHEREOF, the Assignor and the Assignee have caused this Assignment to be duly executed by their respective authorized officers as of the date first above written.




ASSIGNOR:

ARIAD PHARMACEUTICALS, INC.

By:
Name:
Title:

ASSIGNEE:

PDL BIOPHARMA, INC.

By:
Name:
Title:

Exhibit C

Form of Legal Opinion


•	The Company is a corporation validly existing and in corporate good standing under the laws of the State of Delaware.


•	The Company has the corporate power and authority to enter into and perform its obligations under the Transaction Documents to which it is a party, has taken all necessary corporate action to authorize the execution, delivery and performance of such Transaction Documents and has duly executed and delivered such Transaction Documents.


•	Each Transaction Document to which the Company is a party is the valid and binding obligation of the Company, enforceable against the Company in accordance with its terms.

•

The execution and delivery by the Company of the Transaction Documents to which it is a party do not, and the compliance by the Company with its obligations thereunder will not, (i) result in a violation of the Certificate of Incorporation and the Bylaws of the Company, (ii) result in a breach or default under any material agreement of the Company, (iii) result in a violation of any order binding upon the Company or (iv) to our knowledge, result in or require the creation or imposition of any lien or encumbrance upon any assets of the Company under any material agreement of the Company (for the avoidance of doubt, any liens and security interests created pursuant to the Transaction Documents are excluded from this clause), and any material contracts or binding orders may be identified in a backup officer’s certificate from the Company.

•

The execution and delivery by the Company of the Transaction Documents to which it is a party do not, and the compliance by each of the Company with its obligations thereunder will not, require any approval from or filing with any governmental authority of the United States, the State of New York, or the State of Delaware, other than the filings and records contemplated by the Transaction Documents to perfect security interests.

•

The execution and delivery by each of the Company of the Transaction Documents to which it is a party do not, and the compliance by the Company with its obligations thereunder will not, result in any violation of any federal law of the United States, the law of the State of New York or any regulation thereunder, or the law of the State of Delaware or any regulation thereunder, which, in our experience are applicable to, or relevant in connection with, transactions of the type provided for in the Transaction Documents.


•	Neither the Company nor any Subsidiary of the Company is an “investment company” within the meaning of, and subject to regulation under, the Investment Company Act of 1940, as amended.

•

The Security Agreement is effective to create in favor of the Purchaser, as security for the Secured Obligations, as defined in the Security Agreement, a security interest (the “Article 9 Security Interest”) in the Collateral as described in the Security Agreement to the extent that a security interest may be created therein under Article 9 of the New York UCC (the “Article 9 Collateral”).


•	Upon the proper filing of the UCC Financing Statement with the Delaware Secretary of State, the Article 9 Security Interest will be perfected to the extent that a security interest can be perfected by the filing of financing statements pursuant to Article 9 of the Delaware UCC.

•

The Article 9 Security Interest in the Joint Concentration Account (to the extent constituting Collateral as defined in the Security Agreement) and the Article 9 Security Interest in the Purchaser Concentration Account will be perfected by control upon the execution and delivery of the Security Agreement and the Deposit Agreement and will rank prior to any other security interest in the Joint Concentration Account (to the extent constituting Collateral as defined in the Security Agreement) and the Purchaser Concentration Account that is not perfected by control under Article 9 of the New York UCC.

Schedule A

Projected Net Product Revenues



2015	$	—
2016	$	—
2017	$	—
2018	$	—
2019	$	* * *
2020	$	* * *
2021	$	* * *
2022	$	* * *
2023	$	* * *
2024	$	* * *
2025	$	* * *
2026	$	* * *
2027	$	* * *
2028	$	* * *
2029	$	* * *
2030	$	* * *

EX-12.1 5 pdli-201593010qex121.htm RATIO OF EARNINGS TO FIXED CHARGES Exhibit

Exhibit 12.1

PDL BIOPHARMA, INC.

COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES

(Unaudited)

(Amount in thousands, except for ratios)



											For the Nine Months Ended September 30, 2015


	2010		2011		2012		2013		2014
Earnings:
Income before income taxes	$	150,370	$	307,428	$	327,133	$	401,876	$	501,272	$	367,429
Add: fixed charges	43,578		36,153		29,097		24,931		39,274		21,758
Earnings	$	193,948	$	343,581	$	356,230	$	426,807	$	540,546	$	389,187
Fixed Charges:
Interest expense¹	$	43,529	$	36,102	$	29,036	$	24,871	$	39,211	$	21,710
Estimated interest portion of rent expense²	49		51		61		60		63		48
Fixed charges	43,578		$	36,153	$	29,097	$	24,931	$	39,274	$	21,758
Ratio of earnings to fixed charges	4.45		9.50		12.24		17.12		13.76		17.89

_____________________________________

¹ Interest expense includes amortization of debt discount and expenses.

² Represents the estimated portion of operating lease rental expense that is considered by us to be representative of interest and amortization of discount related to indebtedness.

EX-31.1 6 pdli-201593010qex311.htm CERTIFICATION Exhibit

Exhibit 31.1

CERTIFICATIONS

I, John P. McLaughlin, President and Chief Executive Officer, of PDL BioPharma, Inc., certify that:

(1) I have reviewed this Quarterly Report on Form 10-Q of PDL BioPharma, Inc.;

(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

(4) The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(5) The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date:	November 4, 2015

/s/ John P. McLaughlin
John P. McLaughlin President and Chief Executive Officer (Principal Executive Officer)

EX-31.2 7 pdli-201593010qex312.htm CERTIFICATION Exhibit

Exhibit 31.2

CERTIFICATIONS

I, Peter S. Garcia, Vice President and Chief Financial Officer, of PDL BioPharma, Inc., certify that:

(1) I have reviewed this Quarterly Report on Form 10-Q of PDL BioPharma, Inc.;

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.



Date:	November 4, 2015

/s/ Peter S. Garcia
Peter S. Garcia Vice President and Chief Financial Officer (Principal Financial Officer)

EX-32.1 8 pdli-201593010qex321.htm CERTIFICATION Exhibit

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section 1350), John P. McLaughlin, Chief Executive Officer of PDL BioPharma, Inc. (the “Company”), and Peter S. Garcia, Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of their knowledge:

(1) The Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, to which this Certification is attached as Exhibit 32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and

(2) The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: November 4, 2015



	By:
		/s/ JOHN P. MCLAUGHLIN
		John P. McLaughlin
		President and Chief Executive Officer
		(Principal Executive Officer)


	By:
		/s/ PETER S. GARCIA
		Peter S. Garcia
		Vice President and Chief Financial Officer
		(Principal Financial Officer)

_________________________________________

(1)

This certification accompanies the Quarterly Report on Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of PDL BioPharma, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to PDL BioPharma, Inc. and will be retained by PDL BioPharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 9 pdli-20150930.xml XBRL INSTANCE DOCUMENT 0000882104 2015-01-01 2015-09-30 0000882104 2015-10-26 0000882104 2015-07-01 2015-09-30 0000882104 2014-07-01 2014-09-30 0000882104 pdli:Queenetal.patentsMember 2015-01-01 2015-09-30 0000882104 2014-01-01 2014-09-30 0000882104 pdli:Queenetal.patentsMember 2014-07-01 2014-09-30 0000882104 pdli:Queenetal.patentsMember 2014-01-01 2014-09-30 0000882104 pdli:Queenetal.patentsMember 2015-07-01 2015-09-30 0000882104 pdli:AcquiredrightsMember 2014-01-01 2014-09-30 0000882104 pdli:AcquiredrightsMember 2014-07-01 2014-09-30 0000882104 pdli:AcquiredrightsMember 2015-01-01 2015-09-30 0000882104 pdli:AcquiredrightsMember 2015-07-01 2015-09-30 0000882104 2014-12-31 0000882104 2015-09-30 0000882104 2012-12-31 0000882104 2013-03-31 0000882104 pdli:GenentechMember pdli:HerceptinMember 2014-07-01 2014-09-30 0000882104 pdli:ElanMember pdli:TysabriMember 2015-01-01 2015-09-30 0000882104 pdli:ElanMember pdli:TysabriMember 2015-07-01 2015-09-30 0000882104 pdli:DepomedMember pdli:GlumetzaMember 2015-07-01 2015-09-30 0000882104 pdli:GenentechMember pdli:AvastinMember 2015-07-01 2015-09-30 0000882104 pdli:GenentechMember pdli:XolairMember 2014-07-01 2014-09-30 0000882104 pdli:GenentechMember pdli:XolairMember 2014-01-01 2014-09-30 0000882104 pdli:DepomedMember pdli:GlumetzaMember 2015-01-01 2015-09-30 0000882104 pdli:GenentechMember pdli:AvastinMember 2015-01-01 2015-09-30 0000882104 pdli:GenentechMember pdli:HerceptinMember 2014-01-01 2014-09-30 0000882104 pdli:GenentechMember pdli:XolairMember 2015-07-01 2015-09-30 0000882104 pdli:GenentechMember pdli:HerceptinMember 2015-07-01 2015-09-30 0000882104 pdli:GenentechMember pdli:XolairMember 2015-01-01 2015-09-30 0000882104 pdli:DepomedMember pdli:GlumetzaMember 2014-07-01 2014-09-30 0000882104 pdli:GenentechMember pdli:AvastinMember 2014-01-01 2014-09-30 0000882104 pdli:ElanMember pdli:TysabriMember 2014-07-01 2014-09-30 0000882104 pdli:GenentechMember pdli:AvastinMember 2014-07-01 2014-09-30 0000882104 pdli:GenentechMember pdli:HerceptinMember 2015-01-01 2015-09-30 0000882104 pdli:DepomedMember pdli:GlumetzaMember 2014-01-01 2014-09-30 0000882104 pdli:ElanMember pdli:TysabriMember 2014-01-01 2014-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0000882104 pdli:DueMay2015Member 2014-01-01 2014-09-30 0000882104 pdli:February2018NotesMember 2015-01-01 2015-09-30 0000882104 pdli:February2018NotesMember 2015-07-01 2015-09-30 0000882104 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0000882104 pdli:February2018NotesMember 2014-01-01 2014-09-30 0000882104 us-gaap:RestrictedStockMember 2014-07-01 2014-09-30 0000882104 pdli:DueMay2015Member 2015-01-01 2015-09-30 0000882104 pdli:Series2012NotesMember 2014-07-01 2014-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0000882104 pdli:Series2012NotesMember 2014-01-01 2014-09-30 0000882104 pdli:DueMay2015Member 2015-07-01 2015-09-30 0000882104 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0000882104 pdli:Series2012NotesMember 2015-01-01 2015-09-30 0000882104 pdli:DueMay2015Member 2014-07-01 2014-09-30 0000882104 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0000882104 pdli:Series2012NotesMember 2015-07-01 2015-09-30 0000882104 pdli:February2018NotesMember 2014-07-01 2014-09-30 0000882104 pdli:Series2012NotesMember 2015-02-17 0000882104 us-gaap:WarrantMember pdli:May2015NotesMemberMember 2015-07-01 2015-09-30 0000882104 pdli:PurchasedCallOptionsMember pdli:May2015NotesMemberMember 2015-01-01 2015-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2014-07-01 2014-09-30 0000882104 us-gaap:WarrantMember 2014-07-01 2014-09-30 0000882104 pdli:Series2012NotesMember 2014-11-24 0000882104 pdli:May2015NotesMemberMember 2015-05-01 0000882104 pdli:PurchasedCallOptionsMember pdli:May2015NotesMemberMember 2014-07-01 2014-09-30 0000882104 pdli:PurchasedCallOptionsMember pdli:May2015NotesMemberMember 2015-07-01 2015-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2015-01-01 2015-09-30 0000882104 us-gaap:RestrictedStockMember 2014-01-01 2014-09-30 0000882104 us-gaap:WarrantMember pdli:May2015NotesMemberMember 2015-01-01 2015-09-30 0000882104 us-gaap:RestrictedStockMember 2015-07-01 2015-09-30 0000882104 us-gaap:WarrantMember pdli:February2018NotesMember 2015-07-01 2015-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2014-01-01 2014-09-30 0000882104 pdli:PurchasedCallOptionsMember pdli:May2015NotesMemberMember 2014-01-01 2014-09-30 0000882104 pdli:Series2012NotesMember 2014-02-07 0000882104 pdli:DueFebruary2015Member 2013-08-01 0000882104 pdli:PurchasedCallOptionsMember pdli:February2018NotesMember 2015-07-01 2015-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2015-07-01 2015-09-30 0000882104 us-gaap:WarrantMember pdli:May2015NotesMemberMember 2014-01-01 2014-09-30 0000882104 us-gaap:RestrictedStockMember 2015-01-01 2015-09-30 0000882104 pdli:Series2012NotesMember 2015-05-01 2015-05-02 0000882104 us-gaap:RestrictedStockMember 2014-07-01 2014-09-30 0000882104 pdli:AcelRxMember 2015-07-01 2015-09-30 0000882104 pdli:AvingerRoyaltyRightMember 2015-09-30 0000882104 pdli:DepomedMember 2015-01-01 2015-09-30 0000882104 2014-11-06 0000882104 pdli:AcelRxMember 2015-09-18 0000882104 pdli:VBMember 2014-12-31 0000882104 pdli:DepomedMember 2013-10-18 0000882104 pdli:AcelRxMember 2014-12-31 0000882104 pdli:DepomedMember 2014-12-31 0000882104 pdli:ARIADMember 2015-07-28 0000882104 2013-04-18 0000882104 pdli:AvingerRoyaltyRightMember 2013-04-18 0000882104 pdli:ARIADMember 2015-09-30 0000882104 2015-09-22 2015-09-22 0000882104 pdli:UniversityofMichiganMember 2014-12-31 0000882104 pdli:UniversityofMichiganMember 2015-09-30 0000882104 pdli:VBMember 2015-09-30 0000882104 pdli:DepomedMember 2015-09-30 0000882104 pdli:ARIADMember 2014-12-31 0000882104 pdli:ARIADMember 2015-07-01 2015-09-30 0000882104 pdli:AcelRxMember 2015-09-30 0000882104 pdli:VBMember 2015-07-01 2015-09-30 0000882104 us-gaap:NotesReceivableMember pdli:AvingerMember 2013-04-01 2013-04-30 0000882104 pdli:ARIADMember pdli:Tranche1Member 2015-07-28 0000882104 pdli:AvingerRoyaltyRightMember 2014-12-31 0000882104 pdli:AvingerRoyaltyRightMember 2015-09-23 0000882104 pdli:ARIADMember pdli:Tranche3Member 2015-07-28 0000882104 pdli:VBMember 2015-01-01 2015-09-30 0000882104 pdli:VBMember 2014-06-26 0000882104 pdli:ARIADMember pdli:LowMember 2015-07-28 0000882104 pdli:ARIADMember pdli:HighMember 2015-07-28 0000882104 pdli:AvingerRoyaltyRightMember 2015-07-01 2015-09-30 0000882104 pdli:UniversityofMichiganMember 2015-07-01 2015-09-30 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0000882104 pdli:AvingerNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0000882104 pdli:Series2012NotesMember 2014-12-31 0000882104 pdli:WellstatNoteReceivableMember 2015-09-30 0000882104 pdli:LENSARNoteReceivableMember 2015-09-30 0000882104 us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 pdli:KaleoNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0000882104 pdli:DirectFlowMedicalNoteReceivableMember 2014-12-31 0000882104 pdli:ParadigmSpineMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0000882104 pdli:DirectFlowMedicalNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0000882104 pdli:HyperionMember 2014-12-31 0000882104 pdli:February2018NotesMember 2015-09-30 0000882104 pdli:KaleoNoteReceivableMember 2015-09-30 0000882104 pdli:LENSARNoteReceivableMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 pdli:AvingerNoteReceivableMember 2014-12-31 0000882104 pdli:Series2012NotesMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 pdli:WellstatNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0000882104 pdli:DirectFlowMedicalNoteReceivableMember 2015-09-30 0000882104 pdli:February2018NotesMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 pdli:TermLoan.Member 2015-09-30 0000882104 pdli:DueMay2015Member us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 pdli:KaleoNoteReceivableMember 2014-12-31 0000882104 pdli:AvingerNoteReceivableMember 2015-09-30 0000882104 pdli:DueMay2015Member 2014-12-31 0000882104 pdli:WellstatNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0000882104 pdli:ParadigmSpineMember 2014-12-31 0000882104 us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 pdli:HyperionMember 2015-09-30 0000882104 pdli:KaleoNoteReceivableMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 pdli:DirectFlowMedicalNoteReceivableMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 pdli:LENSARNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0000882104 pdli:ParadigmSpineMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0000882104 pdli:HyperionMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 pdli:KaleoNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0000882104 pdli:ParadigmSpineMember us-gaap:FairValueInputsLevel3Member 2014-12-31 0000882104 pdli:February2018NotesMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 pdli:DirectFlowMedicalNoteReceivableMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 pdli:ParadigmSpineMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 pdli:AvingerNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0000882104 pdli:February2018NotesMember 2014-12-31 0000882104 us-gaap:FairValueInputsLevel3Member 2015-09-30 0000882104 pdli:TermLoan.Member us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 pdli:KaleoNoteReceivableMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 pdli:WellstatNoteReceivableMember 2014-12-31 0000882104 pdli:LENSARNoteReceivableMember 2014-12-31 0000882104 pdli:LENSARNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0000882104 pdli:ParadigmSpineMember 2015-09-30 0000882104 us-gaap:FairValueInputsLevel3Member 2014-12-31 0000882104 pdli:LENSARNoteReceivableMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 pdli:DirectFlowMedicalNoteReceivableMember us-gaap:FairValueInputsLevel3Member 2015-09-30 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2014-12-31 0000882104 us-gaap:MoneyMarketFundsMember 2014-12-31 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2015-09-30 0000882104 us-gaap:FairValueInputsLevel1Member 2015-09-30 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel1Member 2015-09-30 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member 2015-09-30 0000882104 us-gaap:EquitySecuritiesMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 us-gaap:MoneyMarketFundsMember 2015-09-30 0000882104 us-gaap:FairValueInputsLevel1Member 2014-12-31 0000882104 us-gaap:EquitySecuritiesMember 2014-12-31 0000882104 us-gaap:EquitySecuritiesMember 2015-09-30 0000882104 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member 2014-12-31 0000882104 2014-10-01 2014-12-31 0000882104 us-gaap:EquitySecuritiesMember 2014-12-31 0000882104 us-gaap:MoneyMarketFundsMember 2015-09-30 0000882104 us-gaap:CashAndCashEquivalentsMember 2014-12-31 0000882104 us-gaap:EquitySecuritiesMember 2015-09-30 0000882104 us-gaap:MoneyMarketFundsMember 2014-12-31 0000882104 us-gaap:CashAndCashEquivalentsMember 2015-09-30 0000882104 pdli:CashFlowHedgesMember 2015-07-01 2015-09-30 0000882104 pdli:CashFlowHedgesMember 2014-07-01 2014-09-30 0000882104 pdli:CashFlowHedgesMember 2015-01-01 2015-09-30 0000882104 pdli:CashFlowHedgesMember 2014-01-01 2014-09-30 0000882104 pdli:EurodollarSellForwardContract1.257Member 2015-09-30 0000882104 pdli:EurodollarSellForwardContract1.259Member 2015-09-30 0000882104 pdli:EurodollarSellForwardContract1.259Member 2014-12-31 0000882104 pdli:EurodollarSellForwardContract1281Member us-gaap:ForeignExchangeForwardMember 2014-12-31 0000882104 pdli:EurodollarSellForwardContract1.260Member 2015-09-30 0000882104 pdli:EurodollarSellForwardContract1.260Member 2014-12-31 0000882104 pdli:EurodollarSellForwardContract1.256Member 2015-09-30 0000882104 pdli:EurodollarSellForwardContract1270Member 2015-09-30 0000882104 pdli:EurodollarSellForwardContract1281Member 2015-09-30 0000882104 pdli:EurodollarSellForwardContract1270Member us-gaap:ForeignExchangeForwardMember 2014-12-31 0000882104 pdli:EurodollarSellForwardContract1.257Member 2014-12-31 0000882104 pdli:EurodollarSellForwardContract1.256Member 2014-12-31 0000882104 pdli:AvingerMember 2015-09-22 2015-09-22 0000882104 pdli:ParadigmSpineMember 2014-02-14 0000882104 pdli:CreditAgreementMember pdli:WellstatDiagnosticsMember 2012-11-02 0000882104 pdli:DurataMember 2014-11-13 2014-11-14 0000882104 pdli:CreditAgreementMember pdli:WellstatDiagnosticsMember 2015-01-01 2015-09-30 0000882104 pdli:CareViewMember 2015-06-26 0000882104 pdli:ParadigmSpineMember 2015-10-28 0000882104 us-gaap:NotesReceivableMember pdli:AvingerMember 2013-04-18 0000882104 pdli:WellstatDiagnosticsMember 2013-08-15 0000882104 us-gaap:NotesReceivableMember pdli:WellstatDiagnosticsMember 2012-03-01 2012-03-31 0000882104 2015-09-14 2015-09-14 0000882104 pdli:AxoGenMember 2014-12-12 0000882104 pdli:RoyaltyAgreementMember pdli:AvingerMember 2013-07-01 2018-04-30 0000882104 pdli:DirectFlowMember 2013-11-04 2013-11-05 0000882104 pdli:KaleoNoteReceivableMember 2014-04-01 0000882104 pdli:WellstatDiagnosticsMember 2015-09-30 0000882104 pdli:DurataMember 2013-10-31 0000882104 pdli:ParadigmSpineMember 2015-01-01 2015-09-30 0000882104 pdli:DirectFlowMember 2013-11-06 0000882104 pdli:RoyaltyAgreementMember pdli:AxoGenMember 2012-10-01 2012-10-31 0000882104 pdli:TranchetwoMember pdli:DurataMember 2013-10-31 0000882104 pdli:AxoGenMember 2015-07-01 2015-09-30 0000882104 2015-09-15 0000882104 pdli:HyperionMember 2013-03-05 0000882104 pdli:CareViewMember 2015-10-07 0000882104 pdli:CreditAgreementMember pdli:WellstatDiagnosticsMember 2013-02-01 2013-02-28 0000882104 pdli:AxoGenMember 2013-08-14 0000882104 pdli:AdditionalLoanMember 2015-09-29 0000882104 pdli:CreditAgreementMember pdli:WellstatDiagnosticsMember 2013-08-13 2013-08-15 0000882104 us-gaap:NotesReceivableMember pdli:WellstatDiagnosticsMember 2012-08-31 0000882104 pdli:AxoGenMember 2015-02-22 2015-02-23 0000882104 pdli:DirectFlowMember 2014-11-10 2014-11-10 0000882104 pdli:ParadigmSpineMember 2015-07-01 2015-09-30 0000882104 2015-05-12 0000882104 pdli:ForbearanceprincipalandinterestMember pdli:WellstatDiagnosticsMember 2013-08-13 2013-08-15 0000882104 2015-10-06 2015-10-06 0000882104 pdli:LENSARMember 2015-05-12 0000882104 pdli:AdditionalLoanMember pdli:LENSARMember 2013-10-02 2013-10-03 0000882104 pdli:DirectFlowMember 2014-11-09 0000882104 pdli:AxoGenMember 2015-09-30 0000882104 pdli:CreditAgreementMember pdli:WellstatDiagnosticsMember 2013-01-01 2013-01-31 0000882104 us-gaap:NotesReceivableMember pdli:WellstatDiagnosticsMember 2012-03-31 0000882104 pdli:DurataMember 2014-05-27 0000882104 2015-10-07 2015-10-07 0000882104 pdli:AdditionalLoanMember pdli:WellstatDiagnosticsMember 2013-06-28 0000882104 pdli:LENSARMember 2013-10-03 0000882104 pdli:InitialLoanMember pdli:WellstatDiagnosticsMember 2013-08-13 2013-08-15 0000882104 pdli:LENSARMember 2013-10-02 2013-10-03 0000882104 pdli:HyperionMember 2012-01-27 0000882104 pdli:TranchetwoMember pdli:DirectFlowMember 2013-11-06 0000882104 pdli:DurataMember 2013-11-01 2013-11-02 0000882104 pdli:CareViewMember 2015-06-26 2015-06-26 0000882104 pdli:AdditionalLoanMember 2015-05-12 0000882104 pdli:WellstatDiagnosticsMember 2015-01-01 2015-09-30 0000882104 pdli:TermloanandinterestMember pdli:WellstatDiagnosticsMember 2013-08-13 2013-08-15 0000882104 pdli:AxoGenMember 2014-11-13 2014-11-14 0000882104 pdli:ParadigmSpineMember 2015-10-27 2015-10-27 0000882104 pdli:LENSARMember 2015-01-01 2015-09-30 0000882104 pdli:DueMay2015Member 2015-09-30 0000882104 pdli:February2018NotesMember 2014-02-12 0000882104 pdli:TermLoan.Member 2013-10-28 0000882104 pdli:DueMay2015Member 2015-05-01 2015-05-02 0000882104 pdli:PurchasedCallOptionsMember 2015-07-01 2015-09-30 0000882104 pdli:TermLoan.Member us-gaap:BaseRateMember 2015-09-30 0000882104 pdli:February2018NotePurchaseCallOptionMember 2015-09-30 0000882104 pdli:February2018NotesMember 2014-02-10 2014-02-11 0000882104 pdli:Series2012NotesMember 2012-01-01 2012-01-31 0000882104 pdli:Series2012NotesMember 2014-02-04 2014-02-05 0000882104 pdli:Series2012NotesMember 2013-08-01 0000882104 pdli:DueFebruary2015Member 2012-01-31 0000882104 us-gaap:WarrantMember 2015-07-01 2015-09-30 0000882104 pdli:Series2012NotesMember 2014-02-12 0000882104 pdli:DueFebruary2015Member 2012-01-01 2012-01-31 0000882104 us-gaap:WarrantMember 2015-09-30 0000882104 pdli:March2015TermLoanMember us-gaap:BaseRateMember 2015-09-30 0000882104 pdli:Series2012NotesMember 2014-02-06 0000882104 pdli:February2018NotePurchaseCallOptionMember 2014-02-10 2014-02-11 0000882104 2014-10-20 2014-10-20 0000882104 pdli:March2015TermLoanMember 2015-03-30 0000882104 pdli:Series2012NotesMember 2014-10-20 0000882104 pdli:March2015TermLoanMember us-gaap:BaseRateMember 2015-03-30 0000882104 pdli:DueMay2015Member 2015-05-01 0000882104 2014-02-06 0000882104 pdli:February2018NoteWarrantMember 2014-02-04 2014-02-05 0000882104 pdli:DueMay2015Member 2011-05-15 2011-05-16 0000882104 pdli:Series2012NotesMember 2012-01-31 0000882104 pdli:February2018NoteWarrantMember 2015-09-30 0000882104 pdli:DueFebruary2015Member 2015-09-30 0000882104 pdli:Series2012NotesMember 2012-02-29 0000882104 pdli:TermLoan.Member us-gaap:BaseRateMember 2013-10-28 0000882104 us-gaap:WarrantMember 2013-01-01 2013-01-31 0000882104 pdli:DueMay2015Member 2011-05-16 0000882104 pdli:Series2012NotesMember 2014-10-20 2014-10-20 0000882104 pdli:Series2012NotesMember 2015-02-17 2015-02-18 0000882104 pdli:February2018NotesMember 2014-01-01 2014-12-31 0000882104 pdli:Series2012NotesMember 2015-09-30 0000882104 pdli:TermLoan.Member 2015-01-01 2015-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2015-09-30 0000882104 us-gaap:StockCompensationPlanMember 2015-09-30 0000882104 us-gaap:RestrictedStockMember 2014-12-31 0000882104 us-gaap:RestrictedStockMember 2015-09-30 0000882104 us-gaap:StockCompensationPlanMember 2014-12-31 0000882104 us-gaap:StockCompensationPlanMember 2015-01-01 2015-09-30 0000882104 us-gaap:EmployeeStockOptionMember 2014-12-31 0000882104 us-gaap:SubsequentEventMember 2015-10-28 0000882104 us-gaap:SubsequentEventMember 2015-10-27 2015-10-27 0000882104 us-gaap:SubsequentEventMember 2015-10-07 iso4217:USD iso4217:USD xbrli:shares xbrli:pure xbrli:shares false --12-31 Q3 2015 2015-09-30 10-Q 0000882104 163575319 Yes Large Accelerated Filer PDL BIOPHARMA, INC. No Yes 85875000 6000000 15750000 16125000 33000000 7000000 8000000 33000000 0 0 0 33000000 0 0 0.45 0.40 320000 536000 64000 952000 1358000 996000 0 510000 0 435000 1599000 13000 20000000 293687000 69585000 2310000 221792000 229682000 88005000 1827000 139850000 34200000 26200000 240500000 65600000 100000000 -72992000 -19298000 19298000 7900000 40000000 50000000 70000000 20000000 60000000 15000000 40000000 7000000 7000000 75000000 8700000 1.00 P120D 0.05 300000 0.98 1.30 5800000 19300000 10400000 522000 10800000 7200000 200000 0.070 2500000 1200000 0.018 0.075 0.025 0.009 2500000 1300000 5.00 2500000 0.10 0.12 0.12 0.155 0.05 0.155 0.1275 0.140 0.130 0.13 0.135 0.135 0.185 13076000 34760000 9096000 28596000 1800000 25000000 P2Y P8Y 28000 2 32700000 27500000 2 0.75 0.75 1200000 3.03 5.62 1000 1000 8100000 31000000 20800000 -30951000 0 241300000 15500000 100000000 50000000 65000000 15500000 115000000 0.50 P8Y 0.0995 800000 259244000 259244000 0 0 0 176200000 66900000 16100000 384572000 384572000 49900000 65300000 2700000 178200000 71600000 16900000 191800000 20000000 20000000 20000000 4000000 4000000 20000000 20000000 20000000 3000000 3000000

318000

421000

300000

594000

578000

2446000

3293000

8876000

32711000

296000

1139000

10700000

364000

403000

2585000

2988000

2949000

3391000

-119874000

-118540000

52000

1308000

1688000

404000

3852000

4238000

1783000

1830000

1815000

5353000

76000

13473000

9744000

26100000

4000

22200000

26100000

4000

22200000

32700000

42000

475000

29000000

18100000

39000

437000

9000000

11100000

962350000

1020601000

355897000

306688000

487415000

221792000

6379000

259244000

532104000

139850000

7682000

384572000

560000

621000

2310000

1827000

293127000

69585000

1750000

221792000

229061000

88005000

1206000

139850000

2310000

1827000

580000

94302000

281607000

291377000

69585000

221792000

227855000

88005000

139850000

221792000

139850000

187305000

-63522000

0.45

4400000

8500000

500000

800000

0.00

0.60

0.00

0.60

0.01

350000000

162186000

163573000

162186000

163573000

1622000

1636000

104940000

271668000

68135000

232663000

0.14

0.10

0.24

0.06

0.13

0.09

0.25

0.06

-0.10

0.11

0.32

0.10

0.00

0.10

0.28

0.08

276228000

281581000

155300000

10000000

169000000

1000000

300000000

131700000

26000000

22300000

155100000

276228000

281581000

175496000

157600000

20300000

1800000

1300000

5200000

2100000

26000000

5.44

10.3610

6.40

9.17

109.1048

P2Y4M5D

2016-12-31

155050000

300000000

22337000

300000000

50000000

180000000

300000000

48300000

22300000

155100000

0.069

0.0375

0.0209

0.0222

0.02875

0.01

0.040

0.0075

2015-05-01

2018-02-01

2015-02-15

2016-02-15

1815000

23772000

76000

1400000

18419000

29700000

2100000

100000

765000

29900000

-6493000

9143000

375000

33799000

36499000

11615000

-144000

29000

3352000

4597000

717000

1.256

1.257

1.259

1.260

1.270

1.281

2000

5000

-989000

-3744000

1495000

3903000

1974000

2305000

-57000

4306000

0.15

90000

24735000

68000

293000

2015-01-27

0.64

1.70

0.42

1.42

0.61

1.62

0.42

1.42

1332000

3588000

0.175

26787000

72992000

-4280000

19298000

10328000

115000000

259244000

384572000

Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $15.1 million or increase by $20.0 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $2.5 million or decrease by $2.5 million, respectively.

Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $18.4 million or increase by $29.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.3 million or decrease by $3.3 million, respectively

Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5.0%, the fair value of this asset could decrease by $158,000 or increase by $179,000, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $137,000 or decrease by $137,000, respectively.

Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $11.1 million or increase by $14.5 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.6 million or decrease by $3.6 million, respectively.

Should these discount rates increase or decrease by 5%, the fair value of the asset could decrease by $18.3 million or increase by $23.2 million, respectively. A third-party expert was engaged to help management develop its original estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. We periodically assess the expected future cash flows and to the extent such payments are greater or less than our initial estimates, or the timing of such payments is materially different than our original estimates, we will adjust the estimated fair value of the asset. Certain manufacturers of generic equivalents to Glumetza will be permitted to enter the market starting in February and August 2016. Our current expected future cash flows anticipate a reduction in future cash flows of Glumetza as result of the generic competition in 2016. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $7.1 million or decrease by $7.7 million, respectively.

Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $2.4 million or increase by $3.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $0.8 million or decrease by $0.8 million, respectively.

44100000

9100000

33700000

1300000

4069000

-241000

-728000

-752000

-1468000

377000

503000

4597000

-4597000

4069000

4597000

-2000

-5000

580000

-6143000

5686000

17188000

8450000

23545000

70500000

149596000

411256000

110354000

367429000

47361000

144083000

40895000

135208000

134000000

125000000

792000

103000

-50000

294000

6494000

-3293000

3325000

-861000

8367000

3076000

10834000

10599000

29000

-35000

-1959000

4434000

403000

4261000

2247000

4431000

3301000

33000

22000

96000

22000

113000

15000

167000

18000

131000

845000

9387000

29770000

5901000

21710000

3083000

5224000

815000

9170000

13229000

4234000

5340000

4188000

15952000

169000

1455000

3000000

347000

4366000

7633000

1455000

3000000

1938000

9000000

80000

15217000

16045000

6210000

2000000

1800000

75000

207000

87000

294000

3500000

1700000

1800000

1166666

643382

501913000

424644000

962350000

1020601000

187983000

94589000

26356000

35035000

575000

580000

-1258000

0.100

0.134

0.150

0.21

0.128

205534000

289665000

33506000

528705000

262313000

50000000

312313000

112898000

-201617000

-148832000

-93291000

223239000

231386000

102235000

267173000

69459000

232221000

102235000

267173000

69459000

232221000

-9312000

-35706000

-5814000

-21416000

363212000

20611000

50397000

1200000

151574000

39668000

49571000

50191000

354834000

51772000

1200000

151496000

50266000

49909000

50191000

57597000

67246000

305615000

286160000

451724000

153235000

276228000

22261000

331423000

281581000

49842000

20760000

49940000

1200000

151073000

40451000

50125000

50191000

363740000

52052000

1200000

151476000

50266000

51071000

50191000

356256000

7500000

53900000

2300000

10000000

40000000

20000000

1300000

40000000

15000000

35000000

25000000

50000000

15000000

150000000

50200000

158908000

446962000

116168000

388845000

948000

1249000

7733000

6640000

-258000

-1554000

228000

39000

2963000

6049000

-1552000

403000

2705000

4495000

-1324000

442000

406000

-989000

-3744000

1495000

3903000

1974000

2305000

-57000

4306000

1595000

3257000

-836000

217000

-258000

-1554000

634000

445000

-139000

-837000

123000

21000

5000

37702000

48474000

157591000

9794000

-81717000

-8970000

29906000

177387000

9287000

607000

72135000

73623000

215000000

8976000

49000

9000

0.01

10000000

3938000

9166000

30300000

42700000

21400000

20600000

149700000

290200000

300000000

10900000

11400000

11427000

10900000

1100000

3500000

1124000

100000000

62000

42000

56250000

50000000

575740000

709470000

164594000

464150000

124618000

412390000

20800000

27602000

123916000

73807000

355008000

-4280000

119222000

19298000

363916000

1026000

1348000

6.46

522000

6.40

277000

713000

8.39

7.36

-46000

8.58

-40000

40000

4166000

3684000

58000

5.41

3.00

7.97

2.72

49842000

75000000

100000000

460437000

595957000

364000

600000

404000

2400000

7000000

49900000

65300000

2700000

178200000

71600000

16900000

1258000

166894000

165141000

163742000

163899000

160268000

157274000

163560000

163314000

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Royalty Rights - At Fair Value</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currently, we have elected to account for our investments in royalty rights at fair value with changes in fair value presented in earnings. The fair value of the investments in royalty rights is determined by using a discounted cash flow analysis related to the expected future cash flows to be received. These assets are classified as Level 3 assets within the fair value hierarchy as our valuation estimates utilize significant unobservable inputs, including estimates as to the probability and timing of future sales of the related products. Transaction-related fees and costs are expensed as incurred.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the estimated fair value from investments in royalty rights along with cash receipts each reporting period are presented together on our Condensed Consolidated Statements of Income as a component of revenue under the caption, “Royalty rights - change in fair value.”</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of our May 2015 Notes were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the May 2015 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td width="28%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wellstat Diagnostics note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hyperion note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avinger note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,668</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,451</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct Flow Medical note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paradigm Spine note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,071</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,571</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">kaléo note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,496</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,476</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,073</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">354,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">356,256</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,212</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 2012 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2015 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 2015 Term Loan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,842</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,423</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312,313</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">451,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">528,705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for our May 2015 Notes on our Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,938</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,366</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">952</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,852</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,083</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for our Series 2012 Notes on our Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">404</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of our February 2018 Notes were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the February 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,419</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,228</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for our February 2018 Notes on our Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,599</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,358</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,353</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,952</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal amount, carrying value and unamortized discount of our Series 2012 Notes were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the Series 2012 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,337</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Accrued Liabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="70%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,588</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,332</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,210</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">90</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Legal</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,139</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">296</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">948</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,711</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,876</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with GAAP for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of PDL believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with our audited Consolidated Financial Statements and the related notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, included in our Annual Report on Form 10-K, as amended, filed with the SEC. The Condensed Consolidated Balance Sheet at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Cash Equivalents and Short-Term Investments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, we had invested our excess cash balances primarily in money market funds, and a corporate equity security. Our securities are classified as available-for-sale and are carried at estimated fair value, with unrealized gains and losses reported in "Accumulated other comprehensive income" in stockholders’ equity, net of estimated taxes. See Note 3 for fair value measurement information. The cost of securities sold is based on the specific identification method. To date, we have not experienced credit losses on investments in these instruments, and we do not require collateral for our investment activities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td width="28%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Cash and Available-For-Sale Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Cash and Cash Equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-Term Investments</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">621</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,682</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291,377</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, recognized realized gains of available-for-sale securities was </font><font style="font-family:inherit;font-size:10pt;">$580,000</font><font style="font-family:inherit;font-size:10pt;">. There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> gains or losses on sales of available-for-sale securities recognized for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended September 31, 2014.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The unrealized gains on investments included in "Other comprehensive income (loss), net of tax" was approximately </font><font style="font-family:inherit;font-size:10pt;">$404,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$364,000</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, 2014, respectively.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">PDL BioPharma, Inc. v Merck Sharp & Dohme, Corp.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2015, the Company filed a Complaint against Merck Sharp & Dohme, Corp (“Merck”) for patent infringement. In the Complaint, the Company alleges that manufacture and sales of certain of Merck’s Keytruda product infringes one or more claims of the Company’s '761 Patent. The Company has requested judgment that Merck has infringed the ‘761 Patent, an award of damages due to the infringement, a finding that such infringement was willful and deliberate and trebling of damages therefore, and a declaration that the case is exceptional and warrants an award of attorney’s fees and costs. Although the ‘761 Patent expired on December 2, 2014, the Company believes that Merck infringed the patent through, e.g., manufacture and/or sale of Keytruda prior to the expiration of the ‘761 Patent.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Wellstat Litigation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 4, 2015, PDL filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics’ Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, PDL filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics’ Guarantors assets. At a hearing on September 24, 2015, regarding the Company’s request for a temporary restraining order, the court ordered that the Company’s request for attachment and for summary judgment would be heard at a hearing on November 5, 2015. Although the court denied the Company’s request for a temporary restraining order at the hearing on September 24, it ordered that assets of the Wellstat Diagnostics Guarantors should be held in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">status quo ante</font><font style="font-family:inherit;font-size:10pt;"> and only used in the normal course of business pending the outcome of the hearing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2015, the Wellstat Diagnostics Guarantors filed a complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lease Guarantee</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Spin-Off, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. Should Facet default under its lease obligations, we could be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$70.5 million</font><font style="font-family:inherit;font-size:10pt;">. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie. If AbbVie were to default, we could also be responsible for lease-related costs including utilities, property taxes and common area maintenance, which may be as much as the actual lease payments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have recorded a liability of </font><font style="font-family:inherit;font-size:10pt;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;"> on our Condensed Consolidated Balance Sheets as of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, related to this guarantee. In future periods, we may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">14. Accumulated Other Comprehensive Income</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income is comprised of net income and other comprehensive income (loss). We include unrealized net gains (losses) on investments held in our available-for-sale securities and unrealized gains (losses) on our cash flow hedges in other comprehensive income (loss), and present the amounts net of tax. Our other comprehensive income (loss) is included in our Condensed Consolidated Statements of Comprehensive Income.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of accumulated other comprehensive income, net of tax, was as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="54%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains (losses) on available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Accumulated Other Comprehensive Income</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,949</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity for the nine months ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">442</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Income</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income comprises net income adjusted for other comprehensive income (loss), using the specific identification method, which includes the changes in unrealized gains and losses on cash flow hedges and changes in unrealized gains and losses on our investments in available-for-sale securities, all net of tax, which are excluded from our net income.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of PDL and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Our accompanying unaudited Condensed Consolidated Financial Statements are prepared in accordance with GAAP and the rules and regulations of the SEC.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued our Series 2012 Notes, May 2015 Notes and February 2018 Notes with a net share settlement feature, meaning that upon any conversion, the principal amount will be settled in cash and the remaining amount, if any, will be settled in shares of our common stock. In accordance with accounting guidance for convertible debt instruments that may be settled in cash or other assets upon conversion, we separated the principal balance between the fair value of the liability component and the common stock conversion feature using a market interest rate for a similar nonconvertible instrument at the date of issuance.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Foreign Currency Hedging</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We designate the foreign currency exchange contracts used to hedge our royalty revenues based on underlying Euro-denominated sales as cash flow hedges. Euro forward contracts are presented on a net basis on our Condensed Consolidated Balance Sheets as we have entered into a netting arrangement with the counterparty. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, all outstanding Euro forward contracts were classified as cash flow hedges.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, we entered into a series of Euro forward contracts covering the quarters in which our licensees' sales occurred through December 2015.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notional amounts, Euro exchange rates and fair values of our Euro forward contracts designated as cash flow hedges were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Settlement Price</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($ per Euro)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Type</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.257</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">728</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.260</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.281</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,069</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The location and fair values of our Euro contracts in our Condensed Consolidated Balance Sheets were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="38%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flow Hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effect of our derivative instruments in our Condensed Consolidated Statements of Income and our Condensed Consolidated Statements of Comprehensive Income was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="60%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain (loss) recognized in OCI, net of tax </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,495</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(989</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,903</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain (loss) recognized in interest and other income, net - cash flow hedges </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> _______________________________</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:7pt;">(1) </font><font style="font-family:inherit;font-size:10pt;">Change in the fair value of cash flow hedges, net of tax.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:7pt;">(2) </font><font style="font-family:inherit;font-size:10pt;">Effective portion classified as royalty revenue.</font></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:7pt;">(3) </font><font style="font-family:inherit;font-size:10pt;">Ineffectiveness from excess hedge was approximately </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">($2)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">($5)</font><font style="font-family:inherit;font-size:10pt;"> for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Stock-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company grants stock options and restricted stock awards pursuant to a stockholder approved stock-based incentive plan. This incentive plan is described in further detail in Note 13, Stock-Based Compensation, of Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, as amended.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the Company’s stock option and restricted stock award activity during the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">nine months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="18" rowspan="1"></td></tr><tr><td width="38%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="10%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock Options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restricted Stock Awards</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(In thousands except per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares Available for Grant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number of Shares Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted Average Grant-date Fair Value Per Share</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,166</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(522</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">522</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares released</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(46</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.58</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited or canceled</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.46</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,684</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.41</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">713</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Net Income per Share</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income per Basic and Diluted Share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:top;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;vertical-align:top;"> </font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;vertical-align:top;">(in thousands except per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income used to compute net income per basic and diluted share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,459</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares used to compute net income per basic share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,314</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed conversion of Series 2012 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed conversion of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed conversion of May 2015 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares used to compute net income per diluted share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,742</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,894</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,899</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,141</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income per share - basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income per share - diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We compute diluted net income per share using the sum of the weighted average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of diluted net income per share include shares that may be issued under our stock options and restricted stock awards, our February 2018 Notes, our Series 2012 Notes and our May 2015 Notes on a weighted average basis for the period that the notes were outstanding, including the effect of adding back interest expense and the underlying shares using the if-converted method. In the third quarter of 2013, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal of our February 2015 Notes was exchanged for our Series 2012 Notes and the February 2015 Notes were retired, in the first quarter of 2014, </font><font style="font-family:inherit;font-size:10pt;">$131.7 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal of our Series 2012 Notes was retired in a privately negotiated exchange and purchase agreements, in the fourth quarter of 2014, the Company entered into a privately negotiated exchange agreement by which it retired approximately </font><font style="font-family:inherit;font-size:10pt;">$26.0 million</font><font style="font-family:inherit;font-size:10pt;"> in principal of the outstanding Series 2012 Notes, and, in the first quarter of 2015, the Company completed the retirement of the remaining </font><font style="font-family:inherit;font-size:10pt;">$22.3 million</font><font style="font-family:inherit;font-size:10pt;"> of aggregate principal of its Series 2012 Notes. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second quarter of 2015, the Company completed the retirement of the remaining </font><font style="font-family:inherit;font-size:10pt;">$155.1 million</font><font style="font-family:inherit;font-size:10pt;"> of aggregate principal of its May 2015 Notes. Concurrently with the retirement of the May 2015 Notes, we exercised our purchased call options and received </font><font style="font-family:inherit;font-size:10pt;">5.2 million</font><font style="font-family:inherit;font-size:10pt;"> of PDL's common shares, which was the amount equal to the number of shares required to be delivered by us to the note holders for the excess conversion value (see Note 9).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2011, we issued our May 2015 Notes, in January and February 2012, we issued our Series 2012 Notes, and in February 2014, we issued our February 2018 Notes. The Series 2012 Notes and May 2015 Notes were net share settled, with the principal amount settled in cash and the excess settled in our common stock. The weighted average share adjustments related to our Series 2012 Notes, May 2015 Notes and February 2018 Notes, shown in the table above, include the shares issuable in respect of such excess.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">May 2015 Notes Purchased Call Option and Warrant Potential Dilution</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The warrants are dilutive for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, as the exercise price of the warrants was lower than the average market price of our common stock. We excluded from our calculations of net income per diluted share </font><font style="font-family:inherit;font-size:10pt;">18.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">22.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares for the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">three months ended September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">22.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, respectively, for warrants issued in 2011, because the exercise price of the warrants was higher than the average market price of our common stock and thus, for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> September 30, 2014, no stock was issuable upon conversion. Our purchased call options, issued in 2011, will always be anti-dilutive and therefore </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">26.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares were excluded from our calculations of net income per diluted share for the three months ended September 30, 2015 and 2014, respectively, and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">26.1 million</font><font style="font-family:inherit;font-size:10pt;"> shares were excluded from our calculation of diluted net income per share for the nine months ended September 30, 2015 and 2014, respectively, because they have no effect on diluted net income per share. For information related to the conversion rates on our convertible debt, see Note 9.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">February 2018 Notes Purchased Call Option and Warrant Potential Dilution</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We excluded from our calculation of net income per diluted share </font><font style="font-family:inherit;font-size:10pt;">29.0 million</font><font style="font-family:inherit;font-size:10pt;"> shares for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, for warrants issued in February 2014, because the exercise price of the warrants exceeded the VWAP of our common stock and conversion of the underlying February 2018 Notes is not assumed, therefore no stock would be issuable upon conversion. These securities could be dilutive in future periods. Our purchased call options, issued in February 2014, will always be anti-dilutive and therefore </font><font style="font-family:inherit;font-size:10pt;">32.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares were excluded from our calculation of net income per diluted share for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, because they have no effect on diluted net income per share. For information related to the conversion rates on our convertible debt, see Note 9.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Anti-Dilutive Effect of Stock Options and Restricted Stock Awards</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the three months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, we excluded approximately </font><font style="font-family:inherit;font-size:10pt;">42,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4,000</font><font style="font-family:inherit;font-size:10pt;"> shares underlying outstanding stock options, respectively, and for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, we excluded approximately </font><font style="font-family:inherit;font-size:10pt;">39,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">4,000</font><font style="font-family:inherit;font-size:10pt;"> shares underlying outstanding stock options, respectively. For the three months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and 2014, we excluded approximately </font><font style="font-family:inherit;font-size:10pt;">475,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> shares underlying restricted stock awards, respectively, and for the nine months ended September 30, 2015 and 2014, we excluded approximately </font><font style="font-family:inherit;font-size:10pt;">437,000</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;"> shares underlying restricted stock awards, respectively, calculated on a weighted average basis, from our net income per diluted share calculations because their effect was anti-dilutive.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="40px" rowspan="1" colspan="1"></td><td width="28px" rowspan="1" colspan="1"></td><td width="32px" rowspan="1" colspan="1"></td><td width="436px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="52px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="60px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Royalty Rights - At Fair Value</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,970</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases, issues, sales, and settlements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,572</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:1pt;"> </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. Fair Value Measurements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of our financial instruments are estimates of the amounts that would be received if we were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 – based on quoted market prices in active markets for identical assets and liabilities;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 – based on quoted market prices for similar assets and liabilities, using observable market-based inputs or unobservable market-based inputs corroborated by market data; and</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present the fair value of our financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency hedge contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,244</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,682</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,572</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">532,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,415</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> transfers between levels during each of the three-month periods ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2014</font><font style="font-family:inherit;font-size:10pt;">. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Corporate Securities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities consist primarily of U.S. corporate equity holdings. The fair value of corporate securities is estimated using recently executed transactions or market quoted prices, where observable. Independent pricing sources are also used for valuation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Royalty Rights - At Fair Value</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Depomed Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 18, 2013, PDL entered into the Depomed Royalty Agreement, whereby the Company acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$240.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment. Total arrangement consideration was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$241.3 million</font><font style="font-family:inherit;font-size:10pt;">, which was comprised of the </font><font style="font-family:inherit;font-size:10pt;">$240.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment to Depomed and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> in transaction costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The rights acquired include Depomed’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus (which was subsequently acquired by Salix, which itself was recently acquired by Valeant Pharmaceuticals) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck with respect to sales of Janumet</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica with respect to potential future development milestones and sales of its investigational fixed-dose combination of Invokana</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (canagliflozin) and extended-release metformin tablets; (d) from Boehringer Ingelheim with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Depomed’s license agreement with Boehringer Ingelheim; and (e) from LG Life Sciences and Valeant Pharmaceuticals for sales of extended-release metformin tablets in Korea and Canada, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Depomed Royalty Agreement, the Company will receive all royalty and milestone payments due under license agreements between Depomed and its licensees until the Company has received payments equal to two times the cash payment it made to Depomed, after which all net payments received by Depomed will be shared evenly between the Company and Depomed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Depomed Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that its royalty purchase interest in Depo DR Sub represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Depo DR Sub that most significantly impact Depo DR Sub's economic performance and is not the primary beneficiary of Depo DR Sub; therefore, Depo DR Sub is not subject to consolidation by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The asset acquired represents a single unit of accounting. The fair value of the asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. This asset is classified as a Level 3 asset within the fair value hierarchy, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by the FDA or other regulatory agencies. The discounted cash flows are based upon expected royalties from sales of licensed products over a eight-year period. The discount rates utilized range from approximately </font><font style="font-family:inherit;font-size:10pt;">21%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting appropriate discount rates. At </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, an evaluation was performed to assess those rates and general market conditions potentially affecting the fair market value. </font><font style="font-family:inherit;font-size:10pt;">Should these discount rates increase or decrease by 5%, the fair value of the asset could decrease by $18.3 million or increase by $23.2 million, respectively. A third-party expert was engaged to help management develop its original estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. We periodically assess the expected future cash flows and to the extent such payments are greater or less than our initial estimates, or the timing of such payments is materially different than our original estimates, we will adjust the estimated fair value of the asset. Certain manufacturers of generic equivalents to Glumetza will be permitted to enter the market starting in February and August 2016. Our current expected future cash flows anticipate a reduction in future cash flows of Glumetza as result of the generic competition in 2016. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $7.1 million or decrease by $7.7 million, respectively.</font><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When PDL acquired the Depomed royalties, Glumetza was marketed by Santarus. In January 2014, Salix acquired Santarus and assumed responsibility for commercializing Glumetza, which was generally perceived to be a positive development because of Salix's larger sales force and track record in the successful commercialization of therapies. In late 2014, Salix made a number of disclosures relating to an excess of supply at the distribution level of Glumetza and other drugs that it commercialized, the practices leading to this excess of supply which were under review by Salix's audit committee in relation to the related accounting practices. Because of these disclosures and PDL's lack of direct access to information as to the levels of inventory of Glumetza in the distribution channels, PDL reviewed of all public statements by Salix, publicly available historical third-party prescription data, analyst reports and other relevant data sources. PDL also engaged a third-party expert to specifically assess estimated inventory levels of Glumetza in the distribution channel and to ascertain the potential effects those inventory levels may have on expected future cash flows. We have received no royalties from Glumetza sales in 2015. Salix was acquired by Valeant Pharmaceuticals in early April 2015. On June 18, 2015, Valeant Pharmaceuticals implemented a price increase on Glumetza and implemented an additional price increase on July 31, 2015. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our discounted cash flow analysis reflects our expectations as to the amount and timing of future cash flows up to the valuation date. We will monitor whether the acquisition or price increase by Valeant Pharmaceuticals has any effect on sales of Glumetza and thus royalties on such sales paid to PDL. Due to the uncertainty around Valeant's marketing and pricing strategy, as well as the near-term generic competition, we may be unable to fully assess the impact of the acquisition or price increase on sales of Glumetza and thus royalties on such sales paid to PDL. PDL expects to exercise its royalty audit right for Glumetza in the near future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was approximately </font><font style="font-family:inherit;font-size:10pt;">$178.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$176.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$178.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">VB Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2014, PDL entered into the VB Royalty Agreement, whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA, in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$15.5 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment, less fees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The acquired royalties include royalty amounts accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company will receive all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to two and three tenths times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB may repurchase the royalty right at any time on or before June 26, 2018, for a specified amount. The acting chief executive officer of Paradigm Spine is one of the owners of VB. The Paradigm Spine Credit Agreement and the VB Royalty Agreement were negotiated separately.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the VB Royalty Agreement royalty right at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a nine-year period. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">17.5%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting the appropriate discount rate. </font><font style="font-family:inherit;font-size:10pt;">Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $2.4 million or increase by $3.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $0.8 million or decrease by $0.8 million, respectively.</font><font style="font-family:inherit;font-size:10pt;"> A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. At each reporting period, an evaluation is performed to assess those estimates, discount rates utilized and general market conditions affecting fair market value. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the carrying value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was </font><font style="font-family:inherit;font-size:10pt;">$16.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$16.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">University of Michigan Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 6, 2014, PDL acquired a portion of all royalty payments of U-M’s worldwide royalty interest in Cerdelga (Eliglustat) for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$65.6 million</font><font style="font-family:inherit;font-size:10pt;">. Under the terms of the Michigan Royalty Agreement, PDL will receive </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">75%</font><font style="font-family:inherit;font-size:10pt;"> of all royalty payments due under U-M’s license agreement with Genzyme until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States on August 19, 2014, in the European Union on January 22, 2015, and in Japan on March 25, 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a seven-year period. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">12.8%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting the appropriate discount rate. </font><font style="font-family:inherit;font-size:10pt;">Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $11.1 million or increase by $14.5 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.6 million or decrease by $3.6 million, respectively.</font><font style="font-family:inherit;font-size:10pt;"> A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was </font><font style="font-family:inherit;font-size:10pt;">$71.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$66.9 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$71.6 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">ARIAD Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On July 28, 2015, PDL entered into the ARIAD Royalty Agreement, whereby the Company acquired the rights to receive royalties payable from ARIAD's net revenues generated by the sale, distribution or other use of Iclusig</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (ponatinib), a cancer medicine for the treatment of adult patients with chronic myeloid leukemia, in exchange for up to $200.0 million in cash payments. The purchase price of </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> is payable in two tranches of </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> each, with the first tranche funded on the closing date and the second tranche to be funded on the 12-month anniversary of the closing date. The ARIAD Royalty Agreement provides ARIAD with an option to draw up to an additional </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;"> in up to two draws at any time between the six- and 12-month anniversaries of the closing date. ARIAD may repurchase the royalty rights at any time for a specified amount. Upon the occurrence of certain events, PDL has the right to require ARIAD to repurchase the royalty rights for a specified amount. Under the ARIAD Royalty Agreement, the Company has the right to a make-whole payment from ARIAD if the Company does not receive payments equal to or greater than the amounts funded on or prior to the fifth anniversary of each of the respective fundings. In such case, ARIAD will pay to the Company the difference between the amounts paid to such date by ARIAD (excluding any delinquent fee payments) and the amounts funded by the Company. PDL has elected the fair value option to account for the hybrid instrument in its entirety. Any embedded derivative shall not be separated from the host contract. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the ARIAD Royalty Agreement, the Company will receive royalty payments at a royalty rate ranging from </font><font style="font-family:inherit;font-size:10pt;">2.5%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">7.5%</font><font style="font-family:inherit;font-size:10pt;"> of Iclusig revenue until the first to occur of (i) repurchase of the royalty rights by ARIAD or (ii) December 31, 2033. The annual royalty payments shall not exceed </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> is any fiscal year for the years ended December 31, 2015 through December 31, 2018. If Iclusig revenue does not meet certain agreed-upon projections on an annual basis, PDL is entitled to certain royalty payments from net revenue of another ARIAD product, brigatinib, up to the amount of the shortfall from the projections for the applicable year. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The asset acquired pursuant to the ARIAD Royalty Agreement represents a single unit of accounting. The fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a seven-year period. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">10.0%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting the appropriate discount rate. </font><font style="font-family:inherit;font-size:10pt;">Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $15.1 million or increase by $20.0 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $2.5 million or decrease by $2.5 million, respectively.</font><font style="font-family:inherit;font-size:10pt;"> A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was </font><font style="font-family:inherit;font-size:10pt;">$49.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$49.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">AcelRx Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 18, 2015, PDL entered into the AcelRx Royalty Agreement with ARPI LLC, a wholly owned subsidiary of AcelRx, whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">™</sup></font><font style="font-family:inherit;font-size:10pt;"> (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx's commercial partner, Grünenthal, in exchange for a </font><font style="font-family:inherit;font-size:10pt;">$65.0 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment. Under the terms of the AcelRx Royalty Agreement, the Company will receive </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;"> of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx's license agreement with Grünenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and (ii) the expiration of the licensed patents.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that its royalty rights under the agreement with ARPI LLC represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of ARPI LLC that most significantly impact ARPI LLC's economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the royalty right at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a sixteen-year period. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">13.4%</font><font style="font-family:inherit;font-size:10pt;">. Significant judgment is required in selecting the appropriate discount rate. </font><font style="font-family:inherit;font-size:10pt;">Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $18.4 million or increase by $29.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.3 million or decrease by $3.3 million, respectively</font><font style="font-family:inherit;font-size:10pt;">. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was </font><font style="font-family:inherit;font-size:10pt;">$65.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$65.3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Avinger Credit and Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 18, 2013, PDL entered into the Avinger Credit and Royalty Agreement, under which we made available to Avinger up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> (of which only </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> was funded) to be used by Avinger in connection with the commercialization of its lumivascular catheter devices and the development of Avinger's lumivascular atherectomy device. On September 22, 2015, Avinger elected to prepay the note receivable in whole for a payment of </font><font style="font-family:inherit;font-size:10pt;">$21.4 million</font><font style="font-family:inherit;font-size:10pt;"> in cash (see Note 6).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Avinger Credit and Royalty Agreement, the Company is entitled to receive royalties at a rate of </font><font style="font-family:inherit;font-size:10pt;">1.8%</font><font style="font-family:inherit;font-size:10pt;"> on Avinger's net revenues. As Avinger repaid the note receivable prior to its maturity date in April 2018, the royalty rate was reduced to </font><font style="font-family:inherit;font-size:10pt;">0.9%</font><font style="font-family:inherit;font-size:10pt;"> and will be subject to certain minimum payments from the prepayment date until April 2018. PDL has accounted for the royalty rights in accordance with the fair value option. The fair value of the royalty rights at </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a three-year period. The discount rate utilized was approximately </font><font style="font-family:inherit;font-size:10pt;">15.0%</font><font style="font-family:inherit;font-size:10pt;">. </font><font style="font-family:inherit;font-size:10pt;">Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5.0%, the fair value of this asset could decrease by $158,000 or increase by $179,000, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $137,000 or decrease by $137,000, respectively.</font><font style="font-family:inherit;font-size:10pt;"> Management considered the contractual minimum payments when developing its estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, the fair value of the royalty asset as reported in our Condensed Consolidated Balance Sheets was </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">zero</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the maximum loss exposure was </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="40px" rowspan="1" colspan="1"></td><td width="28px" rowspan="1" colspan="1"></td><td width="32px" rowspan="1" colspan="1"></td><td width="436px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="52px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="60px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements Using Significant Unobservable Inputs (Level 3)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Royalty Rights - At Fair Value</font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in fair value of royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,298</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,970</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total net change in fair value for the period</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,328</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases, issues, sales, and settlements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">115,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,572</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the estimated fair value included in earnings for each period are presented in "Royalty rights - change in fair value" as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:677px;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="341px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td><td width="5px" rowspan="1" colspan="1"></td><td width="9px" rowspan="1" colspan="1"></td><td width="66px" rowspan="1" colspan="1"></td><td width="4px" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total change in fair value for the period included in earnings for assets held at the end of the reporting period</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,787</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72,992</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Hedge Contracts</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the foreign currency hedge contracts is estimated based on pricing models using readily observable inputs from actively quoted markets and are disclosed on a gross basis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Warrants</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants consist primarily of purchased call options to buy U.S. corporate equity holdings and derivative assets acquired as part of note receivable investments. The fair value of the warrants is estimated using recently quoted market prices and the Black-Scholes model.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td width="28%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Wellstat Diagnostics note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,191</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Hyperion note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Avinger note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,611</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,760</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">LENSAR note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,266</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,668</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,451</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Direct Flow Medical note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,772</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52,052</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,397</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,940</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paradigm Spine note receivable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,909</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51,071</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,571</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,125</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">kaléo note receivable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,496</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,476</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,574</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,073</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">354,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">356,256</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,212</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">363,740</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 2012 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,506</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2015 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,235</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">205,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,581</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,228</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,665</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 2015 Term Loan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,842</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,423</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">312,313</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">451,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">528,705</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">___________________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font><font style="font-family:inherit;font-size:10pt;"> The carrying amount of notes receivable excludes the debt discount of </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> arisen from the CareView transaction (Note 6).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, the estimated fair values of our Paradigm Spine note receivable, kaléo note receivable, Hyperion note receivable, Avinger note receivable and Direct Flow Medical note receivable, were determined using one or more discounted cash flow models, incorporating expected payments and the interest rate extended on the notes receivable, with fixed interest rates and incorporating expected payments for notes receivable with a variable rate of return. In some instances the carrying values of certain notes receivable differed from their estimated fair market values. This is generally the result of discount rates used when performing a discounted cash flow for fair value valuation purposes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When deemed necessary we engage a third-party valuation expert to assist in evaluating our investments and the related inputs needed for us to estimate the fair value of certain investments. We determined our notes receivable assets are Level 3 assets as our valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values and required yield. To provide support for the estimated fair value measurements, we considered forward-looking performance related to the investment and current measures associated with high yield indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in similar sectors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Wellstat Diagnostics Note Receivable and Credit Agreement, as amended and restated, is secured by all assets and equity interests in Wellstat Diagnostics. The estimated fair value of the collateral was determined by using an asset approach related to the underlying collateral and was adjusted to consider estimated costs to sell the assets. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The loans under the credit agreement with LENSAR are secured by substantially all of the assets of LENSAR. The estimated fair value of the collateral was determined by using an asset approach related to the underlying collateral and was adjusted to consider estimated costs to sell the assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the carrying values of several of our notes receivable differed from their fair value. This is the result of discount rates used when performing a discounted cash flow for fair value valuation purposes. We determined these notes receivable to be Level 3 assets, as our valuations utilized significant unobservable inputs, estimates of future revenues, expectations about settlement and required yield. To provide support for the fair value measurements, we considered forward-looking performance, and current measures associated with high yield and published indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in a similar sector.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair values of our convertible notes were determined using quoted market pricing or dealer quotes.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Hedging</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into foreign currency hedges to manage exposures arising in the normal course of business and not for speculative purposes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We hedge certain Euro-denominated currency exposures related to royalties associated with our licensees’ product sales with Euro forward contracts. In general, these contracts are intended to offset the underlying Euro market risk in our royalty revenues. The last of these contracts expires in the first quarter of 2016. We designate foreign currency exchange contracts used to hedge royalty revenues based on underlying Euro-denominated licensee product sales as cash flow hedges.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each hedging relationship and on a quarterly basis, we assess the hedge effectiveness. The fair value of the Euro contracts is estimated using pricing models with readily observable inputs from actively quoted markets and is disclosed on a gross basis. The aggregate unrealized gains or losses, net of tax, on the effective component of the hedge is recorded in stockholders’ equity as "Accumulated other comprehensive income." Realized gains or losses on cash flow hedges are recognized as an adjustment to royalty revenue in the same period that the hedged transaction impacts earnings as royalty revenue. Any gain or loss on the ineffective portion of our hedge contracts is reported in "Interest and other income, net" in the period the ineffectiveness occurs.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense for the three months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$40.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$47.4 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, and for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">, was </font><font style="font-family:inherit;font-size:10pt;">$135.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$144.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The uncertain tax positions increased during the three and nine months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, by </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, resulting from an increase in tax uncertainties and estimated tax liabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In general, our income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 1996 forward. In May 2012, PDL received a “no-change” letter from the IRS upon completion of an examination of the Company's 2008 federal tax return. We are currently under income tax examination in the state of California for tax years 2009 and 2010. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, we do not anticipate any material change to the amount of our unrecognized tax benefit over the next 12 months.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes is determined using the asset and liability approach. Tax laws require items to be included in tax filings at different times than the items are reflected in the financial statements. A current liability is recognized for the estimated taxes payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are adjusted for enacted changes in tax rates and tax laws. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Notes Receivable and Other Long-Term Receivables</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes receivable and other long-term receivables included the following significant agreements:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Wellstat Diagnostics Note Receivable and Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2012, the Company executed a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;">-year senior secured note receivable with the holders of the equity interests in Wellstat Diagnostics. In addition to bearing interest at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">10%</font><font style="font-family:inherit;font-size:10pt;"> per annum, the note receivable gave PDL certain rights to negotiate for certain future financing transactions. In August 2012, PDL and Wellstat Diagnostics amended the note receivable, providing a senior secured note receivable of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">, bearing interest at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">12%</font><font style="font-family:inherit;font-size:10pt;"> per annum, to replace the original </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;"> note receivable. This </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> note receivable was repaid on November 2, 2012, using the proceeds of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> credit facility entered into with the Company on the same date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 2, 2012, the Company and Wellstat Diagnostics entered into a </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">5%</font><font style="font-family:inherit;font-size:10pt;"> per annum (payable in cash or in kind). In addition, PDL was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics' net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics' products, if any, commencing upon the commercialization of its products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. PDL sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, PDL exercised one of its available remedies and transferred approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$8.1 million</font><font style="font-family:inherit;font-size:10pt;"> of available cash from a bank account of Wellstat Diagnostics to PDL and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby PDL agreed to refrain from exercising additional remedies for </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">120 days</font><font style="font-family:inherit;font-size:10pt;"> while Wellstat Diagnostics raised funds to capitalize the business and the parties attempted to negotiate a revised credit agreement. PDL agreed to provide up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.9 million</font><font style="font-family:inherit;font-size:10pt;"> to Wellstat Diagnostics to fund the business for the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">120</font><font style="font-family:inherit;font-size:10pt;">-day forbearance period under the terms of the forbearance agreement. Following the conclusion of the forbearance period that ended on June 28, 2013, the Company agreed to forbear its exercise of remedies for additional periods of time to allow the owners and affiliates of Wellstat Diagnostics to complete a pending financing transaction. During such forbearance period, the Company provided approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately </font><font style="font-family:inherit;font-size:10pt;">$8.7 million</font><font style="font-family:inherit;font-size:10pt;"> was advanced pursuant to the forbearance agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 15, 2013, the owners and affiliates of Wellstat Diagnostics completed a financing transaction to fulfill Wellstat Diagnostics' obligations under the forbearance agreement. On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">Except as otherwise described here, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">5%</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> per annum (payable in cash or in kind). In addition, PDL was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics' net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$44.1 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">, which was comprised of approximately </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$33.7 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> original loan principal and interest, </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> term loan principal and interest and </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$9.1 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics' obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">When the principal amount was reset, a </font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;background-color:#ffffff;"> reduction of the carrying value was recorded as a financing cost as a component of "Interest and other income, net". The new carrying value is lower as a function of the variable nature of the internal rate of return to be realized by the Company based on when the note was to be repaid. The internal rate of return calculation, although increased, was reset when the credit agreement was amended and restated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June of 2014, the Company received information from Wellstat Diagnostics that showed that it was generally unable to pay its debts as they became due. This constituted an event of default under the amended and restated credit agreement. Wellstat Diagnostics entered into a transaction involving another lender, pursuant to which Wellstat Diagnostics obtained additional short-term funding for its operations. At the same time, the Company entered into the first amendment to amended and restated credit agreement with Wellstat Diagnostics. The material terms of the amendment included the following: (1) Wellstat Diagnostics acknowledged that an event of default had occurred; (2) the Company agreed to forbear from immediately enforcing its rights for up to 60 days, so long as the other lender provided agreed levels of interim funding to Wellstat Diagnostics; and (3) the Company obtained specified additional information rights with regard to Wellstat Diagnostics’ financial matters and investment banking activities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 5, 2014, the Company received notice that the short-term funding being provided pursuant to the agreement with the other lender entered into during June 2014, was being terminated. Wellstat Diagnostics remained in default because it was still unable to pay its debts as they became due. Accordingly, the Company delivered the Wellstat Diagnostics Borrower Notice. The Wellstat Diagnostics Borrower Notice accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$53.9 million</font><font style="font-family:inherit;font-size:10pt;">, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations. On August 7, 2014, the Company delivered the Wellstat Diagnostics Guarantor Notice. The Wellstat Diagnostics Guarantor Notice included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 24, 2014, the Company filed the Wellstat Diagnostics Petition, which was granted on the same day. The order granting the Wellstat Diagnostics Petition authorizes the receiver to take immediate possession of the physical assets of Wellstat Diagnostics, with the purpose of holding, protecting, insuring, managing and preserving the business of Wellstat Diagnostics and the value of the Company’s collateral. Wellstat Diagnostics has remained in operation during the period of the receivership with incremental additional funding from the Company. The Company continues to assess its options with respect to collecting on the loan, including determining whether and when it will foreclose on the collateral and proceed with a sale of Wellstat Diagnostics’ assets, whether providing further capital to the receiver to fund Wellstat Diagnostics’ operations for a period of time prior to sale will best position Wellstat Diagnostics’ assets for sale, and assessing the value of the guarantees obtained by the Company from Wellstat Diagnostics’ guarantors, including Wellstat Diagnostics’ stockholders and Wellstat Therapeutics.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 4, 2014, the Company entered into the third amendment to the amended and restated credit agreement with Wellstat Diagnostics.  The amendment provides that additional funding, if any, to be made by the Company is conditioned upon the agreement by Wellstat Diagnostics to make certain operational changes within Wellstat Diagnostics, which the Company believes will allow the receiver to more efficiently optimize the value of the collateral.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the second quarter of 2015, the receiver initiated a process for a public sale of the assets of Wellstat Diagnostics and retained the investment banking firm of Duff & Phelps to organize and manage the sale process. The receiver filed a "Motion For Approval of Sale Procedures" with the Circuit Court for Montgomery County, Maryland, which is the court having jurisdiction over the receivership and a hearing was held on July 22, 2015 at which time arguments were heard from interested parties regarding the sale procedures. No significant substantive disagreements between the parties regarding the sale procedures remained after the hearing and a decision approving the receiver’s sale procedures is expected shortly. The sale process is ongoing and Duff & Phelps is actively contacting and holding discussions with interested third parties who may be willing to bid on the assets. In addition, depending on the nature and value of the bids received from third parties, it is possible that PDL will credit bid for the assets at a value corresponding to some portion of the outstanding amount due under the amended and restated credit agreement. We anticipate that the sale process will be completed during the fourth quarter of 2015.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 4, 2015, PDL filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, PDL filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantors' assets. At a hearing on September 24, 2015, regarding the Company’s request for a temporary restraining order, the court ordered that the Company’s request for attachment and for summary judgment would be heard at a hearing on November 5, 2015. Although the court denied the Company’s request for a temporary restraining order at the hearing on September 24, it ordered that assets of the Wellstat Diagnostics Guarantors should be held in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">status quo ante</font><font style="font-family:inherit;font-size:10pt;"> and only used in the normal course of business pending the outcome of the hearing.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 22, 2015, the Wellstat Diagnostics Guarantors filed a complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through the period ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, PDL has advanced to Wellstat Diagnostics </font><font style="font-family:inherit;font-size:10pt;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;"> to fund the ongoing operations of the business and other associated costs. This funding has been expensed as incurred.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective April 1, 2014, and as a result of the event of default, we determined the loan to be impaired and we ceased to accrue interest revenue. At that time and as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> it has been determined that an allowance on the carrying value of the note was not necessary as the Company believes the value of the collateral securing Wellstat Diagnostics’ obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of </font><font style="font-family:inherit;font-size:10pt;">$50.2 million</font><font style="font-family:inherit;font-size:10pt;">. There can be no assurance that this will be true in the event of the Company’s foreclosure on the collateral, nor can there be any assurance of the timing in realizing value from such collateral, whether from the sale process currently underway or a subsequent monetization event if PDL makes a successful credit bid for the assets.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hyperion Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 27, 2012, PDL and Hyperion entered into an agreement whereby Hyperion sold to PDL the royalty streams due from SDK related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. The agreement assigned the patent license agreement royalty stream accruing from January 1, 2012, through December 31, 2013, to PDL in exchange for the lump sum payment to Hyperion of </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">. In exchange for the lump sum payment, PDL was to receive </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> equal payments of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> on both March 5, 2013 and 2014. The first payment of </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> was paid on March 5, 2013, but Hyperion has not made the payment that was due on March 5, 2014. The Company completed an impairment analysis as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. Effective with this date and as a result of the event of default, we ceased to accrue interest revenue. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance that this will be true in the event of the Company's foreclosure on the collateral, nor can there be any assurance of realizing value from such collateral. Hyperion is considering other sources of financing and strategic alternatives, including selling the company.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">AxoGen Note Receivable and AxoGen Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2012, PDL entered into the AxoGen Royalty Agreement with AxoGen pursuant to which the Company would receive specified royalties on AxoGen’s net revenues (as defined in the AxoGen Royalty Agreement) generated by the sale, distribution or other use of AxoGen’s products. The AxoGen Royalty Agreement had an </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;">-year term and provided PDL with royalties of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">9.95%</font><font style="font-family:inherit;font-size:10pt;"> based on AxoGen's net revenues, subject to agreed-upon guaranteed quarterly minimum payments of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, which were to begin in the fourth quarter of 2014, and the right to require AxoGen to repurchase the royalties under the AxoGen Royalty Agreement at the end of the fourth year. AxoGen was granted certain rights to call the contract in years five through </font><font style="font-family:inherit;font-size:10pt;">eight</font><font style="font-family:inherit;font-size:10pt;">. The total consideration PDL paid to AxoGen for the royalty rights was </font><font style="font-family:inherit;font-size:10pt;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;">, including an interim funding of </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> in August 2012. AxoGen was required to use a portion of the proceeds from the AxoGen Royalty Agreement to pay the outstanding balance under its existing credit facility. The royalty rights were secured by the cash and accounts receivable of AxoGen.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On August 14, 2013, PDL purchased </font><font style="font-family:inherit;font-size:10pt;">1,166,666</font><font style="font-family:inherit;font-size:10pt;"> shares of registered common stock of AxoGen (AXGN) at </font><font style="font-family:inherit;font-size:10pt;">$3.00</font><font style="font-family:inherit;font-size:10pt;"> per share, totaling </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">. On December 22, 2014, PDL sold these shares at </font><font style="font-family:inherit;font-size:10pt;">$3.03</font><font style="font-family:inherit;font-size:10pt;"> per share, totaling approximately </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 13, 2014, the Company agreed to terminate the AxoGen Royalty Agreement in consideration for a payment of </font><font style="font-family:inherit;font-size:10pt;">$30.3 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, which was the sum of the outstanding principal, interest and embedded derivative.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to the pay-off, the Company acquired </font><font style="font-family:inherit;font-size:10pt;">643,382</font><font style="font-family:inherit;font-size:10pt;"> shares of registered common stock of AxoGen for approximately </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> at a public offering price of </font><font style="font-family:inherit;font-size:10pt;">$2.72</font><font style="font-family:inherit;font-size:10pt;"> per share. The shares are classified as available for sale securities and recorded as short-term investments on the Condensed Consolidated Balance Sheets. On September 15, 2015, PDL sold </font><font style="font-family:inherit;font-size:10pt;">200,000</font><font style="font-family:inherit;font-size:10pt;"> shares at </font><font style="font-family:inherit;font-size:10pt;">$5.62</font><font style="font-family:inherit;font-size:10pt;"> per share, totaling approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the remaining shares were valued at </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;">, which resulted in an unrealized gain of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and is recorded in "Other comprehensive income (loss), net of tax."</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Avinger Credit and Royalty Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 18, 2013, PDL entered into the Avinger Credit and Royalty Agreement, under which we made available to Avinger up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be used by Avinger in connection with the commercialization of its lumivascular catheter devices and the development of Avinger's lumivascular atherectomy device. Of the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> initially available to Avinger, we funded an initial </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of fees, at the close of the transaction. Outstanding borrowings under the initial loan bore interest at a stated rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">12%</font><font style="font-family:inherit;font-size:10pt;"> per annum. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On September 22, 2015, Avinger elected as per the voluntary prepayment provision under the Avinger Credit and Royalty Agreement to prepay the notes receivable in whole for a payment of </font><font style="font-family:inherit;font-size:10pt;">$21.4 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, which was the sum of the outstanding principal, interest and a prepayment fee.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the Avinger Credit and Royalty Agreement, the Company will receive a low, single-digit royalty on Avinger's net revenues until April 2018. Avinger repaid the note receivable prior to its maturity date in April 2018, which resulted in the royalty on Avinger's net revenues being reduced by </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">50%</font><font style="font-family:inherit;font-size:10pt;"> and subject to certain minimum payments from the prepayment date until April 2018. PDL has accounted for the royalty rights in accordance with the fair value option (see Note 3).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">LENSAR Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 1, 2013, PDL entered into a credit agreement with LENSAR, under which PDL made available to LENSAR up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be used by LENSAR in connection with the commercialization of its currently marketed LENSAR™ Laser System. Of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$60.0 million</font><font style="font-family:inherit;font-size:10pt;"> available to LENSAR, an initial </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of fees, was funded by the Company at the close of the transaction. The additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the form of a second tranche is no longer available to LENSAR under the terms of the credit agreement. Outstanding borrowings under the loans bear interest at the rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly in arrears.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal repayment will commence on the thirteenth interest payment date or </font><font style="font-family:inherit;font-size:10pt;">December 31, 2016</font><font style="font-family:inherit;font-size:10pt;">. The principal amount outstanding at the commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on October 1, 2018. LENSAR may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The loans are secured by all of the assets of LENSAR.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 12, 2015, PDL entered into a forbearance agreement with LENSAR under which PDL agreed to refrain from exercising certain remedies available to it resulting from the failure of LENSAR to comply with a liquidity covenant and make interest payments due under the credit agreement. Under the forbearance agreement, PDL has agreed to provide LENSAR with up to an aggregate of </font><font style="font-family:inherit;font-size:10pt;">$8.5 million</font><font style="font-family:inherit;font-size:10pt;"> in weekly increments through the period ending September 30, 2015 plus employee retention amounts of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> in the form of additional loans subject to LENSAR meeting certain milestones related to LENSAR obtaining additional capital to fund the business or selling itself and repaying outstanding amounts under the credit agreement. As of September 30, 2015, PDL has funded an additional </font><font style="font-family:inherit;font-size:10pt;">$9.0 million</font><font style="font-family:inherit;font-size:10pt;"> of principal under the forbearance agreement. In exchange for the forbearance, LENSAR agreed to additional reporting covenants, the engagement of a chief restructuring officer and an increase on the interest rate to </font><font style="font-family:inherit;font-size:10pt;">18.5%</font><font style="font-family:inherit;font-size:10pt;">, applicable to all outstanding amounts under the credit agreement. On September 30, 2015, PDL agreed to extend the forbearance agreement until October 9, 2015 and provide for up to an additional </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> in funding while LENSAR negotiated a potential sale of its assets. On October 9, 2015, the forbearance agreement expired, but PDL has agreed to fund LENSAR's operations while LENSAR continues to negotiate a potential sale of its assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company completed an impairment analysis as of September 30, 2015. Effective April 1, 2015 and as a result of the forbearance, we determined the loan to be impaired and we ceased to accrue interest revenue.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Durata Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 31, 2013, PDL entered into a credit agreement with Durata, under which the Company made available to Durata up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$70.0 million</font><font style="font-family:inherit;font-size:10pt;">. Of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$70.0 million</font><font style="font-family:inherit;font-size:10pt;"> available to Durata, an initial </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> (tranche one), net of fees, was funded by the Company at the close of the transaction. On May 27, 2014, the Company funded Durata an additional </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> (tranche two) as a result of Durata's marketing approval of dalbavancin in the United States, which occurred on May 23, 2014, and was the milestone needed to receive the tranche two funding. Until the occurrence of the tranche two milestone, outstanding borrowings under tranche one bore interest at the rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">14.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly in arrears. Upon occurrence of the tranche two milestone, the interest rate of the loans decreased to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">12.75%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 17, 2014, the Company received a payment of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$42.7 million</font><font style="font-family:inherit;font-size:10pt;"> constituting repayment in full of the outstanding principal amount of loans plus accrued interest and fees under the credit agreement. The repayment was made in connection with the acquisition of Durata by Actavis plc.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Direct Flow Medical Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 5, 2013, PDL entered into a credit agreement with Direct Flow Medical, under which PDL agreed to provide up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> to Direct Flow Medical. Of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> available to Direct Flow Medical, an initial </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$35.0 million</font><font style="font-family:inherit;font-size:10pt;"> (tranche one), net of fees, was funded by the Company at the close of the transaction. Pursuant to the original terms of the credit agreement the Company agreed to provide Direct Flow Medical an additional </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> tranche, net of fees, upon the attainment of a specified revenue milestone to be accomplished no later than December 31, 2014 (the tranche two milestone). Until the occurrence of the tranche two milestone, outstanding borrowings under tranche one bore interest at the rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">15.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly in arrears.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On November 10, 2014, PDL and Direct Flow Medical agreed to an amendment to the credit agreement to permit Direct Flow Medical to borrow the </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> second tranche upon receipt by Direct Flow Medical of a specified minimum amount of proceeds from an equity offering prior to December 31, 2014. In exchange, the parties amended the credit agreement to provide for additional fees associated with certain liquidity events, such as a change of control or the consummation of an initial public offering, and granted PDL certain board of director observation rights. On November 19, 2014, upon Direct Flow Medical satisfying the amended tranche two milestone, the Company funded the </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> second tranche to Direct Flow Medical, net of fees. Upon occurrence of the borrowing of the second tranche, the interest rate applicable to all loans under the credit agreement was decreased to </font><font style="font-family:inherit;font-size:10pt;">13.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly in arrears.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal repayment will commence on the twelfth interest payment date, September 30, 2016. The principal amount outstanding at commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on November 5, 2018. Direct Flow Medical may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The obligations under the credit agreement are secured by a pledge of substantially all of the assets of Direct Flow Medical and any of its subsidiaries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paradigm Spine Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 14, 2014, the Company entered into the Paradigm Spine Credit Agreement, under which it made available to Paradigm Spine up to </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> to be used by Paradigm Spine to refinance its existing credit facility and expand its domestic commercial operations. Of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> available to Paradigm Spine, an initial </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of fees, was funded by the Company at the close of the transaction. The second and third tranches of up to an additional </font><font style="font-family:inherit;font-size:10pt;">$25.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the aggregate, net of fees, are no longer available under the terms of the Paradigm Spine Credit Agreement. Borrowings under the credit agreement bear interest at the rate of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">13.0%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable quarterly in arrears.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal repayment will commence on the twelfth interest payment date, December 31, 2016. The principal amount outstanding at commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on February 14, 2019. Paradigm Spine may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The obligations under the Paradigm Spine Credit Agreement are secured by a pledge of substantially all of the assets of Paradigm Spine and its domestic subsidiaries and, initially, certain assets of Paradigm Spine’s German subsidiaries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 27, 2015, PDL and Paradigm Spine entered into an amendment to the Paradigm Spine Credit Agreement to provide additional term loan commitments of up to </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;"> payable in two tranches of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, of which the first tranche was drawn on the closing date of the amendment, net of fees, and the second tranche is to be funded at the option of Paradigm Spine prior to June 30, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">kaléo Note Purchase Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 1, 2014, PDL entered into a note purchase agreement with Accel 300, a wholly-owned subsidiary of kaléo, pursuant to which the Company acquired </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> of secured notes due 2029. The secured notes were issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and are secured by the kaléo Revenue Interests, and a pledge of kaléo’s equity ownership in Accel 300. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The secured notes bear interest at </font><font style="font-family:inherit;font-size:10pt;">13%</font><font style="font-family:inherit;font-size:10pt;"> per annum, paid quarterly in arrears on principal outstanding. The principal balance of the secured notes is repaid to the extent that the kaléo Revenue Interests exceed the quarterly interest payment, as limited by a quarterly payment cap. The final maturity of the secured notes is June 2029. kaléo may redeem the secured notes at any time, subject to a redemption premium.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that its royalty purchase interest in Accel 300 represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Accel 300 that most significantly impact Accel 300's economic performance and is not the primary beneficiary of Accel 300; therefore, Accel 300 is not subject to consolidation by the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2015, Sanofi US initiated a voluntary nationwide recall of all Auvi-Q</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:11pt;"> </font><font style="font-family:inherit;font-size:10pt;">units effectively immediately. Sanofi is the exclusive licensee of kaléo for the manufacturing and commercialization of Auvi-Q. While Sanofi has not identified the reason for the recall, press reports indicate that a small number of units have failed to activate or delivered inadequate doses of epinephrine. It is not known at this time when Sanofi will reintroduce Auvi-Q in the U.S. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of our financing transaction, kaléo was required to establish an interest reserve account of $20 million from the $150 million provided by PDL. The purpose of this interest reserve account is to cover any possible shortfalls in interest payments owed to PDL. As of this date, despite the recall of Auvi-Q, it is projected that the interest reserve account alone is sufficient to cover possible interest shortfalls until at least through the first quarter of 2016. PDL will monitor the recall situation and how it may impact the ability of kaléo to meet its obligations under the Notes, but at this point it has been determined that there is no impairment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CareView Credit Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On June 26, 2015, PDL entered into a credit agreement with CareView, under which the Company made available to CareView up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> in two tranches of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> each. Under the terms of the credit agreement, the first tranche of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> was to be funded by the Company upon CareView’s attainment of a specified milestone relating to the placement of CareView Systems</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, to be accomplished no later than October 31, 2015. The Company expects to fund CareView an additional </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA (as defined in the credit agreement), to be accomplished no later than June 30, 2017. Outstanding borrowings under the credit agreement will bear interest at the rate of </font><font style="font-family:inherit;font-size:10pt;">13.5%</font><font style="font-family:inherit;font-size:10pt;"> per annum and are payable quarterly in arrears. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the transaction, the Company received a warrant to purchase approximately </font><font style="font-family:inherit;font-size:10pt;">4.4 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock of CareView at the exercise price of </font><font style="font-family:inherit;font-size:10pt;">$0.45</font><font style="font-family:inherit;font-size:10pt;"> per share. We have accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 7, 2015, PDL and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. On this date, PDL also funded the first tranche of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of fees, upon attainment of the modified first tranche milestone relating to the placement of CareView Systems. The additional </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the form of a second tranche continues to be available upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA, to be accomplished no later than June 30, 2017 under the terms of the amended credit agreement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the amendment of the credit agreement, PDL and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant's exercise price from </font><font style="font-family:inherit;font-size:10pt;">$0.45</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.40</font><font style="font-family:inherit;font-size:10pt;"> per share. At September 30, 2015, we determined an estimated fair value of the warrant of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For carrying value and fair value measurement information related to our notes receivable and other long-term receivables, see Note 3.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">. Convertible Notes and Term Loans</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">  </font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td width="28%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="26%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Principal Balance Outstanding</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Carrying Value</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Maturity Date</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Convertible Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series 2012 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 15, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,261</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 2015 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">May 1, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,235</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 2018 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 1, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,581</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,228</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">March 2015 Term Loan</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 15, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,842</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">331,423</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">451,724</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, PDL was in compliance with all applicable debt covenants, and embedded features of all debt agreements were evaluated and did not need to be accounted for separately. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series 2012 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2012, we exchanged </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$169.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal of Series 2012 Notes for an identical principal amount of our then existing February 2015 Notes, plus a cash payment of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$5.00</font><font style="font-family:inherit;font-size:10pt;"> for each </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount tendered, totaling approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$845,000</font><font style="font-family:inherit;font-size:10pt;">. The cash incentive payment was allocated to deferred issue costs of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$765,000</font><font style="font-family:inherit;font-size:10pt;">, additional paid-in capital of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$52,000</font><font style="font-family:inherit;font-size:10pt;"> and deferred tax assets of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$28,000</font><font style="font-family:inherit;font-size:10pt;">. The deferred issue costs will be recognized over the life of the Series 2012 Notes as interest expense. In February 2012, we entered into separate privately negotiated exchange agreements under which we exchanged an additional </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the Series 2012 Notes for an identical principal amount of our then existing February 2015 Notes. In August 2013, the Company entered into a separate privately negotiated exchange agreement under which it retired the final </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the Company's outstanding February 2015 Notes. Pursuant to the exchange agreement, the holder of the February 2015 Notes received </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of the Company's Series 2012 Notes. Immediately following the exchange, </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">no</font><font style="font-family:inherit;font-size:10pt;"> principal amount of the February 2015 Notes remained outstanding and </font><font style="font-family:inherit;font-size:10pt;">$180.0 million</font><font style="font-family:inherit;font-size:10pt;"> principal amount of the Series 2012 Notes was outstanding.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 6, 2014, the Company entered into exchange and purchase agreements with certain holders of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$131.7 million</font><font style="font-family:inherit;font-size:10pt;"> aggregate principal amount of outstanding Series 2012 Notes. The exchange agreement provided for the issuance by the Company of shares of common stock and a cash payment for the Series 2012 Notes being exchanged, and the purchase agreement provided for a cash payment for the Series 2012 Notes being repurchased. The total consideration given was approximately </font><font style="font-family:inherit;font-size:10pt;">$191.8 million</font><font style="font-family:inherit;font-size:10pt;">. The Company issued to the participating holders of the February 2015 Notes a total of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">20.3 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock with a fair value of approximately </font><font style="font-family:inherit;font-size:10pt;">$157.6 million</font><font style="font-family:inherit;font-size:10pt;"> and made an aggregate cash payment of approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.2 million</font><font style="font-family:inherit;font-size:10pt;"> pursuant to the exchange and purchase agreements. Of the </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$34.2 million</font><font style="font-family:inherit;font-size:10pt;"> cash payment, </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> is attributable to an inducement fee, </font><font style="font-family:inherit;font-size:10pt;">$1.8 million</font><font style="font-family:inherit;font-size:10pt;"> is attributable to interest accrued through the date of settlement and </font><font style="font-family:inherit;font-size:10pt;">$29.9 million</font><font style="font-family:inherit;font-size:10pt;"> is attributable to the repurchase of the Series 2012 Notes. It was determined that the exchange and purchase agreement represented an extinguishment of the related notes. As a result, a loss on extinguishment of </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded. The </font><font style="font-family:inherit;font-size:10pt;">$6.1 million</font><font style="font-family:inherit;font-size:10pt;"> loss on extinguishment included the derecognition of the original issuance discount of </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;"> and a </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> charge resulting from the difference of the face value of the notes and the fair value of the notes. Immediately following the exchange, </font><font style="font-family:inherit;font-size:10pt;">$48.3 million</font><font style="font-family:inherit;font-size:10pt;"> principal amount of the Series 2012 Notes was outstanding with approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> of remaining original issuance discount to be amortized over the remaining life of the Series 2012 Notes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 20, 2014, the Company entered into a privately negotiated exchange agreement under which it retired approximately </font><font style="font-family:inherit;font-size:10pt;">$26.0 million</font><font style="font-family:inherit;font-size:10pt;"> in principal of the outstanding Series 2012 Notes. The exchange agreement provided for the issuance, by the Company, of shares of common stock and a cash payment for the Series 2012 Notes being exchanged. The Company issued approximately </font><font style="font-family:inherit;font-size:10pt;">1.8 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock and made a cash payment of approximately </font><font style="font-family:inherit;font-size:10pt;">$26.2 million</font><font style="font-family:inherit;font-size:10pt;">. Immediately following the exchange, </font><font style="font-family:inherit;font-size:10pt;">$22.3 million</font><font style="font-family:inherit;font-size:10pt;"> principal amount of the Series 2012 Notes was outstanding with approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> of remaining original issuance discount to be amortized over the remaining life of the Series 2012 Notes. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Series 2012 Notes were due February 15, 2015, and bore interest at a rate of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.875%</font><font style="font-family:inherit;font-size:10pt;"> per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On February 17, 2015, the Company completed the retirement of the remaining </font><font style="font-family:inherit;font-size:10pt;">$22.3 million</font><font style="font-family:inherit;font-size:10pt;"> of aggregate principal of its Series 2012 notes at their stated maturity for </font><font style="font-family:inherit;font-size:10pt;">$22.3 million</font><font style="font-family:inherit;font-size:10pt;">, plus approximately </font><font style="font-family:inherit;font-size:10pt;">1.34 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The principal amount, carrying value and unamortized discount of our Series 2012 Notes were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the Series 2012 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,337</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(76</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for our Series 2012 Notes on our Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">347</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">996</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">404</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">76</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,783</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">815</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">169</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,234</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">May 2015 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 16, 2011, we issued </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$155.3 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount, at par, of our May 2015 Notes in an underwritten public offering, for net proceeds of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$149.7 million</font><font style="font-family:inherit;font-size:10pt;">. Our May 2015 Notes were due May 1, 2015, and we paid interest at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">3.75%</font><font style="font-family:inherit;font-size:10pt;"> on our May 2015 Notes semiannually in arrears on May 1 and November 1 of each year, beginning November 1, 2011. Proceeds from our May 2015 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem a portion of our Series 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders had the option to require PDL to redeem the May 2015 Notes at a purchase price equal to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal, plus accrued interest.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 1, 2015, the Company completed the retirement of the remaining </font><font style="font-family:inherit;font-size:10pt;">$155.1 million</font><font style="font-family:inherit;font-size:10pt;"> of aggregate principal of its May 2015 Notes at their stated maturity for </font><font style="font-family:inherit;font-size:10pt;">$155.1 million</font><font style="font-family:inherit;font-size:10pt;">, plus approximately </font><font style="font-family:inherit;font-size:10pt;">5.2 million</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock for the excess conversion value.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of our May 2015 Notes were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the May 2015 Notes</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,050</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,815</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">153,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for our May 2015 Notes on our Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,455</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,938</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,366</font></div></td><td style="vertical-align:bottom;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">435</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">952</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,815</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,852</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,083</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,188</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,170</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Purchased Call Options and Warrants</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the issuance of our May 2015 Notes, we entered into purchased call option transactions with </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> hedge counterparties. We paid an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;">, plus legal fees, for the purchased call options with terms substantially similar to the embedded conversion options in our May 2015 Notes. We exercised the purchased call options upon conversion of our May 2015 Notes on May 1, 2015, which required the hedge counterparties to deliver shares to the Company. The hedge counterparties delivered to us approximately </font><font style="font-family:inherit;font-size:10pt;">5.2 million</font><font style="font-family:inherit;font-size:10pt;"> of PDL common shares, which was the amount equal to the shares required to be delivered by us to the note holders for the excess conversion value.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive up to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">27.5 million</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock underlying our May 2015 Notes. We received an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.9 million</font><font style="font-family:inherit;font-size:10pt;"> for the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates through the 120 scheduled trading days beginning on July 30, 2015 and ending on January 20, 2016. If the VWAP of our common stock, as defined in the warrant agreement, exceeds the strike price of the warrants on the date of conversion, we will deliver to the warrant counterparties shares of our common stock equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of our May 2015 Notes. The strike price is approximately </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$6.40</font><font style="font-family:inherit;font-size:10pt;">, subject to further adjustment upon certain events including dividend payments, for the warrants.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because the share price was above </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$5.44</font><font style="font-family:inherit;font-size:10pt;">, but below </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$6.40</font><font style="font-family:inherit;font-size:10pt;">, upon conversion of our May 2015 Notes, the purchased call options offset the share dilution, and the Company received shares on exercise of the purchased call options equal to the shares that the Company delivered to the note holders. If the share price is above </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$6.40</font><font style="font-family:inherit;font-size:10pt;">, upon exercise of the warrants, the Company will deliver shares to the counterparties in an amount equal to the excess of the share price over </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$6.40</font><font style="font-family:inherit;font-size:10pt;">. For example, a 10% increase in the share price above </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">$6.40</font><font style="font-family:inherit;font-size:10pt;"> would result in the issuance of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2.1 million</font><font style="font-family:inherit;font-size:10pt;"> incremental shares upon exercise of the warrants. If our share price continues to increase, additional dilution would occur.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While the purchased call options reduced the potential equity dilution upon conversion of our May 2015 Notes, prior to the conversion or exercise, our May 2015 Notes and the warrants had a dilutive effect on the Company’s earnings per share to the extent that the price of the Company’s common stock during a given measurement period exceeds the respective exercise prices of those instruments. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, there were no related warrants exercised.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The warrants are considered indexed to PDL stock, require net-share settlement and met all criteria for equity classification at inception and at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">. The purchased call options cost, including legal fees, of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$20.8 million</font><font style="font-family:inherit;font-size:10pt;">, less deferred taxes of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$7.2 million</font><font style="font-family:inherit;font-size:10pt;">, and the </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$10.9 million</font><font style="font-family:inherit;font-size:10pt;"> received for the warrant issuance, was recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the warrants continue to meet all criteria for equity classification.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">February 2018 Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 12, 2014, we issued </font><font style="font-family:inherit;font-size:10pt;">$300.0 million</font><font style="font-family:inherit;font-size:10pt;"> in aggregate principal amount, at par, of our February 2018 Notes in an underwritten public offering, for net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$290.2 million</font><font style="font-family:inherit;font-size:10pt;">. Our February 2018 Notes are due February 1, 2018, and we pay interest at </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> on our February 2018 Notes semiannually in arrears on February 1 and August 1 of each year, beginning August 1, 2014. A portion of the proceeds from our February 2018 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem </font><font style="font-family:inherit;font-size:10pt;">$131.7 million</font><font style="font-family:inherit;font-size:10pt;"> of our Series 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require PDL to redeem the February 2018 Notes at a purchase price equal to </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">100%</font><font style="font-family:inherit;font-size:10pt;"> of the principal, plus accrued interest.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our February 2018 Notes are convertible under any of the following circumstances:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During any fiscal quarter ending after the quarter ended June 30, 2014, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds </font><font style="font-family:inherit;font-size:10pt;">130%</font><font style="font-family:inherit;font-size:10pt;"> of the conversion price for the notes on the last day of such preceding fiscal quarter;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of notes for each trading day of that measurement period was less than </font><font style="font-family:inherit;font-size:10pt;">98%</font><font style="font-family:inherit;font-size:10pt;"> of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon the occurrence of specified corporate events as described further in the indenture; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At any time on or after August 1, 2017.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial conversion rate for the February 2018 Notes is </font><font style="font-family:inherit;font-size:10pt;">109.1048</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock per </font><font style="font-family:inherit;font-size:10pt;">$1,000</font><font style="font-family:inherit;font-size:10pt;"> principal amount of February 2018 Notes, which is equivalent to an initial conversion price of approximately </font><font style="font-family:inherit;font-size:10pt;">$9.17</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the indenture. Upon conversion, the Company will be required to pay cash and, if applicable, deliver shares of the Company's common stock as described in the indenture.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, we were required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, we separated the principal balance of our February 2018 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of </font><font style="font-family:inherit;font-size:10pt;">7.0%</font><font style="font-family:inherit;font-size:10pt;">, which represents the estimated market interest rate for a similar nonconvertible instrument available to us on the date of issuance, we recorded a total debt discount of </font><font style="font-family:inherit;font-size:10pt;">$29.7 million</font><font style="font-family:inherit;font-size:10pt;">, allocated </font><font style="font-family:inherit;font-size:10pt;">$19.3 million</font><font style="font-family:inherit;font-size:10pt;"> to additional paid-in capital and allocated </font><font style="font-family:inherit;font-size:10pt;">$10.4 million</font><font style="font-family:inherit;font-size:10pt;"> to deferred tax liability. The discount is being amortized to interest expense over the term of our February 2018 Notes and increases interest expense during the term of our February 2018 Notes from the </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> cash coupon interest rate to an effective interest rate of </font><font style="font-family:inherit;font-size:10pt;">6.9%</font><font style="font-family:inherit;font-size:10pt;">. As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the remaining discount amortization period is </font><font style="font-family:inherit;font-size:10pt;">2.3 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The carrying value and unamortized discount of our February 2018 Notes were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="62%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="16%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount of the February 2018 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized discount of liability component</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18,419</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(23,772</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281,581</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276,228</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest expense for our February 2018 Notes on our Condensed Consolidated Statements of Income was as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="56%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contractual coupon interest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,633</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt issuance costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">510</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">536</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,599</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,358</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:start;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amortization of debt discount</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,830</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,688</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,353</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,238</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,224</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,952</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,229</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, our February 2018 Notes are not convertible. At </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the if-converted value of our February 2018 Notes did not exceed the principal amount.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Purchased Call Options and Warrants</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the issuance of our February 2018 Notes, we entered into purchased call option transactions with </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">two</font><font style="font-family:inherit;font-size:10pt;"> hedge counterparties. We paid an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$31.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the purchased call options with terms substantially similar to the embedded conversion options in our February 2018 Notes. The purchased call options cover, subject to anti-dilution and certain other customary adjustments substantially similar to those in our February 2018 Notes, approximately </font><font style="font-family:inherit;font-size:10pt;">32.7 million</font><font style="font-family:inherit;font-size:10pt;"> shares of our common stock. We may exercise the purchased call options upon conversion of our February 2018 Notes and require the hedge counterparty to deliver shares to the Company in an amount equal to the shares required to be delivered by the Company to the note holder for the excess conversion value. The purchased call options expire on February 1, 2018, or the last day any of our February 2018 Notes remain outstanding.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive shares of common stock that will initially underlie our February 2018 Notes at a strike price of </font><font style="font-family:inherit;font-size:10pt;">$10.3610</font><font style="font-family:inherit;font-size:10pt;"> per share, which represents a premium of approximately 30% over the last reported sale price of the Company's common stock of </font><font style="font-family:inherit;font-size:10pt;">$7.97</font><font style="font-family:inherit;font-size:10pt;"> on February 6, 2014. The warrant transactions could have a dilutive effect to the extent that the market price of the Company's common stock exceeds the applicable strike price of the warrants on the date of conversion. We received an aggregate amount of </font><font style="font-family:inherit;font-size:10pt;">$11.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates that occur over a period of time. If the VWAP of our common stock, as defined in the warrant agreement, exceeds the strike price of the warrants, we will deliver to the warrant counterparties shares equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of our February 2018 Notes. The strike price is subject to further adjustment in the event that future quarterly dividends exceed </font><font style="font-family:inherit;font-size:10pt;">$0.15</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The purchased call options and warrants are considered indexed to PDL stock, require net-share settlement, and met all criteria for equity classification at inception and at </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">. The purchased call options cost of </font><font style="font-family:inherit;font-size:10pt;">$31.0 million</font><font style="font-family:inherit;font-size:10pt;">, less deferred taxes of </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;">, and the </font><font style="font-family:inherit;font-size:10pt;">$11.4 million</font><font style="font-family:inherit;font-size:10pt;"> received for the warrants, was recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the purchased call options and warrants continue to meet all criteria for equity classification.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">March 2015 Term Loan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 30, 2015, PDL entered into a credit agreement among the Company, the lenders party thereto and the Royal Bank of Canada, as administrative agent. The credit agreement consists of a term loan of </font><font style="font-family:inherit;font-size:10pt;">$100.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interest rates per annum applicable to amounts outstanding under the term loan are, at the Company’s option, either (a) the alternate base rate (as defined in the credit agreement) plus </font><font style="font-family:inherit;font-size:10pt;">0.75%</font><font style="font-family:inherit;font-size:10pt;">, or (b) the adjusted Eurodollar rate (as defined in the credit agreement) plus 1.75% per annum. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the interest rate, based upon the adjusted Eurodollar rate, was </font><font style="font-family:inherit;font-size:10pt;">2.09%</font><font style="font-family:inherit;font-size:10pt;">. Interest payments under the credit agreement are due on the interest payment dates specified in the credit agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The term loan requires amortization in the form of scheduled principal payments on June 15, September 15 and December 15 of 2015, with the remaining outstanding balance due on February 15, 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any future material domestic subsidiaries of the Company are required to guarantee the obligations of the Company under the credit agreement, except as otherwise provided by the credit agreement. The Company’s obligations under the credit agreement are secured by a lien on a substantial portion of its assets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The credit agreement contains affirmative and negative covenants that the Company believes are usual and customary for a senior secured credit agreement. The credit agreement also requires compliance with certain financial covenants, including a maximum total leverage ratio, a debt service coverage ratio and a minimum liquidity covenant, in each case calculated as set forth in the credit agreement and compliance with which may be necessary to take certain corporate actions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The credit agreement contains events of default that the Company believes are usual and customary for a senior secured credit agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">October 2013 Term Loan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 28, 2013, PDL entered into a credit agreement among the Company, the lenders party thereto and the Royal Bank of Canada, as administrative agent. The October 2013 Term Loan amount was for </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">$75 million</font><font style="font-family:inherit;font-size:10pt;">, with a term of one year.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The interest rates per annum applicable to amounts outstanding under the October 2013 Term Loan were, at the Company’s option, either (a) the base rate plus </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">1.00%</font><font style="font-family:inherit;font-size:10pt;">, or (b) the Eurodollar rate plus 2.00% per annum. As of the final payment date, the interest rate was </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;">2.22%</font><font style="font-family:inherit;font-size:10pt;">. This principal balance and outstanding interest was paid in full on October 28, 2014.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Customer Concentration</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The percentage of total revenue recognized, which individually accounted for 10% or more of our total revenues, was as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Avastin</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Herceptin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Xolair</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biogen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tysabri</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depomed</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Glumetza</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the FASB issued ASU 2015-03 – </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:inherit;font-size:10pt;">, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for the Company beginning in the first quarter of 2016. The adoption of this ASU is not expected to have a significant impact on the Company's consolidated financial position or results of operations.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. Other Long-Term Liabilities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="70%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued lease liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term incentive accrual</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax positions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,035</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,356</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Spin-Off, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. Should Facet default under its lease obligations, we could be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$70.5 million</font><font style="font-family:inherit;font-size:10pt;">. If Facet were to default, we could also be responsible for lease-related costs including utilities, property taxes and common area maintenance that may be as much as the actual lease payments. We have recorded a liability of </font><font style="font-family:inherit;font-size:10pt;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;"> on our Condensed Consolidated Balance Sheets as of </font><font style="font-family:inherit;font-size:10pt;">September 30, 2015</font><font style="font-family:inherit;font-size:10pt;">, and December 31, 2014, related to this guarantee.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Notes Receivable and Other Long-Term Receivables</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for our notes receivable at both amortized cost, net of unamortized origination fees, if any, and as dependent on collateral when the loan for which repayment is expected to be provided solely by the underlying collateral. For loans accounted for at their amortized cost, related fees and costs are recorded net of any amounts reimbursed. Interest is accreted or accrued to "Interest revenue" using the interest method. When and if supplemental royalties are received from certain of these notes and other long-term receivables, an adjustment to the estimated effective interest rate is affected prospectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate the collectability of both interest and principal for each note receivable and loan to determine whether it is impaired. A note receivable or loan is considered to be impaired when, based on current information and events, we determine it is probable that we will be unable to collect amounts due according to the existing contractual terms. When a note receivable or loan is considered to be impaired, the amount of loss is calculated by comparing the carrying value of the financial asset to the value determined by discounting the expected future cash flows at the loan's effective interest rate or to the estimated fair value of the underlying collateral, less costs to sell, if the loan is collateralized and we expect repayment to be provided solely by the collateral. Impairment assessments require significant judgments and are based on significant assumptions related to the borrower's credit risk, financial performance, expected sales, and estimated fair value of the collateral.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Queen et al. Royalty Revenues</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our Queen Patent license agreements, we receive royalty payments based upon our licensees’ net sales of covered products. Generally, under these agreements we receive royalty reports from our licensees approximately one quarter in arrears, that is, generally in the second month of the quarter after the licensee has sold the royalty-bearing product. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the quarter reported to us by our licensees, that is, royalty revenues are generally recognized one quarter following the quarter in which sales by our licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also received annual maintenance fees from licensees of our Queen et al. patents prior to patent expiry as well as periodic milestone payments. We have no performance obligations with respect to such fees. Maintenance fees were recognized as they became due and when payment was reasonably assured. Total annual maintenance and milestone payments in each of the last several years have been less than 1% of total revenue.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The balance of accumulated other comprehensive income, net of tax, was as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td width="54%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="13%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains (losses) on available-for-sale securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized gains on cash flow hedges</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total Accumulated Other Comprehensive Income</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning Balance at December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,585</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,949</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Activity for the nine months ended September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">442</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending Balance at September 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,988</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25" rowspan="1"></td></tr><tr><td width="28%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Cash and Available-For-Sale Securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Adjusted Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Unrealized Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Unrealized Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Estimated Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> Cash and Cash Equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Short-Term Investments</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">88,005</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,206</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">621</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,061</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">621</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">229,682</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227,855</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,585</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293,127</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">560</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293,687</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">291,377</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effect of our derivative instruments in our Condensed Consolidated Statements of Income and our Condensed Consolidated Statements of Comprehensive Income was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="60%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain (loss) recognized in OCI, net of tax </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(1)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,974</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,306</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,305</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(2)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,495</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(989</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,903</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,744</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net gain (loss) recognized in interest and other income, net - cash flow hedges </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(3)</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The location and fair values of our Euro contracts in our Condensed Consolidated Balance Sheets were as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11" rowspan="1"></td></tr><tr><td width="31%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="38%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash Flow Hedge</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Location</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, <br clear="none"/>2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, <br clear="none"/>2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid and other current assets</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,352</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">717</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The notional amounts, Euro exchange rates and fair values of our Euro forward contracts designated as cash flow hedges were as follows:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21" rowspan="1"></td></tr><tr><td width="19%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="11%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="9%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Euro Forward Contracts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Currency</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Settlement Price</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($ per Euro)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Type</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Notional Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.256</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">241</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.257</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,750</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">728</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.259</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">752</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.260</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,468</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.270</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">377</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.281</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Sell Euro</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">503</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33,000</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85,875</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,069</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17" rowspan="1"></td></tr><tr><td width="59%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net Income per Basic and Diluted Share:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="vertical-align:top;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;vertical-align:top;"> </font><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;vertical-align:top;">(in thousands except per share amounts)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Numerator</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income used to compute net income per basic and diluted share</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69,459</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">102,235</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">232,221</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">267,173</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Denominator</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares used to compute net income per basic share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,560</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">160,268</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,314</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,274</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted stock outstanding</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed conversion of Series 2012 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,247</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,301</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed conversion of warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">403</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assumed conversion of May 2015 Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,431</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares used to compute net income per diluted share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,742</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,894</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">163,899</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">165,141</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income per share - basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.64</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net income per share - diluted</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.42</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33" rowspan="1"></td></tr><tr><td width="20%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="7%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2014</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,827</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,310</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Foreign currency hedge contracts</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,597</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,069</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Royalty rights - at fair value</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,572</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,244</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">139,850</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,682</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">384,572</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">532,104</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221,792</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,379</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">259,244</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">487,415</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td width="70%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="12%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:italic;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued lease liability</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,700</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term incentive accrual</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,446</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Uncertain tax positions</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,035</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26,356</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dividend payable</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">293</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48,474</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37,702</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with GAAP for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of PDL believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with our audited Consolidated Financial Statements and the related notes thereto for the year ended </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, included in our Annual Report on Form 10-K, as amended, filed with the SEC. The Condensed Consolidated Balance Sheet at </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 31, 2014</font><font style="font-family:inherit;font-size:10pt;">, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Principles of Consolidation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of PDL and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Our accompanying unaudited Condensed Consolidated Financial Statements are prepared in accordance with GAAP and the rules and regulations of the SEC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Management Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Notes Receivable and Other Long-Term Receivables</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for our notes receivable at both amortized cost, net of unamortized origination fees, if any, and as dependent on collateral when the loan for which repayment is expected to be provided solely by the underlying collateral. For loans accounted for at their amortized cost, related fees and costs are recorded net of any amounts reimbursed. Interest is accreted or accrued to "Interest revenue" using the interest method. When and if supplemental royalties are received from certain of these notes and other long-term receivables, an adjustment to the estimated effective interest rate is affected prospectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We evaluate the collectability of both interest and principal for each note receivable and loan to determine whether it is impaired. A note receivable or loan is considered to be impaired when, based on current information and events, we determine it is probable that we will be unable to collect amounts due according to the existing contractual terms. When a note receivable or loan is considered to be impaired, the amount of loss is calculated by comparing the carrying value of the financial asset to the value determined by discounting the expected future cash flows at the loan's effective interest rate or to the estimated fair value of the underlying collateral, less costs to sell, if the loan is collateralized and we expect repayment to be provided solely by the collateral. Impairment assessments require significant judgments and are based on significant assumptions related to the borrower's credit risk, financial performance, expected sales, and estimated fair value of the collateral.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Convertible Notes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We issued our Series 2012 Notes, May 2015 Notes and February 2018 Notes with a net share settlement feature, meaning that upon any conversion, the principal amount will be settled in cash and the remaining amount, if any, will be settled in shares of our common stock. In accordance with accounting guidance for convertible debt instruments that may be settled in cash or other assets upon conversion, we separated the principal balance between the fair value of the liability component and the common stock conversion feature using a market interest rate for a similar nonconvertible instrument at the date of issuance.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Queen et al. Royalty Revenues</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under our Queen Patent license agreements, we receive royalty payments based upon our licensees’ net sales of covered products. Generally, under these agreements we receive royalty reports from our licensees approximately one quarter in arrears, that is, generally in the second month of the quarter after the licensee has sold the royalty-bearing product. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the quarter reported to us by our licensees, that is, royalty revenues are generally recognized one quarter following the quarter in which sales by our licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also received annual maintenance fees from licensees of our Queen et al. patents prior to patent expiry as well as periodic milestone payments. We have no performance obligations with respect to such fees. Maintenance fees were recognized as they became due and when payment was reasonably assured. Total annual maintenance and milestone payments in each of the last several years have been less than 1% of total revenue.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although the last of our Queen et al. patents expired in December 2014, we expect to receive royalties beyond expiration based on the terms of our licenses and our legal settlements. We do not expect to receive any meaningful revenue from our Queen et al. patents beyond the first quarter of 2016. We believe that cash from future revenues from the Queen et al. patent royalties through the first quarter of 2016 and from acquired revenue generating assets, net of operating expenses, debt service and income taxes, plus cash on hand, will be sufficient to fund our operations over the next several years. However, we do not expect that our acquired revenue generating assets will, in the near term, replace the revenues we generate from our license agreements related to the Queen et al. patents. In the second quarter of 2016, our revenues are likely to materially decrease after we stop receiving payments from these Queen et al. patents license agreements, which currently account for 88% of our year to date revenue. The continued success of the Company will become more dependent on the timing and our ability to acquire new income generating assets in order to provide recurring revenues going forward and to support our business model and ability to pay dividends.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Royalty Rights - At Fair Value</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Currently, we have elected to account for our investments in royalty rights at fair value with changes in fair value presented in earnings. The fair value of the investments in royalty rights is determined by using a discounted cash flow analysis related to the expected future cash flows to be received. These assets are classified as Level 3 assets within the fair value hierarchy as our valuation estimates utilize significant unobservable inputs, including estimates as to the probability and timing of future sales of the related products. Transaction-related fees and costs are expensed as incurred.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The changes in the estimated fair value from investments in royalty rights along with cash receipts each reporting period are presented together on our Condensed Consolidated Statements of Income as a component of revenue under the caption, “Royalty rights - change in fair value.”</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Customer Concentration</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The percentage of total revenue recognized, which individually accounted for 10% or more of our total revenues, was as follows:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15" rowspan="1"></td></tr><tr><td width="23%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="36%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td><td width="8%" rowspan="1" colspan="1"></td><td width="1%" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Licensee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Name</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Genentech</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Avastin</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Herceptin</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Xolair</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biogen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Tysabri</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> %</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depomed</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Glumetza</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Foreign Currency Hedging</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into foreign currency hedges to manage exposures arising in the normal course of business and not for speculative purposes.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We hedge certain Euro-denominated currency exposures related to royalties associated with our licensees’ product sales with Euro forward contracts. In general, these contracts are intended to offset the underlying Euro market risk in our royalty revenues. The last of these contracts expires in the first quarter of 2016. We designate foreign currency exchange contracts used to hedge royalty revenues based on underlying Euro-denominated licensee product sales as cash flow hedges.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each hedging relationship and on a quarterly basis, we assess the hedge effectiveness. The fair value of the Euro contracts is estimated using pricing models with readily observable inputs from actively quoted markets and is disclosed on a gross basis. The aggregate unrealized gains or losses, net of tax, on the effective component of the hedge is recorded in stockholders’ equity as "Accumulated other comprehensive income." Realized gains or losses on cash flow hedges are recognized as an adjustment to royalty revenue in the same period that the hedged transaction impacts earnings as royalty revenue. Any gain or loss on the ineffective portion of our hedge contracts is reported in "Interest and other income, net" in the period the ineffectiveness occurs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The provision for income taxes is determined using the asset and liability approach. Tax laws require items to be included in tax filings at different times than the items are reflected in the financial statements. A current liability is recognized for the estimated taxes payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are adjusted for enacted changes in tax rates and tax laws. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Income</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive income comprises net income adjusted for other comprehensive income (loss), using the specific identification method, which includes the changes in unrealized gains and losses on cash flow hedges and changes in unrealized gains and losses on our investments in available-for-sale securities, all net of tax, which are excluded from our net income.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, the FASB issued ASU 2015-03 – </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simplifying the Presentation of Debt Issuance Costs</font><font style="font-family:inherit;font-size:10pt;">, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for the Company beginning in the first quarter of 2016. The adoption of this ASU is not expected to have a significant impact on the Company's consolidated financial position or results of operations.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. Cash Dividends</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">January 27, 2015</font><font style="font-family:inherit;font-size:10pt;">, our board of directors declared that the regular quarterly dividends to be paid to our stockholders in </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> will be </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">$0.15</font><font style="font-family:inherit;font-size:10pt;"> per share of common stock, payable on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 12</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 12</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 11</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 11</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;"> to stockholders of record on </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">March 5</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">June 5</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">September 4</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">December 4</font><font style="font-family:inherit;font-size:10pt;"> of </font><font style="font-family:inherit;font-size:10pt;color:#000000;text-decoration:none;">2015</font><font style="font-family:inherit;font-size:10pt;">, the record dates for each of the dividend payments, respectively.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">15. Subsequent Event</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">CareView</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 7, 2015, PDL and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. On this date, PDL also funded the first tranche of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">, net of fees, upon attainment of the modified first tranche milestone relating to the placement of CareView Systems. The additional </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> in the form of a second tranche continues to be available upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA, to be accomplished no later than June 30, 2017 under the terms of the amended credit agreement.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the amendment of the credit agreement, PDL and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant's exercise price from </font><font style="font-family:inherit;font-size:10pt;">$0.45</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$0.40</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Paradigm Spine</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On October 27, 2015, PDL and Paradigm Spine entered into an amendment to the Paradigm Spine Credit Agreement to provide additional term loan commitments of up to </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;"> payable in two tranches of </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">, of which the first tranche was drawn on the closing date of the amendment, net of fees, and the second tranche is to be funded at the option of Paradigm Spine prior to June 30, 2016.</font></div></div>

<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Management Estimates</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.</font></div></div>

Effective portion classified as royalty revenue. unaudited hange in the fair value of cash flow hedges, net of tax. Net of tax of $123 and ($139) for the three months ended September 30, 2015 and 2014, respectively, and $21 and ($837) for the nine months ended September 30, 2015 and 2014, respectively. Note 1 unaudited Ineffectiveness from excess hedge was approximately zero and ($2) for the three months ended September 30, 2015 and 2014, respectively, and zero and ($5) for the nine months ended September 30, 2015 and 2014, respectively. Net of tax of ($836) and $1,595 for the three months ended September 30, 2015 and 2014, respectively, and $217 and $3,257 for the

EX-101.SCH 10 pdli-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2111100 - Disclosure - Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 2311302 - Disclosure - Accrued Liabilities Accrued Liabilities, Current (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Accrued Liabilities (Accrued Liabilities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Accrued Liabilities (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2420403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Cash Dividends link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Cash Dividends (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Cash Dividends (Summary of Conversion Rates for Convertible Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Cash Dividends (Tables) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Cash Equivalents and Investments link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Cash Equivalents and Investments (Available-For-Sale Securities Balance Sheet Classification) (Detail) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Cash Equivalents and Investments (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Cash Equivalents and Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2412403 - Disclosure - Commitments and Contingencies (Future Minimum Operating Lease Payments) (Detail) link:presentationLink link:calculationLink link:definitionLink 2412402 - Disclosure - Commitments and Contingencies (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2312301 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2414400 - Disclosure - Convertible and Non-Recourse Notes (Future Minimum Principal Payments) (Detail) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 2413409 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) link:presentationLink link:calculationLink link:definitionLink 2413408 - Disclosure - Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) link:presentationLink link:calculationLink link:definitionLink 2413407 - Disclosure - Convertible Notes (Interest Expense for the May 2015 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Convertible Notes (Interest Expense for the Series 2012 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Convertible Notes (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413403 - Disclosure - Convertible Notes (Summary of Convertible Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413406 - Disclosure - Convertible Notes (Summary of May 2015 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2413404 - Disclosure - Convertible Notes (Summary of Series 2012 Notes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Convertible Notes (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Customer Concentration link:presentationLink link:calculationLink link:definitionLink 2418402 - Disclosure - Customer Concentration (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2418403 - Disclosure - Customer Concentration (Percentage of Total Revenue From Licenses Over 10% of Revenue) (Detail) link:presentationLink link:calculationLink link:definitionLink 2318301 - Disclosure - Customer Concentration (Tables) link:presentationLink link:calculationLink link:definitionLink 2418404 - Disclosure - Customer Concentration (Total Revenues by Geographic Area) (Detail) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) link:presentationLink link:calculationLink link:definitionLink 2404405 - Disclosure - Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Fair Value Measurements (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2404404 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Foreign Currency Hedging link:presentationLink link:calculationLink link:definitionLink 2406404 - Disclosure - Foreign Currency Hedging (Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet) (Detail) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Foreign Currency Hedging (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2406405 - Disclosure - Foreign Currency Hedging (Schedule of Effect of Derivative Instruments in Consolidated Statements of Income and Consolidated Statements of Comprehensive Income) (Detail) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Foreign Currency Hedging (Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges) (Detail) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Foreign Currency Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Income Taxes (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Income Taxes (Provision for Income Taxes) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Income Taxes (Reconciliation of the Income Tax Provision Computed Using the U.S. Statutory Federal Income Tax Rate) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419406 - Disclosure - Income Taxes (Reconciliation of Unrecognized Tax Benefits) (Detail) link:presentationLink link:calculationLink link:definitionLink 2419405 - Disclosure - Income Taxes (Significant Components of Deferred Tax Assets and Liabilities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Legal Proceedings link:presentationLink link:calculationLink link:definitionLink 2421401 - Disclosure - Legal Proceedings (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Net Income per Share link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Net Income per Share (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Net Income per Share (Net Income Per Basic and Diluted Share) (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Net Income per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Notes Receivable and Other Long-term Receivables link:presentationLink link:calculationLink link:definitionLink 2407401 - Disclosure - Notes Receivable and Other Long-term Receivables (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Organization and Business link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Organization and Business (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - Other Assets link:presentationLink link:calculationLink link:definitionLink 2424402 - Disclosure - Other Assets (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2424403 - Disclosure - Other Assets (Other Assets) (Detail) link:presentationLink link:calculationLink link:definitionLink 2324301 - Disclosure - Other Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2115100 - Disclosure - Other Long-Term Liabilities link:presentationLink link:calculationLink link:definitionLink 2415402 - Disclosure - Other Long-Term Liabilities (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2415403 - Disclosure - Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) link:presentationLink link:calculationLink link:definitionLink 2315301 - Disclosure - Other Long-Term Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Prepaid and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 2408402 - Disclosure - Prepaid and Other Current Assets (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Prepaid and Other Current Assets (Prepaid and Other Current Assets) (Detail) link:presentationLink link:calculationLink link:definitionLink 2308301 - Disclosure - Prepaid and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Property and Equipment (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Property and Equipment (Property and Equipment) (Detail) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Quarterly Financial Data (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2423402 - Disclosure - Quarterly Financial Data (Unaudited) (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2423403 - Disclosure - Quarterly Financial Data (Unaudited) (Quarterly Financial Data (Unaudited)) (Detail) link:presentationLink link:calculationLink link:definitionLink 2323301 - Disclosure - Quarterly Financial Data (Unaudited) (Tables) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2416406 - Disclosure - Stock-Based Compensation (Additional Information Regarding Our Options Exercised) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Stock-Based Compensation (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Stock-Based Compensation (Restricted Stock Activity) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416404 - Disclosure - Stock-Based Compensation (Shares of Company Common Stock Available Under Share-Based Plans) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Stock-Based Compensation (Stock-Based Compensation Expense for Employees and Directors and Non-Employees) (Detail) link:presentationLink link:calculationLink link:definitionLink 2416405 - Disclosure - Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2422401 - Disclosure - Subsequent Events (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Summary of Significant Accounting Policies Correction of immaterial error table (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Detail) link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Summary of Significant Accounting Policies (Schedule of Property and Equipment of Estimated Useful Lives) (Detail) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Summary of Significant Accounting Policies (Schedule of Revenue by Major Customers) (Details) link:presentationLink link:calculationLink link:definitionLink 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 11 pdli-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 12 pdli-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 13 pdli-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Cash and Cash Equivalents [Abstract] Schedule of Available-For-Sale Securities [Table] Schedule of Available-for-sale Securities [Table] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Axis] Major Types of Debt and Equity Securities [Domain] Major Types of Debt and Equity Securities [Domain] Cash [Member] Cash and Cash Equivalents [Member] Money Market Funds [Member] Money Market Funds [Member] Equity Securities [Member] Equity Securities [Member] Schedule of Available-For-Sale Securities [Line Items] Schedule of Available-for-sale Securities [Line Items] Adjusted Cost Available-for-sale Securities, Amortized Cost Basis Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value Cash, cash equivalents and available-for-sale securities valued at fair value. Cash and Cash Equivalents Cash and Cash Equivalents, at Carrying Value Short-Term Marketable Securities Available-for-sale Securities, Debt Securities, Current Debt Disclosure [Abstract] Debt Instrument [Table] Schedule of Long-term Debt Instruments [Table] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument [Domain] Debt Instrument, Name [Domain] Warrants [Member] Warrant [Member] February 2015 Notes [Member] Due February 2015 [Member] A borrowing which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. February 2018 Notes [Member] February 2018 Notes [Member] February 2018 Notes [Member] February 2018 Note Warrant [Member] February 2018 Note Warrant [Member] February 2018 Note Warrant [Member] February 2018 Note Purchase Call Option [Member] February 2018 Note Purchase Call Option [Member] February 2018 Note Purchase Call Option [Member] Term Loan. [Member] Term Loan. [Member] Term Loan. [Member] March 2015 Term Loan [Member] March 2015 Term Loan [Member] March 2015 Term Loan [Member] May 2015 Notes [Member] Due May 2015 [Member] 3.75% Senior Convertible Notes due May 2015 - borrowing which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. Purchased Call Options [Member] Purchased Call Options [Member] Purchased Call Options [Member] Series 2012 Notes [Member] Series 2012 Notes [Member] Series 2012 Notes [Member] Range [Axis] Range [Axis] Range [Domain] Range [Domain] Base Rate [Member] Base Rate [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Convertible notes Convertible Debt Total consideration given for convertible note exchange Total consideration given for convertible note exchange Total consideration given for convertible note exchange Incentive fee per each $1,000 principal amount tendered to convert debt Incentive fee per each $1,000 principal amount tendered to convert debt The amount of cash paid for each $1,000 principal amount tendered in the exchange of the Series 2012 notes for the February 2015 notes. Principal amount a $5 incentive cash payment per each to convert debt Principal amount a $5 incentive cash payment per each to convert debt The amount of principal tendered which a $5.00 cash payment is made per each to convert the Series 2012 notes to February 2015 notes. Induced conversion of convertible debt expense Induced Conversion of Convertible Debt Expense Deferred issue costs, incentive payment allocated Deferred Finance Costs, Gross Adjustments to additional paid in capital, equity component of convertible debt Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt Noted obligation allocated to deferred tax assets Noted obligation allocated to deferred tax assets Adjustment to deferred tax assets resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. Debt instrument, interest rate (in Percent) Debt Instrument, Interest Rate, Stated Percentage Unamortized discount of liability component Debt Instrument, Unamortized Discount Debt Conversion, Original Debt, Amount Debt Conversion, Original Debt, Amount Debt discount recorded to additional paid in capital Debt discount recorded to additional paid in capital Debt discount recorded to additional paid in capital Debt discount recorded to deferred tax liability Debt discount recorded to deferred tax liability Debt discount recorded to deferred tax liability Minimum conversion price percent for note conversion (in Percent) Minimum conversion price percent for note conversion (in Percent) The minimum conversion price of convertible notes in order for holders to convert their notes. Maximum percent of common stock closing price and conversion rate to convert note (in Percent) Maximum percent of common stock closing price and conversion rate to convert note (in Percent) Maximum percent of common stock closing price and conversion rate to convert note. Debt Instrument, Interest Rate, Effective Percentage Debt Instrument, Interest Rate, Effective Percentage Convertible notes, conversion price (in Dollars per Share) Debt Instrument, Convertible, Conversion Price Estimated market interest rate for similar nonconvertible instrument Estimated market interest rate for similar nonconvertible instrument Estimated market interest rate for similar nonconvertible instrument Debt instrument, convertible, remaining amortization period (in Duration) Debt Instrument, Convertible, Remaining Discount Amortization Period Net proceeds from the issuance of convertible notes Proceeds from Convertible Debt Convertible notes repurchase price as a percentage of principal (in Percent) Convertible notes repurchase price as a percentage of principal (in Percent) The price at which convertible notes can be repurchased as a percentage of the principal amount plus interest. Debt Instrument, Face Amount Debt Instrument, Face Amount Conversion Rate per $1,000 Principal Amount (in Ratio) Debt Instrument, Convertible, Conversion Ratio Number of hedge counterparties (in Counterparties) Number of hedge counterparties (in Counterparties) Number of counterparties that are part of a contractual agreement. Purchased call options cost Purchased call options cost Cost of the purchased call options. Number of shares of common stock covered by the purchased call options purchased (in Shares) Number of shares of common stock covered by the purchased call options purchased (in Shares) The number of shares of common stock covered by the purchased call option. Proceeds from Issuance of Warrants Proceeds from Issuance of Warrants Debt conversion, shares issued (in Shares) Debt Conversion, Converted Instrument, Shares Issued Debt Conversion, Converted Instrument, Amount Debt Conversion, Converted Instrument, Amount Cash paid to exchange convertible note Cash paid to exchange convertible note Cash paid to exchange convertible note Inducement fee Inducement fee Inducement fee Interest Payable Interest Payable Deferred Income Tax Expense (Benefit) Deferred Income Tax Expense (Benefit) Deferred taxes included in purchased call options cost Deferred taxes included in purchased call options cost The deferred taxes on purchased call options cost. Gain on conversion of convertible notes Gains (Losses) on Extinguishment of Debt Debt discount, derecognition on exchange Debt discount, derecognition on exchange Debt discount, derecognition on exchange Debt Exchange cost other Debt Exchange cost other Debt Exchange cost other Share Price Share Price Dividends Payable, Amount Per Share Dividends Payable, Amount Per Share Short-term Debt Short-term Debt Convertible and Non-Recourse Notes Long-term Debt [Text Block] Convertible Notes Payable, Carrying Value Notes Payable DocumentAndEntityInformation [Abstract] DocumentAndEntityInformation [Abstract] Entities [Table] Entities [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Entity Information [Line Items] Entity Information [Line Items] Entity Registrant Name Entity Registrant Name Document Type Document Type Current Fiscal Year End Date Current Fiscal Year End Date Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Entity Voluntary Filers Entity Voluntary Filers Entity Filer Category Entity Filer Category Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Payables and Accruals [Abstract] Accrued Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Asset, Current Derivative Asset, Current Derivative Asset, Noncurrent Derivative Asset, Noncurrent Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Variable Rate [Axis] Variable Rate [Axis] Variable Rate [Domain] Variable Rate [Domain] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Contractual coupon interest Interest Expense, Debt, Excluding Amortization Amortization of debt issuance costs Amortization of debt issuance costs Amortization of debt issuance costs Amortization of debt discount Amortization of Debt Discount (Premium) Total Interest Expense, Debt Cash Equivalents and Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value by Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Change in fair value of acquired royalty rights Change in fair value of acquired royalty rights, Level 3 Rollforward Change in fair value of acquired royalty rights, Level 3 Rollforward Beginning balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value Gains (losses) included in earnings Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Purchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Ending balance Payments for (Proceeds from) Productive Assets Payments for (Proceeds from) Productive Assets Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unobservable Input, Unrealized Gains (Losses), Changes in Assets and Liabilities, Continued to be Held, Amount Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unobservable Input, Unrealized Gains (Losses), Changes in Assets and Liabilities, Continued to be Held, Amount Accumulated Other Comprehensive Income (Loss) [Abstract] Accumulated Other Comprehensive Income (Loss) [Abstract] Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Measurements Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Fair Value Level 1 [Member] Fair Value, Inputs, Level 1 [Member] Fair Value Level 2 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Level 3 [Member] Fair Value, Inputs, Level 3 [Member] Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Royalty rights Royalty rights Royalty rights Financial assets: Financial assets: Financial assets: Cash and Cash Equivalents, Fair Value Cash and Cash Equivalents, Fair Value Disclosure Available for Sale Securities, Fair Value Available-for-sale Securities Assets, Fair Value Assets, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Foreign Currency Contract, Asset, Fair Value Disclosure Warrants and Rights Outstanding Warrants and Rights Outstanding Financial liabilites: Financial liabilites: Financial liabilites: Derivative [Table] Derivative [Table] Derivative Instrument Risk [Axis] Derivative Instrument [Axis] Derivative Contract Type [Domain] Derivative Contract [Domain] Euro Forward Contracts [Member] Foreign Exchange Forward [Member] Derivative, by Nature [Axis] Derivative, by Nature [Axis] Derivative Name [Domain] Derivative, Name [Domain] Eurodollar Sell Forward Contract 1.256 [Member] Eurodollar Sell Forward Contract 1.256 [Member] Eurodollar Sell Forward Contract 1.256 [Member] Eurodollar Sell Forward Contract 1.257 [Member] Eurodollar Sell Forward Contract 1.257 [Member] Eurodollar Sell Forward Contract 1.257 [Member] Eurodollar Sell Forward Contract 1.259 [Member] Eurodollar Sell Forward Contract 1.259 [Member] Eurodollar Sell Forward Contract 1.259 [Member] Eurodollar Sell Forward Contract 1.260 [Member] Eurodollar Sell Forward Contract 1.260 [Member] Eurodollar Sell Forward Contract 1.260 [Member] Eurodollar Sell Forward Contract 1.270 [Member] Eurodollar Sell Forward Contract 1.270 [Member] Eurodollar Sell Forward Contract 1.270 [Member] Eurodollar Sell Forward Contract 1.281 [Member] Eurodollar Sell Forward Contract 1.281 [Member] Eurodollar Sell Forward Contract 1.281 [Member] Derivative [Line Items] Derivative [Line Items] Derivative, Forward Exchange Rate Derivative, Forward Exchange Rate Fair Value Foreign Currency Cash Flow Hedge Derivative at Fair Value, Net Derivative, Notional Amount Derivative, Notional Amount Earnings Per Share [Abstract] Schedule of calculation of numerator and denominator in earnings per share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Stockholders' Equity Note [Abstract] Cash Dividends Stockholders' Equity Note Disclosure [Text Block] Other Liabilities Disclosure [Abstract] Schedule of Other Liabilities [Table] Schedule of Other Liabilities [Table] Schedule of Other Liabilities [Table] Schedule of Other Liabilities [Line Items] Schedule of Other Liabilities [Line Items] [Line Items] for Schedule of Other Liabilities [Table] Accrued lease liability Accrued Rent, Noncurrent Accrued Bonuses Accrued Bonuses Uncertain tax position Liability for Uncertain Tax Positions, Noncurrent Dividends Payable Dividends Payable Total Other Liabilities, Noncurrent Fair Value By Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Receivable Type [Axis] Receivable Type [Axis] Receivable Type [Domain] Receivable [Domain] Wellstat Note Receivable [Member] Wellstat Note Receivable [Member] Wellstat Note Receivable [Member] Hyperion [Member] Hyperion [Member] Hyperion [Member] Avinger Note Receivable [Member] Avinger Note Receivable [Member] Avinger Note Receivable [Member] LENSAR Note Receivable [Member] LENSAR Note Receivable [Member] LENSAR Note Receivable [Member] Direct Flow Medical Note Receivable [Member] Direct Flow Medical Note Receivable [Member] Direct Flow Medical Note Receivable [Member] Paradigm Spine [Member] Paradigm Spine [Member] Paradigm Spine [Member] kaleo Note Receivable [Member] kaleo Note Receivable [Member] kaleo Note Receivable [Member] Fair Value by Balance Sheet Grouping [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Debt Instrument, Unamortized Discount Assets Assets [Abstract] Notes receivable, Carrying Value Notes, Loans and Financing Receivable, Gross, Noncurrent Notes receivable, Fair Value Notes Receivable, Fair Value Disclosure Liabilities: Liabilities [Abstract] Notes payable, Fair Value Long-term Debt, Fair Value Other Long-Term Liabilities [Abstract] Other Long-Term Liabilities [Abstract] Guarantor Obligations, Maximum Exposure, Undiscounted Guarantor Obligations, Maximum Exposure, Undiscounted Accounting Policies [Abstract] Schedule of Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Property, Plant and Equipment by Type [Axis] Property, Plant and Equipment, Type [Axis] EX-101.PRE 14 pdli-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 15 pdl-logoa05a01a01a01a02.jpg begin 644 pdl-logoa05a01a01a01a02.jpg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
/Y#7\S2VNH>;-%0FHMK/4+9T'L#=6<[?>V;&/ M;NH',1/P_46/ $\\M?\ .!/_ #CYH$T<]]INM>;6B8,J:QJ)X$CIR2R2T##V M.WCD,G;>IER('N'Z[3P!]9>7/*_EOR?I<.B>5=!L/+ND6^\6G:=;QVT0)ZL5 MC"@L:;D[GOFKR9)9#?_+3Z'_R+D_YKS*_E+4_SRCA#*?)_ MY'?E+^7^L#S!Y,\B:9Y>UI87MQJ-HKK)Z4M.:5+$4-!E6769LL>& XML 16 R39.htm IDEA: XBRL DOCUMENT v3.3.0.814

Cash Equivalents and Investments (Narrative) (Detail) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Dec. 31, 2014

Sep. 30, 2014

Sep. 30, 2015

Cash and Cash Equivalents [Abstract]

Gains (losses) on sales of available-for-sale securities $ 580,000 $ 0

Unrealized Gain (Loss) on Investments $ 364,000 $ 404,000

X

- Definition
This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 17 R54.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Feb. 12, 2014

Debt Instrument [Line Items]

Debt Instrument, Unamortized Discount $ (1,400)

February 2018 Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Unamortized Discount (18,419) $ (23,772) $ (29,700)

Convertible notes 281,581 276,228 300,000

Debt Instrument, Face Amount $ 300,000 $ 300,000 $ 300,000

X

- Definition
Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_February2018NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 18 R48.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes (Narrative) (Detail)
$ / shares in Units, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended

May. 02, 2015

shares

Feb. 18, 2015

shares

Oct. 20, 2014

USD ($)

shares

Feb. 11, 2014

USD ($)

Feb. 05, 2014

USD ($)

shares

May. 16, 2011

USD ($)

Jan. 31, 2013

USD ($)

Jan. 31, 2012

USD ($)

Sep. 30, 2015

USD ($)

$ / shares

shares

Sep. 30, 2014

USD ($)

Sep. 30, 2015

USD ($)

$ / shares

shares

Sep. 30, 2014

USD ($)

Dec. 31, 2014

USD ($)

May. 01, 2015

USD ($)

Mar. 30, 2015

USD ($)

Feb. 17, 2015

USD ($)

Nov. 24, 2014

USD ($)

Feb. 12, 2014

USD ($)

$ / shares

Feb. 07, 2014

USD ($)

Feb. 06, 2014

USD ($)

$ / shares

Oct. 28, 2013

USD ($)

Aug. 01, 2013

USD ($)

Feb. 29, 2012

USD ($)

Debt Instrument [Line Items]

Principal amount a $5 incentive cash payment per each to convert debt $ 1,000

Unamortized discount of liability component (1,400,000) $ (1,400,000)

Debt Conversion, Original Debt, Amount $ 26,000,000

Net proceeds from the issuance of convertible notes 0 $ 300,000,000

Proceeds from Issuance of Warrants 0 11,427,000

Gain on conversion of convertible notes $ 0 $ 0 $ 0 $ 6,143,000

Share Price | $ / shares $ 7.97

Dividends Payable, Amount Per Share | $ / shares $ 0.15 $ 0.15

Warrants [Member]

Debt Instrument [Line Items]

Convertible notes, conversion price (in Dollars per Share) | $ / shares $ 6.40 $ 6.40

Number of shares of common stock covered by the purchased call options purchased (in Shares) | shares 27.5 27.5

Proceeds from Issuance of Warrants $ 10,900,000 $ 10,900,000

Debt conversion, shares issued (in Shares) | shares 2.1

February 2015 Notes [Member]

Debt Instrument [Line Items]

Convertible notes $ 169,000,000 $ 1,000,000

Incentive fee per each $1,000 principal amount tendered to convert debt 5.00

Principal amount a $5 incentive cash payment per each to convert debt 1,000

Debt Instrument, Face Amount $ 0 $ 0

February 2018 Notes [Member]

Debt Instrument [Line Items]

Convertible notes 281,581,000 281,581,000 $ 276,228,000 $ 300,000,000

Debt instrument, interest rate (in Percent) 4.00%

Unamortized discount of liability component $ (18,419,000) (18,419,000) $ (23,772,000) $ (29,700,000)

Debt discount recorded to additional paid in capital 19,300,000

Debt discount recorded to deferred tax liability $ 10,400,000

Minimum conversion price percent for note conversion (in Percent) 130.00%

Maximum percent of common stock closing price and conversion rate to convert note (in Percent) 98.00%

Debt Instrument, Interest Rate, Effective Percentage 6.90%

Convertible notes, conversion price (in Dollars per Share) | $ / shares $ 9.17

Estimated market interest rate for similar nonconvertible instrument 7.00%

Debt instrument, convertible, remaining amortization period (in Duration) 2 years 4 months 5 days

Net proceeds from the issuance of convertible notes $ 290,200,000

Debt Instrument, Face Amount $ 300,000,000 $ 300,000,000 $ 300,000,000 $ 300,000,000

Conversion Rate per $1,000 Principal Amount (in Ratio) 109.1048

February 2018 Note Warrant [Member]

Debt Instrument [Line Items]

Convertible notes, conversion price (in Dollars per Share) | $ / shares $ 10.3610 $ 10.3610

Proceeds from Issuance of Warrants $ 11,400,000

February 2018 Note Purchase Call Option [Member]

Debt Instrument [Line Items]

Number of hedge counterparties (in Counterparties) 2 2

Purchased call options cost $ 31,000,000

Number of shares of common stock covered by the purchased call options purchased (in Shares) | shares 32.7 32.7

Deferred taxes included in purchased call options cost $ 10,800,000

Term Loan. [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount $ 50,000,000 $ 50,000,000

Short-term Debt $ 75,000,000

Term Loan. [Member] | Base Rate [Member]

Debt Instrument [Line Items]

Debt instrument, interest rate (in Percent) 2.22% 2.22% 1.00%

March 2015 Term Loan [Member]

Debt Instrument [Line Items]

Short-term Debt $ 100,000,000

March 2015 Term Loan [Member] | Base Rate [Member]

Debt Instrument [Line Items]

Debt instrument, interest rate (in Percent) 2.09% 2.09% 0.75%

May 2015 Notes [Member]

Debt Instrument [Line Items]

Convertible notes $ 155,300,000

Debt instrument, interest rate (in Percent) 3.75% 3.75%

Unamortized discount of liability component $ 0 $ 0 (1,815,000)

Convertible notes, conversion price (in Dollars per Share) | $ / shares $ 5.44 $ 5.44

Net proceeds from the issuance of convertible notes $ 149,700,000

Convertible notes repurchase price as a percentage of principal (in Percent) 100.00%

Debt Instrument, Face Amount $ 0 $ 0 155,050,000 $ 155,100,000

Debt conversion, shares issued (in Shares) | shares 5.2

Purchased Call Options [Member]

Debt Instrument [Line Items]

Purchased call options cost 20,800,000

Deferred taxes included in purchased call options cost 7,200,000

Series 2012 Notes [Member]

Debt Instrument [Line Items]

Convertible notes $ 22,300,000 $ 26,000,000 $ 131,700,000 $ 131,700,000 $ 10,000,000

Total consideration given for convertible note exchange 191,800,000

Induced conversion of convertible debt expense 845,000

Deferred issue costs, incentive payment allocated 765,000

Adjustments to additional paid in capital, equity component of convertible debt 52,000

Noted obligation allocated to deferred tax assets $ 28,000

Debt instrument, interest rate (in Percent) 2.875%

Unamortized discount of liability component $ (100,000) 0 0 (76,000) $ (2,100,000)

Debt Instrument, Face Amount $ 0 $ 0 $ 22,337,000 $ 22,300,000 48,300,000 $ 180,000,000

Debt conversion, shares issued (in Shares) | shares 1.3 1.8 20.3

Debt Conversion, Converted Instrument, Amount $ 157,600,000

Cash paid to exchange convertible note $ 26,200,000 34,200,000

Inducement fee 2,500,000

Interest Payable 1,800,000

Deferred Income Tax Expense (Benefit) $ 29,900,000

Debt discount, derecognition on exchange 5,800,000

Debt Exchange cost other $ 300,000

X

- Definition
Cash paid to exchange convertible note
+ References
No definition available.
+ Details

Name: pdli_Cashpaidtoexchangeconvertiblenote

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The price at which convertible notes can be repurchased as a percentage of the principal amount plus interest.
+ References
No definition available.
+ Details

Name: pdli_ConvertibleNotesRepurchasePriceAsPercentageOfPrincipal

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Debt Exchange cost other
+ References
No definition available.
+ Details

Name: pdli_DebtExchangecostother

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Maximum percent of common stock closing price and conversion rate to convert note.
+ References
No definition available.
+ Details

Name: pdli_DebtInstrumentConvertibleMaximumClosingPricePercentage

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The minimum conversion price of convertible notes in order for holders to convert their notes.
+ References
No definition available.
+ Details

Name: pdli_DebtInstrumentConvertibleMinimumConversionPricePercent

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Debt discount, derecognition on exchange
+ References
No definition available.
+ Details

Name: pdli_Debtdiscountderecognitiononexchange

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Debt discount recorded to additional paid in capital
+ References
No definition available.
+ Details

Name: pdli_Debtdiscountrecordedtoadditionalpaidincapital

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Debt discount recorded to deferred tax liability
+ References
No definition available.
+ Details

Name: pdli_Debtdiscountrecordedtodeferredtaxliability

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The deferred taxes on purchased call options cost.
+ References
No definition available.
+ Details

Name: pdli_DeferredTaxesOnPurchasedCallOptionsCost

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Estimated market interest rate for similar nonconvertible instrument
+ References
No definition available.
+ Details

Name: pdli_Estimatedmarketinterestrateforsimilarnonconvertibleinstrument

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of cash paid for each $1,000 principal amount tendered in the exchange of the Series 2012 notes for the February 2015 notes.
+ References
No definition available.
+ Details

Name: pdli_IncentiveFeeForEach1000PrincipalForDebtConversion

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Inducement fee
+ References
No definition available.
+ Details

Name: pdli_Inducementfee

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Adjustment to deferred tax assets resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component.
+ References
No definition available.
+ Details

Name: pdli_NotedObligationAllocatedToDeferredTaxAssets

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of counterparties that are part of a contractual agreement.
+ References
No definition available.
+ Details

Name: pdli_NumberOfHedgeCounterparties

Namespace Prefix: pdli_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of shares of common stock covered by the purchased call option.
+ References
No definition available.
+ Details

Name: pdli_NumberOfSharesOfCommonStockCoveredByPurchasedCallOptionsPurchased

Namespace Prefix: pdli_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The amount of principal tendered which a $5.00 cash payment is made per each to convert the Series 2012 notes to February 2015 notes.
+ References
No definition available.
+ Details

Name: pdli_PrincipalAmountIncentiveFeePaidPer

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cost of the purchased call options.
+ References
No definition available.
+ Details

Name: pdli_PurchasedCallOptionsCost

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total consideration given for convertible note exchange
+ References
No definition available.
+ Details

Name: pdli_Totalconsiderationgivenforconvertiblenoteexchange

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Adjustment to additional paid in capital resulting from the recognition of convertible debt instruments as two separate components - a debt component and an equity component. This bifurcation may result in a basis difference associated with the liability component that represents a temporary difference for purposes of applying accounting for income taxes. The initial recognition of deferred taxes for the tax effect of that temporary difference is as an adjustment to additional paid in capital.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 25

-Paragraph 22

-URI http://asc.fasb.org/extlink&oid=51819886&loc=SL6014347-161799

+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

+ Details

Name: us-gaap_DebtConversionOriginalDebtAmount1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Conversion Rate

-URI http://asc.fasb.org/extlink&oid=6509012

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Remaining amortization period for discount on the liability component of convertible debt which may be settled in cash upon conversion, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleRemainingDiscountAmortizationPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
For an unclassified balance sheet, the amount as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain. Such amount is before the consideration of accumulated amortization.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28555-108399

+ Details

Name: us-gaap_DeferredFinanceCostsGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Deferred Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6510177

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 6.I.7)

-URI http://asc.fasb.org/extlink&oid=34349781&loc=d3e330036-122817

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 6

-Section I

-Subsection 7

+ Details

Name: us-gaap_DeferredIncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The per share amount of a dividend declared, but not paid, as of the financial reporting date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DividendsPayableAmountPerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Consideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7656879&loc=d3e7290-112610

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 40

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=6928171&loc=d3e6835-112609

+ Details

Name: us-gaap_InducedConversionOfConvertibleDebtExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest payable on debt, including, but not limited to, trade payables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_InterestPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.13)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),16(a)(1))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13

-Subparagraph 2, 3

-Article 9

+ Details

Name: us-gaap_ShortTermBorrowings

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_DueFebruary2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_February2018NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_February2018NoteWarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_February2018NotePurchaseCallOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_TermLoan.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RangeAxis=us-gaap_BaseRateMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_March2015TermLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_DueMay2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_PurchasedCallOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_Series2012NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

EXCEL 19 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`+"`9$<"//_T#0(``(=/NS):86*T:UKHIT926J>2HKJ^^["F$H:/%QV.@Y%Y7QOMQ:$T:W,3V M4W>2=>DVFZ&ESK5W-F^I4RY-;W*\6MR:D#X;FU.PP\CFP/&3UR7.7J=@](%, M%WNB9,1XKGZQ\A3Y1O:F+LQO:CPX[VK`XWSFM@/_K'4IT/.$O-OZRI' MX[,JG&[\6V>#+4/ST_:W'>7\'Z_EY";N[7@3S/UP4F!_L3&58VW-,)T;U;T+ MN^_.[5[S,:%R51UU2Q_RPI"&,T])7GR;HY'EU/]5^^E):5V@9Q4L"R_X4O0F M4/9Z_S]3T.?@Y'-APLB\:(^!$@?$J0/!=*'!NFC`>GC M+4@?[T#Z>`_2!U^A-((B*D MQW8OG*\M"_V/Z'D4X$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8 M_`)02P,$%`````@`L(!D1TAJMI,?`@``ER4``!H```!X;"]?`[+&Q8@-B MIFIS]Z%>5.X/1UU8.AL01OKF75B/T,!3GYOUEW1JRW'H'E(M31/KZ7I.]?STY^S5 MZVY33:^[4*V^MM,AE4WU?9C>;;'V/ZG^6'_?ZX32_#]MLY M]>4?%?6O!:IZ.4B6@X02I,M!2@FRY2"C!/ERD%."XG)0I`3=+P?=4X(>EH,> M*$&/RT&/E*#0`!D;3A+"FJ-U`%P'CM@:.W`+V%H[<`O87TK(T>MCEZ"]!;.'H+T%LX>@O06SAZ M"]!;.'H+T%LX>@O06SAZ"]!;.'HKT%LY>BO06SEZ*]!;27LE:+.$H[<"O96C MMP*]E:.W`KV5H[<"O96CMP*]E:.W`KV5H[AO0VSAZ&]#;.'H;T-LX>CO0VSEZ.]#;.7H[T-LY M>CO0VSEZ.]#;2>\JT#O1VCMX.]':.WA'H'3EZ1Z!W MY.@=@=Z1HW>\TCMW[91V;V4Z]H=\ZYK?AL.B*[QS^3BEVZ=;_VLN4W^&U']]@_7\"5!+`P04````"`"P@&1'XY-;J6\#``!\#P``$``` M`&1O8U!R;W!S+V%P<"YX;6R]5]]OVC`0_EG3[7ECJW&XPSL1B1VLJ5A`?ZGY\N;<*L62V:+KQP7ZIUODB6JPQV^M@BI.A6D1S?_@8Z=5 MF:VDY3G)M%'A;ZF>]1K`Z$&P%Y;'0]W#,^^&O4ZI@:=CS6`?6;A-VU'<5K+@ M)@$]7SY09?Y3*LJ8=HGH;3-1!;J[@@Q%3";"(!W)G:A,8?$.4[(_C>:S\606 M3<8$3]%\>C<>+O`A6N"_^\GL#,SU&9BN#^;[<#JD\E+S@N<+JA$*!;_3A2@C06Y[Y<*T&DRRI4"P3;D%N(5,MOMM30X M@G\"`S3QE$!I8&[6&,%4UF`P#2J'F$PY?>()M_/6[;Q,4U[Z6?D]DI@['$B" MU2,P-!S@UI'2,Z?6FWM7"U#I/_V(C&3/5]^QR:P/*?:H;F@9F_$Q+WB,.\5] MW[;*"_I:8Q`3E*=Y@B-]ETMK5L$:+?/"S8HH?]+PDML&GQ2U?&@D9L?=G,T8 M=W.ZR$PN%I8A^M*'U3N0/[L[[M:L8_?6T&FT:@ZE@5\6Z%_RZ\_^A;GN>!1F M1I5"2M=0JP:SD_J5LS+EA_G!!17,#Q/A2HUS+\P4"DA(S89JHMKU5W],M^U) MSS)QGI@R"9Z8,CO^=KHU@Z!I/W1O3MT/Y.)-Z+\KR,6I;;UOA,O3,0=M.#H# M$YV*N1,&%'('OS^R,^S<^]NYJ>F%#Y@CB3_FQLV#QCDZ<_="(V;NGCMU^WV; MOA/6_#%QQN"V<[CW/R"HF]>->Z%7MQ?>_12HY_6'KYAWWRS!\;=V^!=02P,$ M%`````@`L(!D1X@/8),^`0``:0,``!$```!D;V-0TD#PB%3>E#'D\PX(XZ.MY@L$&D^)EFF]-\;0FE%O'#SUNWN M^^R[V:04C@GKX=E;!QX5A)N]KDU@PLVS#:)CA`2Q`KS;^3K!I"!0@P:#@=`1 M)5GU:K;&-J8D@[XJH^.:!UQ8J58*Y%T[E%VF8F<$K\-1#K)OG_[^Z2%E2-95 M[H/JJYJF&3635!<'IN1]\?22SB97)B`W`J(J*(:M@WEVZOPVN7]8/F;5N*#3 MG-*\N%W2&2NF;#S].$QVYF\PK+LA_JWCD\&T7518PY6[31J9EIL^$TA"$%XY M5-9TQ]2LZ>U75 M-U!+`P04````"`"P@&1'F5R<(Q`&``"<)P``$P```'AL+W1H96UE+W1H96UE M,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621 MA'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_> MX%#BVR]*+41B1%G\@MNN01.+5)#3(3 M/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7H5A)VH3X$$8: MXIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7`\:V@S&L%&KQMUAVC2 M/'K^!?F<-0HACA*FNVB M<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y`\FIS_I,C0'HYI9";V$5FJ? MJH,@H%\;D>/N5Z>`HWEL:\4*Z">P'_T=HWPJOX@L`Y?RY]SZ7ON?0] MH=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA*]+',<$X>RPP[ M9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X M&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#AWE[7YAGE<90 M-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1`O)256`Q6\8#*Y"B?$R,1>APYY=< M7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*POFH]M!5.S_Y9 MKF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=WP6#R_7#)1P_E M.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%`B.5'`86%S+D4.Z2D`83``>LX=SFWJXPD6L_UC6'ODRWSEPVSK>`U[F$RQ#I'[!?8J* M@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X`Q\U*M:I60K$3]+!WP?D@9CC%OT M-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%FAHSU8NL.8T*;T'50.4_V]0-:/8- M-!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0````(`+"`9$<\0I"Q MAP(``/@-```-````>&POS1'"E5+Y9\\KDA5FJ!B*''.]DPG)D-*7 M0X3#*.`EFS-5@$247(5P5D/`Q=^)%(?P\>+CKU*HVP_`K8-/@X'_>'G;QR_L MQB4$CN-K&L+1=`*]EY,._?V\>J]'/3U`?2\4WB.YM?5/U;,]U#LEAJN6U0^^ M?CZX%=H+O#F4M9NV%S[S7UGJYXO]%_W(T'M5RT1!)GC3.6/H@"@HGL`:4>UO MW1-!A01*MZ;681&.&'8>=XB26!(#9H@1NG7PV`"VFRL_1KB0-K?+T,\S])M, MSP M+;-/)^S)?-^N.4+""8IC_NK/5MKT?*6]34^=1-KU^4J[.5MIL_-]0O4(=Z;2 MKO[W?GK5$-*:=#IS3HV"N"14$;Z3@,QD>F]DT\X(TLPXFC/=-..-W54HUI]A MG2R:+,49*JGZ0=9"V`UWSK17\`4$L# M!!0````(`+"`9$<7F!A:[00``!84```/````>&PO=V]R:V)O;VLN>&ULE9C= M.K]*('D'_29$IG$B"GS!!RIC`YUXHM@B:V1269)'WZ2@::ST%V MPQ6VL)>WI*7M+7_5E\]2/3U(^41>BKS4EVH8K(W97/9Z.EWS@NE_Y(:7]K^5 M5`4S]E0]]N1J)5(^EFE5\-+T:+^?]!3/F1&RU&NQT<&>IC]"TQO%6:;7G)LB MW\$*)LK@VU=]N1(YO^=*6S!AF\V<%7P8O.0!R9DVDTP8G@V#R)[*9]YH4-7F MNA*Y.XG[<=!SL$-7_U,DE1G?P99KH?_?_Q&0C*]8E9NE#?;PW&$PH!&ER8[A M+KL7_%DCT#40EAJQY4OV,`SZ`6&5D3'_*EEM1/EH60%9":7-PG6W MOK(0I2C$+Q>W/=-K^?Q=*O%+EH;EBU3)/*_ODK`?G,,7DJLS(I#260J;E M;O+LT+@8[,73K'ZPNA3V0$VSP6ZH$#2ZFX\G\\5D3.S1XFXV'5\M["(@!%`(H^#+J^FEW-1Q,"H!A`\:F@!$`)@))3NW8. MH',`G1^#%E51,/5*Y(HLQ&,I[*IG3H8TE965`4!?`/3EW1],RE04G&Z[( M8LT4A[LOX.Z+X[MOF%#DGN45)[>1G);8L=_<2 M9H6>EEN;-!P+40V3/2K?2,7M8)!1I10OTU?RG6>/=FTC`R4>>"R>2\,U^<%3 M;@.R*[(.Y\ZL[=C,9!.%&@\\'MO)4!7/R$RP>ID+WA@8E'?@LU<6A:C'8#;NGMX,PH[\!C[UO7/2ZZ*MLZ@K@.?KT:F M3Y^OF>:N(X5]U>BC/(6F#CRJUJ:,Q59DO,P:3T=+!QY-]X(OV4LC:HIN4H^; M=@:KHK)O3WYPP,6N^-J&;]\HB$(WJS)]MT:H8W,ZI&R<[53 M3*T4I:0>*;M1F%PI"DH]@OI2!SE;NE6C/R$(!:4>05NRR(&%*-25^A)L5S:A MF&`I*DL]RK9EDWU8B$)SJ<_<]RO0.TQH,?58W+$4'0]?L"AV>*K8X0!1*';H M%;M#J)`B"C4/?;G7*]2<*<5,<[F%C1+"HWD+ZM"**-0\]&C>:NAA6XIN6W[A!:+0 M]M!C>RCZ@E!%-H>>6SO MC"IJ5,R-DMF7U+OJGRA&%-H>>6SWU#_D[*T146A[Y$OK7;40.4,4VAYY;/?D MXC\9YE,3A;9''TOKD`U'B$+;(Y_MG:@%;E70]MA74!^CIJ7=[=J%0R8O&T2A M[;%O;]@9U2VBT/;8MSOLBBK&)!.C[;%O?WB$:K0@"FV/O35V!RI&V^/&%M%C M>^?;>8Y))D;;X]-J;G)VAV^<&&V/3ZB[]Q.)*+0]_FOYW5PU8]Z("FV/_U*/ M'X$89H8$;4].K602K&02M#WY2(G>FAD2M#VA^Z\V;Q]J,KX2)<_<9RQ=/R9E M>>J^;=F?W2XTBMVFQ9W?RLP^VWV4"LBJRO.1;;LK9Y+5GVYVY,/7K&^_`5!+ M`P04````"`"P@&1'2-H=BW("``#`"```&````'AL+W=OF[H5![^4LML'@2A*VA#QQ#K:JB=7 MQALBU9#?`M%Q2B[&U-0!#L,T:$C5^GEFYEYXGK&[K*N6OG!/W)N&\']'6K/^ MX"-_G'BM;J74$T&>!9/O4C6T%15K/4ZO!_\9[4\HU1*C^%W17H![3V_^S-B; M'OR\'/Q0[X'6M)!Z":(N#WJB=:U74N2_PZ(?3&V$]^/JWTVX:OMG(NB)U7^J MBRS5;D/?N]`KN=?RE?4_Z!!#HAN^RQM1.LID& M+V09;SF06@8324WTPC%5[![JWIVV!V:M;/V#2<#WF>=>1& M?Q%^JUKAG9E4;FC M)?\/4$L#!!0````(`+"`9$?W$U6SW`0``.P6```8````>&PO=V]R:W-H965T M&ULC9C;(^L=0Z.D6H&K"G=B^V:FHN=JX=<`(U M&#.V$V;??GV02F*XC6J^@6MS\6^;D^EN=%E3\_ M+K_PAU2P#NF)?X_YM4:_%UWGG\KR9_?P]_YQR;H^Y*=\UW159.W76[[-3Z>N MIK;E7Z[2]S:[0/Q[K/UK+[?M_E-6Y]OR]..X;PYM;]ERL<^?L]=3\[V\_I4[ M#:JK<%>>ZOYSL7NMF[(80Y:+(OL]?!_/_?=U^,8N2$4;Q[AA-V1R M/,:0DA./`7K!I#[$0II(PQDU82L0,:T)4#-W*F:!HQ6?!0/U)5.J("?`.FR3AA@EY6&%.:8#X1-J.G,=L(\*BAL0H7.#T"ZOQMTP.XO M`Z3<@_!X9>H_?3CAM`V\-T_IL3._=$TYQ&7H_GW-?P.ZKZ%=7P#[(R'UM#AEG MMO3G/SVQ0Y"O:,YO`?NM"JT,TL_&E>&]*09.:3#G&(`=0PDZJYX5\+C=X^G4 M>ES[%CD]K3C+\#BA0USJQ[]>O5)7O)_\FJE^.Y7CR535,6 M_6WA=MO=M\NG4.>[6\/I_RYZ7Z:;L\9+F.'AZ:\C'?+MPON]?]02P,$ M%`````@`L(!D1Y'Q,2^"`P``C0X``!@```!X;"]W;W)K[DZ_;>L MD2^J^)'OVJ/.-O2]G=QGYZ+]IBZ?I-'09[A51=/_>MMSTZIR-/&],OL]7/.J MOUZ&)U%HS&`#;`SPHP;$&)"K`9WEJ>'IE4?S!LP8L`<#<,/S6P`V:R",@;C+ M*!AJV\],DK79:EFKBUFT:/OJ\86P;OG1^# MX!Y9VPB.("2U$70E`AW_F@2&DC`1L!T!"I`X1`SF\%\GFPDG3IH$2I,.M2*6 M/:5N"#$H&9"J1WA,60Q1B4VA$&/"("RU,4PPQ@C"-@[&!1($ED8A:6201NTV MX+`]FRD-L^V%FR8;2L/LTA`*,8G-?,`L@J#4ABAE$+-Q'"'&*"R)STCBMB0P MDS6W,PDY*,EF0E#/`UXVL!='BYC1(FPM,:A%V%UT_YH/;EYL-QP4DXC9&1S\ MO/[?3VK[(6#&&_'8'$2!P24)1-$4$GYJG;-4RJZA[>9(%A MUH:Y-00&F]AU!7^''%30A\-]]16\W""0^9`*NUV--Z,PGE)J: M.(R82&QN54=LIL''*`YS+S^P=J.EK`_].:/QMNIS>^ M1HM7!(RGW=D'XO'B!?*3X,4K-*XG03LB8&2JGU#P"1L/7L%-W&IYR@[R2U8? M\JKQWE2K=_#]=GNO5"MUR<(G7;*C/AM>;PJY;[N_HGMKAM/2<-.JTWCXNYY` M5W\!4$L#!!0````(`+"`9$=3;EP3&0(``#P&```8````>&PO=V]R:W-H965T M&ULC57+CILP%/T5Q+YC,#@O$:3)HVH7E4:SZ*P=X@0T-J:V M$Z9_7S\(,9$[[0;;EW/N/1"0OC&'Q>T,H M[]=Q&M\"K\VY5B8`R@*,O&/#2"L;WD:"G-;Q<[K:(X.P@)\-Z:4WCXSV`^?O M9O']N(X3(X%04BF3`>OA2K:$4I-(%_XUY+R7-$1_?LO^U;K5Z@]8DBVG;\U1 MU5IL$D='=)F)^'^+GCYSX_G4J1S<.&T">&D&\(!@VA:9%9T)$/2M$2!1VA MB:-YT)*/R2!ZM`2\N\&(.-NN)*.*7UIE3MF+CHWO&9J[]1#?I*MM&HCO=*-T M?>V>OBPZ?"8_L#@WK8P.7.D;;:_?B7-%M.KD2W7CW^,,H_4$L#!!0````(`+"`9$>=NJXDR`4``/`?```8````>&PO=V]R M:W-H965T&ULC9G;;N,V$(9?Q?!]UYH9'H/$0!/':"\*+/:B MO=8F2F*L;:66LMF^?75TALJ()@+$-L7Y-3\IZ>.(U^_EZ4?U4A3UXM=A?ZQN MEB]U_7JU6E4/+\4AK[Z4K\6Q.?)4G@YYW?P\/:^JUU.1/W9!A_T*L\RL#OGN MN%Q?=VU?3^OK\JW>[X[%U].B>CL<\M-_M\6^?+]9PG)L^+9[?JG;AM7Z>G6. M>]P=BF.U*X^+4_%TL_P=KK;DVRY=C[]WQ7O%OB_:Y+^7Y8_VQY^/-\NLS:'8 M%P]U*Y$W'S^+NV*_;Y6:,_\[B'ZW2?][7A5WY?Z?W6/]TF2; M+1>/Q5/^MJ^_E>]_%(,'W0H^E/NJ^[]X>*OJ\C"&+!>'_%?_N3MVG^_]$9<- M87(`#@%X#H!X``T!]!&@H@%J"%`?*47[ZZ&_3CV!&0+,.:#KO^J'JAOH35[G MZ^M3^;XX]5?':]Y>A'!EFJE\6%1=XZF?OV:HJZ;UY]K2]>IGJS-TP:[+'>^" M4H_[0$2=NZR:\Y^30"D)ZI-`'J_E>)+B51]//-Z$*=K>1-_EV)M`Z[0.N_5* MFT#)2DKW@9('FG;KE;:!DI,]J8@GQ>-]>`K=>U(L$W`HYK'A.B:3=.ZY#A)D MHA^5X$='_&@6[\0\[C3+0WLEVM&7[7`9RF0W.L&-B;@QW`V(;@Q+0TQB8RY[ MX2)DQ6MV:Q*\V(@7R[V@Z,6R-(Q%940_]K(?+J2M]O*]8Q,],4[,9.,O.PJ4M'8S<^03/+5< MGS75'OQPI4570Y\^&86BI4!GQE.@8T2=;:`SZTADZ>B(<]`9V1'PX75*VQE7 MD."*:Z'VJ,1GYC;0FG4F`GITQ@GMK.P,>3;.P#3KT1DF.,/@>WD]0-P\!NC9N8K M8041*%E+)+M*64-`;!$!G-M>7D4`YS]DF)D,9&,):XE`S!LD+:\G(&5!`>** M8E@#`\>XAQF%&,>!8]/+(`<;/%!G!B8!Y($0@1CD$#$8+ M,ZX2:!Y(.3>M)49;*3R'&-"!TW.ZTAUM<1#/W)H).`]D"*=C.%I*P3G&<(X< MGU[&.7(,`WQZJ@\I!]VRF5QB($8./"].XBU>!NP=$@5:.@,/,U=C2O&.,>JC#:R)(W@WZ23FLL$8]M7@*T%HBRG81Q'[XPM! M%YQF[I5B#+'H`PDM3_EEQF*,L>-L7Y398@I@*098R@)#\U**%D MGBBA?&M22M%,,583!+9D^!$G[&\`3L\4*Y10-D_%O),?85M*J9LI!G;"P)P, M00J*7?(R*2@![H$2>B47EY2"=HJ^;Z?`EHQ`XD"VF5=V9LH2X!YH::NM//U; M2H$[Q>!.'*(P?1<^6N-$UK[YD]^]!V)SUKB6,IFBF?V$%+I3C.X4T'U:)8W[ M)*G5,\7X/FZ5)%;/E`)X^@SX3KOWUC9\#HF!DR[C[C;H`X`SF<4J6`K*3O%! MNCQ].PS$U?<.P8ON&A^+TW&WP5HN'\NU8MQ/*6L^;R+?= MEN^D_0ZN-E+[/5QMI?9F[J[NF_G[?*09_N:(%8^XYH@3C_CF2+>WO?JPL;Y^ MS9^+O_+3\^Y8+;Z7=5T>NBW0I[*LBV9LLB_-)?A2Y(_G'_OBJ6Z_VO8^[3>D M^Q]U^3KNKY\W^=?_`U!+`P04````"`"P@&1'37,4=]D"``#7"@``&````'AL M+W=OQ,G00LXQ.`Z-;X]2U'O;]V.MHT[M%;FS/0Y'S MDVR;GCT/CCAU'1W^E*SEYY6+W(OAI=D?I#9X1>Y=_;9-QWK1\-X9V&[E?D&D M1EA+C.)GP\YB=N]H^%?.W_3@^W;E^IJ!M6PC]1147=Y9Q=I6SZ0B_YXF_8RI M'>?WE]F_FG05_BL5K.+MKV8K#XK6=YTMV]%3*U_X^1N;"O/O;$Y" M\N[BXCH=_1BO36^NY_%)ZD]NL`.>'/#5`86+#L'D$%P=EO7AI`\?#1!-#I$= MP!LS-^]M324M\H&?G6%<["/5-85(I%9FXPAC',;E4&].*.M[@5"0>^]ZHDF# MC::<:S"DJ.:*V(0:'U79*$$"RB!A1+94:(1)9A%0;[Z0:KU?94%$R[`A!9,#,*$\Y1!$%AA M040+$)$%D8`0T7\A8(4%$2]`Q!9$"E9(_$B%W!59*,D"2F*A9.#[2&91@NAN MB2S(+)QT`2>=XV`P3IG.2S$.HB0`<6P91FD,XV0+.)F%@T"<[#&<[$$T7WR%;VO00AG=-H\FF,/,-[;96O=F! MT;%A;PYJX6SXJ==G:N;.S&,W4&)2F6;@QK[&I(;L94"J`-('I(;L94BJ$-*' MI(;L942J"-)'I(;L94RJ&-+'I(;L94*J!-(GI(;L94JJ%-*GI(;L94:J#-)G MI(;LJAI5.^9#,R'=J"'P";ZT<-[G*A?YD>[9#SKLFUXXKURJ9L.T!CO.)5.E MXS^IK^B@NLSKH&4[J6\3_7F-?=-P9MB^^ M2(?DX9#\-!2W;VWWM7]NFF'U_7@X]7?KYV%XN=UL^OOGYECW']J7YN3O/+;= ML1[\W^YIT[]T3?TP%3H>-I0DZ>98[T_KW7:Z]JG;;=O7X;`_-9^Z5?]Z/-;= M?Q^;0_MVMS;K\X7/^Z?G8;RPV6TWEW(/^V-SZO?M:=4UCW?KW\QMY7B43(J_ M]\U;'_Q>C>:_M.W7\<^?#W?K9/30')K[8:RB]E_?FK(Y',::?,O_+I6^MSD6 M#'^?:_]]ZJZW_Z7NF[(]_+-_&)Z]VV2]>F@>Z]?#\+E]^Z-9^N#&"N_;0S]] MKNY?^Z$]GHNL5\?Z^_R]/TW?;_.=/%F*R05H*4"7`B9>@)<"_%[`10O8I8!] M+V"GT,Q=F0)1U4.]VW;MVZJ;1^^E'B>)N;4^U/>K?KK8S?'UH>C]U6\[0[3= M?!LK6C0T:4K07!0;7_NE"9*:6(I34%QLH`)%(;?`4@L\=X*A$RQ78*4*[%R! M#2JP%CUF+&1;KCH#M6KB"-=">%"AP:=7-_TL!H MD5UW>A95HFH"(7W8`LHZ(@V4X>L9.'(YV(;O*@ M&5%1A8J;U%@E+$7$1P%AR40C13B7"M%)`9&SREP9^:1!J=O2".Q#Z7BR@V0""Y<8H3$5IG)R&3#,LS91%=UH<\;5&5!&L` M[8B$.]L!Q+&1[7"XIL-I"7889J\ME-EK1&`NB#(6_"@+T8B4.W&,M*V:`F853'F;!0#*$$ M"$WD%4X(1U?(S[DK6IS+?46=L MGFLY$\>0RH!4>=-6,K(RT=87Z+2QBFZ[@:=6>69Q;./-P#\K;P\YW%2;+.-< MA%P%.K\]3!2<<@RG##BU,DY9!B68"26,HX!N8D!E`*J\P2@9,M,T4:(#JH)R M!5\O3=2EI&UK;`RF%F#J9)A:2%`S3DE.":]T%"90:"E&50M4=3)5+="2 M$I,:>4Z#T*?#F"#W%J&J!JDZFJB589.RN7Y:>+0%]\XP3+4RQ5-4"6MU5 MJCJ+/H(HE6>_A32U\/FA,K=M]/TH8-JELAT4R>2TP&C*%)_:&U`*DG3;H M,;):(*N3268A!24U5;57+TI5V-L87"W`51O0D)Q>9.6=-LH<:O[MO7TS"><`17+P>+'VD\Z[JZ7IK;R@C7_1C=EBX1[O@P M^SM2&1\;?T=JQ7?'WYG.-3?O=G?;E_JI^:ONGO:G?O6E'8;V.!VO/;;MT/@H M)!_\&GANZH?+GT/S.(P_LW%QS(>1\Y^A?3F?K5X.>'?_`U!+`P04````"`"P M@&1'YW]=5*,!``"Q`P``&````'AL+W=O&,"*+]0V2_KW\84E;(7Z@F>& M<\Z<\:6\2]<\.!$%OW()F]TP,H_Z?51C+G4],1.QA@321) M06B6W1/)N,)5&6NOIBKUZ`17\&J0':5DYN\)A)Z.>(>OA3?>]2X42%62A==P M";(91`RT;A7O3TPO,(^R#8*V% MC5]4C]9I>:5@)-E'6KF*ZY3^%/E,VR;0F4`7PD,6C:=&T>9WYEA5&CTAD[9V M8.$$=P?J-Z)&-A9-FMX;M;YZJ7;W>4DN06C&T(@YW6`6!/'J2PNZU6*FTQ6= M;M/S+7J>'.8W#HMM@6)+H$@"Q?]&3)C3+6;_3Q.RVE,)IHM7QZ):CRI>U%5U MN9V/-)[)%[PJ!];!3V8ZKBPZ:^=/-AY#J[4#;R*[VV/4^_>S)`):%\)O/C;I M2J7$Z>'Z0)976GT"4$L#!!0````(`+"`9$>UF=R'HP$``+$#```8````>&PO M=V]R:W-H965T&UL?5/+;MLP$/P50A\0RK3C!(8L($Y0M(<" M00[MF996$A&2JY"4E?Y]^9`5N1!Z$7=7,[.S?!0CFG?;`3CRJ:2VQZQSKC]0 M:JL.%+=WV(/V?QHTBCN?FI;:W@"O(TE)RO)\3Q47.BN+6'LU98&#DT+#JR%V M4(J;/R>0.!ZS378MO(FV49J:/@@W1N.WV$:X3X(5BAM_))JL`[5E9(1Q3_3*G1%D8'(E)6]OS<(*;`_,;41$;BR9-[XU:7[V4F_V^ MH)<@-&%8Q)QN,#.">O6Y!5MK,='9@L[6Z=LU^C8YW-XX?%@7V*T)[)+`[G\C M)LSI%O/X3Q.ZV%,%IHU7QY(*!QTOZJ(ZW\XG%L_D"UX6/6_A)S>MT):&UL M?5/;;IPP$/T5RQ\0LUZ2;5V*@.=''W?&!.\7Q-=P^%Z?:!8L@(+*!07AERL\ M@5)!R"?^/6N^IPS$]?ZF_C56Z]U?A(4G5+]D[3IO-J.DAD:,RKW@]`WF$NZ# M8(7*QB^I1NM0WRB4:/&65MG'=4I_]OE,VR;PF<`7PJ^-6A^]EKN'SP6[!J$9PR/F_`&S()A77U+PK10S MG:_H?)N^WZ+OD\/].OLAVQ;(MP3R))#_K\2$.7_`'/XMDJWN5(-IX^A84N'8 MQT%=19?I?.2Q)^_PLAA$"S^$:65OR06=[VQL0X/HP)O([NXIZ?S[60X*&A>V M![\W::32P>%P>R#+*RW_`E!+`P04````"`"P@&1'T8Y_Q:,!``"Q`P``&0`` M`'AL+W=O@$ M5_!JD!VE9.;O"82>CGB'KX4WWO4N%$A5DH77<`G*SUJ_A^2E.>(L6``!M0L*S"\7>`8A@I!O_&?6_&H9B.OXJOX]3NO= MGYF%9RU^\\;UWFR&40,M&X5[T],/F$>X#X*U%C9^43U:I^65@I%D'VGE*JY3 M^I/O9]HV@LV@\-8HVOS''JM+H"9FTM0,+)[@[4+\1-;*Q:-+TWJCU MU4NUV].27(+0C*$1<[K!+`CBU9<6=*O%3*B6H\J7M15=;F=3S2>R1>\*@?6P4]F.JXL M.FOG3S8>0ZNU`V\BN[O'J/?O9TD$M"Z$>Q^;=*52XO1P?2#+*ZT^`5!+`P04 M````"`"P@&1'K`<5'J,!``"Q`P``&0```'AL+W=O@_)]:&\F<3TU# M;&>`59$D!:%9MB.2<86+/-;>39'KW@FNX-T@VTO)S)\3"#T<\0I?"Q^\:5TH MD"(G$Z_B$I3E6B$#]1$_K`ZG34!$P"\.@YW%*'@_:_T9DM?JB+-@`024+B@P MOUS@$80(0K[QUZCYTS(0Y_%5_3E.Z]V?F85'+7[SRK7>;(91!37KA?O0PPN, M(VR#8*F%C5]4]M9I>:5@)-EW6KF*ZY#^[.Y'VC*!C@0Z$>ZS:#PUBC:?F&-% M;O2`3-K:CH437!VHWX@2V5@T:7IOU/KJI5CMMSFY!*$10R/F=(.9$,2K3RWH M4HN13F=TNDQ?+]'7R>'ZQN%N66"S)+!)`IO_C9@PIUO,_I\F9+:G$DP3KXY% MI>Y5O*BSZG0['V@\DQ]XD7>L@3=F&JXL.FOG3S8>0ZVU`V\BN]MBU/KW,R4" M:A?"O8]-NE(I<;J[/I#IE19_`5!+`P04````"`"P@&1'7(@_)]&&\FX@E>#["`E,U]'$'H\X`V^!-YXV[D0(&5!9E[-)2C+M4(&F@-^W.R/>4!$ MP%\.HUWL4?!^TOH]''[7!YP%"R"@4,3R!$$/*)/R;-GY2!N-Q?U)]C MM=[]B5EXTN(?KUWGS688U="P0;@W/;[`5,)M$*RTL/&+JL$Z+2\4C"3[3"M7 M<1W3G_QAHJT3Z$2@,V&71>,I4;3YBSE6%D:/R*2K[5GHX&9/_454R,:@2=5[ MH]9'S^7F?E>08&4&\^IR"KJ68Z'1!I^OT[1I]FQQNKQP^K`OD M:P)Y$LB7`KOLNL2$.5YC_B^2+.Y4@FGCZ%A4Z4'%05U$Y^E\I+$G/_"RZ%D+ M?YAIN;+HI)WO;&Q#H[4#;R*[N<6H\^]G/@AH7-C>^[U)(Y4.3O>7!S*_TO(; M4$L#!!0````(`+"`9$>#I;TWH@$``+$#```9````>&PO=V]R:W-H965T:,"*'\0V M0_;OUP^&,"NT%]S=5%57^U%.VGS8'L"A+RF4/>#>N6%/B*U[D,S>Z`&4_]-J M(YGSJ>F('0RP)I*D(#3+[HAD7.&JC+4W4Y5Z=((K>#/(CE(R\^<(0D\'O,.7 MPCOO>A<*I"K)PFNX!&6Y5LA`>\`/N_VQ"(@(^,5ALJL8!>\GK3]"\MH<N-Z;S3!JH&6C M<.]Z>H%YA-L@6&MAXQ?5HW5:7B@82?:55J[B.J4_>3[3M@ET)M"%<)]%XZE1 MM/G$'*M*HR=DTM8.+)S@;D_]1M3(QJ))TWNCUE?/U>Z>EN0&UL?5/+;MLP$/P50A\0 MRK2=!(8L($Y0M(<"00[MF996$A&2JY"4E?Y]^9`5N1!Z$7=7,[.S?!0CFG?; M`3CRJ:2VQZQSKC]0:JL.%+=WV(/V?QHTBCN?FI;:W@"O(TE)RO+\GBHN=%86 ML?9JR@(')X6&5T/LH!0W?TX@<3QFF^Q:>!-MYT*!E@6=>;50H*U`30PTQ^QI M&PO=V]R:W-H965T MW#2E4?=I\=&,"J M+]0VH?OWZPM04O&"[>&<,V<\XWS0YL.V``Y]2:'L$;?.=0=";-F"9/9&=Z#\ MGUH;R9P_FH;8S@"K(DD*0K/LCDC&%2[R&'LS1:Y[)[B"-X-L+R4S_TX@]'#$ M&SP%WGG3NA`@14YF7L4E*,NU0@;J(W[8'$Z[@(B`/QP&N]BCX/VL]47F`LX38(EEK8^$5E;YV6$P4CR;[2RE5]S<@E"(X9&S.D* M,R.(5Y]3T+44(YTNZ'2=OEVC;Y/#[97#^W6!W9K`+@GLE@+WV76)"7.ZQOPL MDBSN5()IXNA85.I>Q4%=1.?I?*"Q)]_P(N]8`[^9:;BRZ*R=[VQL0ZVU`V\B MN[G%J/7O9SX(J%W8_O)[DT8J'9SNI@<.>-+ M,:%YM1V`(^]:]?9(.^>&`V.VZD`+>X<#]/Y/@T8+YU/3,CL8$'4D:<5XEGUB M6LB>ED6L/9NRP-$IV<.S(7;46I@_)U`X'>F.7@LOLNU<*+"R8`NOEAIZ*[$G M!IHC?=@=3GE`1,`O"9-=Q21X/R.^AN1'?:19L``**A<4A%\N\`A*!2'?^&W6 M_&@9B.OXJOXM3NO=GX6%1U2_9>TZ;S:CI(9&C,J]X/0=YA'N@V"%RL8OJ4;K M4%\IE&CQGE;9QW5*?_)LIFT3^$S@"^%+)+#4*-I\$DZ4A<&)F+2U@P@GN#MP MOQ$5L;%HTO3>J/752[G[R@MV"4(SAD?,Z0:S()A77UKPK18SG:_H?)N^WZ+O MD\/]C5?4$L#!!0````(`+"`9$)NSI`$``+$#```9````>&PO=V]R:W-H M965T&+"!.4;2'`D$.S9F6 M5A(1/E22LI*_#Q^R(A="+^+N:F9VEH]BU.;-=@`.O4NA[!%WSO4'0FS5@63V M3O>@_)]&&\F<3TU+;&^`U9$D!:%9=D\DXPJ71:P]F[+0@Q-\09?"R^\[5PHD+(@,Z_F$I3E6B$#S1$_;@ZG/"`BX`^'T2YB%+R?M7X+ MR:_ZB+-@`014+B@POUS@"80(0K[QWTGSJV4@+N.K^H\XK7=_9A:>M'CEM>N\ MV0RC&AHV"/>BQY\PC;`+@I46-GY1-5BGY96"D63O:>4JKF/ZL\\GVCJ!3@0Z M$[YET7AJ%&U^9XZ5A=$C,FEK>Q9.<'.@?B,J9&/1I.F]4>NKEW+SL"O()0A- M&!HQIQO,C"!>?6Y!UUI,=+J@TW7Z=HV^30ZW-P[OUP7R-8$\">3_&S%A3K>8 M_3]-R&)/)9@V7AV+*CVH>%$7U?EV/M)X)E_PLNA9"[^9:;FRZ*R=/]EX#(W6 M#KR)[&Z'4>??SYP(:%P(]SXVZ4JEQ.G^^D#F5UI^`E!+`P04````"`"P@&1' M"9VH$J4!``"Q`P``&0```'AL+W=OM.GN@K7/]GC%;MJ"%O<(>.O^G1J.%\Z%IF.T-B"J2M&(\ MRVZ8%K*C11YSSZ;(<7!*=O!LB!VT%N;]"`K'`]W02^)%-JT+"5;D;.954D-G M)7;$0'V@#YO]<1<0$?!'PF@7>Q*\GQ!?0_"K.M`L6``%I0L*PB]G>`2E@I`O M_&_2_"P9B,O]1?UG[-:[/PD+CZC^RLJUWFQ&206U&)1[P?$)IA:N@V")RL8O M*0?K4%\HE&CQEE;9Q75,?[:W$VV=P"<"GPEW632>"D6;/X0316YP)"8=;2_" M#6[VW!]$26Q,FM2]-VI]]EQL[N]R=@Y"$X9'S/$+9D8PKSZ7X&LE)CI?T/DZ M?;M&WR:'VR\.[]<%=FL"NR2P^U^+"7-<8OS8?BO"%F>JP31Q="PI<>CBH"ZR M\W0^\'@GG_`B[T4#OX5I9&?)"9V_V7@--:(#;R*[NJ:D]>]G#A34+FQO_=ZD MD4J!P_[R0.976GP`4$L#!!0````(`+"`9$=B`T6OH@$``+$#```9````>&PO M=V]R:W-H965T&,"*[2&V6=*_KR\L2RK:%SPSG'/FC"_EA.;5]@".O"NI[9'VS@T' MQFS=@^+V#@?0_D^+1G'G4],Q.QC@320IR?(L^\04%YI69:P]FZK$T4FAX=D0 M.RK%S>\32)R.=$>OA1?1]2X46%6RA=<(!=H*U,1`>Z0/N\-I'Q`1\%/`9%X3X(UBAM_))ZM`[5E4*)XN]I%3JN4_I3%#-M MFY#/A'PA?,FB\=0HVOS*':]*@Q,Q:6L''DYP=\C]1M3$QJ))TWNCUE`PMH@-O(KN[IZ3W[V=))+0NA)]];-*52HG#X?I`EE=:_0%02P,$%`````@` ML(!D1WG_AUZC`0``L0,``!D```!X;"]W;W)K&UL M?5/;;IPP$/T5RQ\0LRR;5"L6*9NJ:A\J17EHG[TP@!7;0VVSI']?7UA"(M07 M/#.<<^:,+^6$YM7V`(Z\*:GMB?;.#4?&;-V#XO8.!]#^3XM&<>=3TS$[&.!- M)"G)\BR[9XH+3:LRUIY-5>+HI-#P;(@=E>+F[QDD3B>ZH[?"B^AZ%PJL*MG" M:X0";05J8J`]T:!0L@H79!@?OE"D\@ M91#RC?_,FN\M`W$=W]2_Q6F]^PNW\(3RMVA<[\UFE#30\E&Z%YR^PSS"(0C6 M*&W\DGJT#M6-0HGB;VD5.JY3^G-XF&G;A'PFY`OA2Q:-IT;1YE?N>%4:G(A) M6SOP<(*[8^XWHB8V%DV:WANUOGJM\JPHV34(S9@\8LYKS&Y!,*^^M,BW6LST M?-UBF[[?HN^3P_T'AX=M@6)+H$@"Q?]&3)CS1\S]IR9LM:<*3!>OCB4UCCI> MU%5UN9V/>3R3=WA5#KR#G]QT0EMR0>=/-AY#B^C`F\CN#I3T_OTLB836A?#! MQR9=J90X'&X/9'FEU3]02P,$%`````@`L(!D1V#T=62F`0``L0,``!D```!X M;"]W;W)K&UL;5/+;MLP$/P5@A\02K33I(8L($Y1 MM(<"00[MF996#X3DJB1EI7]?/F1%#G01=UPTO MAMA1*6'^G4#B=*0YO19>^[9SH<#*@BV\NE>@;8^:&&B.]"D_G/8!$0&_>YCL M*B;!^QGQ+20_ZR/-@@604+F@(/QR@6>0,@CYQG]GS8^6@;B.K^K?X[3>_5E8 M>$;YIZ]=Y\UFE-30B%&Z5YQ^P#S"?1"L4-KX)=5H':HKA1(EWM/:Z[A.Z<\N MGVG;!#X3^$)XS*+QU"C:_":<*`N#$S%I:P<13C`_<+\1%;&Q:-+TWJCUU4O) MLX>"78+0C.$1ZK`M/'J6%+AJ.-%7567V_G$XYE\P,MB$"W\$J;M MM25G=/YDXS$TB`Z\B>SNGI+.OY\ED="X$#[XV*0KE1*'P_6!+*^T_`]02P,$ M%`````@`L(!D1[Q"8$9"`@``&P@``!D```!X;"]W;W)K&UL?5;;CILP$/T5Q`!-Q4E9AEKJ]=YFEXJY96=%W&:@[YT3^.U$FFF.(PG[C MH[P5VFY$61H-=I>2TTJ5H@HDO1[#5W0XH;6%.,3ODC9J-`^L\V-ZS?W?7->Z?B:)O@OTI+[HPWL9A M<*%7)`PX^6K'LG)CTYZL=YT9;(`[`SP8 M[&+G>"ODW/Q&-,E2*9I`MM^V)C:$Z(#-A\@#Y39E>WOCJ#*[CPPCE$8/2]1A ML,.V"R-8CV($B/F8/B^P61'9C M`AR#(CYF)O'V"R)[CP`.O(^9";RM[ED5>SBB@$,_`;2=P&DQ`&UL;5/;;J,P$/T5RQ]0$X>D5420FE:KW8>5JCZTSPX,8-47:IO0 M_?OUA5!2\8+MX9PS9SSC8M3FPW8`#GU)H>P1=\[U!T)LU8%D]D[WH/R?1AO) MG#^:EMC>`*LC20I"LVQ/).,*ET6,O9BRT(,37,&+07:0DIE_)Q!Z/.(-O@9> M>=NY$"!E069>S24HR[5"!IHC?MP<3GE`1,`;A]$N]BAX/VO]$0Y_ZB/.@@40 M4+F@P/QR@2<0(@CYQ)^3YG?*0%SNK^J_8K7>_9E9>-+BG=>N\V8SC&IHV"#< MJQY_PU3"+@A66MCX1=5@G997"D:2?:65J[B.Z<^.3K1U`IT(="8\9-%X2A1M M/C/'RL+H$9ETM3T+'=P0;7A8]:^$O,RU7%IVU\YV-;6BT=N!-9'<[ MC#K_?N:#@,:%[;W?FS12Z>!T?WT@\RLM_P-02P,$%`````@`L(!D1[J(5>:E M`0``L0,``!D```!X;"]W;W)K&UL;5/+3N0P$/P5 MRQ^`,YX`NZ-,)`:$V,-*B,/NV9-T$@L_@NU,X._Q(PD!Y1*[.U75U7:[&+5Y MM1V`0^]2*'O$G7/]@1!;=2"9O=(]*/^GT48RYT/3$ML;8'4D24%HEMT0R;C" M91%SSZ8L].`$5_!LD!VD9.;C!$*/1[S#<^*%MYT+"5(69.'57(*R7"MDH#GB MN]WAE`=$!/SC,-K5'@7O9ZU?0_"G/N(L6``!E0L*S"\7N`]/@$4PO70;#2PL8OJ@;KM)PI M&$GVGE:NXCJF/[:7E)U!+`P04````"`"P@&1'L`P*;K\!``![!```&0```'AL+W=OA>\U^>D,V8X8:RK#@35 M#W*`WNXT4@EJ[%*U6`\*:.U)@F.2ICD6E/5)6?C8BRH+.1K.>GA12(]"4/7O M`EQ.YV27W`.OK.V,"^"RP`NO9@)ZS62/%#3GY&EWNN0.X0&_&4QZ-41M;[<0H[C^E,BQ/( M3""?"#@8^32_44/+0LD)J7"T`W5_<'IMHMI&;R7)2(%O3FC& M$(^YK#&[!8&M^F)!8A8SG:PMXO1]C+X/&>[7[LHR1:3QTWR+TSRC<`Q:K+%/'XRP:O;(4"UO@DTJN38^Y9; M19<^>R+^=GW`RV*@+?RBJF6]1E=I[!WU%ZJ1TH!-(GVPI7;V)5@6'!KCID<[ M5Z$YPL+(X=[JRWM3_@=02P,$%`````@`L(!D1V^XHK:F`0``L0,``!D```!X M;"]W;W)K&UL;5/;;MLP#/T5P1]0.8JS;H%CH.E0 M;`\#BCYLSXI-VT(ET97DN/O[Z>*X[N`7BZ3/.21%JIS0O-H>P)%W);4]9;US MPY%26_>@N+W#`;3_TZ)1W'G7=-0.!G@324I2EN=?J.)"9U498\^F*G%T4FAX M-L2.2G'S]PP2IU.VRVZ!%]'U+@1H5=*%UP@%V@K4Q$![RAYVQW,1$!'P6\!D M5S8)M5\07X/SLSEE>2@!)-0N*'!_7.$1I`Q"/O';K/F1,A#7]DW]*7;KJ[]P M"X\H_XC&];[8/",-M'R4[@6G'S"W<`B"-4H;OZ0>K4-UHV1$\?=T"AW/*?TY MY#-MF\!F`EL(7R.!ID2QS._<\:HT.!&3KG;@88*[(_,741,;@R9U[PNU/GJM M6/&MI-<@-&-8Q)S7F-V"H%Y]2<&V4LQTMDZQ3=]OT?>IPOTZ^_U^6Z#8$BB2 M0+'.?\@_MY@PY\^8_YNDJSM58+JX.I;4..JXJ*OHLIT/+,[D`UZ5`^_@%S>= MT)9>BSB^`0``>P0``!D```!X;"]W;W)K&UL?51;;ZP@$/XKQ!]07'9UFXUKTFW3M`]-FCZ<\\SJ>$E!+.#:\^\/ M%]=J0_LB,'R7&63(1B'?50.@T2=GG3I&C=;]`6-5-,"INA$]=&:G$I)3;9:R MQJJ70$M'X@R3.$XQIVT7Y9F+OO$JF!)[U MM(87*NNV4^@LM+FC[D)50F@P2<0WIM3&O`3S@D&E[71OYM(WAU]HT5];?7YO M\O]02P,$%`````@`L(!D1PFZHD3X`0``$P8``!D```!X;"]W;W)K&UL?57=CJ,@%'X5X@,,UE9M&VLRG.6<_%IZP!%/IBM)6'H%:JVV,LBQH8D4^\@U;O ME%PPHO125%AV`LC9DAC%41@FF)&F#?+,QMY%GO&+HDT+[P+)"V-$_#L"Y?TA M6`6WP$=3U8G1",A MNB/@P"]T@,[[8CIH2K?:1?1(&D#8KA]#I1J:/7/(IW&;X:H1$3 M6S.9/PE_X.=%][/+NT#$1E>Y-$ M!;^TMA7.HE/_>X[LI?^&YUE'*OA%1-6T$IVXTJW#WO.2'=KP=-_(/\/4$L#!!0````(`+"`9$?R'QHOI@$``+$# M```9````>&PO=V]R:W-H965T$V*H#R>R-[D'Y/XTVDCGOFI;8W@"K(TD*0K/LEDC&%2Z+&'LQ M9:$')[B"%X/L("4SGT<0>CS@#;X$7GG;N1`@94%F7LTE*,NU0@::`[[?[(]Y M0$3`/PZC7=@HU'[2^BTX?^H#SD()(*!R08'YXPP/($00\HG?)\WOE(&XM"_J M3[%;7_V)67C0XC^O7>>+S3"JH6&#<*]Z?(:IA5T0K+2P\8NJP3HM+Q2,)/M( M)U?Q'-.?/)MHZP0Z$>A,^!4))"6*93XRQ\K"Z!&9=+4]"Q/<[*F_B`K9I M>U^H]=%S2>_R@IR#T(2A$7-<8C8S@GCU.05=2S'1Z3+%.GV[1M^F"K?+[+^W MZP+YFD">!/*K%G?7+2;,\1IS^R,)6=RI!-/&U;&HTH.*B[J(SMMY3^-,ON%E MT;,6_C+3&PO=V]R:W-H965T MW#2E4?=I\=&,"J M+]0VH?OWZPNAI.(%V\,Y9\YXQOF@S8=M`1SZDD+9(VZ=ZPZ$V+(%R>R=[D#Y M/[4VDCE_-`VQG0%619(4A&;9/9&,*USD,?9FBESW3G`%;P;97DIF_IU`Z.&( M5_@:>.=-ZT*`%#F9>!67H"S7"AFHC_AA=3AM`B("_G`8[&R/@O>SUA_A\%H= M<18L@(#2!07FEPL\@A!!R"?^'#6_4P;B?']5?X[5>O=G9N%1B[^\5O75:7BD82?:55J[B.J0_V_U(6R;0D4`GPCZ+ MQE.B:/.).5;D1@_(I*OM6.C@ZD#]193(QJ!)U7NCUD]G.@BH7=CN_-ZDD4H'I[OK`YE>:?$?4$L#!!0````(`+"`9$&PO=V]R:W-H965T9_?NU>06CAO$EV*:ZNKJ, M.IT\"/U@.<;<^*K*FFW,G//KVK)8EN,*L1=RQ;5XZ-I0FZ\+&K\1@UVJRI$_VUQ21X;TS'[@_?BDG-Y8*6) M-<2=B@K7K""U0?%Y8[XZZX,32DB#^%/@!QNM#2G^2,B'W/PZ;4Q;:L`ESKBD M0.)QQSM!XW;/_:,H5\H^(X1TI_Q8GG@NUMFF<\!G=2OY. M'C]Q5T,@"3-2LN;7R&Z,DZH/,8T*?;7/HFZ>C_9-9'=A<(#;!;A#P)`'#O"Z M`.\9X"\&^%V`KYLAZ`*"20:KK;UQ;H\X2A-*'@9MK_N*Y%?EK`-Q-YG!FD/: M7HCPCHG3>^I&=F+=)5&'<1O,5L5`D/T8X@P(2P@85+B0BBZ#.\X`)=@IB!C4 M\"W)889$D>E!,OW6+$\Q8J9.'R+P6@)?(7!A@F!!0:`0>&J5+6:K8GP(LU,Q M`839JY@5A#FHF!`N:+50T$HAB&""<,'24,?2:$%!I&%II&%II&%II&%II&-I MO%!0K!#,?.:RA\YZ*E]^;ZH#]I5.A.-HV*J"8AOT=0)R0&,G(!=T=I9)+0ML M5'U9:@OQ9BC`)M*;ZVF9"[:17H6O8ZX"BN&/=@(";V"O`SI,0,%,64O-S5&Z M2;R:H0#;26_N2LM7,,#G?.NN=`YSOY038S!A/^C2YH@O^C>BEJ)EQ M)%Q,*LU8<2:$8Z':?A'WF8L9==B4^,SE,A1KVDYM[8:3:S^$#I-P^A]02P,$ M%`````@`L(!D1YD35M\R!```11<``!D```!X;"]W;W)K&ULC9C;,'J`30.F4E84QV\DA)W MWWYU(%TA"]+,12S)'WX1`/F+UNI8-S_;O92=]ZLLJO9RL>^ZPX7OM\][66;M MA_H@J_Z;7=V46=>?-B]^>VADMAV#RL+'((C\,LNKQ7HU7GMHUJOZM2OR2CXT M7OM:EEGS[Y4LZN/E`A;ZPF/^LN^&"_YZY9_BMGDIJS:O*Z^1N\O%'W#Q0R0# M,A)_Y?+8SHZ]8?!/=?US.+G;7BZ"80RRD,_=()'U'V_R6A;%H-3?^1\E^ON> M0^#\6*O?CNGVPW_*6GE=%W_GVV[?CS98>%NYRUZ+[K$^;J3*(1P$G^NB'?][ MSZ]M5Y`F!I#1`J0+@&+%7`TC4@5`&A M:T"D`B+7@%@%Q*X!B0I(7`-2%9"Z!@P]GSH7.(>=]^?5N^X]F^R+ENOFOKH M-9-A';+!%^&BC^K%O7:\VDR>TB__MK_ZMA8!K/RW04DQ.#)7E$&.N::,X)@; MRBPYYB-E0HZYG3/L:#X1(N60S5F1N_,BG^EH(X[Y0IF88[[.F9@MS#V523CF M&V78(7\G#`0<\T`9=E+\21FV@H^482?%#\K\SMWO9^]I"B,[A9?3%$:B$/(* M@E40DX(@"A&OL+2-84D4WC4YG";EQ%33?,)^S]'_\;<*;;<*R:T27B&RI1NY MI!O;QA"?3_*:^0VFJ;NM1V M>`R;!S%\>[:Z"E+9QJ&IOH3CJTNE1&RJKT&*9L8_;'1F9+&C28-?[:K`@$X5 MYM>['@=9\/C.X&)E<&*6+ORO*+&R+T)%J7'>@=4_@!@(HD&#-P9=F="I,KPU MZ'%$YROS14':R01?FGN*188*?B<8]/.=YQXXL$(9@ MRAFM]H+47@P[`;3:"SK9"UKM!86#@2,QC@2,R4M?7A*^C#E]T\7"EHRCID+=N?O\JKU MGNJNJ\OQ'MF]S+:GDT+NNN$P'NXWO>6=3KKZH%]:G]Z@V7T9I0,``.T0```9````>&PO=V]R:W-H965TO)GW8L9VUC=9_VG.0K3.1UE4SW*4=9FUW6U]=\A+436YK)Q:'%]67\AS2KF"](A? MN;@UQG='%?\FY1]U\_WPLO)4#:(0^U919-WE7>Q$42BF+O-?3?J94P6:WT?V MK[WO@FM(5"$>UDT_:>SOS:M+,>0 ME5-F'\,UK_KK;7@2>3H,#Z`Z@-X#[GGP`*8#V&>`/QO@ZP!_:89`!P23#.Z@ MO7EC!/Y`X`."29'AX,6`J7H,C_T@QE`[$T4\2EF`P1(31AFEE&"P%,!X2$*& M:PMFS`F`-@L!GS&'`P(?%AH,YG!3-F@16]#6$WH4U0;A/$H1HM.)FQ1'*/:("P@OF561S/:(D.;SV&: M:-`6&6F\IZFR`;2#(.YCH,0$$0M3"D$A+BF>D12;DD)44KQ$$@1Q@DJ*ETB" M($YQ36IIM+ZAZN'G&T:XA0)=+K0O!*X7`3J1-4BK1B?Q8T@"(+['T.EKX8&" MT)5G%&2N"8Q:I@J96Q4(6V3KW+I`X,+`<5O]Q[8^A"2/(:D%`N6@2\$H!ZP% MU#97T<5@-)4O,G6NY9)PB:GA8U--"*73=C#Z:J*89;9"C&?IM62NV9((J+)- M6+2YC=[&2[RE:"O155!O@;<:-.FFV37.U]]15?Q;9X7Y3B&.KOH9*UG`:'VY:>1G_7+C_P['Y#U!+ M`P04````"`"P@&1'-ZF9Y[@%``#O(@``&0```'AL+W=OHK;O,$&8VA#0)S8;IP^ZS`TY@BC%K.Z'[ M[==7JN-*Q]H^-"#_ST67\Y-L/+]D^8]BGR3EY&=Z/!4WTWU9GF=!4&SW21H7 M7[)S#Z=D MDT^*CS2-\W]ODV-VN9F2:=_P_?"^+^N&8#$/KG:[0YJB^7^R_2C*+.U-II,T_MG^/9R:OY?VB@X[,[L![0SHU8!PU(!U!LPW`N\, M^-4`#R`ZO?`-(#L#Z1E`=7KEVV7=&6A?@Z@SB'P-ZAEOYRWT-KE.-?$VZ2>; M4,^A(OUL$^8=I)]OPKU-^BDGPMNDGW0B!R9!6R%-?=W%9;R8Y]EEDK=0.,\BLLJJ<3XJF-6_KMBJQHFK]7#`6S8//VE.GH8WF%FAX:-,L30VU*5:CBJ]` M84WE`:9";)I'J+&&>H(:9M.L38WB-LDS=&/5_`DUPJ9Y@1IITVR@1ETU037- MU[FFUKGF[5Q3X$'#**KM4:LY-1HI9%C_LX=B6"AFA-+2%FG)C$A,AS"H!PE`ZA5_U^#1$6-81&"!'8=1; MOMM%?76,5B^=J.L1#P4RS,2^#_;A3+P2IFVK\Z43]>$(P\*A*":`Q4+8>V?" M6&.Q4!83!F))6U$L!R)E$ZV<(I@-2CP"D">T/1`418Y`*+*(R2S''D1,WA"E MJ;MV?*0=Q`922;&I0W%&`*OLV]6R$WEU`I?"S%`$$L!`21P^4+81C=6&Q[* M;GT/E`29$HH?2*G'\J;4NP>H$N:%$I,"SDGA\(%RCG(/ZD*1M(I63A',!H4A M%>-K<@E%TG6+@1*+2H\U:5)($?DJ93XW*-@H\IG32KO'J!*F!<* M2ZI!7MKA`T4@A72+;!D_=2*?DRM#.(0CU4'8%!Y2NS%%",NY1:8Q[ MIXXJ85XH*QG`H'(<;1B*029]UK[)+($O?919##!+.6YI&SE'T<(!6I1C!^8H$#CU21:*'#LP M1X'`P>%%.38*CC^6XMCR;1?#(S<+3@IL+7"TX+CP(#<4J MY(8B[>HV6K5Z>.*F%>*%0X?.YD M??SW.!`Y8"E0\@@`%>W8(@0*%4'&@?``1=IZT[H9B!PL%2B>!/6H02C2UI17 M3A',!F688!XU"$7:07:!@D[P\1H4)N>HQB?H[?D^&ULC5C; MCN,H$/T5*Q\P-@7X$J4C37=ZM?NPTF@>=I_="4FLL4W&)IW9OU_C2QHR!WPYBB[IE3# M8W>*^TLGRL-HU-0Q)$D:-V75KK:;<>Q;M]W(JZJK5GSKHO[:-&7WW[.HY>UI M15;+P/?J=%9Z(-YNXKO=H6I$VU>RC3IQ?%I])>M7!AHR(OZIQ*TW[B--_DW* M'_KAK\/3*M$<1"WV2KLHA\N[>!%UK3T-D7_.3C]B:D/S?O'^QYCN0/^M[,6+ MK/^M#NH\L$U6T4$UGWXV^TO_9*-HO)*FK*7].U:L?K M;7J3)[,9;@"S`=P-"/,:T-F`W@W\>#;C66@`/AMP.T`\93[6;5>JZ`8@[8Y(`:#AZSR*8L)D@[QV`\>TAE\O1B>DH3S-/. M]`2\`,8P3Z^6)T=1F*3>NBD)ITB0>FD9AQ>9"@9"Y2D!4XE\U#)+"H$I9(940AP1_US3Y3R6-+1;?$HE6<"L04RM.MC@$)N(3\S$5K-CC2(^.9,@/8-/SQ"B M9PC4,X3J&7QZ!EO/KJR\RW^0GL&G9PC1,]!/^\0!L8GXE`RVDAV+$_B4#$%* M!I^2(43)8"HT2W/`*V*B4IJY,O*I&$)4#*9$G8N_C7*N_N#3,MA:QM?_&?39 M'P!`%;\$,A7/$D<_453Q^JGO7SKE5E$<4S!%U;X4Q5:[:__D4R@U M%?JX@UIJ8DH/VT(M53%Q#QLDFQ$JTB6I/.A+^^1'"]\LN.P+BT^R6G9]16!6 M['CJ_B#U'9S*4_B[[([56T?O4FE9#,>B1RE5&+(-/DR]/)9E(?[0RV. M2M]FNLFG\Z;I0&ULC5K;;MM&$/T501\0[<[> M`]M`([MH'PH$>6B?:9NVA$BB2M)6^O;$LZNQRYG#/S.&2-Z>J M_MYLRK)=_-CO#LWMJWA=M][5^737'NBR> MSX/VNQ4HY5?[8GM8WMV<(7]ORU,S^W_11_]8 M5=_[+W\^WRY5'T2Y*Y_:?HZB^W@OU^5NUT_5G?K?<=:?)^T'SO^?9O_]G&\7 M_V/1E.MJ]\_VN=UTX:KEXKE\*=YV[;?J]$SA_GH9?HAJ'Y0?`.``N`[1E!YAQ@)$.L.,`*QW@Q@'NPX#5D/N9 MN?NB+>YNZNJTJ(?K?2SZ9:4_N^[:/"V:\\%ZN"`==TUW]/W.*G.S>N\G&C%P MQGR98R"'6,\1P>8@]W.(45G,`\:D"V;5)7+)!G+9F"$;0-G8_`0F-X$=)C!H M`H>C#`,=`^9PQFBK5/XLE@G3HK/X_`2."=.A"0(.TPUANEF8QMEH;"Z;-8)Y M`QKRX7@F'X_"B?D)`I-/0!.D;#YA'JC1%DP.MI[#K-,!B%40F7#B?!T"04AB M"$F2==B7,3*$_D=Z)8Z4C*`A696E`T&"SRV!>X312N5`#P@$FEKV.EML1EJT MEBP4G57XQ`L(ELH(8GF90P#`:R(8KEKH>;DP)A!3<*5`6]%2X8J!=I*EXJY3 M,H?HJ!T1"U<)M*@4:*X6:$DQT.%Z.G.(=@8,E1!7"C2N!=0EYHJ!%E4#X*H! M2*H!(!E'J[/4K1$,3`B0U3N&I4`)'CC!@TCPP`D>)(('I.9NZ4:=SQWA@@>@ M0N)D#\@E:(H83O9@1<1PL@$33DZY1.Q#J@83B@K*ZG@)"N*=]DLKH>:3%*0HO)2FQRK%I` MRP@:2P-\;/$C*S0*A\/)U2"Y:D-,D9771(H1D9*5UQ2%E9!BK_80!`'EJ;5O M.*$:)%1-W95P;=5X$25<6S5!0DE`N@#O\[0@+YZ\)^J7X?1LD)XIMV&XSFJ2 MA!;+=5:K!+38>2_L[BD^MLR1%@Q3)A%NP7)ZMDC/FLJ)NPNV(**%:W'62&@Q MJ+FD?`]:?X"Y0(C(O:)&+3Q&:5.!&#.RLA9LOU0HM[8)6;NY+37&D5M"G&0=DBP0S=MQKM2)7*EC=Z:< M)-^Y*P7EG"%6ON/$Z)`8@:@JCK.E+H@2YMJ8BX*5[^9^$SRY\C$N=IV56OF< M&!T2([5_Y3ECZI6$&,\U,J\%Q'B-6J:B/*?G-.:1QH#PG)[SG%[D.3W7H3P2 M#]A\OM<])P'!@7`2]$B"0*P@SV[HBORFY_J2#Q(ZKF_C$!`<""=0CP0*5"Z< MS_0BGQFX;A24@(YP?3^7@.!`.%D&)$MJ0RMP_C*(_&7@FE4P$CK,=3KR$!P( MI]J`54L]N^!\91#YRL"ULN`E=/CK=.0A.!#V00QNB$3K")R;#%%$!]?`0I+0 M@=RD\^#R-AOCO`F6("9R^HU8OX2;C)R;C%I"3.0Z700!,7'N)ND],`:&`^)T M')&.#<4L9SJCZ&EHY#I>=!):T.,-:@^,1N%P.#5'I&9#\K2D(`BIXBA).T1$IVE"/5#E+FD1[I8GK?4D+*$G8DE)[8`AFE77$94Z< MGA/2LR&<:^*<:Q(YU\3UP"1QKFEN2UUWTY;?`T,PFQ)5;!.GYX3T3-T<)L[! M)I#PO3!('F]".J58A7VPQ3&G*E2=.T0DIFGJOVT"P>J[:M]N=WF5ZJJBV[ MZ=2GCO%-63Q?ONS*E[;_M[=I]?"JV/"EK8[3JV^7]^_N_@=02P,$%`````@` ML(!D1WN3!3)X`@``-0@``!D```!X;"]W;W)K&UL MC59-CYLP$/TKB'L78[XC@K3YJ-I#I=4>VK-#G(`6,+6=L/WWM3$A=N307@(> MWIOW9@;LY`.A'ZS"F#N?;=.QM5MQWJ\\CY45;A%[(3WNQ),3H2WB8DG/'NLI M1L>1U#8>!"#V6E1W;I&/L3=:Y.3"F[K#;]1AE[9%],\&-V18N[Y["[S7YXK+ M@%?DWLP[UBWN6$TZA^+3VGWU5WL?2,B(^%GC@6GWCC1_(.1#+KX?URZ0'G"# M2RY3('&YXBUN&IE)*/^>DMXU)5&_OV7_.I8K[!\0PUO2_*J/O!)N@>L<\0E= M&OY.AF]XJB&2"4O2L/'7*2^,D_9&<9T6?:IKW8W703U)P42S$^!$@#-AUK$3 M@HD0W`GA(B&<".'_*D03(7I0\%3M8^=VB*,BIV1PJ!IWC^1;Y:\B,9O286.0 MJH&(WC$1O19A$.?>52::,'#$;'0,3&V0G0[Q9X0G#,PNH,W%I`!U!9O`UD!D M5@__3+)_DL2P&=AL!JI9@=&LQ)X@M"4(58)0;Q-\Z':BRE"83F$RF*5VF6A! M)C)\/DPL4C*1)@.C#(:A72=>T(D-GQ].(.26Y=%Q^W%IT/O%>H=Q3'^(;?[7U+?&=/"''/?B>OLA[=,8_ M$#W7'7,.A(N=?-QV3X1P+'R#%S'$2ISA\Z+!)RYO$SE==:JI!2?][9">_RD4 M?P%02P,$%`````@`L(!D1[&=_A$!`@``FP4``!D```!X;"]W;W)K&ULC53;CILP$/T5BP]8$S#)-B)(FTO5/E1:[4/[[)!)0&MC M:CMA^_?UA1`GD<<]IV256ZV*NL2G'6K.W@52)UYIS*/VM@ M8E@EL^0:>&M/C;8!7)5XXAU:#IUJ18U8,J]47U66O`K)4&YLYC&;N=^L/*QRD<<3D%@"XA.0N]U^*&/A]\)C M.HR5?HBO9\NM;QNW-%79TQ/\H/+4=@KMA38_C+O=1R$T M&'_IDS'8F$XY+1@&PO=V]R:W-H965T@I%. M=Q]UTR>25E=5_VI.4K;!G[*HFJ?%J6W/RS!L=B=99LT7=995-W-0=9FUW6M] M#)MS+;/]8%06(421",LLKQ;KU3#VO5ZOU*4M\DI^KX/F4I99_=^S+-3U:4$6 MT\"/_'AJ^X%PO0IO=ON\E%63JRJHY>%I\94L7ZGH(0/BWUQ>&^-WT)-_4^I7 M__+W_FD1]1QD(7=M[R+K'N]R(XNB]]1%_JV=?L3L#78;D=_;>LD1M5 M_,SW[:EC&RV"O3QDEZ+]H:Y_2;T&WCO:+SP#1!K@_C.(!QS M.U1FF[79>E6K:U"/G],YZ[]:LHR[VN^"9ABLQX)WM6FZT?.-`8& MS+.)`0RQ-1$QPR`O=J`8P[S:F.2&";N%W%8#V&KHN!JP'*2X`XHY8*,#:CK@ MD)7/I-N(=8$>Y'B'L2=6 M!:A2:4H0>72U!KDJ-`.QB;CT#HA'5P-Y3`2'V$1<.@?@T=4`?D6R<,XBN10/ MJ$=?`_6D1'TIN;0/F$=G`WM<+AQB$W%I'G"KL]F,"U2EIO.$\.EL<.D+Q!Z= M#>9FBT`D$Q8J)C/)<6U)8/$IZO-S=3E>)1X=#5]K'@S$)N(2_$HN'IY.@^#,R_3 M<1C\\O)9[0:KD0Y=8"8N-:*F&MT?'9A>@(DA9$;TJ$MKJ*DU@N%AN%<8UZZ) MFGIT?[Q+=1AS1T3N@H3&[5`IZ^-P[]<$.W6IVO[P;8R.=XO/9+D9;@+OQK=D M^0T;[VJT?.WJ]'FF2W,WP]`9WLUP=$9,5YOA!]WUZIP=Y3]9??I>O5VQ[O^'U!+`P04 M````"`"P@&1'+XCT_O,!``!E!0``&0```'AL+W=O<.1Y/INB%?%,-@$;OC'*UCAJMNQ7&JFJ`$?4@.N#F2RTD(]H< MY0FK3@(Y.A*C.(WCSYB1ED=EX6+/LBS$6=.6P[-$ZLP8D;\W0$6_CI+H&GAI M3XVV`5P6>.0=6P9DI6^\PB'.!G"[V:[)'U?A#BS1Z^']=1;"T` MA4I;!6*6"VR!4BMD$O\:-&\I+7&ZOZI_=;P0!82R+Q`-A.XN\;2U$CN,/$(<1VBOB4 MAB"[#T7V,Y'\[BIXTD0,Y,G]?16JQ)EK6XU)=)P03ZEMPKOX)EEMDT!\9R:* M'P`W^;+HR`E^$'EJN4('H4WKNSZMA=!@/,&PO=V]R M:W-H965T'D3=/=G*ILI5=]GLHO;0B'S3!U5E!'&<1E5>U.%RWM][;I9S M>51E48OG)FB/594W_YY$*4^+D(3G&R_%;J_TC6@YCRYQFZ(2=5O(.FC$=A$^ MDH<5`PWI$;\+<6HGYX$F_RKEF[[XN5F$L>8@2K%6.D7>'=[%2I2ESM15_CLF M_:RI`Z?GY^S?^^%V]%_S5JQD^:?8J'W'-@Z#C=CFQU*]R-,/,8XAT0G7LFS[ MWV!];)6LSB%A4.4?P[&H^^-I>)+%8Y@]`,8`N`0`00/H&$"O`J*!63^N;[G* ME_-&GH)FF(Q#KN>.KYB<#F2DJ2S*>V,DD")G$()/:$Z3(W*0^<\,1 M!MQ(<-5U+3;=#SX9*;F'Q$$T0^ID'FL@FY2QMWR*`$;L-&8(C9G'[,]NTI@B MTNGR,'CH[CF)Z(<3)IDCA=4@QKDGQ&?RB57:9Q;@,_TCZG/^N:,49@+$QP4( MO=E[`\+!U3C,`HB/!Q!VF\H40A*>N!8"9@'$]`"'HQ',!(B7"Q#,!HB7#Y!K M(W"QQ9R`^%@!N>T%!H0GCHV-8&Y`?.R`W/8#`T)2`HZM`#!'`,,1N&,M`>8( MX.4(@#D">#D"7#F"8T,`S!#`QQ!@JO:OKP5C_PT4<;HI8*8`/J8`?F\&",PD MA!D#&,;`'9L=8,8`7L8`F#&`ES'`E3$X-@C`?`%\?`'LOF!6P20//I('N^3- M%UY,R]34LL.;**9EZJ5EBFF9>FF97FDY[WCVW=WLPJF4>JC46K? MN,TJF/"H*3Q7YS'A42_A44QXE&,='8V&3G5W1[E#=Q33'PIFU=785Q;[])59=77^_T<\^CJ"QKXFL:L0ICX&MQ?KBDW%EWWM M:S3Y9G#(=^)7WNR*N@U>I5*RZK\5;*54HLL5WW?D]R+?7"Y*L57ZE.M1#1]* MA@LE#^?O/I>/3\O_4$L#!!0````(`+"`9$>>9CO5M0$``#@$```9````>&PO M=V]R:W-H965TF%9$2;J3QC-4D@G2,QBM,XWF%&1A[5E_ND,46PM`H=56@9CA"@U0:H7,QG\7S?];6N(VOJG_<-4:]R>B MH!'TS]CIP9B-(]1!3RY4OXCY)RPE%%:P%52Y+VHO2@MVHT2(D7<_CMR-LU]Y MC!=:F)`NA'0E)/F7A&PA9)\(V#MS=7TGFM25%#.2OA<3L2U/]IDYN18IEY3^ MN$QERF2O=5X6%;Y:H063.LQQBTE#B&:+*/,5@HV!U44:9.G+\!CN,<53&0(U6U"6%6G82OZ%E?S.2G"78[[9)0[ZV"+* MI/QD`V^:/)$S_";R/'*%3D*;^^*:VPNAP2C%#T6$!O.,UPF%7MNP-+'T-]M/ MM)AN[W3]6=0?4$L#!!0````(`+"`9$=C&PO=V]R M:W-H965T?Q MW8G6A#^R,VWDR(&U-1'RMSUZ_-Q2LM>DNO*P[\=>3VZ+G%U$53;T MN77XI:Y)^_>)5NRZ=)';&U[*XTDH@U?DWL#;ES5M>,D:IZ6'I?L-+;8H4!"- M^%72*[>^'97\*V-OZN?'?NGZ*@=:T9U0+HA\O=,5K2KE24;^TSG]C*F(]G?O M?:OERO1?":N''48 MK#$K&X-!R,:&H`'AR02&+#"411\/)*,T`2C,PQ0KL M8L4![""$'(3&06@[B"8R$E,+@VDTQH<0:QOQ@"'(YJZ3[>0J2 M,(2%9S/"LY%P#`JW,=/3K-M?V=W]92/@[777Q]9&W)AD=>]-Q&J*.9?5K?L_ M!3S*N_H@-+/8N_J,,&%Z8]RXA#J,U%[TG19YD>P<]\T#IUK\0]02P,$%`````@`L(!D1ZB/ M07K>"@``1T<``!D```!X;"]W;W)K&ULC5S;4N,X M$/V5%!]`W+I8$@54A3O,P#`,R[#[E@%SJ4T(FX1A]^\W3JR@-JUVS\,`]I%: MZM8Y:LN=;+]/IG_/GJIJWOMW/'J9[6P\S>>O6_W^[.ZI&@]GFY/7ZF5QYV$R M'0_GBS^GC_W9Z[0:WB\;C4=]511E?SQ\?MG8W5Y>NYSN;D_>YJ/GE^IRVIN] MC=C8&L#6X M!FUJT!)S\UR]SY+?>_7P?TTF?]=_G-[O;!3U**I1=3>O.QDN?ORN]JO1J.YK M8?N?IML/JW7#]/?8^]%RPHL)_!K.JOW)Z.?S_?QI,=YBHW=?/0S?1O.KR?M) MU34:SY?^]N[?9?#*.339ZX^&_JY_/+\N?[ZL[OFB:T0U4TT"M&RA@ M&^BF@5XWT'P#TS0P'Q8,V\`V#:QT2&73H)0V<$T#]S$'QS;P30,OM1":!D': MH([Y*G*%N,DZV"!N$L,-XGA###AH<9,8@K8U6\?0:S'Q=8R]5E+-TVNE MUU*/Z1A\+0Z^CL'78N+K&'TMCKZ.T=<)\3OF$J.OQ='7,?I:''T3HV\*:5Q, MC+X11]_$Z!LQ\TV,OA'+OEGO].+HFQA](XZ^B=$W[>CW5[G1,K,Z&,Z'N]O3 MR7MONDH(7X=UW@E;BU:+SGNSY=7I*F-;)%>SQ=7?N\:7V_W?=4\-1BTQ>QCC M*,P^QG@*=SC"']?($QI)^_I1A;D'Z^Q!C2S]\QAO3S%<:0?OZ!,:2?K]&\2G(\ M-QA#CN=6T,]?>#QD3`<##"*#.MC#(#*J@WT,(L,Z.,`@,JX#1"`+9&`'1QA$ M>F!PC$&D*PQU12 MM,5&;=&H6PO5-[RPB1&WF>P=R$[)V2F1G=9:MXT$E9\B05MRG"676M(% M.:,#EUBRFXF2(SN>L^.1':"B<^03,P#,C`)G*2260#O*=[2COYD1^3BM@R)'[UE%AK0BAL=B217*XH\^PVH M64.;A@(=M$$9_0=6O@'I=SL7=TU<4_T&97UVL7%`/"I6Z`$IO=:9/FC9;;8V MP+J;V=N`E51(-?73[F8;[Z2::G4@=I)&07@D'A MD<`+!`0HZW^98;&YFY(D;T*93C&5*M%\-)909< M-K-=C"A%:DXB%*M'2I(1'JE4D/1FD7,!JT8J5:-/J=IJ8B?*B^?%2HQ"$F/( MQ7:MD,3XO/*Q0/S$Q4J19O/#9E0ZS?M*SA:K1AJID;?VA1_J%9OFLV_UC-^ERG)#;LT[5F6:PQB^D- M5:V5WO1TV$+E/,TR76.FD^OK7(=/G,J>8[`,-BA/ M,)Z28Z,2@QP=;$%+:0,\15+6A>&3\ MF9+I7H<+32H?C%S0K'09) MAX5,'[0BQ'7F1>N,I;$)@G7VU:0\UNSBL2R/K>"A8'",45:1J*\8E7N:MRS= M+70'_S9]-C"L-59J+,H8+'E*N["&I(:S5K)*4Z*<'S*GZ26M#@V#2I`PJ&29 M7"H!@Z[+]&A2<:<")9LVE(CSELQ(%]90+I"QP^I"B9(`2])G\+U$APK.$ZT2=0=RTTGXJ9CN>E4]XR/,L[SO\.I?:W&PS+A:)Q\72V-GN#6#?VZ8W],2TZP+;T3K@I4#;P7[VZ67L]RS+/>E8'N[Q*BL@UF* M>]>M]M^\$ZN]YVL^,,TSZ8IG:>Y%-`\LS8.`YH.K4(BG'5CV!DQ,\D1P80Z_ M&\P<0P66O@%S+E`3^Q[2!-ZS934L.8,@4[@,::;@J/?G37D!`GKN;"RP&45` M='>DL8N0Y@G&L#Y@A2&@/,$!%=K+%BBSNP56$@(BN\N\JPELIA]$F7Y@*1P0 MA5TK8;.->]$K.LT&DR_=0F1WN2J8@F9[+!8I"LF\H>"+I`JV2JH1C?T(:]9Q M/CDXQ$BVA*/@JXX*Q'J7G1][!+>\+?$27]Q32$[AOD58DQEQAPA0L`1@J6$1[I2 M]22#K@"(=V0Y>SQC<3V>)VLMKUJH?-QXLN*Z/5I#KR(J$H0KIH".&C]4Y&?; M'Z%:&T1%-;P]7@%P\9[/J5&F*"\2$D1ORZ"CA`[7T+4_]M6@/L%RD>4KZ`!7 MQX6<^S+E<7'B2G12!ID"N?58\'Y(YR@1)6$L7TP'N)HNY'0F4R2WGKOH.17X MFC;`16WMN#KDH4^N,!>Q@$N;=AP!=Y`:KR:G^`($13*`MM&>HG']8=5]/'Y=>HS'IW MD[>7>?UIG>3JZLM:KF'KC^6'?5O7;V#K)W7]%K;^I*[7WEU^[8LB;M;^6=[4 M]$WS\84Q_8]1[VZ_#A^K\^'T\?EEUOLUF<\GXYWZ4\8/D\F\6OBBV%PHPE,U MO%__,:H>YO6O]='U=/4M+ZL_YI/7G>9K:];?G;/[/U!+`P04````"`"P@&1' MRI90EY`"``"I"```&0```'AL+W=O^(40X;RW3,\(/FJG MMO$"WT^\%M>=6Q;:]L+*@EY%4W?DA3G\VK:8_=V0A@YK%[EWPVM]O@AE\,K" MF_R.=4LZ7M/.8>2T=I_1:H^T1"M^U63@UK>CX`^4OJG&C^/:]14#:4@E5`@L M7S>R)4VC(LG,?\:@'SF5H_U]C_Y-EROQ#YB3+6U^UT=QD;2^ZQS)"5\;\4J' M[V2L(58!*]IP_72J*Q>TO;NX3HO?S;ON]'LP/6DRNL$.P>@03`XH6G0(1X=P M@0SQ-XIG(];CLL<%DP.CC,3':/U9I"JUC.3.5P;61F.N3( M<6F]E7$>%]Y-!1HU@=9L;$T`*7:V(HTFB22^]2'1SA8E M`?)AE'@!)9ZA9"!*;*-$:1B#++8J?T"2+)`D,Y(<)$GLH4/S8&H0>;$D$GG+W-`BN M3&OR,0VR9_U3$L\Z55O"SOHVXTY%KYU0*\*RFAMS@U9;?;]]LN_430K8G_/5 M/@?LLGKIX(,]TZ7L?2"518_/Y"=FY[KCSH$*>7WHP_Y$J2"R3O])KM^+_&^8 M&@TY"?69JH5M;E+3$+2__QA,?R?E/U!+`P04````"`"P@&1'"=W(>+`!```: M!```&0```'AL+W=OO.&BO7!C_:(J;<`'!KK%9@;KE`#YU[(%7Z;-?^5],3U M_*;^+73KW)^8@5KQWT-K>V>68M1"QR[!8C\T>> M'#*WJSU-2W+U0C,F#9C'-6834:\11;Y`B#.PN$BW7&31 M1;KB)U_VVP+9ED`>!;*[-K)[DT5L(V)D-$EWE&Z7R3\ID]^5R3?+Y*LR"2U6 M95:H^O^H:(:LCG%D9_C)]'F0!IV4=3'F M.M[=&%@UWE[B\CNH_@)02P,$%`````@`L(!D1T))&.YT"```-#4``!D```!X M;"]W;W)K&ULC9M=4]LZ$(;_2H;[)M:WU`%F3DMI MH8%2*-#;M)B2:1)SDK3T_/OCQ#;H=5<;W?`17FE7TNK9E6SVGZKES]5#6:X' M?^:SQ>I@[V&]?GP]&JV^/Y3SR6I8/9:+^B_WU7(^6=>_+G^,5H_+YO/[M8'NY7O]:SZ:*\6`Y6O^;SR?*_-^6L>CK8$WO=!Y?3 M'P_KS0>CP_W1<[N[Z;Q:LO_MIV^V-PTC'_N>C_>#K=V M_]MD5;ZM9K?3N_5#[6VQ-[@K[R>_9NO+ZNE#V8[!;#K\7LU6VZ^#[[]6ZVK> M-=D;S"=_FN_3Q?;[4_,77[3-Z`:R;2"?&TB^@6H;J-P&NFV@7QHXMH%I&YB7 M!H)M8-L&-M>":QNX7`N^;>!S&X2V05YL\ML*]WJR^S5E]WJ2]UK,FK@M47?T60].=Q?5D^# M9]#6YC]T>]-3ZU&;C5O4&,IS5O4 M.$ISA!I/:=ZA)E":8]"(@M*\1XV@-!]BC2DDI3G!?DC-*6H4I?F(MLAY'F?T M]Y]DMQ]JME],NI!1;,'/2BR!]WTH,"'WCJZ)CX; MS6*K$451T&8T9T:#F5XHF,:,CLR\$KHH8E.1/V-6"#X9SB<#/EG*U)&)3$E; M,*8L9\J"*4<-?VPC4^2XSV*%*@K.&\=YXR)OA"E(;US:FT9Q%BN$T-(EG?&< M,QZFQI,!Z'=-S<>=BO%.Q5FLJ)&FDN,)W'A"#-C^>'P#F1!9BT%;6C'O89[-N\D52A/W0AT/DC@$6I/EB"19H`HBF"GI> M8J39H::G)25";UCN"0"?ZN4*(5IW8J))-S2D;)R6H46/ILV(K-I#TECI+$D8 M$%WDM"(NA20DZ`D+)ZE@R1/@ES12NII/YX2>9"$@#1=Z;3TFH?CQPGCQ5^BU MU4*.M)G$D52'<4/)*%BT2X]/BJ6W,H2DTLRQ;I(*@-'6IQZ?1* M>"U"Q;/4FH7Q39&5[)>/*2@3%66.)*0-8(XO% M*XD8Y(X'BN6@0@X&*FA.4:13AE@2*B"A%K0A%,F$(1:$"D"H%;D->J)$V:/X M4V5&$7:EXOHJ#$6"AHHML!046)K>V3U1ZIS,(E/!<5$[RM!Y3^03AEA6*?:P MV`3Y.P5U4"@D%^4LL100*Y$+]AI1 M`;**.CJ+Y&JRR%*`+)-P6=,@:C.^CAF3S/B:98P6W(X4JKV"P7)KJ&S_Q*+: M*QA&B%ZQ0-(Q:Q*'D6,=EUV"O>_1+)4T4,FD/&:K+YU5?6D6)1HH87I'G>XV M#.HDLCA(2-`3EC4:6&,4R1H-]T[LP4*SJ-&(FL1A6,-6ET-'RL9I&7K$PD`# M#`P)OW<:6>"Y\;,LT#$+M$CT85@6F"P6&)8%1F0@W\0[W'#$YY7H%TL#`Y6' M(8OG&Q/3P!G6&DL#@S1(S21+`Y-%`\-?0P,-Z+/)*8H,67V,S6MG"SJQ*PMO2&[:9.94T=>URPL&'I.[?W-KYG M%<9P!U;+[FV;L[=19,E3V3@I0F_XIU!XLJ`O)^S.YU!C3M*4)N<@>26\,.D9 M9&L&BS4#?9UOXUK`##5]GY]6H3\LS]RN618Y%Y&@J-M[W M1(G;6,=>=CB\[*!K`E?LC`U.TL8&2.KM59A4:?&I+Q7<(T^6F0Z923]>>..@ ME!DF4.=8U#FH8FP"4XY%G6&HY!!)Y*WSMX)XV""[V/,LN#^RRGC)WXF.4>)W. M1Y[EB,=B*-"V8HPXR]AB2>*!)(ZDZ8F/ST-&IDVQAR$/AR%'/XOT\84M/K9! M4RR7/#X2)VNB$Q2YQ`[W+)(\ON!#ECM'/D;2*T%LCI9=(*0?UNR6G*,Y9U/W MG:B37-[S+"H]/M2B\[K?7?/MEIR#I`:=XKD[-^#4KMT_"\!64+D^24 ML26GQY*3+A7>>GC_::A(U5%/Y4G5,:AD,4Q4]YY_D0HJ4T?>Y1U[0+QQEILE MEO$>&._(P#KR,>.EEO/CIDA=-O_4T_RRKAX/VO]1>OY'J]^OMT=19/6=/(NR_;*759$U[6MU\.MS M);)=;U3D/@V"R"^R4[E8+?NQ']5J*2]-?BK%C\JK+T615?\]BEQ>'Q9D,0[\ M/!V.33?@KY;^9+<[%:*L3[+T*K%_6'PA]]]9W$%ZQ-\G<:VUWUZ7_+N4O[J7 MS>YA$70YB%QLF\Y%UCX^Q)/(\\Y3&_E?Y?0S9F>H_QZ]K_OIMNF_9[5XDOD_ MIUUS;+,-%MY.[+-+WOR4UQ>AYA!V#KD?T>GJ>R?UZ' M+S%59F8#J@SH9-!&QPR8,F"?!APUX,J`3P:4H`:A,@@G`X8;1,H@C'ZLH"9;^1^=)86B/>8(88L(\`PRA)LQ7 MZ,>(63M@OL%8W(1Y@9C(A-GH&!X98[U"/XD)\P9S9B;,=X"AG['\MDA3I:BQ M4FRH%-4\,&U&P`,S>N"#!P9RF*U;/-1HP)0]A@1!8`[#L3!<"Y/.5GZ`/.J0 M:$:Z<$B$:XGP-.%43T;+>.T*W.A`R[Q";%ZA3I<@-68=:C$8(YPR6]H.R,'G M1D?RD,246^L28?E'.H%L%(PQ"L8N%$RP'!+0*MQ$CF>`B2UYIEB4%$0)35'6 M$&.92R?E]C#=5\U';&2$`LUIIU/A-N0%0&C/%0M;YD@66QCX!I`\,?F,E7CI M2)($`83")3/_NQF7C&!-I#1(@=`E0R#C0A"P$#2RRQDQ"^^8,U!>%EM\F*57 M=0YA+JU#4%TE_';S?(6@B!FY;P7!;%`U)+H<1FQ6@T1EHVM7>,>Y";6VHV`^ MJ+J1R*'I9Z#$$L@L@F.@&.OZD<+Q;0K?A'P#$!*&!&G[&30(D19%)9HD6(N. MJI;RJ1%%5HA2CH2J3`F$TM$!@)NBVD@)MHQ9]I&9M&]>>.ZT]JD@TO*V/KQ#$ M;(%0J:%0168=0M2I2:'&*J=W).`6P:&HX-#XMM*^4KW_VUBV*J"M3Q,'#86@ MU$89M%UIZD+>5-\B!_-=!R"Q`U1ICKO7UQM0>/!"=XHL<-!4!G9N"0D38INO M.W0#H7%[]DSLDT"UC8&]&['Y0`^QS.T4BQ]CF0-+(2@EED#HAHMQ!Y8R_5@9 M8B3%D3`O5.@8>A(=#_+@V(@=H'$DS,N@B[WID%>T,-F@XL:`N`6F6CX"#"'S M$Z&O77D5HCKT-[FUMY67LNF(IXU.M\6/_979?)Q%]V_M)/[\TJ;0?NDOF/W/ M$*OE.3N(O[+J<"IK[UTVC2SZB[6]E(UH,P_NVJ4]BFPWO>1BWW0_XXX]PZWP M\-+(\WC)/=VTK_X'4$L#!!0````(`+"`9$>C-Q#K:`(``)X(```9````>&PO M=V]R:W-H965TTL2`@%'G=EJK?NP M,YT^[#Y'C<(4"$MB[?[[34BTP8VL+T+B=T[N/8G(],2[=U$P)H//NFK$+"RD M;"=1)+8%JZEXY"UKU#=[WM54JF%WB$3;,;KK1745(0#2J*9E$\ZG_=QK-Y_R MHZS*AKUV@3C6->W^/+&*GV8A#,\3;^6AD'HBFD^CBVY7UJP1)6^"CNUGX3>:Z(&?)3L)YS[0M6\X?]>#[[M9"'0)K&);J1VHNGRP!:LJ;:06_FT]OY;4 M0O?^[+[JNU75;ZA@"U[]*G>R4,6",-BQ/3U6\HV?ULRVD&C#+:]$_QELCT+R M^BP)@YI^FFO9]->3^28#5N87("M`%P'$HX+8"N)[!=@*\+V"Q`J2>P6I%:3W M"H@5D'L%F15D5X+(;$>_F4LJZ7S:\5/0F0/84GW.X213QV4;B'ZR,V=$;:=0 MLQ_S-$?3Z$,;60;US)/+>(F%2\2`^)BERQ#L0YZ'-EYF-61R'_,R8"#T,>LA M\]56I$*[)(=\R<4F.30P2/T&L<\`&X/8C1XEPRJ)B=XP3<\\0`R`?QD\L@QV MEL'7@25F&>PL$\<0H]A7S=+%<`()POYRDI%R$C2^5]02P,$%`````@`L(!D1XIFZVQ<`@``U0<``!D```!X;"]W;W)K M&ULC97?CJ(P%,9?A?```X46U"#)B&YV+S:9S,7N M=<4J9("R;1UFWW[[![&8JGLCM/R^<\[7UIYLH.R#5X0([ZMM.K[V*R'Z51#P MLB(MYB^T)YW\A9-W9$W MYO%SVV+V=T,:.JQ]X%\FWNM3)=1$D&?!I#O4+>EX33N/D>/:?P6K7:H(#?RJ MR<"M=T_5OJ?T0PU^'-9^J$H@#2F%BH#EXY,4I&E4()GXSQCSFE()[?=+]&_: MK:Q^CSDI:/.[/HA*%AOZWH$<\;D1[W3X3D8+2`4L:>N:#M1>)[+?XR MS[K3S\%\682CS"V(1D$T":8\;D$\"N*K`#X4P%$`_S<#&@7H)D-@O.N5VV*! M\XS1P6-FMWNL#A58(;DWI.R]G//%G&6?"I`HU,I)F-S40+%[*U M$3`1@2Q@JB)R53%FB.P,K@3%C%@Z:W@:9'W:($]`"IK83MF]?&Q/6B1RZ M%XS-S'SS#9:=CXR_B9I2Z;UW;2^V?BWEL`D"4=6T(^*)#;177XZ,=T2J*3\% M8N"4'"92UP8A`''0D:;WBWQ:>^%%SLZR;7KZPCUQ[CK"_S[3EHU;'_K7A=?F M5$N]$!1YL/`.34=[T;#>X_2X];_"39EIQ`3XU=!16.^>]KYG[$U/?ARV/M`6 M:$LKJ16(&BYT1]M6"ZG"?V;-CY*::+]?U;]-W2KW>R+HCK6_FX.LE5G@>P=Z M).=6OK+Q.YU;B+1@Q5HQ/;WJ+"3KKA3?Z\B[&9M^&D?S)04SS4T(9T*X$"!> M):"9@#Y+P#,!WQ$"T\H41$DD*7+.1H^;GS<0O4?@!JNH*T],B]SDJZ(0:O52 MQ%F2!QE#<,1 M3,('L44K=B([-I2X!>*5W.//Y)ZL.$CLW!%V!I)8G0)7%CL;`:,(`N`2*N]@ M('KP!],5P^G:1ID-IX\-ST[2FZV4PLAM)%LQDJUMI7G'9O]+KLQN(D$ANG<2 M6$?&0$[T)^&GIA?>GDEU^DQ'Q9$Q2948>%+=U>H6628M/4K]FNBVS<%J)I(- MUVMBN:N*?U!+`P04````"`"P@&1'Z6!!WET"``#?!P``&0```'AL+W=OYCKVQ(J=GT=0=>6,> M/[GRJA`D&1!Q/O4+>DXS7M/$:.*_\5++>I0FC`KYH, MW)I[2ON.T@^U^'%8^:&20!JR%RH#EL,G*4G3J$2R\)\QY[6D(MKS2_9OVJU4 MO\.RW^,F/= MZ7$P7[)PI+D)T4B()L)4QTV`(P%>"?%#0CP2XO^M@$8"NJD0&.]ZYS98X")G M=/"8.>T>JTL%EDB>S=[C.LC,@V$PG<:$+D1I(T",D`NTF8$6,'.!MC8HALD=1^B!(S1S=",%&4?H MOB.#*&T$C)R8#9II=5;:VI@%BMQVD@=VDIF=Q&DG>6K'1@`89DX_,U`&W(9L M$,SN.4H?.$IM1R%P7KGTZ96S$=(0=%XY&Q2#S'WE;-`"I.&-H\!ZOEK"3KIQ M<&]/SYU0_T,K.O6FUT@]?S?Q-5B6P!'?R%YF6L\U?9'W^$1^8G:J.^[MJ)"/ MKGXACY0*(E6'+_(\*MEMIT5#CD)-4W50I@&9A:#]I9U./;WX!U!+`P04```` M"`"P@&1'Q--[U!("``"&!@``&0```'AL+W=O]=@#"810>H&5>VATFH/[=DA3D`+F-I.V/[[^D&RIO*B MY(`?S,PWWP1,,3'^)AI*9?#>=X/8A8V4XQ8`43>T)^*)C710=TZ,]T2J)3\# M,7)*CH;4=P!&409ZT@YA69B]%UX6["*[=J`O/!"7OB?\[S/MV+0+X_"V\=J> M&ZDW0%F`.^_8]G00+1L"3D^[\&N\K7*-,(!?+9V$,P^T]P-C;WKQX[@+(VV! M=K266H&HX4KWM.NTD"K\9];\**F)[ORF_LUTJ]P?B*![UOUNC[)19J,P.-(3 MN73RE4W?Z=Q"J@5KU@ES#>J+D*R_4<*@)^]V;`2/1STB\12KJ.A!FD]M\511"[5[+ M;+,IP%4+S1AH,,\N!OH0>Q>!D0]2N9`D^B@$E,F[4^ASFEBGT!6(,[]`XA-` M5B!Q!%"4+EUBVZK%#`;S)491Y"^#5LH@UR?$?H%TI='TD4:S%0?96J.I;31; M-)JC>./+8[^`P01CZ(-52]@&?Y8;7G&-%[G%7M?8J0/S.,V]L/T"AC,(HIUAG9<](N)!MOI_[]TU/^`U!+`P04```` M"`"P@&1'V+BU1&<"``#N!P``&0```'AL+W=O15-WY(5Y_-RVF/W=D(8.:S_R+X'7 M^E0)%0CR+)AYA[HE':]IYS%R7/O/T6J;*L0(^%63@1OOGM*^H_1-+7X%>))@P8,1L3`Q8N2&E"HAD12`&S"N!2,54`9@57 M@<)"+)T:_IMD>R>))1.Z9$*]6=#@PRAQ)XA="6*=(#82),O8%IGJO="83A<) M;UNB0<570*4)6MX!;4U0FD#H-H4>F$*6*6170=H4,JJ@*'1A"@L#$Q>F-#$1 M6BY=H*T%@FCAMI0\L)18EIQ2-HE990'=GBQ0LE@X3266<02=IDQ0#.`=4^D# M4ZEI*HR!`'`>XS*U.X6`\_19*`@^?92!<9NUA)W&.<*]/3UW M0GV61G0>5<]`W88W\4VT*B)'O)2C34^B:_H\Z_&)_,3L5'?DU5M_0\T@M!^\MTG4=\_@]02P,$%`````@`L(!D M1S-,\=.M`0``&@0``!D```!X;"]W;W)K&UL?53; M;J,P$/T5BP^HS25%B@C2EE6U^U"IZL/NLP-#L.H+M9W0_OWZ0EA2T;Y@S_B< M,V=\H9J4?C4#@$7O@DMS2`9KQSW&IAU`4'.G1I!NI5=:4.M"?<)FU$"[0!(< M9X3<8T&93.HJY)YU7:FSY4S"LT;F+`35'P_`U71(TN2:>&&GP?H$KBN\\#HF M0!JF)-+0'Y(?Z;XI/"(`_C"8S&J.O/>C4J\^^-T=$N(M`(?6>@7JA@LTP+D7 M@P3W4 M)>#06S\MW5S'NQL#J\;K2UQ^!_4_4$L#!!0````(`+"`9$>[3ITT>0(``!T( M```9````>&PO=V]R:W-H965THA?<$C&OB3(R8]9'Q)3@X="8('2>H[QP,@-K9K7P/O[:EA(N`4N7/C'=H>#;3%@T70 M<6._NMG.!0(B$;]:-%'MWA+F]QA_B,6/P\8&P@/J4,V$!.27"]JBKA-*//.? M6?2>4Q#U^ZOZ-UDNM[^'%&UQ][L]L(:[!;9U0$=X[M@[GKZCN890"-:XH_+7 MJL^4X?Y*L:T>?JIK.\CKI)XD8*:9"=Y,\&X$-U@E^#/!OQ'6\<&,#_XW03@3 MPF4"1U4N]ZV"#!8YP9-%U,L>H>@I-POYFZDM*H-$O0Z^Y"N.%>04H>X M[I-O4AS$3Y.(AZ:R)":=SQ:@?V\/21SM+.L1."7FER'^FF2[Q!`OTVR7FN(NN`Y"YVZHR$=X0C\A.;4#M?:8\2-;'K!' MC!GB58(7WKH-G]6W18>.3-S&HJ?5]%(+AL?K,+[](RC^`5!+`P04````"`"P M@&1'^#:XCQ(#```%#0``&0```'AL+W=OB8UM323A"ARG_[X"(05:H/;! MDM#NOKO``ZB^TO&5G0CAP7O?#6P;GC@_WT41VYU(C]F&GLDPO3G0L<=\>AR/ M$3N/!.^E4]]%$,=YU.-V")M:MCV-34TOO&L'\C0&[-+W>/S]0#IZW88H7!J> MV^.)BX:HJ:/5;]_V9&`M'8*1'+;A/;I[@$J82(L?+;DR[3X0R;]0^BH>ONVW M82QR(!W9<1$"3Y5.Z;]@1AYI][/=\].4 M;1P&>W+`EXX_T^M7HFK(1,`=[9C\#W87QFF_N(1!C]_G:SO(ZW5^4\;*S>X` MR@%6AT0Z1+.03/,SYKBI1WH-QKEOSU@,(;J#J2-V`9.-XUS]E"B;6M^:(B[K MZ$T$4C8@;1YT&[1:1%/T50)L$LH=#(G*'B"Q!4CF'!,]`(KM`5);@'0.D!H! MD%ED-F&,IJ%'.."K)`M M*@9E*+>K(+W37#)6T!89G;0$E8X0/M303:PA'VS(I*TPBTU5L;H1BA.'CH\W M9`)7VCLUTSHU<_6(EG--JEC,48^?)'! M+_PUX]$R/N5M2CZ$465,1\?"#U8\U72$^);I"#[V`/FFH^I8T-G+-Z[E'WST M@;'/:2NK/E&4T2P$1>'0L2*ZZ!B(@GV95T9J_%S+//@X!H-CL"_TH&^;^IYC MZO@X!H-CR.P#I'-<;I(JUGZN,XD/:S"PAMR.`>3FO'`(^<`&$^S"(:2376P2 MUP3TD0TFV:6](TNC(UUK%?C`ANJ&[0STW?G3/_M9I!U3>S(>Y6F3A M7VM=3_SW((^Y'^9-?<9'\AV/QW9@P0OETV%9GFP/E'(R91%OIFQ.TS?)^M"1 M`Q>WA4AS/J7/#YR>EX^.]&UL?53);J,P&'X5BP>(P82V MB0A2T]&H.1/Z M%+7&]$>,==D"IWHG>Q!VII:*4V.'JL&Z5T`K3^(,DSB^PYQV(BIR7WM112X' MPSH!+PKI@7.J/L[`Y'B*DNA6>.V:UK@"+G(\\ZJ.@]"=%$A!?8H>D^,YY?@,TQ)\PE(R[;^H'+21_$:)$*?OH>V$ M;\"R9'8C2B1]D455F^# M:EN]%O?DD..K$YHPQ&/.2PQYF"'8RL\>9,MCXI.E1QIO"Z1;`FD(F2X$DL-A M6V"_);`/`OM5@F2]RH>0,F"$Q\2[)-MVR?[CDJU-O";JJ83&EVDL5?(GW&ULC51=;]L@%/TKR#^@ MX*\FC1Q+C9-I>YA4]6%[)@Z)K8+Q`,?=OQ\?CH,KUNW%P.6<<\\%1L]QYM#;A`6\*,EH_3FP'@_G/]J0:;19%X$3.>*#JE8]?R52"=5AS*NT7U(-4 MG-TH$6#XW8UM9\?1[:S11`L3DHF0S(0Y3YB03H3T3L@^)603(?O?#/E$R#]D M@*YV>W)[K'!9"#X"X6Z[Q^:GBC>YOIL:2!L4[D+TV4D=O9:K-"O@U0A-F,1B M=CXF68<@>Q\2SPBH#5A@2PDD#F!;"'PN#2Y(0:N^CXC1/T#H$.RQ@ MF4Z:ADO+/RDM7Y2V"I:6>WF2#*&@9Q^T0A[(68'>_\V(N-C.(D'-ATZ9B_*B M<_-Z3LS[^!#?Q9LJ#L3WNMFYWG27+XL>7\AW+"YM)\&1*_TJ[1,Z MM.U&M^-Y0E*SX7K4&ZA>'_KMW/3+_\`4$L#!!0````(`+"`9$<.HC%2 M1@,``)(-```9````>&PO=V]R:W-H965T9Y[6[$ZWR]H&=:2TL!]94.1>OS=%KSPW-]YU3 M57K8]R.ORHO:7=F.6<77A8U?6Z<]E)5>?/WD9;LNG"1.PR\%,<3EP/> MS+8HDI$/\*NBUU?X[4OPK8V_RY<=^X?I2`RWI MCLL0N7B\TXR6I8PDF/^HH#=.Z:C_'Z*ON^D*^:]Y2S-6_B[V_"34^JZSIX?\ M4O(7=MU2-8=0!MRQLNU^G=VEY:P:7%RGRC_Z9U%WSVMO27SE!CM@Y8"_ZA`H MAV!T&(7!#D0YD-&!6/&APH18^I M.TP0$9B$6$B(3D)\DR3L28A&@L,DA%E""TMHL""3I<<\ZI@(%A+J0E(RD=/( M(B0RA&`HIUFDL]Q78!_G28^CI5T+L]+#?!-I@^*L;7'4I/4X?IW4QA M#"&RI4\JD49-"IB43(&&DDG@>IA&F7+`#C7(,5H4B<"MZ@X4@]N(`JD/-T@1 MA-I,HTS-__>SSJO7C%W(Q=9;4 5,U2[VY3.FR]19$++O;D$H#$T^PV'H+ M"BT[QINK`U#A39EGR@T4$(X3L>3SLL5;0Y=N?FUMFQ2\V[KT0;'@_G MCUB>MN[&,S1;(V!\(P_S$![/GJ`X*SQ;0^.BI&8;!%E$50A+`%J(L!#0$@I+ M"%HB8>EN']XM(\OY.3_2GWES+.K6>65"_LK0OW!V'FY`XS5L^0]02P,$%`````@`L(!D1Z+C0O89`@``"0<` M`!D```!X;"]W;W)K&ULC57;;ILP&'X5Q`/$!&P@ M%4%:DT;;Q:2J%]NUDS@!U6!F.Z%[^_E`*(YL;?146(##X: MVHIU6$G9/0$@#A5IL%BPCK3JRXGQ!DLUY&<@.D[PT9`:"N(H2D&#ZS8L"S/W MRLN"722M6_+*`W%I&LS_/A/*^G6X#&\3;_6YDGH"E`48><>Z(:VH61MPS\F$V#@9%/LS6Q2Q]F!<7$_LP.Q>3C!B@ZAV+CGU%)[;HV!&`?H'$ M)P"M0.(((#=E;E-:3&LP:)'&?A8(W)W3S)[3;%+G%QGS&8M\8H$0]%EL\HE%'/D@+U/( M%X6N9E*LG!3(FV+U_Q13R/T_!$RNB`Z?R4_,SW4K@CV3ZK8Q5\.),4F43K10 M6U^I=VD<4'*2NINI/K=7M1U(UMT>GO'U*_\!4$L#!!0````(`+"`9$?H_Y=F MUYX``$6S`@`4````>&PO6*/A\YBL" M1GHL`2$6KZ+DZBY`SDR[LBN=F9U*V]U3.!B$R*`4E62$FD%*5CWYX?S!],,T MT`T,^NV\G"^8I^X_\9?,NNZ]=L0.BE*F7:X>%U!.BHS8E[777O?+W]3U)OE^ MM2SKO_WD:K.Y_OPWOZEG5_DJJWO5=5["+XMJO_^YNZ^-W?;'[WK)IM5WFY M2<[*>?*\W!2;N^1%R6,659D<)?55ML[KO_G-YG=_\QM\A]\[3;ZNRLU5#>_, M\WGSU_/\NI>,^FDR[`\FS1]?SS:]9'@<_S&RA#^^+,H\>;')5_5_[WC\;7Y9 MU)MU!OMXE:WRYE-OGKU,OGCQ^LWOS]Y^?98F+UX][34?<7!X=W?=>G_0/_K[ MYG=/M^LU/O]E4<^R9?*/>;9&6"3/LDWK_:.CP?!H-.A8_--JM8)MGF^JV?LT M.2=P)Z^WFWJ3E?.BO&R^=@;KG--:OUQFK5\7V;)N+4!G@I?6L-@7<&;?)W_( M[[J>D[V]S:^K]0:6`(O+-ML6$OQC&R]DA&^K):!:MKX#^"SS=>NQ5U7'B_1X M\A2`>%FM6^M[F:TO\^1L-LOA*7AFSL]WC/5=OEP>O2^K6P!NGM55"<^_J.MM M^P5W^F_R=5'-.P]2\?I_^V__+8:\;AB+%%_"EZW]-Y^4>://_OVHA7NO7SU[ M_NK\^;,$/IV_?OGBV=D[^./\'?SS]?-7[\Z3UU\BEK_^^GER\$V9;><%P.H0 M+O,WY\^2@R>'757;&A"M3I,GP=_-24=[W_AQ\\>W^4U>;MO(\J+< MY+",3;+F!UK'7S-O[^F<9I/?)67.=X' MV&Z2S5=%241D4]RT9O)C%>6L:E.85U5Y5#7G2Y,RWW3N&2>M-E>`[3SD[J=E MR!:$JAKA`^3C^?/L19V`-KUY^_SW\-R+;Y_OIE6[R=)KND(`&Q!] MK@#MX/+JV1\LX78<$E[C?0#4;"WU*BLO\?EDD17KY"9;;G-\M"AOX-*M"%SP M8W:3%`E+^XM'G%=%XMB MQN+.V?Q/6YX[6:RK57+V^NF+!.9-SG%>F.?<3/V*IW[7GIIO^LQM<%N":+@L M_@SG=PDB8$?"W[P_3-@ ML3=$W'?";8\IS4C)WV]A=K%K^#\.6Q#BDZH^"(\CK\6((K^- M_SP9#$?$@@Z>#$:GAX1@L`+X_SK/DQ5S^APY/>#;]89N^G_\/RK2TYO(Z5.@ M%O5U/D-@+.]2^O[)<"`CGXRF?N02I?A'#MP2U\/-X$S'ASSY()V<3C[R=J;\ M890.)U,=^B-2O3<92MM7^090>%GO3_I0*,^5VT?`](`O(&F,4+LTM01B'(K2VK;8O(LA[D`[C63KB7+ MO_"G$Q;;&UWD:V3*>!5X0VW9=`,CK-W@+>UXG5]GQ=P(I+,`0!V<9>=@_Z#F&SK+*R:V%/*\!3T/WAIX3/X`T_V#EUB!8[-F2'+FGHCC7PP;A# MWC4F3[YSTM6J$`F'[C:P!&#:>3F#AY,#W&)RTI2?T?#V>7V=S?*__02(:YVO M;_)/?I>TZ7`U>W]5+>?YNOX,,:Z8%9L6*L`UD[.IV=)SG:G$^:3?ZP^\ZI,F M@W[:[_=5Y\BV&Z`?2%Q_"P!SNCM:,N36=BLE8ERZ?\K1I'/.P?$HG4Q97!@< M#]/!R?'N1239QK/9)."R0)CE6R'.(W*K6\SB> M&)$?GB2_T1.*6'KNP4R#)?MIF2W,;N'0+I6WZVU!K4>\:3%QEZYMKL:#]QS> MJP=M./KJ_;N-OK;O5O<23L_.?Y]\^?+U=^>/4L2?JI0GPHLW,&5XN>.\S>EJ M=;*ID+E70)"1+W@+#GR/?Y$P=KVNT#0R3R[NHN.W^>\*#=A_9LT0I.19B_?@ M)=TX;E@M`*-PS%E51SA^A[D@W^'BF*1*!"K:&P@O(>J1;$ M)5!):KC/P'+HTR'.:*4H%6EBRN5>Z';?%6!9?_<[("G/\GPN;^BQGK4U,&OV M>1[E(V^V:SC0F@;8C8FP<;YTJ,P>!$LX3.#/^980)CF+"_=FGON.(=S>4Z"K MB(M\&5FN?-O]KJX22(`8'Q-5+-+DS3)#C0)QY[DJ&)TGN:T)?1YS(EYUBQG4 MFT>^*,H,2-C."=[FUP:"+4E[]WK0JH',`F:)OQY5L@24^,(<=N%'B-(Y>\"Z M5%2'ETNX!GAZ.XV`X7I?F+5^EZW11QL#B!ZU0XN.N]DPD*-0N,_U_W1Y=`MD'D%;LI.N-)YE6QY6Z<^`_9+)% MCSWP?'SU'>!&GK0H_U/MIP%D M66[GL&*@&YF1]`YF>*9,AJMR><=\!,9#7RX:$.AR^A<.4[@B@/"KK,PNG<$3 M@SHN\F61HQD>76(E,)*Z1OCBHC.6T:XM^(*[5NMO^9SV4.>1C<(3V^5&QJ\V M;HX"5EV`V#TC-P`Q7'D2):,90EY-T(LM;'_!;OX[#`B`[VF!Y5U2;R]JN-6X M(YV;%]?[6$>-Q&.=LUH1)/R)IT,5L9+BM,&6\;7BP!?QY>P5BW-U1=8N&$T3A8E[`EP"\`C@1EL$'65%RP9`6]/"DWE(CN,TK6-0F5S3T^^LEKQ$)/\*%@)M\+]5S M*+Q=YGJ'+M&X1`L6,D*X];6G2<^!HN'>:SH+GL/1G0X"B9O$JXCA2GYZ.?G: M4CRX.JOL?9[D;A:*6@'I:L4B&>-71LH>']^*3V]-=X9WN^FBU328A2[=6CC0 MV69KZ.",:,6\0#59KT%5FU7U6E(]#%B@<0V%8#!+;Y&8E$2&9FAI6=# M44"W5SD#B"P!N)3;JV)VA?`3Z;DPY!W.XR+W(B9@70X\`:XJCK"%\=?+.S8D MZ`0]I%DT>*T;%C9!Q"$';M74,5!0T8/#5J:WQI6I8^0,/#QR$%P1PK;@D1;9YXDP;?ID8%DA[ MI9\P=&9=&4;L4K*Q@<210C1"ANF=`-KG.>X$11*`:4XPHO`7\#E0H(.MZKUOF`&/C83B=B%;SL2V#S>,J-1:$70&2B7= M-&>."XDFTIPVPTP8J\F"1=G`O%9W8E]*.$T,34T M&';2B#19HI&.KSD,4N?+)1$P1Y<(?/HXD0H\\EM=MJ%6.RF4)4LO"/HK]>;6 M-;,$X4));525/VWGEX9AP*\.&^UCEBTI#1.07%3K=76;KP%^,];7UD7]/C4' M!A(PX3.PY-0?!MK`:J;ANZ!J]]7V87Z7JZ$=NQ12,_-^YU!H,%P2V^0X)2/F_`0R1& M&'9SFPMK;A^XVHV9+%0E8;&`RN[7S*I')%PN@\6OW^>;QBUF);(&B729H412 M6B#X_2M-F-/-7SC+6B\)@B\URD%#H9-O\/K3J?!S;R@Z4T,^DNQRG;-H1C`2 M;NK,NLY>QM>/P(ICN8B1'W_X%T;/3+2%675#!/>:K;M`IR7Z&>.`;V&-(^9>TUOTKGY3>Y8A>Q? M]^KD=:"8VYI\#Q;.!H2MD9`41::Q@%U4M\KMS!FQN,L8TYPUJ68D;L#^ MOA%D*6I++Z[1"4+F`Y2MUDO\AG0NM`)9"P!)/X#?93+XE%ZP&1YH7@`=9'MYY0?:=00$`BOT-*1.^S6.VD'`HJ13E79UYJC@K'P,`7^26JUDX@X,.<5X3V M[5E1)A!)8;%U6_5H&MV9+)`%W36`06\Q+`IV>$Q3BG&4R04+L>2A8JG672MG MS(K,9&"RN5H[R$?G)`#08-X=+IMADL1N-Y(#G.+>RD*!GTC`P%BK0G#*.AW2 MY'JYK46X*`%SRKD1?+8+C+T2X7>QE1.12N_6:#&I4J42K9R(+ZC+7R^S62XRG">,,D+>HDR6$S>$Z!A2D$!G M^&CC>%(:.B"FR^(]P7)3/-M6UH"L1>N<[%L2IX^N)BS)$ MED5Q1:)B##\G)Y_JI2+C,&K2V2;WM__=52YQ>ULR/,YF%-#`9.6IV!D%%PAC M5IBT%)A[Z/JBD?'2W5?EYC"=G"ZX'2)VY@5S>G$1\Y]>8H.4,_%\C"["=[ MJ@`EW"5RFB^=G:II76MD>X2A`BC/&BF;F,S,1VR8GYS[A"D\Q\^).Z@EIN^> MLZ@;.KE*YJJ;YW/CKS3\!)^5)!+FC2_A%)?) MR%]ID'9:"LA5`9BQGET14T>XLEF)PF.<.+/=%*BE!]KQMJPND+YEK$E<;_%F ML.&=**&7A6K=&MMM&#L(EQB'T;#,>W5ROO6\>%G?^%:/=A@5A0@3#&!!(O#1 MO?,HT&G8,#$OGXP^(J,ADL..*;C3?3"RE)W//_[PKV%4.ERX623VJ_?C#_\&=P\( MY(IRAD`(*C=K[X^!7>`WF#[8E&6,,*94$?V)<.&W1(9#`_&@_RFJTD3/A$0& MHR%ES0A?6+BO/X?Y,?/%INPV0G)?H55PQ^\O5=&2>"#*K&?C"/G%_"=4)&&I ML(6SFPS-@LEHF'R:#,?XGQ/\SP3^\WL$QG77K_]0+1&L@SY\/H;_G\B_7Q1P MZ`#-NSJ[6!?)?_RO9#"`K^DY^L\I_/\9X,T*-O#5$E3RS9\S?.P`?CV$9W": M'W_X9WQ\!/_Y4F+?F&+.[BAE"S$.[<(E*T+LI:3'9OH89ZXPKT2?#%X5\=.! MQEES9C"S?/9DP_&M.8+&$7J\:RA4X(FBU$X.)51-MFL82Q01FLC9RY]OU]41 M('FE?C&W(#^_H8+&!%_7%88:JC.T91P0VB"$@Y[!R1S'(4ID*OW<_ MT@TE#6#.*Z@6"S*WA@9.&EFL+&CN4Z]N4\=C6J."?7,NEN<=#>J6?.2GWK(NIDCTG5@]R"1ORM! M13I0%%>OBFL64]">+AM%$R[&AA"G9W,M#<>K#V(]NW@QG8;?/WJU'#EGQ@O* M*T5(D6CB-,ULCF$/+=ZE0C][6&"=%0[$I\U(C^R='=NY;.9RC99]VHB$.ER" ME'B)1]9*5"7'05V'F:>I2G/>"!]0=P\2DA/$5U:404`^W@,.R<>3^F2_%(+> M)\G;C@7&DMV6PH\1V;).%J]2@?:IG=>J]&@?5DU/UD@DTP3VP!;Q,< M-^+JIG,J5KG8)F@K]#X?[D)D[1T.=O3Y-7.C[A0W!34T-,;?1MZQI$>YWW4< MU))ZB9E1G-;F1(6N';VOXT<5H_4&W%LHEPC$236_4VF%""Y M>2S5CW?%KD\2GE3EQ5-$5LPQ$_3&!:#DHA#_"YDH*2**+KK&$+&*Z8ZLMB\* M'=R6RKOQ-^#1A5@>,-"M6-R[&-)0S9O&N%%+KA+%WV+M5D[\QN MO7A&="Q3GLE\@03`\B79P#_):D4[$'X\NS\"W75GIU_0[\<]4<@R?]?R3GP.ZVY@,^^ M:81X8IB^#SM_2LIMZF)Y)+**@_':H?!6FLXL_M.SGG)?-.P?Y-H6AV7-P80U MV2_6:#^Q,K:TN;,%'._@UN7G21&)ER2"/8AC]KF81$IZ`G""(W-;6 M^<:'O``:<\@^V_>%EGB6KSQ%:9L/3-\M99/,ID/3VF4916T,IR)8HSTJ"TP@ M++(H,9#)/ZM-S%]NXU4=,:S6+A3-6X_AG6B!B!>^!-!YK*30&H7$6(4F6E7!#-\WE4\SZ@0Y*$/+R/,+)/ZE4.?IB\ M`KT8(`70,Z615.]!J@836=J'0URXA83UDYXDQZ?I>'(*'P;]83H<3>#3<`2? MA@/\=#Q-!],1W$+1CF#2KF)*>ZV`9Z4(?)X`3_ M>X:A+!20Y\('J`9/(W2$;`P`@_$T&8T26%M_T/'JK23!T!OX_S'1M7_N>+P1 MD4(O``0&\FD,>WHD>,-C18!.Q[#KX^/TY'1,?Y^+.KM]=6!?/1ZB*J]KU\?+V&B&]6Y7*M;<-J%2 M;NG.42P$Q86P[9,^^M2:2&9M3TLTMI_2O#*)-H&E.C:T<\4:9BW#V!`:X7I; M%Q\2XB8'(S>0/4.33`A\IZXY?--52CNV6=-(HY?7F1S=[[N!LQ/[OX'6-QRXWZCO.\-W;C@JI\POJPV;!9TEC")<->//.NMTA3`+ M"!ZM)5JQ@4RG-!W)3?=,J'.@ZB+"\,:M.`PC>C(\-H=6E.'^<0F6T$(F7N0:C\9I6QJ;DH^^>#(>]D5L9HG3\C%"/:JUKM[/V\6L:3":] MP9Z+"F\]A4MZQZS+H&E/%[XGP13Y>E;4$E<93QD5RB41-I/>T"[SS;.7)/WY M"H?.67S+L2HJ)P,-QE!C=HMYDB[TP>7,L&%G#GHC&R?(I^A>P]!DL0%ZJ\OW M,PZ]==Q7ZD&@69?JPYP>TK')_@>T)TP-.D_TJ!G#2N$4<^(W#LV? M(IJ_]FJ6Y#DG;RK4VU"!(5E>W8).`L2].Q$T+%E'OJ+NBGF^J$XJL5SN#I+Q MWMGZW5QXC988>.U-F'H(XIAQ[[7/[KN8LJ]!^9H3M5N\/#%TB)@T86`?"X;XG/PQ^@*%A1BH;"=;AKT`C4YO2[KEH`SY< M`.>GV62B1GR-88ULJZ^4SH?9`4!Z'G,8E7N2V\B"E3&K\8]G9&F@93V*4]^:\P@UO?&0Z@_BLV-;B="@ MM%7U`JM(C%P_ELEWKW!T^K%6V'LD`'?";SIQRR-6U5Y=I]WH(T%OY_)&TX^T M/),,NL-2E<:\4I'['0@3YJH6:[VC%%EG"4_+V6`B<;]F;V>T()MY[)FI\]#I M<^@H/SKJ)1T31N)].:J"3<7^EN98;C'#!1`*(F)\='4'6V"M7@( M*>8GD5LP3A",''MFA@F[%]5:LZ]E*7`,V6]I6@V6#M8=B7&6)?F:%C_^\"]X MY=#PJREWS9H6'+_!KY.EOW3>:HEN\T?&U22"Z)<]KX(+40ACWXFZ^-!^-H`# M!):T81,4[@._74QX+T8GV\5E%*OT[!66G&.U^]>#%\;Y=VBJG4A=3TW0X'KM_&?868M/T^`3AI6\^22:C83KHCP-H'J>C*?I,=9PG MR?ADFHX!*]ZA"&MRX$I/06M''`GGL!@#H:+-IR-2=<19LUK9:I>U*%:$.>D. M<.I:B;CN->V9])H;LA*O3:S\K%C/MBL4B6;JYB(.R\J-#MXS>.7+7,:13>(A MD!2NN`X7S/Y-[[R'A$H>EYA.M/!VY:3,8F-'(F'7&L4"2MN,Q(:@=A$&Y?/] M$D+-%!IMU^0*!"-O=U MOD8K1M=\Z)&!F3!#Y!_>)@=UL3^6!`8+=EN.76_-?. MG"5FD3E2T8J*UMH;0MGONM:"XO.H8"WG?./KQ?>PGGE%B1&K"XT!Y4K0U7N0 MK2CY989"UK)8+*L_8\U3JIK2W(S?JVP+=C6777U1Y5?(:0!_7L!_EZ`/K3[. MIC@,?)]-T>/S]?:ROF_]@+Q_DC79B]-*0.4=Q/;&DNQ!+MM_^57RLE@`,\)D M8BU:UX'<+(WK]NZ',B+P'T`2RFC0IW!0\ZQI'=`2"R;7_!XR;1\%F;LLN$CFL;)]2]P*3YY)@]\4RV`!5UGM=48WC??-X1(N8OJ*BORA6()9,Z:,C&-D)`S16TR/NYDI9QRH MC*.VW?!;I3MBY#^^RO,E]$`>"+QRXUOLYJ MCH+;6\`,,=0D<'`QDXUG^ MSJDIK,GR#Q:DQ3A)#.>H^%O.\9807K*.N(+1'&?LU\0!7!56MO!1KACPSW&N MYE&L&P922+4J9D%E#\F3XCR`7,3;.XF/![6.RP:;@7[K;=]IL!89Q1#%H))F M$@ISQGABJQL(B&N*VRTO"9<*CMQR<=Q=^66-P6ZSGR>[6PLIT!2$V4Z$=.6` M*%J:UX>%U(*D[RQ,^[XOZSMMIWU+LO?\)\_V1D\0^I`PT%\J7:+Y345G//X[ M/`*TP`IQI*"T9V>^(I=4-*TP/$7Z(/&!QDZE-K7>B*2YT_#"/F>!*"-LPEYJ M;V0)66N/J,*#K76LLXH?PX%RS<(^R;:!07DX^!3A-9Q\"MKK>:1&'6=7.<$: MS97(81'S<""X8=FF.2]E9W:0-:T;J9J#W%[&4)>)B4*,SV22O%E5$C'62_)C MG/"$(C2'XPO?(&23%SC-')L0;+G25=V"E-:IQY-UQ3O@P">?IA$CF+^?4LK5 MO/%D<&(CVM9^:/QQ./*!%$UYY8R9X1':;BDU.5^SW3PO+[/+7-)KE]>VH*T( MBT3[I6;KTAL"U:30>>EW$Y^BMO2/F($M=LW'9+#[!NEK2+KCU6V_RUW=)CXZ MGX&[JVYD:<@8Y7)PMI33X;!NEZ0]87ZFJX+$Z3H%"=EN%201D`3BZ$(X'":8 MF8HN/H51AVS!F\/XV-M*P5B\UAV%%@G.O>2I)+O!P6X76`=TC;8B>(8P'WB< M;5H`('#ZG@IIU\@7-D+G.0.?+/Z,__4F6TO;;>\:1FB>;2]QE9R,@JYE38K< M>0KL6$`[,R<-;D0[;S]K55.29C'I1/>N>Z.6.)M"1^'%^+L:(Y(?=EN#"SFU MD9[A:/#;M.NN4GE6*N=MK3@J^+J5IN:HLEK.0TT";#^@:$@-<63_'UD+_,C. MTN#L^B1K*2>LIWKJ0DMJ,O+CCZA9T.`5JZK&M6DD62#I:K)76O MT"\&.1/","S[!#$'%8R7)-I8 M@,G)!F!%8V();[%AE+?*!C]4-:^W%TM,0?*IKMXBQK_A::E'"F1#T*S7Y.2S M_!!EZ=FZX"`G])NE(N1N7#E-?Y9H-[C)V,^9J8&XQQ<6+<3*4;,8RT5+ER2? M6N[DZ;@'C`?6/O!1#I;5+KN9="0U`+&K7.6?UBR8VD*:E94<(RQ=JQXZK;ZL MF@*F6RU?8B:[DYY<._+5WV^0E(I5`"&?>-I#>_G?;63M/OUE90]IX/@ M,"Y/V73\IT4'0-(Q%7K(R(!B522U.7+JV,[F$!LU%38Q1XP^PB0(/\/ M(0,A@8M%M"88IN_DFR#VW*005-60L>31IJ!XV?:&Z2`+*X[L*/H5-'+AF.I& M(M%@>F(BPFZ]:2DWWQEA"A;&W*RZFHM68V*443M5+OOTB[ITC:C,\ MUDCLJ&LN]J[WRL&O%.IWY^TD:M)ROKFX:R[FBP.B>DUJ`9*LK#15&;PU=YT? MB6S.U@4TWVM.^Y?/SM*8CPY(6=QK)N7NN6CM.T7_=5-B)I>80TXMR-SA]V** M+LC6:4J/@W4O*WI@-P?8PE#7VS46$6!CFS)(++=1+:O+.Q,0U;:KP]LD\&1K MD,LN5\GY-4;0+5_5749VM;!_^T7;N+[+FZLJVSJ'FU\RQGW[ M!:$WDKFU;VM(N&?C+E"D):1$VS63M@L.V[5WX"35JNLLQ.1:A$:1@UM.7!7Y M0OSQW'P+Q!T6LAM0Q`YJ/KH+^Q6Q;HJ+Q@$;CTO_N+/`1-Z%+)H]Y=(;M8S] M\J[+-!$=I@6F*,'YN6RHMD+FWI;2OZ0E-/`KQNR]<7LF`?1#S)EJS<3XV'N, MF1X8;:XTF/8>8;\D3MEEPS06"*F[YE?R4.N#0X&(L7#8&W?:"G>8"G\V\X@- MP&B:1\QO>YDRB\"2B5>A#MH1NHQ):W\0#_[^)LV4PQWG2!GFOIWASV/I#*KP MDQD\6I*U:0@O=MG!C76QR[R_VTCN#>,1H_@O5O!\,CCNG38D39LR]A$%33L1 MRCKDBI8^5E\#3R\NX;BBLN@#88H!1Z0?#[HZ^ID"+VVJ]G-\6 M1DBSSMBG^7J>+R^SY.#YLKA<8AFSS2$Q^B?'D]YQL/ZHK-:]$5YT(*E-)Y]V M+MD'.NC*.T)$OLK+/]^M5`PS?0!:C(9KG:>2]<"*XYU6SR?-D`S^G#BED$@Y M%)[,1&A%E(ZEV=SD MSJ@9!$VA'"9F],&I(H$\B"5"KT$GQC=PV\;..U3CB"2H_UUVG=$37Z-;5,(6 MT'CQPMLZ4JM87U\OI2(:Q\ZX%6<1DV/;5^GKVW41QE]%JK]JD0J[,I0?(E,- M>R=_I3+58!#Z=`*!!K39R5]-0Y'F\[!0,#0.]?7'VK,M,A^$FSBD0-=-U MO/Z!\?.N\B_B$DWQ&=%_(C+[06P!\!5"A0&2HVN MR.+B,,4&"7@`@#_Y'`W?)OD98Q/T^L7DE-G5NBJQE=4=7-1BGBSS[?M\561M M2+P:<\U(([ARH29]@WE[^-Y@*&DX-B94;H4=DW?7A7#2 M4Z:6![@O8REYQ!20N,YN!8RA.ZD)G5+]-K?\4AU8X6P\;%U\?T0[C6RA\,)` MN`E>WWV6OW#2+O/>-]<"0VDS5_)YJRU5.]KBU;L2WXNQ;7-%;UX/?;%K.9U+ M<,I'YUUNVF.#9634G_L(FZ,WNLWQ>$78I\A%G#8:U!F;+BPTJ(7L'7:UP3SV M$OF>LXMBT49!&^CK.3.-PAE2+\1C!-<0R(>B'KK`):>WX5G0H*)&?TY=GKJ< M:$RZ1T">>-2#4%7"$ETE)9Z@&\!!X=!=O,:.F]&KBA*NWU&#*;EK8[L@X4-7 M=Q?K8F[R0/'"D&A18L4S#!7&FOG(5N8X,6`'%K6C:J%7F:\1[MN7.C_(%08" M:UICIUJ[%YH%NFU+H:7BY0Z_J5D6$%KG%!FB<1&V3D9&0_A]ZQOU,@@YU&+P M\.Q!<6@O4DRUJOVA8HAZ`6\TQ(312"SWW"RPM7X/2"YZ@GPAI.$@P7(1-*E MS9T>-P[D/,>F;#))M%E=\Y<30/0V&-Q57&'=9J4Y9!*8'Y$N`S0994%.2J%$ M=MF1E!I`)"P8R2FX;\*XMJEDOU@X$_<#H\%^U\_]_:^=PP?]:M?/) M#NW<$JZ_F'8^-'[VIG8^[+8>_*J=_ZJ=/T8['Y\V_!Q4V.=#E/)@1!AHEB_? M?A_7ROWP@WM4\ZY!"(//WKYYD;Q\^1357Y3=L:#`+;(`VI^O`H*D<1,&YOS?V3+FZ*NDA__Q[\G!_5V@1TO2I#>:@Q#+2])9:`$ MTZ2^JP$PAW%3?IJMBPRDN9HFU**EX.(J2!/B0ES7ZW_ M\__%_EI7V3(:YG,\,;);F(G?)0)W',T.&7B7?P>W<]+_U.57DE"[T-)YLIV= M";!N_UV.(0\"(SUC*&G!V8(-^9FZ6S9T%OPU$L##@3O1B)W:A>P(P"A9&>5M M(:[WN*=^TGQ-07C?1C.+7[!?3-ZF6]`]29OZW(=E;.HH0;JF6$C;_,.$ZE%O_-%>J\QJ3L"62>G?IJ'T&2T4ZT-0RR8YS>5,HV,@P MXAX:6S/@`6R;7Z4FBJ&-$#?(IN%#X3];*1JE0Q94O;ADBYB_8-&L/JILLET5 M-UF-54&Q5#`\BQ9XN(^%5H*)W$^9[+/&ZQDQ_=FF6MW)"+U0=_'A-+I<9\BN M,-B>S.]7TK*".:OZN]C3P+*W^AO0[34<&(JJGC7?Q>+XL%L2H9A]2L3`.RF;?HR]!,#Z5PGPKTT"Y!J.'R#_37X91E58Q6/,JB=4 M&;H5[S2E>MM_,;EO(!6KFS*??-]B-,J@V(24D_@EJP/#7(B@AHQ$RIT M\"!![U>)[B>2Z%RV&4MV'R30V<8$'T6>LP-VE$&NMRLLC_IG-HJ8_L`!S?7B M3*M7L.V)[AK+/Z@J_.>=9%]!5&_<"UL M]3"R3>3DGS1*^J(HX@O7&HQHM#Q\&GL&#K+!@YMUAI]@D/7P]`2;'Z.K6UC# MO6\=G*2GTWYR^,!5#OKI:'CB&JUHCPULBX7,B*^#[Y;M6[+4R6#`C02>#E4]GG1#KW+3?Q*E_.M?)'7KJ:LTT:AR@Q3H=GDP]TXWUC<5Z([*)'LJKUKHORJFF.Y!RV=G,VI M/G.K$#QG[*JE)"AQ+Z5BUJXD2"Y='B[72`8F90\*[++LH(SF=6MDWV23/KIX'3@ZN*[/^/?__Z.+FW9&FB0 M#OM]+5H/GYI_JQKOSL_>MEZ:8,OL8WI0/HY. MT^/C$^D^G8XG`]@U>4N^1*WFZYRJF[7'&:13J8P_&:;]R1"'&VF-_M/T=-QO MIE0WA\"G^ES*'T;K3P?XS60ZT,4-AI/D?;;\S_]9M4$&+XQ/>1OT>7I,_TZF M8_==?ZK-$?`H1I-Q>C(:NT,938[3X>08/QV/TN'`-SD84?-K`*"_!9^W6T\V M>B)H9P3JQ@UCC-))_UB^CW3MUO\/)B-JFC[L3]+)B-<>Z]4U/(&]G0R`Q&/W M!&X1/IS"#H"M#T_P`"G<4]H:$V4+J!\Z@U2E+[Y+Z8^()C8/R_6Y$3CNP M-.V\\FGGG:8EWG_]4JXX8.PWTN*E)&5W5:T[C!3,E,E&(LR.["2J4P;>%26@%J)PT+MW!JL!D2M/<+0RMG/" MX%UM+=',[*UM`'EK!HE?]D&[Q;J)#U;_K,645=@Z="R>:6'`ILZ+8@X;)!:*-I"A8(\D(*^"Q"7FG(U3T2%D77>TE$;=L'Z`PV# MWNZGIN>FQ2)MU,NZJ+8;HRVE6@U\J:B&<'-&MKL"1'GL/J&Y'%1:#Z1XWVLZ MIAB9)E=!%[(5VM*RJ]Z(+N#B$AG76PYW#BZ0NIHQ.=KAJQB5+Z)IA MZUE>,KPZY^XEO!VIA>?=!/@U/5E[\GX--)I>M?V:62(9:-6 M<)RF/YX9CIP6N#TJUBH1YX(N9DG4:<2U:G.&05GZ$B0%&[@S$[=/&+\C0B5W M"'8*&"^7@>61\(-?_*N&4N"J:]CG(MP&8Z-Q7A$A]F(Z'AZ>Q?RL MC"4/H[NP&F=KX>S6"^VDEJ$/56,HC@!7C]"TZ^QG2)_H MJ4V4^HKHGQ,:Q M>2O:T?)U_>,/_R+;2LEVC;F(;C6;['LD0><:FC!J$BS;]]/4_&7\1;+-5-S,DH'0S16X!/NEW"M\?D0QB>#M+1E#YIOTYF4@]K?9ZJF9C:=X34 M!8W.;9)E=D+^S0`-W#H*"+0P4]B)6O'_;'KF?UD="Q_/)!C->(46DVI8XXB MX.;-YYYY5\@+VT4:II0WDC,?9N_[6^]@U9->W$V%8Y%8BE*D,S(T/5,N^\0[ MI[BQ:"5.*R2OSKVJ]3),@V*G,6"&S!'PAHH;?&FSNJPVDC0-"809GU51T9#0:PE#<@%M$P_2Q/-B++_FLP_CPJ#(!7.=*_O MV"A=Q5`&:0/IA6\\ZMO"AYNI6F@S-02H:T'W MF9(!+AY!57##_&^N2/:.[9=<+4/J"J2\`(=-WG(9D8\[UNHP-0H/AIEU3-,P M7\HPWB6[EZ.LP7`;?[I[=.[5I3=4/>7@"6HT-/4A-UU]I9`X8XN]$0-V_$1K M'_30CW*.ZC+]W>!W1*>`BXP'_O&I>=R[0HAO382`"N M;TRAZJ\8>/SF1^E(#\:_S\S//A,D1N,,IQRR%.-3Q'% M#TY/3FGN47K:1X_A`?I.Q\E]&W&^(8]2+`WQ7$=MNGDP.O12JG>MQYR0@4,2 M0>2CM"(>BL9$=K,]VNUSCD3$JCR2NANRO`:T>K34%V6NKY54U1Z!+88!EDC: M(AZ%`E(VYY/A84,TO4_.QM>$>5L)+_4QACSPY/!A<7L=X[8D1W93-XSP?.]? M5N4E]\7P/[>L.^:G'4(BS_+`H8][R7VK>]<80EYH^&493Y=NSK5YP0G[FR#J MQIH^?;W_C@"3??P8*$XY)_\PS+]P7>DS[/GEBS]@R2^.)P>1%-,EU'3?=#X[ M`5+L-2[D>&\GB"GSRG;B;,T-V_2Z;Y)!_U,2/K!HSBJ-)G5%6^1=Q0BAL#<*.GH$ZBR,)2,2NSD?T>8'*% M.I.;5%6\8<<&$3YC#!BF*P^BS(I4H?51@R M/JXV<$VQA!U`,N74.;YU6RWN"1+<6ZB`&7JPQ`IEXHA3/&O9`)Z#?IEUOY=D?!8_+9F&AOGZOW2%O74,AK:)TZL=60C`%.Y"L2-0&MR_>N]%X'BDEO M*@8!UBE3GDH'B7=6X.#K=,3!\-HT"1VZM%4B<-A&-&\1%$`W)-#L5/-N;ZGQ M0FNB*G!\AQ=K8CPLUA$(B2OX`IP.9=%`4[\9]95*NNW45-V! MO[L."=<9+DP%2]SL$>PV@*@$K&_CR:91V*-%T(4O<^H4%>OSM4TB$U`=#Q>D MQ@V%@M-W?,;M7T;A;"MM@48!9N8$;:<^FHG7CG5,$7MPGN>#DSR]WV'"X)N1:[< MZWPM[G>!NQZY6Q-^21)FO`@CDK0FO9@&6=O9_"8C_UJS[F`'9KSV[0HF]G0? M!GZ%/8K,4:!+D[X%I@3'&6)UL:2ZC%40/?/`53L)/J!(931@J2,RISLHJ:MN M#S&%_-8,)*F`V$4W2%*F_-Q5-??N4I>+"!($T3V_Q^>@Y%Y3EAR)$[=XF>;4 M\_0"AD-JJBEMW)0Z)`3[[9CBCX*@(R=E9MIO1@9T$G1S$!L.^/,*@"B-%"7W MB_O9A4%3.ZEYU?:"_>=4S(KU!`!@<>VLYZ)B8&068F_#>S4.>M[X3L[D$F/Y M8]%\:30R5,(=)$:JV`*?'$V,"O>4"<)>-*;AP`:Q7'[@A MN*507#7Q-&U'M@"-@>1V2'%3':"M1PD!S`FJDP!1)4P@M,-[O`(MY6!:%@3*7B M%SE0HD,)1-]-"["48E"*E$IN6";2Z,'%;V+]"XEJ,IR9HGSH.R0;52E53CYY ML=.<_(DX^X#7->8J:B2IN7`XP*U@82[CH,S(O"1?!Y?=W'4M=R$Q`8TZ?XZ* MWRK,R$(C+(%>1.,,+[5KBEFVQ%(RS%&`\%^18]/=[=208#=-6USHB(1FG7S+ M6B"[:NT&7+]12U9(_XG??!0Q0*"X57&CX)E]QH1O@XQU;0IRG5ZPTQOF112< MD=G(!<-B?"9F=VJ'.%E ML4+]C66)')%VIC4U3/<'5GJ/63U/D[HB`[_V]+:G;'0JGD_ZV:/-!,%?^`/L M(/?""=H#2#!Y?)!%.F,2C1AO?N[9GG4)3;;D"L0 M7=`7U7I-;.<507%':DOCR9`C8Y!.5/O<4XFBG/951H^ZN^*JAY%;9;E,6'(3 MMNXJU#8D]5)U="$W,<0`U^_VJ)*M*GV0-CFH^;` M9*>>9ESJLW1%"Z=S-UO,%+:=C-/K37A:L-UWXMW-@;:WYYUPSD(CP=!RIF`G%K` M^@O5P4NNLI"?.!%-613MADW1KF@+@ZZ^*JZ5.LTXCP%!Y%F]$_]262K"XQFAA:IUXC35;6_79K@NA:6,ZGW>L+[9K^L:HSDT$)"-`U\C&6BWE M,/UIH+7>58RD)4JQ1S3X535C_NXETZ#L/B53`>.^''R`5T*$\MS(_0VEL%-] MPOD\$8O2GAT4)B1%EDB%_O]0)/ZKK=,(#:[X"5>J<>O(S$V<+I()T(Q'XOF/DG#F0JLTL,R(]_3 MVMT-3$N3TOQ#YT(X)V0-HY@>]*8GR0(U,5KTI[A@XUI&ZCV(+D*%M?2HPKF13Q=0G- M5#$1=2=Q];+2Y\[>08RVC6%N0<"9\Y#<4#$0'W\6=.G;:VS/\[+%1C:O.^5] MSW-T@:/@0`>CXRB$B+LV!RUJ7P.$%,BE\#J+"PDE3;`GDO(56DB%]42U?AAR MQXRY'3XLP@0E1&])1JE#!8&0&.F;@N'VJJ(VEA?,&T2;ORB<7*7IX(%WA\W: MAL>*R9"2<^TUAH%JKT4+IS?SI\APL;XE"%64>4ODT#6V%_J*RW'-W*18P89J MI.!4H&DA_Z^<+8+*HS3ZSECY623K,*)B;QM:@BB&QM^-M0?8$]2*RM[=:H0E M;,D"!]*@8`TA>6R;^C`Y$*W@?'N-LI3<<'C[57Z;_&.U?D\NRXTX=:0$YITI MA%LF0)^W%`*,RT(OA=Q+\HX(:LAVF!80:_1#9)3VU:&S?>55$!?)2QD#!MB" M*]'WT?*@BB1I>JH]XHTI?5%.!.,RN[V3]%K4-?$73GUI\L=2[&"YU@?G*\HJ MD)=7FAK*J!/ZI&0P<-!L]SVAL6LPZ*"?)1BB4E$(%N(2QLYPDOA<9$W^A`Z0 M#=S?*[N^>\#[F;N19QM#?ZN(CC5)&U3.BOYRZO>O-S4805]81.D)`6RU39?UM[-"O1!+JD+;*2Z#0]);M"TBAO0]8B6R!D M=AEHKL+^/JM5N<,3"+WR$?-$-R&J\_R]U.7`_`L0+"M[[`1&%3QM>6B3V]=P M2\3XMW??[3(*N]@_5O`*5SV%NQ;7<&]I\2X(6*NWWKBE[@.YFVH)1([K'6"Q M@PT+?'>*+HPZZWR'`DZ%>:@"1D(D"V,K.*<"982UPWM1[W9D(+O*^QICU.6- M?3(8F%@`&^-V?RB4<3V:4B!$ML5]I>K]%5FN\U(I.7DYE63W3+J)M-Q0)8W5 M38KKTVHP_F1L6.=MLXH+QT"PWH3]K+AF*5E7.U0E;Q7MM!88 M`SJW'8Z5CPMT([;AXH53Q8V*H(GOP*R0PWN)EJPV<6HD+S5JGQAKS83?--BN259MO0O!?NILJD,J`T2L!T M#/)Q^RUP7P/J&&Y&5=..,V<%,J%`@_S`P$YN0>3F7NR>C`GAD-IUM+=B0;<9 M=77J-[R=X6"+[0[)N.>K,`8-;5S4]31MI(6XYUOA>*VH8/I M42G,-6BX8Y9PP<9Y@8M66`U\PD:\I_8H52`T6T(2&=JNKE'LL89^MRN\!\.@ M-=&+/8:(9E9@PA-[JGSW3"HIZB\9UBS&,DF<2R7!F"[;36HBD0_==M.Q(]QF MTMF^*L-1T@0C:MR^KH20L;/IRCO8Z"Y3D3-6!>P@XZ;-U\6IED+!1924IBR= M%-GR$[&*8`>/;),_B)_LPR5V=S!X7-$WX5FEIDY&0X8^+L'\[".0RWT(I*%+ M$MN"M<=(R""R68,<.9.2:"X`"L\,)?9-?EG,,`((_9%XN(&-&$O7^:!Y\2&< M?5]]E9?1)$/YJ=WW*ZS=,.SJ^M7U.K?\Y%_OR<X^EXN2+YI)&)H M-J(U.2"<6:A+9M>2#A^5"F4F]@E,[W;M7.+P=C M1&RG"WE)&=S=UAL15HD/$@2(-G/9*P$9YSE*27[#,1$(W@;5"=]V:P19"(+: MX;KUBK932:D-`%\1UKEP3_@^*G[40)9Y'!\B'SB;5@UE0BXEQB3A(,BY=C(3D]&O7Z?0OOI_92/ M&O<&OTR,5`)+\95DAJJ<4>)?M=2BF;(&&7<4';<9[-Z=,[AH%`C&=!]0+,)E;/EPD30V*OH2\-`*\E$$X.&H`A061J#B)/> M\7`?1+0VD'O%.O8+D=#!,]$M)ZF'+)@!^4J=Q0D%3N;6&*T>%E(C^/=[QT&; MK,($A3^XGEKOD[^Z-J>;OX[NI;$*`>QMIDK0D=V2.L$]6IGCT<.-/J[N\#AT M3ITP2Y/7%61&OK9V,2@)?N0C-1+./GBY:75_#?CD`]N_?B!!S^R6X'P^8@-94M%4 M":!L-Q!T,<2VF>Y6=;6-C?1=_:A-9-OTRXIYW'?:T_GNK*HUQL0PZ26>VLZA\2##9RM>DF#*]$,SC;H(I#SZ47GJC))=B MA<%XI!__Q[\G+T'.7"?G=R!VK#SI"Q8166P:4+GQ#BKGFUT%_"3R6] MDYY-L4T33;&U.;KH&D-%K8?U#"7QS-\-CI3@LB3.@(-1%J`7ES8X/+A,<$^: MULQCT?I:V6U!\,3&XU3I/>N-Y;@$+S)FD6V2^M4LEWS'^2HO*,'542`!-$'- M=FF@$5>2E-:\>2?NEF(8"_&F!@/A0<@EY1-:<$+"LO"2J068T;7Q;^P"H M9;'(.Y?9Z!*QLR_$ZY+:9`V&5I+=KT"'Z4O1I"#W%^QP9@%7Y\1>`&0Y1.N# ML%P@DDO)!Y1YM8S#G8:_+@O07.9XANC_*3-Q^U.,83O%_+Y2)I[!1D%@/)RM MFAZR0"[O3F23_!B7&`?!%^[)B5$\493(\_=TR6;:H743];8B2")J`46LY`"+ MZBY'G$=W`Y%&+5_3LCWUP_D#6N5I&J.4P5-%H?D MG5>"=&_)B9@3Q3R:NI8N#G6"&C;:;U31N!9K/C6:4EH'C/VJR!<<3;*=;=CE M6J%[5,)[,I^!K@0YS'Z'>8%R`>5/-7A(KF"S%/$^4'X=Z]22-B@"]S+K!IV0 M9"6NIZ8@HEXNGS_8.*Y^:+-3JPE%)?*,/G.,XUE MI#O6G7]_C483=D.U*0/A.*_A,YMB&JXNR#*P185VK_2C.*VZ8B`F72ZK`)\_ M=O3#LRT`*-LI\HX>+O/RJ*',:T6^MNPKZ]`B35;"\]+HM%,:U0D#G7MBGCY0 M>1!HY^''$TV%L0^CN6AY;TE3/NS:ILS`G%ZW.L_0)S^!IU(>R^Q3<:M*.CD10+1 M8-B;`GEO6+:C6.'"HP-;1K.@C.U[[RH#L);=3&'=9=TP:86\:I^[F<]#RP?% MUN[B.^3T\')_5O,U[M!"R;HM.4<.B6BYLTM/#(:)X^3;KI4VP1EEB-?@9B]::1H^YJ#NTN&!EWRRB<8B>X MB]3)UAJ[\LE,&Y1AO>AEG.7,L@R%8J:'AAY@Q=Q^#%7]C%,XLC+64J#SOA_^ M)@((3E,6TAY"@`C!1L\_7R M2#<\U8N654AJJT'#@,:=6E[^M('U1 M84@]"@,$8(SPX#Z$IK!&`V].%6_HC&('4\/;]>).0VT.<=B7*)8X"1"-;4X6:1B_V MF"SDZOX.]LMPOF?(4!@J-A'EK#&"*FF33@=%XP6V4$I'SUV1-9H"1CYQ-!U6 M*XRLG!F?1E`VRBF&DR[!*UQ)*'--?CIWA1`C]D%C`J20)4**J%$ET%:U)HA: M,IL>8^X1UW)J=+@R[D&`GM3A:7@S6C=AMV-C]"!-[&/1Q99/XQ=/%INW][1U MYW]I)/$^DO1A%+(Q>NOF6_*84!J[B\!(?=F;CN$HJ/6K'%L;-^BLS9J;!B94 M6$!C3:U$B:8`?1^$C#AIKKROWXKH6&B@U,)7*O<$P53B1;G+4I,G8TO[L.3K M*"!K\(@WP''0O\I?)-VLL]O2Q8$#4:.$T#=\([53_STLW[;/F?_[-BW_P;C:2-!3-9_:=A$*!("!>&V[`+G&&Q,9BP MCS4\,<)D>7>$55+G'E/H4O-"8D40`ZZ@P7P@\/9#=X9MH<+>L&%_>.KXA/F- MHLN*ND;;C)U.:LMR%VQ-F''KIY/XIG<.=#PKWZ?)*RWM<29J"M?3K#$WH-[D M6MJE':XJ('\KBK:6'77=F_V]YB?I=JDR1O5EL5!$8986VV2+C0Q&#<91S*-< M`Y'4$W9#T9LT7R-YO6)@IB]^(NH>27D^% M!&&;K`*+#=)U:<7(/[_`P.'8A;M0(^!!A*I2JU M*7W!\V\8\RC5_2(O<\R9%,+AAODM/@4"<(5QJ7X5,H*-D7(QL7A$H=P9LJP3 M95GG65DMBN2;\Z`,C@_0*VFL6V0]`!;AP/C/V?:F./K[Y#_^%W!Z$LG5*45P M<*5%>SJ#E(V!2X!-*FYRUY+4TP/G@04H;1>9>DH16M&8)%X"UEE&UYS,HPEE MVL%<;AQ*,)5)/:"]I%0B3;NW8]@7:EA:J"-+ZA7N%*C*!2=O\$X)93#*05UC M&XS\V.@!8H77,M%$+$HCIMIB MLB$)^RO0Z(,!<@IY]=4@X3ZKR2Z%DV!3QVBSAE2AW,R'P.HE%VC_=#D6[.&3 M0HJ^(=++MP#^947,S1YAUO""&'UU>MHAYU3%%+__X:(^9VO\D(QX0LX M"XK,:T>(Y'\9?`C9N@L@1%JS"1*'CGB]MLZH`]P+D!=JSV?J^J5?5 M+2O?C@P1!;M@O=C?,:RKE>>;9B%,(Z]3=S_VCRM27E=8WF%7_CI1*`F6\][L M7O(4Y(1OB_PV:HE@QG2\(Z@I[I+101_B('8+B<63Q\3B($H0VUUUAO*VZ["V M1>76B+ZT>=Q,0&95731)2MVN#>_2H*`>J6M$K`5[Y>DK#@0[962P=LGE^ MAWL`Q6H;TSUB.R.(3(:"W2:1H)V*2MV[+2.&%30L2YUNY%LJI<)JIE-V`G_R MV,3)^RRC9FJ1/WK)/]1N43YQJ-\;3VSBT'?2O[T=D:V+HN-R78^YQ`2'$:(, ML*BET[O"ETM#444S')#*<^#E-<%:KA66GZ20X(@YESK$,`GNH"G%#=%5[F*_ M`TFJI?L[('1K_9V.THK;"-TYNP0A:L$$VL3K>?)"0?*A`NUO#"W4,$):XK*N MK'_E'BH5<[.&5Y7D-6I^A(<7C/9(LO2!`=M!;-:%Y0)_.:KS4(+298E5']K> M;0WO1;H(XA**&(_O2@,!8W0BH`%!)5%*YU#GG[SZ6=TD"B1',EE`K@P?^I8^ MP.V-Q2J&46SHTMU1/T&7W8Z2&00%-;ZDP@5!]1F*:_$#KD!LVZXU7]1T'O!7 M$\7O5@J2+WX4;8^<)CZ+I-4Z^DQB;5X6+,L5[1;.;Y@A,/;1\W"$._I$]Y+( MH`TX!X;Q1A=V9"&@NO'>L;GYY.2$NIZ/1D-G[TB&E&%YG`X'_>19@6H!QH8* M[QJ.T^EHDISVDY?Y9896N,'H-!F>'DO?Z4$Z')\FI^.3Y!WEE,,LPW0Z&,"' MD_1D>MS4"BP)>D,$E# M1+:MW.;$S[EO"HLCR^RVWA9D,EM?%!MQ5*6845NLJ(H%IL0ZH=V4EL9)4DYA M9M=8Q8TWJ+SUEEM'P<7::$]:4J93B467R%/%4NF(H9%_&78@4[I+;1W0,M`N M-T?LG(+X72X?EW=<&C33LMG`E:C$##QZD;E2GIE[]L[K&JY@HYJ,PUKWF-"J MU4U8S8?Q[CQ)P(3JV95=4T;=J6Z`V+&!F=4Q+T^1I#7_T[;>N/2(I=J$1+DB MN^QFLV1BH"'`?%A_VLX+$*BBMUODS- M,5@20XY-;M)US<*!\*2,(U(TB;4&HOFR4`Q)2-U&U4QJ25TC^9]MN"_V"RH9 M#=\NLIMJS0UM:7FNF`6%37`>\IVRQYGMJ+F6'F*UV-!0^74:9^;[XT6E]W&,6"6!2I5PY\C)P8\__"L] M\>,/_W9(MT"*2\&IHEG+\VV=C49OI/C#[;W4JM_>*L88/^=UFO9UG6I/%S5MS*^,UE]=FPJ)7R59%^VQZ/$C>T)I#C>\J&R%@61"FW.),REM@U"R^S M?8)4:52GL-`9]PQ9%A?2GX0$P_QB*111)S,&55>@F6I/4BR"JVM+1FFVW%^+ M,,K!SB11U,$^@&96ZS*7DG*YL&,I<1C4(@V`H0D)B-^^VL2;WV@1!EBS01+QHK'>!BL*.ID&*S:]'PRE>?U779`8BQW^ M6I/XIZQ)W(#PKU6)_8)^K4K\:U5BI+W_M:L2OZ3TQJ^49'59+#"JX^@UUCJZ M;4;.J"VC5D:UY+`DO"#D]@*,`WR18,""[79O\_EM!2+DTP)5GZ?9LH#'RJ*1 M7/9E-LNE]^?<=5:=5:"J8UJG"@E/JZ-W^,6LLY(-C^.-)QAVL2K1I+>5IB)+ MWW"P8=&3W<"/5&I/'1>$+R(&N^X2"B6R[(&"PU>49P\;?E*A&\XL]=X>KEH9 M7.LEN\^%_V##CV6U;@*"`Z@V5UL>@4RW1:EA6K/<5MAC/+_3B#=7Y"`/8FD\ MK[4'9<[PW@@#YM$\K"\*(H/.MZ$@X];GBI6`UI6TZK5BZU\.DVQ8C*;]H`[9 M"U/_!%9U=@$J+4A%V45%!(-"SC2P1U`#=1:R^H%.!A@M?9@I5@'?_[9@Q8P_ M.D4LJ#9*YT96.M)XL9<%^QQ)UT9`'/G&;?7&RAW;C8`U=?8`+`'EA%4RYL&^ M,VY,3>H;-C+XN5'0HG?5651V]S MX<[1L='&U9B>WGR'YLN7%$SJPW#UB*PC[*D:4[\EZVEX8#O,C<^HDS;'&7VM MP4W/$+9TROJ?<=LNV5SN>4YW$,M!RC<^?%8DLN0):#?_[/X+PL80-!U*<,5? M^2TJOA$\C_\?3$;I<#3Q8V*:0FL>SEY`"Z84G1N>#-+)R2`93H_3X?!$*AO3 MV`ZTK74>PP`3?G]\FIZ,A[0"9QP%L(V'(_@TG@S2Z7"\BVAJ26B27-`;X8L< M(7F+#G5V[W-77(6!DX>VSH0OHJ'B?E;1$;E^RSQ0C,RE+:3 M7Y$X;:ZH*X&85^VA3S1F@I4_ME'90F,3K)Z)$Y$K\LF`SK$USX9:^V)M@J[B M@R?C";W*!AF:!L;(N8F5S:S%7@(SI7C`/')2+BDT5'@"+FMZS,.EUMN&L8U' M5`R-"W_0^MF8S\85&0S8AE$DG@Q/S,JB,_K0^%EU65)!PVA`>?N(,A,T),HT MT6U[!L.VP*C8A)"^80B:LA*N[H?!V4910H][3N[!0K$4>N?8\75*%[D@VP0C\@=)"6.WSY!,!C&3IF&U>"+MO[.R1=;L>`N M4/4,JY:W7_$18>*GMY&BFEMCW(]$(X:GILE\9%`V'+M==M$,BDQN]IFX-'K6GA"(B&DHD@=Q+@8X8A*Q[?`1[K2_5K!E7QY@4FX=L$ M]$4VR]N=G7S=X78@2[D_YWDR/C'+>C3#D%L:7JFA@3/E/JZ<,;H3=B+LKS`$ M+Q#\_-L[1<#0(-R_EW-E'RKA-/=\'$:@!3J%V+$_)MM*&WPK_8D85Y0GA'NW MM&H'/??4^3Z2#+"T[;SV0N?A\"=#Y_Y?!)W?Q=>+.C/Z&5MF"I8P(K6Y-5IX MV#N9QBM+U/FJ.,+O*(DVS(\ M1B'55\B$AXGX$5?5$<4LB%QV&@P'I%&*DKOL-\3Y<&C5QQOH/(K%,C?Q.9X' MGL8"!+>E1P3++%!]ZSAB+`Y`J%Y_WC1B14PV;8/FF[UO@+%KC4;3Y)N.M7KS M)IYC5>+!X8L'T^/DT)F9`A/9BX9&[MPP[47LMNY2F3F7O/R"VQ20-&N@].X* M:":U)[^JD^<4!/L*TW^#;W99&!M@]D9$_^FI\>,!9*XKDVNDFQ^-IQB#V*=X MQ_%DDIPQ/)V7@GH4\0;'&2$CZ.B@?C2V6<*UI%!"]E%LY$QK:*46EVE.[P'E7D;46 M-N^;\G`J&MNY39Z&"^MTJ70;&WQM'YR3I?P"G\JI'P"!;EMKV")E^`:]CJ(7 M5(HDD1P3%$K**%4`':^D=0HW;F?0N.SRU.F.V..+!I3]^1Y7U`32K0Z?:9R: M-)\1[8+CQ+F*!A90ZO<_57)GFC!$ZQ+ZPMD?R+'PX@SV9%GMS>S@5^'`488U M,=+2#OE+13YI!3@C7PBUT_!=`!_*O6+W\J=B78VYE-X!@-+^I/]PQC5(D50V M>9>Z;#J95V,9_X4X%[,K_/=T=$+<8W3^K9(KJEK!;JJU1.Z0?YM846",\BC=;&1'%YLCO3F52N]K="4Z M.^7^A$5PZ@(&S7RLIKKCS(77,8H83Z25:Q+.?-<2"(WLL%&B4#4HK(_)=)Z" M&`#9+T79\DK59$>N7L&[KE=]EOT&N_GMH)<5-T160DGS-!O\R)DY!D-!DKPB MFR5_D9MY+RB>1QZF*C'*]NXEPR^\)XG04ELC=P+*!1O+H:%.ER+86=%>XC07 M65T8G-+P7M_-44LP<_+S<&I,EAU6!1+MEE+&/XI$/H.TXPH,^L8B&:S-F<7P M?C5OUCLC[31@0:6M-(',2$7:'P[9K$OB,V',2*[#3@T#H&?U#`"^I3(.6%*( MZA;=U4;LJS`M#U#*L3-R@$OS2>N,UJ)#+YB7??O=V1N]+A:H,=')Y;EZKY;M MM(Y]5]^;#-K(IIU%V",;81;Y6_6."89UP-7C0'/)C7MQ#?+S/`AEY+V&"W%' MA!YO?PJNXI/94P@S#+1!?*:,R.:C*%(#5<0B"QG&+16N@(&ZN7FK0#PV5R9C MDY)I7"F*?61OA1)G6-C*)EP)@J77[4PKQVC-_WFQY!:YK0*O]U!1J7-DS[IH M>7..,3@>A];*X5=T;@NH\F=D+^L;<#URL!8P M;V@G/`BDB"UV\B";6U<9Q*NX2\=K(P56:P+M0`'M-A?>8*E&YL;<$Y^#]!G[ M^-KM-HT)3XK1CJ)39VR9'H#.I,=PY-:'4C9L)HBRGQSQ,!K>%-7&*J+23R@JF,&(P=O M,7)H=UO)ELG(KR+B>6L=VYT!V.J2?^R3;"M`A%1,HAWV@`M*64S-2*Q M)Z.A?.:(:;,`AW=)69\K!88[MD.WLSN&+&AI'*VIP>0/8P/#`#$LAE-H/?&>O.R;(6FXD MCD(U5M2[P(A*?5#$V!$;<()`Z;:GZ@%;8/]O=BKUC1;\@^VHCO.GG M-;)*]<)]K*Q11/F(IM8=N#@SD=GL<)=8+`IT<$[?6;&>;5><2E)_GOSXP[]C MWQ>.@L-,[!HC);5&FNAA/B?&_``+L_54,`5.:@5D5-`-,2[G#&K/'UNJ#^<` M2G4`T!<#+9&J3@IKA)='?>(Z^8P9=_"HUQC=$LSO"@93-!'+$LZHI$-KT\*$ M!R-_-$;>D)HJ0L%+-="X:66ZFNLAQ.?XK84[G0]N2)/WCG`(V;9=,1\#']-- M'H.%>3/U(;9KY%;$/:1_5$OP0/YG*KPIY'BK*/UTA5-3'IH&VQ(I:D$=L^K; MD@[R.:^&GIZ82\"I]-4CD$FYKCDMY MZGR9)5ZJ)S8)R6]10,7QSWS)UX3%5C[/@%9/6531\O==&XDR/,#8_FEOT!^? M&%N#$4@_:XBC]YQKE"%(#`^7%`:I(C?%CUM+=@?54+)AD5,C4S>L8F$]7"/^ M;.,'I(JX,4JYXZFYQAC5I@^/13B%->>T-$42D[QU$ODYA=UPA?.%R>)(FUKE M;L@'B-->V8MX9VQ)X\#+=;DM^$,9JUR[>!!R>71W7='&0;8 M8&Z,Y/L`SY_WTC.:$_*`MW2IJ]1F]5B M[*]K4MKJ@7C<.\56A_?D]7KWNX--9AV/*H2`C`T'=$?JR*.\W+&]_J2N[MB$ M/CW0?WJ(S_L`E+OQX#0Y3`Z&HW0Z'1K7MR8CT5Y>\,F@GTQ&&)4U.3U%#_?DY!Y/^"`]`;5@D!Z?G"03>'Y$$5N^ MI!U\-^[3O\/AF((34G2OPX<1?'.ZZX)TWG:REFTLW^THHBBWK%@4N[S`#[%"TV#!_.@W.\%BMHL:G$9(RKO[!1;-;CJ(.%Y`(VONLRGIY3"6` MQX4A[!DF,C!B\B\B3`3`QI4ON16%,?.AA>3G#O-X9##'KX$;/TG@1B=3;D9O M[([3:)?HDB(TO@JM!FNXSE&8JA14S]_!'\(RE1_J$TU_(J?HO<[/MOC5[>4< MA,Y0[^:T]*7+S5G_$MR;^YSEHSV?T3(S%!^/W_O:ZOMT80'J'59C9&5B205, M:KGFY,`G(90/XBVV^Z(>R>^N'CCKH!6F"]YIA`@BF MM)&Y-W=W+8AOT[#7)TN/,S=$ZL%%&R:;4JO1QJVUX=\=VY5R">[HA+S5H1&I MT4S"1X1ZM=9WF9(F#=0VS8%+HD*=]8=3)R466O5:DU1J&\6(35=VVRKY!&=# MS=")+[A2VO'.IJ%4)Q7.O6;BZITQ8S5]GQHO=A],*F60J?P:HODM1_V$;O3X M,01WY9%]LT'(+UFA,/JIC1TH-KZL;!?Q0-T7GEHL"BJL?L/6P1)E4G9;2JVK MI!4-Z*HO9Q0!L!5SK]>@Q7"=EP45LN*5Q\'1WBP6\W,8VJS*I3J[M'4C^Y:K MR>6#@]!W`1H*$#H4BIE>K$A28@CZ^S/DD6.A!A'<&75W53D MAB77)%7%!@:%)>T8OMBB\-="H7&K/"3W2GF)/6486MT] M8N11TXACKZJ1(%,G.V;95<716^8;QGMM/L,50[TSXTDRZ*=3LLK+AY>N6XZO MI)\4RJE0+_:=55+PZS1).V/)MA?<#0YCK2@.1TEQ]X8 M/SY)QU.TPH^F,/?PU_+$OY8G_NLO3[Q0S/DEE!$.XCW^ZHH([ZHAW*2:YVA1 M.?J"?6"F65:K>J\GPZ)H:[;WP[J"8__2"MV08"_H= MD-=>Y'AYQ(=.^/PY0\WY8=_Z\?F',S[9@$NKKNL=S-3:_(9/IPUZF"8_(;OTE MFMFXQ/0;&(#>=K<=VQVT#FR<#HY!=L#,\TEOC)68J:A+;W3*X$\!Y,AAE!@ MNCI^HN2G<_7X$9F:NSK0!V,LDG/2@P$!@18@C>;8'@5[DLUR-";`N_Q<'YZ# MH8[M\B)'-DJ/3\9F?=,!)LM/>Z-VWSN,PE'1IB7TG?OK67^6/&>[(%VF':1C MB$V;[:C4J5E37:=!",)%I4V<0'&=41<);I>1FZ*!Z_R2FI/%+-OL-"7!5YHG M&I)"]Y1FTY#'A@6\'9ZIPEVE=LW!$);*9AO\9.PV@X;=9J!V&XHEM*M`'R4Q M(#_L1$>=!(..PS'';D@-::)1V(+E0GTU0*^=F^G3K)9W+28CH3;OD.UV_[:G MF#_J)78\_0,%:ALB1`(-Q?+<1W40#D(<46S%=ML^UXCJ58ZGQBP?[C5U_7;V MIG+-^08C6P>`B^B.QT&ME7!&=?]B)";;_U;<"H6$J:B%H`=0OMFNI0FC\9%A M0BJP:F*#L/IO>N<]!73*M7.X=T:%[)AJCV^!6ZU9D2)4@>\X"G"`5;;@*^1K MM!3)NARR#<9TOO[QAW\MJR-VV?SXP[^!_$F]&IS?^<7;99\<10BOM'P!0L=.Z[FXF[$.^NUP\:&8;Y3O0']1HLI M."+I?<<4""2CK;.81N>ET/CET[T]S"5?2\`+358!^<]0Y&JP(8.%$ M&XGM0NZ94=T14>1@:C)=FK-$!8&KI3J;M]Y".[TF(#DRRGEFV!FX(D\;&HBI MHC$W,7+VO\"D@H"KQ"5P]>5G5]^$$O[Z+F8^KPN\]8X9>"#P6;H-=T4)A%0T': M]%/FFI/.8F\>8-W=0$S*;5+(`6\18#B.-2+BY_+81.$Y=C2EN5R;3"&9^$" MO(_@B(\H'H3LL(6C/V;H]K!!KU".66*Y_[[5IY(>2%%``[W3L4 MMU^5DL/%`\)H8V?%;,/D`63FB+N7DIIEIZW`W&]V@7#W";1>K/Q$&.2_[_V MKJTWDN,Z/SN_8B"L8"[0I*>GYRH@!K@D=[6&=L4L)2N`D(ITZ=.I?O>%U' MRC_#XM@GXEA5134K`RG<.@>71,6&]`*6BEG#0,MUHW`5'JWC9;%JR#BG26F.V M5K7>X+/6+!5;6*\8^QDU+J1XQR&"V@K"9NN%:$;7Y=!X*>WP(:#0>;RA(+MC MLY(SP5=EMS8R$QBXO>4(?@3L6:QNT:[C9TH@#)GDY>O/[F^+`027O`E->^!ZZ^YH1F MZ/LEPVXGG@^%,:>PKB1B3TMHW;<2781PD42LJAN;<-SFA.NX%P)G2/G\GOS% MM!S.57_9>K`7))ZHU^D07X_P2U\Z:IW.(?+TZAH5X[5C'@Q.GE$J-UC+@0B>S5ZA)"F/-6T(]J(-F/:TVAY'0UE!E5X)%1.<=. M%;&AN^ZQPAP#F_G'E?;T@&?>U@ZET`8[)]AX)+J'IM&GA5D#:R!8NZ9J M>XME<%LDV8Y#?2YG?07=5*.D0W"J4BM[:(,>3]5)N8!;<4__%DAW+\#[&<=` MH@4K+K'\?:?"Q%#P["F)EDRG\[M%0WKBJ%@1U7ZB2OT<_$#5'7PS)^H*PCI? M'1Z>XNV)-LKF6K@?B,3TK.\T7[52R4H2("85$[YT>^S$13'QRWL*U,9DL1L0 M+RC@WU9X7FC+P6I^97@6'!?'BF\=",AVC]YW-W+Y=!0WI?GKF505.(>VCDQ4 M)ZC7836ZCP91,!;H6_>!G-BY)&A++G0Z,R1Z,.9*+?)Z8U((BO2ONF\:W,%3 M;34IE.G&C>Z?R.Z+'L*4SO9WZMUG.3!*X[;S#EW24U.D^3`^"WI9MBC4?:DY MK:F7RO>"L_]::^W)D79`VFX3BHN7!6:SQ].B[C)R'35OT>Z+PCXH),$`;MIB MK58%:$H>DX51UHG`$G4)P5D,N!*'%RYK?C+H,6382J;*4U&Q,5WNKS MBK&HD#;JO7I_W.^O/X*[HG1C`]W%TC[5\5!<:)<=VBLF,.GY;?F9X@>HQ:@U M(=OYT9/M*8X48I-MX9OF$-PM32`2:,$=GSN@3G^'OB5K_ M3/95W[W%?MVFCM&N[:#>3T`2`$=;B=1TU,8MI8:U,;^$_L5RCXQ@YLPDMQ26 M#^/4NC?:!\6I(,QH8=']ZYG:JC?=`RZ?,6/TUU!,XMAI":J[/(7?M M0K@7-Z06K-G^9K)GK7N?F3(;\`Z\JS_KW;5:JC=.6->UHJ`%@`?6),TV@)5S M<[/4,(8;\+0C_=-&1#8A\9G(2CS&IG3%3&52P#K7G%-@_-^8?#]!`."42[T2O9SUN*B.RMYW?FY!TFUE)2ZGD M7&[T=CI?`<[CEVT:Q6$34FH()1+E$1S`0\<<85N62XO/999/%ZX$O?0IK;4*(O)V\[3:1$>2KV! MV$IZC6^:]H=";)B2\I&>$:#$;`9&K16>:2T&T&+F%4L'OHO$$&;,_LZ@'D9! M[(H8@FD40(.8*S!*L]IC*GFR+^"=KBZG7[ES_].Q'[?*DCUPD&@#'CU*7QB@SB8&TW>E$O MG6[8,0G,`@O3].CY?H)^6J,$6H!.5IU`V/V5[M[8E4EWAC8132NZ!>O*J_O# M9S#!`+PWP]L_K^F6XEGJ@&\RH8I)\":@_`F^IQB0A3Z]]X;7$>:=L>^B*.@( M+@UPVGF[7F$U8,`D:;18$_?-3C(S"IZ_GJMYDQ"0E+H]G'462QBT!(PMTN7" MV0TWJ:'8(Y*]B6+\7C60G)K?MTPL32NYSPV>AT+NAECGFF=E-%<>W;HO-USX MZ.1N[V\@/?GR/GBYM?-KX_AMYB((V*2B#`B7W"`HXLE``Z!Z1SH+XWL`*XLU MN10'F`_Z#9[CUJIRZ0,*7P`6 MS??9M)[$K2].+7G#>]<8Q^>K^?*^;0+!,2.6W[*7/AT8K;%FF0%]BCC(^G!-:5'HUP_UO^@*[^?W!%Y+O5^AS""-DJ M='/G!B(*YF)B8>A51GPGU!W;R_,;J_#;SZ@,V%D1UT`-B#DH M[*@@@>2S!=G-%N+">'TB*M@=W)$;4/S/28\"V@U@SQP2LY%D=KN^HL?R`R#5 M.-)%H%?R*95!M',.B/O+G_[CG3ON?>WWY!R!@[_\Z3^#-P'&0**/!OKI;[(: MY7AITCK6&_@$O+5]SB)8H\%M7:$#+"&,N[HC2%"A?ERO-P88S&FM#?U:(H!S MKOO&-OBYK[38<\J8OV^!;\=PYT"L4T-54SC\,`>-0:\:]#[O#8;PSQ3^&:E_ MOH3%N$E]^\_K)>Q)V5>_C]7_4_[YHE$4HU;SOIV?;YK>G_\'W)0_IW+XSTS] M?ZR(#F`X7RV5N'W[ASD4VU/?/E=EH!MP/?\2[6BZE@S]U4,_,MZ M<87H\_'-3I5'C=.*I!JR\6"Q"UV,G8%0;0Q*9#BF;.50XF-+@9#DI4-V0+7[ M&U*$:]QI>ZK`[;6-@$S(-N_X,!" MN>>AP`22O@:")J:%9:`S[71J5$:>)RP)_.9+Y`YXG2]H!"+WC5"=8,O\``-% M@K:)^0(;\3F\[HT.TO9%@&&&_Y$M7@NCY*8^QC5=MX$^&6(9T&VMPF36G&7C/I$B.+HJ=OF]N2/D* MFCH;>\`@9!]K5@1A4_EZW0_@'QRX6 ME8$09/\/%&]A4I@4`=P]P(HMK6P$-F>,(*,Q3KFB#[R;Q9 M!"/"^#V-U(/VG=4<^Y9",<>NL'V=-^L`WV=L=P'9BDWPTCIG0=4<@&O]](!9 MD64&!;AE\P,P.MQ%N,_)4NPXV[M@6<0M'!P9NV6MK,C,-!59@[Y&S>76P=Q2 M7(*I:;7&:@'G2//KE1^O&+-(SD@0 M9\YDCA.GM!YFOG."/37)O!;N8);SS17P'[WJ./?W^,Q0MXGUZ!PIZ1O7J7F_ M)A!$PB0(ZA`%8QL8>M1<] M"-"[M2AW9"^V+QCD8211B),5W,ED2$W?>:O%#M4C^I"LWSYBV[LQ`3AZ>CTS M%S9*.[M\H3-%_='Q@-RL5VLX>JQ$[[ZMX"B!P5"OR?"4;!1DZ4.UKTN1S/WE MX=D+;;$Z//L6O]GO5^K1\Z^]LP:Z%4$<+;F=M:@G@@!:51D$8+QUM9.9,?Y*$'D] M)M-/H:'Q4),((J>#1=YRZ#TLD9G:IKZUC@/J>(@@=,WRK'BCKSZ+H*2C,_(O M"I1/%]8#]U8/HVD92MS>@XQJ*U5-))YY&1!_V0K?KEIZ-AJ>O=X8/R$0R)08 M1:^"1_GV?H,N&X%G[QFCQD$;VH:EKH0W\]^I46@%B1_UT?OQ>OE%JR97_^-G M2"";#_5GO_Z[XJ*3XN*M.C;,_V],R'^7[=%>%DR,*]6Q(@QTQX63RV]2%'@C M*38?O(6[)3OP9@>^X!<46`XPM5`9!O-%=%/WFFXH#F_-S-_:&U(_YN%:5!W) MRQ.:.#<#6?!`J-%GO?&L&(YF"-PT*`85AF%5ZK@$\1V&0'U6HZK8C3NJY_]8C">XM^56H%R-"D&DZ'$N6",#8$G48XGO=E8 MT5:I"+/JG7">U4N+J.U"HL#R#GKE%/X]Y+0W+C9PX"J!Y*O68#CI515$AO7+ M1%6#[:H!)89X@?U;HKCG@8$5U`J4_-M0S>F!R^MN*RSH9*AF/1X7T]D0_YY" MZHOQJ"B'I20<2V#[O$?/>OV#X0!_8'1>27^5!Y-^JJ+N758M9=7Q(%!(6@O2 M&YO'+)V^T<(R@.SK\X`5IB;Z5AH[7H+!!YX05H#\1$_D>>\J) M-ZA&]U.I1@B=Y&X;KH-:8A_K< MY3G/?>.@;^KK'-8Y&,W4Z1FR_1-(-6;"L/DX2%-R%"L#UA+?'N*:"15]J=YF M4[@V1?;1K;7VIL5LTC?)=KJ.LNP7E;I%=:H4,)]A>'PAG<#L4ZJU)16_&F'N MFHX!JM5T6(PFP_(]@NX?^M[K4B'`+$64^W,BND(,`>!>^I_[:?J"BLFLX'WO?[T MR$"3BL!H*%(6T\'$^VV@KJ>^^.UEU$PB5(;$ST>S2?!;?SP3OWTG[X^R&(RF MWF_R_\`NZ%*T+L9D8W[JS_6A=`^G7+%),9X.+.$!AI$2!3#_&+ M;D?K2#\CB0L+AJR/4_!1];!*/MPG'[_OZN42-%9*BIU?K=8`8=T&'M2*6/I% M.2O-23-_QC__\AX9ZBIH2!%_OZ^/0;\?_'WX04VKW@3UY%$9](MQ6>I?)TK6 M_.KD[=GANZ#2""30,8&%T:_J-(S'4Q;FE&QU`O4`@;ME)BY MC4#'BOYH`,U5^M3/BMFP[T>P^DU`J3XQ!]5:?U+")Z-)J0=7JF?;#_/E__[W M.EPR56$XHVG@[Y,Q_API85I_UI]H=@M;48V&Q;0:FDVI1F/%<\8(R5`5@]*R MS0IER;[$COTB(C*[7%;S6A1N51M*WN^/^?.($*S_+T<5OD$&_5$QJFCL,1=E MG19O,`9^3!*W3I`WF,(&CKBK2.($M:K3(>Y/G^E*_J^Y8J6.WW``"!%529WH M60UAKS'KVV@P+2;]$7T3Q7<[,?ELB96\%NJ^Y*/7JC6,;W16+YAIX$@W8##_ M]M7=M7\ S9>^]0ZU=!DR;A05ZA\"H^^(IDV!-C99&>8+JS8.IG[]>;6XJM MS7RJ,M\Z'P;$17T!6>HC/^6GT?%`>`WX]YX4$8%`Y.C M<3!3=SF0^7A0"MJ?\6TZ&$Q4-S`^JA=C\#A+]10G'!0Y2_.A\VUDEOJ"-BR0 M_Y:?)V8Y48L`[_&8J&-F.:L4!P*P12AI9CD#P,,)_E8JN0!_@WJ=_4^ZJ'[B M#AJQ"UXQ1@))8&U)076-]X,UD]F;VSBGQKNQ7A6+F%]#F&\4FWG)S1R99CI= M]=Z)\/XTBW=F(S((@7/O&;['H6OUGE$W*S!*6HE#TCV+'L!-<`:^ MM_BW1Y")/$J+Y M#\6;Q[;923_2[`0+`DGJ8NK""(M-L=BH7PG.SS.D'A5_&173"2(&@(U3, M'ZP5\1Z%^=XGJQS&<5=U99WMTA"UTVUWH.6`M)%1H1ST)3YXOM*=9\#D/1KV MQG,*$6'-0J*3L8&>!7"[#551:1*Q];^6`3B:1"?E)+=+UGV&$DULU#W%@7+V MU=QHL\56[TX?<&<['EB,<]D!P?ZD![6S\^EJ\3CPLJ?/"!Q5?KM4\I;QYC0: MFVM+__KHM?2)ZNV5ST&?H[C0<[QE9Y@-8%A4*'.J^TA)!Z_&@3]+I[Q\S<1>,'[J MUY[-'6X>-_R@B3YB@HQ3]+#&BY+>-_''##]>\H:VCCG85^'ZQ3B;'P1:[)KE M/=RE3YKC/?VV59M?59.=DKLC>/AD+%*Z2SK*;8/A#1K%N%91#%%,ZQ-'5D^M+DGAH>IX"#9JP!S.IX,G9="P!VJ58C*MO,V9/Z&SI#='!0>JJF)#V-$\N%B' M5JJPO^UR\O;*:3$L0;;=&U2HX;8'4,LIS[2DLO,A?-A>)`]GK+F_B1.J%1+Z MYXQ_3HIQ574ZHZ.RWQM5<'N-P`U$O:2G6\ZI.IT5Z%G&Z@2.5/D*;S:;=$U] M-NSCSP'JPI4<"H;W:#[!3I71/8G.O:QBG\8=E-^"HPXP>$/0SWO[O6_/CGM[ST`CUT#@ M//.#$-SS_J#7']!!#`QC]?E!KYS&O_P:<'D&=(2#1R76[(_B7U*?9:[/2?S+ MM^L/JL]AIL]RD!O0)/?E./[EX=V5&6T5K3F8X9?!O?<;2$W(##;XTGA7I8B( MPD@LW%6.=1PJSF-=C.WEXD;>D'NND:E"1W1D,Y2.+KQ^G6Q_J4$'60!3!:4\ MK%^LJ;)2-[J*/8E#!5)V48\$#!JW72_$4AGZ>B&!(?\E?9D5_3_[:H! MV[S]P/#.8@LO-<$/B2CH7=SD0\(U40Z!/(N2PD?VS=]_>.A#YO2_AJQMC%9[ M1.!^.F&GE[CY6+,A&_S@["ILB2:8@(U%`Q/P[4<6GLP($R_3RHR^KS)>IJ_HW=\L#G>X]?J>F M+K_?W*DK;)#X$B4`[C.X&0]O-NDOT59OH-P@OEQG3/%=Z@-B!XR%2TB?22!N M[+NM"(]^56M'FJ=.%0>V8IFJZ(KE>G!SQBSS2T^BHC1[C6-XLW:,+`AP8YN\ M&=RP,F:98SD-B)N221#VC-$"D;^4R2>Y!L\$_EW- M8_1YD0`N)3P)AGD7-9Z5TX/*9OW>V*8Q[65E$W]Z*51[AQ!^NEGLW\PA8SFH M_C:$NU>OKN97'(1:+V\DV/T"J&Y]@XD+&'A]:3$KM2=($KDMA2-#DVM:Z0C^ M8;YIG*P(2%J6;";'/CS2F#182@Q80IH M:$'$NV1P`$P2K]$#*0I=T8I8&T4J.F6L`7MSFP,8AKE)\2B`/G23P7H3<@]& M)U,X?QK,3:[S0>^(M6=J8^\N04>ZX)JJ)3!/1QT)?0-X)[<< MJ$Q@5]`\>T^VMW/"?6N$<0!=9N^N8)04"PT9*+1G4G87;.9*@M;0Z4##LFH& M9JB('PDQSWKN>FX@4M2WC6Z%!F//JAV+A%GK-(F+4[!26$068KT.J]7'];+#YP7[,W\Q^;Z[AI]CGLGC/M5L-=B MT,F+M&AL)ZP1#QT&E]7\E).#4F6&5/QEY M]`^F2?(0WVTA#_480$F4\AN\:2[>-U?SM.ZK'!Q,?ZX-*4OW0#BK40X/1C_[ MEE0'X^26B.^V;,GAN]>'QVGYGO!L/8#M0C%4/*\_T]:,,ELCTS?^;%LSL.01 M;,T@23KYK0$]+"?0*]/[E:I2=:_RI1*%TPRV^=$LVCUM+2*CN#"B&!X;R/(Q M[AKT_M7Z8[+S0;2%BWKY[L(=H-O=@-#N/7?$ M0G>G@X/^@U@6!1\$%\D$#?P_V_Z7U42/RQTO?;Z%026U-#:L^[5P:3<@#G,G M$`71,CU0AP>87D2+AS:@5SH?Q$$DH-3;]6KC#B!K'PBBUB.:MQID3SNFH`D_ M2$JK$!CR0M9%;0$E'$R:/6`6#.4@_*X#K1[&DKVAU]!+C"5+6@E2$7ZY69T0 MTJ@(-TS>.B91,NBKO"#%[,+YH=EJY%^<*H<+833%8>,$2@>91!&?G3'O4[BFY&&UKU$0;'"1WU2`#0,,R MK6*J@HGZ3_,`DANZ-LAQ_5V+QV+YN];UXO=3Q7Y0?&O=N5':D1N](SOP..?, M=C?/;F$BW4P\^49VLGMF6^I`@OD&MM);>-(>N@4[4F*^L#M^FW$L M?,`-_V08L7^"5Z\8:PX4+KB"-)18(V>0#FNA)3EP`I9SNE^S^O> ME_5RD5+S;T=5VT$N>(M@/:S5NV)L>T^EYV17![DG;@Q'G2! M$\%Q?9%VKW.\Q;/X,EF_.HD]DWP1VDU`*5L^"Z7+]BO,K^'M1J&("A*B0!Z# M)^\`-CK7`>Q;$2+BN#MY&:Y93@Y)/L,C&DV-NT/O0CRT9TDRQO:2'#L)X?(8 MY]ACBW0@'#'Q$*'=+TNUDW$)VW^Z2<=ZE?ZD0#REA\EV,')L8; MBSR8^?5`)R/MM9_@6O)4#I-ES+IFM59)(K,-%#YB3'#YW&W6"TAMO"&`%1_\ MAA%ET@ZCMB==U2QPS!>F4W^3=`Q!E^JS1U4?]Q]5??*XZM.T^BL!3B2U/X\? MW^,[R,P@?6)=[5&7,TM>6EN1"M7G`,OEL,NN0W!D0)GY//!7VRVY#RT.\^&T9_.'09.,'K,DA!4:8DR"W ME9MDU$^3Y=?WKDY:*("D5[\3UBV&YSEIK/]0JY,/L]Q[-GAN@MEN,7IV6S0; M5(/+S+4M$9:R:'?TO$N0W)__:TN[84(45`*)5RO4$R&K&.-IOXZ_,OQ&*7AG MDKW)L4S?+6-=Y>.ER5-XE"[F>#CGO*#+8;:,=$P.!Q?OFX)UJFR[Z`W-?:?$ M%RK3WUZ&`Z"J;)E!M@PM:Y4M@Q%*9;XO=,=FTDN5H?699LO(F*;LF/7#+%%& MONQ29:2XF5IG.:\@R)^H?+J=V#B"*T^0(Y^VXU2&T6UEGL)12-:A:AVIEZAE ME@FIX_.<7:I^7C*G&+H\^3O1KTP">`*C."(I.;> M35ZS';T3'47T#*1,?6-C$XYB`23&07K#`0H^T'?.4SGJ&'7XX_I5G;:%B%WY M^N,*4GKSP\?$9Z8H*JPYOXVJ\*(%TVH';7_98N]->O:-8NZ`Y33J)$CP.1>< M%@T3*%XI:942PRT^X`.04K3CY]?1YYMG\S_FG7N).=7>:?^S4^()*4W./_SB M%^#:'WP-L43I&'@R".'S*>/I&)FY]JRW`$)S&[.'<-(%Y8:9FUXV2 M?6_540FQR(P3:DBTJ;*##F7?WN$[014TD2=D(Z`J86S8*4?.&(A8\%36=XB-X6<$0F:^!WQQZ714].WRA#(=03441Y_$[5EW'9S4H3W^HD99[NP750T0P"?R[!T1%S`L0:8A3<83QD% MV\B-I3_.`9,&=KS>;]<=Z\\NV=[[!=.GPY%<+W?8NO,%TNYS>B%L0DWVVM_OR,S1Q8G9@ MR[DCBJCS&N(6+TQ:))H$#0RT%=[8\H10#OJ]Q?P^ M>15$G+,SP*[E=IU(IITMMZ)VPHX>@"TBPC1^2-]);W^U7MP*Z*18J42AY#>) M8S`[F(U".!P=#+O0V4B7]SY_WE?7W8/JO5><,,FQ=,AQ-WHE.`!,V[K@]*28 MOALN)UX(K:=RTY"E"!S91W.-=R]0*M3.U\QOZ19^^$Y&)CIQ&[DM&T51='`) MET"/(#$;/OC@TRI9BT4Z?(JFM>!Q^W'MN-7DA2QU&TU"2DVUM5TBT_!R#@)> MY,.':-,A6'35SF/QW?II$GC@ZO)RC7504VEXJ6QKI(TC+5390:?911?95=_LX%QE]:!Y MD[H#B9730@TZ*.Z26L?X&N=5BHXJL)N)8)M63J)M9?74L^Q^!4"T\]ZSD8#" MO)`()*![0O$5<7+P,"'JC-_H#NBTT;>X!)[Z6F,0P#78B] MTTP3X<$Z-?':$-YE75MZ>U9B,)N?A4`]5>#%HH&;T@09:'A>SM6ZQFD)RS:B M;/=G812V\-B!Y-WH)PFJI\Q;``7/!A!-;YK(#9QN8U%?UAM<@?F/Z9OO#8O1 M`6FQF(A7+JIQ1(DLHD(5E2.U3DHW&U#=&X4LN"$5/6M6MXA%?AOC6"BKS9?'J",N8<`2MLUU`SXQJ_5*<@Y+37Z; MD^0,)`6*ML`(?JU8%08X2O!G?L)WT=7TAMKH/HJ^V"W[Q27#8\@GT%X7S.6@ MOW?06^SV\0)(C-ZK._Z=P;R3X&AI!Q/#]70NWSO8(H`;:O@I>^1\%%Z'<3YX M$=&)'XN3Y\&C);AIK!7R[D3?A.,(XXK$SBC>^0(6!+E.@X&VXNY2HA:8.^-+$_K1WG:CJB+,;7" M%;C@((/PY0F3U3"\"-7K/H#XD]41[H_A\Y.TB5<$6'O1;VJ+YN03AUA MH(`TQ[TRU7@PYR,I*K@7>;..CYS; M#KR"W'D%=LT\F02QK`]2A04]6/0QD37[EW>C?3[SLFW0,-._4?79CN(\D"/G<=:#8M MRV.4L](AG3L136>#>DA3J];B:W/'MQ8,T.(`?KO21![*(-EY9;Y\P$RU`OG% M>G47"P/LO2)84:GZ7<0K\>`)_\:'B#S'20F<<$;.-0'%G M;]UM>EG27D7&>PC/.,)G>G'?D\7818;'F",1K+5_GFJ<1*IS;IW+.:T7&N-$ MAD4062"`*0OJ1>^W=4O6_1XYEN2VQ>J?3I>9=Q!M!,'>PW,;LZI@X]KGJDCL M&SJ6<6C+9=T`GFA\W5OKFH=,Y14<*./:U3LW@V./ MV[JWZ]4^TWBXBX5<'#P#BF$T]):*+]9/0D=B4$7O.X:15TM*,/*XF"0FBABF MG([6R13A^!DQ!8ED0+MN]PY-=]]VM]%@!5P?ID[#WU&K_8@1A+/_D<7[" M;8OW$=E`HK;Z:1I[DFX^?C/V%>S(^!7D\>DAR57_JOI^25G^^N[7HROQ0 MVV(EIBZQ6`G9)2V&Z2Q\UITHOI9;6RAZN%T+"#L$;4U<#Z`#$Q)/=:OB>:Q< M[J!_L#_VRQJTC4NI2$+]>4X$"Y5.H>`K`B&A'.ND6E"N,*KD.\0\1XNY$2V1K_L9[\A)+V]_Y5V][^^O\`4$L!`A0#%`````@`L(!D1P(\__0-`@``AR4``!,` M`````````````(`!`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4```` M"`"P@&1'2'4%[L4````K`@``"P``````````````@`$^`@``7W)E;',O+G)E M;'-02P$"%`,4````"`"P@&1'2&JVDQ\"``"7)0``&@``````````````@`$L M`P``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"`"P@&1' MXY-;J6\#``!\#P``$```````````````@`&#!0``9&]C4')O<',O87!P+GAM M;%!+`0(4`Q0````(`+"`9$>(#V"3/@$``&D#```1``````````````"``2`) M``!D;V-097)PC$`8``)PG M```3``````````````"``8T*``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`A0# M%`````@`L(!D1SQ"D+&'`@``^`T```T``````````````(`!SA```'AL+W-T M>6QE&PO=V]R:V)O;VLN>&UL4$L!`A0#%`````@`L(!D1TC:'8MR M`@``P`@``!@``````````````(`!FA@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L(!D1U-N7!,9`@``/`8``!@````````` M`````(`!#"0``'AL+W=O=NJXDR`4``/`?```8``````````````"``5LF``!X;"]W;W)K&PO=V]R:W-H965T&UL4$L!`A0# M%`````@`L(!D1RT7,V?'!0``[!T``!@``````````````(`!:"\``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L(!D1PJ';**E M`0``L0,``!D``````````````(`!%SD``'AL+W=O&PO=V]R:W-H965TL!Q4>HP$``+$#```9``````````````"``&UL4$L!`A0#%`````@`L(!D1UR'.(2E`0``L0,``!D````` M`````````(`!ISX``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`L(!D1]T#.D>D`0``L0,``!D``````````````(`!-T0` M`'AL+W=O&PO=V]R:W-H965T)NSI`$``+$#```9```````````` M``"``>M'``!X;"]W;W)K&UL4$L!`A0#%`````@` ML(!D1PF=J!*E`0``L0,``!D``````````````(`!QDD``'AL+W=O&PO=V]R:W-H965THP$``+$#```9``````````````"``7M-``!X;"]W M;W)K&UL4$L!`A0#%`````@`L(!D1V#T=62F`0`` ML0,``!D``````````````(`!54\``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L(!D1[J(5>:E`0``L0,``!D````````` M`````(`!B%4``'AL+W=O&PO=V]R:W-H M965T&UL4$L! M`A0#%`````@`L(!D1R>>BSB^`0``>P0``!D``````````````(`!-UL``'AL M+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L(!D M1_(J/!NF`0``L0,``!D``````````````(`!.&$``'AL+W=O&PO=V]R:W-H965T9$U;?,@0``$47```9``````````````"``?!E``!X;"]W;W)K M&UL4$L!`A0#%`````@`L(!D1Z#9?1FE`P``[1`` M`!D``````````````(`!66H``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L(!D1[;X*/DL!@``BR<``!D````````````` M`(`!4'@``'AL+W=OY,%,G@"```U"```&0``````````````@`&S?@``>&PO=V]R:W-H965T MQG?X1`0(``)L%```9```` M``````````"``6*!``!X;"]W;W)K&UL4$L!`A0# M%`````@`L(!D1R#T,=\X!```[Q4``!D``````````````(`!FH,``'AL+W=O M&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L(!D1YYF M.]6U`0``.`0``!D``````````````(`!YXT``'AL+W=O&PO=V]R:W-H965THCT%ZW@H``$='```9``````````````"``>22``!X;"]W;W)K&UL4$L!`A0#%`````@`L(!D1\J64)>0`@``J0@``!D` M`````````````(`!^9T``'AL+W=O+`!```:!```&0``````````````@`'`H```>&PO M=V]R:W-H965TB``!X;"]W;W)K&UL4$L!`A0#%`````@`L(!D1RAYHFYX!```=1<``!D``````````````(`! M4JL``'AL+W=O"```&0``````````````@`$!L```>&PO=V]R:W-H965T*9NML7`(``-4'```9```````` M``````"``:"R``!X;"]W;W)K&UL4$L!`A0#%``` M``@`L(!D1W+I'Y`A`@``MP8``!D``````````````(`!,[4``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`L(!D1]BXM41G M`@``[@<``!D``````````````(`!:+P``'AL+W=O&PO=V]R:W-H965T[3ITT>0(``!T(```9``````````````"``>K```!X;"]W;W)K&UL4$L!`A0#%`````@`L(!D1_@VN(\2`P``!0T``!D````` M`````````(`!FL,``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`L(!D1PZB,5)&`P``D@T``!D``````````````(`!(LL` M`'AL+W=O&PO=V]R:W-H965T_0``!X;"]S:&%R9613=')I;F=S+GAM;%!+!08`````1P!'`&,3``#X %;P$````` ` end XML 20 R55.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) - February 2018 Notes [Member] - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Debt Instrument [Line Items]

Contractual coupon interest $ 3,000 $ 3,000 $ 9,000 $ 7,633

Amortization of debt issuance costs 510 536 1,599 1,358

Amortization of debt discount 1,830 1,688 5,353 4,238

Total $ 5,340 $ 5,224 $ 15,952 $ 13,229

X

- Definition
Amortization of debt issuance costs
+ References
No definition available.
+ Details

Name: pdli_AmortizationOfDebtIssuanceCosts

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph 8

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebtExcludingAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_February2018NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 21 R46.htm IDEA: XBRL DOCUMENT v3.3.0.814

Accrued Liabilities (Accrued Liabilities) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Payables and Accruals [Abstract]

Compensation $ 3,588 $ 1,332

Interest 2,000 6,210

Dividend payable 24,735 90

Legal 1,139 296

Other 1,249 948

Total $ 32,711 ^[1] $ 8,876 ^[2]

[1] unaudited

[2] Note 1

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedProfessionalFeesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

+ Details

Name: us-gaap_DividendsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_EmployeeRelatedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

+ Details

Name: us-gaap_InterestPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Liabilities

-URI http://asc.fasb.org/extlink&oid=6509677

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Income per Share (Narrative) (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

May. 02, 2015

Feb. 18, 2015

Oct. 20, 2014

Feb. 05, 2014

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

May. 01, 2015

Feb. 17, 2015

Dec. 31, 2014

Nov. 24, 2014

Feb. 12, 2014

Feb. 07, 2014

Feb. 06, 2014

Aug. 01, 2013

Feb. 29, 2012

Jan. 31, 2012

Warrants [Member]

Debt Instrument [Line Items]

Antidilutive securities excluded from computation of earnings per share (in Shares) 22,200,000

Stock Options [Member]

Debt Instrument [Line Items]

Antidilutive securities excluded from computation of earnings per share (in Shares) 42,000 4,000 39,000 4,000

Restricted Stock [Member]

Debt Instrument [Line Items]

Antidilutive securities excluded from computation of earnings per share (in Shares) 475,000 0 437,000 0

February 2015 Notes [Member]

Debt Instrument [Line Items]

Convertible notes $ 1,000 $ 169,000

Series 2012 Notes [Member]

Debt Instrument [Line Items]

Convertible notes $ 22,300 $ 26,000 $ 131,700 $ 131,700 $ 10,000

Debt Conversion, Converted Instrument, Shares Issued 1,300,000 1,800,000 20,300,000

May 2015 Notes [Member] [Member]

Debt Instrument [Line Items]

Convertible notes $ 155,100

May 2015 Notes [Member] [Member] | Warrants [Member]

Debt Instrument [Line Items]

Antidilutive securities excluded from computation of earnings per share (in Shares) 18,100,000 0 22,200,000

May 2015 Notes [Member] [Member] | Purchased Call Options [Member]

Debt Instrument [Line Items]

Antidilutive securities excluded from computation of earnings per share (in Shares) 0 26,100,000 0 26,100,000

February 2018 Notes [Member]

Debt Instrument [Line Items]

Convertible notes $ 281,581 $ 281,581 $ 276,228 $ 300,000

February 2018 Notes [Member] | Warrants [Member]

Debt Instrument [Line Items]

Antidilutive securities excluded from computation of earnings per share (in Shares) 29,000,000

February 2018 Notes [Member] | Purchased Call Options [Member]

Debt Instrument [Line Items]

Antidilutive securities excluded from computation of earnings per share (in Shares) 32,700,000

Series 2012 Notes [Member]

Debt Instrument [Line Items]

Debt Conversion, Converted Instrument, Shares Issued 5,200,000

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Antidilution

-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Diluted Earnings Per Share

-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Contingent Stock Agreement

-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16(a)(2))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_ConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DebtConversionConvertedInstrumentSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_DueFebruary2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_Series2012NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_May2015NotesMemberMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=pdli_PurchasedCallOptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_February2018NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_Series2012NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 23 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 24 R57.htm IDEA: XBRL DOCUMENT v3.3.0.814

Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Schedule of Other Liabilities [Line Items]

Accrued lease liability $ 10,700 $ 10,700

Accrued Bonuses 2,446 578

Uncertain tax position 35,035 26,356

Dividends Payable 293 68

Total $ 48,474 ^[1] $ 37,702 ^[2]

[1] unaudited

[2] Note 1

X

- Definition
[Line Items] for Schedule of Other Liabilities [Table]
+ References
No definition available.
+ Details

Name: pdli_ScheduleOfOtherLiabilitiesLineItems

Namespace Prefix: pdli_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.15(a))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

+ Details

Name: us-gaap_AccruedBonusesCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedRentNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.15(5))

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph a

-Article 7

+ Details

Name: us-gaap_DividendsPayableCurrentAndNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The noncurrent portion of the amount recognized for uncertain tax positions as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilityForUncertainTaxPositionsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 25 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Income per Share (Tables)
9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Schedule of calculation of numerator and denominator in earnings per share

Three Months Ended

Nine Months Ended

September 30,

September 30,
Net Income per Basic and Diluted Share:

2015

2014

2015

2014
(in thousands except per share amounts)

Numerator

Net income used to compute net income per basic and diluted share

$
69,459

$
102,235

$
232,221

$
267,173

Denominator

Weighted average shares used to compute net income per basic share

163,560

160,268

163,314

157,274

Restricted stock outstanding

167

96

131

113

Effect of dilutive stock options

15

22

18

22

Assumed conversion of Series 2012 Notes

—

2,247

33

3,301

Assumed conversion of warrants

—

—

403

—

Assumed conversion of May 2015 Notes

—

4,261

—

4,431

Weighted average shares used to compute net income per diluted share

163,742

166,894

163,899

165,141

Net income per share - basic

$
0.42

$
0.64

$
1.42

$
1.70

Net income per share - diluted

$
0.42

$
0.61

$
1.42

$
1.62

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R50.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes (Summary of Series 2012 Notes) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Feb. 17, 2015

Dec. 31, 2014

Oct. 20, 2014

Feb. 12, 2014

Feb. 06, 2014

Aug. 01, 2013

Debt Instrument [Line Items]

Unamortized discount of liability component $ (1,400)

Convertible Notes Payable, Carrying Value 331,423 $ 451,724

Series 2012 Notes [Member]

Debt Instrument [Line Items]

Convertible Notes, Principal Balance Outstanding 0 $ 22,300 22,337 $ 48,300 $ 180,000

Unamortized discount of liability component 0 (76) $ (100) $ (2,100)

Convertible Notes Payable, Carrying Value $ 0 $ 22,261

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_Series2012NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 27 R42.htm IDEA: XBRL DOCUMENT v3.3.0.814

Foreign Currency Hedging (Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges) (Detail)
$ in Thousands

Sep. 30, 2015

USD ($)

Dec. 31, 2014

USD ($)

Derivative [Line Items]

Fair Value $ (4,597) $ (4,069)

Derivative, Notional Amount $ 33,000 85,875

Eurodollar Sell Forward Contract 1.256 [Member]

Derivative [Line Items]

Derivative, Forward Exchange Rate 1.256

Fair Value $ 0 241

Derivative, Notional Amount $ 0 6,000

Eurodollar Sell Forward Contract 1.257 [Member]

Derivative [Line Items]

Derivative, Forward Exchange Rate 1.257

Fair Value $ 0 728

Derivative, Notional Amount $ 0 15,750

Eurodollar Sell Forward Contract 1.259 [Member]

Derivative [Line Items]

Derivative, Forward Exchange Rate 1.259

Fair Value $ 0 752

Derivative, Notional Amount $ 0 16,125

Eurodollar Sell Forward Contract 1.260 [Member]

Derivative [Line Items]

Derivative, Forward Exchange Rate 1.260

Fair Value $ 4,597 1,468

Derivative, Notional Amount $ 33,000 33,000

Eurodollar Sell Forward Contract 1.270 [Member]

Derivative [Line Items]

Derivative, Forward Exchange Rate 1.270

Fair Value $ 0

Derivative, Notional Amount $ 0

Eurodollar Sell Forward Contract 1.281 [Member]

Derivative [Line Items]

Derivative, Forward Exchange Rate 1.281

Fair Value $ 0

Derivative, Notional Amount $ 0

Euro Forward Contracts [Member] | Eurodollar Sell Forward Contract 1.270 [Member]

Derivative [Line Items]

Fair Value (377)

Derivative, Notional Amount 7,000

Euro Forward Contracts [Member] | Eurodollar Sell Forward Contract 1.281 [Member]

Derivative [Line Items]

Fair Value (503)

Derivative, Notional Amount $ 8,000

X

- Definition
Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 13

-Sentence Column B

+ Details

Name: invest_DerivativeNotionalAmount

Namespace Prefix: invest_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: instant

X

- Definition
Contractual rate at which a foreign currency can be purchased or sold.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeForwardExchangeRate1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value as of the balance sheet date of all foreign currency derivatives designated as cash flow hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-Subparagraph (a),(b),(c)(1)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

+ Details

Name: us-gaap_ForeignCurrencyCashFlowHedgeDerivativeAtFairValueNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_DerivativeByNatureAxis=pdli_EurodollarSellForwardContract1.256Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeByNatureAxis=pdli_EurodollarSellForwardContract1.257Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeByNatureAxis=pdli_EurodollarSellForwardContract1.259Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeByNatureAxis=pdli_EurodollarSellForwardContract1.260Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeByNatureAxis=pdli_EurodollarSellForwardContract1270Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeByNatureAxis=pdli_EurodollarSellForwardContract1281Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 28 R37.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Oct. 20, 2014

Feb. 12, 2014

Fair Value by Balance Sheet Grouping [Line Items]

Debt Instrument, Unamortized Discount $ 1,400

Assets

Notes receivable, Carrying Value 354,834 $ 363,212

Liabilities:

Convertible Notes Payable, Carrying Value 331,423 451,724

Series 2012 Notes [Member]

Fair Value by Balance Sheet Grouping [Line Items]

Debt Instrument, Unamortized Discount 0 76 $ 100 $ 2,100

Liabilities:

Convertible Notes Payable, Carrying Value 0 22,261

May 2015 Notes [Member]

Fair Value by Balance Sheet Grouping [Line Items]

Debt Instrument, Unamortized Discount 0 1,815

Liabilities:

Convertible Notes Payable, Carrying Value 0 153,235

February 2018 Notes [Member]

Fair Value by Balance Sheet Grouping [Line Items]

Debt Instrument, Unamortized Discount 18,419 23,772 $ 29,700

Liabilities:

Convertible Notes Payable, Carrying Value 281,581 276,228

Term Loan. [Member]

Liabilities:

Convertible Notes Payable, Carrying Value 49,842

Wellstat Note Receivable [Member]

Assets

Notes receivable, Carrying Value 50,191 50,191

Hyperion [Member]

Assets

Notes receivable, Carrying Value 1,200 1,200

Avinger Note Receivable [Member]

Assets

Notes receivable, Carrying Value 0 20,611

LENSAR Note Receivable [Member]

Assets

Notes receivable, Carrying Value 50,266 39,668

Direct Flow Medical Note Receivable [Member]

Assets

Notes receivable, Carrying Value 51,772 50,397

Paradigm Spine [Member]

Assets

Notes receivable, Carrying Value 49,909 49,571

kaleo Note Receivable [Member]

Assets

Notes receivable, Carrying Value 151,496 151,574

Fair Value Level 2 [Member]

Liabilities:

Notes payable, Fair Value 312,313 528,705

Fair Value Level 2 [Member] | Series 2012 Notes [Member]

Liabilities:

Notes payable, Fair Value 33,506

Fair Value Level 2 [Member] | May 2015 Notes [Member]

Liabilities:

Notes payable, Fair Value 205,534

Fair Value Level 2 [Member] | February 2018 Notes [Member]

Liabilities:

Notes payable, Fair Value 262,313 289,665

Fair Value Level 2 [Member] | Term Loan. [Member]

Liabilities:

Notes payable, Fair Value 50,000

Fair Value Level 2 [Member] | Hyperion [Member]

Assets

Notes receivable, Fair Value 0 0

Fair Value Level 2 [Member] | LENSAR Note Receivable [Member]

Assets

Notes receivable, Fair Value 0 0

Fair Value Level 2 [Member] | Direct Flow Medical Note Receivable [Member]

Assets

Notes receivable, Fair Value 0 0

Fair Value Level 2 [Member] | Paradigm Spine [Member]

Assets

Notes receivable, Fair Value 0 0

Fair Value Level 2 [Member] | kaleo Note Receivable [Member]

Assets

Notes receivable, Fair Value 0 0

Fair Value Level 3 [Member]

Assets

Notes receivable, Fair Value 356,256 363,740

Fair Value Level 3 [Member] | Wellstat Note Receivable [Member]

Assets

Notes receivable, Fair Value 50,191 50,191

Fair Value Level 3 [Member] | Hyperion [Member]

Assets

Notes receivable, Fair Value 1,200 1,200

Fair Value Level 3 [Member] | Avinger Note Receivable [Member]

Assets

Notes receivable, Fair Value 0 20,760

Fair Value Level 3 [Member] | LENSAR Note Receivable [Member]

Assets

Notes receivable, Fair Value 50,266 40,451

Fair Value Level 3 [Member] | Direct Flow Medical Note Receivable [Member]

Assets

Notes receivable, Fair Value 52,052 49,940

Fair Value Level 3 [Member] | Paradigm Spine [Member]

Assets

Notes receivable, Fair Value 51,071 50,125

Fair Value Level 3 [Member] | kaleo Note Receivable [Member]

Assets

Notes receivable, Fair Value $ 151,476 $ 151,073

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermDebtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) more than one year from the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesAndLoansReceivableGrossNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesReceivableFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_Series2012NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_DueMay2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_February2018NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_TermLoan.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_WellstatNoteReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_HyperionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_AvingerNoteReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_LENSARNoteReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_DirectFlowMedicalNoteReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_ParadigmSpineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_KaleoNoteReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 29 R52.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes (Summary of May 2015 Notes) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

May. 01, 2015

Dec. 31, 2014

Debt Instrument [Line Items]

Unamortized discount of liability component $ (1,400)

Convertible Notes Payable, Carrying Value 331,423 $ 451,724

May 2015 Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Face Amount 0 $ 155,100 155,050

Unamortized discount of liability component 0 (1,815)

Convertible Notes Payable, Carrying Value $ 0 $ 153,235

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

+ Details

Name: us-gaap_DebtInstrumentUnamortizedDiscount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_DueMay2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 30 R61.htm IDEA: XBRL DOCUMENT v3.3.0.814

Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Unrealized gains (losses) on available-for-sale securities, beginning balance $ 364

Unrealized losses on cash flow hedges, beginning balance 2,585

Total Accumulated Other Comprehensive Loss, beginning balance ^[1] 2,949

Unrealized gains (losses) on available-for-sale securities $ 228 ^[2] $ (258) ^[2] 39 $ (1,554)

Unrealized gains (losses) on cash flow hedges (1,552) ^[3] 2,963 ^[3] 403 6,049

Total Accumulated Other Comprehensive Loss (1,324) $ 2,705 442 $ 4,495

Unrealized gains (losses) on available-for-sale securities, ending balance 403 403

Unrealized losses on cash flow hedges, ending balance 2,988 2,988

Total Accumulated Other Comprehensive Loss, ending balance ^[4] $ 3,391 $ 3,391

[1] Note 1

[2] Net of tax of $123 and ($139) for the three months ended September 30, 2015 and 2014, respectively, and $21 and ($837) for the nine months ended September 30, 2015 and 2014, respectively.

[3] Net of tax of ($836) and $1,595 for the three months ended September 30, 2015 and 2014, respectively, and $217 and $3,257 for the

[4] unaudited

X

- Definition
Accumulated appreciation or loss, net of tax, in value of the total of available-for-sale securities at the end of an accounting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change, net of tax, in accumulated gains and losses from derivative instruments designated and qualifying as the effective portion of cash flow hedges. Includes an entity's share of an equity investee's Increase or Decrease in deferred hedging gains or losses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossCumulativeChangesInNetGainLossFromCashFlowHedgesEffectNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 55

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51821188&loc=d3e1436-108581

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 31 R47.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies (Narrative) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Total lease payments for the duration of the guarantee $ 70,500

Accrued lease liability $ 10,700 $ 10,700

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedRentNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph (b)(1)

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12069-110248

+ Details

Name: us-gaap_GuaranteeObligationsMaximumExposure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 32 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Income per Share
9 Months Ended

Sep. 30, 2015

Earnings Per Share [Abstract]

Net Income per Share
2. Net Income per Share

Three Months Ended

Nine Months Ended

September 30,

September 30,
Net Income per Basic and Diluted Share:

2015

2014

2015

2014
(in thousands except per share amounts)

Numerator

Net income used to compute net income per basic and diluted share

$
69,459

$
102,235

$
232,221

$
267,173

Denominator

Weighted average shares used to compute net income per basic share

163,560

160,268

163,314

157,274

Restricted stock outstanding

167

96

131

113

Effect of dilutive stock options

15

22

18

22

Assumed conversion of Series 2012 Notes

—

2,247

33

3,301

Assumed conversion of warrants

—

—

403

—

Assumed conversion of May 2015 Notes

—

4,261

—

4,431

Weighted average shares used to compute net income per diluted share

163,742

166,894

163,899

165,141

Net income per share - basic

$
0.42

$
0.64

$
1.42

$
1.70

Net income per share - diluted

$
0.42

$
0.61

$
1.42

$
1.62

We compute diluted net income per share using the sum of the weighted average number of common and common equivalent shares outstanding. Common equivalent shares used in the computation of diluted net income per share include shares that may be issued under our stock options and restricted stock awards, our February 2018 Notes, our Series 2012 Notes and our May 2015 Notes on a weighted average basis for the period that the notes were outstanding, including the effect of adding back interest expense and the underlying shares using the if-converted method. In the third quarter of 2013, $1.0 million aggregate principal of our February 2015 Notes was exchanged for our Series 2012 Notes and the February 2015 Notes were retired, in the first quarter of 2014, $131.7 million aggregate principal of our Series 2012 Notes was retired in a privately negotiated exchange and purchase agreements, in the fourth quarter of 2014, the Company entered into a privately negotiated exchange agreement by which it retired approximately $26.0 million in principal of the outstanding Series 2012 Notes, and, in the first quarter of 2015, the Company completed the retirement of the remaining $22.3 million of aggregate principal of its Series 2012 Notes.

In the second quarter of 2015, the Company completed the retirement of the remaining $155.1 million of aggregate principal of its May 2015 Notes. Concurrently with the retirement of the May 2015 Notes, we exercised our purchased call options and received 5.2 million of PDL's common shares, which was the amount equal to the number of shares required to be delivered by us to the note holders for the excess conversion value (see Note 9).

In May 2011, we issued our May 2015 Notes, in January and February 2012, we issued our Series 2012 Notes, and in February 2014, we issued our February 2018 Notes. The Series 2012 Notes and May 2015 Notes were net share settled, with the principal amount settled in cash and the excess settled in our common stock. The weighted average share adjustments related to our Series 2012 Notes, May 2015 Notes and February 2018 Notes, shown in the table above, include the shares issuable in respect of such excess.

May 2015 Notes Purchased Call Option and Warrant Potential Dilution

The warrants are dilutive for the three and nine months ended September 30, 2015, as the exercise price of the warrants was lower than the average market price of our common stock. We excluded from our calculations of net income per diluted share 18.1 million and 22.2 million shares for the three months ended September 30, 2015 and 2014, respectively, and zero and 22.2 million shares for the nine months ended September 30, 2015 and 2014, respectively, for warrants issued in 2011, because the exercise price of the warrants was higher than the average market price of our common stock and thus, for the three and nine months ended September 30, 2014, no stock was issuable upon conversion. Our purchased call options, issued in 2011, will always be anti-dilutive and therefore zero and 26.1 million shares were excluded from our calculations of net income per diluted share for the three months ended September 30, 2015 and 2014, respectively, and zero and 26.1 million shares were excluded from our calculation of diluted net income per share for the nine months ended September 30, 2015 and 2014, respectively, because they have no effect on diluted net income per share. For information related to the conversion rates on our convertible debt, see Note 9.

February 2018 Notes Purchased Call Option and Warrant Potential Dilution

We excluded from our calculation of net income per diluted share 29.0 million shares for the three and nine months ended September 30, 2015 and 2014, for warrants issued in February 2014, because the exercise price of the warrants exceeded the VWAP of our common stock and conversion of the underlying February 2018 Notes is not assumed, therefore no stock would be issuable upon conversion. These securities could be dilutive in future periods. Our purchased call options, issued in February 2014, will always be anti-dilutive and therefore 32.7 million shares were excluded from our calculation of net income per diluted share for the three and nine months ended September 30, 2015 and 2014, because they have no effect on diluted net income per share. For information related to the conversion rates on our convertible debt, see Note 9.

Anti-Dilutive Effect of Stock Options and Restricted Stock Awards

For the three months ended September 30, 2015 and 2014, we excluded approximately 42,000 and 4,000 shares underlying outstanding stock options, respectively, and for the nine months ended September 30, 2015 and 2014, we excluded approximately 39,000 and 4,000 shares underlying outstanding stock options, respectively. For the three months ended September 30, 2015 and 2014, we excluded approximately 475,000 and zero shares underlying restricted stock awards, respectively, and for the nine months ended September 30, 2015 and 2014, we excluded approximately 437,000 and zero shares underlying restricted stock awards, respectively, calculated on a weighted average basis, from our net income per diluted share calculations because their effect was anti-dilutive.

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for earnings per share.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_EarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 33 R62.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events (Narrative) (Detail) - USD ($)
$ / shares in Units, $ in Millions

Oct. 27, 2015

Oct. 07, 2015

Oct. 06, 2015

Oct. 28, 2015

Sep. 15, 2015

Subsequent Event [Line Items]

Price per share of investment sold $ 5.62

Investment Warrants, Exercise Price $ 0.40 $ 0.45

Subsequent Event [Member]

Subsequent Event [Line Items]

Amount company has agreed to advance under credit agreement $ 7.0

Tranche 1 of note receivable $ 20.0 $ 4.0

Tranche 2 of note receivable $ 20.0 $ 3.0

X

- Definition
Exercise price of the warrants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 13

-Sentence Column A

+ Details

Name: invest_InvestmentWarrantsExercisePrice

Namespace Prefix: invest_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount company has agreed to advance under credit agreement.
+ References
No definition available.
+ Details

Name: pdli_CommitmentToProvideFundingDuringOneHundredTwentydayForbearancePeriod

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price per share of investment sold
+ References
No definition available.
+ Details

Name: pdli_Pricepershareofinvestmentsold

Namespace Prefix: pdli_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Tranche 1 of note receivable
+ References
No definition available.
+ Details

Name: pdli_Tranche1ofnotereceivable

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Tranche 2 of note receivable
+ References
No definition available.
+ Details

Name: pdli_Tranche2ofnotereceivable

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R43.htm IDEA: XBRL DOCUMENT v3.3.0.814

Foreign Currency Hedging (Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Asset, Current $ 4,597 $ 3,352

Derivative Asset, Noncurrent $ 0 $ 717

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Current Assets

-URI http://asc.fasb.org/extlink&oid=6509628

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_DerivativeAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 20

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611

+ Details

Name: us-gaap_DerivativeAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 35 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes (Tables)
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Schedule of convertible and non-recourse notes activity

Principal Balance Outstanding

Carrying Value

September 30,

September 30,

December 31,
Description

Maturity Date

2015

2015

2014
(In thousands)

Convertible Notes

Series 2012 Notes

February 15, 2015

$
—

$
—

$
22,261

May 2015 Notes

May 1, 2015

$
—

—

153,235

February 2018 Notes

February 1, 2018

$
300,000

281,581

276,228

March 2015 Term Loan

February 15, 2016

$
50,000

49,842

—

Total

$
331,423

$
451,724

Schedule of carrying value and unamortized discount on Series 2012 Notes
The principal amount, carrying value and unamortized discount of our Series 2012 Notes were as follows:

(In thousands)

September 30, 2015

December 31, 2014
Principal amount of the Series 2012 Notes

$
—

$
22,337

Unamortized discount of liability component

—

(76
)
Total

$
—

$
22,261

Schedule of interest expense on Series 2012 Notes
Interest expense for our Series 2012 Notes on our Condensed Consolidated Statements of Income was as follows:

Three Months Ended

Nine Months Ended

September 30,

September 30,
(In thousands)

2015

2014

2015

2014
Contractual coupon interest

$
—

$
347

$
80

$
1,455

Amortization of debt issuance costs

—

64

13

996

Amortization of debt discount

—

404

76

1,783

Total

$
—

$
815

$
169

$
4,234

Schedule of carrying value and unamortized discount on May 2015 Notes
The carrying value and unamortized discount of our May 2015 Notes were as follows:

(In thousands)

September 30, 2015

December 31, 2014
Principal amount of the May 2015 Notes

$
—

$
155,050

Unamortized discount of liability component

—

(1,815
)
Total

$
—

$
153,235

Schedule of interest expense for May 2015 Notes
Interest expense for our May 2015 Notes on our Condensed Consolidated Statements of Income was as follows:

Three Months Ended

Nine Months Ended

September 30,

September 30,
(In thousands)

2015

2014

2015

2014
Contractual coupon interest

$
—

$
1,455

$
1,938

$
4,366

Amortization of debt issuance costs

—

320

435

952

Amortization of debt discount

—

1,308

1,815

3,852

Total

$
—

$
3,083

$
4,188

$
9,170

Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block]
The carrying value and unamortized discount of our February 2018 Notes were as follows:

(In thousands)

September 30, 2015

December 31, 2014
Principal amount of the February 2018 Notes

$
300,000

$
300,000

Unamortized discount of liability component

(18,419
)

(23,772
)
Total

$
281,581

$
276,228

Schedule of interest expense for February 2018 Notes [Table Text Block]
Interest expense for our February 2018 Notes on our Condensed Consolidated Statements of Income was as follows:

Three Months Ended

Nine Months Ended

September 30,

September 30,
(In thousands)

2015

2014

2015

2014
Contractual coupon interest

$
3,000

$
3,000

$
9,000

$
7,633

Amortization of debt issuance costs

510

536

1,599

1,358

Amortization of debt discount

1,830

1,688

5,353

4,238

Total

$
5,340

$
5,224

$
15,952

$
13,229

X

- Definition
Tabular disclosure of notes including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ References
No definition available.
+ Details

Name: pdli_May2015NotesTableTextBlock

Namespace Prefix: pdli_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Schedule of interest expense for May 2015 Notes
+ References
No definition available.
+ Details

Name: pdli_ScheduleOfInterestExpenseOnMay2015NotesTableTextBlock

Namespace Prefix: pdli_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Schedule of interest expense on Series 2012 Notes
+ References
No definition available.
+ Details

Name: pdli_ScheduleOfInterestExpenseOnSeries2012NotesTableTextBlock

Namespace Prefix: pdli_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Schedule of carrying value and unamortized discount on February 2018 Notes [Table Text Block]
+ References
No definition available.
+ Details

Name: pdli_ScheduleofcarryingvalueandunamortizeddiscountonFebruary2018NotesTableTextBlock

Namespace Prefix: pdli_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Schedule of interest expense for February 2018 Notes [Table Text Block]
+ References
No definition available.
+ Details

Name: pdli_ScheduleofinterestexpenseforFebruary2018NotesTableTextBlock

Namespace Prefix: pdli_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of notes including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.
+ References
No definition available.
+ Details

Name: pdli_Series2012NotesTableTextBlock

Namespace Prefix: pdli_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfDebtTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 36 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814

Foreign Currency Hedging (Tables)
9 Months Ended

Sep. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Euro forward contracts
The notional amounts, Euro exchange rates and fair values of our Euro forward contracts designated as cash flow hedges were as follows:

Euro Forward Contracts

September 30, 2015

December 31, 2014

(In thousands)

(In thousands)
Currency

Settlement Price
($ per Euro)

Type

Notional Amount

Fair Value

Notional Amount

Fair Value
Euro

1.256

Sell Euro

$
—

$
—

$
6,000

$
241

Euro

1.257

Sell Euro

—

—

15,750

728

Euro

1.259

Sell Euro

—

—

16,125

752

Euro

1.260

Sell Euro

33,000

4,597

33,000

1,468

Euro

1.270

Sell Euro

—

—

7,000

377

Euro

1.281

Sell Euro

—

—

8,000

503

Total

$
33,000

$
4,597

$
85,875

$
4,069

Schedule of location and fair values of Euro contracts in Consolidated Balance Sheets
The location and fair values of our Euro contracts in our Condensed Consolidated Balance Sheets were as follows:

Cash Flow Hedge

Location

September 30,
2015

December 31,
2014
(In thousands)

Euro contracts

Prepaid and other current assets

$
4,597

$
3,352

Euro contracts

Other assets

$
—

$
717

Schedule of the effect of derivative instruments in the Consolidated Statements of Income and Consolidated Statements of Comprehensive Income
The effect of our derivative instruments in our Condensed Consolidated Statements of Income and our Condensed Consolidated Statements of Comprehensive Income was as follows:

Three Months Ended

Nine Months Ended

September 30,

September 30,

2015

2014

2015

2014
(In thousands)

Net gain (loss) recognized in OCI, net of tax ⁽¹⁾

$
(57
)

$
1,974

$
4,306

$
2,305

Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax ⁽²⁾

$
1,495

$
(989
)

$
3,903

$
(3,744
)
Net gain (loss) recognized in interest and other income, net - cash flow hedges ⁽³⁾

$
—

$
2

$
—

$
5

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41678-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ScheduleOfDerivativeInstrumentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 37 R56.htm IDEA: XBRL DOCUMENT v3.3.0.814

Other Long-Term Liabilities (Narrative) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Schedule of Other Liabilities [Line Items]

Guarantor Obligations, Maximum Exposure, Undiscounted $ 70,500

Accrued lease liability $ 10,700 $ 10,700

X

- Definition
[Line Items] for Schedule of Other Liabilities [Table]
+ References
No definition available.
+ Details

Name: pdli_ScheduleOfOtherLiabilitiesLineItems

Namespace Prefix: pdli_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedRentNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph (b)(1)

-URI http://asc.fasb.org/extlink&oid=6851643&loc=d3e12069-110248

+ Details

Name: us-gaap_GuaranteeObligationsMaximumExposure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 38 R44.htm IDEA: XBRL DOCUMENT v3.3.0.814

Foreign Currency Hedging (Schedule of Effect of Derivative Instruments in Consolidated Statements of Income and Consolidated Statements of Comprehensive Income) (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Derivative [Line Items]

Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net $ 0 $ (2) $ 0 $ (5)

Cash Flow Hedges [Member]

Derivative [Line Items]

Net gain (loss) recognized in OCI, net of tax ^[1] (57) 1,974 4,306 2,305

Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax ^[2] 1,495 (989) 3,903 (3,744)

Net gain (loss) recognized in interest and other income, net ^[3] $ 0 $ 2 $ 0 $ 5

[1] hange in the fair value of cash flow hedges, net of tax.

[2] Effective portion classified as royalty revenue.

[3] Ineffectiveness from excess hedge was approximately zero and ($2) for the three months ended September 30, 2015 and 2014, respectively, and zero and ($5) for the nine months ended September 30, 2015 and 2014, respectively.

X

- Definition
Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (a),(c),(d),(e)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeGainLossOnDerivativeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The effective portion of net gain (loss) reclassified from accumulated other comprehensive income into income on derivative instruments designated and qualifying as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4D

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

+ Details

Name: us-gaap_DerivativeInstrumentsGainLossReclassifiedFromAccumulatedOCIIntoIncomeEffectivePortionNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The effective portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments that was recognized in other comprehensive income during the current period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

+ Details

Name: us-gaap_DerivativeInstrumentsGainLossRecognizedInOtherComprehensiveIncomeEffectivePortionNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net gain (loss) recognized in earnings during the reporting period representing the amount of the cash flow hedges' ineffectiveness.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

+ Details

Name: us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_DerivativeByNatureAxis=pdli_CashFlowHedgesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 39 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814

Other Long-Term Liabilities (Tables)
9 Months Ended

Sep. 30, 2015

Other Liabilities Disclosure [Abstract]

Schedule of other liabilities

September 30,

December 31,

2015

2014
(In thousands)

Accrued lease liability

$
10,700

$
10,700

Long-term incentive accrual

2,446

578

Uncertain tax positions

35,035

26,356

Dividend payable

293

68

Total

$
48,474

$
37,702

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of other assets and other liabilities not separately disclosed on the balance sheet.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfOtherAssetsAndOtherLiabilitiesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 40 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814

Accumulated Other Comprehensive Income (Loss) (Tables)
9 Months Ended

Sep. 30, 2015

Accumulated Other Comprehensive Income (Loss) [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)
The balance of accumulated other comprehensive income, net of tax, was as follows:

Unrealized gains (losses) on available-for-sale securities

Unrealized gains on cash flow hedges

Total Accumulated Other Comprehensive Income
(In thousands)

Beginning Balance at December 31, 2014

$
364

$
2,585

$
2,949

Activity for the nine months ended September 30, 2015

39

403

442

Ending Balance at September 30, 2015

$
403

$
2,988

$
3,391

X

- Definition
Accumulated Other Comprehensive Income (Loss) [Abstract]
+ References
No definition available.
+ Details

Name: pdli_AccumulatedOtherComprehensiveIncomeLossAbstract

Namespace Prefix: pdli_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the components of accumulated other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

+ Details

Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 41 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies
1. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with GAAP for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of PDL believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.

The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with our audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2014, included in our Annual Report on Form 10-K, as amended, filed with the SEC. The Condensed Consolidated Balance Sheet at December 31, 2014, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.

Principles of Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of PDL and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Our accompanying unaudited Condensed Consolidated Financial Statements are prepared in accordance with GAAP and the rules and regulations of the SEC.

Management Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Notes Receivable and Other Long-Term Receivables

We account for our notes receivable at both amortized cost, net of unamortized origination fees, if any, and as dependent on collateral when the loan for which repayment is expected to be provided solely by the underlying collateral. For loans accounted for at their amortized cost, related fees and costs are recorded net of any amounts reimbursed. Interest is accreted or accrued to "Interest revenue" using the interest method. When and if supplemental royalties are received from certain of these notes and other long-term receivables, an adjustment to the estimated effective interest rate is affected prospectively.

We evaluate the collectability of both interest and principal for each note receivable and loan to determine whether it is impaired. A note receivable or loan is considered to be impaired when, based on current information and events, we determine it is probable that we will be unable to collect amounts due according to the existing contractual terms. When a note receivable or loan is considered to be impaired, the amount of loss is calculated by comparing the carrying value of the financial asset to the value determined by discounting the expected future cash flows at the loan's effective interest rate or to the estimated fair value of the underlying collateral, less costs to sell, if the loan is collateralized and we expect repayment to be provided solely by the collateral. Impairment assessments require significant judgments and are based on significant assumptions related to the borrower's credit risk, financial performance, expected sales, and estimated fair value of the collateral.

Convertible Notes

We issued our Series 2012 Notes, May 2015 Notes and February 2018 Notes with a net share settlement feature, meaning that upon any conversion, the principal amount will be settled in cash and the remaining amount, if any, will be settled in shares of our common stock. In accordance with accounting guidance for convertible debt instruments that may be settled in cash or other assets upon conversion, we separated the principal balance between the fair value of the liability component and the common stock conversion feature using a market interest rate for a similar nonconvertible instrument at the date of issuance.

Queen et al. Royalty Revenues

Under our Queen Patent license agreements, we receive royalty payments based upon our licensees’ net sales of covered products. Generally, under these agreements we receive royalty reports from our licensees approximately one quarter in arrears, that is, generally in the second month of the quarter after the licensee has sold the royalty-bearing product. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the quarter reported to us by our licensees, that is, royalty revenues are generally recognized one quarter following the quarter in which sales by our licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees.

We also received annual maintenance fees from licensees of our Queen et al. patents prior to patent expiry as well as periodic milestone payments. We have no performance obligations with respect to such fees. Maintenance fees were recognized as they became due and when payment was reasonably assured. Total annual maintenance and milestone payments in each of the last several years have been less than 1% of total revenue.

Although the last of our Queen et al. patents expired in December 2014, we expect to receive royalties beyond expiration based on the terms of our licenses and our legal settlements. We do not expect to receive any meaningful revenue from our Queen et al. patents beyond the first quarter of 2016. We believe that cash from future revenues from the Queen et al. patent royalties through the first quarter of 2016 and from acquired revenue generating assets, net of operating expenses, debt service and income taxes, plus cash on hand, will be sufficient to fund our operations over the next several years. However, we do not expect that our acquired revenue generating assets will, in the near term, replace the revenues we generate from our license agreements related to the Queen et al. patents. In the second quarter of 2016, our revenues are likely to materially decrease after we stop receiving payments from these Queen et al. patents license agreements, which currently account for 88% of our year to date revenue. The continued success of the Company will become more dependent on the timing and our ability to acquire new income generating assets in order to provide recurring revenues going forward and to support our business model and ability to pay dividends.

Royalty Rights - At Fair Value

Currently, we have elected to account for our investments in royalty rights at fair value with changes in fair value presented in earnings. The fair value of the investments in royalty rights is determined by using a discounted cash flow analysis related to the expected future cash flows to be received. These assets are classified as Level 3 assets within the fair value hierarchy as our valuation estimates utilize significant unobservable inputs, including estimates as to the probability and timing of future sales of the related products. Transaction-related fees and costs are expensed as incurred.

The changes in the estimated fair value from investments in royalty rights along with cash receipts each reporting period are presented together on our Condensed Consolidated Statements of Income as a component of revenue under the caption, “Royalty rights - change in fair value.”

Customer Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of our total revenues, was as follows:

Three Months Ended September 30,

Nine Months Ended September 30,
Licensee

Product Name

2015

2014

2015

2014
Genentech

Avastin

32
%

24
%

28
%

25
%

Herceptin

32
%

24
%

28
%

25
%

Xolair

10
%

6
%

8
%

6
%

Biogen

Tysabri^®

11
%

10
%

10
%

9
%

Depomed

Glumetza^®

(10
)%

14
%

—
%

13
%

Foreign Currency Hedging

We enter into foreign currency hedges to manage exposures arising in the normal course of business and not for speculative purposes.

We hedge certain Euro-denominated currency exposures related to royalties associated with our licensees’ product sales with Euro forward contracts. In general, these contracts are intended to offset the underlying Euro market risk in our royalty revenues. The last of these contracts expires in the first quarter of 2016. We designate foreign currency exchange contracts used to hedge royalty revenues based on underlying Euro-denominated licensee product sales as cash flow hedges.

At the inception of each hedging relationship and on a quarterly basis, we assess the hedge effectiveness. The fair value of the Euro contracts is estimated using pricing models with readily observable inputs from actively quoted markets and is disclosed on a gross basis. The aggregate unrealized gains or losses, net of tax, on the effective component of the hedge is recorded in stockholders’ equity as "Accumulated other comprehensive income." Realized gains or losses on cash flow hedges are recognized as an adjustment to royalty revenue in the same period that the hedged transaction impacts earnings as royalty revenue. Any gain or loss on the ineffective portion of our hedge contracts is reported in "Interest and other income, net" in the period the ineffectiveness occurs.

Income Taxes

The provision for income taxes is determined using the asset and liability approach. Tax laws require items to be included in tax filings at different times than the items are reflected in the financial statements. A current liability is recognized for the estimated taxes payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are adjusted for enacted changes in tax rates and tax laws. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.

The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

Comprehensive Income

Comprehensive income comprises net income adjusted for other comprehensive income (loss), using the specific identification method, which includes the changes in unrealized gains and losses on cash flow hedges and changes in unrealized gains and losses on our investments in available-for-sale securities, all net of tax, which are excluded from our net income.

Recently Issued Accounting Pronouncements

In April 2015, the FASB issued ASU 2015-03 – Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for the Company beginning in the first quarter of 2016. The adoption of this ASU is not expected to have a significant impact on the Company's consolidated financial position or results of operations.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for all significant accounting policies of the reporting entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18861-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18743-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18854-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 42 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies (Schedule of Revenue by Major Customers) (Details)
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Genentech [Member] | Avastin [Member]

Entity Wide Revenue Major Customer [Line Items]

Percentage of total revenue (in Percent) 32.00% 24.00% 28.00% 25.00%

Genentech [Member] | Herceptin [Member]

Entity Wide Revenue Major Customer [Line Items]

Percentage of total revenue (in Percent) 32.00% 24.00% 28.00% 25.00%

Genentech [Member] | Xolair [Member]

Entity Wide Revenue Major Customer [Line Items]

Percentage of total revenue (in Percent) 10.00% 6.00% 8.00% 6.00%

Elan [Member] | Tysabri [Member]

Entity Wide Revenue Major Customer [Line Items]

Percentage of total revenue (in Percent) 11.00% 10.00% 10.00% 9.00%

Depomed [Member] | Glumetza [Member]

Entity Wide Revenue Major Customer [Line Items]

Percentage of total revenue (in Percent) (10.00%) 14.00% 0.00% 13.00%

X

- Definition
For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

+ Details

Name: us-gaap_ConcentrationRiskPercentage1

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_EntityWideRevenueMajorCustomerLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MajorCustomersAxis=pdli_GenentechMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=pdli_AvastinMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=pdli_HerceptinMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=pdli_XolairMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=pdli_ElanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=pdli_TysabriMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorCustomersAxis=pdli_DepomedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementBusinessSegmentsAxis=pdli_GlumetzaMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 43 R40.htm IDEA: XBRL DOCUMENT v3.3.0.814

Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Mar. 31, 2013

Dec. 31, 2012

Schedule of Available-For-Sale Securities [Line Items]

Adjusted Cost $ 229,061 $ 293,127

Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax 621 560

Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax 0 0

Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value 229,682 293,687

Cash and Cash Equivalents 227,855 ^[1],[2] 291,377 ^[3] $ 281,607 $ 94,302

Short-Term Marketable Securities 1,827 ^[1] 2,310 ^[3]

Cash [Member]

Schedule of Available-For-Sale Securities [Line Items]

Adjusted Cost 88,005 69,585

Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax 0 0

Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax 0 0

Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value 88,005 69,585

Cash and Cash Equivalents 88,005 69,585

Short-Term Marketable Securities 0 0

Money Market Funds [Member]

Schedule of Available-For-Sale Securities [Line Items]

Adjusted Cost 139,850 221,792

Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax 0 0

Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax 0 0

Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value 139,850 221,792

Cash and Cash Equivalents 139,850 221,792

Short-Term Marketable Securities 0 0

Equity Securities [Member]

Schedule of Available-For-Sale Securities [Line Items]

Adjusted Cost 1,206 1,750

Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax 621 560

Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax 0 0

Cash, Cash Equivalents and Available-for-Sale Securities, Fair Value 1,827 2,310

Cash and Cash Equivalents 0 0

Short-Term Marketable Securities $ 1,827 $ 2,310

[1] unaudited

[2] unaudited

[3] Note 1

X

- Definition
Cash, cash equivalents and available-for-sale securities valued at fair value.
+ References
No definition available.
+ Details

Name: pdli_CashCashEquivalentsAndAvailableForSaleSecuritesFairValueDisclosure

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563

+ Details

Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.2)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AvailableForSaleSecuritiesAmortizedCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CashAndCashEquivalentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_EquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 44 R53.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes (Interest Expense for the May 2015 Notes) (Detail) - May 2015 Notes [Member] - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Debt Instrument [Line Items]

Contractual coupon interest $ 0 $ 1,455 $ 1,938 $ 4,366

Amortization of debt issuance costs 0 320 435 952

Amortization of debt discount 0 1,308 1,815 3,852

Total $ 0 $ 3,083 $ 4,188 $ 9,170

X

- Definition
Amortization of debt issuance costs
+ References
No definition available.
+ Details

Name: pdli_AmortizationOfDebtIssuanceCosts

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph 8

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebtExcludingAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_DueMay2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 45 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Revenues

Interest revenue $ 9,096 $ 13,076 $ 28,596 $ 34,760

Licenses Revenue 580 0 580 575

Total revenues 124,618 164,594 412,390 464,150

Operating expenses

General and administrative 8,450 5,686 23,545 17,188

Operating income 116,168 158,908 388,845 446,962

Non-operating expense, net

Interest and other income, net 87 75 294 207

Interest expense (5,901) (9,387) (21,710) (29,770)

Losses on Extinguishment of Debt 0 0 0 (6,143)

Total non-operating expense, net (5,814) (9,312) (21,416) (35,706)

Income before income taxes 110,354 149,596 367,429 411,256

Income tax expense 40,895 47,361 135,208 144,083

Net income $ 69,459 $ 102,235 $ 232,221 $ 267,173

Net income per share

Basic (in Dollars per Share) $ 0.42 $ 0.64 $ 1.42 $ 1.70

Net income per diluted share (in Dollars per Share) $ 0.42 $ 0.61 $ 1.42 $ 1.62

Weighted average shares outstanding

Basic (in Shares) 163,560 160,268 163,314 157,274

Diluted (in Shares) 163,742 166,894 163,899 165,141

Cash dividends declared per common share (in Dollars per Share) $ 0.00 $ 0.00 $ 0.60 $ 0.60

Queen et al. patents [Member]

Revenues

Royalty revenues $ 119,222 $ 123,916 $ 363,916 $ 355,008

Acquired rights [Member]

Revenues

Royalty revenues $ (4,280) $ 27,602 $ 19,298 $ 73,807

X

- Definition
Interest revenue
+ References
No definition available.
+ Details

Name: pdli_Interestrevenue

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate dividends declared during the period for each share of common stock outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

+ Details

Name: us-gaap_CommonStockDividendsPerShareDeclared

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h)(1)(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.9)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7(a),(b))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.9)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InvestmentIncomeNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_LicensesRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.7)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_RevenuesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ProductOrServiceAxis=pdli_Queenetal.patentsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=pdli_AcquiredrightsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 46 R45.htm IDEA: XBRL DOCUMENT v3.3.0.814

Notes Receivable and Other Long-term Receivables (Narrative) (Detail)
1 Months Ended 3 Months Ended 9 Months Ended 58 Months Ended

Oct. 27, 2015

USD ($)

Oct. 07, 2015

USD ($)

$ / shares

Oct. 06, 2015

$ / shares

Sep. 22, 2015

USD ($)

Sep. 14, 2015

USD ($)

Jun. 26, 2015

USD ($)

$ / shares

shares

Feb. 23, 2015

USD ($)

Nov. 14, 2014

USD ($)

Nov. 10, 2014

USD ($)

Nov. 05, 2013

USD ($)

Nov. 02, 2013

USD ($)

Oct. 03, 2013

USD ($)

Aug. 15, 2013

USD ($)

Apr. 30, 2013

USD ($)

Feb. 28, 2013

USD ($)

Jan. 31, 2013

USD ($)

Oct. 31, 2012

USD ($)

Mar. 31, 2012

USD ($)

Sep. 30, 2015

USD ($)

Dec. 31, 2014

USD ($)

Sep. 30, 2015

USD ($)

Sep. 30, 2014

USD ($)

Apr. 30, 2018

Oct. 28, 2015

USD ($)

Sep. 29, 2015

USD ($)

Sep. 15, 2015

$ / shares

shares

May. 12, 2015

USD ($)

Dec. 12, 2014

USD ($)

$ / shares

shares

Nov. 09, 2014

May. 27, 2014

USD ($)

Apr. 01, 2014

USD ($)

Feb. 14, 2014

USD ($)

Feb. 06, 2014

$ / shares

Nov. 06, 2013

USD ($)

Oct. 31, 2013

USD ($)

Aug. 14, 2013

USD ($)

$ / shares

shares

Jun. 28, 2013

USD ($)

Apr. 18, 2013

USD ($)

Mar. 05, 2013

USD ($)

Nov. 02, 2012

USD ($)

Aug. 31, 2012

USD ($)

Jan. 27, 2012

USD ($)

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 20,000,000

Repayment of notes receivable $ 21,400,000 $ 20,600,000 $ 0

Share Price | $ / shares $ 7.97

Equity investment, shares sold (shares) | shares 200,000

Price per share of investment sold | $ / shares $ 5.62

Proceeds from Sale of Available-for-sale Securities $ 1,100,000

Proceeds from Sale of Available-for-sale Securities, Equity 1,124,000 $ 0

Unrealized Gain (Loss) on Investments $ 364,000 $ 404,000

Commitments and Contingencies ^[1] ^[2] ^[1] $ 8,500,000

Investment Warrants, Exercise Price | $ / shares $ 0.40 $ 0.45

Warrants and Rights Outstanding $ 1,258,000 $ 1,258,000

Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross 53,900,000 53,900,000

Financing receivable, modification, cost as a component of interest and other income, net $ 2,500,000

Financing Receivable, Net 50,200,000 50,200,000

Asset Management Costs 11,100,000

Interest rate of note receivable (in Percent) 5.00%

AxoGen [Member]

Accounts Notes And Loans Receivable [Line Items]

Repayment of notes receivable $ 30,300,000

Investment Owned, Balance, Shares | shares 643,382 1,166,666

Share Price | $ / shares $ 2.72 $ 3.00

Investment Owned, at Cost $ 1,700,000 $ 3,500,000

Price per share of investment sold | $ / shares $ 3.03

Proceeds from Sale of Available-for-sale Securities, Equity $ 3,500,000

Investment Owned, at Fair Value 1,800,000 1,800,000

Unrealized Gain (Loss) on Investments 600,000

Avinger [Member]

Accounts Notes And Loans Receivable [Line Items]

Repayment of notes receivable $ 21,400,000

LENSAR [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 40,000,000

Asset Management Costs 9,000,000

Interest rate of note receivable (in Percent) 15.50% 18.50%

Amount company has agreed to advance under agreement $ 60,000,000

Debt Instrument, Date of First Required Payment Dec. 31, 2016

Durata [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 15,000,000 $ 25,000,000

Interest rate of note receivable (in Percent) 14.00%

Repayment of notes receivable $ 42,700,000

Amount company has agreed to advance under agreement $ 70,000,000

DirectFlow [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 35,000,000

Interest rate of note receivable (in Percent) 13.50% 15.50%

Amount company has agreed to advance under agreement $ 15,000,000 $ 50,000,000

Paradigm Spine [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 50,000,000

Interest rate of note receivable (in Percent) 13.00%

Amount company has agreed to advance under agreement $ 7,000,000 $ 75,000,000

Maximum amount of additional funds, upon attainment of milestones 25,000,000

Tranche 1 of note receivable $ 4,000,000

Tranche 2 of note receivable $ 3,000,000

Hyperion [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 2,300,000

Number of payments to be received 2

Periodic contractual payments $ 1,200,000

First minimum payment $ 1,200,000

kaleo Note Receivable [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 150,000,000

Interest rate of note receivable (in Percent) 13.00%

CareView [Member]

Accounts Notes And Loans Receivable [Line Items]

Interest rate of note receivable (in Percent) 13.50%

Amount company has agreed to advance under agreement $ 40,000,000

Tranche 1 of note receivable $ 20,000,000 20,000,000

Tranche 2 of note receivable $ 20,000,000 $ 20,000,000

Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares 4,400,000

Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares $ 0.45

Notes Receivable [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 7,500,000 $ 10,000,000

Term of receivable (in Duration) 2 years

Interest rate of note receivable (in Percent) 10.00% 12.00%

Notes Receivable [Member] | Avinger [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 20,000,000

Interest rate of note receivable (in Percent) 12.00%

Amount company has agreed to advance under agreement $ 40,000,000

Credit Agreement [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 40,000,000

Credit agreement, stated interest rate (in Percent) 5.00%

Proceeds received under remedies available for borrower's breach of terms credit agreement $ 8,100,000

Amount company has agreed to advance under agreement $ 7,900,000 $ 8,700,000

Financing Receivable, Modifications, Post-Modification Recorded Investment $ 44,100,000

Forbearance period under terms of credit agreement (in Duration) 120 days

Initial Loan [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing Receivable, Modifications, Pre-Modification Recorded Investment 33,700,000

Additional Loan [Member]

Accounts Notes And Loans Receivable [Line Items]

Commitments and Contingencies $ 800,000 $ 500,000

Additional Loan [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 1,300,000

Additional Loan [Member] | LENSAR [Member]

Accounts Notes And Loans Receivable [Line Items]

Amount company has agreed to advance under agreement $ 20,000,000

Royalty Agreement [Member] | AxoGen [Member]

Accounts Notes And Loans Receivable [Line Items]

Term of receivable (in Duration) 8 years

Royalty rate on AxoGen net revenues (in percent) 9.95%

Guaranteed quarterly minimum payment-low $ 1,300,000

Guaranteed quarterly minimum payment-high $ 2,500,000

Term of royalty agreement (in Duration) 8 years

Total consideration paid to AxoGen for the royalty rights $ 20,800,000

Initial interim funding for royalty rights $ 1,800,000

Royalty Agreement [Member] | Avinger [Member]

Accounts Notes And Loans Receivable [Line Items]

Reduction in royalty rate (in percent) 50.00%

Term loan and interest [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing Receivable, Modifications, Pre-Modification Recorded Investment 1,300,000

Forbearance principal and interest [Member] | Wellstat Diagnostics [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing Receivable, Modifications, Pre-Modification Recorded Investment $ 9,100,000

Tranche two [Member] | Durata [Member]

Accounts Notes And Loans Receivable [Line Items]

Interest rate of note receivable (in Percent) 12.75%

Tranche two [Member] | DirectFlow [Member]

Accounts Notes And Loans Receivable [Line Items]

Financing receivable, gross $ 15,000,000

[1] unaudited

[2] Note 1

X

- Definition
Exercise price of the warrants.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 12

-Section 13

-Sentence Column A

+ Details

Name: invest_InvestmentWarrantsExercisePrice

Namespace Prefix: invest_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount company has agreed to advance under credit agreement.
+ References
No definition available.
+ Details

Name: pdli_CommitmentToProvideFundingDuringOneHundredTwentydayForbearancePeriod

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Forbearance period under terms of credit agreement whereby PDL has agreed to refrain from exercising addtional remedies.
+ References
No definition available.
+ Details

Name: pdli_CreditAgreementForbearancePeriod

Namespace Prefix: pdli_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Stated interest rate of credit agreement.
+ References
No definition available.
+ Details

Name: pdli_CreditAgreementStatedInterestRate

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Equity investment, shares sold (shares)
+ References
No definition available.
+ Details

Name: pdli_Equityinvestmentsharessoldshares

Namespace Prefix: pdli_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Financing receivable, modification, cost as a component of interest and other income, net
+ References
No definition available.
+ Details

Name: pdli_Financingreceivablemodificationcostasacomponentofinterestandotherincomenet

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
First minimum payment
+ References
No definition available.
+ Details

Name: pdli_Firstminimumpayment

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Guaranteed quarterly minimum payment-high
+ References
No definition available.
+ Details

Name: pdli_Guaranteedquarterlyminimumpaymenthigh

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Guaranteed quarterly minimum payment-low
+ References
No definition available.
+ Details

Name: pdli_Guaranteedquarterlyminimumpaymentlow

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Interest rate of note receivable (in Percent)
+ References
No definition available.
+ Details

Name: pdli_InterestRateOnNoteReceivable

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
The initial interim funding for royalty rights which was terminated.
+ References
No definition available.
+ Details

Name: pdli_InterimRoyaltyRightsFunding

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Maximum amount of additional funds, upon attainment of milestones.
+ References
No definition available.
+ Details

Name: pdli_MaximumAmountOfAdditionalFundsUponAttainmentOfMilestones

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The term of the note receivable.
+ References
No definition available.
+ Details

Name: pdli_NoteReceivableTermOfNote

Namespace Prefix: pdli_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of payments to be received
+ References
No definition available.
+ Details

Name: pdli_Numberofpaymentstobereceived

Namespace Prefix: pdli_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: instant

X

- Definition
Periodic contractual payments
+ References
No definition available.
+ Details

Name: pdli_Periodiccontractualpayments

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Price per share of investment sold
+ References
No definition available.
+ Details

Name: pdli_Pricepershareofinvestmentsold

Namespace Prefix: pdli_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Proceeds received under remedies available for borrower's breach of terms credit agreement and applied to amounts due under the credit agreement.
+ References
No definition available.
+ Details

Name: pdli_ProceedsReceivedUnderRemediesAvailableForBorrowersBreachOfTerms

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Reduction in royalty rate (in percent)
+ References
No definition available.
+ Details

Name: pdli_Reductioninroyaltyrateinpercent

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The term of the Royalty Agreement with AxoGen.
+ References
No definition available.
+ Details

Name: pdli_RevenueInterestsPurchaseAgreementTerm

Namespace Prefix: pdli_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Royalty rate on AxoGen net revenues (in percent)
+ References
No definition available.
+ Details

Name: pdli_RoyaltyrateonAxoGennetrevenuesinpercent

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Tranche 1 of note receivable
+ References
No definition available.
+ Details

Name: pdli_Tranche1ofnotereceivable

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Tranche 2 of note receivable
+ References
No definition available.
+ Details

Name: pdli_Tranche2ofnotereceivable

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_AccountsNotesAndLoansReceivableLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs related to asset management during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.2(d))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_AssetManagementCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(4))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i)(2))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Date the debt agreement requires the first payment to be made, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 470

-Section 50

-Paragraph 3

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6479336&loc=d3e64711-112823

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentDateOfFirstRequiredPayment1

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Post-modification amount of investment in financing receivables modified by troubled debt restructurings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=49124121&loc=SL6953676-111524

+ Details

Name: us-gaap_FinancingReceivableModificationsPostModificationRecordedInvestment2

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Pre-modification amount of investment in financing receivables modified by troubled debt restructurings.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 33

-URI http://asc.fasb.org/extlink&oid=49124121&loc=SL6953676-111524

+ Details

Name: us-gaap_FinancingReceivableModificationsPreModificationRecordedInvestment2

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Cost of the investment.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentOwnedAtCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value of the investment at close of period. For schedules of investments that are categorized, the value would be aggregated by category. For investment in and advances to affiliates, if operations of any controlled companies are different in character from those of the company, group such affiliates within divisions and by type of activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 1

-Subparagraph (SX 210.12-12.Column C.3,4)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-12C.Column C.7)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 6

-Subparagraph (SX 210.12-14.Column E.2,3)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 5

-Subparagraph (SX 210.12-13.Column C.6)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010

+ Details

Name: us-gaap_InvestmentOwnedAtFairValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Balance held at close of period in number of shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 4

-Subparagraph (SX 210.12-12C.Column B)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 6

-Subparagraph (SX 210.12-14.Column B)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 320

-Section S99

-Paragraph 1

-Subparagraph (SX 210.12-12.Column B)

-URI http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010

+ Details

Name: us-gaap_InvestmentOwnedBalanceShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. Excludes amounts related to receivables held-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10(3))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_NotesReceivableGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Net amount of the investment in a contractual right to receive money on demand or on fixed or determinable dates that is recognized as an asset in the creditor's statement of financial position. Examples include, but are not limited to, credit card receivables, notes receivable and receivables relating to lessor's rights to payments from leases other than operating leases that have been recorded as assets. Excludes trade accounts receivable with contractual maturity of one year or less and arose from the sale of goods or services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesReceivableNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromCollectionOfNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale of debt and equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale of equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.3)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_RoyaltyExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_UnrealizedGainLossOnInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_WellstatDiagnosticsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_AxoGenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_AvingerMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_LENSARMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_DurataMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_DirectFlowMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_ParadigmSpineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_HyperionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_KaleoNoteReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_CounterpartyNameAxis=pdli_CareViewMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_CreditAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_InitialLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_AdditionalLoanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_RoyaltyAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_TermloanandinterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_ForbearanceprincipalandinterestMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=pdli_TranchetwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

ZIP 47 0000882104-15-000079-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000882104-15-000079-xbrl.zip M4$L#!!0````(`&F`9$>I^K\AYP\ M;R?FXEMJ)KM\G4Y-ISN)>T]//TT14!QV8_`(G,3[UQ]QLPW!#B0")+&F:KJ[ MC$#26I_67=(O_WI96B=/"+NF8_]Z*IVU3T^0K3N&:2]^/?WWO#6<#.\N2[@W^: M3UJK%;VUNNAWM+ZN&]UNIZNI\D"Z1WI/1;HD&ZL[8]O/GU]-'S5A?G MY_ZC,Q?I9POGZ3QZ>"ZW):75EEJ*=!J_ML:8S//0>]%3_T4U^:*!S.QWR(., MYNA%?\QN[S_Q7^@D7S#M)^1ZV:^$SS)F8[J.*DN][5O/S\]GP9L.7I#F;>4\ M:A&_8)GVSR.M_YL5.B>- M6J05PJ:^?>_MEY(OK`S+3+Q!?CC3G65`V_9`:<<-,7HX..7N.7D:-W1-/7NN MY$'&3%UOA0^T)T\R7EB[K86FK;;O/&CN?3"0Z$$&*L@3[%C(S7PG>)+]DD^P M[)>")UDO>1@M#M)I<$Z>QTW]!T9J-6SI&3Y,-/4RFW;"IMY^4_,8DFW7TVQ] MB\V75UA^5H+6TF`P.`^>;INZ1E9#\EGI_,_KSW/]$2VU76/S[<:M[6B(49&MLE__;XLM=5?SM,OA[VA&B$RQA6;2G^P.[9 M_AO(-O;:#UI*>]>AL6T=_[;K,OXEHM`!FET%)%/GCQI&[M>UYW/*UVO,$C`$ MDQ>20VJWY.[VJ]&3CY`CAM`M1Q#JU0RA@&8J1S13"]),+8EFH:CZ*])H?]U@ MQUCKWE<\1_C)U-'PQ73_\D7B7[=KA&SD:=;9BG1L>^XU6MXC7"6UMX1$"]^L M#7\+?S1(YR\KR]1-+QS7B6&2-J&Q'$WN(FMRIY?^["X.S.Z7\\R/1Z,Y?ST< MKN5PO(BXT5UJ09J5M8A"P0.+J/9%Q(I454&J,@,()B1$!R0$&X!@R%;-)R&& M^M]K$R,#FXM'P="0-;4&RH;.UZSA)A=Z<$?B-N%7E3?PREX;;]W",2R!>%H[5KVLAUYZ%DW'OU M$$Z6GFFS9_J>$V-2'&DR'%49Q3H[R@UHZY3Y`0C]A!DIY9F%T?KMXVKW6-3 M(*SNZ%`E3!-T!/,:0`H@9$T0LX%P+=^Q^M.Q-!,#6FF@=9^6#72IU'PN%8"UX6!E M(I^9T_\'J[7A5BLK<8"2)2M8K6)8K4S`M7Q#`-(!5`%;:SJ`%7,`'"UN\%J3 M[N(!X@3CR`%1<+TJ_@8G%CL$>`;!9F0?IOLTZ M?-:P\6VS"O?@QK].ERO+V2`T]QS]YU>B@1P.-7IB:J>7\<\'Y]9`BS`EL2;H MWKNR70\')^WNJ=*UAGU;]+XZ' M.-R7?Q`%!^;60%,[E2T&,-0$!A;SL-E6PATB-#1U#QF!+N4/"`YW%. MOHU<_X`MT=1!YLR:*0<@O%RWF;;(_D+`EOFL8D[&G2JX/`2HRS_9HSA^F M2J3JSI1)D/4H+FFLAD-L::#*3)?EE+B$@A5QL\;ZH^8B8ZQ95AC1=F$QT5E, M`;8/$[@ARXK%L$05FDF,/%@5RH:%K!H#5G)=0$WH>@#GNRTAX0`9W>CW3;,7 M8VUE>IH%'EM-'IO:DJ26O)LT!8\M=,KE/2/A#GEF#J]3)W>3%6N^0J!"N!'"C0U85F&2>Z\VF7#W4;,74)U<7ZZ[+1.[@':N6[E5 M_-GD9N]DC?8,),'VJ;V>667L55KM?AD);HXR<>`.L:T9P3&J,;(`CA%/CA$K M0*W!@X@@4Y!9/A[C\O0_I"A!=&5J5M9+!.^P8ZQUKVOF"S@)U/?DU9#'5EW+_RA M*6M&\U-JF&<2[K%1\O#]B2PNA.^C*JT<'HMF:I4#76D'/FB5[;I MF<0+X,%R5UIME;**R28&A"H8"%64P.TBH2@07VR&FZ)H4XQ/M-(V_C"9E5_I MB,V@)6]3/_DB-C+=5%%^<^S?MOF$L$OFZ#QY[:U'"XNC8:#'_H^@C5=O6-F60[BLH"0SQ2^)L@>X6K((A,%E@%0?LR M+I-Z3S)FVWKND4'XU!A;FNM^?0AJ4W>O?,,$!(](X@_4%,R=`KT=)&/499*. M/">.BO@[D!WASQ>Z>AU9!U8SP.HP":"PDK$P5<3 MICI<_F,$#*_BP*!N2RZEK)V&EICKR-9(][OFGYUGH3A>IG+8IU[4W99\/.N$ MT_/Q%.:UA_W'Q&3\A*9":V;:[LU=IS@P8R?Q#\6+XA5$H) M>M)2@_G8L4MY'.$'U_E4GO#/86Q):/S7$*,JO:3KX_B/#*[PM*8#F658#.]< M#$>(V^254<4N3C@07`R>TM7VWY%ED8%Y62N2)Q!0D$W'2,&]CJ2+FL_3+_/A M'6#FXC`AA$),,YU?\#'+DA^_:Q9RP,(N0R(=)&V3[6L^/,^)B9'NS2P_46B8 MNF:!@KW(11.PZ1,XNM&P9IB+Y7QEVB!7*0$Q@Z@@4860J+`VZA?2@J^6*N)[ MM#,_#<-P@30-#\C8MR@$OM"-K<)`;4YS\_!R.-S9\%!A?:%DB&<.%(,4$ON+3C([YX+%$.P93:RA`$CZ'P82%# M#H?U'$X5%F7!B`O8!_2".&`AE!8O_(;PTI<`9P)!+#6G1DBAR1I%5Q*#^#F& MC32=0.ZPGL&">#8K\6P^/%F(V[$4MV-))_+$?CH*C(?53U=;0!P+XEA0"Y2[ MAK1A^"U:\,D;1IKI[('O5O<"UR%Y]),L<:CQ.#=]@)'MAF:5!1/EO,J#@ZEZ-1//$`<2U?H4 M!<^LQ8'`^FR&],F=$$5>C\HBC@W\'Q%43#6W$?2QO_+;_>D66163<#"L8DW6BZ`=@"Y`-I!S+HPT`X\:8G]5W&`O3-78,Q[(T/$>6-7/PLX:-,?D:UG1/.I,[/<'PD7?" M7%N/5!$P:!H"!H(@('DJ+R"`7014457R?@3(?2F5C-Y]:W>ZZ9WI_DRFH!V, MS(4]?=$?-7N!HJ\V"DI;RM%*1Q\C_%X2^@CEN<#:E2!+P M;&J)UT#,MND(`+N6/P1$2=WHZKH[M-(V_C!W13[^X9L(KS3L$0(M7U\ER!_/ MLZ:4O,&OCGSNH"7+Q?*YN_8T$GBA))#&SA/"\T<-(]?_9`X<<'X<_!$TU'G, MN]IJRRU)I;G4?0[+MVI\9\S$U!:VXWJFOK,Q/WZD\1@CP_2&"XR03X.4H7L8 M11FCX@]+%,XJSJ0?+7/W"-8/TK\RQ!.X2P3TM)4;L6Z&+\YOR+[1-L[#0PXH M3M98\S3^T'>$N_M3JK0NA;!44@K4I?CM59IJ+:MJ#:0<2+E*I1QKM7MA+%,> M$ROO#Q,]YP!NW)0_M!Y!0W)2548GNRVY2]NTZ]RJ"8-U:)`E1DBA66#$UW97 MD]1NR7W:G%9NY[4M"H%@I^W MR*_>PO8=^NI-_IV8!$X.#`3MLN[`%`0,!^=79?96W1,.I12@"NZWL.<4E%M@ M>A4)\R!3!UG*"N,:4KN,P(3KR6FP@FO/L[)H2BH<6>R0:3FIX&C*M:2M\G'X?\.D[2/RGIW< MP.?5#*(`_#2U*H"\:!;:;2X+C5?ARI[L8N!4PZN,5(IC&3*SN92TVTDW!QN* M M;?]#R:R2J^ME_$VOYFC?5'S44& M6'Y5ZK9^";O9B!WWF4Q=PQFUSA\7?;N/^J_S!P(*TBN+!-4F6>0!?;UYI,(4 M%&;=D&NXPNP7V2^7JLFEI3#EW0J!FESVEDE#:W(36X4)[NF?@[&K$/4-12@3 MK3XX*!<\!(.T5VA*OP@%D]GUD$S(R!D%@X0M;2B$&\';N:&0:D]SXWB^%`$4 M<0B>,)!#1W/FX'ND^7%4=C=?)%VH3@FU]R6[4'M$7F&3O+;2+,TV3!^BR`67 MJJA+E8N>XAJ.K+E8DV16Y@:CK;'!K$Q)"64_H=$M()03[E5WLG?)WO1F>F?W^KWYD$1U.K: MUZ\$E.#\U3).+@S#D6>Y=OGR&E1B(FJ3WAVVB\%PDN(*#VX%P?4>P?6*=N)* M+1935X<#]"#L&A.BEG=;!F&;8-4NK$39WSEV3$D]F_HY3F5PNK%?L,-9MJ=3 MY#/&(1A#]S3$(G'GQ*U/].IKX':3"G<[IVLV]^\WR5.SN=^^DO(@V!THP.Y` MVN5'Q<[M$$=9]SE9>`,OPJ"0?X!YA9Y$6JJ#`X5OVT3"IWH M;IJJ];;-"=Q#Q^H^*O\FNH()89EJ0KB8=0418X%LJ%=UKQ-T'Y0UX[4_P?TX M#+K6-GYC_CC_>D[;2$QR4E6Z2&6<4J_>2C-T[U]I$MAK5ZZ[1F]REKR!UQK> M;%\3B,$'YE89GU5_(SQ=5SA*"?A6M6^/O\G>N.&90&Q-S:G:B@:Z]2E12#02 M0^'5*)Z)WUZV()"I*^-.067SSK8X!#[MV?EC37+^KKRS7B1!/?AZ54+ MB;J/.,AMGZ5$XK;]G68ODF7Z(T+6.S(N@=!21!\4Z&]+NUV!?I)X/-N+N9&5 MMJ'BI;E;F0(A*>]D>>;$-M32&3AP%FHR%E(Q0E]=Z'(X4I^>^KW&^JGD2JWBC]_`$0=@$B?X4WW3M.K5VH@%X>)_[ZG106+3+R>664<3LGU MLBY:RF!K_.B[AK$6[]3GG:/QL\2DFA58>'>Z`(0X-ZF"]]CR(,$%MN7SQ'Q` MX/,0P\D=O;O6L/[HMXUCI$V,#Q\@`L2)WVGMQ5*VBJGN]$X=U7/`8TFQ$I[C[:FK$25 M4I2HNA]$!R5:FQ)-K&1Z-QY27W#1-J*0A"`%2-`"C;^=W(C(&Q/_7B)=^2M MP=;F)V_]WKI5D/S0B_ M9Z6DS9(Y[O>!JH;&W&1S!1Y??2&OE/]&+]"3R">"A5#C/H/:DZ1AE7(B\NMBN6'/$MI/^)>)!KJ&@%D:PT34]NYBW%SL8T)PM]%`GOWF`^WQ][Z*_ MUV3`TR?RQVLID'S.'\\/3'!/$F3-L$+U7=(1L3^*OQ(_V/NQ_YL!7 M;Q">/Q(4);YNF$^$78FY^>]\62\1UCPG4:V2=RS_2(PF]:F]3B;(=I:F?;B; MB$G^H-TW^TE_+7ZVF^%;-++7KY9&]J=P=3B?]\6365[N=24\:]OJS M65<]O7S0+)=,[-7'MUV.UQC[OYFNKED_D(:GH6#+T7NW/U,&LXG2EE5Y-!P- MI;ZZ[;T_4:73RU9L61WK:3N4B:,'T?6PQ4VPLF;D-S?/6-I*9]QK2[(T4&:S MGDI:#>*Q=-3V[/3R5@F'<;"7`^/P1YIW%)WQI-_MCF8S>311I)':&4J3>!3# MGMH[#:1*UCBVO;P:13C"_%SI=\>#WFS4D]21.I$DM3M4I2U7A@/I-.'*'.SI MU3A\X9RC>W4\E,8#B0!`ZK=[2J>G3$=Q][W>C$"2R-3;9,?^I[?]30,A/28_ M8\VZL@WT\CO:Y.AXT&O+2F_:G1Z8B#=7))E^.MI>V^XHY$TGK0[W4%7[;1[ M$V76&RGQ<,>$=:GES>3SR>CJ MZ\VGX=WU\)\G5U_&9_NC2?:8&LX?CK6VB54:CCF7^!G-E/&4K(/!A,C?SI0, M8HLI59&($/SB['>?ZB'5OU^X^;OM/-MSHK4<&QG!D7,XQSA&E3:W<6S7_Y+O5GI?4JE4]?JLBB7*DE^J\A$&!A3R0(P>`%)B M?GUN#V;%##@`"="$8EMEB<+2Y_3=^_8=5*V#,HUZ\G+@JXH%+58/V6;[;QZ, MT\-DNWC(/N:[7,K5TKGL,]_M1%^0/'?%A5A)%(!\^M1#%89+FM/:$CI.<) M+ZPJW:[`"WI"Z1"B+'@6,8?XS2A%<85;"=-S"6\>\)@/M-$Q18)PR"E(C062 MN@:L?>SY@C,SY0KVHI'!4@*>GB+,( M.BU=;70@-;E*5:Z]WF%;BQ0'V(;9J`ED&DX&7\'VFM/KVN?:2QW>9O`IX%X< M98S`'D-"QVB%%QOS0KSOB_\E3UA>4-N$']EZNMADG]:+:3<;]MUSBT^`LJHM MME=/6HLG.E*#)#*:0HB&(\3A()K&$H84=@1W%]_4L]$[QFL<(VL\`YP'@).P M%._\E&\.XHDIV><057L/"93#TBD,>!S$GA0KJY_`@T["LWL2^EVJH_QOT2IQ M,R]ZD%?I\$(HYUW/Q)"= M@3EF]9>'>>ABR<$80<*."F4Q!C."!+6^M"R>24)83],X%6\([?#EB4-8G3(: M02[LB7*0.3%&RR(^["P-3O8J`^R5H!YSH>!H^07;XY5$WBO$,98":=/(K[$] ME)J3-P3S5/F-)$!(0!&$?"B`*!OC5"6_VN">MF+*U1N">YH`"VVDAPC/11FC M50I1(:NMY03W_IF$)YL M?#$SH)^*"&:P4HQK)ROA%0'U$E..7\75'(GV--E%)&CFM.?(LL`,$IC':E-9 M*I3_%9MZ5L,;.'=22Z9IU![^9<+@"J'!M)=N,\I?:3YGG0%VM[B?+ M=?XX66X?OTT>B]A\\F-Q=W\W?WIL'Y"1*N^^GV!A*N]0,$U`W2XG4# M^'@[9HB04\C0 MEO"2C5G-S,-DL9S\N4Q%QR_PTR_9]'Z]@!V)D\7ZOR;+^\PO-M-EGGI)3CO_ M"@X1S8B13!'M"O'[_V'R/_DZM19L=A(& M'YZ^:OM8?B2(>J?@F]8"K]E;TECX;"72#!%.."A"3-F@K0AU0N->^*RYXO\_ M^-S_R[$X#G(K$V*P6`<'V2682UTQJ33MF1-"VX[_9R;R0[[*'C],UO_(MO%^ M-1LCTO(((AFE!__#@@6)*[L2@$@(CGOE0$*PU.1ZJ'SJ5`-[KC3Q#H,7BJ"+ M!E>E4.HU9KUB-R%:J.O"_KKV+3+A@Z"2.:),X(Z`4-7"1%"O%`+Y%[HB^_82 M/D^U;U9#+F,-4=[J@!@WQ->NE^K>T2!6Y(H<[TN(/-&^11QQ:G)2)$3A/>*, MUS&,\FR@NJ$5OZ"K^#99S+9Y5IX3`S,/&<2V\$FK?*]A\WQ/YSH4LP;((CW! M$(,8XB@0A5C8Q>1(":QZZDH907O4/`GG9Y"?QO%"U+#E+EO/LN7MY/#& M$,@1II-!,B`H&UE+T(F@N7AG%\_+*UE7>R39+W^B6DPV8Q*)7MS44 M9W?KAX[LMHX&1^8I08X+H95D-%CC+:&!J.AZFHU1-QT]D:="!1:K.1B_AV3\ M\OED"O9RGHUH/R6/61+^CE?+N>[ M4^:3L<40"(L"VR"-!^-B25FV<\1C)WO;]$QHO86VL.9W=XOB;/2/'/0M7?1) MP<%B=>O!+Z]N;U;9K_!G^,0_OL.+'F>31_#85&.UC48FMNUUFA M]GOFP*5/S];?)NOM8^KZ;MXWL+01HR`<6'^CM5;86T]8<+Y,=XP)X`-[[7JZ M8Q+.0/'%-XR8!WASB[\7[4_U(<6;F[\_>HO*Q8QLB]2,2!Y`;P2S01MI(JJV M)1K3(VN_A8]? MS.>"CT6^.J.];J[G#SS1[_#.[-8SL#.B79#2D)3P&"*8`@DAN@Z$5#L#D>XC9I,<9K'SSC$J$5*0-7!OC&(,"4]X:I6D0B("EK`7!,F?D,GG M#?`XQ"CX"\VPP)I:*A6$0R"B5J>[IL9Z%'H&\:H8'6JR.8\@1H>%L0Y,K6-! M2PH!41U28LO[@GA5IG!PI-P5I;"0O:K(&:$&,XZMK_M/4PH+&]<[8)*7W)RZ MY%LFB%6=K.C'-AMXPQ0^9G*;W\HB3`^WFR$J++6&204:D MB+?$XZJZ321M!_C5J!/\KL72.E*PT]<9VELK0S&,>2(8Y0:3:(U=?`) M<17YE__XA`GR%<$C!!VDLJ@-S]ZGA6:;[>?]"1^[Q["Q@06_;1H/"+&3Q@8L MHXP$<1T\LS6G`?+4`2%&[](S9X]CKB$Y:5NHCW$VVWS[=6]NP2N1VV9M$$`77[/"EG9_V/67N66^@($(N\]8)5=MS:SMW$QHY3-,K-4]BZW,P6F\)@S$!OIOGMJ@A9\U5U MZOG*6F*$9,YR+KG$RD299E%4LL(@9^V5^]2^FHS@&0:?7KJ>9;-M/JF#]G3Z M"YYO\FVQW?/I`S04\TG.TC[<*7Y&2#TIYJGRR306*I17=9/F!-L_X],]JW$T MPC%B9MD\6X/)W4Y^+!>3/Q?+Q?;Q+V)%8N:H9L(Z)]*A872D8@5\2"]^QXB- MLS($KTW)=)U!>+18[68O3:KFD'F^ODT7]>;K_&[W5\4?LR-B\I/'/!^\"6(D MHI@B9IB(RA+*RAD#7HK@.Q%S-3F*$](FY%1P;6)VM/TQ^9%M;E:?RC!RYB;+ MY6YV[R8U<`]4NGJ"DJ*CDV6E^L+F^\;<<.3@@Q`/0=K(A%'2U`TQGO6;N#': MLS!'X7T90:?XFZ$/'*&`$ZZ1,CR-9$)1);572,*1>_DM>Q,"NU6M17VW= M2=(F7\YVOQMLK_B1_RU;[>:7?8%7DD-3TX(.E.DTLTEHCSCQ7'MK!&'.>XZ3C?N\MEBOI@6]BU% MLY/-9`HF#YST:IO/JR^:K&9%F`L>*H>/S(9ZJ&B5<]3? M@8`Z,+E5HL)PZ$4EI--7=3X&VJRN06!W45[9Q3-`#_[UL9A'NRI>_FGWNB,8 MJMXVUFV`.8B25@0LJL56NU!-E3(0UKJ^(R9=6GH0VOA^-*TA('%`T+5BL=B4['=R:-'K1``4;16N(8 MIM(SJH?5"JL:]CBR%_)PKOZT+_`]$Y"#EF``/4^SPU,YGUAGK2!6&8^-UM9` M`B@ML2P>,CK\9V#GMZ%3N.YU0(14Y)IC`C&]I,)*8DV0(#@^$F:'R2&O3$ZI M$!DHY27T!XP%A!^6^:B]DU'#?TE_`J&"(!'",`E(/XN$O]U/BI`UF_T3?@?6 M;OG8-3E?8<&]Z)3\SG81R!FK:B5!IY?5=BL9-<562<84BVG,,PO,E3%=.J<4 M_:;9KH'/:<#*V-BU@=8JMG6>O78KRGG+OB,:6 M2:*=Y8S69!M34IV]6:1F-;/OHTVQY-+^Q[+U-(MD(@X M(LFX"'7?A(@=W6F,/&[(.\S2,[C<44DO=FKRZNQ29:37$$U8[V6$?#[$NLV7 M4S=\<(+)Y=A](O)^F^VY;38MC1IYG2:+2`&Q"):JEE4GR0%9O2B;]+=4_UL? MUQ%ZJ'FN.QO/!>V<$)$IPIS%FL4Z@PUXZ)P!,')^49`72][;NPLYF3.!":PX M8D$+^).JD5-Q(%V[*/"R57H.$:=:9U$L=9*LN)?3:!P9^2U?D&12&3RDQ MD:_*WND0.S>.B041(>G2AS=*$^I07:^1P0VGGYA=T"M#!.?RAW(8XL:W_<:S M>[TZN::WP27OZ!#"R#.B&^4GI'.[K(687A0Q^4](4?,C8"$3$C*3>W3HD3R M`-P+*NRY6I`[-^^\(#@22I3W6GB&:&!5%AJ-/!"=7!CE+CQIM36=*4Q1VE)I M*&BJ3_`X41958%W@>!BL>A[8=?:0K>X'VF!VO:W'7+HANRA[4GZ`H%EV,EB*(>R0PQ@.WMDX]TTC5_M02 MM"]CP]PT!):-7;N1U#?SIHV^&`;R]V_YRFRWD\4J@;N9?U@L81?R538^YNX\ M[>,4*4*1AGP1>8BS,2*^CBE48+TK(:3;/OY<=`T_7;OV1[:^NYE_W!^P498$ MK['FT=R5PPH+@:E&Q$(Z@T`UZY`<.Y1Z;LE_E[0>(N59M+U9I6S4$#E-4A4H M`#TA8L9U?:/8:&J`&G4:-;.;/Y>+V^)$VBR7^32=_/^1M[H]S&:3[4U%>$[= M>;0(VV[OD(1S1:/1ABH-OY&HZ=;A#/='E[5F#IP`JL5$$57M M!P@6N5DVLX]#73[USUZ/F.[M)R6%IDX(XUB@/()"\$HV)/?M`3]5ZP\EG@.9]&S&ANHU2U"[=6#)4%NBHUO/8&X:?6 MB71Y5EW-.SEV)E([L=>*.QD=+)H&#-;0!5%/=@H8#=>FZLK4$XMYWHI3D\`T M6WYN1G8]T1Y0O/#IND4@TA'M4:J\4^0B$D):BR+DN9`>Q#/!6^2SQ71:/E[E M/G4_[W;P]?NF)(+,BU#G(X.8QG'*:!-#"]J?_-?IFWH"2@MOZO>'Q13*G#K* MZ@;'?#DH@F7')41E+\@4VIL*R94,LLB3&8K8@*6I;UF*$/>RY.:!*/0=JBI2 M3X)X+M:Q[M+.!25.!95$"(&$089JSY`U,@BF4.""'<+`WPER,H;=8?@N+V@? MF7^:+-)'O_:!?WJ&E$$$*R;`<5AJ77"5>T6R?_,=MR1T%,RS@1^H-[2-.^64 M:K`HL'7<*VV,U[8^MY?[F_:"A>?3+)N5N4\V^_MJEIJF[K)9&F?9&AYI\_4Z M_PX28-?99/KU9IXB\'XU4[W"DGC/??OX4K!X88;O#_ ML?=DNW$=QWY1@*[JKE[RUM5+8B".'<<)D$="'-E,Y*'!);C*U]_JX9Q##OMP M-@Z/2$J"`-GBB*RM:U^\1*T*#5A=*HYQG$K]]A']6!$#R1?A&$-+<=@M![PJ:ETB0\@>@%T3GQ`@U*( M*JA:2\L?MPEOLMS6N!4=J\U][EBI25WW1;`Z<'WKU/'&C1@@YY"MJ,'BC,8: M4RE""W&SV-A25,=@>C%2/#>2VV2Q,#(XQ.HEK"'DY**@I-B6+#%LSV)+)T#K M\*VS15S;2#EH(VH],6#Q=E"()NGCGM>$V[$3SAV*&T5O%WGNH'/`I!V4@.-V MW.IZ.&$?>CX`]*=%X[9H\XOE@Y[ZB^7O$V/P#5X_-OHU1PM?189\GQX_J*H= MA2TDCJ@+7ONZ/JR5."KS1,$"T>Y)>+N]^O+@6Z[KJ]=.R^(K)-MUBAAB3 M>(WB.QK..D9=[$A#5/&)R9<0ADS7GH3J*=L>_>#!W8A]NC[[,$P>3J6_3NZ= M40@NHIC[&EVFFGQ:G_`3;R:[T&VFWW#^]T%B&N6)DLVV6UAUM9I.'$CM?8Z! M0PO`5@T!;"5*Z_HZD`(:,PWH01"-=!Y/2_#G\3__?+&X.A.L/Z]V8V^D_L?/ M?+?\_798GKUC68!@)KHP)_$]"KL`.OH[1R2?&:' MM%JDHUA`1^VS5:D7I5G@WLY;\P1SSEH'ZUD,>]0)*/9IJ5D`WV=V M;W,2&BADB>*%XL:I=@./*K/&UEJM2W@RDGQ)+/;30:)R3+O`R$S*1`D5G<%! M![%V?=>6VSP(\I(8_&-YL1I]NOE\^?'[BP^_7OPRN?1CD,,30#2GYB=KC6A)Y]L=!]?BAP*#YG>. MNAS#][)D/U_>G'T2D*\O MSA=W:^A_$:HN/UY>/;KC]846W8D.P'::G@"BB@`9RMB]5*&OCT'8[*0]&+\' MI%EG*"\_MJ]?O?PXPZ8'*4Y[%4^1&("#YACK.*2B0NY**H\.(#P%_%'HF0'F MX=^<#DU73%4^D,V1DR)BY<5:!8^&VHK#_OS<%T'SM/O(=0X&3%(E&5^#.*3M M6(,J2D%@=+XW"B^)\SQ+[:%D58.\6-UF&536U*ZP!>-5$HFN3UWV^2(8GY;9 M5FQ.26WA8'0D,NYJ9`Y1K*DA+U[TB3#'+Z.E)!B0U^L$&RTA.GJGP(ZCM-YU M$<&T*'?`'X7>"VJID$RMX,01!=#562V>J(BOQ,.$-?1^PY=!\[2"FR6\2ZY8 M1]HHU"IY745+H4_)@W+]W,]+XCR/EHJM<30F2D:UQS^UJZ MO;KJ%DCO2CV#X@1)J=;8"RJ6:"$."0@6+O5-0'>##MMA.`K,;7D2>3?9)'"B M\25@,HQ"SP%,!;73B@;A6##O"S1_7=P<1=,`JAW25DS5`(:H/.4QJ>-=%U<, MT?8^D#P#Y*WT]:3DG5:L61SDZ@G7^YX;R(H[^E(P1X-\=;LXY\OE[?7B>OV) MN#S_Z^7RPS&T1G*&"Y)6NF3!P<5R1^ML1:"QTZGD.OG=`<^SP=]&=U^;4I3X M&;-XZ:A9KY^?@!]MF.@>,O8$\'^WVNNY6J1[E(1GV^K9NK6F.=:FE,PXB$L& MWX&M<;4?O`.[A^-8:+<1645CP9;8\N[)DB*.=X/L;?F$KUW^\5@X_[)>WWUQ M)%5C$2()@,ZI5J@D-%@'JH;-X9"[8J5WD\+0PW$LM-NH"@U&Y)JX>J\3`OC1 MKRX^+Z^FY@=7$LA1F+25$EDWP[!Q'2.A.=:I#XJ7>N MPR2!GX#E66!O)76(Y'+5[:7%=J`@USJ`W38T],TX.CP3[I_D[X_5R35C0)U5 MBMCZ^$6<71XWG0?53YDHUUO`'HACP-Q&52U*#%7.;6&!P!?(E!%,2G6B7?\H M,&]_N_W4IC]_:`N5VX+]J\6OB^7UQ7\7=UKE+Y?7&XWE?S_[M/C[0K[9ZD7$ M\W_?WHUMB$']X>//CWMP=_%")PJ@0=52/&B%E=85K^R)(O:U%]L9]E,C,#^! MMDE!$#N&$&HQ!"F!+S:$@4!J,H_26;+70*!T]R'YN[N+Y]??+>7;_>GL8MF^ M6J\N?TMGU[^VU3:KD=SK\O'CXL.1,L6E.*<])`RF[?P0@UH'D@67^MEH\G0, MS9Z'TVN@XC;!*UQ8N3:#)[$"E-:.X4_NZ.NI_G;T'P""=X\L MR30@QP&[C=PU.R:,8+QE%^6S:CT_*()$$QNIV[8/,NH(8`?%??WSY1/_X.[* M1QHN++3A];%&ULIY,R^UX(SH-,>LM"LU&N?'`476H2L-$3XBRO,1WJ3@;Y?R ME?^MBH@_?&Q?SNOS2#]>+7Z[N-UL6'ZP(>M9URPWA,6X=L.(:L2J*_JD0(_Y M`RBYO\JCU2,MO`N'F3#>YY;5AM^CJA7SHV).SA>CG5LOHK(L>!@&75]R7"5'/+^#[('Z8 M@'/U(4??C%\-HNZS'H;06ZMFZE(O$/'#9+N2A$HY M:._:-G%M2/R[,5L>314B4O!@8AKVK`FN?B*]"AYH=A:_ MA-[6-E?C8+;@-[>7-Q?O'IMB5A[A-_$N!] MNCU?G*]2,!(PW=ZLOU,YNUK*][D>UOK<[839Z2`_\Z?PY^EOL,_ZC9UO8:WS M'CR$7;VYF"F&&D);-2V.BV"[9HZ'`O30PHUKX\9AC9/2_9UQVA?S,'E`%)*7EQ$S!,Q>V+%>!<<.O;)36P_--V[LR8V?VC[GBP\W MB_,5/[9SPJ:BDH>8C;CYCH/H*A@YX0$F./&-#7NQ8;^5ECY4<+6=`H\&@FU+ MR7B@OS:0IW03XAO63?]ZKU9&XF.=4Z)DL?I6="AK)UNLC"TFO3LK,Q63>%VL,A>%M.7!3;^OM6IFYN7&0E2$O=H6B"E:;MD*A-?N,;R.Y M*7O_C0V'6YG3*S6VN@0Q3%2@W68EES$/3X@0W?LR3_1V@J!],B$;C*Q)B7&* MN17J(AL)@=3`R&"BFF#D_9[Q;XQ\17X&6E\!BT++GHTN$=08S6(@_4YTZ8PL M/-K!B#YK+%0LMJ)W*:EF.[""%4SMHS?X[46]A(?!Q9F:DX92F+E`ZVX=])O2 M./4JC*-OO'@1-^-0XV14:GZ%,^!)W,1DR>CA'06%DZ%34-^,TVOQ$B6P8E5\ MT1Q-,EQMTXGKQY=@\O&!?[.A+[WC)(;PR^::HCPO]H%5>WVCFZ@F.?F-A2^4 M(P=EO0XE5JLI1=%W]ZR(6D]Z[.';BWH)YR*4#-H&+[$3^FK8(IHQD423!22C MW3=>O`[KA.(/5J]BNQ95BV[W^,:'5#G2[#JM76O[_FQY]LO=`NYM!>=G7*3= M/'BIBM6^[:Q!(&TL1QB/$'IRW9!E[UU-`/V26!U^JR/HUNKOK=:Z:H?B_WLS M'E(.<6*PK?-`]L+QP'VLVA46G];7XB#6BLJMD]`QNAKZ7HQ@4=,$7/M!LJV7 M7:B0G"+%R%@QUL1K@Q+9`I6>0`J55;`?*$>-4&)5;7"E%F]$.%%1Y7%7;;NU MTO63$OG@)@":'#[<#M=62F45%7D671^%3T@6Q@GV$/K35EK9KJ-Y!USC[L/6 M6O/I\OKV:G$8[7)MYP840&TG-*F`.&O#(D3"V"U;,%["*YJ`<0*29\![REV0 M4]<'-KIRY<5SB0&+82)!-[0?>$5S`-T4"W-79UU8P!MM6%E84#Z6: M]3Y8(8&R_:X%JUUX4P38M0^44=2XR]F+ZJC:0#NY/A`@>#5QQWC4W^@%><4VZ3G+2"(_'!EX`WCF?K99`)H")Q7%.)952XZBY M-,/$F$SPDQ;Q]9)@U[-E%[W.E:V8$^Q(:WWK,5XZHSI#[&0*RCX3[%"#/1(11"+X_ M^_?E55MS=7W7,1R7YW?C>T_$?&U.6#[3_FB?^Z]`M;S9U=?L36ROQ>J80F71 M("6E@;)APN!_;41]_,4=Y,S%EQQ58O(4#1K,ZS9Q(2=6^B:HJ\]?+A>?OS^[ M^L_BIMXNSW?1M(`UV171`*P]@,Z#0Y9,DKBKT^QOD9Q;!Z93)O$P;;/8S@<) M3V(=\!=?M3^=]7BYVALBPKS*+RB=,+G6Q%&5"2F7X7:1SL[TKO[71M1#E5^- MJMJ"8$L&K]K]]-&6V!JZ%1%?I:`>J/RJC8DSL=-:*]L6/=C1\^%:INZJO#YR MMNT71WI^/BLG@4U.'D@777)8!W?-H);Z$LI_`]J9\)]7[S&:JJ)A5%5!(17B MNJ]:+$HEZI*$7QM1#]1[6DRRA)UH,D`[`>^XQE%&V6]=8/@UD/-`E9?`ME,N MQ(8+9U.HAI&*W0LYM_AY2"*1C!(VA)F8CD?R`?W)]_NV-XC^OR@.M M`G#)FHM05FQ)@'L[$M^-4,VE\H)W(:5@M(TA),M@-0SDE/#L)3SG-T7.`U6> M+[JB,]2J=MEYYZP:I5.[?@_[K.2\_VY[ER96B<35&>SG")FR)K7UY\%7Q4F3 MLN4^H\FU/Y6B87LVY?XG?U&$YZP,B%_2MNQ4%I\$LT*H;BSFU-I/_W]=U-M5 M5$A!!R^2%Q-YB<$R6SO6`JLQ_1F,&23PB;+":9Y<`4KM<&>HOE27K%.DQ]J? M2OW:,8_N+2`\YY.#0$!DE49*$J%K*N0&&J(OAX2L[Y!ZNYY7P/7>D,5YZU8Z+%MAE9@E;V)!RKY8C!#'A*(*MGL^L M#?X&7"?#95XW7(NO&&Q%864@KZS\&NLCI?2.C@W=DO!A9B[K6&(0=GM2?*7QF5>_2#^5?3B:(AS M96-&<5!K&.-*[J_0MQ;!+Z@?9HRX;3#M-J9S$A(Q1^`T5`%UKAGZA7.MT_1- M$N90_2!JDU)QT1MTT=44=1@5)_HNLS/5^W12TFQ&X$=U\::<(01PA4WP6FQ@ M56KH<,[E67'')'0GQVQ>K:&$/)6T;L>FP#CM8KY7J\5WACW*U&'IN*$4+F=>C*.H$![<0^Z3?BXZ&T&$FV]<.#% M>GJ7$71J/49,-0]F,]<*D+U3SL38\C_B=>"#;D,/G?9]#X0Z M-#6+:,7::F#4!CT!:#V\$E5B5T%^/Q)UH#K11,`YD2U,%AP8+*,LA7)0,>\T M)%J5`7YZT.JQ/DWRU(*_#)-.KNZ^GRQ M_&654^O%&K=YE,EAQ+;HQCH@:R*O+[2R$1$U';>"T6HSB-X+J%.@H?\&3P?0 MJ=9H4O"))#`V(9J``QJ%2Q]`>[#*?1D\MCGXSD']?_:NK<>-8SG_E0._2^GJ MKKX%2("^GABP)5MV@OB17HUD(BNN0G)UK/SZ5).<(3DS'`ZY)'CGX^.V]I=[TBPRH_:D3+C"+.PV MU/70,2[=).%?`IL336Y@#E0N57_,R)62`"[?GI/6O!FL`RN&!8N*4O1ELH2HB(7/8IF'1;O*F;.R?TEX#A1$SC+)0JO4%B!,D2!FXT4Q<76KKM2IYL`O!0L3VGG/?`B M>R(8+"@G58X&0&<"17*KFN?3'#JA_FBU>*PK\)D!N>4#OY&8%(N9-#%*"GW( M!C6MIDQUYP3\$^,SR@!$$BQH9Z+Q0.%7,&%;1,'R4+WFS;$]K<3BU.XWKG52 MGILDC/,4'=E-1V$!@CSDL[7;"P?DEA=!(3KY20?(QM&\-8$=NW'S:SR][.WTT__K%,?U;SN^FB^FD^O:N: M3RXVGUW`'H?KB\');:O^:UK]8\10K/I+N]++=Q]0A)$6+0\AI6!L--:9>A"6 MU/#&$3N M1&2:8]0V9LLSK\'RH/JF+*[&Q^S)T-,8W0?MX=.GZ7HO3>TX-*+F($,;>/U7=_^Y?SZ5BE M#+;J)AL$3?8)21!]R"KI9L$W!M\!%K?+:CWD.V[406F;+)-U&8):L0Y1LTZOBC$;;[E79M1!M M#HY1=AE6?CO,BM,FAM4@*1ZRYRG'3X;)+BOJ]JQTW_%V66$87$!! MEX[1X?BMFT:GHB"E%W4J7<]L3\`RI-)P!SPRL-Y;$4/-"M/MRW&-4_EI,G\[ M_V59>LE6?G?]?4=?OG;9X"BX<$ZXY'DH-M34T_6$"%'*@1.!7C8.4?5T+EI9 M^UTN!/GS5H2@'>,YRN!0J9J+E-LC::[`Q>J3"_>X_.-A7EZ23WM]=,DI\F6C MTF5T84#$U!Q"!-X[!WMMBPY+?@2[6S`JU__D3:AH#T9#A,H(@L9@>./*\DFVKI MS+O-Z(3BPWSO/J#?.3IE^K[V=W#I^I-M7S[H=,S?J!F:K\*A\1/904HC1(0K'N?B>PD?6)_R.TH?S'Y6,$AV=Y_ MU0V/BR7]]/G.;I58?::_>=_*,*]\FQ*:^16O.-?[]__%0M M_V\RG(J#%*VB0-&2/F*9ESJ8S58J17=K;P/I;)4O*EX7X"XXAYF^/CKIO@Z# M3X'FUZ^+R>_SZ3`R/%@2+O*0HI8Q)9_U9I0G(4/:V_8CPUX*,G^O9O0CJKL_ M3H?'?9DL*-8?AH>1RT[.+:G;*7%2D>FB@3;Y(A/TB% MP,!E,HE&&/31]Z+#U"W0^>WYM;)UVCF73"IK+R0$!YXUE\NSU*][Q$M!YXI: MV94)7EH8"JI40(_9UM,@%'?)]VME9E\*,M?6RC:+9)T2"Q+(U5%_K;!6B,5B[[>;D5*MJL,E#LSY4O M6IFTCY9\+YUX4ZTL7X2O''/9'6F\9%DS@3J@;71/*]RLT7EU$Y=P)#Q75,O6 M\Y@-R8R2/`0"(QK3.#M6\'Z#!2\%F6NK98JIM),1"2/-L@!N5!-E,2^P%Q[! MOP%X1JKE((*U1I:28U%ZJ2,AT]@M=/W.\CC'H7%$K)P-(UXBN MD'(ZD_NG>.,->A\/:.47@\RUM3+&&`2%$DQ1E"Z#TR(U*8R2*.[W!7]WH0DC(A>!QNL(AN#)GOI*C\F8^J!RQ$UX')DIT?EIY;>UL/GX*?^)G40[A M6LP%JW72/D,VILP/XQOFO`'G8V<^)5R2-:R/;JT:5E43%]$HNV,[7`Q11562 M_9Y^ARIN)OR2='H+G2=HP2XJGBT>+WSUD@PA2`@8R4D2R4G#H)9-`=VN,1"@ M+\O&,VD4/K$0*%U\S1'X6IU\J'GDUG7%U2-.7NZ?TX63[.+WUVQB?MP&\9^7M'RR,>:%UG?5M)EGPG2+]J)`-%H$UQ=D)4@="S5L&=X"NV[7W/6 M=,OH#`29-9G6DK!'\M0;V,%Q[(B()F>J7;$U1,Z3*!\"77">G+$ND2N>D!P" M"$U%D6)Y(J+T*^_?$%QUN8;J_<[U_-3:R/+JOAC4M,E%TZ M08!E6)M8'7+70Y):M>[W6/Y.`V6WU/1YH,F>G`RA``(%UJ0`60!H7*L<=\U7 M7=#)65O#G\;G92%:F?8K@<,"BZ%,Z"5]'T4V7#I6@T/*H+?:M=W@\WS8R'WQ M65X8'-04<`BOP(I2KVA=V$R4('"L"=@'SLL1G$''XG`[Z6D0*8T:A;$I.R,4 M0Y&!U7ZOXBSW0"3Y7P.B)Z=4I(A,!4"'W!IK/V-T/6MN_'14=HZG&PYWO%@MC]BU;8.YR5# MA^1[K\B#`EB+`BUS=*`)(GK?1/48#K:^R=>(^ZR/8N:6$+2S-P<%?+\[W'L%!ZRC.8!!(%_>)"(Q5> MM! M#[V-S%ZO_A/`V;T\OI1C*C!EIB]&&7WBJ4E?1]57J0J,D&%H3L)FS>4X;-Y5 MGR;3V73VL8RR*6IXLW9B]20=]Q+VD2V0V<"5XLJ%T\F'YT^J043,!G1XND)+)KO/0 M1_D5V3OUO93'LE\L>.&YBUX*+5UT.<6D-/T$[+1\];QN/`.7QR.AO39HQ602 M=.*\Q$3@ML=>8;;ZX%C*G*+7(`1+@1MN&X>J;01 M0QL8GH>W<7<00)4J9<=TF401LN7,-R?G!V>@/0-;I]Z]CD5$1%9\F"\:0SC6L\ MP*0ZD\,W:&&0(-@:,.=4VDX'KKI3H M/"Y?FN-KICP=#P:T(T?!E(G7V0JVC7'IM$<\,Y_![O@N8AG MM1O44U`#C!QABX`8??1@&W^1?.7^]E-&T<$8$-JLW!2!'\L(WO*UM2UOE0:_ M*P9R+WGF)XNJ_/O#B,G@752E*EJE)&)V9K-HE:0&>(9^Q#@;)3;/BEC+Z7DR M4FC(-$2Z5R98Y^D_BK]JI%CVY@!2G#\74F=6@1ZU-M^_R7O%Y.0<,JT",'(? MLTQY4VI?WIS$H7[X,G3A.7$1/V,M'S<1I'W,#"IK`N>08HB,.UO"HHV:2CX= M4%,',TZW`.P6%HQ1-"42FJBB#8)Y9G(C2E[S_EXZ=CB+?PM*M1#,[U]TXQ=O'[N')NI\NO)1]ZM!-FO.'? M\HEDNBCJIA@&E4,EC75UL"I%@%6N5KYB]/_!F[-+X[59.9Y_MR)G\M&Y1!]0 M*)4;7U:J[-4Z^VQ>,?Y".#I@*;:1B'$Y2LD"LK*VW;"XV9]*_#B*3NH3XJ_@ MH/#=DI].FF2GR]=$%\O3L_'*$RL8;,T)E)36^EW@$IS\YVQ2[QJOGTZN_")@ MHDW$5TP,$@?ORFR`.I=EK.[980!R((#J8>`6[)Z:!\ED>,EML5[G0&?(@Y:B M=(GQ5+8C^T[Q*1=:\Y?']FEI2_+M=9DQ2>K26)N$S](TCS])=[(A6MV6XW;- M[5X[5;31,4N'`TD"]S;@YFT.4E"F*Z;M70*WH/Z"MY)K$1D:7GQ"0`I>$>JC M4F3B1V>8GXG14^]C4HJB=6\U>DGN7QFDS)M$7B+W'ZKYO-ILKZC"PV*YWL5]D]3)[FYQ[[B0ADG& ME>>EIMEC4YT:*1SKVN*VUW6`DUY^U]-??YW\F?[\7,T6E:]FU8?I_EG?JC_" M)`-6@+5:EXE4G@??9*JY]#VWWG;.?)"K802JLA6$/@;ZRVEK&=*8*K]8VO:F69S6.)?);T<9@H_3H*1A3*C8] M;P8Z*D/H_JLS3--%V!CJ(E.15%^93Y=XV5L`7@K>L-'S-GEA#NCKWCS,[LXY M`*VT4,%G!,C&EQT8JAD$+J3HEE<);=O.VA`U3R)\<'5$21IE:RTG0R,U(&G> M9GR]]1W(A<*+$+YS/&=)O`C2BJA<)!S):>(`QC:+O[`[+*.?X"X53Z%W"&=' MCDQ.V3(7?0"4I7"_%A`BMSO[`E0GJ3">[,]SHF)5^KE;94HZR=W=S:OR>SJD MD_6\=HIG+JVTC*3;$S-,U'H^B/;2(-+SL%I?M\O"*,(NP\P1I9]4Z0GRG#G) MI8JQQ)6UTF>6=Z?)MZ7^'%;FTR^3\FJ\OBAG";YRY!.3G366H7>)9,FOO:1@ MO?30+283LIVEZ:7B/$J'1)XT>%84S9'D>T(Z.;=9S$24^M2M541IV]68IU-Z MK@*WFI,(Y^AX*+L,0T8'-;$&1*<"4<,PK0];7CV.=K#4W^N_OEF5].P,R7NU:=^1UIP1/NPNNI5]PE@'V??AQ!DMQ"8%4(SKQ#$:$:P8V)] M,0&$D%X!'1""?%M"T-U""%R#2PDL,DZAXI"IZZ`1`J0U^Z!8ZU7?E!`$ZFER MDE1)`^[44J&14@&M@2%!")&$?>TJ]:IO2`A$]LB`!A$@CBLGA3582QIT:P@, MA7VPH2`#^:9DH/:,:M^4`7>2Q!AL"F)$!4VX:]TB-VH?P"/(0.$7RN`?PW+Z MSUE574T??W-:PC2+*XO]N*7%FMK.+ZR=B MVQ-*$CJBB8A31J)(N<^:;6Y1]H[RE7D^BZJC)9H[II3#VB"HM(13#<^0^F2W MFD[`\^.)9M5\\%.:@5I5Y759C.-\=@=%SO)N.4G-+U?N\G*ZF*T.OQX;8U-- M=+C./(MY@*<#%P")?-28!<.<#*81E9`Q$U4:G'E@8YQ6!-].SFV8=?E/G'+5`CNJ@-9BT-)*;:!L9$RORBREI\NS9?S".E6'LN.5,FG1?*QTJ#N"SE M_L`/G1"^=?&>Q7RE`M=``M/8$>455<2T:2ZA.#-?1M%N+]ZYY5M^+%)+60T`TZ&*KG;:3H$[:G_7J MP6A*#4H7ZKP71"HOU*HOQT6MD:;%^AUA0B6G>1O(SB3I MIQ!T`@ZZ),\M=\9J%()'1&'%4%0-!P3"4OY2C9Z6A=1+[E.Z-2_&?OCP$8B_ MA4__40SGAZ=D;_@@I+2UJ041:FR0.,?K[CLI%(ZQZ<_''X@\3'0'#5NTA^$\ MX0%5S8:UPZH<'4IY) M[!^'B65(:C`(%SEL1<,1%(NN(38R>QB?[6+SL/9DQ.93TC>)Y80Q*9V/TAG% M!#5T'9"`6(R0/"Q91LY#;(=D;80ZQ>O`0^KW"<)(M0HH]0_J(.8;?B&QOIPL MH8PYUFJY!J\^8.RU=TR/=%!'=;KXN(">6<22``V"*CB6D(9FX7R^.IUOM2@KM\ M@^+&`KF2!""6J:`L;0A.G3[/L^"]!-_=3V8/1?&IJ$OPEW8B"0?>%SL*$0,K MYR%H!-MD&TC%'#6%TNV7$+WTO)3ZSOXOKFS`&'-I/7*1P*:D#?4>Y0WWE"OU M`NKCL)S_:SA9%N%_EN7BX9_%UV*"/\_J_Y+/\^&TNDZ#OPY#AAUJ'J8>05+* MM!;@[IS$,M+U"Y'4);;KK;=.R8^AZ83,[&AEDYF(@0NO'(%D4"C%%66D8<9H MW=4'>5)FR/J#^$6:$5*'0)6!O<&9<90&U#!#K#U6,X=H.B$SN_MECA97\U^+ M^==RM%&=_\MVOU'VC)A`(.H)Z;%4E+>-9CC(2`Z,G-R\-=U!]R'^OA;5HB[< MPW11.Y'/M\.%&TY&]7$I5.1USU+]<./B?YO.OE3`7$J]ZR_Z;3HOAI-4ZZ?J MOTKE/SBC^E5V=3E=-3U!/K[IJ4"(Y719C#_/;/%S,1GOLXS]6Y9?8=5$JS>LKX_%L%K.ZX&TOY>+V^SK MZV/HZ0B67@V*+=*1%I0KJ@X*,EARPS*F**J-8^94'( MJS:.>Y,E>1CS74C(<_!Q+D'5RQQ7]*:Y@T8Q'RC#J>?.$$,:"7F,LYU-N"8[ M+2"G9N"5I=-YC\W0*#EV`K.``F08FK3V8Z+++OM0Q;@\D%B\EG2J7].[L$7Y M%4H3,QU.'N#COJA&\_(^K?N"0L-\NC0^0Y`AC`NDC;"26PKFH3U3UD2AM41$ M4/T?__WK[6PY&0\6MV4U&#=7L>>IZ"FG(_#C53&8S9,*5C]_>1CP__H)'B\& MU\#?X&NMM]GU:H%AD@0PD5;<_,A_8GZ!!W?E9)*8A/7:M=,?";I`S1]_&LR+ MZG[UAG#R<#%HR2L&Q=_I]\5X,)\]#"MQ83$`!FA=:]F+NJ"'387?4&^ MN;G0"WK07#;^MDW?F[66K^#JBOFG6I`/G\J;VT6.5>6159(1%*-$PCK"G;*6 MHM0O(XA38#KES;2\+D=#L)@_E^.;1/,`K&"^'E6T9VX:BGVZ'%^A9CDO]!"$C,T(L=?K]-[,_3&5#US:]J]^_$S?UV[2L MY]DL'F;7'\O1;7G3(!9N69X//($X1L2P==0KHYLC-*\T?C6GA3MB'&8'8\AK M.BW1X;3$FXEQ?SS)>'QQ/[LKQIF]*,*#=BR=&CKB-/60A#?V(B@*&_925#N. MYZ7JV(UR]'"4HX>CG$F6.!]_J"<,U38S7PS^&E:#8GHSO`'K6#!-TQ6P_>&T"Q#YGUHB6U-;_K96HR&XR&U>W@>C+[J[H8 M?.Y@#K9%M?SR)WPV??77X7R5)@^J1I"S:G.Q],3#H'J,!Y.'P?5\=K=^L*$* MOO3W8G!?3VV"QR;P5/JZJNJA=3"W@?C4/"?X.C]^`J!?% M/,E]LEIR"$I8)BV`-6[(IOHI/9/6@O]/D0DXWUX.N$\/`M.)Q'%Y?5W4KPC; M)3-YPYI_%8._0+N#X?C/9;58T;K^Z_B0G"\&#C0--7Y2[/(:C!D8GU?IF9MB M"@2,!BF6P@=KND`$_Y@L[XK%_PY7W_6EEN9=N5BL;*1($*OU\G?#^;]!C]4" M+"KQ"%_1@&K5TC3+FT1E@IN\&%P!2TWC4J<6%N6HO$_F-00#3KLTV00LG3\+ M'+2D#E-*4"TGBX;WAK?1[.Z^2*=2JU56Q+R:\Y3;WGUK)\L+^I:UY\9]J*L_F7 M8CA/\&]0G$V3CY]`D"C7@-UGU)X"-:$@C".16*(MDA$UVD->9H?M^FCE]0K[ MC>ON#%4)(<-Q8VQJDXS6^E9/+I\TMYH0^$-1&T)/J.`3^.#K M;"POB6!,""6Y1\Q3+F3K%IG7^3O$W>%-I];7;%Y`>;!J;AL];-UQV8#66;2Q M,KM%T_=NQ1/#N(F!2P6&JC!B:_Q/)ZU#.C-1AL3V+>;GD'@>'L^&"+3=%N"M M,\I#YD>]2NT<*K38%PE+,VL+('7H?+\"VX,>M'-5T&-)E)7:.0=R2\<.C<`4 MH1F,P@>Y^V+XG0EL#]+0]HTBC6C*SU0ZGG$^*-Y`F4D+_]DCL!W0M7L8FU$$9[UGJ\K?BIK/Z]->%F MS4(#Q+->M6^6KC$!"@:L@X+,,R*FL&G#A\XQ4JB4[UCP#6[2:PC>,8J]!'L7 MG(>@>6"MS0M/,YOG.Q@"WXG@NQH;/"%:4A1X1`2\H`@;J8E2/+OKD$$Z?C\\ MODYJHDB4DEK%+$J#UY622+88==AVP=2^-U'U)B7<,A:LL8S8"-D^A3*Z$14) M/JN@W[&H^M(1HKP5S&(M!!),."RC?]R&*JN)WJ^H>A,1+RU4!`H2.$P-2A<. MFWM!TOKLXEYJ&7[7+FLOEN(V+G+0,1B%E,4!>4J\7D]@25$,"N[_+[:U%W%Q M&PXA,,4Y53ZJZ(2D'ML-T\J/DLXIJ375=;]?^Z%TX68RJY;[P"DZL9`5HIAX MSJ,*R@6$C%R9@+7PZDW/VF,J9A('V0+)0(J M_73?'[/`)0EB#5(%P@HZAUE_IV+JVRW4"6XIY@YYHPCL#TU;IQ)1CF!S4IMZ MQ`K=BDN7TZ(!2)H65=6!'=WL`FWR8[3M0[0G$W9" M=CHOV`1F*(J8<(ID5`Q1H1IV@,],2Q_XMV6GYW:=U0R*+HFQ(=P19*+QK78" MRH<(?6-6NC3CN/4X.NZ=Q"IM(D_;:0Y>TZX"Z:6L_#J<%%?7&]?5CC8KZ\"2 M)(/DBT'MHB#G5LI"54R=UD3Z#-)Z+_$9&<\GMV]ZEI7I1)=*(8DT-)D*`7)Q MX#&YJ^SM"]^YDGD,S>L;>U?3\'=J!EN6U6UZ\.HZS6$[VATIZ6D01C@%>3MS M+("L&X0?".39-9T=HCN).0'I74('[$(,Q`-K$V8CP%SWJ"E`/GY35BQ.[/L M[!ST>!O-`P8W&0RB#H0O+23.C?"#15F[RRN3WB5\@3C31L"_B$'*3P(CI,76 M0:QO@QY!>FHO'$[23*'Q73DM*PCBR0.MA_L=;?`HCWJ>\S=:'"% MQD<$[7=\AAKU_=%_/5IVUQ#2GZQL#(C^5T M-B\7#Y?KEAH0U?8J*]28C\7B=C;N2R\ZHYX@:M*'+Q7JE_W M88KK;3?PBNQ]5V+MO#-N*%.(8V8U(C$J0]:0KK!'TEE&5K)AJ!M^B+47\H-( M:7!*TS0.7A,'=[,CM3.Y(I34]LE7)7.<0044DQ0RL`,U+IY.T&]JI"'Q#134SV?W*+Z95B. MGW/DQ+U63`N18'^M8=PKU8[:)L;D`T$HVT4FR:DXFL@><=*`&?'@6WB,@1CO MM2,-D6GZ;48DR>!3^HFL;Z[X]0V6RVG3UKS&8/X\'XZ/+S&\EQI9)V$D[X#L`"[C"DO$7@XHK$F@C73;37+*SV,,E]Q M.DX>&Z^/UDA(B%\D!`C[1:A>Z_N1<;8"0';]M MF$W321P!787H0`7!-3JB+&_PII1DT;>7JA.PT:,53CGVGO"H!`L)T-<'W["A M;-Z(`+5MEJ&]E(WZGLSC-ML+LOR4TRO%")0N0=(H)!`O"6UW#52-V8&M@HR[ MAY7]E)V(G=[XXI#%$/^,MMIB3K25#3MING=F8$AFM>XIV*EGN3S.AGC)GE%. M<0CR(C"F"62$-C#3ADQ041XR%>US;(?).R%??/*2S2N^D?*TKQ.G-"G#Q^`A$E?(0(Q4BD05L%5MCE@-')N;)35ZX/H&J MDS#2HQH&M2?W%EP;=TA)!\F];AGA+GN1\('V>>EGIZ6G$'H67OMP-D.ZL*>" M,5Y1HSP#+MMR![C.+V[W^HWGL9K.2H83-[N[FTUK_-/*+!;S\LMR46?L,S>< M3*[J6_GISN?OPWDZTS[^`-E$Y((@D']+)J(SW*S';8.7P6)KBDM54['U!NP% ME)Z5X\Y]JD.Z=$HM#YH&P7@PLN$8[-F_08Y[SF^"H(Z9H)AD*HT-QPK MY-S;Y+@S02B*NI3G93P>F^K^V&A\W>C+QS;X\W'FL[X2\7_O5LU/#\92?9W]>/:M0;6K M\MD7#@XDOBB%Y"Z.O*A\%JPX0!G#"L:H^>%*O@K`EH.(Y&_X>_JZ:P6J47+/ M1R1'SE,I6<-PJE0-<(Q3];H1^SB[E;\N?Q[VP2M36V3:LIR8Y&!69_6`5\YK MJT.6>`G/&(F;7C%J_SCFP4S61PT%@A,F64..)0Y7LX3.:NQ@&GQ;!W,?P*8> M3"W1MC@Q2A*8%^.(L.(2-^"UII##W06SBP?1!570./1@V)*#A8&=$9>Q@ M(JHW9&?=$N$G'DQKM9B7S2Y7R*WXF>K`(&NDM^SY]X1JZI$L4+3VY$ECU<0Q MF++BW&9M1>X[16S:D13"GG5`0FU-SF)@0&J)5TC*OFV\CGI+QG8_.HG5L::V M'5.`\\,MF=R8]WIG4$T]C!BJ=AS:VE;.PEUU<@-B01G__A&;=AB#,'L#K=]- M@[4)',0AF*PVU?'[\45OQ^7"U]G%S_/IL;%%IO,1O;OY?FR]L\.8L.7O+G=# M?KR[.?_7/.C=-KL.J/>,B9VPBB#'U-2*O,0M9C.6O>AK.M\`;O]X!IO3%++*B&!U+)#1 M(:^X&>,8^7^3-K<;NXDVI[(`E'7K2&Q),JO\D`4RZXT_2]RT/L#+O2QP]#R. MCNX+KZOW/F472T:;AM2&2SQVH^J1QY]W@-TTHXL.*%'PW,9Y6`FCK(4E;M;0 M&,W58R_IKQZXY_!T3.+@6BT5@O*0#$0[G-@:>"RFTEV9X[O`;IK1`3JK7:@4 M%0=?($8V MQ4&(1NXP.1!HHJ+".@Z]60I,5R$1T&]ZE#4!)@NWM0:J>LO6*KH?5@QB;SBT MO66%G7`2V[K-&L@G2+?CG=!KUBV4%G).*HE/#HN$1>Z+.#3A-OZ M;%NM?'W.L0MRP6H-S'Z`+L;N81ZTTP=#MZT#^7BIBQH<"ZRB`FO+9&LV\_@H M6^NH])L%^R:`3NIGTVKZ\UA;"=BJ8XLI1-X9L_`>1D(_[H:#$,!F(<7IE)N6 M$(BE%?0X,!@L:CG%89$0D.]-3+-WC!W9.XYF1\VC9>MUO0`:H:LS.YUV$W/% MJ52G2^O_=)PIT'VSQMP:K;>=-1KH*I:.H-JQWUA8L3513I8X$%=L:`]Z2ZU4 MZ;LW7DB?J89H[7ULV%88MMH;SWGQ$"*&*)RJFV5"\Y:?EU%NFAVVR0E)&R:V MZ$JTOMBT_,8DLMLV#>I82AW5(=;V,B5LC5KC354MU1L'+R\GKN\!]IOAU>FT MFFJ'2LD%%G6T0O"T<;8F/3C$D'SW96GQ*YMILM-I-\T02=L,$$-UH,A%$.XQ MN(ZQ=D5MG^SJ)?JZ^GK1BG0_WTAX\W]GXVNQCDT@2YM/R!7(J9"K=QP6HV/E MSI;?[*O!#>UD(J.JG%;_J<8<+1OYSB4NI4((OK`-2V/6'D9X=->@^!IAF$@# M""+I0"Y4.=7&UK)HTA6KCZFOH\>NM.K4&!S56Y<$B,ID#4EN6%0EK0Z]:-_O M64&[^63R&O6?[->%Z,I!J$:^\N"-5G$94AH7L7;\PMGNJ?(UPC`Q/G.!(]4` M&C<.9'*7.4$$)6D-*(;7(&G_BR\>LVGG@(#@9U' M2!XLM[W-U@VG0.A#KB3N;\"_2?3HMQFPVG0%9/EX"G'(=9,@DR7 MT7GY4W#\NT#8H)P!!9FM7/F.HF>SM`4.L/UQ:K)=TWH.;:+E\2Y:SG"*7PXM*_5 MXP.V+Z>&1!Q"&[FY>$HT6+H.\_N'ZMU:KZFT`<%RWM1\8L,A`ZX+B;DM'#V*."_>I&MVGNG0@'B;A]7"_HK-$`>(NEBL]8#E03^E/Z_1Z@-EW% M$63<\:JHDV8?`86`R!E5SHBX2QD#]=/)NN?8XXBXM0<=HM$>7_XYDM_!/&O&'^_^31;5!/\_/7V_-=6/K#' M)E;Y>W^4+VY"O@`[8;A^]MW##Q1,YUS-+5H MC.RL$283\[`T5_M^V\:(\WQ,[FWJI;9M^WPV-\93&.O#VI/J*0QJ-;.T$IH%I72(E.QM7^C`6.-F2J3T(S[PK)?;ZXN9K=?YG,MIX'G M(Y<"D=KF0$S5B+;V%W$%MW=GE]=_ M._O]YYLOE_<#"QX)!G;[`3'80`%-*KH6%81\JN%E7IN>+%G<&(T\0;3CJ;3M MRRCBV:P)8AM0)!RQ#A=3M-OC@1IE1AO#>PY7Z;SE%;Y\F/TVN][D$?LL`4"$ M(.%(]48G,B76Q>BNQEQCZF;#K8F\]J,GB[5U_D8-T#:B%JK%1<\EQ]5X?\N= M6.0VX7R";+N&]V>56V=-##ZPAE2PKF3#?B/+YHJ3I\JV-1"A:%&7J$T$D\@S M1AR6F(AT3Y/M>O;3/_EV=G$I!/#\WEI;]?+E/6NHLUG\W$C,]#FK3C&R`V<" M,'J)+3@.4SVCV;9COG^529].WGVYN+K^_B6T\H*4?_A1SSTK7^AY5\N'^\"K%VN50VBX@+1X_9]#I M84KM^NO]!_V7^H->0^2IVKT2K,YG5Q]^WPX66R7\TRA!RRLJ+5?:P!+8**JP MMCGR`5AHWA]8OUU>?YK=?KCY=G9U]^W#Y:=?[W8@YT"U)=&56CTM1>.2(`?5 M8LB.L(PC1^_/S/+LWS>?9R.+Z>'AH41;?SD:"[#5.`L)4J\)D)$2DH&,+8A?(J9@?<6?@ MGQ.ZO\UN/[<,^Y9$TL/5KON^C)YRNV75$OYS$B)JY:)P2@+"Q;!EKBKDOB]# M$6T4((\B\5Q8/?**>M*%H,)`N>7Q(GDPE%O#S0"9[1]FP0=KZ>4@&WWK.25@ M(,$9I(RMQ$]GA\ZJ`;#B4U_/(=&9?7Z\3J!Y-A6H%'2%/4,JJ^O8G^UIZL")!_E)(&P_IK`!4Y+R`STC4=@`3?SE*>$K'W,GV_. MKO]P>JB4S46)%7EN/3]"*7CQPIERC3%TS[*+S1[/C=0I-IC77&WEHAFB=5XB M/X5+(R%*78D0Z@.,Y"^SN[9V5DC!;Y<7LXOT[9X"Y$)Z^'J_M(=3:E=4UNMD6^B93U\+N+N M@E5U&*O/?6;F!_E(NU'\6EN)(89]E!J1[FA*[4ILN:I8O+P0)JIRM MH:`L>NSWU8BCV]@4>[A2JXUPDU/;62G-)H;HO"?,R*D,Y3&!G[VI0<-`:#S&/N(%G\[ MN[Q:#E6['\_QX+4Q7UY]O9N-UV5N`Q91:]9")S5[:&7T10U390UC7U^RPQSW M$?(95-RZ^T"B*2R*Q7!T`?)8_#"OC47CJ6;]$BKN7&48$"/(S=5V)V6HH:9A M"'6@KOQRQ_%X(0VW^B;O;`*T*D77]DQJM,-X&YNAO\-V'+/I*MY<2)R@&1-FV_96L<$OK2@!\TMUW[YTP_DM7EV MB;<2:M/&")/8M4ILV_8M&$`VL?;K:$`;?1C(=_?%*BTZ?[#,ZH^W/@VU#UC]D5VIOY#`5(A!KJ)4BW5&P8"72WVN5%FMWP=<^?)V M=GY7KV[^\^/LXO+\[&H2<"V$M@6=@Q*X1@^4U`#<^@CI16X'@WL?P/VW_-?M M[@%Z)66T4?A`C<%RM#ZL4V\4;3^7/[R,7Z8!!<6L:H,2;EJDKA[8[):)E:S[XO1 M,5CKWP=:/Y_=GEUR?. M_>^SJZLO=V=WD\S*^>BM"K:*T](@80Q!6II58!C)U^O-G-OI\-I64HY M1,4:Y2MUG@?7&T#UYX/,YG[.TVKRPBS(A6(E_E'(V.9Z!`O$2[P8N/OBWP-. M3Z,_D;,G/<0&:3G\L"P&*D5W1R91"F)<[\@0KROUS&VD3-D/.-XK6`?0G M1V?(@VL!>2A42BVK)WCO^A)KB>G>"5I3Z$]T29PY^$(:$J')P0W/[T[NQ9[^ M!!7>!TP'T1\B58592R"+UED`U<8,+LS*N]AW%3PC_6E/8H?D?Z(CAYA4JPP6 MIZ)`+3O6HM/"?D#$^/R4J\T^7> MK`.SU\F>+/ZA";C@8ZQ,$H6AA9*:>';Y!13N._%0D=V8W[N/4$?08MOW('Z` MG#-8A0ZFDE"PCX,95=UY6/#V/@7Z9"T6`Q@FMHPYJH`<`I($?%XY7-49$>L^ MSA,V!B-T?_'#ITEUO+E"8(QEW:K2->9,0`6':\VBZAZ/-&'W!/A\:DS>R:=; M!YMIDWY4:A#K**/A1""-VYHWFFT;>3E M$C8W&!^HRO8@-VB)`!Y)JB-.5G3HQ:<`HX0( MUM$[W,;;,6R;C?V,.FS4L3[^,"%7EX#QA'D\;F`HVQ@ZU0OC+D]TH7G;1TO^9B$'1QX),)&3?%MFV0I2XC%WM2`'*=\"?:.<28`C>R#DR8>*D&/690A"-8V\`FH8R9:^)<2W/6N=$GI005,)9(,M1E6ODAI>RK0H MO>=+V>F@/T5.I*@:4C$@UUQH[ECPI/5&IV4TE7*L22/ M2ACT_-8" MY(NQA5.(6AR0RF6HV)2ST,_O4#22['Y+W\$+YJ&0?"C69DZ^%!^3'T5>:@3U0N>=&B4_W_VKJTYCEPW_Y54 MWMEECV)/./,2#ZK\^L#SDRWI&&K>ZZ2M77> M]B*I`1`$`1#\/A=B-A:DC`C`,8KN#.6\?G/^=X,?Z>^5GA3 MIAYS[F14E"`24\)1"91DB%V3U8H>X@K.^EZ9O26+_RA]J+3*Q5EFJ8Q=Q3)O MV^6*-M:@VJ_2ASHQ]-SH:$+6GG(%2!I!"TUY'#X\CM`]`\B%R_N4P78U[5Z; M`3[PTWA@^T>V/KOE?<\SYK3.&Z>3S[/Y\G9Z.48OE\$9PQ.G;1L4EIGN#=5I MX7Y*->&GWF:VZK/0`2;TP,Y"2JP5)BM2N[/73"Z58\"6OUF0-B3 MZ[?QD+;LW$'-@6=H3WB[>(C61HN496M7QCDA=>Q6NDX]0)Q)-]&S+F]U0S!C M.3AE90A>%L*LL)D]*QZ#N8>P9QO8\U16Q;-9=66:-=N"^[QHFC*->D:34A6B M="%;5`X1`PAL@=>=BS95/6P\DTG%!]AT]7^A[TTGM\WS8=&B#IFR'9F<9.B\ MC=[[DL]+0R)7_3!X,9%_C'VU$6IL+W%DP>;R/EBY:,J#XLW">Y=8S:9^1BO^ M%O-\\7M3D.4OF_1?GTYY4W1UM2(JFMR47S_C/A+DC!"H^&'DG"QYI77'[)>< MK?F-SQ/OQ0?Q;\UL.5F\>_=N!SW797J/:NIQMAN]0Z;)+80Q)H`7&Z[I@O2N M?/4^Z'PA`M<7(=\OA*9M`QC'09343/4[`Q MTD'%.WI2$V+/W-?+6N\$*KI,98^U!K(`XW36QG2^7P8ZGV%@/8N*A<=BLHMR MJQ\<4QL359VB7O:08)Y+45@OS&9'PC$K^5A!T)E3`<4D'6]6 M%A(R[,AFI:LGTLZU"TG!U2W`#GKM!N?P6,F8M15">:UTP>Y5-F_0TTE)E:#* MY?CQRUC14I^X7GR:J[J$B;/$LT[:>Y5SZ.(,+6,%5R'9R!W=-J'UQ5/PQ(/P MG6UYAP&T`M$IL(H\+G:\X%2\U!R=A0#SZ?O3'C$.$G,(;9+Y,K"2C%E-"1F= M7;:MF&66JCK4*2XH.+V8(S">]$TCO(LQ2\E42`9T:F$\*:NJ]RU77)W!FB/8 MG39$M$&8+#-ZIF+@\@%MM(?VM"12*/<3\_9+LZ!49W'77!W+(\NY3C'%:%P6 M)NGH1-CD)*5S7,^,6=PRZ:`L1XD]B-(`/$41"CQS&?X+C'G?BDU;JWZH#FB/ MDWNY;&X/QD1E@@K3G"EM3@"4!E*AK3MZ81XJ3%2MA>@1=TN&0Z0<,FK4+C-C M9!0^N*"XP`VO#$D)6E2'AE);TX,[2AGF7[\MFB]4G$R_-STXS%0"?J03[V-# M?V%-IWSU/W=KZF_?7,\7S:?)'WL'X\`#U;4Z(7)A+";%3(>*P='54,O;Y)@,E"%D(73!;,L1',"'5:O_$I<2W;9&1$T9#@8DF1Y$45Q(3 ME.1O($>LMKJ&3M\&BWB+]ACR$&T=I\0EQP`%=R(7RMC60S*O7^&+GA#[HN:( MS8*RN5OZ;\L/=Y.;Z?5]H>Y8_J6Y^MPL*<.[N#XDIJ,5O4$[V-$?@$##/E!\EZ$@LH(7@66%4;3&8#RA2K95JSOL/V1#3`2 M&(+4V22.$94NY!XIRPY-K*B`*E?#F+##D`J67R:E0"(5$36)P;,,?3Z&1 M>5M#6K#7V@(';_,4*<7Q+"?**($J'\R;WB8MLDVRIOGCV]7%'\ M/IRU>3'_ZB["+YOC^.+ZX4`^>$,Q;B0D*G`*^CQ*!Q1!NR5$/@3I>S8E7M%4 M@TT#DX242:_F:SW(J%)7G*"JZ\,_LZE&`H-P7D8RBY+"4"Z2O7V(;_3+/5=0 M:N<-]5;M-9C$:W0Y%HHD\%E)`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`<_@ M8FFI1>,,1KUYY451"T+-1OL3W_&Z_`@E7L5(@R4_9SFX''@R2=N"6(WV(;2+ MJB]":<&^Q]\;,-+8;7/PAN<<=2D=(F][M<5&KB>->GD3K?_DWGN$ZG3I)?,V,Z9`` MOZ79^LN[2S1B["@"1B$1A<[(A+6L13^G_,+R(7RU07$>S5T>.EBIDHV99$AE MZ+-,A$?.VI'%K.M+>Z$UZ[E@[97D8(&'9BQY"@:AL$,QI3@8*WE'+X:YOF1` M@WT=O1T%_CC]/%NU0&I!_<5UF-,&N%I-',]G/]-6 MF/$#?!:L!:$,VL`D,PQ:-F@4RH:>!H&6MF=+'BCO&14?FXOAB8HV+[E-$B)5 M<[8%VT4158W[:+7M6S;D\L([``].)(:+/K89)ZWI,U'"]5;/N*-IIU!E9,)`J&).-3"R"D"+H MS2`315>E63U78E;DA*?3YM?FV]WB\LMDN5[3[\WB=OK[3?-^T5PWM(NO/M[. M+_]W_R(PJAR%%=($[Q0PK57H#@U2L9Y1M%L-S'U%/+%^8V6(4:5SY!DYH+/* M4KSLO)!2I)J>5A=.K],K>'&](H=:+N_*`^4P7QZPHTQ!Z'8Q%=0"$3(@&-_J MPJRIZ,8L/*-)CS"'"SVR`$X4CA_,*5"X2THPYU+K8!)TE94H=K3,T^\4[V97 M^QLX0F%^=HD!A660$85QK:S(*?:7CO*N6GN;O\O[OIHMEZ\[9_NYL24&V=MD'FG*(0RLVLK6YP9IY@X)_?Y0\3'PZ([Y1K+E_ M?T,GO9M=)?JOW[Y6.>0N*Q$"'(]1%PM9`]NZ2G4RAL0LX M*G>L\2$*.KB0:^R8HE$$7U-)GD:?)P'__61QL?AX.[EMKE8YU_O-*^O1B@0> M%R0L1\IL)==9:YFT5Z'++YC:OK!O/T$UTSO&'^FSDV`GT66K6($G287,A7(Q M.W!`175TK(NC7@M$5W63]W=W>V7^:*4YOM5B"B-"=IXQJ/3')BTLMLI///' M87:Y^E`?5M"P0$?)/LR!C"ZD3'E=%D!'@BSTI!O9=7HR/'PVV"MW\$\>C+1RCPB\EN)@80=?/=H"/"8R@-":HU>47;;".J;< MV82]N+M=WDYFIXO\2-1CA-[L/7!'5#R M2-5R2KX$@+3>7/FO3OQ)&*OXLR>%C8ZA,()Q4Q$9:Q5^6$>&VLFNF?E7'U[ M?]F&S&@#K;9(0L8LI'-D4X]M!ZE,:!PGV[?)]"K]\:V9+1LZ-A\]Z#WH=3F$ MC%Z:DB:B\";1OW1V]+J>@Z1(9[:#UYA$QVLP9.UR_ZR<9UHR<`7.TKKNY;;# M5!=K?`LV>'\-'GH*87YSTZR:0!?70ZGO.F%$]\?\YV9&N=#\^GH7<+#5CX\" M^F2#!2(\..0036HG7`KPI*TQP@7;1K/:4:%7,L).X#_"%6AZ3;6D3IR674B, MK1$8;<4JVP;]BD8@=][@OOU*KK=*C)_5+&A-*M"RH@`A+8=`X<0#G2,RQ!1K M;$J./Y9F)P/!(]6II&5)\$1IKF1962K/C8H:I84Z5+V>)7:I#S4=73'2(28= M96&,<\A=:)"@>KBA]X;GXO^+4KX[4]O%&]Z9<6=Y/%??>;(^JG3.E-HEV7;+3@,B40 MV*IO7*H'NFT%[G1J]7>Z*(D>`4VA7>0R2<5"Z#H8DJ?Z*I+UE&IG$'MDBPEF M+8]<9A:2(?O240==,2'R<#JYO[BMUUQ<_S99+":SK59T7&'W\1Y`L#Q?^"%7 M:__7YL^.^!A(+RBME]9F+(F^B!MR@L@-55/58G&V#3@]K-0Q^M,^^]@LILVR MP`NG/RZ_3.CXVGN7[6B'I`-*<"**5):]3,6U>PVEK,X)/GCJG`5TX7'I%THD*+:IB_E ML#OU=HV.D0KH,@7.7.)./2R4$?45\O%"K]^A'BK.GJA1C M2)"=\U1&E(:]`"<[A%3)ZVM-L4U1L+]VIS3.+A$G)(6**>[H.&>D+/?)NAS` M:YF2J8%P?BSEQD99M*S%1QY+AI'%0Y/X+L5[8UD'$2)W+9;4LX\ZZ-,B=[U`"$4R5GF]!A0X) M7=U_O;LI=8FRNIY?3/3V9(C;SE/^CX)J.=%*@ M[?)[!=Y4<4)JN79(GC.5'?KLK8DH*.WM/#O6O#F:6=1':O"] MF=TU^X,AZ^""*0DLG2X2J<0/)K0HPR;UL"(H\GO<$G7][=T%&MYD-H./5`') MXJ16\&0Z/.%LJA(0%?)JE^TET,CIHQ61T8Y3V@%HIA4QTV*`G87"\WO)S>W]YLKD2I%A39%/2&M MP^:3^]/H[)3Z*MIL,3MC510F>\^]ZLB(3,\C*5BA?#^QTQ.3]%EK8\GG]EVG MRF8.]6+QL5E\GUX^5F4]&G.UF'[^>I0>5P## M+ZS2OBN%(&30&0O%7>:1*L?HVH/=!U%%"LXMP,E"A3S+GN(FR,1T#)+*'!D= M$RUH&GF?4+5.%NPIG>\\>PH,4HH(P0GM,$B5?.[.<^]C%?V$VB?ZK1I*?K)L MKLK#NL(\56[:]A_>SI'2L<`=G3<6O"\W/ETMX7J82Q@\%;%?CH-$';N=!*HG MH];D\(D\6G-HBW+R>?FY])<+=1"'>WJ MJ).N/EG1UJ6OWV[F]TVS&C=:?[9UT8=$0]&ZHE1<&P4J9R-P??\4=?D_6VVG M;LCT'_Y83O]Y-KWYEW\D_>A?_^G/8[5?&_KZ]/)V,Z95;^K',[J1G(KJI&BQ M--@='2V"M>:S+CYGOG]5[U"-.>)+V^N%EG#UX>4OL_73W7,MTM;KF1"RBM9G MF9DA+Z<$K%VE[-SCH-:./LJM,_*E[/$JB_!#;"5P2@N;"]P711X`839`*K1( M3J$9V$JOL$X_RF[ZC_]G[UI[W$32]>=SI/,?4,_.:%9R)T5!<>E,5@(#VDA) M)IOTSM%^I&V<9@<;"W"Z>W_]5H'Q_=9NL,']C$8SMIM+U5OO\]1;5>]%'/RG MO"&?)T*X&W?@*L62*$'I<@-:(505V33Y`!GE,!'/VN043W7]1%A:D493QF"Q M#%L58V`82E48Z,MG1>48Z++R.L;@F5Q6$426;`)#90I? MJ*B>)PK065VFR.7H:/KJ2>RRR@TPCY63441\0*V*+=)/9%I9T9-7=6DVZ<59IQ^G$[$3YP/B]>O M-6]AY2NLY7*46FNFHK&NXQ-(T1[5=E]MIW=D\8K%-,8+7*V?; MIY1)VP;C&'XC72/?(W0]V=-4TW"[TT3E?$A4E;`-0]+^$7#,XDZ/UVZS&" M=HFK=#U-6%0*4:EEVJ8]$[2Q4=`B:UB+!#V=;!9"CX_?^-BQ/[[-7'5UE\B* M28GNR);B&6))5\K77$I?-=M(/.3,X04=/[58]RON\\7:E1W7,A1=Z6I=HBO, M=M29:4,4MBEA05O%NF(7N8]!T@O3X`LW+8[:F3A(V(MFI*LJED@K8CDN(;)+ M;49G7.QIJ^%=7:9*W_@O\O);W9JA"+$7KRH1QFC"ZQM2O MO"OR2JWF[IS+3'FSQA3/ZM9*X.6VYIF:0SR3*1:U=.(Z76(SO( MU%_6O#*DY&71)$OJ:5N,VU^JIU.^@#%5C;-%*6J^`F7;^D+?Z/2`ODR]Y&U_ M]&?I3KC=`7IOD@O#M1E?:3'94S6/*I0WMW3"[?+6[P@WV-N2E[9[E_.P;JNR MJ7-%T57J$=IUM'GN7-?5UTN3FH:Z>B9Y7//C)(D?A+/Q!@2KX@KQK+T1C^6% M;S9,[MKBX:M&1,D#S50\;OU[+B/3E+L<%[KAK+F2Z6M)ZS:T_-D]8_^0/_F< MC\3'KW;WX%[.;BKOV--;IA*S2Y6N:=M,(=P^=*A=]M9UUN-Y-T24[.VNF&3N MXZ@?)!N#C?;ZW9NV8W95JNJZS@S7];1I\*T`C-Q=3Z?!B6`E#_QZ$Y[=PEW0 ML+B:&(9M$49X@S25N;HW@X9*UL)RF,E,]JP6;JK7\B'?6L^7Y9O3P4;7G-M:\P:IM>2+Z MG%)1F'6]%NO+1JD7?Q^)JV_]1SL8!8-0N`_T^#-2D?LBG409QW8>O5\D(IHE ML_\2I^'V[;'5((:E?$$N]4QB&KH8C!DR7>TB78TGKZ;=IQ+% MZM'24FX=JNA=W;&X5:"XKF,SRS!FHI#-M0`3?96':Q#%'WX2BHGY@T`@UQMW ME'%F*O[[R7\,AY.A4"OW<1RGDR2PA@*KNQ*3KV@/>Z]-Y5BR3;C!2[MVEUFF[,FE1+JVNB$XLWH6+I-Z M\"5DCO_C$XV:GN7P9;A*F:6I@BZ[=)K2R";*AOA_>;6`X*ZFO*S-L\&:'4/; M3[./?P^#1*SVGCX&/X)H:7]O=LV'T9B_(K^`[G,Z=C4^HH9#NKIE*Y[-S4ZG M%(/170][?X$8EO?NRG,8)XPFXKAZ=]K8`V*'59GRM8UI=CW3=53%%!5ZRQ`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`UE\GWT4T4 M#+:_])C&3O=_HJ>.]!!(]_Z/0`I$MMN@+V6QY!<9-*1!G$CQ))'"A4W,<"0E MT\$H@J,EGU\HAN)'[EKZ$&;W4I&%,K]XX4]CC@S^#/X._GLPS2#S1I)N[X/% MR^*!E/%?=K\T3#F\^>)A*++12'=/TD14V91\J1^F>>-%80<_O9<&4?P@^2,_ M>DKY/4F0YZH1G13O"!['1:<'$^'4-K\C%5?R##YG3_-PYT?5MWFVH&?,U,36 MF*%IENS*NFJ+.K.E:S4Q%$_3VC)3SQ62K_.?A*H4NB?H8#+RAT)_1,FBDG_% M2`M=X<*3A%RD7'Q\MDERG1C$D:#9FT;.CG7R1$]`*CED),=^7[#[M>C>#1D_ M%D\)!?2*[XNO&<4)-W7?E?=D\5@\^''^X*QP^0BB:'I-?M@HOJ=COU=^?[X. M#OWD>S@J&NE/LKC\(<=M\.C[X_3X*;\L#:<\W8G MLT]BWA&M';V_,J\XP3T4G^79M6^S_OQCLO$)>5O>7VGTYZ4GS)^\\6GS&^53 MWZ>UI:'-[N`V?9@J?)Z-ON='4Q6\B[,L'I;:6GR[H>-'*9_LI)^*L]=W2PCE M?UZ"W^+W^1-F/Q7X$+_L[<8")]3$>H))RUD__NGO&71JSG6(^ MO1ACWA!AYM_!(==/B":44%Y5P%U4-%?-04=#%33'[?ER0<]<*Q M'TG^L%PDB`7@\B(!F*X,TY7+IRF:])>JA5!]GW,5JD$%#"K3RG2@*>-YU)(; M7``N>*U<(#/6(8R`!ZI8Y_N]/[\GW"#IBYVI.+GYJ=<+@L'@PJRO?V[9IHW" M\J!HMD]?E5HU2+*-X^-9<^F^]5:50GS&LJH5!LQ6X30%=75;-H`8(+9PWZ]R MQZAN6VRO7.:*TB*#\>"=ZPJV;$C;K8;;./,C+,-.LPQ;WEI5QH]2/YZ(@]N7 M[*U.'YJ?":]MUC9%S2I;Q!TLPA-+K!W6U#[AM4*7L)D$%@.+M83%9*9TJ%*= MQ0H&6S97QNOW^X@N=WE<>X6^:UW'_0G>>7FW.G9&O4_3G>2PD!47_P: M](2L^U8V"T@\PGU2)9[KB=QCEN+:FJ.99AEKJJJJ7KO[9*VFM7`/SQTAA3]E M/DYIZ7:[ZCL>#V;.YZ/^;,M.5*(0VS/\3/LA0N=?A,D:"*U2HNHYN144IV282<3V@/M@?9`>Z`]T!YH3ZNT M!V>XT)^VZ4_K5[0O%UH1]+$[7@"(`^+`V-`?Z`_T!_H#_8'^0'^@/]`?Z$\[ M5JP'ID5K?8ZK_Q=QV)F?24[H?Q_%*1=%'E=?%H#+,RA4!%3DZSLAPS4^.V1U M"6/VJ54;DAHSTI%-N7:1-&7PQ7U(#0JJ`=5<1O*\IFL`^`9\`[Z!:0.J`=6` M:D`UH!I0#:@&5(-5%/@&?--,;0/?P+0Y;36\"SO;^_O3F/\M'M5UG@=6/KS, MUC&R.FLU+;E#"6IL`A%`1(T6/W`!7+0>%Y@I@`@@`H@`(H`(V$[`!7"!F>+T M>W>OQ6'?^L';%23PT6\P#54JQ$N;MR_^Z`$0`\0`,4`,$`/$`#%`[%5`C)*. M)L,]!>@"NC"!`6*`6-L@QB@N3OI!4DI"'C]*:1R%?>DGDO]S0<<4,E\&JF9E M(7='"ZXI(*W;*``\`<\S']0#HH`H(%KM#*IC!@4\`<^&PI/I*N`)>`*>S8,G M#%Q`%!!M-$3EW%-``3R;X^IJM'TO_#;._&A-8,>.1CH9;Y$>%\Z[*!P%U_=! M+@.9DI\7'J./LT+%\Z;PQU1)LV#3YQ"!PHF@'T_NHF#&!,<(6&(UI$%C:L=0:EK&;1!<*_2H;D,1#`8&`X.U9:4+%@.+@<7`8C7; M85J'LII.N\!@8#`P&!BL7@;3E`XWPL!@8#`PV/DU#PR&E218#"P&%GME+";L M,+W"#$E@L.C(L^4&^X.4Q[;BP+OAW`T.[Q]#_RZ,PBP,TAML M1U>/S8M+,%4]WS<%"B_=XP0L``O``K``+``+P`*P`"P`"\`"L``L``O`HG5N M1:W/Z_R-_R5()4ID*GV.LR"M2GL:O$'?;-@=Y6;:]+0SU;F8[E.K0_GYTGS@ MFZX!=1LWX!OP#?@&?`.^`=^`;\`WX!OP#?CF=?`-I1VJ55;ZLO&##ZH!U8!J MSA3XJW08J2Z#5-,''U0#J@'58!75%KZIP%F_]4=ZG_PG<9['JCW/`R%?O/,` M"J4#%\`%<`%<`!?`!7`!7#Q7'#)3.E1AP`0P`4R4AS.$=5AUQ8^`"6"B]9B` M_53M#MYK\=;W@KMDXB?Y_IX!?_W&$='EU,VEAMQA!GPJ`"_`JPYX:;2CR-65 MI0:\`"_`"T?G@!@@=J(93--6Q_C([FE;920+@!7@!7C`0X5OY M4M_*I'=?>%?>!LE0^AC[HZH4"$QTP2<^JMDQU,KJ]C8%#G7/VH#$!4."D0XA ME950!"0`B=9#`GX!P`5P`5P`%\`%<`%<`!?`11-V\0[<^#7:OKUW&V=^5)7& MX,CA6,'%23](RMXKXT>I'T_NHD#ZB>3_'"7`K:,Q?9NX5>:O2N,H[,_>U!3% MK"XSQC[9OB1U1AVBK".%C]Q1:76^=T=+M!6:5[<=!I8$2X(E&\B2RF!) ML"18L@FZ"I9L]$8#F!),":9LA*Z"*2MT@&)R1Z>5I8$`2X(EP9*-T%6P9(4^ M<=3HZ*2ZL`^P)%@2+-D$705+8M7=7J9<\!IXF_E<+ANOW_#YM[?C?A3>?.O= M!_U)%/P^L-(TR%)KU/\8^G=A%&9AD'Z.LZ]!3\BQ;V6>'R9_^-$DN!7ON>5" ML:.X]^??_N]__^>WE6=]&&5!$J29^S@.1FGP^^B3_R1B<_+$2,NW<]F/A("_ M!H/W5YXCKOJ'\J];YTH*^_P'OY==*[JLN8;&3->4#8,QG8AOCBX[Q-!-P[KZ MV\J`+0K_-AP&J?0Y>)"^QD-_.S\OW!Z%H^#Z/LBG`YF2GRL=\%(T4E#(1AK$ MB11/$FDY.[P4C_)?N_&H+R[KBT^Y"OL9__(MX_\;!J.,7SB0/HQZ\3"0'OQ4 MXO\.XHC/1^G-3A7:U=W&Z?N!C>T%0K:'C/#2+"=BW_*GA$+4Q??%UXSB9.A' M2R0MBVMF#\YQ)_6"*)I>\_Z*7.7?.:GTRN_/U\VAGWP/1T4C_4D6ES\4ADK^ MRT/8S^[YU5P04[KC5!;YXS2X*3^L#>>\W8MN1G,*U#=ZB!W@J90WYOT5TW[> MRZ[+$\#T1OG$]QDM:2?ZA_[5][X*HH>QSH)\UN0S:ZY^7B?F/5;!,^61?WTH M#(.[..I/W5/ODR"0/O&_W:>2R\V(/A0)BG2$(GWF=N=1>@06!XN?%7S+^S1T M;/;^4,^-XCR_,C7NSY0MF@;*=2MLH\O:!L4#8P&Y2M M,"2%TY-I0+:YNTM-49_*G*;JZW,K MO)N:,I[B/B3U`1>`"P[LM-Q1&^__X62AB$@92/[C+ MI#!-)_ZH%_!VI1EJ79]R^Q?%H.K0L*:@K6XS"1`#Q!;N4VAEA5X`+4`+T%JP MPA54"06T`*T:H&6RRBKV73RTX.RP>07;#],>'W:X.YR!B5I'.#CZ!RZ`BTW' M6`JI[!@+B``B=ONRKN=Q:B%BC.J\HO=)!X@"HBX>44K'J'`Y^$H05>>!)VG[ M>A'5YIK@L()>#^[@OK@CRCEL=!I4"^\3X'*7\" M/:X:B.?)BD=LHEF&UR6R22U3*ZJ!R(9L>,IE5`,II"0*@M#S%P0YNV+O:AP* M@*``2*,++*!_Z%^3^]<2!^%V+:4@GU=5MP$%0*!(E2@2"H"`Q1LE'Q1G0`$0 MZ%C#=0P%0%``I`WX1N9RI,F'LK4E33Z4#,I[D.$-K@`7'!@IQ55!P>``\`!KY@#C,J\F9LRC*``4``H MX!F=1AVPJK97&A2UA6H:%\_"KS!I,JII(-04$*L58EIE9ZM`%I`%9"W8V=4E MH`&R@"P@:QZ5;U97*O+2H06_`=32:!H3M8YP<(H.7``7Z_>II++5(_``/+0> M#WIE=BG@`#BT'@YR1Z\N"^^E(`)E+%#&XORDLUMP2*I9FZ<(DFJBC$7CK#`P M)9@23-D\IJRM[B(8$@P)A@1#MIXA9`)&.UZYNCR^)/&Y&J6%3+DZ1O]UM2WD,W4&_*O\V!%T#P4[CAU-%*Z'EW'FM@ MF,Q]GU,=^WHJ0T&Q1AE?Y!2.W!-?(&.WXXS=IA)R]45G=0FY:O)ME4EJ`Z>L MM5H.=6CC`FL$;M9-J('"0&&@,%!8@RD,+^"^^^.!_'FHY4B'.I]1WZ(I21:O MX^*]DF>(XZW;=X[\8]H[MRFQX?=?I]-W=2[01R$.R"RS9%*R")2MDR5[7\;S^[B7:".15 MF$];:X]M-3MD[]MY.R]*I^S>W7&2KK_-MG_4/FN=MCMG;>^\[PV\3N?XW&ZS M=?OGI\-F;;.=;VX6I80$B>C!S;1\9A_]=)+PGM!,!?S)(%OF],=%3O^+5)QG MG%!\'_M)I,2US+#]%MMOU]Q^Z_;6W'_;:4(^ MB^[V=KNJL(T-I%\FJ5+B(_TVR<09N1$!@`0@O0)(OY'?^2H<@<7!XCM5ODV\ M.%`SY5R\JB+:+0<8`\;J@K']>P$RRV6*-R#W3L'Q]MD]L,.KC@#;-L%6V:DX M`%O=P/;\-PMJ@<2:T5YE[V4`IGL%TT:_!5X'!]S<=T+?I=+/"QE2-XII$HOY MCH&J:*!&HJP=!53.G[4O(5F+-Q]KLUNKO957&^LR]WP?]J2":<`T8!HP#9BF MPLWMZX6&>T]#S3CJ88"#'D!@(+":01$$]OR2NTZW75F-T6:C9ET":\C6J8TF MYX;V#2"9:W[O9"P"-O&/N"[IVKMC_)UR/^N;B'E MM6*#[4>_`7^`G^!O[:9A>XX@TYEI;)` M8"`P$!@(;)L$UB8/K++-92"P6RG#-:N.O+@ZR$J)$1J>RN@R[W5%1-K#D]YY MVVUY@VZG>][N=SL_$6AU4O9=MN.:)^)SL"@WN+P5/E MWX:@:R"XV5,;]\;$F/L^WPHH.$[(*="X$R=`K;>3^%I[I]8^I*XV-^;JDT\6 M`GW/]2K#0%WF<]T<$K@`7/!#<8'G.>UV#S101:1?G_WBFY3M'P_D:D,M1SK4 M^8SZ%DU)Y'C!LUX[\?=FI_T&_)>]WT\/%8.*O4!.;WN5G07TI%"6*&F0L_CL MQ#5>9,&++-B'U*P`[L?9A[0)5PJ;DQ(KA'IWMO]D8^ M8VZ:L1.RAML<>ZVF[`)LS'[,>@]P[[;N(!K!S[#6[%Q\RI-C5 M"&SN>%?C(]#\<78[KF%I[%_83E]_I=^Z4L.=`7H:C!YLKGH8:R=)Q*\=^7:9I?.2_O@C?EX?0("BK/BC;N\ILGM-JH9HM-`(:,;^OZWBH[XS4R_-E M>ZJO-.ED(*9V'Q*"HAK1S_Z\6>,=.;UV98NS>Q$0+N@72^0TP"%/Q%B/UN$ M']0EWDM#-/&L[)W;KNRXYKK`'_$U-.+U?NR@LC?$]T4?$%T_+-M/.?T&I[]& MC+,_3K_K>$?5U5+8=[\?R@7E>DE$?83],5L,J7'6"R((G)*`4Q(VL=?1++*^TZ_P6$+PUTV/]:6GO*QY?,N-(V".9::S3^.R*0+G M,PYW&;K'QZUC][3;;G5[K6'OO.6US.$NQSVOV^MU&GVXB[G\\1<_CX2J'T^=!J&9NZA$4LBT#G*A`G"9\/D]E/A@$D M?WVN8QG[6H;B@L2N(I)^)B;R2HF14K&8IFHJ4[I.QZ;A-*"KE;C6^43\.AQ^ M%N,D%:;&I([$>-&6CL=\[`Q/XZ'@3BU_RI:/T;$?%@'U.`R%#/XJLMQ^_Y8T MA@!AE">)PQDCPQYC(U+E%VG*/ZS<$,C\HG,!:%?7IJV#99./]`80JVN2#UH M#")6OLHRF(FY=?F=)HDB";_Z8",X9,W3-0NJ((\[+])%\\ M@R:*K@Z(JW--LJ2&YU=R(4Z?)<^=X*>-"QK^F%B%FIL1]PGZWG0PGHFL&&7J M6\$CFC_;=NZPEO#[,;2#JWRF*C07W`MYD4V2(@P(?72=-+I#B/ZKB'WSJU$> M+@>Z\O!G/)*Q,G]L;(J'\CJ$RI,%D@QZ%`TD$'?D_T)YE4FMTD4PDQ(H4G\S MOE_8.#]V8,*]!R.\9L:<.4<8(;+,AG%S$$M$#$WTL0T-L%Q.E&MV_"9[4868O`7J". MY@Z=B*B#,W(TF6C(LB2MB M&B=E46@OZAOBTB`KK1"3L/Y@*-ZF:D$UD1Y7H/(G4 M&[XVRXDU)T07*LT69VOWWI7#<\C5-6[VLE>Y_*ZR0W&AE"E:*-K&,5GV541* MLG&(K#M[*T+PD\RTMR(HLDK4:S)?DNUU$ANKE9'[3(+S!;_AD/,GZW-%*I\D M[*DGI9DR$WQEW7)VNDF,-)^!\,DJZ7PN';I3+UF.QYV7KGZ6IX7YTLXP-1:`,H&53Y&B2YV_&\7I??>?IE6DGQH?QU;F?&-\NQ[?WAPMO(.B\***(,[#DZ)G@DSVKX<+[/2?O M]X*]WV7\_MS5'ZQ>/RD?'/WZ&#*7(AV:E063&,.1)<#?UO'WQS*8_Y6#>4`0 M$-P=!#^8/`DP"`QN&8-GB\3B.:<0_\4I1,`0,-PR#!=ARNW%,F`16-Q.P927 M+\CB;(P7[D!$Z8E=J_9V5+=V\@%^@!_@!_@!?NHI'^`'^`%^@!_@IX;RP2E5 MKZF[*A[<%HQC=G:8VMJB$)L@N-H("X@#XH`X(`Z(JX_@@#@@#HAKA.!J(RP@ M[D=`',ZMS,V6%:3@ZINBK`M.*CNW;7-CWL#):WVGU:HL]567J>3[V!T^^T-HZNNBC6ICT8J!?4:[/V'RH& M%8.*0<6@8E`Q.(E0+Z@7U`OJ!?6">L%!W&UR=L]RL">+@DP93I/?(1,UCG!< MQVM55IN[+MJP::,-C=ACC>AZ+O0!^@!]P+8`Z`7TXA'/J>_UH!'0"&@$+`7T M`GH!2['QK-WS$KWM;M/3>5^27(95(09+#*\5W(T"+.WI=Q$D!1?A7J<"RX.S M43[-%/Z^4^NE+L"L;&/\D[)]$K6/R7@#HJS>+'C>P&EU*TLVO5ZBC4#>ICTP ML"18$BQ9/Y:L,!T/A@1#@B%K@54P9*W3;F!*,"68LA98!5-6&W%W^][N)=H( MY($EP9)-P2I8LDJ6[#G]3G4%L\"28$FP9!VP"I:LZ:(^./)1\57PAL\N^'%B MJU*:MXOJS96059/JT-9*5L`5<`5<`5=-D15P!5P!5\!54V0%7`%7]2@<6:-, MY(:2%>;/:SM+HR0,;$.GRE?12*6B[3K":[E'2.W62)51$!:(`^*`."`.B`/B M@#@@KE:"`^*`.""N_H+#(9KYNQ.93?8G,[=S1:Q`"Q`>@`9``Z`!T`!H`#0`&D!D\,0X-[GU MLO$K,!])G#,1R?2KRL68AEM9$3.LF*+.XHTS+ERG-ZCN)*!]K[$(]8)Z[=;^ M0\6@8E`QJ!A4#"H&)Q'J!?6">D&]H%Y0+SB(NTW.[ED.]B1)ITDJP%+494MEN]OT=-Z7))=A58C!$@.*$=5N8SR*$;WS!FW' M13FBFGA@8$FP)%BR?BQ983H>#`F&!$/6`JM@R%JGW<"48$HP92VP"J:L-N+N M]A%Q@R7!DF!)L.1#+.DZ[1Y8$BP)E@1+@B6WL*@/CGQ4?"M[!7[.)52I<6L-TR M)4OOGLCXFE$Y(J7'7L;T;4`?"9O\X5+J.!/)6,@KJ4-6J8-QDAYD,EQ]@TQ< MRVQM05C+T^FW'!)$)8T=BB_THQ+7_)]*6HR3:A!4BC4589)E)+\D%BS29TAZ M99+&%:G2=O1D@=]%I=W#6A!2HZB=\"R*^+9VQD+'5RK+(Q7G&7WVPX(EKF/Q MYA,!A`:71--4352S\Y(E8YPRZ7W]\8/9;3:9I\UY',53BK M2*N/6D>5:;4!:37=:G>K[);1WDK:VCS7LPSOE+YF$Y!-E9\32L+9X^HY__SW MGXOLX%+*Z2]<8(O_G7TK]!6Q%F%Q&`B[Y^RKVZ893G?F$UB)5BUL)TS%KVN]J_+]OSD]9-/_7 M_O>7TS="!_2%]/.#H_-!:S@X/>D>]4X[[5;OS.T/NYW3GGO:ZI^=#]TW_[BE MRJOB^Z(C8MO?U+7X/8GDPS'L#IC`_'FGD/FA6!&@F=\;(JPEG36%>^V??/DO M.J?F_0?FX(.ZE*'XG"849X7.,R*V=*1SZSS37WXH=43_M_917]KOC79,E[/D,)ED.F-M80[7Q"QA M2#Q8T&S2=5.*Q6=\412IU-%/5OO$4D_5E5;7W&@N"$!9+KX5,J5A MTZW\'!G\561T-T]7JL8L1?,T'4V)D_G9FHRR?5\LOXJ`LW2+=N) M=$Q3PE-)/DM:A':F9'"E?2.^T"@;B3/.5.BL3(..27B1:=5\JZX,)?(LDK_$ M?KV*+JL?:Y`SH)'!8'7::^T^@R(YLIS80N9X\# M``827N#KG7!0U/,-P^?3#^)8)Y\GDH#IB/>Q?RBNQ$=BDZ_B@KZ<"N/I M\3]QFDR8Y?BD%DS.VIW]%(M/?IZPF^OUK0MM-)"]I2FKYUB'S&;F;[(63.@F MK,J?GA[Q=KZERFN],UD^^;Y&<1=I`M_2&7^\\6BW]RX3_U2S/"T"R>P=%/ZR`QPM MLC&BV)P:M.9Q;A#*Y]]HZ']Z75=\-H,PV91%)]G*I.I;H0S9$W5?&D8W?;:" MXROFC[7V9]%R]]VR669N(:]E&G`_`AE)[F506(//EF-%=G0Q35@<&!+G1V5L MHE:O,"'LM0[#<6$-2:!"/5+FR"-C!U,U"DL[/W^8(62:+66MB*1[2#*64^UC MN!]L)-@PJ.\^A6?T4VFIJ.NIM#[WH_%,,PGR3% MY>1AX=##III-.'5D$:YY\VAM%30C&B89NFQU!FY*OX1B/DGYF>3"'%X>.K?Q M]3-!PZ2<:`PK(-*<:K+387ID15/BYMZ>@[JV85?^)#\URVG"E[Y+W8;2*+G/ M3<8R67DTMQELPJVM*#WZBX*\PH@UL$B-8\O)@G\GZ5=VX!*C(&P!LB**V.]? M4"2'*UH5AL,7-L=&#$M"7;*.:9WNH[XLFIA;J,7TGVIY&1.I:#];81SQ*[GF M1$U)FBV2Q3F_,3J/!)AE2Y_ROJ:(!T=$N=.PR-@H6=JR+O7WJ8HY<6V3CT77))JD*./<2E[3DU<"ANS(?7?G!" M,AG-Y454K+X;#U]Q/I,42"XF1`IJB@_!HTDA3YHB#!L4F`52ZS*;3Y;%I3]9 M[=\+)"XSBG28Y3D\FQ#PS4-NC&4!KI1BF;2T:O<;XA(:3X_`68&-^6(534^V MO!PP"^)>_%XG11APT,AC,G'@C>']EES9T77LX&Z9.=NQ0,6Z-$MK#5:4XWI0 MO/J6$.RD/#:;JU.8399C#0W.UDV_WB5V0SG<"5*R;P4%IH3ZZO+D2+`3%C/$"@4F1FS6"4DZE>&'3*PU'O-5PY"DHSL,4_TZ89*7/FZRJMM&1^:1!6?84VFS8,;'M1YV9JV1@13YA".57W.VR;J8J4E6 M9<4H8Q7F%I,G.3-08UF$N76^YX:0S8#-TV1$WV809<8NFX_2Y'66W/:4!*^2 MD&P>`9DT(B*4Y#0S)D%39\^@D-ABZ+M71$ M$;,UM\I_+GUEXW@9\#HV?Z#N'5!8*>-\'J.?)`=?^`M_)H:7J2K3`W?;D?RC M24=K^BV*]9@-HG4MR*SF\'55\D*/$N!.LZ]+_5IB\5:F#O.+` MII/4+";JL(`D^3*\Z/Y_:;NL8C\NEE$6CL%"0628)7:]*IORDAUKB5DIXTD[ MF.NPC5.7H6F1E_AU%JMYO-UED8R+(EXI2A4OO/#:'[/*8EXCR:P/(8QD:1KZ8*/8T7[A3J#$D>F=3T;:'R&GQBL;R_^S]:W/;1M(WC+^^ MMNKZ#E.^DWN=*ICAF92SV2I9LG=]/4GLM9W-L_\W3XV`H8@U"'`Q@&1=G_[? M/3,X\2"1U(`"J$[M)B*)PTQ/]Z\/T]-=L0?`VL_Q7N'?+%4!-Z/WS=': M*\=J-3VKR"%\KU((?XN2O1*R>H/!V_/SM[TWX_YT>G9Q.7PS?:L3LJ:CX>7T M[6DE9/6&8"ZY;KI(-2?I5,P*&9FF8R.1N%5JXV)3@JLO=>*KCWB,WKI(LI^* M9)%[4F-57H[)IBUGW>)S=.;M2YV^_<-J"FX6+425<'\Z-PYD+:&W_-A*[@8\ MV#,(\N#H'9/E)*2.DF3I/[*4\-MA'S!_Y*%'Z728(JOX'DWW.8'_:"+`*S8Q M.V5]'Y3U?65,"-R5*('*]K4K)W8[VIM&;R;`%*#7C9RF]3790454SG9B=R^E\SA M3YB3.<>G8I%+*5YG?ZRM3#&HL>_KMV6@-,$M]PV.\L+#*DU73N3VUX[6'O_T?:T0;?WT/54G*(8[>*A] MY?%Y[7[^0+UNU._W6,]>#<='E&AL3!7& MP;A^,6O*RN-]5&F6<(9PYBFJO8ZFZ^ETA#2$-(0TA#1VD>9L>$9(<[P(=K?M MWN@Y%G;,$I+566`_%%N+M&Y+#: M($U39*UNRXC$Z1F+T[`[('DB>2)YLB5/PS[)TQ'LZ0:Y\W72]JVNHU/:\JG/ MK&X021L':'L(:MU=OYK"FNUH[-68&$MMAM8^!&L*[U"PEZ"L0>Q(4+9ON'@Z M?7J2-85[",P(S!K$C@1F^\63G<%9[^E)UA3NL>C,;V^;^F!AF7NKPSQ42N9C M%/CNG?[W/B5E!H.WO?[;R9NSMZ.WD\%DU)OTWZB2,F_@CW=ONZTN*:,NO__, M"963.5HYF:R6C*P4DLG:':FZEP_79,%BR[K$\_:>NH4IJ5>B.F M`Q;VBS"%8V;8R0N?7)#O@/)5.P''"MID]6F`O/LCS/F[B][EY;L!H$QW]+8[ M'G0OIAG"]`<7HU-'F(\QK)6_-%UG*L1LI.SN:)(^92T?[KJZO#1B01KRU/,3 M74AI4TFE=S[6H\1N8*7B2EE9JL0\+C45E[`I`LHR5IJ]G4=!# M]=C-Z,>_V+_MGYQ70XSB%ETGOW#(R6 M4)GB:&2CE4AM,A\]6*Q4)V6*%<%`_CX+5847>*^O">RP7_F=VGC2GY6LO!-7 M<8IM->#[J?E>R197*EK.409+W1IG@F/52P=,%*[;*&*%RG09Z3Z'KEI5[!2I MRRDOM>(HNLU@5RXLI:L?J;$#[91JMXJD;I3/$7#GM? M,-V`D2L8&OLWJLOG^X+VYZ'W=[!<818F:_'@+M"CWO1R,IB.SL;GDXOS?G\R M&/44V%Z)',E M.8JT;D9:<&Z44Y7W2I&ZV4X2:<=+@5,Y%-R),@9^NN-0M_50E_D!9 M26_3.'H%UE&465:ZT2.7:[Y<1UV+8U'-!HLW&Y,)ZWWJQVL/C`28&"C=($ M.T=X&3MN8#%5F=\-0.?Y,U^WYEACST:*RI[@\^IFF^_ M]\AJOKVS8]=T/78166"A=E2[/?I*T/QH?HV;WS:\RN\:M:WX8_W.O[(>WAGK MX2*S'NX/U]`1F3WHDP]W\@3,U[`ZH_LXVL1QQ'&/Y[@]@B!4Q[;9M49.3$H; M1A_B'^(?XI]GQ#\[6PGMLP)V2">ANNO$5HUAJ]-K(K5&_;/#B'^VU;#/,A5( M=(^C,9\YNWTN4MH^QKZ[\WF)HP[RY7?875IM"))*([DX!LM]N5ONW!&(6&UW MZZG];:JLL]IO69+$N4J2(*XCKCL"U[W#A)M_8L(-,1PQ',$<<=U)F#4'HSDD:YQ$MX5PM<4EU7V]3G\T/D&J$;LUDMT^BR!@A'`-8+E# MZ-/XPD34L66=::;]7K]^H&H*!^!]5&>/\(;PAO"&\(;PAO#F=/%F['2[74(: M0AI"&D*:>HN9#^U5_VWZRC\69^C,B]40/J%OT^A3?T!^TE[B$/.<5'B=&&CW M-H6'T.I)VQ#6$*]IB@:NVUDBN2"Y(+D@N7A6UQS*-`YP&D:? MVJ-K8VN;8<0\3:-/RV)EQ$`GO,LX&-@\Z=(4Y5NW:T`B<<(B,71&9];2I$DB M2"):+Q&D)$@D2"2J+IHS'%-^EHVP3X/"K&V)!S6(9(V#G+80KO8(TJ3^^@7$ M;JTA7,MB3@VB7.-8[AGNO5'R"&UODXB1B)&(D8BU5\0F5%2,A(N$JZ88]<3: MGLW)BQ:E9U%Z%F78/":X-K56M(^8IVGT:5FHC!CHA+<9J5X0R07)!MJV'>AK?VUEK'-X4[[?4&>HBV MCVD>5`25@_[$D821A)&-H)7"2,M;BJ, MG.G$7EU!`DD"20+))O`J@:1-0[([MM<1@3!RQPVL'Q,.=-ET_=$&5B):X(?B MU5PH-.WUN]__U(!([M,/[\M>)'(>.AQV;NH)]G@L!%]^*6#`NV2P*0!O) MU\TDAVW6VO:2TCT5C=8%*%43])&F^G/YH6$4+WA0`>0>7I,_6$D:(O8*%_$[?L4[3@:W;"K>\E<_@3YF30"Y`IX$LI7F=_ MK*U,,:CR!G:!:+V-.0<[[(&KP?S\8M#[_D&PK.*YN?'0^P;3([_PX/OZ;1EH MLR=X6!)&Q2[HKRGX$TJ65Q]O-31=18&G'W3!Y9R]`Y1G?Q?>M;!E;Y'O1'QW M+]_]8LP78CAK#)H;2%$1 MN0@-2C>PF;?:]+7?%EL@I"&D(:2I^1B1,Z#.M_5Z*Z=E'M;CE!`2-XT^=?+0 M!^56V'4GB(/LTZ=\2J!-@\63 M`N`-"C?)S@5X<.T-3_P;P?Q0)G&Z$.&#YP,^)_`??2$\YGWH1@NAH]6[WG,1 M+9:QF,-U^&;SA%LNK1PS:/3R;GL)'2L`")P\\EC!N-N2)/A)2\9)\Z/Y->R, M!KD61)\'Z),/=_*TU7:/D2S\91X+P7Z%W^:2O04;P2-&(D8Z@)%^`Z/R(#YJ M"8K7Y%=M)B;!^E-*8QVG1AHFK?GY)3;H.L1CQ&--X;'3.W=-VJ+=DDQG##>P M'!UH)68[)K/M?$25F*UMS%8JB;;^BN9Q8L-@;W?J$9L^)S:E,_UTIO^$9/SH M=LWQF8R\.&(P8C!B,&(P8K`V,MCC[=A:6*SM]2EL,N!O(F'7W`_9RR"2\@<6 M"S>Z#N$:#S,V/UR\=U@H5&YGPK^Q-0H?Q/-PGTR76\@-5/OIGA3'R3+1]G=/ M&]WPH'Q9+:!+@U:Y<;!C'6H:?[24CA67[WLYJK]\P;K(U$$-(0TA#2$-+4B31^0QEZW MSJ:O_6.1IB7;TS9)]K=JA"[@4OHS7WAL%D<+QETW7:2!.A3]X>(]\\,D@H'> M\2"Y@\MO1)B*IH;Q^K6$\4BGV*=/4^#C618+Z3G#,VL:HBDK6;?)22A`*'!2 M*/#R;&JM83%%V@DB"").#B(&SEEW0(8"H0"AP#-&@9<#9S*T?D#JM$T%R@K; M-2O,Q^,J0B:E=C*^JK>G@TROF(L]GQ'>V!Q[/LLF!9P&E#?6=M72^`@W[6ZL M,XW5HM>-YX"Z+5;"&$;PILMNZF$,H0RA#*$,F35$-X0WA#>G`3>4'[8`8&\ MY]Q%)`>9_^_^?ZR-O@I"PV6UR\0K]7:=!"U^0I6^++&]56Q?LIK*,`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`0W!EQ>COK6RA&N+WI]E*".'20N MIU%4KRD"4+>)3W*Q^[;R<;:-&T*-LCZ<:^/(P[ MPRX)A`77?K?`8OM]?I,.&`N@KK3G^U-ZK[$8G8!L(UAEAMX[AG".HOA_4G4M/N"PF>I7!)?4)X;,&;=BC1NMX`RXG% M4=Y%\4SX>+@M`DKBD:N`,BEH"V.7XU(4L"5Q('&@3`F2"]K9>SKF(2%Y-D)R MNLKCI3UCBL(B)"TGKE+&'7OAQ:9P_I/$,AH4/#Q2+9D=^HY0(/;(.R"5DE*# MY3?F12F6WLQJ2EFEK'F;:G&R5KVJ,?;`P!E/[94Y.IC`=1"K<1^_>M__^F__I(]ZRV/0^`K^5'$ZI;\*B!QB'3\ M)&8_OWAWB:'3?PS^]>7R!?,]^(*[R:M>M]\_NW@[/1M-S]Z,W[YY>S:X&(\N M)[TWD_ZDVSM_\=>5=2G3^(%.P9N6]5A-G-7'M:KP_0Z,-F'O0S=:"-6SZN'B M[T\P^'U@_+[A[;`>%6AO>,_I7K=KL=GTY)'-ID=M:3D\: MDH[1I^\8G!A]\N%.GC9EXQA-=;[,8R'8K_#;7+*W8"/0J0-BI$,8Z3`/\`A*^6H3O&?34KN1;68L)-:YI-O'@J?$@=7,_0!-7PV%ON/1=QD./ M7?I!BD=,58#L-:D:^V).?3LW16@MIO<2LQ&S/<1L-67L-D&/$#.VC1D)^8C9 MFH=\^YG50)4G8+\-@RCH<'88^?"V#<]]B"7W>X'^A%>_]A-XB;N^8-O&\-(/ M63*/4@GFNF3BFPL^DS+B)9KLC"^B-$PD'<]\`DPY#F8TCC[$/\0_Q#_$/\0_ MS:0/\8_MZ/&I1X?3A8AY$L4DA*"8+03YX3(?.@3;@>/Q(:+87N7K=OM,?V*LX M27!&<$9P1G#V1'#6'P"<]>U5"B,X(S@C.",X>RHX&T^/B&?EPGT_O^AKB/J?N8I.$D821A)&$-5S"'CPV?T0B MMH%PC2$6<=QSX+B6!.KK5!-_*'='>(S#;/FUT$G" M.*.QM5[O39&>NHTLDHF3EHFNTQ];ZXM*,D$R<0(R,7`&]NH)DDR03+1?)D83 MIS\AF;#AO.WF_O9:[]9]$C*)?5>=^DRPB5V4)C+A(0Z7XC$-0J/3B;'WQI/: M.:LIXE6W/B?1(M$JW7=&765)LDBRZE!:`WO'N$BT2+1(M`K1ZMD[4G3JHO7X MCMT6G:[_7K#U@V1>+JUNXD8B1B97O`Z0]I#Y^$BX2K!N$:T&X( M219)5AV2Y0RZM(M?JXO[+#S96Q['/$QHHY%B9T_BCC9%.NI6WR07)!F+;=GSVP_JHZ(HG%?:@" MZQ-A5BV=-?5#\8H>/%%&@>_E#WSRNGR3H;7S`@_WB-R9$BW&/Y)'DL>#Y7'L M3,^LU00D>21Y)'E\I'Z3S47V]PA*PY#3F) MB);AL&5MD!I%Q,80CCB1.+$9A"-.)$YL!N&($Y\S)S[OAH7JXUI_]M^J.V-J M1XR]TAT**=)P'`1\]$;]$WK%W]DF@OTYVX^/=#OV-O.:LI`4;B00(!#8"P3& MU%6,0(!`X#F#0(\L`0(!`H'G#@(3ZLUN(];2H%!@$X(P)DWY&01:3P^0&W_\ MP!I2/\A6;8!PFQ&=QB]]W08>`0T!#0'-UJ@1'7$CH"&@(:!I3V2J\4M/0$-` M0T#S5$`S)J`Y("SV8\*O`K'I^J,-K$2TP`_%JRQ5J]_]_NFI=M_@ZJTID)<- MR.H$A)OB'*'76R[2E4W\$/U0CU4GIA2?O>.&+X(4B\ODI#,><(6 M_(Y=P4]2IG`;"!X.-H4[RLVCU:#AEB3V754W0?W(;WGL24==_DY>1WV7J]$,O=CC_T'J)#H!8?)#1RVQN-[\J3!07,82C&^)]PH5DO^&F7) M**5>I\O@00%\_=AWJ@Y`AJ^CQ.?(:AE=%?&6:0R?D&/A/6(!P"`+6L%;DODZL?`WP!-0 MFG=,*,['UR71PR_,WL&N[MCMW'?GS$_R$?/E,HZ^^0M]OYT5Z8]M,S+0IK(2 M2(P27JROBH-TOI?_1E62(@H'`@F'WVKJ***9M\$G[H?X+DLTZG<&=FF$Z+B9 M;_U$KE.HLSZ1)NCN5AD:1F](0/-P57$\,7_U1J-.[Y@,5C4&T/8)W32.88J` M*[<^0-KFB5?O!"L&C2O\&_C%R@1'G;YU@GV\ M_.7/,K,6M3'B&!!&O8$$X`OPEA(T$H&8@.?*+,IM3F/`Q&A#QKHD%AA[G@A@ MWO@9,#V5^6U`0C:/`C!_"I,+%(&0LEPP&FS15+"74@A%=';V0Z>1XM4V+#"L MW%-,;.SQ=3M9::7_X:&RG)"+RV94?_7>S9H-'U&^;;AZVP9KOL.^`#=LMN96 M+'EEQ*$#HKT.*9(D0',N%^-"^@WWFDMP7"Z7\]Q$-,Q7^AE'E\D#.B%Z6&MN M@WXS]_Z=RD092"`"@3)L@->W$&9E%JNTS;T:.8]NP\PV4#X\XU?1C7!R_TJA MNI8\)*JZ!*Z'STOCB,@41%C/CH3GT?DTZO+7?@*/=_635M;R8ZX$+E`)?%!* M0*WP'[IK&?L(UX5@^P;L$CWH32!.R[+G8)5DFJYP#.51!2=`\^3*)9F#*'CQZYE3!REB*T_Y+):)0+5E\K6`>V&(`*(QBB*QK`,-!<\_@JHG=^WCK5_*$A&C`,'/XX6^A(> MN&G`M5T%M]U7:],.+7M3V\:I#1;<-5`#OIME2]'HFDRJ=G[H%W\!M_TF;MFG M:,'7MI)VG9"6XK+(R[@G8T=I)NA(N3Z785>?-P>8Y1.D97R253LNLEC4( M!B\OC,RDD"*Y:Y(N8;*%@]]A'[;&39RU9;@%&6<\N.5W$D,+0&__56[G&3\N M%D`Z2R+;1*P;VS9'#-8I1_J1!E>5:1]0THHFFE6>D:IZNN5[<,ZD*SDYFX#.E[AYQ;CN M;NJ4;,["XHW2P,LRG3:;O5_F0JKMV!2H@KL#;G9/;M`"`69IDL99*I+ MW6XYLM4\Z-M.FD^L=SE4[:M'FV:E&T)[#=XR?P.A2\;DM:KH:DQV'?Z7;7:X@\+?F& M]L:4)5(79EPY_[*2:[XI]$1!?Y*MPVW?,Y*MC;*EK:K6JXH\@:U6@)Z,&LA% M]J+IZTRT];C/=GC>,TI=]Y(-)K1DFY8L<\XQV7/[H2NG\.;O==\KNU$E'\^/ M,^<.-QLK$8[[/:_L[[_\F,I7UYPO7[_E,>:VRX\B_HSO_`+6\YL`)OC7__[3 M?_TEN^H=]^-_8F[RN90BD;\*+M-8>!_"3QC1B>$!;W!>OX?1E13Q#<:`WH?+ M-/F$^?>N'_AJ#OFST7=$,_V3F/W\XMTE\NX_!O_Z#MZ,W@HG\Q'EU.>A>]M\.+L^&+OZ[X`>6U?2`[9=/!UOO<",QT M]6=W5CV)+^I`41!$M^K\&U),XF''!8_A0NUXJU-"$D- MU]PW'E\0P2\RRY)583%A5I8L/%LJ\;4-G[0.9JK3AW;5D;9=1*A2CZ"[_*:? MX@.3A/IS^34AAIN"RF'\'EZ3/UAG?[LB",PU/[_HOE"?Y9*[V>?]A1\$[-H/ M]2!YFD39%[IBA/KFUO>2^>OQM+?,&PFZ(*I\*<7K[(^U,$,Q\'))QN(T?6]C M;X\=JCJJT?S\8@C4>?"D?K4<@+D36]$?=N>@?^B=P\'XT%M'A]YX=O`;#Y_F MT<B> MM.,C MD/;9ET$\,?KDPQT_@1CO(;0/Q)*LN&B?HCL>)'?L$WXOV2MVGK#";;,&F,-F M-XJM,PGFC;CV0U40YPT/>.@*QA-V*5RS&=73)Z*LP2.5AWV\_=.PML5/3CCK M"J7QQ56IKFXEPV9TYO2']6-44U8?[SMZQZFG!^CF.&!$*Z(5T8IHU2):47"- M:'6T0&1CO!=R`=L7D/@2)3Q0F92FL#8>)<60CRZG6JUP3W$)8DHBW$D1KJ7> MZ9-S&]&G559=G2KT8I/BC&8P(KV;$F>[*3PI7?&4O-:4T)JUP&J;XJ>],Z=_ M-K4U\Z8LY6.CI,V#C&9!*CE_QU3@1+CVV]EUHMW'.,*B45*?13R.HJ\C_Z3Q MFV_VMEX?H-Y);,V^G#IGD_63Q4]%LD)66V23[I.;V!8H;)8.H9`#A1R(/L^> M/B>WJT$L1B[\KO3IUT"?/1RB&J):76?0IZ@616T:`C"G''PP59VS0L[8^Y$' M60]-W912':VG:!@Q)!'NI`A'OO-)^#Z-HT^MAFE#U2>Q#_E]IR!>3^OW]387 MH"7'[Z0W?>/V&OXLV))8;C&QN7G+I2S>(\,%RGU8D;]^= MG0_?GI]?]`:#MV_/>MTWPU[6BN3-^;NS8[8BL;7V.\#QGIRD/JY5XQMTV):: MZ?*K!JA8RE=-ZV%!HYH=@LV';>3^429SJ`O7834C(1#6!DEGG M9[X`ZQ]^3.9@X.5-G&/A"O\&>\C,L(V4ZD*<1$P*;*LR626R%"MN#Q5WC.DB.L^DO5 MQ1I&@<-:%%S"/!@OODQ\\Q/=^UKUDBXWPLG>BEVE==.D1%Q'V$7'4[][6NIU M4QQ8T6SVI>X[JD5;=I^0A_=Y:14O5NRBX=2RWZ5['?281IAIO]?["9M?Z<98 M_TDC['*5,0&NJ^ISQ%4C+?.][ESD8_L8U+Q;UKPM]-C1\&W.@/4"]O=80%PN MZ<.#>;QEL1R6JDX9I=X8^A&O])-]W2@#GI.&#USC1G$<@7FE>JU=W65#`<#@ MJJ5<2ZC<4K88;&:+RJJ9A=(K#K8/OU:8GM\X^0F;VLDD5TR*6X!QTH7I97T[ M!TUA'H/0GH;\A@-[P=,/[S#>*HRV;B^LMIQ;@C&,BC;9PY@P"MJKGA'4#0_C MS%[7G0Y1,@/%,;=^,E?UTX6Z7+>:G_LBYK$[O[._G*5[*@+1V,9DNNM8KPMS MLM5T;#!X9-,Q(/!AS:9Z1[YOTI)QTOQH?DT>)\V/YM?D<39[?BW);*XU@D:9 MS37N#_9&>S5XZ9]B@Y=]NCP3RQ'+66"YK+E-B>/V[')S6"YM#90ES?$\Q7B_ M!G]'X;6GEVNS1T'\1OQV1'ZSEGU"_$;\M@._#8C?B-^.PF^J9!%Q&W$;66_$ M;R?*;S7E#C?!NR=^;"$_DG5'_-9`ZZ[U6V%GA]'O+".?NOJU#R3SW2T$??D> M\Z&B5/+0D_O4;&X8$=LKQT]]4O,13$8Q<^(>XA[BGI,ZRTO\TS3^(?0A[B'N M(>XA[B'N:1?W-(X^Q#^MXI\FH4_KHVF/9ZEW^5%$?;3X_D/Z)'DG*7F$W,0_ MQ#_$/V0Y$O\TEW$?XA_B'^(?XA_B'_:R#^-HP_Q3ZOXIUGX4V,;FU[KHVJ_ M1J'(:^?-8+K4<+.->+:5V$WA,WNERA]BJUVK"CQE%?+>X,R9CJPU'&O\ZN-] MCRDP3EA#6$-8\QBFF?9[_?K%K2D<0'A#>$-X0WA#>$-X0WASVGA#OA1A#6$- M81'$=X0WA#>$-X0WA#>$-X0WI`O]:1- MM@\\`MC^;*6+*%ZJCI],8IM!U5+T*2'GQ"`Y'VZ_AC3"/9(&6V'<-$4FZK9A M2"Y.6"YZSK0_(8D@B2")($U!M8`!A4G,W80.KS<) MCZP2\=04^,GO5Y.(D8CM0:>A,SJS%E\DX2+A(N$B_44B1B)&^HN$BX2KW<)% M^HM$C$2L9OW5'9^1<)%PD7"1_B(1(Q%KF8B1_MI'N.@P6?+3'SR.>6AOSY!P MYX13%2B%A^2"Y&+]OI[3'TU)(D@B2")(4Y!)%XD7B1>)%YM$B\R$$G$2,1( MQ$C$GJ&(1;$GXHP2O>4W)J/`]]C_Z:I_3D@$^Z,SIS\<6N.^0PE'XDGB^0PU MH&WQ.W7Q>OR1M/ZT[3N27Z*$![8XAF!G'X4V`(7F1>E5('*-=@@!S4/QBG45 MV10VL]>(('"=<*/JK;HB($(P0C!+-$LHDSGMK; M42#\(OPB_"+\:N^>*"$8(1@A&"'8\1!L-.@[O6Y-`7E",$(P0C!"L'KW-/H] M9W)&-A@A&"%8`SB/$&QODHV=P<1>F5#"KZ>23P(X`C@"N$TF6IU97P1Q9*(1 M@A&"U5O)?3IQAKT1(5A-V74_)ARFO^GZHPVL1+3`#\6KN5`@V.MWO_^I5BKN MAFQ/-;PO$-@8X.Z<13.6S`7\/Q;BU0(>,V=+>&3D229"3WAVIO19+!.QN!)QL9Z#KL/Z MW0VH<7@OFA\SU M8S==R(2'+CYLSA/F\E3"TJJ%-P_O-%*^VH)5^B->_MI/X/&N_N96O_DJ"CS] MZ(LH7B(+"?99N""%B2_N[V9!A-]AL`5594Y5T/RA]&7"EK&_X#$\`D7D]\[G M#OR272[^D_K)'9O#^@`@2BV!14$IO,/=]&P?P%$F\-P$I"B5"*8@KR!Y\!;Q M#:[#[Y5D<1?A0J)$PBB^BH3])XWP5Q@6B*/#;I4&B:ZDB&]0RW?8>X#=)6)O MJ`;OXM-EE,8HO1RNY8&,F)+?6:0'JB")!/@8`IQ5(/N452`[3]@[9)A_/EB! MC)9@WR503[H4RV@!S)Y1_OP:+)4%"$?3QM\J8JO[/H3L@YM$%;.L-U5FV>S\$,PFOBR$M=>""PB@@1 M#^'EV?C`[A'?C`V$,,GMV+'?]8?=S@A'&@#DVC'372[G.&&D(F@@/%#$5*.K M:T58K!K,:>JB9M-L-<96)T@9CP.)7L92%>,@4[\C^I-D3S80$L?@8J?,L$T4^D"&;JAMQJ+5\,IHR` MA[./'/"5C2\B?V\LI,[E<1NU^WO^]_ M>(@OM"(@>)],EUM"DDFT_&F-KXK'3)9).4PU&6K^A.=M9-R#!/C__<1>2K"( MK@-_F0#=%`?M1F:@J&LH"B234H3515VC\!)\DS#Q00/-TB0%9\/#2$.T5"A8 MTL\XAGPU@)]@/6_0([I62@IO][_!>+P(!@.8?^6'6GO!U>_#F^@K#_GS6+R7 M+DP55FX61/_KAS\HPJTM5[&:9N'@/L^LVYM(S#%:!QCP'OX=P%06=I8-Y6^W M95.7>W%Z+1\:/P#0O\V8-H&@L=08SZQ&/9--<_Q)O>JE,&3XY6_L%W\FV&?7 M%RJ.A;]N`2IE\.73?)C:"$;_3Q0+KAYZ`0OF<2PT<_[Y?G7JI8*EZXQK+%5'4LDGG%WX$L$T*PA14 M!C`WRA+>[Q6O`5T+0H.NT2W\7QE[>%/%=O1!`CD8!85(.$:W:VV,LPE%4CPT M?TW)G5'SOQ),`J?#1XSR@M+.)E+QN%0<7-U%7&O%RMO*HHJ3$2)%'HI/YGZ, M#!7"`L:2QW>`14$0W:)EEX?JTR7Z<6KQ\;N`(S,8>2@NCUPWC:4V^#(KL#]" M,[`/QB`@'!I+'&:4XG.`]QBP:!CEDE'BIP4'A,M<:BT6R"KK:*S0O;0KM$%X M4!#$MV5F*Z+<*($F9GOT8,\5*K9POZWT$@L;;W9WU:IZQ!-:9E5$BB>*?7.! M26-WC@:"KX)>,D&[`(6?77YBG],K$*0E?(TA,1!Q=L-C7PE4^?)-7Z-EEMQU MV-^C6\#M>&5`D4"I3?0>,OZRA,MBU!8>R!B:4O`=^NXW>NL!.*0\)C6+!?CT M3`)/^C,P@)0_Y\/CX>;2I7\&N76C,%KX+N[PH@F$.X):^^DQJ->K[1+4+:&` MI_GX=_6=/S&\,!;P!.%4!F,>4S(",7:%V1G:^J\&!PDQK*@G#FY=4OCO.9." MB4$:FO,!(U!7P`_X(:5]D[R.U0P&,R::V"V6-T!KU`**(_IFB@O M#A@>K,<'?[@!_`GLCJ*(,_T%'1XV,!>@5V$B#*4YSGUX"4YZOP()0_(>YT"@2,030ZD M`Y?(;%UN6A6]:7C%D9C*\LA7HXB^*QB@[N3K;$GP*O)Q1&!QR@I#2,HUQ*]*PQ- M:#Y#\=+`$61[ZZ!N/%]'+/*0"`8W9S-#JQP1S`T*&#J6:#2/TD#M=,DUF0#0 MB%7P`638$^9O$.W1]\XJ2E60V%6/+-_Q76]:[,_@X_)'XX_]0:>?_;@2PF#G MVCMYM>1Q<[1 M5GB_7\WXLFPJ*,-)+;[,"*G"4`6.W:`M4C5S%+CH"W,T[K`_A,$G#`?A^F?, MF"TB="B`>_].I3;8BD24+73NL`M8:70!86'3 M&9B%,/%8(;T2'[`'$5?@1C4N($$>SL_"#DNT`!*CT=6>L'J\$2*9`$?A'.$5 M[\15G.(Z(37/TVL<):#$N,,^P)3`HU5SO'<5$K`ZE\A>'!@8]0_R!#QZ_=KR MSH.*S\@T2+*Y9W/#+4>1^-E3]&`*6=VD#A\GK16!G'1Z96&M2/*D,]DBJW84 MVSJL-<%F;96!_<<E]JU0.-"[ M=?2F7/'D?$-/[?Y)F:I7`%O@_K\Q*=%6+%N0*'79J\O[[$8O`K"`Z)IPHC:U M.6A&Z2.?538)KH3*"45^5L,";S'@,4;DM5D(+S:^8A)S]ZM*3XV];!L/D,T% M.)REP0;[5HM(S)?*3`4JH&]0(8&*CW(6IBIY%_<:0'L&D01Q-[Z$TMV1,A*^ MX9LTG"Z7".X:!N&6)/:O4O5*E1];A0<8N3:>]3Z&\?XKP\7(K+;AT=_&30;@ M4<^\.D'W8^WEAN*8PJ?C:K&X\<5MON4*9.3@+.CW((*JC%P])0P9:G63N4N% M?U:,H%$M3V!89=7!>P)]JN6!9%.U4V("K%<$W^*'R]=4+"TJ3V@ M4#D398*9E:V0%?-I0KA+YP;IJ>I4#@QB+],K\!Q0&R19H#W?>-:_X6K=<#]0 M_A30$UZ*&KIBEZ#WZL:XTPDO]'C"'>-6)NC:1G$B2VN)6SHW:"7CA5F29$<+ M+&9)9I8-WV3ZX(8R0*XR)DI60J%/"\(4Q-J%/IDEP:5K%*^.ZV1[=$*9HYDQ MN_:6!;_3T:"RK[;!M/K#'#S(]PORX&_NTN6CU4*LU=^H8\0.@6*'?7^52\5C MH-`Y>!F!><0'0+,T%,SDBXV<[;MDGLH2Q^)U:"'KBY?<5T($LMQAEZG(9I"&1J@PP**JJV?C^'.F>)53''I% M\G2"3MBU#OO<"C2?M3,0`EN_PNC6)F-1&=LHBU?X4@59,`10<56'P@1:,SOP M7II9H(1*RE3,H)A`?$/EA2A2"F1KC:.2DY3!L(I9.&W#)12#I5V;YN[:N#R. M[U""[XM1*\=!1#&"`=,'`I%9;V\JRWB_/^LC\0*A= MPSF3?[ZA(R:U'#%1;D)_[!B7?^.QDDW$+TZ4P*]N!&[27;&EF.V?Y^=*-A\K MV72.!+RAI8JKHJ_!=<0U64GPBL4K$]S4&W&8&JE#S6HKSJGM?`DX,C4>9'!T MU'HF!.7K6-I]S_?=R]%C=0H@-\>5D[8]Q5][U=J-'7;8ED3)S1*R4XYD)2L2 MQ`0>M4QCF7)]LB4/4@AW'D9!='V7'PK?E#4)=ZN@$X^YYU\OV&<0)G%8QJ1V M?>`-#$,C<[DMA3++G_SGF_74R?L.E67;%[$`7R?4X/'/-QV<`CIV8#9F*3\* M1@RY-)SP1/FP*K%..W-7*N.E`F=3QPB_"22A.:I66V]\<;WIZ,Y],3/G@G&` MT6P&;J$*=*Y0T4??+S=TH]O0[-/@H/&!*Y=?`..!IW=>R=_;QBPZ2AF*ZRCQ ME3DLQ9+'RO`E++""!>O;0AO788W/6F(K'RL9*`.-O5)^GC*EIW*B8E/BTN;$ M'$70Q^3E9&DY(3+Z_5DY!3%J\GI[D\X3I;^HD,"V%)C.ADW0@Z0KVR^&850) MN^]><<[1&U([^IWAULR.>Q([CK:973J;NK:97?JMELWLC=DK?B5Y!>%!)N7T M%76Z2&W3E+8ZS8FUW;-8E",2PC,$[LB&`C?6>'QWG.06%?TO4EO.$YT?J4-> M:J=0R?QJ`I5_7_Y4*:%D6^[>_`/O^ZH.[?PW*F(+)=023 M?P.?1VF:2CRY@'"FS"*==;8Q!H9%X%[]6CF5?AO%@7?KET)VY2-=%R+V1'#- MV1/*`,S'C4&=L5_6V!Q>T,JVE;"2O6..6))?]QZ\H7 M9\)7&6!+68*_B?!_X5X3VU2'7LL9C25_G&/\$JQI\2T+)&#L4'^MJ*TSRB66 MZ%TE<3CD_9[D$\IF$)IQW/F*^(9=R_=A3"IZ,+L9( M.JVFX"7%*2E.:35.*;%LQ9,'*ON=:2,#E2V*4_9ZU5,ME2!A;UCL8#]9I')0 M6$]KDD`QKR!CSI.^!W\2+#DKPHSW M-;L4*SBO>)+8O_H!C`*P:/$D&0-+$4^)Z2Q>%1S%$@^9^;TI&N?.XRCT7;:X M`T/=]U@@TJ]BX?/UI&!][NZ[?K?;Z>;N"';D*24WFAH9>2:B/C)F2_%\URN_ MVPX=_8(;,4Z(E2]CH.5Z"*M:8I51*+)[FY7?H$%#UOE[?--`JUW\TUESYF7K%M^`$!DUN?`^(J2]0 M(\;0ZC([,>[%_-:P5O6$;',Y)LR.H-[JXFVYC*GTO[U2--]`3+^(7E7) MJ2GU4$IO]:7;\G;9[TNSG*H`9XS5AE4?(),EK1ILF1/P^K.[7>`(TE*J>CRG_4(;G39M>LH`*K+?LPQV50%*_.QB8DQYAB$BYMJ:%>&+I&&$KVM&O MPZA##IWY$@NRJ#V:#)WP0]8,=&7ZO1&>WXG2Z_G:+U,`\O4%R57-0F!4U^A4 MM>_NO5*[2V#^8"A:=QT(E86C:7O%I6_TKJ^1,0ET-#U[S!KUE=R4G"1ET8?: M`]++:G:H'`8`?*V=`Z=4+L/4US"$>=1G,QP07-X+8\VHY?9VD;[&$G7^;_- M;F';*O3]LAX8+1]ENP>)'UD8ES;#:3/\!#?#08_09O@C-\-']VR&EQ7UDVV& M]XL-^;7-\/[6S7K:#*?-<+)):#.<-L,WNF##L\:>U/E?$4>T!U[/'KCU92<` MKF,/W!7!IV^T"5[+)G@NR*7:KYMWPK>L@K;OSC]]?,]^^>4"]V)QIP(L)RQX MXJDFMKZ7-1[2#SEH][QR&*APXK-VXUG8:+'>/K!<+NK_QX,;7]H!5(M[Y-/A MM%_')KE,9T`"'OH!+@0,YUIM`:E.F4S>25CZ'S:?#W'89UA84#Z!JFVDZO]C MZ=7`YRJ.JA;RS[)4MK]/F]AJ$+M,S3*2DN]0T38;6.ABTB?.X2-"`-G$:Q=O'V,2QONP$P'5LXMR`A@.`,U7. M4;)H0Z>.#1W3@$!OY@RV;>;LL!J.B1!E73%-8\^\Y2-&4,UC=(ZMI3U9Z]G0 M+P$O]22BT%I?*/M)VXB(^BS*#\:'3Z6.$&1DQL.&41CJ%.7")-_8I!4-\R!= M^#=#!Y+"UA2V?FS86FUU/WG0>F3OY($=@;`9^3X@ M:`WD..3LP=3I=KOK-?@F9_C]DP6K>X-)-J[J>/7WM9PT^+4(/>/VJN^)+#,L M._Z>IC@TQ:$I#MVR.'3>F%''HY\^#-WO3"@*W2C. M/D84VO:J6T'??Z>@169WK0'@.L:K5'H4@$I6IA[:_JC(%Z`0X4)M4JBL9.7= M5?R*(D9V#1ZF_H3\4[2%-=HS#K'83>XT6F$`[`/(5-$D4Z[!#IBT0F1?-Y69 MZF1^5T7IM[ZV])0EE@D+KU^AO?*ZN_RFG^*CFM.?RZ$,?LQ^"F[)XF6^.!O MQ8.52#!7!(&YYN<7W1?JLUQR-_N\@5`/=`4!`;OV0SU(GB91]H6*?>AO;GTO MF;\>3WLPGJLH!B/_E0NBRI=2O,[^6#/0BH''^5_@64"[`);LV' M_.(?$Z_X,][X"#6:GU\,@3J51Y2>O>EQQ9W]Z:%W#OJ'WCDK<+[[56'45!9Y^T#NT\_^I[/Q?!4=;33OXOZNH8SF\\WLYJ/=>!?78 M2Z/&?[@7EW=8@V.3?1.KE)8`8WX87'@]]ST`^Y\,Q/<1SZVJN=V*'%6YGVA% MM"):$:W:0JM\Z(-&J%>BU2G0ZD%C[B$"&C?(D`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`K8[VY&GW M,(]1"/D+MF!FOT:J5=O;C:W:B)&(D1YFI-^PY=\A?$0H3BC^I,+W#,K=5^+R MQ&/$8TWAL<.RAQK7"^4D6\Z0?+>X\]$Q))[V=XG9CLELUCHQ$+,1LQ&R$;,U MAMEV1K:6!DN:D[9'M#JEG+-&T8KXBOB*^(KXJBVT(KXBOFI&V88&'7VJOU;; M#G7:MB=<MU`9FZ&'-?CQSU@L(Z!O>$U=;-J+HL^H4O%)5"(> M.OVIO4K$S[[2,`$1`1$!T0'4Z(^=R712.TF:LOAXWR/;L!#4$-00U!Q`#;N- MG1J_^`0U!#4$-4\#-9.^PBC6,1NG?L[\*[%NP"+HZY^T"%:EJ$'0^K5]N.8LAS9NCN9G2?*[J[ M&=V9+TMGVJ^XA']'(5O&/IYZ9HO($X%DJ<0/L>`>C()%5U+$-^K$M!\NT\0T M/X/'^3<"?O]/&N'#%CS^BL%8K$6.A]\]7[I!9%[`&>",E/A&7W8:2="VK/ZN M(O@'CV/^4#%X(O8.@\THB6($[)N@N`"W*]F8L:4I*^PQT*\!BY:)#Y>Q)&)7 MZ1W[O?.Y`_?%RR@&D6/B/ZF?@%3"*JE-#!06#UY\PU&8LOT,[L)E,3R12[;D M<8*O"4'(0"1=X6>B>`."K,K]=]AF,+C-QET1^DRX,9=K57H5$`@]+'S"FP`L MA%>?71@O?*O0@837#G2K$A^X$LHND5FM$(WBE:7,F`+6)/#YE1_XB0\W`$,P MF5[]6[@),EOI'EC;Z#KTD0_9U1T+!,`TN_63N2EJ@E=Q]>O<%S$']KT[O-1( MJU9UVTM:5VA$5Q'I=6%.MHJ(]$>/+"+2GWY_6)V#WI'O.VO).&E^-+\FCY/F M]Y3S>WSN^W#8]A2B9L103RS&7`RWM]?YE/Y)'^,N2$FU?(GEZF2Y2W#-5SBN MISBNWF-1=5"6-,?S%./]#C8>A=>>7JXO>!S?8<3GGQBE(;8CMCL*V[W#P.## M+/=T`_Q%Q2>M;6J30)!`G()`#$@@2"#(,"&V.U6V:PD.DV%"`D$"<8AATI+J M/-O#3&>'4?!LCRRME^^I5N5S*%%0"Y-1)).XA[B'N(>XA[B'N(>XIU7<0WNX MQ#]MXY_6>[2/)]JY.HUP_WD!DCB2.$)LXA_B'^(?XA_B'^(?XA_B'^(?XI]V M>*P[5N#JMMV7_0//82<\89<^OPXC":20JX46;`DJ536CJF;%?535K'S?J.OT MSGJUDZ0IBX_W40%%@AJ"FN-#C6:::;_7KU_$-X0W9-H0U!#4$-00 MU!#4$-00U!#4D!=%>$-XTTQN([PAT\9&VXM#TU1;O[?W]SO5]#6L:S^/4+E4 M.KJ&C?<]MMEKZ.CE]+O6FI@V12+J-F!((DY8(FJP^$DN2"Y:+Q>D*4@B2")( M(D@B2"+(=B*Y(+D@37'\V-US2=@_OX%QB9AR]!L,0U:)>&IZ^^2W'DC$2,1( MQ$C$2,1(Q$C$2,2>A8CUN\ZX1^DI)%TD7:3`2,1(Q-HF8J#`)F-KH=B3ER[* MKTQ^^N7M;Y_//U%VY=/#4.O09M1U^N.Q+59IBD#4K;)))$Y8)"A%@.2"Y()4 M!8D$B<0#Y!B<.>/QE$2"1()$@JPGD@N2BZWD&':=XLYD8JW9^LGO09!TD731)CJ)&(E84T1L MU'>Z(U)@)%TD7?7L!`S.)B1=)%TD760>DHB1B+5,Q(9GSMF06##V M(X^YYU\OV.>E'PK*M7QZ.&HEZG3/;+%*4P2C;M5-(G'"(D'9`B07)!<;-^"Z M$\H6()$@D2A93R,2"1()$@FRGD@N2"X>:%'3'Y%(6(CB/9=K_CFA;8H>N('#,VM'[@XF7%.$M&ZC M@,23Q/.)-^I)1$E$243M:M`):5`23Q+/AHKG:#(D\23Q)/%LGGB2@4LB2B+: M:!'MJ4R!`8EGS0U9#I<@OU@#@_!7XH7LV%HD&OW_V^ M])C),M$LKH8"C[$)LX2F^P#!`(#`B]*K0.1(<`@!S4/QBG5H:0KW?W=T$AZ9 M8C6401L-G>F@)C=N`^%:P4=U&XJ$8(1@A&!M\70)Q0C%",4(Q6JVP\9.?U33 M;A<1@I$G22A&*$8H]LQ0#.VPB<4* M281@P8%[RPW.!\FV;7'#N^'81T3U5D&KZXA/4$-00U)`7U1:\L9"LW_HMO5_Y'>[GC>SNYQ$@ MGWSR`#5*)[D@N2"Y(+D@N2"Y(+D@N=B7'+W1P.D/1B03)!,D$]GF3'?DC.PU M/R*9()EHO4R0_60W@O=O;;4)%XD7B1>M'5.(D8B=B0--AD[_?Z4Q(O$B\2K#O_KS!F/ MK>TDD'B1>)%XD8%(N96/S:V,W;G.KOPBX@7[)>*A+08B)#KA'9_AF3,=6NO; MVQ1QJ%MKDTBWCO2Y3PP!;'T);#H82+8D_$V>P'RV_,B]*K0+#_TU7_'$3` MK:MAWH:W]N!5,@I\+W]34QC37F6,AVC[F-(9=9"RCA(^/6?8MY=[=S!%6\%Y M==MAA)*$DH22#43)GMT,94))0DE"R2;P*J%DHP,-A)2$E(24C>!50DJ+"5"C MGC/I6RL#02A)*$DHV0A>)92TF!/7GSJ3KKUC'X22A)*$DDW@54))\KK;BY2E MK($?$PYTV73]T096(EK@A^+57"A,[?6[W_]4)Q7_O_5_&CE.O$^FRRT<#YSZ MT]IPBL=,EHEZB*[]`X_9N!R'#(M]F0OF\CB^`]1A?`'"E+!HQD*L8\5BX0K_ M!GF+B6]ND'KP70(W>.(J89XOW>QR*V/YKM<9,K@J\*/U`UP'38['OA0AF\71 M0HW[@L?BG[ZX94G,0\G=!-[$7F+-+C;^H=-8OFF-,)[+O9CAB[\`AOH-UN-3 MM.!K!I3!=`/;:MR><*.8X[*]1E+HMWX6RT0LKD1<&$V#KJ-.!%IBH]![-(?O M.IE+$+F5N?347-;#-(?,Q5%R(&3B+W@B/#;C?LQN>)`*M711&K.//.:>?[U@ MGY?`.PH)2D#@L*\\T(/K#P8_1>N___UN":\'P5K[Y?P&0$;$JS\H^E[Z\$7" MWH$]S7X5'F+C^@-N18S@DXAX`4/S6"H1M8!V+(K9(L(?#2C!CRZ7`O\`/,,F%TC";5PAI4+"B^K<2 M#+9,@702WMY(O&L5./^!2^$)L0#*A\`'4F+5REM@\/":7X,4PG+ZL?=JR>/D MKK0$R+%QPI*(<2E]8&W@)F%^1ND#R/##&V"=JA#%(E"FR'_5&1?'SK&DO#^`2.`'#@%W$C`C;(OY+JCGQ2P)V) M'P!]P`4!8OLSP!N@:!I&5U+$^FEZX`HUP/)1LFN&K`1KEH(DXC1O1`CBX:RP MOV,DW;R.7T4IK)A(DD#@A`"'U50`Y8RL(MUB\9_41YF\\T7@@<1%;!E'-[XG M&!A]@"&)(N`V"&<+P24,2E$,T1*\FU#"W;&F_"V'Y0VBZ"M.Q@@E@D>^5K`L M&O\RNJM1N6D#P16I)[Y^`1P!P$9W3B2$M^6RB3V MYK,)E*`?`!9DVQ97>.(B. M\E\VR@*PEU*)48"\#?J*W<)82A`";]7V`P_UJQE?@K1Q=[XJ#RD,/PZ48BT] M#L>)C^3>OX$)]=69O)6&Y$8X?OA-POC5X_0\.^LF91.6NW6\&40L:"&J%_>_O;Y_)-2#26ND^D5FD^)KZP9Y$'#-885X9.^L#OY`@6+%Y;_$>W]%7L/WBS772]D]ZM58\]Y ME+5WOXUWKTVWKPGW>,/-V=L^P^N7Z57@R[EX>FN-K]AKA%565.*&H`[PDPHY M(ZOK==P<2_E/&B';&,]_&?NN\O%BN)('H&_4[P_HE.SOO_R8RE?7G"]?OX,! M_1/'@C-$NGX2LY]?O+M$3/W'X%]?+E\PWX,OX!FOSKJ7W7'_8CP> MO.GU>I/N].+MV_'H[Z(U[^VD_@\:[^ MYE:_^2H*//UH0UN6$9?]77C7L+R-Y.,=-\"?+)B"81.0'711(H1H15DWHRR` MZ[50UACP"@970'%$!IQC7TF:GT43`FQWV7&S;:O0FX3(P[4WD73-W'B1N.!<4. MU_TGY3'R/UP/6#LV]AJ:5QC36Q,(\8Z*`+?@P:Z[#V`MW8N=8C6C)0-\_]I8*O M"$T\PRG@8,.2^MJ\14M=:G]"+[\`!\1%>$/HT^RX[F,K=BX8"!R2POW5YDMF ML.@='RU>L>`>3(VM&?O:V^'JM?![Q?0Q)JI4[@M8+,),YEI9LFHB>I3\^CH6 MU\CS:0AOTE[&-6")1*L)[I1H7X="2Q;_YF3;2/F,84:+):Q\F`F?(8FO/!W, M9-&1S02LG#DHA8@$\F\46X$[40G1?L MTY:!XMA6!4=!#0X$'">\!2,1H0E&**\GQ\%<>#.DD'PAF-H,1*>")\7DO,H. MO+]8:J#A<0BKI^1WY9$==A[>J>%FH\WH"!*04Q+=*\.8"',&V\L,$PN\1E/T MQ?MLLT[QJB*8)I%:L!?9-/(95%ZF='0$%'\HRKS!'#[4R*V8RN_54+_P;X51 MO8\U_&8,QM6H_VY\>38>3+NC\?1\K*SAR^GH?#J>M-H:7K-]>P/4IT@P!A1[ MH$4;V;P;[S/T`Q!3<1#0NWDH(YG'H(07<-, M.PE5PV[GS')&E2UZ?3><6,[VN85L:?5EX08CI,FD% MI3<8=?I-E93><-CIU2HJMW-?[49A9!]3DV(PJF.TF;6%O%QJ]TMY?\)36PFX M$YLF47QG3":E%E26$MB#YJLK@7Y@Z0+Q;'8];0[NBW+JLQ`%TGD925_O00!M MP>M`]\1+XVR-M#96\:-5R&H'VCBXO6!'>/K6C3@D3\WOGTD:QW M=C;.@HPJM/@K5RVK^P[[>/F+V5-%]YYEP85^]Z
J7#=OEWO9]8(!(,_.5) M]>\_?6;I$B,'T6()/QH'G(>5X9O0Q@5::Y."!BJ0B&0PNYJ@ MA'1NAU_V/HKG9J&&Q"3(7L#BP31#GZ\0`-YWIJ@%D^YVV'D`E$JOYQHP?;59 M;<8(]5P03<5U7C,U+DY,F/^B"%9"A_*$YPU9+[F/6$A`'95`2K MODC%%Z3$V&?,?:GW6-7H^#>UE5Y:VP4LGMZT9_CX6">PY$N2O9Z[;IR:K$L5 MJ4-2J`":^N/Y2,])=_BQF@K4F+Z4X%H)LBW&N/!J$9+D"II[Y\/N- M2<$)08A8KV\4S[[1D?OB&IL#(/MO!4[?GO>[D\$`F'PTZ+][TWTSNLBV`B?G MO3>M#G[LL!78_%!(FX`=#325Y"%1E%'8RB:OBB*O[K/G^5D:P(V>O9Y94HS/!*6-]*\G(^L9+_F=BK-GOV?/0?CIL$L! M`XSSBV.Q!"!4`\:AZ)0;G!3FP,#D)^;P,TNC+KJ5".-UR:FF\$>:I\B ME[1DQ.2Q[!N560.C0U1>&Q%>E6?;*>P,N7JWAD694;TXXY&8Q>JP?^:I3`#) MT:T^FY&]-C:[=?"JU,7]LN*UV8C5K`!,@=#J0$O@?Q7JI`579SAT')U7@NK,J.2=-\##GKB,@63 MHI@O7^-F2\:V:NYSW$YBU\"VB3(>@"ZC[O>:3OX\BCR5 M$B'T[J+9M%*V4V99E?+O#C8T[MMEP6Z"$E/=Y9>8>^(\]#[@1E&1]RX/VW[I MCP>7[Z9GW6[_#-SG_L6;_OFYLD`NSL\G@_%9JRV0-7MCW%''!>3J>0%%2_9+ M%%Z_4KT;2V1M)":T"L!^6SL?E6]S!DAQ-$E*/\O"JE!B'Z'^0L$KY\SF:?7R M=2-B8VU9D'7#W"0@'7BPIFGS:]5B9-&8O'-LWRD')T#5"C=-=##DD8&Y78]] M?S?IC.S&*8\U\N0VLC+@5^@<@#8/_2C.S^BLGA17"3TJBT0GPF0&S>[GQ=YC M[HJG[2SE2_%89V-FJ2#)T2C7ZWYO9ZF7@.@\#-.%DQ]0+Q/MFM\(%>3+S%15 M_4>YDJ&XCA+?9.SEOQL?S!A^Z*V6,E04"<_3:[!-2_%#Q*B-8)8=_MLP,,>< MC-#G1!Y8>0M%1G:6Q5[7>F3^2?FL7P.?H1.KCH*HE07WXUH=9FXO7JXPG#GT MU%Z>6\=.KF(MW%<>V6_1C=K!8WW'B'$1F`*Q=(7PYE%C'V3@*QB MZ.RK'WH_5&PV;6T8"IE-RQ*)LJSAG$)Y!(HS3&G6!01?>:"MDB+%V)!O$Q?^ M6:5N%P=`]09N4FS.X8$#5?LCB?TKLY<7&R\[E?<\UYQ8D,6>H!LM8-#*X%(A M+GVL'+Z+,?KF_V^^D8IQNNQV@B@;GN#_\##%:C@`3P-G31C]$`_<"IW$KH\7 MSUA6J(N9^EP`:QMA;,X]?=1EEH:@4G4V.KS*[*WJ@[99$8%5H$!PO(IQZQ8> M\%EH"YSU.[U.7_TVV79G1\F)VE79;):C>>"[BC\],>/J2'>)#AJJ!WI'&Y!( M!(;MR]O+$9X6WEYY00DNS#?4XR[4[=JKM52#VPV*NY=,U#8[\15K-E@ZI1$`@M#(?U7%#/(!GHW^@!X M474#)BH`(]68\%NS\36+E8>)$S/KK=P_`^_@0>3+C![I\5RD+AA\=^M!YX,6 M$E1ZL*5HCLGLR%?%Y4L5#_Q?[4=5#G^6:_R"+ZV)#"Z+TO)1AM>H/;D\FJ'_Y,"#EY/O/J[(RP/)EJZ74&QY6:*+R.5`;<4L0FO\TP229+.0'Q2Q6JU6RR M:@:AR6"5:)FRG=BEB*ZH=(,LX%7\L>T"U4CCM566]H<\!AOH@Q$4W2DLJL6$2>VKHM)YF*;^"M*JNKF&,CV<4Z M;UL:W'K?@9GZ1S_P[3<\'Z^\1(P"W*(^](1T8_\*5@;-8LT^>;)M19?OQCPF M3[Q4O"Z/6V)H9![)_-!\'II??4BYLND1@TSW$^_QH:7[G__HF!/Z[SZ><7^* M^%.'_1U\[AL1.VLJ:R>^>^C^8$#\LOK_$\H(ZN5OO#J@:(I%E#7[_BGQG M\W3;_:_*#KKA7%5E!!ULF!UWOH.!/5OF`6;/91^+9);7/"PJE3MUS]>B,?O` M=%5"TSU3M7)VZX'9GAV+F:M.S,;Y_@3B;N1=U>J;^<+\J`(MF9&E#]X41PG5 M;>:^+#98+8FO@Z*ERV]^>-#0*@8T:J#M?K1'I4=]M\H04>A<.!J;-RGD"7 M4A?K+E5&+UX'TYF!:Z3]6F7/F0'HHS#*L_)\>86EO90ZP($;PA;Q977LJF*7 M(=KK9%U#?GWJ$.XU-^]G+RMBY'4IC0Y3NQ6B[)B;4-167S'?D\`M#W/"*W\[ M&L%^>%?X&$"@3VC#U=<5+@]T(4,T MJWEV!C-'?*=DA^:O67>=MQ25?R9";G-P[TV45Y?Q&U8#&_FAX+)V5ELWFQ4H MQB?D/+K-8A6^7JJB7TP:9E6;P4%2$6/L)":USRH0R5V5>I/7G,8C8*!7=#)N MJ!5C>7S/B@.FW8J-SXZNS!&>DJ8% M&L6)3K]'&T$%K2,=02\"L!UFZNTIKQY#Y?=$G9*\+J.B0U:7S4HDZIXXA;I] M\ZD!<#5[FXU"4-5?P^@V,'7@U'FV#4N+YH$ZZ!#&89P5W,[; MNN".LF)J+!9!]1UL1[=UF'@;FIKTASRC-/C0I!6;_!-"%"W;EEOUHL-*?Z82Z9B-*8VF3@'2X,@KV@_=Q%XPC>CU5* MRB3R1.#KH[GX[<8!O8GB6!D\ORDJ:HC:YP8?T7/#DBC+LU! M)PO[*;\U#0*F/4EC#(._HKVK`Z-->W5+U#;Q:&!Y^]UA+[6NTW-RU`S5:JHP M1,Z-^X>TG4*/%"33^59)="T4=ZO'5X(Y:_%6'F"Y5ZQDX>7E*PQW`=^KC9(L MA0_/'&R.BE1-XM(C?@"U'Z2FKH92VP*3`G7KE6I0K<(A2M0W,BEP0H+%7E1? M!K1[XQNAN+/4`$8=B6%LS,M("T MZ^Q:A2!^OINP0L_LB'%18$1!69K@QH8"PLITOU2?;-Z?1Y-*H1#-:H%IC(/O M\K<'2,H;(?GO\*Z8+T6J+98M.;99)TWW2IRW]K*TVC=FM2J:I@.C0:#)F1GF9<[79$U>LWCJ0PB3 MM3?*WEN$3YO876V`CV.T!Z M50>4M"&VH#IAK(I3&SKVJ>S-%<[4\2M]9U:VI.J]P0W;MZ*^%I9-+I=Y:3:-75M..3L;#A5= M@2TH;M1]V&HSS[@L8X0J42/`BG)]O;.".+G(5$ZG.G';@KR?!&EIGG>KT#3ZV@AXCO\,DQ`"G_E M\5T`H\E8WS0K=-4]10ZHC-S6%MM!CGV#5/Y4(' M^;&8$>9$&1%#MW(MN!V^4EA5'&9XFA0C9E30!/N+J6G0I5Y+9C1JJ* M&;CR\&("?JEHFPIQ!<8Z*W,)+E26?(SOWLQROBS:M*!-Q[6-AC<84UCU:4F5 MA2VK<0+%YJ@\,MK'OEYUY!UI^WF@.FLP%*IJ'94U,]#\O0 M"$^21;#/&*BE`3BF(!CZ!*H?GU(Q*L4,H=EH+QQ/=GPA*V:'A=_TJ]PH1K,U MRF//$LL-EMJ?K/K1QL.N'O[9><^D7">T"%N6ES$K65;DYI9L_!E*X7P5Y$Y4 M<=3F!&M#::2S$36Z_IUZ MUUF8$HR"%.]0ZX;9+WDM^/^DF?"8]=98JKO>Y8_@JH/0EN#6WXI83=XH)$J* M]`#D1B-,&^_'"'(6<5,AL2S,9MJ/R)(M'_#;NY7.2!B7^IXX9%7Z'"K*5(A&#K:N@@@F:2*KVL9)WH0_CF01LK;3Q)%>DSH"BT.%Y M.-UCTS.^I/X+$VP20+IY>7P/D/G/.7:=)R4]%FV(I8R<%26QR<4W7/#PN)T2 MAZ@ORHSSX).+:68].]98]3;+<=?*E:],+_0HY=#U'P)@I`D^EF*0O@BD1[17>9 MS&OYUX51'XBB.LH6QC;;3.DE/(^@N\V=J`C46[PWSM'?!#%;U?\$K8MY^8CB MMJQ<*^_[KM>S7+P'56"\+S^I(O:HX(%6UD%D)+\NE/&Y%]="BWD3)"M<#`JHT M=`7+&.'DI@VP*7=4'#3(&W]F<*Q"+7H4%LZA'460T13,.7;U*"JSXKY^C/E!+#?0RI+G;Q M8;/TG@@7V3D6O+J_WRE[)Z1:T58=K+PRUL19*7N;$WRM#L!:,:3\4AD%7E:Q M2<6=3!X;'EGC"UVD20GCY\O_)P]**<(M[2D:URE_%XX1 M'^.IAZP6JCQ&T'D94?VO*6ZH!+"7$XZ(Q6O:+>H[;&-Q0+,43` M<-PWTW4J`X4@72PQ$E1.'LMG94TY]"W76E%'QQ^;ZL>M\E7S3,K MK1&\9[O3*C9$`=_!E',W)3JR5F]#S=_Z<$3&2,V="W)$5J*W,A^'X=G'G/WG MQAC4>:[S(O58F1_X%!-<+S]DN)H=E==1"8UA;H*P/+B3OFR3H=UAA>-B=HZQ M[5;6(7%7QV47=Z0]1-%!P*(YUPQ6>*MCH'BFY*&8/F/*]I=%AMW%WNW4XB1.6+F@UFK`A3*"I91&KLZ7;@XN(E??HK^)<&-G%//3)V.0D-5K\VQHOJV06[QKF7G; MZ*]AV/SZ0,%KM>&564'%H0QM9*K,_=`\J>(KETOCL)<*OV99LO%]0_OAH#+. M&P:0%V%6>G4K)4RE`RN8KM;>RI-TPQ5U[,PD)>O#9CH3!1.C"_+OH?#V/Z9T MUCFS55$\/Z.NU^+/;;_5ZIEA-F>2\*BUW:+Q147[%' M6ZZ1W1X;^4D,U-[*P+CV\P[.&Y.$AD5+97425GM+NA^J$3?=B00T]AP;FQ?. M-/)MD>JT53;-/I\(\S,(9B"Z5ZFYKWQV9+V+CHO9*5KEZ\U-G)/N.CU#1,O< MWX8!@.G^J#)R,BM(1_`0`I07`I,S%,@GYF`Q=-@7),.U MF&[2[TPL+4&NZ,S!*:.1,>(>X#ZMKAQ5;I*4G:PV>3Z)GQ?#*.H1ENH-%8?_ M9!9OOXBPYBG:BO`7F`.^WC=^8]R"SW.A#AA43D68NOBCD@UAA0#];M?IVC+0 M;-LSH\[8]C+7;,_83O)LX6:8/OJHMFHT.RA_5>T5>?98PW9(P,DSV'$'4P>X ML71NF-?JO%;'Q&TA6+=%(+=\6DT1_7-]6PZ.]L`@7YLPGK!+MH]42E=&YU--R4&9] M)VV'U7!,7"X+I.L$D$+_8\#6/.;(G=[LM\W5*0CJ'-G573XM?W-/R:V-4H-T M`5Z-Q*K#F#P`U^+V@B=N?%<4U8X\+.P9+3./S[SLSRNW3$8-#=Y0OKBX\VW;WN^N5K1Q?NRT\U!J6=.I7'TL92=0QARNLH5+XU^ANF(/UQ^[2W.O;;M/\7-I$':^N77Y:,T,W M$>B"&9@&:-@K.V*(;0E%%I52N_6J1$=ICW,'_:&[<(ALXPBF!<4IJY(LY-7NT(RH=B?QP]+#-GEG MY:WR[HC^2MNHQF_?;T&`\H2#ZNV4DT$]G71RQ.."YX_%4=B=!/ M,MF>PVG_)_8+ET#&SW<2C+?]W;Y&$&O#HCL'.74'S,:ZW[KBQZ'A9]S4E5)/ M#WIXZ@!<4>*S3BI8]V:+]$E=LY%G)25QANY<=8@*=8<3=.,V2?UF.VV]#MR# MCC`ZP&C48#?XD@>L5/>^SN_^M.V-.K;2B'./UV%9D]ARAUPL7(/9G61+/'JP M'_.6<85=J,L@(E:7"B-@"<5$P,^E#A`50Q)L1"N+GR5&E;:AM.JUD^VFT6:M M4UZE5F-2:*NPJ$^W0J"\X9HZI*7.:F+E)AX$VN+6AO5,M7_-G1'4\#'P3 MU?=-%N58`W\FM@Z35W-+51>7U:JW>J@DFC9LSU]A?7O]\M[^BN%9[D&[T?I< M,SZ+]*Q8S&+5!!9=0_$-#3-5!#[/KQ?8/4'(JM)"=U_YV97J_^#S!:;!H7FO MJN:_6`9W697]P/]/ZGLH!%AX).1A8JH7?Q5KB")7"J6NZ\(BN+&1!*4"3OE\ ML^:W9H!J6-KB5K4"KK$.QS7\QT:='4371%I@BK)ID:L+QH@YU90-46 MW+8.>8%VMV0U.UFI6X/42COOR7B5W9$JUQ7T!ITG0F_[&AK3)S-BSK*:[<4A MQU(;R#HXV/9))MU/3E,1-&F0ZY!07$=%9X!(P2G6^#+M`'S5?T]F^7HK!''N MH:#XML2L5%UT8EV5*0#28_ASN6=I=725[COY4!\::2-MH589;@?4^%@7NG)! MC7(EP-&V>AH5C+1<`["19&X+3^B/:S'[RQ2$EE/,OLZ8_6#_H+U>EFK0OAS, M7`_>FX6L/W@_L1V[/$H4W?JH-U'_:%'T_LCV;%YF@6*0JA_LQ=1-]*"_L3&I M>:;AW#I,L%Y]=$INHQ]6%:">R9^EV3_*$_A-L%[(S"=?]MG)H M,X]_>C5#=Z_?F5CR\L@6LWN&=2,^YMVC*AEXQ^L;/NS;/G>')VP3/TD3G?"T MVBC]ODR]4G=H+35%"V[A5;/X5,>?^^(+JF!%L8_"I;:GMN0+J,.9IK-I#O(J M%]U-^`VV\`IE3AP:[>^HK*_1>JK1^NY' M_6[*J(X]ETR(>R949M,65^5@J7JBT5.Q?JVWU>_-EMA2E MR.1@$\0=Z`@=0'O[[I$A_0K5BY['"6YI%?L?I2*/.L97\FITE!!3>Q?+P)=S MN`@SF+CN5NG>/MWJ^I\'Y(Q.G>!((! M::+6::+=TVYO13#;EG/KK.\;CW?+;WW"W-85EW?:V8A<3Y?I6NZ[=H\PKZ;" MLF4@/*T=L"]7PL/L3/^F)-G-WH>G9F72,?`IH(EX#*J.)*Z&(-=''G//OUZP MSTL8",6WZC"WWXFK6+>B&FZ*LZ^58'E@3:H!+C_9L!N_\H0C[,K;=^4K1^I6 M)J03MU5;%'%O=6A=6_+;4I5^PHSJ:(&=:-S2*;Q2YMAQ4@&LD^J>I3]:',UZ MB-#NP3ICRNI".WZ<&[5*#]67@VD_4<)LW.>9^JMU9&*Q\:#=EN-U#R!-A[W9 M=,)NS0QXLL-V@Z-OO3=2Q[1*(=JR^E>#),TW^E?M@+/.J@`VS>!_`!\>:?^O M/'U-1Y>-?_S5*8J$.7G(:-OC_F^Y1=+?`/0`W\F;L&W:YJVY)I53$K"2*XN[ MUI9V-8S\$*N50IDE-:WJ!ZNL;I1K/RLB/+-4=]!8;+:5>*9A4)G?1A5;Q,Z( MA]9-S-!2,65LP]@2J%1G*NL5J%@Y5P<:8WX9Y'T>P$E$1>*4LN)P55VTI M<[QGO92!]DVRTV?:W#%5?M9A+8_J_T\*G_((52,ENBWPLR68\94'&O;[@\%/ MD2ZV]#%KRO7,8AJ6@;Y\^F:X,4%'%2[+6Z"MY.F>!EHUV^Q9\U[.?YX*&D+&/=)5#/-+=[_;/T])NJ`NY+ MB1F%Y8DK%]X#6J:JWZSNK)Y35.'4[YW/X*SQ\*O#?N-&-YZ;W3WXY.#>71*G M,A%"`QM?;Y"U(CV?3$K$>V-^&T0LVWC5.RH65[:W"6L'.[9X?WK+0I@^#=^UM*W&)&:P2*"ETA897_FNUQ5P\.3NG!K?N&? M07[!(H\6OHN@@_4O],%QW=X!WY]H,%F@57$E0@'/RBR,_#$_X56QP&;O3FD4 MY@GE^?3A#I4BW&+T0#@ M*Q-=PO^:3.]W2RA?"E4;1ND*H>*>!S87^F#69@ M7J\$I#*=\:RN"$KGQM*7>L4Z[`]5M<&\#RL]H!CZ:/;JA#JUIR"XC$IM@-72 M.ZCYI#1E3[`B+Z82J(9[NO+]`AD##),KW=%9SUA!%%9LR@[])]AV3E5P\T0` M4]2N#?Y'4@"70JU_.85*BP]XG&6!\#<'6U<$`)!9H:G!8P$XW$S+E MHWU,F<-"RV;:^4%,M-^?/9;84.28%XG+%*4QTSO$*O&OV!!T5OEUM:4QJ#G0 M>;[J%ERN`H&)B"(K"(VO^*Z?>XM%$3#T(O-O\W;VN(5]^8NQ]5^G+[ M*W2DR56A>U2O<)?T41NKWFDSX&I5?GJ];A@H7343]=CSF_O31XO9D" MSP?FPJA=J8J7CN-5^["/=5ENO:L2@1178`"LAB35J()8,X]N=6Y$;D`HV^-* MIP6LHQ:,&,MC*1-J\V8(AI.D+D:3B?DR\G&=$H575^B6KUIDRL8PY4^+RB=D M-M00_;O@L?BG+VXIB:F.G1[MN8[O*<.X^81>MBK[%!/)5]+F+DX=+8MJVKZQ M7Y]9<'=>KA=Y[Z$Q9\-.2H/GIBI2E'=D5A*$U,&`C*4J0&7PL9V>KJZ\2YOE2/1"-* M#40?252^<-%VZ9FX6):M_$QQKZ5SY?R[/9%K:PD"6*S(\V=W>4EV^]J]+ MA:<+JU,U]*JFW10Z5!T`+<4SU!`#&96/:[;%>-U4J:!J1:A(*I(/#8GJM`XT M4@]O-7-D0^NAIC*5TKY791_RZ4VT?:VO;1GZV6GEM2I2C4",1L/9^RWUM!X" MK`V@I^"E5`9AD97^WF2H5%1_Z9#$G>ZQF)U#-[?B;F;5%E"AY*99`];",#"D MKG4#!*"3)0!Z57Z,\XJ2UE3^X=>9V"W;.WSL&_J'.P[M!UA MU55I",T+JGY?P1H+P66JFXR`-E*9!KH216&TX#[36@-C?$R$H7]U$NN5RE(O M?L9Z&GDOT/O7,?O[+S^F\M4UY\O7O^"9#;45\27FGC@/O0_XHD_%TR_!J@XB M'/<7(-Z;`&#HK__]I__Z2_&$\/H+C.@23/#\"J5,X<,G,?OYQ;M+E)]_#/[U MY?(%\SWX`ORU5Y>#M_WAFS>7TS<7_?-W;]Z^&?7.QJ/+2>^R.SV_&'5?_'5E M,$:^4*NKV!LNZ&\Z#0N6%2G'U"(TDJ>+M*/2 M7[:U<>F>)=J1P.(XD=?=Y3<].9VNJCZ7'QJB``4_9?^E\SA3YC3512#H?7*C8*`+Z5XG?VQMBK%H.+\ M+TQAP*&$/[_HC5ZP.+HU'_*+?TR\XL]XXR/48'Y^T9]^7WE"Z=&;GE;WVM'5(C=,/I@HL@LB&Y?SWT/]`;1A_BGW?R3#W?PXNBTNI]_ M7!6^K==R+@[XOS&G.$H;B\1E]KEL4@.7-8RG+C(W_9_HE^]*I);8!XWC+*(/ MT8?H0_9!/5A>B=035Q%7$5<15S64J\I%QFJU.DU8NJ`-4QD%+*MW=S)1AVUT MEF[LJW/L)+O'L<,:S7''D.U?LV(-ESS9V:4DKK.G,9Z``Y^>ZS96@B!F(V8C M9B-F:SNS#4\L,KO=!CX[C'QG&X\O;Z;GR_>8_QREDH>>_('$^%3#D[4PVAS6-R5NU^OXR@-O5>FP8CK"C&;52G8:W/$ M52=0K":S6PLC[D3`YRFN;2%$!80%A`6$!80%A`6/&=_KA' M,&#!5]\QVM%Z)_Y7?J=\+=K&:@3D-HAP-7-=R=VWZ^TWB(3MXKU#Z+.5V$WA M-&MVP(-LU08#H09GH?$<4+<707BSP^92_YB;2WML)9&(D8B1B+5,Q'JC@=,? MU&\PGHIXT69ULT@)&TVSIM+Y5.GXN:PC//,A@]Z':=;G>] M.\4SCT83#M@S:5MGN?:G/60<9"C;1WN5Q'4"=ICP^0?JUB_%HX_+D-RY'5GW)QB]^W08U00UMJ)3N M&YXYTV&?I(NDBZ2+,@*:(&*/W[(<#MON:'R)$AY0"*VY/D1S6><4Z-,X_CG= M$*Q]=FF,(-1LZI%8/&"H5$HW#Y;?F!>E6#7M,;6;S4-5P^NU8M!-X3Q[\9M= M27ADBM60,3#H.,^GO7+>?$&S/6,"/"8?I M;[K^:`,K$2WP0_%JKAL-]/K=[Y^>:O<-KLXE/IWY*!/*,NRKQNL) M-XHY-C)[C230;\N;$Q9H/^AN.41ZR&P<]O'R%W;+)?-#D)O%,O!5X^U;/YDS M'@2,+^$K%UF1>>(J@6MN1,C#1#J,AQ[#L8%F\]A,8%,LH8B#]ZF+^74LQ$+` MU>Q6Q(*)&QZD/('+\5X/!#B,$A8*^"*)V)5@W'6C-,0+9E',I%ARH(@([CKK M!&\"+^RH@I]@>/HC7GY_JY#]"ML]&9W;!!#O0_8_/,P.8/0=8'TFOKES'EX# M7Q\+.+[KC<\Z70:/"C:U1CQD8B#.(,_7()!L&?NAZR]Y@.*^QD-*>'G(?#!Y ME:HO7<\7*.!X6Y3&+)F+$(CCRP1L(%8^N&*J-#AL&:22<>9R.6=+?H=HZ(HZ^^0L% MV<>;Y70XLC;/#OLR%YK98+[(OCI,-!8GIB)&&C`?"E3N"V2 MR5&M@^\F8WM3!X4.K@B^`066^]XK-`GX$O7'<26N;X]ME9V1K5+"OS$NI3CR M(O6GEMES(]O=`M*C"17#&*Y#N,UC&'U`B&6!/Q,X9?Q[':V5\9>`+,L$L'@I M0BDZ#+18&8Z-&E.7>7AYE%MG"`TW6N1#<1TEOI*.3..5;<`4$8/=SGW`P(I2 M!%U1XKWCP6/W&!JRT'B;R6]/6:I5.T^O4UA(^';@J#=>@%7/P[OJXO&]EZ^R M>GX"?);X2JC@%3/?QKJ913G^FA@*_1E@(4UD`IBQE<`?TUBF'-5?I&Y=IY,F M^APL;*"6><&&1Z&<"E`N>UB$7_P%W/>;N&6?H@5?"R;NSO9/2>$U_@>F72R$ MYVL6G$6@7V^1_&7J.DYV!SDTG4K3 MZC32.I9SF$V_ MEQ@:_AST.I-C`E-9S#;`TI>-\`Y/BFY\ST2HD-YHA*F8V=5=A?[P!CGG)B3F M1HM%%,($(O>K6H,5CS9[V+KD7`D<7VXKZ;`;7KJ^BM6Q[?F&6&0/]/3QEJAO,'["W@">4.55B M^6WXS`U)CBD5_6YG8%PK?*F#OFS&_9AAI%8\8JKW+_1HTAE;%G60 MB@7WA/(E-%4;.XRB] MGBO^\5"24)N))`GT].Q9I?VSSEGMT\-9%/IMJY4*KH@.\GD"R+%0MG@RY\DN MXH;/!PJ*4.]NP>6H5E)?SC/LT8,(E'L=ZM>=HU*!N](`6)VS()(`S)ONM4/K M<:=GE]1(*XPWQ5YF-#1TH%LH"S9AD'HFB('1;!4Z4Y:.6;`H]J]5<".W\CQ? MNID%:6>V(]L"KNU+.X.S;G^`W,37PG`]6EZS.%KH!?!G,U@#)+*A_HS#W[DE M@M^$VA(S)G#54LE_MQQ2N)<^PZEM`AWL5!O[K09[K6];'F%*.MJ!P[Y'QDQ6 MP"("4[T2T2[NOC>V37$&&W&&#VX270'A^]T'XPS\L>'D6MAW;#OPY8?5+7"E M*NR&$YR5>()34T!AHXMG#K%>1?![X1I1!1%#;.K#)]@_BJ)Z0XN M[;#R+D1ODM&O;!ZHI%*1&"=+J_FJ2YP)0E/Q#+7&YLPW5#QESC+>B0H8@&<" MN(;S7F!FK)_<*9W79UZ/W!\%B*_YF8^[;!<55A.V`UQ?$=RJ1VKA$! MTK#08N48"&:F;$%7+HWM(E\_CX4I#=95;M'6UY:>4CE4U5U^TT_Q0\P'4I_+ MKPFC>,&#RBFB'EZ3/UC'/%T1!.::GU]T7ZC/J;6]]+YG`U$,(L>\;MV6@S9[@8:5$*V?/^FNGRTZF8(;^^/"ID)?O M0S!AHE0"\,L?[H5#.GY[O[K84E=C\%!)J..SY/UL^(`^.X01-QQ&VOVP&_$@ M\6`=/'@IW%46U-U/=C[I;*$%48M5C+KOXZX10!)K:V)MG3Y-8:9GV5'F_]HO MI-B4]3S(ZR8L("QXKEC0[SN#P81@P(:GWYQRQ772]O.YZ"2UID+.XFVW62@ M"NQ'=,&HT"85VGQ24XJ*;1**$8H1BATUB-4?6^L&30"V8KA&"Z$+<5A( MLFST6DRM[DD5F5H[8D*TY;,DZ:'\VO83FQY/P0?1Z@3S[2P$^Q5^FTOV%LP(CQB)&.D`1OH-[,Z#^(A0G%#\286OCG3PA@EG?@"! M#;H.\1CQ6%-XC(ZUT;&V-L@W'2G:P'9T?HV8[9C,9JTG)S$;,1LA&S%;8YB- MSN#NSH$7\%W,W21531S2913FUVMDF219)%DE>SL M`4D6219)EGW).CNKOT[4J8@6Y0UL]E^S(I(4)CP^$K4.<&@7G>2"Y&+]OF'7 MFO=(\D#RT'IYL%>_E,2!Q*'UXM!S)E-K09!3D8@Z=QJI9B]%C6P0KI8RF-M6 MHQ6%#8]7'_-!KFU]XFJW@.D)(0LBV\"HAI,4].J<_L)?C21BY8VR7VE[Y?(,R M!DC4)#SA1K'*]GJ-S&=42F\TZ@P8/"J`'Q[[5O5(YH>,7U_'XIHG@BUC/W3] M)0\87V!BF<-XPI8\=C#E#-N@5-E(W1PR`$H1W\(;$A&R)4"I[\+U,WAG>.VH MUBJA@,?$$:"HIQJE'(]@P[/.Q"K!.NS#.AUN12R8EPK-(8I!1D"[T$,F67+0 M$EF1'R3HL68_Z$Q&W]OA$M,%9V7:4BQ\'H8I#X([Q0MQ#'"I>N8H0B@*_`:6 MK"JLVL.5%]R=LSN!+'4EKOTP!!XI7:)EJ\,^9LPRBZ/%AE<[BJ7@>9I/)4NQ M-0^RVC*-W3G'3Z#X`Q8M5<9D$O-0V*X)*E> MZ`GIQOX57B7`%'?T.JM7)1&+A2?$@G&VQ-1,G9:YL8=0A_V.=9[P-9'KID`D M/'.(@V/E+:71XSQ=8XEUIRI2>;0 MY;!ED,(L73=.12%XG8.5RG,T*RH:+\,S)/-%M`"S5G>J#P2VP,)O8Y$`ZR$? M9\L!G[BOA-O**BO-U[.K^5``-V@^^-H'0%D7&IB6'\-;5..O!0=Y]),[A3E- MG6(F"DM`NV\^#%D`3EMY\JC3M[L8C MIUU;?3;J<6>CQ]W9(UO%!N^)4&GH$B-N[ZE2 MT';0UFPHDT_O(=+U':$YA M4[R^.;`9!4HXEY5@^,L>R-WEDDN6H+;F+TY:,D^9'\VM8 MBBRY0D2?!^B3#W?RM"5]CY$E^&4>"\%^A=_FDKT%,\(C1B)&.H"1?@.[\R`^ M(A0G%']2X:LC.[QAPIF?1V"#KD,\1CS6%!ZC4VYTRJT-\DTGC#:P'1UG(V8[ M)K-9JX-(S$;,1LA&S-889J,CN;MSX`5\%W,WP;)M;I1B?;FLTAF);'.C2TUA MGV=Y]H[.X1(6$!80%N!]/6`!`A<"%P*7HX#+T!F,QP0N>X`+U0_93MMS73V$9ST*/'&5J,XE M'-L0N)%,K)5N:Q!%&P?NS["H`=4-H;HA)&*UBMB@;ZV6&(D6B1:)5LD*MWBZ MF42+1(M$*[_O;-0GT:K3M7T&'FQ6"I/BC\='HM8!#FW]DUR07&S:QAITK6UC MD4201-R?R[I>N:F%$F.S3NL#U"&)(HDZ>8D:.%.+[N`SD:@Z-SRI]C&%KJR+ MHJURHMM6HQ7U(8]79_1!KFU]`=(G*:/<:NZKVXHCI"2D)*1L'E(.G.YT\/3T M;`7?$4821K:%5PDC;:9<]Z:VSW,01A)&$D821IX*1IXYO8F];%/"R!WCN]0) MI/&#U1_Q\JQ$H7K2QS1VYUPU_^!!P#XL,8%),AYZ[`\>QSQ\X.0-D7VGABP@ MYF$H7)4==NLGOFWKV&@WV'+/!,@-7BC"><*-8);>]1EKK:26WT6-?I9[#YL*[QF->*RP/P1;>^ M.V>Q^$_JQ^;YFQ8;Q^^)P(>',SGGL?X&K[Z(%J`=[SKLR[9;S7WX](@!6?ER M&4??_`5P"Q#(RH*-.GVK#(#$^WCY"S9%7P#%](PS8F&+)9RYX70@'7")H8:A M34'/B%V)$@6N[I`"YN(05H3-HP`L$9DSF/CF"BG+"WG#@U1T&HF;;0-YM)I1 M6A1T@]'G94NQD7%OC7[-Y`]-*`+@#GR1;>!E"/#T:J+7[9S9 MI4EEU6=QM%"?0.NNJ4H$1\-.JURV`))E`*_NS]D.;0<0#D#S]3#__G'^0:P MW+%0'>H:C(2%QYCQ3Z:F65N?B0K:91HR(L M_L'6TP-M!G<&T7%GN!Z^.0$5$S],M8AD?.#D08"R;:8)&;EN2E;UXP?[Q]P/Q'W:0!O*WHJEC$$S\('R M1=E1M<%B1W&!@L7E<P9:58$!.6!1F`!,);J;>W_.` MU,HPQ8T!$_HR<7X6"GB8DG^PI)-`BRJRXP(,:P0^%]X)[^7*2S4XYP9<2G_F MNR:2A!K<%4VSY'JF*:GIB)F+EL?%O M8C^]\M@I32QO^A7N;HNW)'(/?24Q#@=%.&B&[`[.&U]C-GW(_U+J7V3\%KQUU/?,=U".-3;PDB MM&ADU>+*+'1\[T+LC)6DZ^PF&JEOUKIIO1-7L=D+ZDVUS=RTJ;2*[NJ^#R'+ MZ=KK:RVD=K90/L4>NO'>A-5!M]OIVO;(2[NWX%Z$KK\$B-`!)@>-E26/G:PBP<5LU33/TVM0*_`!-T^Y.V=W`AFDV(G.+M!"`&XI6V*)-NWH M:Z?9,(':6M\R(D?Q"]RA.5&R5!KMM^.^'KP%]Y)4;DY9858N](0$M72%5^&. M@:,=,O4JO>\GQ,(2H_8&O<[$>C834N\S7`%+"+3K9SN,OR]->$.%OF)AXH:@ M>T%.N0G`:56_::,?O:(P26/X,MC66:]KC59RGC9(*;)+>2N&Z0_:ZK!?XF/R MO](PF#&1T7X6!2"S"#FN'[OI`M,S72%?-])`.&@)5'8_I!C]TOWJ]L31(M M]SG/\1`'5T\_#7&>CUIM$P/NC^]?X%T.Q-MFNS-K;SVP M1/A&^-8*?%/F!@+'52KA]5*^0@$Q\%)&!@UW&@YOQ";,*=V9GSS`H-I,9[Z: M4-KZWB!&F\WU*AO9()06Y.4^"1[WNRD.6-!V4&RFR+#Y=PN<8PS%5>,Z)ID`9*$;X2_A[ MZOB[)9!1G)P`)W\9*6DQR<2\'-7)$I!7XQH@MO%QI8=$A42E7E$Y3Y3=D0!S M,9TFI8V12CQVV;U4$Y2ES3OS05_EOV]3ZQLT46[YC]ZS3ZP[7RQ8= M9.,49ZY*>6Y_7LEN:XT-NG&W05O6OLIH]V_`7@O5"18P-S?IBRO'.RN'=,IY`NEF=9N=URD=6,R5+9XQ`(Y.YFM*UFQ#E(_ZK>6\ MJWR"XE`U;J#A&5PTB550"`@<``"K$[HK^?'WN74PV M43GI>6D-_"[%Y(]K=IWZ^D?$NW(@7S<9+C)7C=L'2W^5)=JI)5.,`/=&^@R9 MA)]4D&KU["ANV9692(HECXT[KH>30V[@\RL_4)DGP#9`X3#WV(H!Z=@A&&:A MBEQR=.1F`4B+<><.G1)F\X.WV:9>^HY%UN,O[U M*78S":^ZS<2N>%`N7;))AY2/O)9R>,P\%?6+V6>^Y_J%%7$J@=],<"/=4H=^ M<6E@=AZ[BN)8;\C$9GY6<&QB:P.\*(NQ!$H;U@/'028*P;U'+NT-AROP2UT/ M8^6@<2E12Y3RM.!BW(NMM"VSF1UA><_9P52NR%74LJ3LSSH#N]OB]R:[Z11< MVW/H=H;6YU!.P2R`2V>EYISBH[@K,=1]\#0"Y@PLOBU%*,T),!4V%/'B/NQ` MZF1':N3Z<[PB'/K0D_*Z"58(8B\)1FD5(!Z:)E5!U^9>?@)\Y5=;,CGNG-F9 MR>D>^-"G7Q9@<>HSX8;7>;G58Q9[M^0O]0&$,)%I/17RH*4YV&1KM#UIVT%V M>1RK$C/:[D#L2<,"R,KJ]UR*,Y:\'-EY&""7?NA'B1/DRC[0M?H5=_H""BF M5[])&B5`+TRQ\>'9ZGCH%KP#;8 MJV/@45CR?C9\0)\=PHAK;+>/!4L\2#Q8!P_N<7CU"=H\'DKD4OWU]75L@&)2 M]WWT93_.%AQ0VXHCXN@NW0&:RYWVNE+8:3IAC5(U-"_K=C?N%-LF6"OX MYJ`@`T$801A!&$%8,_CFL1!VD$5\,D$7G2^[)7Z^(?&!7%W[KF[_`5?W$%KM MX;C:QZ>7O:DS[)W9YI5BW?,YKVGIZBK>`\"G812K:%5PDE+:+D9.ST M^^NGV@@E:XZG4:/I9J;1OE_-T,?3*MN294W]QXL(FUO\LC\VE%;TE:G+1DGS8_FU[#L:'*M MB#X/T"Q$>$XH3B M3RI\=1P,:)APYD=1L!8R\1CQ6%-X[/0..,J$QW3"\>0$G$Z7;6`[.LI(S'9, M9MOYT"(Q6]N8;?>3`XW@Q(;!GK5S%\2F)\6FK3[EW00#7-UW`=_%W$U259ZW M4M+-%@PTB)2-@P#K^+F5V$W)J&G$R<;&9&,-CG)TL2EKC_=1SBDA#2$-(0TA M#2&-Q>3UQ[F&)P]#[2CE<$:%'`C`",`:QHH$8+OWV7#&@P$!F`T`:TGJ5*W! MN?-RN?YH9MK^F"XH,#"96"NO2+!_P@4U1CUK5M6IP`O)PW.6A\&8Y('D@>3! MW-=S1F?6"I211)!$G(!$#$;6:B2\(OPB_"+\.N84>B1"Q8&"4@9*&29#CM/=J?`?:^M?UK) M7#!_]LJ,7GCLA@>IP"7<-F$/<`8G++ZY`J['!RQC/W3])0\87V`66*>1G-D6 M,=(?\?*L7JAZTL+A0<`^+%$$@/]"C_W!XYB'#YR1(K+OU",)!3D4 MKLINO/63N9:0["C:=KEPV*U@JB`8K)`?)A%;Y@OFXH)%:L%8`BLEN:L73[W@ ML9*\*T8FMY$5T&!SX5WCJ;P49[OD`'I"=M@?@`,88?;F.:#ONR_=4N.DL.OO;?P(_X(GSY*\\/4L5)*/DN M@#;'Y\,80,92"=8BOH)[_X:_=8>N>\8=27'/Z!S&E\LX^N8O8"GA5BL$'_0[ M$[LK*.>@@V4FFFZT6`!Q@!#N5\64"WX'NDK$K@^3O6>E54FX\NIM5X%(^5C\ M)_5C_<0U@;A#\GHB\.%AV?@,HUQ$"[#%[Y#L*"E:/N!9H#S-%>9Z\P(/O[X2 MV=/@\]5=Y4'F+E#),)`H`*<@YVE4T5*6)Z6T^[U<)[XM<5IP;3[SGK(XIF`# MZ<<&7";,`[+BZ^\A4RP6BC?3!/D/O3HR#&QH*/20<;&4R@''S\MX8!,PLUMC M'&1"@&Z4@^O+8>'E/$`.N>+2!W'/^$;R0*DZY20KSHV%*X#]2K)6EC.XB2<` ME M<]^=`S&60`2%K1Q&+A9^NL"Q5]%RT/V>(8(7(@/W1E+0RCUVS& M]'J=83UFC&*M61PMU"A30$A+ MJ1V$U5%6J>!+I@`8:!>N7>JP4/C*L-,V!5P<78%642U82P8&"$8R!^V:#5H9 M@Z1J'Y^LM\U*JF(5R[&2(:F&NR(`ORP[#+(T5_Q3N0"97XB;'W%F:I&#Q`=N#`!Z"H8^7OZ2X7?F M%(4"WH,+!.R?)($!;GS>`C0[OL.%\<"8N%)<>!?@FPM6D@3EXAKT1&9UQ3*' M4KY'5+4E<>4'`@"RR:$31ZLN4-@B5GXJ_R;V"_X_9,-/+8\WT\=-->)RXS.S MYDJF#$=_VL5-/P_-I'*`!R-#QB4$E8)!N%>`\BY?8OBXPSZG5Q(D#/$>N"R\ M%BHB->-@S>E@O[*1,*1_I>S?Z#J$<:FW!!%8%5S>%S:I@`0`1.*'J=)W"[&S MJ!.,V]TO4-^LM9+XE<,"*NAB7T2\8+]$?)UOB?![#O9#R#1A,[W@*(58V0G@ M(`,"!+3P8M"C1(.]<&WU5EP@,&HBC<&/MIM0<5^-6Y^B.Q#P-SQ4D8$+'G*/ M.QH-%G[H@R'(E7_-K^$56K6LO5CI<)DHH.8JL@U2SD.;N-VUK&@('JQ8>5F[ M$Q8K=WVI/,@3-18X+5%@`S MNS(S4RH9IO`VC2,O"G"79<_I]7!DQ12-LW M5H;1[W3/["QNA[W/)K/D=]K4*@1A'='!V_%2D86&_)5[39"LB)]MX00".RM@ M5^"4\4DE`EM1N,A0'TQ2%;J7[EQX:0#+4N2RY(L.E_]/&@J&NKUHD`MF%.KE M2[#9L\_P(&T!Y(D#>@L,(;0,IU<\4-D$AEV*C;:1DL3L5Q;B\]7H-*P.^C="1.Q-_59[/RHW;H4&' MK)<)6FHJ-GN+H>)E'&&8+=_/70,"9;]MU*RE03P`2%*XJ=DSYBSP1:@W_DHI M`0SWI$R8T<HG.E\ M0RSCL"L!*WAC<@Y3B=L4*@60$8%5KKPRL!7 M(*7#T2;/!(P8^-)7/?3,.!V,T@6I`C8.PO;-7X!-F>!!=W!G;D0,W@A3@34' M]P"Q6AS&Q'U7S[7X6CRP$T#%3(' MP0*NQ?G#6+!PT M*_ZT>>&SA`KT^E!*Z]G6,:DO(\N["$IQF-`9[LV"9W`'O$)`TIPHU1:NNQ6' MQ:R*2-5^0:C]N;77Z79K"$VM1J34-/KXKO5@DW*+_;!P@%7D8D-T9[^8S?ZT MZ'?Z?5N1G"]S7Y9<^\P!1V`K+_#9WW_Y,96O MKCE?OOX%$!=Y\1),X"\@16^"R/WZU__^TW_]);OB5_[O*+Y0]@N`\,<(^/U. M_SN_7EE(\.&3F/W\XMTEAAO^,?C7E\L7S/?@"S!/7TW/Q^\&_=';MV_.+R87 MH_&;LS<7X]'EI/=FTC\?O1V_^.N*C.^Q3)L.$#;-UL@("!(>8HMVO:G?2,#; M\M&TL2Z0MU!PBK'S+$&GIH@IN"$^G/YH6$4+WA0 M.5?=PVOR!ZN#M.#:!H&YYN<7W1?JLUQR-_N\/S;<^EXRAS]A3N9PLHLJ9RG% MZ^R/M94I!E6N"%@<6!YMK/^X0U%!-9B?7_0'WS]X%KIZ*MO[R-9ROT>V@98#[9+K< M0ED@T$_WE.R?+)/R6DZ&>LG@>?GRG=:Z/F.!:$PHL]>C6"9MG9,$4O)*4R60 MY([DCN2.Y([D[C3D[HS$CC;/7_>[3QZ$(UH1K8A63TZK=FP:-(-6Q%?$5\17 MQ%=MH17Q%?$5;9X?T7N\%,MH(;Q&1B`H='."N^=_"]*%2/Z7KQ'.SN/Q2;2A M3C+2GO#F2]I7N)]`/]#&`DE>+1MZU/.`-O1([HXN=YI.TWZO?SQ"D0"2`#XU MX1HC@+T!R9WM+?4?$WX5B$W7'\3)<-]5S-Q`\/CG%V$4BA<_/NB#EJASCY-K M0=B\FX^&[\:0W/>N/QM/!>'0YZ;V9],_?]=Z\^.NF MV(@AT1=_(22#4;%/T8)O1[+[EN5H-?74-VL-6C\);`,;W+'W4J;"8P5]697` M!_-=K:G6MH6DSL&^#]GY,O8#AGSHL&0NV+OSSV^8;RC_^7?URZON@.7V4>\G M5E.8[+._6`;^[`Y7&H?R,182UIDG?A2R:,8NQ56BF((#!["+2&Y@@4.HX+#; MN>_.62S^D_KP3G@Y3YB';_.SM[GX-K@BX`D0)HD8AP]N=!W"HSQ];>#S*S_P MDSMV)=A2CQU^\T,UF2L>J`?)N1`)XQ(>X,'+7'R1E[IJCK,X6JB+71['B@Q\ M@:R/DR_&E+_'03"1ODS@1>S63^;Z=\^72F!DAWV9^U*M8CZU6"1Q))?P7O]& M,.Y%2_5F'GKPA"#`H8.F-#_/HE@-YR):@,[#>5W[88CC,I.:^;%,V']2'B7YV?3-\/^F=(!EY/Q8-2[ M:+4.6$/\7K?#%-W8+Q$87U]$O&`E$C82.H]F#)7NJ=CWN(6I)NB'X++HS^6' MAE&\X$'%PNWA-?F#E6W(7!$$YIJ?7W1?J,]@X;K9Y_WYZ];WDCG\"7,R';[` M:`[X4HK7V1]K*U,,JKP7FAO;9QOW>7?8355C^?G%I/O]@V9\U<$P-_:.?5^_ M+0-M]@1;FE;<[+@#T:<8[J`1Z2TE&$6?2<3UZNG/8IF(Q17HZ4'7(:XBKK+" M59?@[VNFZNW,5(=E3VEKI*#-2LO1)B51G1U&YC-"_R;(Z1-PVM/+,?JQQ&S$ M;,=BMIT3)5KB#-2B#'8-NK]\C]&V*)4\].0/),;/P+8CBX.XI\7!2%/M")'_-C8U.6$N_;/_.%8(!@ M@&"`8(`.I.Y`6Y66D&!:@A]B=$/ESJ#QQ0-;;-0@2C8.?G<^5%Y?9O2Q,:KO M#(?U-^AJBGS5;<*0<)%PE>X;3>IO.7DJHD5AEI]^!YT?)QQS7OFW/-WT_K1$ M\J]JP:#60@.?A333_IK:6?G([;T#^S=T3Y4*(U123)8R?1;)!HCNTY],]= M,BTX_-.V&QQ?HL1>9)\0:Q^)&X#$>5&*1Q,?D\#:%$ZRML&Z,Y7:L`,[G#K# MB;U"9P^1IBG,0&$30AI"FN/&7R?.I-LGI#G<"+1<0VHWH3ZD4,+1Z/2$U7K< M*`R%+A:C"KY@@93/2S]\]6$V<]BM8.KHC:HZ@S5J%B+T5-T2K+2"UZI,8:D* MNT1IC/]="/@/=TVI#2SL\DEXMU'DL0M58N8")@.7A3YW&#@]<+4NEO..NR)A MMUC(!I#?TQ5MW.A5(D(>)HZJ*,/91?3J"W[AWK'SZUBH(BJ;GL/Q1U4/!JM9 M+$)_=L=2/4X>!&S!$YA6I?Y.:3;P8^Q?I;J>A?EI"52$.?`9%J8I4XEA^9@. M^SR/TL`S;_?$C*=!8L;E`[ET1G5T!0NI:\@HXKKJGBO!Y@+^B_G6\,*K.ST6 MF#"X@ZN$0#I@8:54/T%5NP$:R_1*)JH>T'7*8[A.S1['S>_T@NFQY+/4%-(_ M965YR@M56L,..U<%<-9X^!">RX]\%X([Z#ILXUF_0YZOBTXEZ&^9B>84R*;I MI3$O*@F5*);7;4I#K-D$3OGUG.6GB?O=?@_8,`;2+9=Q],T')A+!W:/)8KQ^ M`_A*WCWA1GJ,KQ%"C#Z>=#LC!D\*X'LKM.JP][-,[D#(D=4-YY:XDP)NDJXM:8?]840`:V?%"C9*9;-L M\>QWO6YG8I7R6(L*\?(BPEH[$L9]4:Y%]<;4]OJ,M;TDDJ`]XH?K6SZ!C\\> M.E6D]64A=/L6T]JA'E:E?A96__-O$%GE_J43+]^==4=O!^_.!_WSRS=OQ].+ MR_.L=.)D.#WYTHF_10E,H2"A6MW5REHE"I,-MN]@_U")OZHH7V9$A8KH<8GH M"0,/88[%^\")^%\#MPX+A:KDEX;%#Q%X/'ZHU=M,(/SZ,UBT.V,_20#XI5#U MO1""5/DL,&@`6&_G0I?'"R(>JJ%D-0P-V&*MO7*=/563,,)]5`\CVJ@)C>6B M+(U`E1LL7M`I`.<=:@]XB\QFCM7WT#!+\'8_7IMGAATX(:,_4-N@*LYQW]`" MJPKJ&H=(07]QE<:`KJ67OU?VK%33P8QKD2BJZ>QK/;,7^36QN!%A*EZ`Z>B; M&I)^]MM")//(`PV$A,-!`:%ENEP&RJ@"BL;1'0^4#6P&"LN)D\":C%G^E[9` M0*/I-J=)B/DPP(X2:J_H) MKED6Y1J#N_O!EP1VL\"*&QZD2%=56A-8',A9LCF4K.8+@&NZC,$R\I?`%,CG M@H-9@42J5B!U_Q*]:Q],$9`X-\[7XC4WB9*N+I*:]- MRVEVGQ)RAUUQ-#A0_-,X5I(=HM_&\\*=R/6)]B^*H>@A`/=<:;<(336X("OR M"2!DO"5#D%P,O51#7*P,PXQGO_DRT0@1)K$Q[O!5,I.H@V:HK?^BR"D8!E+= MP`,WU2`"(.5B!=`XD^B\-BJNJLB<@J(<*)=2Y+*FK\FIHAZ7U4?-'IBCY"Q- MP"R!%\@YPZ"F-!"GYO%GN55T9S*\ZPHTPZX"%+*4!2'B(%$&@=$`. M[8I\V>4*9%6MUFS8)<"_%^1+R,[>*^JK>Y!84FI_R]2(K91B_7?J7>M?E3Z* M1<&-YE"E7M=\]&OHCB.P%W!^JVPXL"6L2^_.N7ZK2)6_`P6M%,LAN0& M0;U[J5K66*W%QG6K>;L5O&(L*X7W259S=SK75R>NLW\CU0`?F$,"D3CDS("[I@A[#,I/5MO\CS&L=!.UH3^R%6Y M:E@/=*1+82VEOXS998RQNR(8I&$G71I'W-P."Y25)9_\I&Q*!1L(#BYN36G[ M"+8$J05T6P#1YAF<94\HXI;9^]@J]2LF><\HS/RSN6H2:XV12E18%3J72+CV)%1(&U[I559C!K.(;C-M M7UHC[3%ICEE]*XM<96[!_'XWS.+G#I"BN`):I[P:)3H+,RLU0BQYOL*_&N,>[BB)%`K10$PSII[B3P, MT2(N!T>5]ZNH7V*J60D)C7X^LAE'9H"IO8>@=(XP+H]V(QB:R'0ZSPWY=';@*,)<$2H=U,=+K(N,I M)R'4'DK.:K@9M`D@5#;5)A+A$];G@NRL?"Z#B0$'0UN"5&#L6&A_107;L&5!+(`T M$ICC?0C^B_@%/)LO:,_MU0FF^^[=\&+TKG\^>#/L=<_[X_Y(=P&8CMZ<7?;: M:IKI'+M24PR,!!4T-#$5MTQ%W*L`,N9!M(1_<_3NHS0`+U\W$BJLX]H.ZUA) M8WE.?0)Z@TXK,.-?H7^*L8(T?K@9$K$HL6AM+(H[ M4-G6"`/7YYJ8D9CQ2,RH0P@E/]MDM50\;:9=[5V)_KPKV^RZ/4*%X9]:X(\N MT&1@$_\0_Q#_/&/^H6H\VZGY)N\"G>6]\V0]A=R6I#:(J(T38>MBV_CB%O8. MN3[$5JTXW#JN7\R:LO)X'Q4<(IPAG'F*8N2CJ;4:IHU?>T(:0AI"FJ="FK/A M&2'-\2+8W;9[H^=X(D<50##E`D(\_:22JB7#HY,>J[2MWWQVFL)(CPXC/;88 M9>MJ3@[L`=4#I&F*K-5M&9$X/6-Q&G:/5EV9Y(GDZ?3E:5A3V;O3E2?:]=E. MV[>AM[+E4Y]9W2"2-@[0]A!42P5.&^]&'Z_RZ4G$6&HSM/8A6%-XAX*]!&4- M8D>"LGW#Q=.:.G\0F!&8$9@1F!TQGNP,SGI/3[*F<(]%9WY["?O[ZT$\LL+# MMFH1V?&^=U'\F0?B3L>=">3 MWAM5+N)B?#%Y.SEJ]=L'#@6UKEC!@L?7?J@'R=,DRK[0VDM]4T,]@_[HD?4, M^M.6G(8_:\DX:7XTOR:/D^;WE/.C8AO['^W]G"Y`EZI*S!=XO!R+@N4FTBNP MD5ZAD<0^4P4$.G1^W$/G!4G/51%WU?9#)L1_Q']'YK]2+8Z_82T.8D%BP:=C MP5]4J2+B0>+!(_/@V[P1P#ML!/!/;`1`;$AL>&0VS-T4]Q_>"-U?:F?VH\)75/BJ#:)]'-%M''V(?XA_B'^(?XA_ MFDD?XA_B'^(?XA_BGP;2AX[P[1-&H!-\39;?8Q*Q#81K#+&(XXCCB..(XXCC MFD,XXCCB..*X5A"N,<0BCGL.'$=5,A.5LD(AN.:&*)O")]:.;-WUK/-"4]20L("P@+"`L("P@+"`L(/>` M8(!@@&"`8(!@@&"`8(`\`SM84&?N9>MW8'X%O4_B1B)&(D8B1B)&(D8&8DD M7B1>)%XD7B1>)%YD(#YML`I^?TNV-;G-(4 M::A;:9-$G+!$C/O66M61/)`\M%X>*"V`Y(+D8I/E-.U/2")((D@B2%.07)!< MD*:H/6JW6Z!W,&Y[..]+E/#`%L?0%D-=G>8/(>#6U3!O4XV_UWJ]-(4QK27& M/TC;![GV/AK70$K[:J'?/W.Z8VO!IL,IV@K.J]L"(Y0DE"24;!Y*6@S'$T(2 M0A)"-H)7"2$;'78CI"2D)*1L!*\24MKUN,?3_M-3M!6<1RA)*-D67B64M(F2 M$VZE6Z MB@)//^A2N&)Q)6(VZ#FLW^T-*;3;(%&FAK#$<<1QQ''$<<1QQ''$<<1QC2(< M<1QQ''%<\PE'1323GRZXG)].9.[)!=$Z?9K")\^R.]SXS!E-J4DDP0#!P'.& M`:KQ15A`6$!80%A`6$!80%A`[@'!`,$`P0#!`,$`P0#!`'D&#\RSSM3+UN_` M_`KDO&,+'G\5"9O!=*TU,:,=4^JS6*EQT7,F9_8J`9UZCT42+Q*OI]7_)&(D M8B1B)&(D8B1B9"22>)%XD7B1>)%XD7B1@?BTP=D3B\%>1/$RBGDBF!1N"E?Y MPEH4EI#HI-M<3D9=6YS2%&FH6VF31)RP1(S&)`\D#R0/E!9`$)(0DA"R$;P*B%DH\-NA)2$E(24C>!50DJ[ M'O=X2AXWH22A)*$DH>0VE.PY@PFA)*$DH22A)*'D$3;U"2/O)5\I5^#'A`-= M-EZ_X>^__)C*5]><+U]_=N?"2P/Q879^P_T`'_(NBC_S0'S.#\Q\$FX4NG[@ M\\2/PB]XS1>@RIL@'0YZ5WVII=O)N&4;S@046V>WA-_F"U:,P506"N^?E%]X7Z#!SI9I_WG^VM[R5S^!/F M9`0!F#S@2RE>9W_\M,K8Q:#*:2>%<(PVY@KMD+FB!O/SB_[T^P?EK@H-YL;> M@??UQT=^X<'W]=LR4)K@DT[0PHG.MF>`-:,>YW/R%XA_FD:?QO%//MQFM*HO M\8\+9IF(;5%(?5QKJ?XQ]L$Z7O*`O>$!#UW!/J2)3'B(PR8NL\]EDZ=-A#\& M3UWP.+Z#(;)_\B`5!_B#3;8/&L=91!^B#]&'[(-ZL/RS6"9B<25B-N@ZQ%7$ M5<15Q%4-Y:I+X1JFZNW,5(>=6*SL[/37MFA.)NJPC<[2C?TE[J>0[#[%OG?# M..X8LOTK3W!#[XY=\F1GEY*XSI[&>`(.?'JNPXU>8C9B-F(V8K:38[;AB45F MM]O`9X>1[RRCGKKZM9_`P]TM]'SY/F3)/$HE#SWY`XGQJ88G:V&RDZ%.X[BG MN0$1XA[B'N(>XIX&<,]3T*?&2G&]-D=<=0)%%"H"8'[U;U%BK^L#G3MJ/^&: M)<&.ANZA5 M(IY:.UX2,1(Q$K'BOMYHX/0']1N,IR)>M%E=[#*BJS&E[>JF^Q4M8"3MMD[; M2Z73YZ*F\,RS#$8/NEVGV[56K+\I:UFWK4LXL+M)VSK+M3_M.:,I[="03)!, MY#(Q&3O]OC4[ZE1D@G8M[]T_BMVYWK?$N(%^R7BUBJ=4;"I_80[C@.HTY3' M)TB_=C$>;5R>_,;ER*HOV?C%K]N@)JBA#972?<,S9SKLDW21=)%T449`$T3L M\5N6PV';'8TO4<(#"J$UUX=H+NN<`GT:QS^G&X*USRZ-$82:33T2BP<,E8=: MK!\4NVE#]W5[\9M=27ADBM60,3#H.,^GO M7+>?$&S/6,"/"8?I;[Q^P]]_^3&5KZXY7[[^[,Z%EP;BP^Q27"5?\"%?8,9O M@LC]^M?__M-__673A;%_PQ/_1KP/91*G"Q$F\NUL)MSD0_@A@>E>1(ME+.8B ME.HB-UJ(7R(IJT\'NH=(W$]B]O.+=Y>X9?V/P;^^7+Y@O@=?<#=Y=7[9[P]' MW>EPVGOS]LV;=Q<7X_YX=#GI79R]N1A>7+SXZ\IBE0G_Q5\(R7X3M^Q3M.#; MP;1T>^"'XM5<]T?H];O?_U1K$&,NF%!48]&,16G,O)RPS"\H"W^K7R^B$'2" M%![^I?B9)_#A^IK%;VA%LN&?QO%@6@C^3K>SGR/@H^ MN;@<,KC2/14=U@6X52SA(UGUY_)#PRA>\*`"VCV$G^P$E+FBB`PU_S\HOM" M?08$\E<_@3YF2`#T`MX$LI7F=_K/%R,:AR&+$`P\E&QWN'2*0: MS,\OQMWO'\39*N*;&WM'OF_2DG'2_&A^];VO)9V2VN4B$7V*X4Z>-C9\C,YD M7^:Q$.Q7^&TNV5NP$3QB)&*D`QCI-S`J#^*CEJ#X47L^$ZP_I336T:*R8=+Z M62P3T[V]NW/W=N(QXK&Z>>RPDS)-[M=.VJ+=DDP-C:E[-C%;6[IG$[.UC=E* MVY[KKV@>)S8,]G:G'K'I&71W1CUI_PZM=^`@]WM]#SY?N0)?,H ME3STY`_-`H#G(>-'MVN.SV3DQ1&#$8,1@Q&#$8.UD<$>;\?6PF)UEEXZ!D/: M9,#?1,*NN1^RET$DY0\L%FYT'<(U'F9L?KAX[[!0J-S.A']C:Q0^B.?A/IDN MMY`;J/;3/2F.DV6B[>^>-KKA0?FR6D"7!JURXV#'.M0T_I0[U>@IW_=R-#D: M/0J1J8]"UMG%6AB`4(A0B%!H\WT]YVQB[P!6T]<>[Z-21H0TA#1/<-C3&73K M+_[9E+4GI"&D(:1Y&J3I`])0NZM:PW?MCM+]K1JA"[B4_LP7'IO%T8)QUTT7 M::`.17^X>,_\,(E@H'<\2.[@\AL1IJ*I8;Q^+6$\TBGVZ=,4^'B6S99ZSO#, MFH9HRDK6;7(2"A`*G!0*O#R;GMF>]_..M!-$$$2<%$0,G+.NM0J+35E),A0( M!0@%]C$4!LYD:/V`U&F;"I05MFM6F(_'581,=($^+)4(7V&]/1UD>L5<+N<, MX8W-A7'&$WE5"&4(90AE"& MK!K"&\(;PIN3P!O*#SL@D&>CGXB5-B'[-"%Y'^:=+3[,WODA#UV?!Q\CZ2=^ M%+[C?OQ/'J1[M2`9]=_V+MZ\NQ@-QV?#B_[YQ>5Y-VM!,KX8#UK=@J2`4VQ& M`A3A2"<5G)P!L=@-4DMF[4G>IG&D*!8#81YJ2_*&!T!]P3[/A8"+;T4LK/03 M:9SXW#?8'=:[HG^>57^1WB/[BPR.W8=A,&U)PXA>ORT#;?8$3Z]\[C'JI5W@ M%M8[W,+Z.VYA/:6A_IP$D+AI M]*F3AU0*GV5W@CC(/GV:PB_/LIQ`#6<=FK*>=1O\A`6$!2>%!9.>M6A`4];1 MHBE>TX&#?8\$['/<8)]S!/VW9^/^Q5EO,!F^&;^;CJ9C^*\Y1W`Q.*O_'('- M9V;%3U8^=&P\LU(XD_J.O!,V/YM>X M^6W#J_RN4=O26ZUW,EU+KU36PSMC/5Q0%+.^5*?)$S!?PS*IMV3Y4S8_<=Q1 M<_>?58[^J<3;3DQ*&T8?XA_B'^*?9\0_.UL)[;,"U.5TJHS8JB5L]0QJ8SSV MH.AZ90R5@N_>D>@>1V,^,DNBV$JRTNJ>[K=?JC\0E2C=BMD>SV600! M(X1K`,L=0I_>BG:@0UGWEL/`?@?53]A/"&$;PAO"&\(;PYG3Q9NQTNUU" M&D(:0AI"FGK[<0][A#,[$H#.O%@-X1/Z-HT^]0?DK96G(>9I&GU:%EXG!BK5 M/'G:0PFMB-B-G,G(6L"-1()$HO4B,>E/21XL MQ'\:%'QN2V"H021K'."TA7#UAY+.3I!JQ&Z-9#?*[6RB2665B*?FEI_\9AR) M&(D8B1B)&(E84T2L-W9Z?6L5:TFZ2+I(NDKQ.&J_66^@CN)QS:%,XP"G8?2I M/;HVMK891LS3-/JT+%9&#'3"NXR#@0)O77+R!V:PWA M6A9S:A#E&L=RSW#OC9)':'N;1(Q$C$2,1*R](C:AHF(D7"1<-<6H)];V;$Y> MM"@]B]*S*,/F,<&UJ;6B?<0\3:-/RT)EQ$`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`+P M><"74KS._OAIE;>+096W0POYF&S5]+CL>TR_PF^A3#G3QMDI7=4PWJXZW6^E=1X)DTFGDL!/L5 M?IM+]A9L!(\8B1CI`$;Z#8S*@_BH)2C>KEP/$K[=A:_JQ/?7O/$3$,[/8IF( MQ96(V:#KU!/\L$,WXD'BP<>G0#>.,6M2'ELTL4C8^]"-%H(M@=HJY,5XZ#$3 M]&(J$O::5(U],1\\@9@_0,NG%WR,HQ*S$;,=B]F&9.`0,S:%&0GYB-F:AWS[ MF=5`E2=@OPV#*.AP=ACY\+8-SWV()?=[@?Z$5[_V$WB)N[Y@V\;PT@]9,H]2 M">:Z9.*;"SZ3,N(EFNR,+Z(T3.0/A"G'QY3C8$;CZ$/\0_Q#_$/\0_S33/H0 M_]B.'I]Z=#A=B)@G44Q">*I"2%O5Q#_$/\0_9`00_Q#_/(D1V:#3?W6B.:8: M^#K5()7"8TD$@UDLTT2PL/@)`YA7>1:"9[(05$C3EA`WB-[-XMYFG;9L"M^V MXT!E8\Y,CL^D$0G+5D$WP5RK*B M-U-X3K-AC6C5ILV$1M&*^(KXBOB*^*HMM"*^(KZB#?;C&/_JXUKZYJ4(HX4? MVDS@;!`I&Q?/R(?[4+]%JT1L0,O>HS2>:H"44<20)(PDC"3L.4C8@\?FCTC$ M-A"N,<0BCGL.'->20'V=:N(/Y>X(CW&8+;\6.DE8[I9<;#6AF*3XA'O-]\8# M9S2VUG*S*=)3MY%%,G'2,M%U^N,IR03)!,E$24\,[-43))D@F6B_3(PF3G]" M,F'#>=O-_>VUWJW[)&02^ZXZ]9E@H[4H363"0QPNQ6,:A$:G$V/OC>UU"Z?@ M.HD6B59^W]F8)(LDBR2K!J4UL'>,BT2+1(M$JQ"MGKTC1:TAT_"1<)5@W`-:#>$)(LDJP[) M<@9=VL6OU<5]%I[L+8]C'B:TT4BQLR=Q1YLB'76K;Y(+D@N2"Y*+9R47PZXU M_X_D@>2A]?)`>H(V(>VY;K_R.]R!'-$.9..0Z73B3+0#2:%<$K%ZK62G/Z90 M+@D7"1?I+Q(Q$K&VB=C0&=*!XGH=W2I/3-ONSQY8?U4=D<3B/E2!]8DPJY;. MFOJA>$4/GBBCP/?R!SYY7;[)T-IY@8=[1.Y,B1;C'\DCR>/!\CAVIF?6:@*2 M/)(\DCP^4C].S\Y('DD>21X;(8\CIS>TYXJ3/![JKSZ0Z% M%&DX#@(^>J/^";WB[VP3P?Z<[<='NAU[FWE-64@*-Q(($`CL!0)CZBI&($`@ M\)Q!H$>6`($`@^;@./@(:`AH!F:]2(CK@1T!#0$-"T)S+5^*4GH"&@(:!Y*J`9 M$]`<$!;[,>%7@=AX_8:___)C*E]=<[Y\_=F="R\-Q(?96QZ'P!7RHX@_8\CH M#2;MG(?>I8X;?<'G?P%BO`DB]^M?__M/__67]6>\XW[\3QZDXEQ*D4BX^Q>? M7_F!G_A"_BJX3&/A?0@_"3>-8W@9OD-6GXS5Y)#FG\3LYQ?O+K&2W#\&__IR M^8+Y'GS!W>35J#_N]8?OW@[>C"?G_=%P.KX8CD>7D]Y%[^U@,#A[\=>5-2RO MQQ=_(23[3=RR3]&";T>\TNV!'XI76>)9O_O]+O=4H*H+$J;XR`\!9/7G\D/# M*%[PH"*G/;PF?[!:7.:*(##7_/RB^T)]!LYUL\_[S_;6]Y(Y_`ES,J=F0!@" MOI3B=?;'3ZL"4`RJ'(DM\@D'&U/Z=@CFJL'\_`((_*!\5D'`W-@[\GV3EHR3 MYD?S:_(X:7XTOR:/L]GS>]YIZ`UR-$_,$2^&.]KK.'M_[[I?Y9+!.QN!)Q0'Q>>WJY_D7B-].E-]JJO7=!.^>^+&%_$C6'?%;`ZV[UF^%G1U&O[., M?.KJUSZ0S'>W$/3E^Y`E\RB5//3D#R3'QY?CH\NI/2:CF#EQ#W$/<<^>-1N? MG#[$/ZWB'T(?XA[B'N(>XA[BGG9Q3^/H0_S3*OYI$OJT/IKV>)9ZYX<\='T> M,*[.,[XFR7M^DD?(3?Q#_$/\0Y8C\4]S^8?PA_B'^(?XA_B'^*>-_-,X^A#_ MM(I_FH4_-=:K[[4^JO9K%(H[MN#Q5Y&P&4Q7VA)+*JQ(A16IL.+F^WJ#,VO7]R:P@&$-X0WA#>$-X0WA#>$-Z>- M-^1+$=80UA#6'`-K^OV>,SFCGAB$-80UA#7D1Q'>$-X0WA#>$-X0WA#>$-Z0 M+W64_H(''@%L?[;2110OHY@G@DGL6J@Z&3XEY)P8).?#[=>01KA'TF`KC)NF MR$3=-@S)Q0G+1<^9]B\?FPKL6,*`PB;F; MT.'U)N&152*>F@(_^?UJ$C$2L3WH-'1&9];BBR1<)%PD7*2_2,1(Q$A_D7"1 M<+5;N$A_D8B1B-6LO[KC,Q(N$BX2+M)?)&(D8BT3,=)?^P@7'29+?OJ#QS$/ M[>T9$NZ<<*H"I?"07)!,9ZP&?=C=L.#5-AB M)=JGIGUJ2@6A5!`2,1(Q$C$2L9,0L<%TZ(PF5+R;Q(O$B\2+Q(O$JTWB108B MB1B)&(D8B=@S%+$H]D2<4:*W_,9D%/@>^S]=]<\)B6!_=.;TAT-KW'["Q"L;;/BSQJN%3C:M$?%"L8*Q@I6D\F&G9/3^F846+]8OUB_6+_: M.R?*"L8*Q@K&"K8]!3L>]#N][H82\JQ@K&"L8*Q@FYW3Z/]8U:P#:VN>YQ(:/[:Z]?\_^/CU!Y.I(R???"FRD\#]79\*;7Y#^Z1<6:M M2NQ9Z+_22ZOM%3[U"DQT'D3>QY_^]<]_ M_+A:\ML$3%"42K\J12\705]]AA_OU?CYP>5%O]L[_FWPOZN+`Z%].""]Y/!) M]\F3L_.3R\'%Q8O^Z>GY\?GE\;O$5FX/=*@.IXH4O=?O/OJA<9"XJ[)?T,`EG>Z"I%`#=0A#D/M=+32, MS$P&2\+4PVN*@@F(PE-!D%WS_*![0+^!95[^^^N[9J[]9`K_0ILR<@-Q`QE; M]2S_9Z5GRDI5%Y\6A'^Z=BWQ%RQ?I;H\/QAV'WU62I9%+;NQM^W[^FVI:+,; M6,-R9O8CV3XK]BFJ.]C`-FZ?L=7=/H\'8X`R=5F(?L[=0#**`M\5]$'%B9J- ME!&#;H=1Q:BJ!547RLM`U?MB4-UO9[VE6*2_$FUL'XFW.ZA/[V?FIZS^3>#I M`R#MX7F,(2"#C<&V+;!]<9:])<'`1@8#]PNO?J83*-R[Q9[?_1J*9!JE5H:^ M_9YIO`>^'7LTM\J9T)=['RRM8!E@&6`::^;&2UCM:KR*LN3(SH4/,;NAK M)20Z7_7M%]0@2S9.?O=Q_[+.DR&R<7DJKX*/*SM4\@[3RU. ML_SP.XSY)I$Z%(G\).+(ZD1'H>7X:OL:U#JI&1QWNH/:ID6;P@A..3`E[N_: MGG0&Q[7YMKM""0Z_;[?MA;[60$I?Q')!;T]P6-`<_=FC+?V?#FI#'F_GS]1D M:M:WL41]`?V^,Y._!,!?`FC_Z^E-05*CWD!OS`SLD]/.D^'V=LEH"A@X;<)* MPTJSW?SKL#/L;F_+Q*:`H48G\-LWK/B:;25NV9GBO;I68:K.%Z_EGY%YD5JP MOS+V?/%>Q1'T5#CYH"8S%29?OTO%BXO!R\&+P"B?W8Y.#GNG](N%>?# M?O?DY>7&=ZGX@GN6=&F?-G[H'7_CS@_]P98W.!B<;/F!IRW9^8'KV<9Z\O1_ M0U8,[Y.?SOAIFGT:AY^BNLUXB4XA;[@G5H8=IN& MW1N(.6I`W(M[(&4/NP>?QMP*_ MAQ]>>#LA!ELCMQ-BL#'86-D8;*T!VV8W2FO02LU-9O%^5B'VEC>M+:9HCMT: M1^FV&&Z341A=GF_:1R6=74N;Z'`'[;C'`&S.2IGZ5LE\SCXE2%JTOJK$T:-& M`HD9V'8&]NM;$;N3#&3>[13O*E_^6HW%FD/*S6\5;U)LS`#6^:R03DR6NFW;9IU]`%)4P[IMTN MTXY'N[U:^'&3[@W=;/IQ[9B6[&M-FZK+WYM=`-V:YNM&%>,*\85XZHM MMF)<,:YJMU7;9ZLW&3V>ZVBB^,WTAY:V!AFN)D.YGRLSTU<+*T=&K]CM7MT` M]]DTOL6R8*`?[MBR?Q@GU;X/^MW'SP)Q[9B6[&M'MQ6[9@T:(:M&%>, M*\85XZHMMF)<,:YX\GR+T>.%BJ.9\AN9@>#4S0[.GO\=L]-IO]??GJ&8@$S` MAS9<8PC8&S#OZIY2?YS(4:#67K_F_Q\?I_9P(F7\[(,W57X:J+?C]^I:A:DZ M7[R6?T;F16K!+,K8\\5[%4=@_'#R04UF*DSL%3[J"@QP'D3>QY_^]<]__%@4 M!P;18^BH,#GS/.@8O.]=!/&Q5K:X!6P;H@'?J_'S@\L+_"CL;X/_75T<".W# M`>DEA\/!V>#RY.)T>'%\>=;M7AQ?O#@_.;X8]LZ'_;/!Q<7!3^O2!IEQK_1, M6?%&S<7[:"9O)WGE]I6P?*M?F>\=B0_I;";-0D1C43&B**THB8X':-+7 M:-]#67PI4[.^#\ZEU1;-_\XH"S"7B8[N?JV';;WVOJNI$A)@.P/U7"!PTU"F MODZ4+UY$(0RZUOU'7X&1>/A2AS+TM`S$!S"[(I$14WFMQ$BI4,1&Q=+`=3JD M@HT/5RLQU\E4_'QV]DZ,(P/G$JC13(R+LG0(QV?4C4<"*U6>LN5C=.@%J0\U M#@(A_3]!]MSQ[T"C`!#$O"@,B)@AEA<(H[S4&#Q1N>'[CDBF,A&@-W)"91.6 M+EY!&P(-VFH%M$&$RE/6(M&QTE*,I3;8P`)Q>%<"E8VA-9%O\W/*IS98M::A M<$4:)%GY45(\`SH*KO9!2!(-MH2"\RO5IUAY:'FL!#YMG$+SQ]K"""L62AH! MQZF"X4+8=&357RFV*'^VJ]Q1(^&W'^R0H0^]&=`%:R$O[#1*`Q_0!]=)X@X@ M^L\T].@LD2=*H8?+AW_!(Q$K^6,!:@!J.&)4$A5((O0H:(@OOC7'GKETV6>B MJ%-\!?2G]CT+HU#EDTB>FHV4*7M^T.N(M5__OD^/=7*-(".BS<[",`7;.,<( MU$%<@M5%KWOX[XZ08*@9M;\#'1/`361J-,V'ER^<$-W2T>H` MJ7^E&@>.T8(&"A:LS;A.[V`P]'0<*/*?RJYD!^HAAXB<%4E67(H',Y\$M5S# MS_DT"H+%830/H10%_6[3V6WK`RO2V_X)?C2B*?[QZ_[8-A"`!RPBY#@ MEM@%F84NGTX6%,Q1`9.,V9. M,@RY.8YBR6UA%!56I31YAZ`B7I)60A2/?%)?PU-,[@1$ME*K/:'A`P_8;\AU M?P]NG[[&9!YUWUMTY<6K*)P<7BGP9\O3.TK932+FCV+,I<@(HP87+YF*T1,Q MBH"S0#23P.VXIM(F'8C?*7<`@V)Q(C)Z@L,IJL%8*0LQR1B#\T[&8G"L8PPZ M0@I'P._'$,T`\>93Y5@;1#*DJLRGVILBJ>6"A$%7T@$@$B.4GNA:8[@#XZ\* M%N@]8PDIE&\"(G?Y@*/2EX(@B)YB\Y9G^05RW)4V*^TLXE>5J1$>=L.ZP3`% MJY#9`MV.4H_T;)0:\!$J#_\5'110$6P./!Y"4K(:_9^ZEAT4UQB7ZCX0J<76 M8.-T?FZF0)'\(_$'&H[0 M6*+;C/1/C7'9NC(;A/5`U">`MKFJ5,55`=`SHN>1$S!'!QK<_Q&2WAV.R/MV#QK+6N7J9=REL99KJS]2?5!Q!.%N@L7I9U=W, MU3\SR2@R)IHK`_8#]89@4!AM/W8J'18K0WB&^*Y3=H:5F8+Z=UJU.F*Q-M;O M44*T3E/TR&CR+IO6D%99/1^1-/`%603>XP>%:1E,RO:=@3OBM5S@[V/WFRAP MJ48FQ=DE.'Z:':>X4)(G9:=(3="]Q+DSX'I)U+(.N#TR=$('6I;&-&*@HF*O M6N"K4^!RP,NT.!\F7)$NUX.R6,X5S,`?HJDRNJ'T6]?<2;6CG`PV&-1\AO*1 M1-Y'T*+5](XLI\8GJ78GW6%=I]--I6*:AP3HS M5$TPQWLH*E?^#7MD.3$H-IFKS.5>5:%`Y_X$CE4`OS`I3%5M;^6I>1=EOJJ$ MRIN/*KDQM+C)1*L!5!(CC;!JA++]^4#ETW`T)GQAM5D3-Z&)OZ64"06KPV#Z MGL*&A`I[MSRI$SR(`62/O+0O^ MRAJLJX!+JUD7."X]6<@8ROY$O@PN/``O_2\0]00#!I!!<.ZEL=ER`PW_3/+' MYQDZ"]$SJ`K("4[R.NG)2Y#CQ%6P>![-SH$7F"FVJ][A2#E7.FLEN.\N*@=G M[N]J(QR:79YACDYQB)X=Z!Q4)W?(((#VID7@X"+]I>A*HSLH;132;>@ENG#( MTIW4?V4C[ZA%UOZ\K47F$GS,U**+NV3GB@E72L)Q&$,KHGD>'U3Z MR.58'&)N/E5$'@5HT+[?,[!H6QW,8ESGM>A4>Z-B9Y6UJECM<0._R_E=,OS: MQB6+&-=3!HN5_*Z5LWSY2=F6"H#S.&(5N)R\K25O&-BHS"M)M]8`W2B0-^?D M((K(^A50C2M*F`TY,0DB!O?:A9[N`,9.VB#-H%=QU9/->EM[`NH'`$*,Y_I( MQ*=YO3"JAF`B&H$%LFDT\L?`&Z%($\-3A!U6\PB M`H_2"J'+:110F\OU`G$5849NC8FPA-6V()PI2Y.[8Q+\)PNL,-FRI^H,)@7< M(!"AZ#VB&^A9&8<8Z=]"/QM0X4%.]6/+D;W=.AHI>&\T!_1%^19GG=F@WXY2L/55-E3A^&KTD4 M9W`E5R,7QAPX=GU]UCO5Y!ADR694Y%S6N]!K\QQTJ_V+ M4S6&?+`H3XA65O<6!IY$^!/:-9?&Y55IC(O=\C]X[@B#(2TR__P?3+0[>B?8/SBYS5)*#D%*F@ MF".^.;.MPVN5KYL'2A7QANL,D-M*)HQ<10^T?N+BMZ':GMC-B=/G^6S.C@+G4_@`&%EL+!Z19OOF/)QLRBYFYXOSL]T!179 M`Y_&ZK%V+NXKT))`#,J!!:*^E2SA5(,^&6]*OCD:UDU(HM-2AG5IHG%^9VE> M)0VC$8ZRTJ7[XA3UV:W_H_&XC`EMWC0WX^+UE!T$_6E0;2DTJTSBS2Z?X:DN#(A M(R>"G(`=H^,MW6H1]PI@GA?(EEYF=$VBB9O/SG(0MRSBK"S=!%C]Z@9E7"]? MR8;32RK.'2M2:5`CFC/LB#PGU^\6BF]RQ7>&6):4H^*&WH,/9:T:!+YXVB][ M310[&CS$Q/"B[V]9\ZD,&E%.U$K"H9(QR3UO?+4+G,J47/WE)5>][B.2`U4%/40;^KA;H7`I?>+>_A M-47!]%:V\%009-<\/^@>T&\;2R___?6O,,^UGTSA7VC3B"*80UK@$%OU+/]G MI6?*2E5W(2Q?N\7B%VQD2)5Y?M`?//KL&_3+[_9G-_;N>=_@9,L//-WR M\[B>^U3/EGP@H0%C=*LV[67[,'Y:C9^BNL>?V>@Y\T1*2PB*_43^`O(W;UIT M-YK0=5:FU@AH)=ZYFAJEQ&M<6&'%2WK+_8.*$SAV&'8,NPW`[@VNU/]V MU-UO)_(-F+>1(\AZT[_*EE@PL[=I,4F[">LQ89NP.,+:VY!HSMN9XR_Q@R6 MO>[6[-/*4937FS`#-\O`$R8@3UXS[;9-NX8N*&':,>UVF78\VNW5PH^;E,MW MW#N%CQ7$<3Q6^F/[2T-L5N]^H&N,^F\2V6!0/]<,>6 M_<,XJ?;E\(GK,BBOZ+[=ZM<])D1C4IF]'N>J<&"V:L>D03-LQ;AB7#&N&%=ML17CBG'% MD^=;C!XO5!S-E-_(#`2G;G9P]OSG()VIY&^Y8KAZBL>2>$*=.=*>].9W/*]P MMX&^YXD%9MY&)O3XFP<\H<>\VSKOG)U.^[W^]@S%!&0"/K3A&D/`WH!Y5_>4 M^N-$C@*U[OI[(1GN&QGA!4J:YP=A%*J#QY^-02O6N2/(K8%F=5=N:SO+T9&5 MSY1>1@8.A>)%:HP*O87X1?D3@&;3VO,U&O=0U?M#"?JPK-!A$HEQ9EDOM^P4 M+*NL@%,S&J+Z%'7J8F.H3A.IKI M4";*+WNT[$"C`CH%G6NBA0P2C;UJ;>1I.C[7R51`=PI@H@JM4K9P!(<_B-A$ M?NI!364`M]&U^%#LY;DT.-L1)D9ZB3T2OX9BHD)E9-!!J``\BI.`(H704Z'O M:A*-QU8EA"@8I)0)%H@Q*GDFS4?!4W7V/`,L6-MX+J_4FD0_W!]O]L[.1)@2U]9Z"8PPBHAU"=O*L-)M=C4 MNJJ['KA9)3&2>#X*;[9GJ7MR$]\PJ[3"DW8JT`'+N,AL^>;*GCE\Z9"^GP(] M`WVOI#4."S.=3_X4LI#>4/I M1DD?FB:BD57F M&KT7:$*<0@%C$\V$I,?"^;_2"`MR=''R"T_PM?6"*(.B%.`$6NL:XFHI)Q.C M)HCY-(0G!6`R7TQ`2ZP`W88[_Y^]:VN.V\C.STE5_@-*<6IWJR@*?4,W'*^K M^IIR:M=V+'NK\I0"9T!QXKEP,3.B^.]SNG&9H=02W`(E$5G[P9(X9-NZ]:SJS85_CE=FT!@TVMSN_&^^[O5LAV3EJ6;A?Z'5TKO>_K!; M_'H#P;QN'A!*_??C"OP&3/Z97"R.FV/+3CMX4!,>W=0WX"/^13!SNTU]^2S[ MZ3U`/;:W'2=0C0?R:AM$*C\T6;7\W^/^L/&@!QX]J!H]]4 MAY-R\.^FVN[]V,,K5YO;EFBJ9@NS%_SWK4=>9G)['^#V:/MQ!`\81O)VU_2& MZ6FNX_9S@VEJ_YUV1)]]YR,XF%!KJV'`VB$*$_:L5V/0X,'+0HS>P8@WOW/+ M9TE?OPM3D_U@^-UXB$-V59;2+G6H#DP MGJLL+8 M[A\,[NJ,?U_7_OV`[K9:+=]!Y+_5DG*G8[VMPKO;O&O?CWH#*K?O.'23=9G] M#8)L"-Q9M0;BKP+X_K5-EV'"JXX+G^.=7MLC#EJM#GZ@-Y#X`?I??4`-L^@K MF,#]59"X`MZ\AJ_>K=;K\-F5?TL;C7ZGT4?Q:@TQO]K>GVQ^?S[R7=9SW/8E MC_\,2IM52-P@J,+$K:Y'9]/;\+ED.Z$PF7NPP"J0!ORP?E.%3-U_X>J^%_)< M4AT/-[LF&/C%*=4/7Z@7-UO?@^02A-]N@^XU/@2`3K"M?`(5Q8?F_M>.TNME! MJN#+^+K-B+M$ZWCK*YEU2SD9>,UA'5#];O.?(W70#]+@-I%X:KK,:N`CH]JE M#Z'B6/E:PM<\W0\?!*;W5R;9'WUB_Z>+LWS#-[Y6UZM%MH*R_^#_UK+)I@;^ M6$(M>;,"?^Y2B[:@/`MX[Y1D(;9^H-39+A/$?8FQVKZNVSHH2%2OJ]7:IQ'/ M0=/GOAD!O@Z!OR.ZR@>]LU*P1>\YJ'[3)4>!I/R33\/W.T=\#H[XJ5[`+$*@ M^VZ_/\)$0#'M,S-OB#\VN^W.1\PPST]-P5G-1E?)91)(8NT[ARST-C,G7RK( M.-J1?_E+^.1Y3K*ATX'^/7M'E\F6$-"\7&UNUZOK^YYR?FPS^ZKO))CZZA", MPN?%D%WM(R;P,:/0NW]7*^W;Y&+IW[;JW[;P;SOO.%?GR4[X[JG.N?(57VC352,;QLV_?HHQS._\YE.W?UW?93[M-]?[=#E^*_]]A>X0O,^W#OUF]]JG% M\HG2^M->!?UA.YF4N^T4>?BO!;OT78?@0U_[0-:^ZC^K+?C[_6E`,+$4>*1 MN-BG7%<[OP('3MQ2Y*[Q3;`%U(#UJ7]]`M#4KX[PV=GZQK*WI:[CY1LU\->3 MB'_)>1_?$]KG&L!'&ZN3.AUU?\!(/Y$N7^67CZ2,;^Y#?;Y+^6C60$:!W?^G\QQGU9W/.X[:>'^J7]>VAWER!`40N^_LH8_+Y MS.=";Z!>>53P8/^SXR)/M`\(%91HF]:?WVL?*Q)]5J=])-"?/P20TI-12UEF)26,/B+HH;Q0K4UE6#(&OW_K*9BE]EIM+(P M7$^R;'GT9MEC#NN[#2H-V>G?5O7=EX;WI,>NKT=_@+K-,VM7'5YD/YJ_!&[O M1['=MQLZ9+Z?MLTJH);EYFS[U0(^71VRZE53U_T.I\UNN;J^'_:)+NOKU;9; M0CSKSIV:4_Z->^"V;;O3:0$?`/H:ZR"N][OL^MCNYQP> MT\L^`L&WA1/.+W./9`W0'XG&NP6-Z]JO<(1USNK@!^E\2,/PK4+_[%RM84BZ MK8.^`]N.XNVZ:MOM_@G#U+V\W_L-(7VK;QEFH%H_U;$9^I6[9A,V>+QM$CZ" MK,)NU[9A,"P?M>,X./YIN]_^K<'MUL?\OL7!O-(&LW6.\QZG5=_];.1%CVGA ME^K6J_U-[?>C9^O3JG?(($D>/(VW^W2[)?QF,ZS;!_?R^U#>\JJ/7]7ZAZ&S M[[;>0K;UHMMA<;@YC>B'""M">H%>PA?:903_B"![5S5-U7+<[1'*F"IL_3ZU M0#].Y-!A\% M:>@]_8.L\'[:-.G'JJF6JU>;[.4MO/A+@WS2(_AVLH3?R98>#N8'5=M`.:MN'P6PVO'V\?R5/W94[_O"/KK?[?I@ MOG^$(T^-N+'Z&VTT,BCIX\P:NTZ^+M9[UT%&7)3W6W[15E?J/OHX_.4!_E% M&_4>9*)5%^#>2KE6?:[5Y=K=7L;3JO%;E@P1S2]'[QXD.T5RZ^%]380'K89? M]O4/U[;;E[S_#?V%PG`G<\+*$I4"<44E9Z&_H#CV/8>Y]A>>-'F^&W[B[9"_ MAI.?@?V&.?W2V)_TP)Z=2ZAOJV;8@!/=S+L*N;&OK/S6EY`;_X>4/YZVG&Q. MPQ^.X?YZVO+?UCS5?G_Q`Z4BEW95_?ESHO?N*P\-"E51MP_:9 M[>[@BWRY.!SAF_WFD,7NN%YV1QWZ/3>[_1FJ5%)Y2!>!26!J?OWZ>K<[>`A_ M@7]D;\*/FIV?@YO#X?;K%R_N[NXNWUPUZ\M=\^H%SG/RPG_\PG_Q6??]P_TM M?!^<.]1NS_RSNX<#:77?N6D\,?UK(***`/BPS#9"D!2JLY!07NF`Y4_"#3ELK MG(D"&I&9!D@9(JVA3%*6PYMH28K>'G!>Q@&-R$P"A'*ED**6:M*C146@STXA'04T(C,-$"TL,I!8E(8AT4A+`?S MZ%V8*YE%`(S(3`4$@*K5EX+H*&6YX/K`N$B(^0B,RTP!I1Q435K*"$B4L M_&/05O$X4X_)3`-DE2D-ME"E.N4P-TX,!HI)$8UE8S+3`+DEBH_0B,PD0)00*+.L931WRI8^C6"]@4*^'+6A,9EI@)@0F@N5 M(P.Y`WA,R?1`PH[)3`-D$"X(P[S0BI38&DV&5`(*0!$%-"(S#9!C"B/' M2,E+Y2D8=V4Q:"M*%P/`3N)`AJ1F09(L!RXPT&!!=/O!,/ET,"T MN8IZV9C,1$!<:V4P45O MH*R4T11V3&82($&DA4>#$3C?;8;*Q@PDQS"--AO&9*8!$E)(9G.**)0,!`ID M,7"*1#C:L!J3F0:H5*;4%%,.^;JP%O*MH1L&X3,Z96,RTP!);2V63.4*$PA/ M8+!T6(S+3=3+QF2F`=(FAV=J2A#/(1>%>'!:KE0B&LO&9*8!,LQQ9*B#Q`\7 MDAN9RYY3%"?1T#$F,PD0%'S$8`**0C:!2YD+-K16K(BOEXW)3`-$M9*N+$M, MC6,<>5,=/*:,]X?&9*8!*IPMBR+T>(1$&LIT-Q1].E[;C\E,`R1*Y*S(F29& MEH9+5@XM7@A8T5)Z3&8B("F=9D9H4F"K@&?S(;>Q.N[V8S+3`&F(U,029AQA M4D)MK`9.L2R/AHXQF4F`)&:*0/*'N;*0L8.!6M-K:UB\I3(V-"(S#9`E>0[Z M<9[[#1207^%A^$L57Y4>DYD(2!980^'`>0EO@3+4#LN5!N'HJO28S#1`SCL* M@\Q&88>![Q0>=BD@9J.A8TQF$B#%)#@NUL25B%I)-;>R=^&"N^@.JS&9:8"T M84(#H1D'!@HUNZ?:?C$.XV@9-"8S#9#CD$B(G%">%R4M;*F'Q3CJW@-H1&82 M(&`VE`MN*45$E-06N1@"):(RFJ"-R4P#Q+@3%E%#"ZA##;6.G8J^]^QC').9 M!LA@O_8/)01G12F-(7S81EJ2^%[8,9F)@`PJ2\2MHJ4@)2B8#P9J+(U6'6,R MTP!9Y4MB2:%<+X6AA*JAQ9N;(AK+QF0F`8+J`3/&<^ER1GP(0&Q8'81*,%H& MC`@HKHK344*13/6R2]"MA M44`C,M,`E;D5%JIA3#B0B"J*%HX!&9*8!4KADF@JA42ES,(Q"#UUYCHIH@C8F,PV0X8IAB:@H%)R663^]X8TX?>;MF)5LQ@YA-1]X\6U1]0_JA?W MYZ4^YMS0#H2Z1STOL6+(0KX)\K843OC%TW[=E(B(ZP*D+Z)ARD&D>=Y1PF M'1">YQRFG#B>YQRF'&&>Y1PFG8F>Y1PF';(^UY`S&!Q4:"A-D#_T9Y'KMG*6 MRNK8HNJ7TC#EU/:YAB;'2N8E@C](B93AMBA[#36+7>7VI31,.08^2RM-.E<^ M2Z9).J@^SSE,.?D^2Z9).DI_KB'6)6:NP!HJ3`YTHRE6O89*Q];ROY2&*6?S MYVFE*8?]Y\DT*;<'S'(.DZXCF*>&*?<;G&LH"H$X%2".2G_TI<"$]H(\>I76 M%],PX<*$6?IAT@T,\]0PY4J'>6J85 MIMRS,4\K3;FX8YYSF'(3R"PU3+I:Y--KB)^0AE!62H2XSC'%D/GI@LON@@JH MBD'9IS.'*;>QS))IDJYWF:>&*??%S%/#E`MHYJEARHTVLXP625?DS'(.D^[< MF><ZDJYKF M::4I=S_-TTI3+I.:YQRFW$XUSSE,N>YJGAJFW)\U2RM-NI!KEGEIT@U?\YS# ME"O#9NF'27>0S7*5.^E2LUF>(4VZ)6V>5IIR[=H\-4RYQVV67)IT,=PLJZ>D MF^9F::5)5]?-TTI3[L*;IX8IE^O-TDJ3;NN;IX8IU__-4L.D^P3GJ6'*!86S MW!.5=./A+"-^TA6*LXP627:P^Y;_=V3'S.&(Z/1#L5;H]"B M:NK][M@L_$\W:\"P??7G9_7V^2\OGWUKKZ_KQ6'UNLYN=\UAM=MFBW6UWZ^N M5_4RJ_99L[NOUH?[K*E?U]MC??G-BP=J_79-4\;RDVAZW%;'Y>I0+S]:A11: M_B0JW,`_ZFRUS0XW=79=K9KL=;4^UMGN.EM4^YOL>KV[RV[JY:MZ?Y%MZX/_ MX%"]^?A)2VD!?1*-OQ^4\']\A3#)JNTR^^-7B)1_RJYW31B*PTU3U]EFMSW< M[+-ZNP33?5G?'NK_6VY2:I&:LJ&9@;6Q@8Z"$;#T!NL&,DQT@"FZN`"2]',J M=<#B*D:&4-,MC,T1IN=EYE%D./G!3TI+AS;!#W*;(=GN)V4]XB#-\Z0T5&CB M!<^\5%@1G9=:7*P`JM<44BN206QP5E___(_?_HN0?[[Y>'+PME:+ M*YAW!\<-B`[TP=>JNSSXAX;VSP/3U%<'_ZB;/ZLO@I`UU,'JKUDU_U.*%@Z^ MM=6OK;J$*W%2*]$M>[[LNNM?#P^_?OWZRS?9S'ZIFXO#.(J2PSNHK2WL?^2V M&;&/"(U)0G_YUNI7!\C?O'7`OV[YZS?[X%'[K\FR-2V*XG#Y]JYI6VUJB&CI MX3]_/SE?LDBJ>=N)N8)7*(.#@]^:>@8?P1S8WY\_?GB$X%K/?E'UU:%]=WBD M5+,`?5()6$X?EX"YVH9CX8>(S)-^5_B*;!J?,%AA*\ M!8%O.H*-C$JDY3[/^R,;1?RS:R[?5ETK# M7.^E;V-CC_WWG"TNL!ZI.U]<78GFYM0K)UV%X_)'W;FN M4GZP>^3034MW@(RGY=V_%^B:SM"S:(_F^@,RWG;6F76B:B]P0/J.ON"86&'@ M@)UC@W-0BV:Y5*[MT_DE0'<\$VU;F6KE5KNK2T,X"\N]N#1Q1C*2UOKJJUDH_UV@3.XR!,19V"+P<0(/1]G[1+1KX MO9I75XNKTVNP2CR_.`$,:<_$S1+$47T\]A&,V[XSOC>F8)0[:KLK@K%TSG%U M;<'VT-:S2EN7\*%!=R#4%4-H2L^$S1-<0H>KS\P#W9OQ!>#BO,.?RZ%>6>7W ML_IK^WDN%KK"MX,8<4,9FI?OHPH/8S2HA^DY]3A^#L@#\^>;I5![]4//W_P[R#!AVT M=]^NK3*@?_D>9+-`YQ.)RQ\$F*N?O;GPU5]8*=SYVV&9[]F-7YZ_E_SOPA*0 M]U-T-FU\.7$.K75`C*5JT'7HV-I.J<-5OEFFPO03M`@I`3U]CT`-'`&K/ MH+'_B`LX-9_J3LP^PA>8+^!]4U^=5,K:TO84!Y1&IV;]:@1?HWL+(`%'M=X/ M&H*V!S)JW]S\#>J+1EQ?5NJH`3%B''K@'5<#T&D,0)*NPL^3RO90O-%SOW/LRO%YT-$Y'<6?5@ M5V38*`[I(`"?/5>0/C@"4'N_@W^O&>:H;6&96WU8"E-WYPOY+U#=I_JNJ97M MQ;QRWT:;DH8`TG);;1Q`1])6-U!=S%?57^KF[Z`OI+.CADU.20C)]34B?9"$H/=^"K\S!N?GJ7F+H\/UJ$/\]U9S]5VCFNF=XQL7@#!8<=AGYJ_A19?6Z*/VMM=$(O$-::=JO\0 M4G(TXPZPXZA;:<4G\6T_,1N:>NN[I['9#^F-LK.F_E+9*BP/>]/IA,<; MU8\]SEM3@:_NR+"V88&J_[E%C?I\;LW&HJN;F_>@H;&>^QK`%I_U9C9D]\%D M]'G>K/RX_P.-#=[`'$SENO3/KKQQK.;,=T*,(Z.$[@0,]1K!6!/X^PE8UM[OU3T-*B.X.-H_`.Z=1$` M-.>7HH%]5&T%\$Q'3V&YPONF\L$#FR]1.+?>5C-K19?OAQ+?"^VS\+1W3HW% MZYDK-WNT!VPD37;K!%9+@I$;W$9JK^S?[R>R-:2K*^T[;L8C' M\77:7`CT`99.`?;]9H&>#^P_S;0'+`A-/07;#\M(BNV0K5R+O61]W]1;WWTE MM!?2&V4/_NQ-VU98;]2Y6<:M`![HN)WN/<[K[H,+0]40%7-'$X;F;<_'L>"& M-0Q'/11V+_0X"L\:N!:5OEVVUN>NW4RA"VPXZGIJ\@!4X6C?]6X\.^[8PW'H MIN'N&,926E]#T]W8/?M_+ZIKF\G>3]MV&/_4]-9F9Q3^:=WT;#C9^['YY\!5 M._=!CJ/L?Q:BZ:"9W=Q5-KP5G7`NN'<$#TIC3[4=ABTH!WM>>^&K5Q]!N753 M_%Y(QM%[WM7JSS=BN2=]96NDG6JP=D.%H.A(ZV4EAMU$N"OW^@@7HK&9S=-% MO1@G&>_]!I'17AV]?KZP%$O%4@[^B0?$Q,T9W M%T(&;DN="^Q(ZA:RA7\OT'=\]\6ED'=;>[]4]+7G;N!C:;Q5H_MMX".EZL7R M'/Q9/:MEL"OY[Z]H( MI%/PXU<3GT,C[ZO9-L6XI^9=VU56=?3G%LQB=H)B=ETU)^I_6BFMSZ2\N?E= M_*MN;L^NM%XG;M_>II"`XQHZ`-=&ZI68*7M!'1JO$VRT;FKI'7)1ZJH+^-8! M>JK:]KBR=C(9-<^2N\V77V/FL5H\&=-WA\F)<(UJYO,9VT9(+(:X/[4`? MPJQK;Y\LAYY$='W%[E_6C\NM`KFE!H,&F+U^A;V7>V%*$*:(C:2$I;$FL6(9 MR:3@A`J6B(05W*3\,9LS>YEPW=R*.!B?MU[\1UC>I-B+W[VP)6B5I)'D)%,9 M)U&B.>&:`A&:&9!Y'"@XQH'5YNR%EP7;D]_7\F;JQ5V*\@FP%* MJ7)@P`6!+$D(+R)!"F8H*3*6)R)*A>(P3"OB'U@KO`EK"E6XN]+261>V0)0R M,2RC(B4F$XP((W)2*%80)4R:1I3J/-]K&C:)I':9H.4Y'L!U81[T)[H"*_ M'3YQ]WW&`#O3(('BCI`A3O\[]J?L>1)I/\/]]%.2'DQ[=MP?[Q]_>$WP>7^[ M?X*"CJ+C3>OA^_-U_WEX2J?1QT`7C(>G+YRZNE[^';JW@;=TAR9K`KWL=VFV MIS[[W7\]40[V86YXOMITOZQGZ)RW=F)T-SNBAGV@92H2FII($\6,()DR,8DD M4"*TYBE/62;,WLQD<*[=&"Q3X%'*8D4@,XQ`K`L2*9,1;FB2Q%I+%64O.\W0MM' M>KAH)DJ7V2O%LU+X%M84BG%^63>=/3O[1LS_/*G%?%6(W<'MBK=# M.?;"EC%-11YE")904((;`HE>9H^ M=?8Q=P.614[SPJ08@@D&A.>1)$S&E*1IA'+42JBD&*8>[$=4#^_2FE@W;H_A M.YJ//9!EQ&5.06C"8_2Q,\,E20LP)!4BBR1/=03J!_$_1X6@_N4TV=[\H^N; MY\IM7WXC4,E-IK@RFJ0L*T@:%XHDF9`D9DPS7C":QO0'<4!':8-7$4WB8?1) ML6[(T^G()&DAT%O*81EJ)R1GJ.UH6TW.>:(B-K`88W(SX#\1Z45>4VC!6;-V MCI<4+V_CWJ$&&UJ725;(2*B4Y)$"(N*"$L,3290Q-$J6)G!@@>BTA_FQ^*ZZL1LQ\!O@2@+FN4J1^E0]'UMW6%*"I52DF48,XLX MUH8-]`&G6?4]C[\_,4V4@70J&(/NU'P2WW;G)?M@*K5FDL<1(XH6Z`AKG9$D M*22A"2M4ACX21"\Z,>5;;8*+;PIU^FBK(^:@WXEF;F]*?L#56S"5JG9%%ON! M,73/6*9T1#27&+`#SJ142UQ'TSR-,,BB!@9N>4Z3K/*L-$$D-HG9>72YWB9K MLFQ0@C&*IMH0HWE,`%1.0$-!6`I(/)4%E7O7EI`<.&S7/&Q7)@6Z=Y+%A`,. M=I9%"4ESC"JC7.$"8*(,LN@E.\A#AN6IH1LID$G2UR2F;$>) MJ.SN_W,P%?TPE8P7:+R9QD@"@.0\923C"9`HSG.(J8B38F"Z;:+CE-[T)[SD MIBP/NK]K';T]]R*A36!EJN,4,F:(R'#BX'HO2)1%.3&9H5F2",#7+SDX\Z@C M?L4T<47`2@X/<\HNJN&&H*1I7L11BHS;S?'9KPO=W6]DGY==^IH,,% MO+1V,$\C(+J0">$R3X@"KI']J-!1`9D6+_M&CO$S.)")33=I2PKV-&GU?@@ESS(&GL^?.WL/K=._&_&4UI3*8E MS0&7B0)]/9%I`C9*C+*8RR@6>43W'N,+Y%%@*(LL++]'C;)_<_.YM0=I[H[C MKV\_WWU2V1U)B781*$A.8FKLA77XKY!51S(ZKFB]W4JXU0.&/0@6I<@E-7 M^#*C">4ZBXFDBF-\EJ(+CE-K%:DQGMN+T%YRQB&P3H06YA2FY&^BFK>V)@K: MT_F[;U8JBZJ]7-V\;O?]=MB3O;!EQ@L1BRC#WC&04Z)`[UTS27A69/9@0)'+ M\8D/\N-J4$A)3A,27S>@JM7@/+",]M(GA2OU\CM/.S.>CAA*F2N3@,:E7F+@ MEQ2X/]@@P=%@8M<%N,/X?X$NC!.9M.,H9BI9I$<91$.DDT9`./>14_U1H4 M2)C/HT;K,I;;:;&QG*678KD@+'E4%%&D<6IQ&1&)82(!`1D!L`/RW2$W%"73&5>)*0@5B20R1?$KQ10I#$W0C"=, M#+WTB-*?7,.\2?1Y=&HY#^ZEU-^";4)0,AXS412@)>4A!QP94BMM"8<)IEA!E1 M$)$(P[7!:33XN.E/E7L.),QG5:,'(>S^>]YZ8"D3D'$LE"`I!R!)7$0DUS$0 MX(F@BO&(1D,O^9FFZN^YE[JO=!MJJK:C*:$H\CA%UHWFU);-H0\0 M%9)DK$AESN(L4P-3W72:JL+G=:1\"762NG7HOO\8VN9"LOMV);!802YS>ZZJX?U&?3.4_$)FY+5YKEOMVT["\46]J4W[QA5.BJ9L@HC)XH"(!J#"N4P M`O.74F,Q=F1OP_)S=!G$8J!^:'BBCWK)P!8H/ZF?`I7:RDUK/]W80^$#HTLI M/6'&"B2\%L@POV@GTCEA"R:8($<>*(.&=/3%#G%)F5JE6;+QR/]'-8W:G4VX M>V"I.;`Y_(.X4F!Y&%8@(:0#^T#XO,BT(OK(JX]!;?B8RDTO5$S!,R`R5\?? M@:T=MPT)5\5>Y-PC(2D/K6\I(MQFJ,!9SL#6L+DXW2+_`01.CP1,K)F,`UTJ M>Z!&LGR[9!K#>8E!@`H%#"\"#,\M,E@X@KUV>7[D`5+\4(S1#^W2N_E6FO8' M[.F02<.`_3/*!S@Q-JF'9-?[JG%J,O[;V5_JB05E8:TT MS:X]UJ`?G-D MG;SAF3DBKQW(\0,LS]#G]5=G)JIMQQXTP(XC5J0.NN[%Z*?;Q6J,_`L)3M0- M3H)99H8JP:U!8*A[I+F2*!<"6(!JB8O"86F.#*)*=$-SWGM@B`4:>A-3F?V@;Y<%I;D6!J.<*8$RS^#T<%PC!H)=6VV< MS$\/5?Y1E918)#X/Y>1%!JW-,Y9:\E%@)2M\D0G-D:4@YU0&I"V\94CD(L,> M3"+KCPS=&5XABTV)3^MK/P9,]'"/& MF<\+DHMKF.FXFL$YM&U)'77YE']7]V MTV\A4O>0&M`)L2@]=BK3H=B@]`7RE!C$@R5%C5',*^?A\3DK5R=PUOOR"6=, M]20:U++>P$%[>L/;99@68YE#&:A1W*6:>4+:<[Z+#IY M5=Z%$QU-F!1+^[.K8+Z3T(W!/HZK<3MM.NUY46%TQXKO&5ERZ3.9@\)-F,@1 M480ACJE!QD@J"9&&V-.+RL^S=]+[*ESQ5(4Y)L.>^53;A3MW[W=BDR:4T& M>P;,>X[R7"J$BZZ6G]'.:$N-/;;T;QH=N)\5>Z M>[NMA.J"")>@4/GQGL+QFT:46E@#RE:&L,@M$D2$J_%0AYI8(KG40OHC$X+3 M96_VZC'I@T317*C+,&K0G&!#?'6FGC7MO'30S6PZ:QRH6./'V>.79ER9\9.: M+"/UK]Q4C2=QPI672'5H)`#Q]N\WQ_M-W=PXW1WYPS-X3Z[,*V+`U;`9!X\XU8]<")F0_)DGUKSVB=\/;98YS:Y7-D)'$ M(>N<0$X*$:II%XK+W.+]&:S)YG;]EYG,0NC>>D_*CTUXXR=*0EG.0Z&I`DYE MI',PY1W(2Z2PM(18@]W136X26;@GKNQN-;1/PAV5S/VZ7?8AV?R'#"L9%LZ$ MIA9:,)##+@/L0SKI/.=88N;TD6T]4SDV^EGV2,1*H5Z^Q_IJW'9])[XT[G$\ M>]QQ/.P=6UKO#-%@<%/515YRBIP!S0IGN"B(RQ@[M@9-&E.D[W,A!L6B:Z"= MD/Y7R!D/CMMD>L-*D7K[(#T&@^A-*^@?49?Z1."W$&H=15&=M5,POQH`:,!B M:5ZI(;'A)&#D36"_N";\H1[)T%[^?RSJQ\:]?1M;"X:IZ)-_*HVLV`CAR*IU;2[GO!U\QB+_V[4N/FW MFLS<9Z=:L-A?1<_$AK/(\E:3VZJ=-MVTV\5S>S%=#1D%U\*L";&REZH=#VF, MS0MIKS`+DG%2!WQWJ2#;QI2R\)*H(D<4@ZPF09K""5H@8XD@/B?L@+Z;D9*H M-Q9$_-B\#_Y&B0OJ*;$4%3ZD%"@J$>6:(R.TE4Y9+-A9)\7UM,)U.OHE4=NW MID+MVBQ;!Y6*NX*KG"*O*$&6"Q='3-Y[] MGT"P3O+[JM:M:[I:NK?5TVP:G,@@$B;C#D0\1^1&G.+K71O!WIEOSLY",MZ+ MR/-S;H']O]97"E3>NYG^W9GI;_7JU4"QAVK\0JY4:$?3QH"383=6\TZWYCDD M,8#H3P9H;1'>O'#]E_FFJ@<7PDL:9:;MJ-H82'ZI)L&GOO0< Z#9<+'FG9W6^T.N`_R[O!",X/-<1]?7+D6'H<97+1!?M], MZC_GN3B)48ZV1]?BJ.)^/3Y#K[>'#&6H6A@,U%S[.07HUX)ON1_@T0JGL`%F MP%+W(77P_B[LC1EH-\\WSH;PQ=6`K\!W0V`<U"315DSX(<4(.)OQ57TQ!?7W'U3 MC4L!8X!IK?\07!H&&/-J/`F[NWM^;IC$X*YWJ$3;*F]Z=L`,NV363S7(1]<\ MOCP9%GA\/APU#ZI:7.T`(I]ON`[NPY2NL.AF4WZQTNNNV#RL(S4QAO$>5,(DJD M":4&-"*<6UY(GE&R-\^4DI.G,>D0(P5'A$'9,8R=\@;PR7#SE%Z>@.:[X^# MXI(P!2NMJM,O&A=\\/`Y9'A9%!JV"R\0R4,!2RHI4A131&@NB6+"RV.3>]-T MJXG$/)%H%^>^;)NB&$TM_]*X)S6V2]MT29Q85M0N"BTHG%`UZ#Q4G6WT(\A"CQ6M.!F0!?6=AI8N(-:Q2I^=0^J"=<&HUDSFO>! MN_[+-6;<1ER`S?C%Y\?-<+^Z=MJ,S73107/1RN8Y,1:=;WUQ?ZZJ9_C/(_S8 M(;0,';H'T',??#?ZRT15\<3=%BPW_OJ2CW?]^#2IGYUKN_N)QAE06=NY^K9Z ME!KE5?![>#SG<<#H[:K_"=M@H*6/=^#,=.O^.P.I=OU'I(#AMR`2;.+5>K[< M)E^8+O,E5.FM)V,3QU5]&."?ZJ99=J&_#<:4:T#`7#=-W73K'.^F[C#\SF6! M!E^HES"A36K@R%^WTW%8/GO?.C^;?`HE<0>FV0O*BWR'R^?/ZO>Z6>9%M$,S MU_Z3[)__"(\T'('PQ_\`4$L#!!0````(`&F`9$>(=GK_KVH``*L$!0`5`!P` M<&1L:2TR,#$U,#DS,%]D968N>&UL550)``.6& M#.!TLK]^)6RF:[@2DH^>\Z.@3?)IFMU^/OYQ=4*N@K.SX[__Y[__V^__<7+R+_KM_"C,)XLYSZJCH.!) MQ:='/]/J[NB?4U[^>713Y/.C?^;%G^E#)R4_>BS3W\K) M'9\GY_DDJ>J6[ZKJ_K?3TY\_?WYZO"YFG_+B]M0&`)ZN:VTM(7\[:8J=R$7\ZM:&B=I5E9)-N''0EQ'1[\7^8Q_XS='\M\?W\Y>$;B? MSCY-\OFI?'=*)I-BP:?G:7*=SM(JY:5H5S;_VUW!;SX?B\*I$(R%@`^!%,O? MMM>HGN[YY^,RG=_/A$Q.!R/Y]4FP*`IA/M^3ZUD?H(H$S?,1\BI)9SH8>$U) M-_*O25&(7O;`^P+>0D`WSKX&H5GOB_EB)MW:177'BR"?WQ?\CF>E8/],.,8Y M/\]+%9!=R(R"N;L9#*`Z"D?2:TX7,WYQ0Y.9])OEQ8UB5:TRT(9C%*DI=[/N MQ(;A#Y+R+DP?TBG/IJWX-A;6V'['WJ)25R.ZJ\5\GA1/%S=!GJV"MV]"527+ MB^63*A5Z^9I7JJ.4'NH:.52STAU5AF.)_EJ(*'8F(HN29-,SP7A9R;A7"55K M98/XR(/0B12&4-B5*'#%)XNB'BI7_NGJCO,JF"5EF=ZDRPA2R/.;L^YR'XODZ>ZBJ+Y:&S#&+==>WQG2L:0 M*UJ[*H&A.#,QNI93,\` M%U>5^+M6]=(KLUG^L_R1)8MI*M[V8D2-I&E>?LTJ-.BH5POCNR2(4KO4]F74=&72UHX[1NN0/N5^7U MHGC[^UE6\4($:-'CO30&$5\R?ETL1/`IP.$7">;R[\Y\D+^4MRRR]NON=5,OO&'WBVX*S(Y^?I1/K2\D(HU`(7-ZM7 M`_@:W)H!"2B:=7M5$]A>R*BD3W_P_+9([N_2"2EX,D`/'>@.XZK9[R("^BBK MTNKI++O)B[E2QU6I.PP=2]+BOY/9@G_A22FR"Z45BIV5#.!A:9:(9">9G65E M5=02*5?OIZ1:5[F0Z=*B$(G1+4W*5'%<,=>B`4F<"X.=P1]9?EWRXD'VO;/L M?E')-%'`G:4O5D7Z:;%/`P;X[#B"=*%A`.WS"OZS9=R0LN3UW.K+K3!Y=;6X M_A\^J;[GZZ)2MK=9JKZ,-B8&`])2&VT4J@[$EA<\OB&[?" MVEG+!*(7ZGQ3('J3]T4RJTUMR"Z+_"&5N["$ M+EX\[HQ3B8XVU*\CSL95B%=K&-(W+(3I_RB%1?VXDFYC4>7%$^-37LC(?55! M;C[KS*S)YHW)Z$=6+..X_^5348#RC-^DJFM/0^EJX^I*^(MZAU=621GGV7(H M"/D-%TY$`M@4UG9F4DR[\)3:Y\:2EWGV9JJ68$4T?!=J,R$+%4V3*T M:(7U:U%M;7>54&M-;_-@9V]:ZVM"I><:M%33@:+I[A_.Z;?7,H.IC8NID MS&#>]GP8"VI4S7#4P6!;:P]#>%GP^R2=-L/6ZMRUFBM4J6L.74=+[D'*'/9= M[X:SHT[='(=J%JY.82C2_)X7U9-QV;-OKZ$?3V9J52>C'NNE9 M?]CMU/1SH&J=;36'(?O'(BDJ7LR>UCL;PJ1*E#?<*U8WBK&CV?:C9I2#EM=: M^.K4AE%NU0R_$Y%A>*^J?/(G3>HUZ;G<(ZVT!VMW+1.(R'1:[\20BPCK[5[? M^&U2R)G-BT5Q<2^?E-$C+R9IJ6HX1AHSP7_'CMZ)B`F\WWA9%>FD7KH6[\E$ M-)M63T/0*Y$TP4L]C;=:>$^R)_'/7#RL,33GN']DT]5T7UW[,;@Y$S)0&^I4Z@Y$M[@N^5\+$3M&#RH;>;>5UXNBJS]7JSX48V-& MS\O`9#+)%_4Y^,M\EJIUO>VIEEU M.DWGIZLRI\GLC5ENN1FVN>Q57BB+:N0O:NH$)'Z6NV/S[&3*;Y+%K.H);RL= M0V#S>9)FP[&^(J,5:DWY9,[GU[SHBW,3#9T@[P2M8K*XYB=KD?2$NH/21L#" M2-+E>9%S46954F+J<\WPL@7^6'&1YTWUMM'IOM^Q(&P:7\RTO3-T,=.D0<%V MOQ5WQ(;'$/4[W">[1E[C%LAG^623CZG]RTU27M=.9E&>W";)_:DG/H0X^)GX<:W(67+-9Y^/1;/Q]L*Q8]G`)A[U0VQ3 MY/K4!812Z+M`/&`(OV9J)F^.SXM&&^:YJCN%"D=UP=AS+&`!`""CF!#+@AY@ M*VX\P4_4QLVS=9%B$7"/W`JQX4(]GOTUF M>'^99):PXFM5-B*&,WRX76)647_+)I]O\X73*4ZEW1_X@U>V\ M4+=X%-<;D)>GM,ECNLEZ-Y2*D>M0Z@/LA2'P(^("*P@;B7EAY(RDZ!W#_P[% M=]16KDL,M<:U*F\))7P53;[1W,LBL>6YV`U#WR)A&$([M%T!=X4W]-T@WAA$ M&U/?UN#]67F#I)YK%Z]]J4Z!C*+H%;P?67G/)^E-RJ=;>VUKG9BY M!(20`A:!R':E[=)&6MABH;5_7EB3OMYJ7[.$/IXE[(U#WS<#V*KXWT]?9ZBF MLU93LP8[OO2AG;SQ&0"=W]D8*:\/^77U?!>$2G*_I88P99F#+O01O_U-KKO`F-]E=1UM=IK6#T] M\]N2$BA2B%$H@FO?=:W(M;!K0ROT\5HE(&CM:.^RK@%H M$=,8!K`]6B?SO*CDOT;N,= M=Z@8)XDV([OWL!O9C5Z@?]X9\$>1EZ6\9CJ927;^$,*G_":7-XH^=K"J7O1C M`(!G81L"EX6(!M"#/FCDQBR_7_QJ;%QZ'YL;0[+[;)%RBXI)BWQ%/[9=QXXL M#WN.BR("/0>[:[G9$>ZWGP"$H16X-I7"#U<;-@3_+L3]]L@ZAVE9[R/3]TOB M214D1?&49KL-W]AR_5ZVA`[3EDQ*[GTC M_-=^=G5XME>DOY%2[`N'#%B$*(B0B`F$!.!SC!`!KY<5N8=M169E:&JGQ-;E M<&&Z,+2HQ#GP1%.>+^<4]ESL3LMMSGI3\ M,GFJJQC;IK`=E?DM$MO;-J?QEJ\*;FMSOP\OXPBY(18Y4H"P!2(_BGR',!I@ M"@%!5NM(:IBKCH>7'=+D; M]WN[D4'/D3PK\.3F7P`(QD*B3/P:-#)U(POLY2:%GOI4.I+732"'=Q#+01%C M@4]$G@V#@(:"5;?A#V.XQYN9!^I+^416/PE]/$O8NUT!^V(`[Z#XAO-Z8^_J M:E55?_^V3HP##V.?(H@=UP943K9%#7^6YXXUG?ZN/G^@4$:9(WH!L;6;_UHX M#@FEPH)#']M1$*!`=H>&(V#O\[$5#5IZ.^NC2SP?0?'[Z]C?4]\C3,&TYL:7 MB9PMNN-5.DG>7NYY()DR"-TH"B/JVC;U`Q^X/EV>*B2.3_WVA&*_,F4QE``Q MQHC_?40IQ'[@T(8;%M)^JS'F,V5E)>S.E+MQ_\$S91(XP,.,0N98$<.AZ]M> M(PR?>/NYG;^G/I4RY6X".;S\"+H(1"Y"EN\#WV9^A)M50\='$28'$#_UTY=R MHM1/0A_/$O8WH'IG`SCT3-GS0QO:5N!`;"&/>!!AW/#G!-8A9,J#??Y`H1Q" MP@1"._00]@FT(R^P&7*=M1F[CG<(GKZ_EMHSIW[B^0B*WU_'_I[Z?J=,>\'8QT-Z)HL*RMA=[+)\G&39:5]:F4+'<3R.&E2)Z#'!=9./!#S\&`ASA/V-J=[9`/8AK/KUZE>E)0G=&P9;,!UVT&<%S&.V"ZF+0T@# M+[0CBS#J>L2R/-=ZKPN8>@9]S*:1`R//C8B\&UW>*^>LN`&0D7Z[P\T'?/^@P=]2/[G,S1LP+<2-3QPD/885$69]*05\W@1S>4!\$CHB* M/80]8`)1Q(T#>^`>Q!T/<18BJ(*'!= M@%Q,<>C9`7*C:#EE*?X$A_9Q.2<"A&`$PP`A0(1!.@YLN/%<9ZR/972-J925 MT'(^HQ/W>QM371;Y=#&I+HHK7CRD$]X24FTJ'KL@!"`@(,+0]P)F(XA8(PKB M>?8!1%3*VLRURV.,870%4YZO6P%MO[AO:YU8#`P(!ZZ#(FR1R)9?F'(;_@+B MNOL;4`U3UV;=:Q/0QS.$O8NG]D3_7?2^Y7:0?RPXSWB5S#[="T>VZVK%7<5C M1#U??L")01`Q%U)F@W#M]V#/NQ>,W9.E0>*Y=J'T4A^9_+5("SXMTMN[-MUM M*AL3!B/!6A023T[Z0ANB=1036=%8'RE\'\5ID,@8SO8;?^#9@I?DNJR*9++K MMHNW16,:,$CL"(64N#B"(F`%:Z?D^'BLKSFI7F>A+\P>*(E1])H_);/J:85T MEU9?%8P=(`84RX<.05Z$,(Z8M[9U:+=/J8^KT_Z*>*O1(5+HY5W/1"Y5<`%[ MJX8V%8OMD#F6L%44ALA'`6+(6RC15;RLKV[ MO2D9NR[$3N0@2G#DTP@A"P0-+SX+^HV1QJZ_T];?AHEAS(%184",'<>GCA-0 MEQ#`;!($B*S=A0UQOY4[8S?-Z7.:_?@?0WOKFXFBQ_O:T!3BFZUU8@R0Y3)D M,<2@B!(P$.):6R=`_2:/S-V:JB_0T262,53^A\B3BF0F;S2W=M83*1!9[E)^8S:_9\_NJS2\9]+ MQQ!Z,*0`V"YTPLA"$7C.^6P:])LV,G@WXV3NYEA]RM4 M%M(*Y'VVPBTZ@)$@$K^0M;0`&VW)74W=&G64ZY;-./I>9H/MX_J;DC&QD0-\ M/P0H\!BT`L'7FA?70OWF-HR%<2;U/$0NH\1R0D"E''IX>9%%CU($B[2\DZ:Y M_$#)KFBNK6X<^@A3QX6$^0$A-`P]M)9;R&B_6UV,C>WF[$"WI-YUX.\SX,>$ M>0ZR0\NV?<>Q?`_`T%G/)`'<[U2RL8'>G"7HDM`X_K^)2YF0T/(JWH7`O0I< M\VSU"81EN>_)(R^_I%E>I-53X_CJ*YM?4EE^G>@+K^[R35^DWCBVC(8B]JEC M1W+LA8"&GD.@8^-&!U3X[5Y6:N[R>7WAZ/X*>3Q#%URM^B(5:?A-NCNXW5@C M]AR,&4,(V'X`0X0)<_WU`B;%_0)<<_?.ZS:@H0(995SCE=)(80QU1DF1"4=57O+BZBXI5*8EME6)'1") MX"L*7(IQ:#O486!MK!ZU^AT&QP>@9$T2>0]]TZ1,)QV479>/010*9I`'`C]$ MC!%;C$-KO@@9[;I)-4T/5T^+OOL(Y3V4'::SQ8OM_@KJ7M6(*0I"!Q*9>-NV M1S%"_T?>M3:WC2O9?[2%]^,CGO>F:B9V)=F]'UD:BW:T8XE9/;+)_OH%))-R M'$NB0`HB=<=5DU@A(.!T$^@^Z&[L/6_!V<`BI"XN\#18#!C<]6C*F=QEQ.S(GZ ME`+B%97I9=7\;1KGJ].AG@H0,$"6@VU@3GAY2:PBW?"`8F#7F5];H7J",8=* MQ7NMJL6N9-GL^VQ:+J;[W;A\>`Y_'+-KVC0OJ-<6BQAQ@"6SP3&3IMG-I6&) M5BT8P09V`7@NE-<:%'@]^^NY5(OIQVKQJ7RH-LM5^;%:O[GQ[7XY6SS,ODV> M+W_96S.F[2@N_PUO?W]S2N:KI2__6FXFRY_A71+;1W:3W_W_.C7FXRG-AT58 MQC9M4WX/M"B<5`Y:H($W!%BIF'<[#D5J0_"U[F7[=;2GDG_?>;I@E'.NC>;" M:6EZ:92NB=#0#N+-,JKYQ&&PN\!_5XBF\E_,XQ2]AJ"=R@=][O!!2 M`^E-^`+JK/#&<(9K*)!*C*&_<"YP)Y&^#;[N#DJ6H/HWPSR9!/I^@R)8<(1B M@(0,>`$%N<2DGIDEP@TW%;B;H$Y(O1,ZMR3__'(_D0$\!+'G%_>O*]R)=?WW MAPO)(?6<$*BPEX`1CW"S&GJ!TR)V+UQAOL]5O3,D^87\<3(__58?:E(X[(2W M`A$(H240"[Y788+\@-?U+J(Z*O7.Z-R:#@QN;1^"Z,\1^8'LU=]/E`0X\ M7A@7Y@R9PDP23XA%KQP<@/S`,FNZ`U[UCDF.%_:_)LM9W)H^3=:G_*VWCQ8& M&.VDQYA:R)$6%F!>SX8+GRN_]6J[0]NS[VFF*]M7GTJI^7\6P3[OES.JNE9?M5[ MC0NK5=B4@JE"D`P>*;;.-N`10M-6]/-CY@?B9_4`T?65XDS[^_WF!;,:,ANI MZF`'$0L=)B'(M`UYNW,P/+UNW[:.]","61 M`*^_;YC=[JDVSPE+'/5+"2VL<$MA3Y)J1H\3KH2\6;-27 M@"\`38XW__<1V]GJH=HLUO?+*&,*D8&`,,\9EL%1Y1IPR8RM9Z:5'?#U M4]T$U2Y6)@V=6Y+_X"B8(8C]VFS<^2%2CC"-.0:A>\^D,))S4\^(A7\:2XA4 MZJK>&9*QA<=H#A'`&"L&XA41$"/<``68],-=U[N(JFV<3!HZMZ8#@UO;AR#Z MX81(Q=I\7@@O)#&:&&.PQ_5(PT<#NY"A.^!M0J3.PV3H(5(<,"`@(4S$D&P* MP+;@WFXV2)"T:K-7")%*W94[`C*&D!E)#9.46A)F@9#ES!M>S\B:(1^-IPOG M=.Q,&BJW(._![;G7%/.US:O^0Z0P=%)"3QG7RGD"F$*T)B4E0VE^UA5"I/KQ MLWJ`Z/I*T4^HB['!D+662:Z(]]QK9WP]:V,X'NX^T*=(4V)>TI#[=]&;P>TG M0U>7:ZO)?RXFN\/]BG?VXUN(\?5YV'B1C.ROQ0D`*G-2&:64LU4JS>G8&*#H6_^P\4;4] M-$E#Y]9T8."^UG5$W\-YF=V4+W;2\8.RM\\5R(9!<*DL)9IH09SFJAY;<"JS M'7!V/"%K#7'5'QBWEAO$/2&,!^#"_J8`B7":O0VD1^(&IUIR%X)I2+E!&#(M M,`B&C%(P.'H<>=2,'.&!%2+N2\`7@&;\N4$T6+6<:BJD1&'&1A'']RN=2KN4 M.WMN4.J[WC<^X\@-(MB$_8TAH*%WX4L\4XTC@ST=V,6\&=;W,Q&Y#OWUN5S. MRE50"G0[#%A888WWRC+&/<).4UZ7$$&`.31:!@SPH$M..VLM@=(R;'PS+R5! MVJJ:B0%K+9,6#-AY.-PL`^:DP$X8B)P72EJI5+`P7F!`@.W@3QA03R7`*J)?7A=8HI'3M9 M">(!AB=#D8=*?#&HH:$&"..L+;B/$U\G0?)V$@/"AE7DC!.@NG/.,<> M^/WLS+A*);0655OV(PV=6].!,1!?V46?7^3_B@;58GV0'WOWN<(K;K!7$$+E M#/@JNWXPZ45ZI];*TXT*:8E!%!J-I'5(0V!PHW-2^#0..1/'T++?->SU/M(?:%P;BX"@@XS@BX2_>4M[L",21M.V1CE/*/8&4 M)/`OY7+^1S59_,=QN;YYK%#4A2V!@C`Z[)R2P!+9;`S$I9T#L'&(KQL625+Z M,[3Z&C^NO_NXM`X\7F@CB%"&.8<%UE!K*5`]4F9A&F7/QR&U?C#)FVIBI8*Q MU)@E"OGPGX6P85-4:GZ!&(>\.H*1)*AZ(9[N5^(3YNCA%@5$,-A>.NB6U]P: M'@9/&^M+RS2+5(Y#>+W!3I4_;)XI++*"4\\(!!:&61"P7S^X)6DG+M>XL#V18D]%(ILD3Q)L MKYXJ'`H_7`ON('(Z**1VS3*B")/#Y<\3Y/">)#OA,$Z9#HX/SRO*_"+480N/ ME15/2O'7!PMNA$8R,KZ$AUW$06@:-)A4`^.^DV10]0A`#E&FUW^2L8"F5X(Q MR33V'CG7L(A8YBL&URWF)S5FH1L::91,M9X\/P2+>1:@V@:8/`FY;KA';/A(PCN35.'28*5Q$_6WJWF,,GT]QOO);'I_A*,XV;)0!&'& MB/$,`,FX``0UVYZT>-!G+AV%W3LZ>2)YIYN'M`7+EDR/Z;_O5FMX[Q7 M7RHUG6Y!GSS'!>W#PDR^S8*MX_YG,UO_--7\6[4(#_ZFU4=4I(_N"\\YL,`B MC3"7D&%BG6AX+,G2_(I,AU'=M>D*$":9'9$!GM[]]3Q[VMK$ZGDKB'+ZI:K? MAR^3'VJU*@_GE)W110&`T=;&V4`7"6B`A6O\;^[3')!,)UX=#9'+P90_+K;. ME(F4R.=UG$6PHZ)A-7G76SV_D\(K;*$2R`GM."#"$M?$G1KLTVR23*=K?>Q% M%P(JOZKT79J>D+#V88L$8>$ED<2]HMYT>%,&?7+7MV9T!RB70KPRKY>SIV!B M/<=/=SX9/*$01]L67&@K#;#,,(^QERYL$%2XM M\`:.@[J\&$S)8M]/[97W\F<`>+Z9[]>E^^7LH7RQ6HZIP/F]%0A*:BE60G,> M_C1$HL8[UT0FGBJ/@]S,`EG/JC'YL1W9<[6:+9Y>#^M]WZ%#;P4EV#CC`666 M[O&Q?(AU'=9?CHL0ICF<^>)\M%M7AUZC]K MQGYH_^G4:>&G\IO+PDT MVWU1K?:VU-UC$[!R:#-*ZZWP5CCKN!=0"BI,,.MYX_0!YA+O.AD\3YH/LOS; MCY^$L<_/.E+9-RDLIY$1%)(8(+B%2'"P5WR2QJ"BP3.H/>,R$&_F4]S2.GHS MNSX*CBVT4$'K`0#(&F-=DP@F&4C4B\'SJY<&*BT\8Q,G?_?XSW+Z%`:PB>;S MMTD83WDX'.-PDR)X6TXP;B2ED'MMG<$-)H:3M%+L:!Q<:7^X])9['&/,#D;U M'GB^4)`Q;(T`C!.A-'$"-T%!\9PO38;C(#5[`J73J_CYZR1XL#%8:SZO%I_7 MU/"*.$@00ARP:55-J#:'/5HF%AL!0V>K+P* M>KG]O[H(^=WC2[&@8[&]QQL&@)W55!`H&2926\;WN?D8F[3K'-!H>,I>T*6*V$U_NJ`DHENHJ#)RRSH#4( MO3DW[NIP%X4T&ABC4#"&>;PO--A+^[(1J>0V&A7U>`&IK#/U95W4. MXYO4QH.,TJF&A27AN[0@&C*D%`)$H7V4*=8^V+*Q#4BBOM!20"(28M?MD=JS3\BGPB$B] M/N%)C(AKLGR"G[HXEP]JV;P(2QW&##EKO?(&$4=\X\4`!1+?^W%0?)?!*,>+ M_X^`U>J/:K6*XW8_UK/%TV:V^CK?I@6>./<]V;;`#N&PGN%8O]\C18DT35`? MD#8M%1,/GC*\%$"=0^0#?L&&?-I!6BU.U7EIT;1P@CH"07!`E9>$.RK,'AN= M6%L+CX,"[!^?9`F[QD-8K:OUUR.U8-][N*"4`@&(_:)B^]HR+1D)++8 MV[/OLVFYF*Y>W(0=67-?+K>C/F9N'VU86..U0DQ#YB7&BGCLFA`"(E$:T8[' M0XKUB4Z>=[I:KF/A<%TME]7_!@/AV"G+.T\7/L8*.N$`AQ!`#@B4C6Y;`]-6 M;C)X@JP_2%Z)^6)79W[>S.>3Y<]?"FUL_^$FKM(D&D./@8380FBMP1CM\%9` M.:]/FH`YYI=RE:8C`&FM+&'2*ZZ!=]XV\W(@5]G8I*LT6\NDQ56:Y^$PN=FK M-+ET3'DE(4.:4RX]0#4,TOI*6TKF?'$1]P*?`NHFI[GV(:.K>F`_EEGW"59F[1]\!I]'#5AE<*D5VN M.0J.'_=A'ZQ'Z35/\X7R7Y39&NS3-VVU0]#T2-0MY=0%\`%FGC-G*-:JIA1).OY4X$2TS/&J2C]X300/>FQ MC(S@F.MX/"86/,V>XC6!?4D":>T;+U+WL9AN5<8&&J(",NB M#3^N\?\`L&D^5O8(K7/E?!ET\J\"?T[6F^5L_=-.W@VH/]VHT$@X99T@U@-B M)0"1!*Y-)RG2'+;LT5C]O.<=@,DO^F[U%IAV!$><'*>*2\L0:\R@X*6FF0'9 M([3Z$7LR+'FC`2:+OZ//L]K&C0H55LP(&VA0=.`<%$F.7_LW=MW6W; MROH?[87[Y1'7-NND35>])7*Y3.@�/9.?N?3LY(%(:J)%'3'LD@TYK`-W>,I3* M6HB/FA"CS0%1P`MNN(0&&"6H9YPW=#FO$FM^#Y,#TIDG77)`3L+AS>:`&"^" M0HB=ED8`PX7G.X]2@$%2EE;'YA(Y(%W9>3P'Y#1(KBW^3RBUWD.GE',..\*T M(`UUU#A[53D@G5G5-1$@#9VW)@/7D`,R..LOF4M`'4::0HDX,$Q0[80QS=H` M)FPHAIT9+NL,\<%<@M/`N#;?!K8`:<$%A-YZSA@$%#34*9S:A&EH/II8, MR_!,S]V<30%C@KV.A(8LUNQ6UM!V>TM-U1X\TI5'#,['9ZR^#4!)#+Q$DUYX MZ1$A!C54,)28@3UXG"J5RV=`,:AOX[OM7&ZM[@PLEX70H#905""CJ)&KH"L8F-BH9Q;W3F20?WQFDXO%GW!A6< M>B`!LL@S[(/*B6T#`U)H*&WJ;/=&9W8>=V^E-5?EWNC,JJXV;AHZ;TT&KL&],3CK,[@W,EQQ@=(SX2PT#L.PUG#JB?8( MA!PF]J(=W-'1&>SC5UQ.0^3:O!VQ++3&-("BK;26$"AA>ZYQF-B#?/#@;A;% M+1F6Z_=VQ-"--)@@`0A!0;41R+7?"TPMIWV=8G`^/F/U=FC@&41*>1-V,NQ4 ML/AQ2P5)##L,GY6;R.4SH!C"V[&Q,Y;?OK?U:C0O3WG/>KFJ'ZM%>%_,4%UL M&L8-])I?8T'ZF!1[T&63^ZTO.V!]JE?E[&/UM9JOJU@L__UT$HME+C\$["'X M<+?[IT'7-RBG7P*PU$\_5?7]HOSR,)VH157V1;:M)UM->G[KYJOIZNG=_*Y> M/!X2O2Z[Y;*:_.N^_AJ^P&G<*$G\)>Z/Y,7^&/Y4_/#.0XZZPQ,*B0F/K<2# M(<"T1D``M0N961WSR,[QTYU$SW2W11PBH1D3]!<+%#>*82PL9<(:+II5ARWR MHEZX7(#7>8COV?76E+S9;<@RKUZFO\=%[.)]-R M]FR5+'?_?JM6[90/\X]5K,L_G=_KW"S M]!?KW3856'RS_"Y!SJSO*9R6V'"KN`,>2JD!:EH8"F> MW@=+8=9!498<&>P0<0;:1&SWC0T4L6&.MTZQEIZXM\^ M*3D;KTO)!$J2B=VL`G"BM97*0T$1AS0V:6]HA%"F[1J]15DO)Q-I>%U*)G"2 M3.QF%8ZQ(/,(N-A)E4AEY/..:R$=60;ZY60B#:]!94(_;:P",RN7R^XFTK=S M"JHI"OJ_#>+M6+!AI>&M&8OI\=8'F?:(Z[6*SL)S4'G9HO4*/AM`?I_7GY?5 MXFO$9?,=?(S->BJYG*J^G8Q!M<]H#J$O+C_KJ>KIYL(TTZK.2(OKT\H M.)&Q1(ISV`MDE;E:E).] MC,0+`K,Z(G;@*.C\C,(19;&084\,&YA`C`C>.KP4D"-I,)2'A?4P(`TA M).IK.9W%P\_7BYNP\.?SZ8!4[)]4$,*T`XPIY;"T6CNIVM,1"9QV*2O[?M*+ M&&1#91"^;V@^;3/8.Z?`CIF@"0EN!':4,/A"KCUD:36FLGN"^^%Z)E`&\7G4 MBVIZ/S?A-*SFDR=3SS>T;T@X311.?%*A`0=>0MS_C':KY!L"/&\7XPWJU7)7SVP#2`>$Z-*V@#"E&H9&6&!#V4N$L M>*92I04B>VO;,`Y)R@CH>;;*"^([&RROS"FTIM0:29"$&D%.PFG:;M8:)#H\ M>^O=,":KY7PT!TN-W\9.CSAHMAGJ^]+HKR&$\/[T)/5SWU083@S'5$-*63!) M``,":64AI,P(0@"J:XCOSU58H8*7Z>!_(\HYT7YBA(PKDZ" MAY?<=_-@N&P;[&[*^T1V1M8=/K@/S"J85!KZH$UQC((!S@@`+8V"^[0KC\-F M3E[DZ,Z'Z07EYNBV=7!>`0P)!&(M.,`((&$!:?5QK_B(JY9FX5XWB3@+J[)DVLG5X?:QGL[MZ M\5>YN-WG&TU^8$&XEHQH!;BU6AGEF!0[:JU0+BU%?^0Y?^FNBT'!OM2-TS^G MJX&^XL7E,%UT[TZL*904`GE!IG".8::,-:]#D0J>EI(T\_3"C MU^TR;+@RH?XIL/9]O5R&(V.VOJUNW\U=N9B'(4LXC*@?6$"!G7`.QZ0A2*3" MTA!*&N2A1&GUK8>*H;^%#R`?'#"C!K(.=2 M!A,1^':S\2HM;62H8/];$/E45@PAX+^53]L[O/7BMT4]J:K;92R3&WZ_74]B MY=XM&P[(;,N!5`(/G6_IDT:,U\5]'KM>YWTV@-Z>((S.GST2_F=P8MOJ2_U8 MW1YI/OYR4$&X$TA2QK$F5!+-`#;-JAB1([M$F@'=.A,420SZ0Q_F3?/O!5-. M8VX]UT+A8,AYH$2S%H%LFE'=FR,U,UL244CBR._S8#TLEM/54WWWRW3R,+TO MYX=YM']&`9"G-OSPA@(.`.6&J99:2M.VOMZ\?YFYE@V7)#ZJC^^4//CK!JWX3"6,*% M#@:T15%?;MH/+36.X]W4YCR#LKA_- M[S]6DVJZ<3GJI^??/X75'?$#G//8`E"'.980$P:`HTSBYS-"*$\&TG@NX2\8 M$+K>\W^?++]5D>C>M;H]NXGOG%!0"QB$@R`%O)48,6]+09QBQXSWKS^37 M]]S/C-#;DX31G>EC$8`,)_;/P6(]?$`_CR@P$]#%/#J-@Z4,*>+(:>4AM%)J MB4=6EC8#KG4.')+X\K[^ZS!;V@&%YEQ;(A2`TG&EL%58Q-5H[K618F3]/S)S M)16&016CS9W)#W(HZ9$?<^R,"E[ZMWYH+G+3!^ MO%K0)?F=X:C]M"CGDX=J?V.V5T856.IPR'A'L=&2(!BV+QG6%?4!$'2#D:E" MYP!;YP+A'.;L[X;URJ@"(F<=-DI;ZEQ,).`JTF8,U!8Q-++[:)F9DP9"VNW9 MOG\W4YVRUD)V^/Y=_3Q_7C7F?]_BE% MV/N9D9AI81G&%%FJPV'@J?*,&$_3F-E;%E0N9N9#)(F'OYVTY[X^NB#00NZE M@(8'&UIB[4B[E0C$1G:5+Q?GLH`QZ&W1[<7`6%8Z1A0_!A@.6!@'9A5$"`R1 M"ON+IX((Y:R'K7HA9%K&3F^95AGO[>0#)>EK?=F)ICG65T%K6Y:3".:D7G9K M`K1O;F&!UUYA&7L>!T*LP4ZUAA?':3ZBWE*QK)S4O9T_+Z=)6R\EBNJ&SR]'2 M_6F%4Q1;'8Y2A('C,NA`ILF#4";P)DFHS;U(&/.^EYA4)".BQ$,&TLE9`PB%Y(K$@L7@9&+!Q#XC7H$;%M MAKDIF08_U9O_HNA:7-Y5B^51\3GE,051W#J&J!6<*<@@,*35R;`':3H&'+-_ M;P"8+B4L:+=\>)ZP['M,`9SDF`)$.`A[KG9,RR9XK+&GB1&7,7L+!X`IS>GT MPENY\YTT91?W>I[V3RFD0`X@Z600;<8UL5PT=]$TX##M"@@KHMGWR]^%Q%@V=2 MA<5/Z_U%4#,\NT"8>@FH5QXC$`Y')DPKR!(XG286HW=+7@"[(4Z,S?6'YV3V MGQ9!)SIP,KPVO(":.`_"&2@%)XXH`<)7H1%4-&A,D"5&`Z_!;YD!CB&8_+*6 MF*EGLVKC?_MP]]WR#_"]XQ,*(RG788_4WF'CD<9.L$![K-P06X4F)LN,V=/9 M+T(OI*/?TFTWDX?J=CVK/MRU__SA[K7F>X&>F_7G?P?R/M7MT%@'[WZ[C`N6 M?GONT%'.XJ9[\U!5J_!-KK^$_;EMY_><'E5N'8?O3^DFE_CH`@,HN!5*$F>U MB773H=HV#*1>2'KTP^@;L:?7".O<%^[`]`(YAK7A2E.$";988D4;RA&%0V5D M=6OXUCM[]S?2RH5@.=8R=B]H;7_]>5HMPH(?ML93]SYN!QY0(.6XQDPIB0F4 M0'J)?0,7H:GJR,D"E]89)HL<[!>R?+A=+#SR(PG=FUAU>4XAK)7"6VZT!8PP M)KR3#0Z:FQ%WA\G-Z"XAD\PP_N^*U?#BU+WAV?BEZ>+I/UOOW]YTZ`ZS"LV\ M=#1&%X-MX+BS#K*&1F;5R'+7>^+?X.TMR+)4('Z."7K6[*]2>CU<-'H:974K[I&'X5B1D=!KM M]0A&AD#BG]5LMER5JU.*/AV:4R".N/=,0H:-=YPJR]LU`PM&=NGK/-CK?D!) M8N3/\90,J!TI!_+-J"(HQ!9!3IG5Q$(O/`.VU:V"P(Y+;\S'K+-@2+NNE;>V MFD(L:*K"4PCB'27K`@3-BJUT:9MJ;TD7^1B7#Y,D+KYWO]ZHCZB8QMK=$AWR,[0.=M!2W3N\?;X+)=X2C MKPPM%#4>&$T5H/%>M@<`@F:%F-"T=EB]92?DX]_Y6"1QZ__*656?\A7NG5`` MKF,G10TD)9K$U!K<&O9>LC1]IK=K3_DXEPN1(6Q*6WU>O9LO5XMU]/L=\5_] M.+C0P',+D'+$(RVY\("U$FF4'ZI?QWB\4F=C-#S7?RT?CWL3]DTIL++.Q:1( M@J%P!``G6D6/,4/&ZW,ZAU4'N7XV.F]-!D;G51H#ZS,]HXQX[ M?%"_.KCPPA)K6#C@/*;$$LH(;U=)$FM%]^8A.A_L.C,B:6;/NOJE?(I_/V+A M?#>N8%0&A23>A_8,20V4!*T^HJ$(PA@W\=J7CW[;!" M6^F])T9`1"R0T%+5DNFU2K,X_Y^]:VUN&T>V_V@+[\='/&=3-YNDDIV['UD< MB4E4*XLN2[&:*Z@8=GJAT5^ MO>7W57E3K[>+_U3SIFY$9P7F2-_"<*\P5IYB3[CV-F#6!@5C!K)I,J^,W<@= M`STTD%F".AXR(_[8[,J0G`O3>-*P8-!3&W1`JA0T#B(=K,'6149=F@-Q_'"> MW"+1"[5L:7,Q,28>(C]+`/M4KV9WZW5U=O7H]H`":\$Y@M%MX#FG#DK:!E%+>7\AG^ZP68%P,$$)#1,('XH7#G'MJ\6-E=KK,[/[OU?Q'6"ESO><@ MQ_M9`_?7[&>Y^E&U%18_QV*+\VJUJ>;A#YMZN9B'17Q^N,Z?3?D>?.R?RG4L M`OFKNF*FN:W601N)@W@T7#>_A0\IEA3[V"&?O-L#"A16/:>Y0\(2KZQ57#PH M-E):X?A%)>`*L]<-3U^KY:Y6Y^;GXE;??U@%6JO'>@MQJ.&'^O[8P[XN-O^^ ME'N>;Q#1T,`0`"V-@5(89)'D#0L6)4;]#)S!/K1`O?#13!3M.S:A];@0OC]1F6"I@HRSR*1&5.X=W*AJ!FN8A[K=:=`O/SRX%[@I'WVSQB9NS+./^GFG]8 M?=[^K-9'-&/7F)5?8I1FO>IJI0WWNL('RX<1;(T(?R`$&ZE:O0H[G!93G4'$ MAM0,KP;G%(0T7LR^^+ZHYK'8NIK-[F[NEM&H^VP^?%AMZS$$-?65A?2(*^^5 MS4M!6+;: MA!_'Q5%MGBJ:;]I1Z:361DM,M:2(VMV"WKB<@]ETT;$W-4>EU982[8R"*&A. M5F,'VH,Y`A/+JF9P5';FX8*C\G7S?P..RJ<1(PD!.DVW@@<0//!2*T`A8E(0 MUD*L',]E%O=R6G:FMX,BF`A,7F6N67\[E4@]UZV0UGAB/0N_J/9*8`1;Z+SV M;\*5V8>\DQ(Q&%;O53(F[.B&O?Y;K^>5"_V>Z%8YK#PC7 MUA+E#`2\J><59@F=FZSCM`]ASPO[#X=/WN6@WX&F=`(1`Y#4R#BM&4$6M/%< M%.9*!;JR;M`#DK=RJ,4@``9[J)2(][U:3:1H09("O04M((VF+J=;:>B\%^XG MO,]?C_(!#C3=W;J>U\MEN?Y6+9?[+:79L^#?$&7G#SF[]B\$X\Y[J('V81JQ M8+5IYX(PF5B^;C\ZZO$!&H=LWI/L??]":DPY$O$";TG"IN<8=&TL+;Q\G>NU M3G5&)SL-H''(ECW)ELTIOH'""ZBY]3A8-(0"WP9._XR.MEI`(U"-@/] MR&[Z%Q"'%8L"`;2*M>,80_MZ`S%=PZ*T?3K#@.(@- MXH89YK207FFG33,3C>C$JOGGHCH5GS&8%K`7TTWW@A"-O.>.8A$/B@'7LI59 M`WT:TZ/5_<_&="(^>4VN_:@;I]#7)VOL6/_#N@&`R>AD;0[%GYQ[/TY&/=:0.1]3D?*XPL9ZP-H("9@-WXO2 MP+1N+6H2%XZLT5NIXI(!KNY"M*EF?_M1_PJX_*HVVRA">/_G*#SX0'@>_O5P M":TC^N52W9RHYWJA1V$!]HB88+UHSQRF%+IV3@*(-%,O:_35:T5@6$3RQ=., M5:OI(1+QG^5?(S]\"I6-/NRX?TB,_'-5S7T5Y+5=5S"N:" M+F*]I!(C)1B63.QO@B:`@,O%#D?:@(Z,^5)(T,D^!3;&2(.-1SC6-]0N1KSM MYRBPF406XTBL/=]:!L)HL@%$;7+QMUFU*M>+^L*YX-'V!7;2LK"C4DPM),I' M-:P!PV*1%MHYEQ],]*>S)UW/V!T;H_4G"Y,X-IR(`^8EO5SWWUVTLF*FK50#_ MG$UZHD>!PFX:ME.KE<0",H^99NW`5,?MO-5LL%[MJ44W5D_"C=D@Q'?!N6\U_WP1;Z?=O\3N]"V)S M_YRNZ`^ZPH!_7ZW;!,;08$]O#NB^!5,RK"RS!?LR#F9? MRGXU/ZB#G&%@8QFT'ZL?Y3+(Q:RJYD$6,KRAFVG;XX6?JNT#<%^J];>?Y>-- M"R.^8@KV^M/+<[I8YB=Z%%@`89&$#G'-G*&>8:AU6%D1"?^[BX5"<\SONV!:'VM><$`PI=IZ(9&*V>\Q+7`/A3,PET[]RH#;'I36@X.20Y_^6MW> MK6<_RTVE?JRKAXM#GHW\HF'5^1F%UE!0K>*9A3"&.<@1:N9/C>'3-;G[T5GG M!>R_3W`F9Z%/5%X&""<9X`YC@HTCQ`7[5$,(G`7J$0=7<'=6$G?"O_--\P!)D'^I#3<0FE;X%?.9COFOIA#TAB0_R?TNF?<, M`:0Y#?JTYQ)I))EK9AA\]YD8'+[]A2H'V"3MG?5P3W> MEV^M?]FXX$82+;@#`#LI*=;4-Z.$TO%<-_+TO56[,]CUP(A<2[E20FM"G9-( M$A_E$Q'>C))ZF>:+&3&<;DC>AD`DB;=_E#M!.7CK>>I.M2^PUX!`X"T.NJ-R M,0+,-F,5/+$FZXB1<$.R-Q`H200>?.ZBPZ=WHGE!A8PYVDRCL&%(CBF@[4B1 M8),K%38D?<-@DD/#4:OM8KY8WL5SA6_5[&Z].VQR?\V6=_.'4HD/YWC[4S-7 MKE?Q@*4YD]#WQQ]PP28:\:T%PL`$$U-0I*4P`%HG?8,QDR#-N'K]LG$UXVHZ MV%Y/?CMIZI>Z%D!A#A046&LE#40L++K-;!5#>KI6VR1DH)-<]H;[O0O9Y,S" M=RE;^67J7_$T?[6]6,3I2;L",\&M$A"3>!,V)(PYT,S#:Y'M%KMN2M5PM-3# M@9*D$W_9N[WGIEPN/]_N;L@[KQ:?[E%P:Q5FV#%*=3##N`SBWLY:3"W+:W`2 MAX4GQ[?J;FZ7]7U5?=O6LW\_#/;B=WNR3R&#H8V]=U+&JW@@=$ZUOA/C5=H! MWFAV[6C?\%``Y3GA#;KY8K:[R"V,]B+Y1]L74BFB+:'"((@7\ANP:&8R1YO(S^/O@'76X6,[6:VSC1L(W&G[^+H'`@ MXN&R$=(2KK'@TH#]Y>5>,WG9,IIJ4#@60C&NU>X23JLM\K"=EP]W83%Q4H\S M6\V_+,M5)\_P&*\KN#`4>&?C6;Y&`AF*?(.J\0A,^,@B33J>Y^].!]3_%]EA MT)W>`ZZ0B)&JDO>&Y*T%X7-*-<<6=`>\25_PZ M3*Z5CA&T$2>%Q]H(C3B"3K!6&P%,ICG`\J=C)#$W!"*IZ4_[9(*+F4]/VA4: MQ-,W)8,5BXB`*M["T.H4EJ>%FN5/OTABJR<8U\I3%HEC58T)BHXR=NY MAK5A6@$F@U/6&Y$1"FJ#$8@L50)H!$7[)=O^3>-H:029A&PR]Z4C:8\2O6LWWH=S] MI>SH4PNF`)!*0B.H8("XL(&(U@,F95IZ1?9HF'$E;`CD)A0#,T)]R1PJ5*-5L%D.U-KM1QU*I M=;DZ&/W'#E%(71]1.$`\A<8Q9ZFR7@OJ'B*=H2<0&W6=L*1OLY_5_&Y9??[^ M9"*[6839^,6J7,T6JQ^/,[H4NI3XQ"(L3#RL#Y`+&.PBP(U$#3[06)BK/L;9 M\*;AR7Y1.CP'>).-B=+E,LRO^O:SJK8?(\.1S?,',J>Z%()8BAQ2#`"C@CYM ME%(-)!1EN]OX5<#JWPV%`ONN]/=RHH0@9[P3&.EX,[#;T@S0RY M\A.NIM6?M`Y2T`NE]R@/DSO0F9(8Y*?_F9YY,;KC:/L"6L09L&'QM)`'@R1L MT@U4P1I.=!V,YJ<:@J!Z>%BR9,UTW`[U_<'6V"&VNL=C"T(-M%!Q86``GAGA M]T5]`DI!Z4L[VQ@Y[B.W@I$1X#PQ98>#[%"/^67S0E,K1;R?FBMGN8**`MG, M"FLS8<4C#YDOHL@&P_"]2,CD5)&W(QAO55&Q!@:3BK*ZP!).DLWZVJ^V+8URL^?I1]M7`A'"63Q&FE(A73(&$V;42JO M)U:D91#:!D,CB;,/$:UR&=>@\WR]:%A@K:@TP6[""$BD%#`4-*-CX4?3.N09 MCJN^2"3QI.;SQI.M:VT,!1&+:,,$SJ.5,"F=9$(<%FF5:4RG!L#0!& M$F%?Z_MRN;WON!H>;UU(Z;PA@DML)(=*$PI,,T[.29K%1*=/VB!P)-$6S]R6 M05#*U7P1;]BH-A>8.]FA$%8YA1FPF!B@F790/8Z6H+2]C$V?O*$020MWKM=_ M5.4ZNGUNUXN@3M]&'U!'+CMU+@S&!%&MD`^+/=$8,*;WL\`RK"-)O/+I\SH& M.FG?:!S#SVK[9WWATWS6KK`*,6-C?4),B+36@]9-AX&$:7N@F#YS/8'(8?4- M@G*Z'L1^=R;>\I0'VWR!E`*_E4MEYMMN;6+\L>J MWFP7LPO94B<[%!8R@X%@4EG,7?C=>]&,EAH\L8N'1F"A'@&F-*_'7_5OU25O MQT&;@GA#L?*0<$=\K%WG1>,;Q]I[ED3=B/[#4:GK@4P:6[^"HG+IXJ$GC0KN M*(:*&0>H,MP8:$B[]'@'GJ@4QBJN*ZW):7,A0?VQ3>&$:=ML*$/=U#AS1K;`0L MA$MS5(SH/1R5K1[(I+&U6%>SK5_6?UY@[%F[(DB0X=Y"(A3!0''+)6UM\V"W M3\UM."YK_=!)8NY+N2[GBQ\WWVX7J]/'SZ>:%IIA;%58N;6C!CKN#'C4I@5( MJSHZHGMP5/[Z`Y1$X=^C"^9'B?D4(WH' M1R6N%S9)G/U/N:SJZ/SJ$/MQOD,!O8T%`15U#!!K3311FF228)ND?8+RC3(Y M%$QI(2'ENOK?175A#WS:J@#06AUT*2D(T_&&5-&N\<1XD9B(`MXH?[W`N4+` MUF_K>G/.=7^L>:$5@M;SH$)S"K"&6OGF0()HF'@YTW@W;(V=U38`1DF?ZZ>[ M./'Z^^U#A87-M@Y_W0TC)KD>_WC/]2F$!V&-(59;HS0V$D+=+C$`)"I#H_EC M1N-U:*#2]-JXH<\7LYBKN"YGV[MRV0SEI'Y[NDM!-;/2"JIWF>I40"$:E2#8 MNX@F43O>A5JC4CL<3FE!#XOU9GL3T+RYN]F_]V2(P\NFA0`8,T0LK'7K"O!>@7KXM-1Z3K=N`#$24P5T&'QID'> M"2>-S46LX6D9JZ.YXW);%J]'*$ORZF93;?]1KLH?>VMZ<[92U;'F<=,&U!F+ MH&1A@NS_V+O6Y<9M9/TN^P`)[I=39W_@FJ1J$L^9S&S./Y9BT1[MRJ)#23/C M//T"DDC9'E.2(9(B)TFE$ED"R,;7#:"[@>YF=&\M`0U($M\[\^9USO<6,$JS M*)\XGN+5X*N;^%VC-=G0/B.80`>AXQ!IQA@AD%:W#8A$(HV?G?GT.K8DVP'I MG+B&,,@;!QE_BE?K//E;!'O/AZP/T[LGK$@FU`*("F`2DJE#(6[ MD5#BY=!\@-WRNQO0DMC_PSK>`%_E^?2/\"FH$?.'I];2O/C+IOM/$[T-],F"04TQP8847V%#J M1+U$`683:W*.U&W8(E)I>WD^75]'+&>+9;;LLWS>7Z]K=K\S'0\8)"=^(3,*42] M(T$WA!>N1\V,(D\17UF*<>[X_4=][<[C?RP")B^"P1-9V'(GR:S M>1RI+TI=E&7Q.2^7NLPGUQ^O;J+MV7QZ>-YC,Z@@@!!01Q`RCC!A2)6CC0J& M$VL.C<]W=P$PT]:,XNYNMCFO>%\$\@\>\_ MAT8/T\G#HYCB[1EJX[+2PK,SX1R52#CJB<;">(B)J*<2Y8DVQOB<@I="=!!' MH\5RU>'9Z/&G9U8@BFVPVI0@6#@,!*@Q@P2F)?6`XW-E7@[3-C2BTU>N(_TR MBXEG&&$E.3=A1R>,HMI_PQ.O7Z"1NCI;1BO1+-XX5BLM;/GV^?7.N*,V&\SBX@ZR76?&O/NR^Q_AIP\Q+ M2\(V&51Z@!UQ.FA?M<-6`IAV.P:-S]79"CSI;LW9W>[%[V:W'U?+G?)ST*OY M(B;)C#C]=QU"-[01&B[`;8D2-N'923LDS:N MG#0L=E@8*@VJ)Q5,C)+!XW/\]0;A1=0./YF5_YK,UX>LB>9.F?-08:<,%@+Z M@*;2MG)[,4]`6OP"'I^GL'6H^A"&#XLRG\QG?^;3'P)X;XKE\FJQ'\"A?>E( MSXP@[YPP'!+MF$<.^3J#+R=6)B9.&Z\/L5V\DC34GR=?X@U-=1='&M:NNO!` M]'XM/]P'J%>K0-Q&=F]^GLT#<<6BV4)-?5ZFI,#08JXDQ\8PZX6MXE4Y9R8M MF0(>J3NR)Q3[6$V>UJFW\=+HS29>^5T>=L,RG[[=7@Z&!]:5DY^140^0@T'3 MA]PQ&O..UXXYSI!)"[C!X_5B=H5<'Y*SO^L1H3'%8A4S32ZN#]M&!WIEUEH$ MK',<`A864^PU@E[3V[#/^PN%D4J[P\=$GW8/N,`P,\ M!IYR*#"%B%#%ZGV2D42^CM3KV1)*YW`4O9*C7[7/J)/*\;`6<8>P]I([6$M? M6)X2\[2,SX/9)DJ]K-GS25!B;WZ;E#$4Z*KP-83.9S_.I?MBU M6^X:'ES7SWMR!K"RBN&PM2%O)";&XRK7+?=2I%U>P>/SFUX&SXO)GON2E]>S MY?9HK_ZQ'L8AK3/I>9D"#G'&N4&**L`,$KB>DXHG5IC'XW6W]H'BZ=*US*^_ MNRT^?;\]*8BRA7>?HU3A1U*U_?:1YZ8B\@GM+XC/:1TSRP@#'@I'+(WU3;VK M+W]RQ5S:`3P9GQ^U$[CZ6&XJ.@,86ZF]6J\VV6E>OH]U2K?,6^J@9=Y@[YCG M&CB.JU$:Z]/4'C)>OVF+8#T2B?_]?H]3H/$_VR^??K?K^P2NSY\_?Q<4LN^N MB[OO-S!=E;>3Q>S/S07O0*)>+\.(]WE$MR_.OZSRQ32FHOR^[1?]$N%9S3[E M-E]-9O,.WAL3+6VRL'0QJ/W#^QS(HX\]O&U3^*PK\-X4B]MXS?C-;/+[;/[D MU+C[-YW&LU<:D/O*Y/?3N9NL9JM'AH*1[[0*I-4&L.5$6%'U9+N\*]H"Y?7FPC%6;DEIK-'WO$G&`8BEUSD(:HN&E%H! M1#UFH_#P:C>>A7K1*@S#9U__;&NHH'@1KO5OBM69AZY^G\]NMP&8NR-4]^6^ M6*[+0_=83NB=28%-L"P09QH[;1RDJAXS9&0@J?X[VX2[@ZH/\0AF:MC=I^_" M%OY+L;A>E^7+>8(.ML\X%0))`!S!`EA#%-6P%GN76(>[];LKG8M`&^!T8HLW MF"E-WX_(:K$>>BZ(@QJ&V:0Y$@QMP)722D<&;K4$4HT.H@&Y#_N,5(I@7E$O M#$J[,-JWU7(R"UYCM;P.F5%;+5HHI720-XV!58H1[VDU5`]$8A*3"UHM)_/N M@-7R.E`NK_92Z(%QP2C36#EA@MHG:WJAL7H<5LO)J#?IOVDP#)]]@[9:.N?: MY324KES$;\O\?C*;JL5T\V:S5=6Z\N8?>EOG[OU#+S_TVR7HZ8[=1=C^Z_/]7;'Q_ZKT MZ^V%G3/WR/N/_'PAJKKB_J^KXOH_>A*4>U/M<%%]^[;M\N2IGUX'KF]_5=2`AZA6] M$K%-/')U$[^;+![BS>WPY8:>*MQPDUQSTV[3^^U\LNAL@VL@\L5O=RF2?%&Z MN_MY\9!O[HILBZ079?S\2VA4_=0SQ>N[NTGY<'6S^7DKWO&RR3.6?PXSX"2^ M]Y#DY>M9&^_(;"ODZ(='_-]&=FQH/^2&:N_AF;)(L-;?D6FJ"/4,0X^18@X2A%2%(>4@,7]P.^ZR M2XC*\SP]%P*Z8^_;&8<;FQ$%&AN\<2^VRYS4@$@0C6>OJ7-,0E,-7G*8%C'3 MD3_N@JQ_?O9Q!H:])0%+PF4_LL5&<=C7?S]GQTAX708I80HCJ36##%%+`.45 MJI8I.CPGXYG2\5(BLF&`^K?(MH/N8!RKWX"D7D!"HP7P>(21XI^?'+^_)&C- MO3(*(-%A:,X:&H:&(*2T&B-GB66`.[OD?UDV/Y>YUF#M0W0JH_:1<7E4C`O-B^PQ09:@! MV##E$%$0254OZ@Z8Q)#XOX2PM`'H(%2G)LRV:?YPL=OY=7Y0W M^6RU+O/E;WF,N\JGZE->3F[S'^+UOYA&Y)0$8<,@,$QQ[QB)Q621Y4A#A@'8 M%+YT&\"YR)%D2_;GS9_ MYHW)6E__I,Q;AY`"5E-$#3?44L"J\7%`TM2_R^WC[HFN$S%L!O@X MH^1FPG2QZ!YY989TV/B`580B[JT&#L%Z6BKO$Q-_?D-B.S`.#%J^=_O"HW#N M[>"[$.RF=V72HJ`'&A7`5!A[Z(+M6.%)9>*-_LYRQ8U1HEN"?F2B_$S%.98P MI&<*,D^UAUZHL$5*&&Q?"&F-/:0L+9:ILV1IWX;8M\B004^&HY;`+\4FT4L^ M[6Z]?RT-&0F2X3&S2GA!+;&8&U/OJS2Q]%%GF<'&."$Z9LFXI\1&N5O^M&BL MR-DW"9G$5'/F"/;$$.^M%$94Z!,@TTI&=);"[)N<$&=Q9-SSH5X+ANE[/)V\ MS$`3`^(A\$)2)P4C847;<4T"EQ@U_K?K<1#L&O[J^#'.FO9+&#!O@%40: M*ZY%$$(9,UKL^,>2TW)\2Y[5L?-LW'/N7YMUZ***WE,2,@$P@D&9P%QPB!D7 M4%;H0T)58FQ^9PGQO\D9#7K.!75W"\)7(#TZ@X]QK%_N9^4V@5,GAXFO)R,SG!%LO770 M(L9)L'B)KKA`*4C+T`\[J_DPQIG3/5NZ2)SP9R&XZ]^7^1_K`(K[E"^Z M2)7P_`WG9=)M:<%Y2M.;4P(&&[ID#!`$)/$(JB#:U!MDE):*":*\PI8=F\B] MC/!H1-\+S3.B@?'&`DPYUDQ@)AC>C%0>;$#)/QM^[IE^+J(NK,X>T1,TH#I1;GZFM+C M@4--?3(A2=`?'99,&!\4R)CPL!J?Y=H--V#M;(X=EX"S,/KV9&%PD6##$8&+ ML_YX2-=+[3/K)5<*"HV5P`1*:TR-%,,RK>)H=T<\Y_/G,,>34.DI"?"^5LVF M4$VPFP'*4+2I-(ZU^Y1PBM>8`YEX8/'Z\XK+ MZ0P]HM=/Z-9C(H_N(R\USZBR4`N&H#/06:B`H;1>>;DCPU4G^F'F5\%:K6'X MK4C(X)2,\0A&_P)A(C)Y>3\I5P\Q=O'(=O-2\TS%0%5&H;!$,424HH94ACW6 M-&T;>7UDQN6VD190Z6?RWZ_+ZX^39:YNRWSCZ7A.^0DKPHG/R!B4R@`&.*#> MA,\PWBG>C5]K"(:[D9S'SJ_6@6X!^^L)SN#VEX'*RVODI"%.=1,?$%;539QC M<3.KBZ0NBWEC2.K!3IGP7GD)C6"!4"^-A8[JL*[7FP`1NRYCBM5%_F/XN\RG[S^'1@_3R8,ORM_S M6'7G.F^\-]3:LS,3S';/8YAU4*ZHDDZ'?ZI9XW#:[87N;M"U*AT7`#!)B-[' M]WW,87&S"`IU6>NY38+1U#YCW$"ND`^:,%48*>1@O8!)OZ]M/Y"(WE:9W1(H MYS`0O9*!7[7/*&98,D.\\Y81H;5EH!8VF9@1J+L`UBX8>"XHIZMOPRD=[YF0 MB'J$G2>"&8LAYF&$&F'#`$)I;._NTF9;;.\$G4[NJ]1)I6>WB]G-[#H0N?.! MA&WD;3&?77=2J?FT]YJBC)FWPX.O;GX*'<+DF4WFKBR+P.@G"DPMRNWFJJ;_7N_TM9BC*5!^=^)5E;.>FTDB!$*;M$\<2A0KQH!M M<3L:W5&7NL]2I\,]=72/!G=Z/NO4AV><"R'"M+-"2N@E(9"*"C4K95\IA@_> ME>E)+AIS6/<$[F"OWZ3@'[W$]1^[AHNINHO+W!'O:1>ORZBVU%*EF-1.>$4- MXJIB!;5JX*FTNY?`YZD8+\^#7HZ;]P.)A2^>#OJHL^Z$WIFQS&F.#.`6`\L" M'X+.M!LSI-0,U[][61%X?@3=&=1_#3$;G#?XFY.N"]R,JJ#X]3I?3`(:Q^[$ MOM0^4RH:7QIB2#CQ'`#C934NK%E?!;/'LC&V`6(OPK$C[\-B>9]?!S,SGQZ_ M,=G4)[,QEQVTQA!KD8+>&>JJ\0$(V'!WL3/Y]95-T"Y"WYXD#&ZC&8H`#,6A MU7UYOI/(N+1_;;^%O%0V-&PLR]4L>MVF'Y;YS7K^)@!VN.A=MY.X(C(F3U\] MIO04O]KQSIG&V%-F,2<.`X"$!&"KW4AEH:!'4PQT[3QK',+I+K+#C\B@Q=Y1 M::!U,@S84&QYA8!&J*_(H(..L#89V>CM:A6GP?JT&D>I'TZX3WY"[TQ*K*2% M2A")"#(6:FXJH!1,#93N2[%N2PJ*KH'K0X5J!N.4Z\$G],X(U7RHL>_@=35PV^S:;XC[@EI)QWTGO:$S!$@D,'8""^I](9YO:T5 MQI1D$EW^2/?Y.)ZS*7HL[XLRLO;7K6*S?,69;NK3,PLXI$)Y"`&@'C(%D-_A M)KQ0?:D>AP]UVY:!YN/;GG`P@L%Y MVMY04>)G+3+"K$'6!@O%,>8X%(KBBAYDT,`J MT+7,G&0KT:H=?+8$DLEY5B=^H5B9?Z90P["S!&V"JH($<WB68O4K,E[_CI^.-VF3:<22(`$!):!S1FIEJ>)&9,#%?U;8D_S[G>`CKC MY?;@--PA,+F%'5I]FBS#RG1XAW[2*'/0>,6@)BCL3TA)I`6OJ`*:I"W7W<50 MIR%:M#3\)*;\&/:A_/XH6YXURTS82)ATGGC@J7`<2U*[]*CB`U-L6V#,>0"D M1:\^+">_E[/#C'G2**..>&>(,%H9+;UP88`554H/3:-M@2WG##_-2I^O[_+5 MGY,C1OJ35ID*8\)26&N@$%@BZW&E?4F'9=ILZ2Y\^'RVG#7^)+[\?S&?S,K# M7'G<)M->_'=.)FYNIL9.+A;&1BX6AL#*T]'-QA#R&'X09G%V0&@$C>O)#$]U1!+A!*C#5A_FCD9F)H:FIBY M&%BXF3B:&AK`>K669D9.=%OI2EP&UL550)``.69$8GE(*G'FUV\5*5*4+,GU MI)ATHSN.+?.>.K?JW*I;MXH___5YM01?8%GEJ/CEC?Y6>P-@,4>+O'CXYP:(&40FS&B[`U[Q^!'\L8/49 MW)=H!?Y`Y>?\2W9YN?DMT'ZUS(O//Y'_W645!,]5_E,U?X2K[!K-L[HQ_UC7 M3S]=77W]^O7M\UVY?(O*ARM#T\RK_K>.?H+\[;+[V"7YUJ5N7)KZV^=J\0;@ M1A958YO"2/?QYQ>?_VHVG]9]W[]J?MI_M,H/?1`_5K_ZV_OKVZ:=EWE1U5DQ MAV\P&P"T?)1H"3_">T#^_/WCNZ/P_"ORB:L"/A#*;V"9H\5MG97U=78'EQA' M\[3'$MX??L2R+'>>0"CR"46Z0RCZTRL/KK\]P5_>5/GJ:8GYN1)I``?B^B5: M9?`:&G[C07F*U_T'R@;\"8]@*!?RRT?*!MUVMJ18J.C#^X^5#5XN9K6=`]79 M4G+G>/'(XZ"7Y&/7^*O-)\GC3\AP8WTCKH,GP^<:%@NX:,5SY]D@7_SR!G\U M6U>7#UGV-$NSO/S?;+F&<5[-EZA:E[`*[JJZS.;U+`W3V(E"PTILSW0TTS5< MS;%C5P^,(-1U:]8\,-"Q4N6L2FT+N=MI,+@2*QN\?Z% MP`(-+C``!O[>0?N_GZ^V+=JE$LT/]8X&T7U6W36P-JW'\'3["B[KJOO.)?G. MI:9O0NZ?:&C:9Q?-Y;+;DK4DTPM4=GURI^<$Y1R@<@%+//7I?BLKYZ^X9?.) MJSG"P?RIOMSQ$)D!J6@+4M#]6H)P+6?IZYGJ5[1F*&B1F9 M9A($L9-T1AW'"F=U'U"X!A>])9;151^) MY:@4P08:<%/0J9XI1J%B9WC"2L71&`JIXJ6(6JNBK'H,B@7Y(_GG&J]&EV2, M]@IIFJYI68$9>E%J1+X6Q('960W"T*4<7X)6U`TP@@ADQ0(T7PRPG6\F<)JK M$T-,$LD3&6.R6H.4]$3&4482&XOU$GZX#[YD.?[)$J:HO,7&;^%\7>9UCH[,3SU33_34]>S$<3U?#U._GY)HOL4R.Y!G5?%,H0,*T#WHH5YBK)<$+-BB MQ9&/_.C$D%1-/YW>G8=Y-ND[3/H])KUB)5V)#E)S>$(2Y?MA(NJHH&%(=1=F MU,SWV3]0^0G_3O7A/H9W-59MHMCUMZW]X#FO9G:L!:[O.'KBZ)YCF'KL>YUY M4XMB%L6495.Q7C8P08.3C%Z"M)G$M%AWABZ!RRJ7TIBG$\MSD,XFE?+X5J*4 ME`2>T$G9+IB(2DIO%E+;<^4K9(Q665[,(B^-@U`WO$J22 M-9+2ZG14L@6L0"=I^9>FE`JH5Z:5K[)^+K5L@8GI):,COA_%9&T8NV9R42>8 M\7H/5W>PG(6>&9"%?^BE26)I6NAY06F=B&3):0M5FI"+(/KI'"K@M_=9^1G6Z;I8 M=-8,7[.L)/6UU/0MTTH#/'?LK/F)P901Y#2A>J)&4($6%FAP\4H3+X64TR_U M[#'.M7B(4S.I.DC-J1F4&)<3T1[15NS/C6200JTW^].NC34++U13S=?3-(HB MVS)-3W<[:W&8,-4G<)I0K#<'EB)\F]SP\*9$;0XSR',OA"WIZH&CE\L#9-D=[,@4W2-F=,A&]5-0XCHU27@JI MU?6XZ6"%RCK_%UQ$J*IGCADY6IR&EF'X491Z@:]MC;.)X4A`O0`^S(1N$696?J/=5HHR4')[01-E> MF(@:2F\64MMY!160["T,(,SGZ]5Z28[D_%JBJOJ]*&&V))A^S?(BA+@WPT_9 M\TS3-%?W#%-STM@.(],U?:T#E^H^TT;I.(A4J^?+`=]LZ>V,^FU30-,6L&T, M(*VY`'=->P!ND*`"*W(KGSZ?WZ/"ZJW*F:-H.Q?_#,JOUK\3C0N*&_U*U!B# MG)%X^A@QA0W1U&,*:'3FFT#MS4C%EAW\%,87/O]]Y3.%LM*28(D+YJS'E:;',F[*"_:-'Q>+( MR@E6!TX$SKS0<#4MCO7(,4*2/XI]NX/EF%Y`$TW&PC)"$=/%RU(<4I^SJTJW M^WF*[;E:RM`QFO=.!XTI.HXM7/R(/EML+GIJ;F?ZKGRW@YS1AW/B0[CGP^SE M;*#:;IA\(4W!'ZK!/7%F\]>WU/&>$-A$<VUEGCMNC-Q>= M9TS(.1Q?1UE9?LN+AP;&3#-3S4Q2U[.T5+-"S\'V.^.>[OBS+["\0V)5PZPV M641@"$^\$E9*,3$SQ71KK?&Y90^.!TF]()K9H7PM"(YY*\$N=+&DI8D=:HF=ZCXV;FXS<(GFLHF@;.O* MY?#V$97UY2=8KC;EN`3\8/HJ;=^9DWV^7-28M`MGG89KA1<9J`WBR>Q%'^23 M:T]:S#,3$5)ES:/>HY9!([6X$F/;V6M_^4Q@^T$<>&&D64X4)VX:V>W.N&>E MIJ5%E*.8\^GJ!FLS&K>(SG>UTF%F3@P[02HG,KI$6X&D]B^.L?*NP#::1$5[ MXXBCAWID1V2A9P2AD7HFMKDQE>H>4Q4;S_,5YS6;\;+%Q'GI$1=Q]`JCDC,V M>1D6[%ZCXN&R)M.P/1+/=8O1`:I>T1M>8BCZXD3 MN([A!(:+H[UMA$$O:%Y@\*L,U>/'%AF>FX)X6..1&.F$<4Q@&+@:04E>N=!' M@+Y)Z@A;"T[*"`<9G"KR6[:"F[LL;-UQ`]]R7,M,'<=US51+M_8BIKI2;B-C M*PK?K3K\'/(HBR+ZA/3E`A!4Y[H?YQ@_U&K#0>DD-8>G'2>5AYL8:OWY(RO+ MK*@W)SG3P(W,--!U/4@BO!ZS/*=?D:6>F["(#MN3%2O-!@SWN6U&FNAT11U# M;&*RP7&NL]D[-)S0##ZZ)B(4G."1C![#4F\6KV$*[\IU5GXC[MI8LN/4\GS? M"[7$C0S+"=U-91NVY(8AU61$X/&*Q:%#!`@D\!NJV>]W$.'NM%B,1!OC]&,- MP2YK(_+%4#REGC>^>J@`W*&R1%_)WOS7QWS^".99`>X@@,_S1_Q!N`#WJ`09 MJ)[@/+_/20G4"JVQ1J-[D!6H?H1E5R;U[0)@>_D\6RZ_`?P#@-'@[_Y7!>9H MM4(%J&HT_]S4`Y"?HB>"E#R'_"VOJC5^%+9%_O:(EE@&A>NK#K)^K&1*S$53 MJ((2;`&2UE]9='Y@QFL4KXLI3FQ84>*XOATDAFX&D>]VMHS8<*F5GM?`B%KO M"6@]-W\4:C\&=6QZ?W;6_#/;X5)^/13K-/=+J8ZHK2M(4=%>X#4ABKQ'1 MWMU9O1];D6'K46CX<6*$NA:9O=K[7JIQ*S";F=%U&-`O0Z53RB'*ZM@4E>9S M$BF@T^H(E:76#,3RB?9KF1")O$U1P#E;LPI&>#WVH5EK M;8Q'NJE'MA$EKF'A+]+8=OMLC9585+E5N1;'E_@.*B!800M6BDSQL\XA_:,0 M+AP%)LBU0'08A7-I@8*3>[ZH<8P:V@`B3.T48XEXHTZ%%4F4T448#%<>+YBQ$@X=+IIAIHE!^E0RQ M"?S8Y#!(M4J2^!29B2PZT=UKY#%MY>5B"A+*C1U)Z`PL@O@>?^R1N*@SUKUE M(_(L+XB<)#$],]3#T/>,SI83ZSZU,/(:4"R0#:QVNZWOX5QJP$T@A62.P1V; M=)Z?-@8Q'8,^/E'EI)%.7H\T^YC,BK(T!;D5;@.2V&T82T3>9\/]R=@/]-0, MTM@*C!3_$^MZ7V`?!"%]QIKYR[H*%/7Q4B8$.QUO?( MACD[/LT7(9)"_4?BD"T.3(0^AM@P$HU\48*;3CKI/=[V8R(L@:TIR+&,9B"Y MG8A%HF]AF<,*^],8UJC$B>\YNN-%CN9:IJ$'8>!TED(OM*G5F>_QBH6Y!44F M1(;`/)R3.0HY5D\:FQ*?E2\&_57/&Y_T\O!'I[H'6WQ,<,7HF8+6"K8`2>LK MC$?B/I*557/F-S9BS[53Q]*U6,=F+&T[RW9CB^G6$/JG*M;3!@C?X7T&9DX+ MIUI2V/22C@\E)]_ZYA\0`7Z*)G+BC0,X$NT=/"-](R:)@?]U0\]-=",)L9Z$ M23]="RR':O.(Y[GCC':^@_5,_#",>`74<(WY\QR7'U#PVKAG)&I*(Y\5^J&Q MS]5\ZM$?XG7;QZSNK+B1%QH^.5!KN7BBD>AZU&N,XP=,9]\9'ZU8`P@:0.#P MGGYG98I."A22Q*8&+/PH481=)DZ(`B=E$]$%7O1(2K\1NICGNG\=K^$9J>MK M=NC;J1NF8608_8$@S=1-_GMYZ&THUHL7U_)<<[\WG)M%.@D9@T#&_5`N[D:X MEN>:XMW>HG1.1&>$FW'R3AY>6NC?(;'=%":69[Z31FX:>([C.Z&9ID:2]&9, MWV52'-9G*U::X?YW03([K.^"8*6*3E94LL0F)T."")2QW^&P2\0)Z>"E;"*2 MP0U__PT,0C10G@=`=;;$[:IR3$J3VW[(O\#B'I7SK74RFKHJD9F6Z&:HV;%A M1&$4:%KL)WT1;I2$5'E,1:85"TP#&.P@!@WDIG!FOB<_?5T-4VF]?'=0[#J= MUQ-L(O9].H'E!,19G<%Y1D*V4RC/4;!2=6Q_3!WG4]@[4]@Z-$K'90EH[S`? M18T-IY"\9B/)YH^ZIFDW95[,\Z=LB;]'@FD;6RLR&BURNBXU3",(7-U)?-T- MMV\.B%SZDQ[R32L.:#U@<`\A>((E@!@S^+-^@6&#IPYW5P=:PP)[%BY`C;HQ M#18GYY&CN((QQ41S?O(GW*\K:"FLY=>=$6 M3F^TL"N.'A:,-(O8YI'D)[M7)#8_$ZZ:9J;^6`!5Y\,I!%"%K4.C#`2FRNW. M7-#TV"&H&]S%;\@Y3,LP'<>*4D?3?,?U-,OH]]#\V*0_HR/!EN(0>;,_@#/P M9QL/WDZC-T/_6Y.?[<5:0(MET$\1$4=FGBT$?I>DLU2+CTN^C!"W#61]!&L/ M$1'7O,61;L056V0(>],WA*(<_H"+`O<[TL8@FT4=3"&$RFX/4=&7&G8UW MQ6(]AXMM-/QPOYYYB1.'?I2&H:;IOI_ZVYNZ+(?I34KRK"I? MVS5`-\.NVIR_&Z9BB$CB^6>#EG&K1"+W=)LHYZ&==>'6,A[M,+Z_Z0*2UQA7 MLOE"3>");1GY3IC(AHV"AB'5_9>Y`N4>ECAJIWF184XB5-75KR6JJEED6&D0 M:U::QH%KV&&::GT2SO!\J@,_XE:45Z&TP-K#QU@&*_)6^^V,LINX9,NF,\(% MHG%"P6.5FK9$LRAWQ71-E37F?+Y)_KO/X6H=43*O`'7TCH M+'5=+=9B(S1,U]<=TXH3K\.6^@Y3<2?D/%1?3L1Q1^WS>B,@XDE=4W.?LN>@JF!= MS30M"N.8V-83DH?23#SO[LZ!N"E]&9-,HXKC00,5H![K=KI+5&713>?J[!ED M#6"6'*I4\BDRV.?BG4VYOQ_*&?+7YZ*>\_UHO5P=H1S@7UXO:W(Q%E':)D-= MPCEZ*/+Z6-XL[TNX*_P44']%H()/64D._O23J`I<@JS]_'9BE14+_-^+"9=P MJIO!*<=RWBK\.H7DMY)V(<4#0NB(T;L"AP=8U>1HTVU-H-S`DB0[L@ZUXA[,Y'GD!6JA@B_6L1YI.D7@RAR3=$Q-98JAHV" ME4>Q1C5>_':]#:-3#=@`*+#:HR!1HF6=W^7)GSB*DDUQD\\BC,I;EJ.*0 M[P[?697P`%_4`BC"]21U3ZA!)^5.G"HFE1ML/9;Y0UYD2_+=MFI#G[E>&/N1 M%CN1DYIFZB=X;=$9CB.3Z7(J<6MCS`2W""]`A[%)CEZ`%B:'N`ER3"]NX]'+ M(6X"S"I3MY.$O:)ND+I):M`!=9-)%>7[`_#SNUD*R=E@_A8UVNYTD8VN MO-AL<\V2\5CT_= M)D2=/??+ZEF8^%&2.KZF1TZ,@V,\J)/&LW_Z]R)(M'FVR+2S3=/C%==&/N:Y M0Y)RTF7%HVGQ+1R(E/,N.PJQ\B\2@0Z1PQ9^A.B=;NP1:];K@4<";?119YMI M&I3>O,^+?+5>;==I-V4^AYL\^\S0?3NVS<`+71?_&5F^T==VAI9/?Q."(ON* MH]$&W/#(S!.!1XZQ$7S-4>SF`I/!)SCV#96ZB#)4G=D[;&'KAW`,8TP[LX/X MSXRNCCEKKXRF/?>)G=0H?>/"]EUPU=YIT;R4=!B4C]93D5&ADZ82)54V<3]B M*J=3-'IFSPV4):KRXF&(@VQ1VY89)5&JV4[LNB$.XOIV^9B:'M6=WRKMJXZ> M+;A>DYOAOGT9))BWJ#=B0*K@!@K1E.`,AGTCYO(57,Q_0J%U--H9(^U4APS[5@KIXETL58BG1(J5Y/[>S@GYW,'(`+= M\C4KB(/03CPKL!S/ZPO![%1+Y12O\E@>(U=ZHIRRATQ543F&)WB*M<9T@F#A MEA#_(U>T'J"2JZA5Q"43JH!0T#CJTE9Q"CF5=:#S>XLI?>8;9F+IH19ZD1N8 M*;&:=@#POQ:_JHI85:RHT7XVXN)ETH+,9F.T7&9EU=QF=?N8E5#L@("0'W@T M=2P7".KI`.;%\!*=!NE9E?0$@=0J*L,)DU10*0T[J9[RJ*/+_R15G:](X?PJ M*S_#NCLG1-9)]P@;7^58#@K,U1;7]ES1+$E"S;!LPW2MV+3\R#:#'I%KTDGI M"#`4:VL/'K3H]TY;D6SOI@5@MPF#(UHLV0/%/J-(_4S'76PZ_(-YBB'=,QV/ M\65]U'J.+L\CQ.&Q=,\XCIE"UF>DEJ+1>[VLE#'_Z#M'*NX@E%@D8@J)6@M_P'.YI`W![%0VYLK2Y7O-0`0VC4`L132?# M8S',)K(W.[2>^4*\$Q2=$$<9Q$Y$^J0T!$B=NZNF^9WN1;SIN7["D.0E]>DB1_;%S[GA6VN'N MRA,JD'65#%G[9J3MVR=XJTM4>8LB,30!1[%IY8_F(X:4T`1\Q5]YNW%-O7DS MR\MBVWE6@#LX\.;BD"/K]E&[;^!Y6JZK/K\D7!W$1_.Q=-'_N/8[;6!K^ M*_J8`)5=2J(DZB,I4C.%Z4DW.KT)%H.%H"ZKJHVXI![+[G3-KU]1MF37Q38/ M+[*2#P$Z52CQ/0^EESR\.JZT.8P3N0ZQF>X;,!H9RLM.0/]&%CR)Y#Y-DN(, MD83[`4G0H4W'P'L+-`N9>LV/E*9_/HD>1YW1%T<(#0=6E.A-,&!RH*,\%J(! M="9]??,XSHY@:(.QN8KFHVRL_2()N<]]ZO,<(13P+.,B'C>0Q\C`DDQ*G:1' MWZ_4D,N;^E4R^]M/#_?X[6JH[QGVJAVLH%&M`VLK:!S@=[2"IE*,*!\0NZFR_EQBO7\J*T=;^]J)3#"YMU>;?9RD&" MAW55R>+,3[$_S>=4^F\#Z1QR?"MQ-);?-=#-X<.H4E:N5N^_RC>OE3>'%=2/ MXY!G!,4))I1A0<+QKA=Y(J#Z?>&Z)3CV^U&7=]<)\YJ=LOZ:0=`UU-H`%5Q] M$G;`2;EK8X/;$QK#H9L'D1C\P72Z8#W MVU5:>?N6W`W\B]P,G#7?Y/7M[.DM0>//BHP2X>,@\!.2I)QR%+'Q6"+F8_73 M#-Q+F:PSW_8AO-Y=O0O#^_QTYA,\^K'LJNYH:'51'=8I(#F81W7JIA!_^9K4 M2$GF4:/ZTY^UC=JUEL!HT[R4YKBOICFTO1-&^U;*-!5DK162M_L%@>_O?RO7 MZ[+>M$5`!&<1P7X:ASAE/$["L=0PS"ADYL&P*->IUK.%?+=':R,'A09+(G7( MJLTG3`@5F(,9\'2^./(U*<7UD0:(9S)%8"N:,ZLDC2%I7D"SGXVH%H<)BIW? M2D'5PB]0GM$T2<,@YQ1S1DG.QDU&(:48MN3;H MT>=T50OJ,ZE7PJ\QG9H=<1^U/IMDWI7-)9879E8=5,I,O--5=&=O MO+$,T9ZW#M?OI!E#64:#).0)"5&<9\DXT$UL"?Q2_!<4&=4@^O7)MU754$2'@:8(40RDB/$1)KPH00:":738S4>Z]C5#V*\3@W$ M:8!T%)S:'1B8*T_&!."T[MCHN:HJ(S7W?!;=*:?40S`'5]14WAC7/W`\8#AK M]D/Y5,KUWMOU6G:PZ\7/79"[_RFR@!$_H"0E>13ZC,<7H)(-7@',F>;>)=B9YN]60&G=O(GA$H??#7B-\&L@0K^IPY71DH:.41E`=C4Z>I75V4-(.YYEX MFK5P7@U!VL2D>I'8KLRNM*I]7Y]<`=QU!,,P#@3G.L[U9;>0_NLCZUY!*Z)<`:>86,]QK0-0UO_KQ!MW5-SUU_=>KB M>1TT9]%;N'Y+B\]_*9=V^:]I6%BZ^;Y;UPW;9 M?I%OZOO[_@2\4`1AUR,/%5#;.S[0`6JWW/!%AK>:DU^;]L%/WHX3\7*`$?853-2\B M.].)MH=[)MUHBP$UKMY,Z)V\B_W!Q!VZZJYYJ)?25YMZF$TJ!(D$]A'%G.8I M3D1$LG%/,V(Q[/IZT\*F6-@T:+SQGJF47^2@$WH#JS%CI0[SM'BAG>69D@5> M9#LE8;UNL3EI];MH+]`XW1&V!W(>G6"+\;R\4M8N*/5V08S+"=I-L_E2K8LH MBA!!@J$D0UA0GQ(R+K6E$_*K>,^YL#Z9B'D%DWP&,=>VFOY-(5H\9HU')^1U1@=JD$Q$G^?@C_ M3**NP6@F&;F.\L;X!8%.O2^_+1=5O6CWT_Z[=?D?JG5?=,&SG-$@9GZ:&1;GN8PWJAK4NPZX5>;/!;@\@=-K=$*WBK/MT5('=,!.@ M;J;'CA4%W>\!4NS-N64'[-8J8'/5M M7K$XV\G1)S<35S$*X56WQQ2'LG^\:^H'69)\13Y5WS>LB^GW(J$IS1'''!,< MH)3Y4;Q;J4W#-.8!:.>T7@F./>3XQJ>R7G@_-_5/'[OL?@+-Z_I":O%_5_$]O,FV3.&(T9R9E8C6$0CU[R`5 M*,(B2D4:!X3D:1Y@G`5]&2GE<9`K[4W3>O"$YM+K.F0`6;E>/\F[C7\M5UMH M0@6#IV8MSKC!'.49IHD]Y!C!&>O0(C43Q]#3WEAX54!36\.`?=WE49OEIOM0 M[IOU8S]^3S^W_>'[14)\CN,@S0*&4Q:'B(>["YE3SK(D]95F;&P4Y'#D8"^/ MU@O1R[L]R//^-0@\T]2Z0@N9WID:L>9LCREJQF+X3@&_\7?50KG9M!/V^;(N,\#P)!,YYCGP6(^X+?RR"^$HS M0SK/=?R=]W*\G9ZN`>P403YU,*3+'[M+/L!1#P@:"U_\B\A/?/.Z?&;PU6M+ M;\Q?#VCK_L2;QW)9%Z)+>!`+\C!(4<3C+`T3,3Q?9&I;L<$/G:)M[U[IG1IP MTZZ,1K%E=T%%HV%7`6*K7=^'?*Y9AU*9P?>MI_MEHZX7..#+/DKYWBWKZG93 M/;9%&N($YPRC@,>,!8@@BH?2?,Z5YE`-BYCFJW^6\$IQ7J\.[@)Z&%4]P3E! M+8>`P[/F&&\!.>L?1@1GXR9F4;SR%@M0`$[SL7I8RE&(>O-S^5@5(0]2%J(T M97X<1W&4`WSX-.YR$.5)56!3@1)3M1.'L+2,1)F3-?]X3N"L M$SS'$2T-0/*&8YXVF4#\^G-%5:@`Y^ MJ&-?&+1X4@S`#F!@+MN`,R9Z4ST7<%CXZH\#/O&U:S&9P5>NI[LQ?!D`7_7^ M++E\V=Z5J_^MRK6H%[S<5$44IR1+_$CX"2>,14F&^>@@8:B<96@7X'HEQ$Z7 MMQ/F265>)\V3V@`?OSZ_RT8P"3J8*>A1L^`1IUB<\`MC=#/P#O,8&HOO$CBC M.+JN<7^#XW;3ROG/9?U0^'F*XAB'3(0H3^/01R(82DT)C6#YA5%1TV0;.XE> MKW&\M^I()CC],,.KFHQ,1E8K-=&':BU7.0?H;.9BA>P,7,IF-*^R&HN0E)R+ M=EVMA>QNY:ORH4"Y'U.2)@D+8D323)"(#@4$D;I)P9[JV(]&,9Y4`[`=()O+ M#N,."\Q,5(E8\(QG(9^P!STL,W`"3>&-Z1L![YET):S+U6V]J+[_HWHJ\LXW M0H%SE(4AX@*%*`S'95=9K+2E1/_I$_4_=JJ\7I;7Z8)W.*#4E/L8#H'I=2O4 M6=GK1SR'<+[KH`EL!AYA&,#K#H(1"HAG[/*GC]779BV/V?ME4VZV;1'DG!/. M\H0'481\SO-T+`^E,6Q!I6XA$SG(/O4?U7D[>7`CT42I["?N*>K9"AB@/7=Y M$\EYDS&C.!^O,8SCM>78``-PGE^;U;;>E.NG?+GJ/MZBZ_I0C'&24Y;%B4]\ MS,3!?88,#15 MDS>(`GL%$)>J4[@CI>43JI"LN<2S^,]ZA!ZIV3B$IOQ7_F""`>`.OU6KU3_J MYH_ZEZILF[I:W+;MMEH7,0Z1$$GB^U&$$R(O#1LWIHB0^#"?T"UE&L>0ZG[Z M73B#8/;1QJOK(%"2U'$4'HC5W.4'EK,^8DIR-XQ@'\LI[[*`!K2/[ M4*V7S6*8AA9)S$."$8\XI5%&2,@/2UN"/(8N*(,]?:J593M5.NM,-*E=-AGW MP&#F`F=E<07:,P@7EJ+I`9N!AQ@&\,;B-!,4(,\X+%_)NY^T!4N"U&=8H)C% M+,3"3\BX\0;G!.P:T.=/Y1O'RZUZ91K.`6:G[ATNL6FZ!X"81?]X`>*"@^AB MFY&':(?PAHN8X=#PD9UM[0KC490'*"0 MW:VWY:H=#_>A(F%YD.8$)RC-F(@#%`W'DF&:<,53\4R*5#*KZ$TL'73JG M5-DY-^\,I#>^'IMH9W*JGI50&OMO'O![ZLJ1)Y6/YY;O2ZX6[Y;EY^6J/U:' M=Q_WJFFWZ^IP1&B8IRE%)&(IP=C/\DS@9)`3$Z8TY^%:@^/V?B_2.U()/-/3 M&7PUHYL#=Y@)#HJ'PT(/9OB\'KR#[&L>4*P)^(R!NJZRF9BK\S";:;\$Z+TT M73_J6[E9?JMNZ\[^^QZ6;!3^7BT>EO4#O>M^]4+3V$X$+!-)B+G/!",\Q2). M=G/>-.KZ7TSU.@.7$ARF$J-J[TAV[Q)[X=Y!^3.3N%8_RH#S&9N8HO9F8A63 MA/KRMI?)\&I8!FW;:M/NU]`5-(I)F`N>I'Z01X'@8G\88E>R]EYEV88)WW)!(NV MY_S<1;TO,0]$P&)">@S=!\("SU_,<11E,+ M4B$XB0L=A`",2`/J3+U()Y(+=J0-!W2AU6:XSJ;[T_Y46)(RE.995^N1X"3/ MLB3>[QM@64"YTK([HP(-:8*C$`4DC9($43])0SR4QC%1VJ-H6,15 M/`9V9K0I1#V?<<#/AM.8G"YMSVM.GCQMB>9,_08:Q07'T8*B[#F_ENNE')3^ M6&YVWI:AC(DT#\.(^TG`"$=A,I23$-B0#OCACGUFT.-)07J=&#@O-6-QB@IF M*3!*3ISD)8TS'J(-;B;NH:^_L?0&&3C&WIL"S!.6B3`+HY#$-..=50TE(!1G#&0[1@`$9W/V\. MTUL?JT7U^%4>E;];Y-?[%V<4\R#,4QRD7;H5%#)T+-BS&=&K$6/+ ML"RYW9#A<>;'/,\PPKZ/TSC'G(RC2B%2.K';:H%S<#R]WI8=WC91+7?W97?T=QDHLPX`('&4]Y&-*'_?.W/;;LN.3-:T&[G!321Y0$F>\DP$))0+J\8R@X2K MV*"5@AQ;W[$\K[GW%K*[LMPK[,RPDZAH@7:PGK>]R8G"K&YN,!?[_9N[SV@V M4)_)F@;NB\9#AMPW"2@-4=\@J$!XHQ&PRN[*QF\WEL;!RP7=_?BJ6+EB7VX% M^K"N'I?;QX*)3"34ST621%@D+.-H;%DXH4HN;Z^T:UC]8J\1NK?1'*U:!W=: MJF9VWZ?Z@SSOA[W`'Z?>EGB)V)F^K#W:,^G$6@SHY:9"RZA,,OFBZQ6G.8DH M8B&/4\ZB&&5#46E,0%,U.L]W[%R?FDVY,L_$+V/23KJM$K*17U\_CX:ES,H` M9V(L1B%<3H2!.)3-(RO;+_(_\>_M\ENYVN]L_&>Y_KW:R(GG7ZJ[[;K?W'C8 M!MUY%TT"&@F"N8@)E[@&*8*K'1+GLGS7@X.=7.](;[_?^+;^UE58OS,4Z$M. M:D#-MZX-'^9K4NF-]Y+^38__H-D[B+[F61`::,_XH\N*FHE_.@VQF>Z]!_IO M7B[7OY:K[7[/U#^K4FX?7[RO/TH-ZV7]P,IVV?Y/W7QNJ_4WJ>ZV_KK==+_N MN"Y7R[Z_^4G^O`A"/XZ"3B'!%),NATZ;+TA'*_+T\:`O#ZB&^\X)J\/RGL>5>)CM?OE5'Z$.4F9+S#R.>$QIT(,>E%*E0P[CM9H9V`OI&+4\K\'%.>A`$C(L8(C462)`>=;V52CF/?WTGS M1FW>($ZOYVM$5'7F;1J8T!DX78Z.YN).0CH[)V>.=B;>:"645W-TMO"8.M3> M%E&&N])"1A(4!B@@'.%@*#2G"6BWDEE)UW,IO;ZJ(5184 MW*^`@.?M6-!@U#Q+"]'$F?R[95W==K+;(DMPEH01\Z,H[BP6Q8B,,@G!()^; M6MN?;Z9+QN;UP5UG!`!0[U,F_FZJ_.K37DJU/>.1@[%:G`\8P%^`F;0L5PO? MR?"`;C6H[0G+OG3?6[6L[SNMWZ36YKZ\^_=VV>E<-T_E:O.T7CY\V;3OJF_5 M*OS8K%;WS?J/NUP3/ZCW]O*]G7[(-BB'U7*^#9E1C0"7SL$JX\;KQ7NA=R1_)C4$V,(V MCYK2V]SFML;4=K]I\WNC]9VH0N:P8VZ"*)M)WW+=A&_?ILN7_[?EYLNKIKQ] MWI8_;_C[;D'_F()R@E".HS03`H1I?7KC?`O&\JB1## M>!F-LF>PZF%9U[+'_[E1MV52U/(L6[L:3X7H_R(!_]&Z/7AMQ\;69 M>^MWIB*G:1-MO$E_O9;2"A5W[:>]2KM&J_JALX\O9=<&%(SY>4A1S#,_2=(T M"B*4CSV`'';DRE4$.FXQ1R'7:Q%*MN[^>*P'C=SWP!*L(93?Z4#[UA\#DS?K#NKFK MJD6;=U2[?R^V=X>[<8O8CS"AG.(HQ!$/8I\C.A0O\APT\]34SM8KMLCV5AWE0P1+&8@U% M."3E6/GT`4`"I&02ZBL(;VW5IM8S<7C.^77CWZ=OIY.VT_V4')S=GV6RS':# M<3=+8"^!W"XG#44[BH(;XAL1YM`-,!.]#1Y6';??NN9J1^6RU&J[*[5S7VY% MN;Q]7);;ZDVU/6CUNVK]X;Y<5]]I_6^K=54N%_^N[KIEY>MN47FW'[[Y=;4+ MA36IS:+\U(P'K9&VL/]B]5C=?:QY]4NUO&,/;87&&P*0(+!)1PL)F5!$<#9L MA5/I6#KG1PMRPM/)1VBNDAY.LFWH)`.>I.%SO+W9/HZ2=(Q.G65M_UT/*MGO M,NQ8_725['&UR\7[D[)MT;`C9,U?Z:$EVSKY5"4MMZMD1\YUY>5'ZP"VJS<_ M6GS3K`#]7^G;<>=N,^L[)G/`F;ELW-UGDMO\^!S/S4E_V(!LWD>YO7U\Z**Y M>[N]K]:B?OBRKNZKU:;)&G<7RUJ/V:=-]W+2C2:$"Z2%YA1!@G,JT.YY=);3 MG.'7WC.*8C.>_A]YFG2N)L]\3?:W+/?;U[_W'IO>J8K3`C:O@5RP)1Q?!PG> M(H9/AMB1.G=4.A;P.1R0CA9;/4&/M9SQ?KB]K^X>E]7;/PP=ZBK['+8(S:#,QC>U+Y/EC[WY[#<+JZ[:;6K^8IURFC&50XRPAK7!$AWXQ0A*L70JA35=%Y-MK1X9@WDS,WX]F\=1[0[ M?A.FOG?,-K9@63 MH7>IVCW\\9=%M6Y^X/ZIN_RYJTW&=0JHAD66B90(H#*4]=;SG+F6\/8Q.>&^ MT^"==RUO+\:6^CT=7O==#W.RL>M]C[`RD=8PL.>FFX&B.E\6/!PTKY.?F^_] MZ,N;Y4TNSPC/-4\S@&#!E.Z=4)EP*_P=Q/)TR?&QN\G1OS_Z>#W+?8=I"DM] MG+P5G'-8&]"3G9T]R\SR8*P_^[FI9MC@#(ZTAD+H_7PJ5K? MP`P2K`046:Y%NV\HM>A-%@RYI8H.=J;3QUT1'9#\OO/,605=8%J?O8G*T>?X M2^O8E07+V`=-7H(R.^OAC'=N(N83ROD3#YYXO`0JVYM,<9JDB,$4Y98(>)KX2%-I7H$SM3"U0,*1`&<-T%Z@8'$,)E`G+ MR00*.@F4+=X9"Y1U*`8"Y8;G\D_I<Q[D>2L\K3J'`DF&5:D`I3S.(>R>%XI,?R3'W[`<[EG,=ZC&2V`T^W?F< M.&WMGKM.U\ZS/<1S;?$R41-/\_A:ZK@(QSH<6T"LRM7[X_+M]]`B;&0.9!( M2E5D/*>:#.NK&ABM)3C\;.0AXKWS*R"6=,8E.3(8.SV=C(G%!;!X;-RN=YDR M,KNT]2RZ$[+M@6`.%ZX?77VT^>&=H!G(X!2_+1/,BJ"Q4<@ID;GII M@DX\?AK<:681;#[OI:/>'(U^OCHY)6JXY M!$1NMIYP&=IV$FX$.CFX.O'\WQCAR-P^?#/,9-X>(;`Z=@^VE$GVM5PLV^5I M7:\_--8_M-/];D7@)L\15RE"C"E()>>*LF$I.B,PM=%%#S.1A7#PK*L;V?J6 M')SS$$,?L&;J-Q%3.[D;G/JYP?GSYCG.B;7M/*`1,0M`=2;J%2*2.GB7L]6G M+ED$8A0(2%80;`@4!4Y`D>"J`%"-]MZ6RX-Y)Z-IIX7.(*-HWABD$8$+PG8F:A8FECI"YW/:NCTZ M03-L:'!>%%+0/*.`9P#GS3QXV-#@*3.J8.EO9;)-W.7>NZ@(FU&A.;?V>2,MK\=680/[CA6<+1F998, MQL1DI[8VA**D?"]0C&1YKM!FDM@YNU^'Z3O.*O'KJM&C;OQYO]C\V97OPLVO MZV9RRUE:@`Q1DB/9VV0*6SV.Y65H.OTX.)>TWKE5"_2#:JLMD7DZ"\T1RHM4 M!APC9*0_'F!G)T8^L9Q5)F]`#C+5K\=];'Y@?U>02J%SJ5'SGX)K1F"31?4V M-==6U_"\#$TG4[US2>N=:^T^/ZBV,A69I[-,#2@O=)UZC)"13'F`G9U,^<1R M5J:\`=ENDJIOM]WK7VK4QU!D MF5*/ZSK9>S1\71OGPC!>2*WV-./3=-O`[/T:H%ZJ+LP(IM?W)?WHSD2IPL1R M>LI,)&SN*F.( M+++$'+`8"8P#Q=G)BTL,9\7%&8C9&81VNG%7+Y?E^D.U7.Z3IW[:`?Z2%6B? M21&$E=:`IUPW=E&AF1B,9S`7QN<1@EF<8"*V\S-I'?UN3I9TOMI.S`)#'Q>I MR_&V4ZT?`K7%F8>+('<[_Q`,O=G)"%,RYTY)!"<[AQ,3X8.J8W;&H,,+WANG M'!8X(PP107/!@$+-_^V-*U"8'W<+9G$.PPN.HWG&T$,,+S%X1QA>+HTZY/`2 M`WG$X<4$?:#A!7L.+[9D?XCAQ3HHJ^'%#5F@X87NC7,!B":`8ZDA)7E>I)H- MJS(0&!W?"VMQ#L,+C:-YQM!##"\Q>$<87BZ-.N3P$@-YQ.'%!'V@X85Z#B^V M9'^(X<4Z**OAQ0U9F.$%I7OC`#;3J"(E*6>%S@%"&02]\4)F1@OQ82W.8'A! M:13-,X<>8'B)PCO\\')QU`&'ERC(XPTO1NC##"\]&=?AQ9KLCS"\V`=E,[PX M(@LQO&2XMZT`%!D62"#%"=6,*RYZVSPK5*#1Q=S@#`87'$/Q+)![CRUQ:((.* M$?@@@PHY_VI\%*X_P*!B'Y/%H.((S.$`ZO7A]2;*N>`4%IP662&94F*XK@B! M!F[G3\U_?[KCIQYOZ#F!&Q\)IF)F)_S6N"*?/+TV>%#.A^#LSITZA'#VV*DK M#@<]V4M9?X'G?;FMP$T!*`&@,9T5`,B,ID0-Q^C35&$W:7$R-9G*7`U#]G!G MK?7066_,0.!4_?5-L;R:1&7!":(MFD:XRG8K@T78AF4K*J/C=.WWUTK^P< MQ`^C3Y/N/LWO7#;^3)U+T<=A;R9ZE^,=J(1S^WA0ZW'2N9P<96SE]JB>\U72 M.'[A2LXF;$?4,VI3S413X\;X2F'G"$!?U=_%ZFNUV1Y?CJK;%9)RR1[JQU7S M7Z109[E0J."Z?1"N`&HP1U)B=(C7+^_8BK^'N7 MDL:GI',J^;UW:^HEG7-X1H9_;Z(S&>+]XZ@#=S7+3^?#[7UU][BLWO[QTC(O M-XM;MKJ3B^5C.X=HZW1^K+YM>1/_GSWCLML/:O]Q]?A0K=N>V;U(<%>MZH?%JOOGQ2JI^D_W M2_/I;MHP+:=8T=K,3`WGT%QV8GG<4M\+YU72^=TUU=[S?1GAI'4^Z;R?6E,= M(8](;NQFFXDB1P^SGO9KL'T0NW[XLJ[NJ]6FJV!Z6S^T.=B170JQR'4.::X% M$5PW9O?;CX5BB%OM"7H;BZS0[/;V\:&5Y>:+?KN];S[X9QXG.Y>3_[ZN-YN? M;)_!]@9MIK:3,K:3U1&8[02N+<9^,?U\#=N(4`8C/A-%#!?/RV>MPX(RSUFW MS8_?U\N&VZ9]3WO[U)H=,N7FUQ$1A"$E\H)+AF0.=U85)^:+R9Y6(F8S1X[] M5[)S;?^]76H&.,YJ+"D)`WDF7UJH:%ZF&"$A>7YEAZ05FI(+^Z(P%L9M!'#UQ=3`]2+$D*ZFT@=>??L\[Q4!O(ZLI&O,B#OF7R.(2.JHW5.FWLSAW66EP[L M7I#*4"$X35.`=8X*RE@.#UM+(M/&]V5\#4VXZOS]IVCW0%P8L..:-CE3]Z7A M>>"TN/LR)5:W.R^>>,UNNKR"X83P!Z4WAYLMP6*I(W2O,#)_/9QXEQIH3'(% M.%"@X#@C*.OM4I4;G3T/9NRRTE'&4OW8\#.*CV7Y)MD$$@#F.W@>"8 M9O)'O4XN/#) M*,2XP#B#!2P0@JDF#/7&.FVNS.UF_9 MZN[(<@8)HSJ#@"%8X()FI!BN7Q:%LGI3+("YB:1G[Z*;Y'CAM-*?J4BZB=&K M$&-JT`B:UP4I!-=YJ5.0B$Y+53A8QKK5)V%/NE[_UF!8;\O%ZF/Y[5V]6;1I M^^;8A1Q"64`,V\,9J:)8H&&Q%A2YU8&PD'8C*]G@7K(MOR5?]@Y:"EI0SF;* M=BG$=A(W>-G-]0ZL&T>3P=,+)F(6%$?4,$9;S$06HX16Q^_*ME4N^@,<[\JG M=L7AI$BC@K1W+3A#.16@`"37AX=W!)96M2Y"&(PLC8./R=Y)VPH70:":R>'D M/.UTT`)EG.H6!GA&!"XHW9DH6]B87M:["`_,^7S*D44,&0<$,X:4!"G,H9+# M,]M0P2;'J[?ETDS!/,Q8Z=;@D?'']K']GUAJE0\T,X6:B)>=+GVWXG[!7.P\ M((LC.PY49Z)'(2)YY8B.,QSSBCM]50G^Q,NFI]U6'^ZK:ONW=?WX9;'ZO-\O M5@AR@1DOLL:PA!2RG6U2Z*P`5C7#@AB,G$<="K8D_"G9NYET?B:]HY9'3,+R M-A.PR5';2=EQ69Q/[ICC%,TQ0#&`V>P5MC8M->RIY MG%JO&B,?V^NJT67UO[_.GPYX^-"?9ML;F14@)`LY1AI(#*409R MU?LD1&;T_MTDCD26S(-'2>M2\GOKE*TXQFT)XPV(>32"G9C:\H^U0^',;GSO M(GZ3S$1EIXGU^_V.J0`;J_)S2[)^*!>K&TQPSG*"(64$"\&`WN\6-[8`UU:) MJ).!J55TYY:MCKJQ,]/'Z-B<=>]U6%%$[Q20$3'SXC<3D?*+H0[8H6Q.*/^C M6BXWVW+;JMS!Z+ZX?X8SK#6B`$&A%2Z8Q(/!5*;F[QA[68DL+[UON\N9QY^. MPYLA?CC'Q69:DG:*,R.(%H>-)X/I=LK8`ZK9@>*Q^$^H=3AF7:\GDTI'#G,01U?7:_]N8".`[&LS%:_6 M)P679:C0C+2/4@D*D51-ZMS;D]3L31=O(Y&E<>]:D*S+BZ6!;$Z%T4Y#9T/0 M0E^G(NDFMNY$S;1W)/IS0AP"V!Q4.4@<=>">9*/7U^K-!_;^M#D(`&X&A%S1 MG%'*:4ZS87$C);FQ7'O8B*S6.\^"2(T/2`.MGHBAG53/!)^%4$^$T4VGG7&: MR?3YV,^I=`!:+3X_?/BR6`WC4R%T*GC! MTH)3FNNT+UW9V(%Y851*U_G'(X\)O4M)YY.3.#DA,Q#[V+3LI/U2H"PT.S8P M-X6V!F"/2>]/ESF(+1>_M>!.HB-B/YON:SJDY*=8LY2)'E*BYPWR3[! M<#CFJRDRW]MS-Q%94/]L'0N2]'E0-%#7:0#::>PLV%D([C0,W637E:69^IZ- M_)P&^Z.:@Q('B*(.VG^<;X2=N(BQ/Q1<+C\T7:UJ>YPHOW17_J^'FG$P!01+ MPFBN)!D=W+J(B&O01OYOL,!G\D''#"@E[5!`J,ROYFZV53;S?`Z M!P*ZD(46!6-`*)!Q*.&PEEDHHYTHQY^.?;BK\\;VMJ@E';-,)B(8N[QDY\CE M'N9Y#F)$21R)S40V7+U_>872!X*Q('07--GJKKNC>9@0-MG"YKA6".0$XPRT MM^0UQH4"M-"#=42)C5`$,AE90#HOD_7@WE63GJ_73^WLJLNM+*4E%&Z*.+! MZC"9.CQN=J,%SUF&5*;R7*8TY\7A.E*&(+=60S]SDROA88'#104]V5HHX'18 M'=3OF=`=K>H=/+R$V(TB>TWHPO">D\@%BNB4P(6$95T-?%$=,DN1X^;G@<14 M-(+*T*H'A\ON1Y>O(I;\ZUO2VHF6F3[%!V0G2L_>6+C4]/(%D M1'!\`,Y$8;Q".%-`VQV'N8;4J\\?J_5#NX@U2-<-ILTO2DHIHP@IP`4&0S9& M"VSU^(F;A4G2H"^[8KX>.9`C/D-9B4[.4E@:?WYN8#\DK4=FU.*(RRDP8_+B M!7(N`N,7Q$N)"8#$["37KFCMWMPI98P M1N)]-?N2S.VWTSJ7V`[/,8A:'%":E*S;.25?PF;GE5X#<>[84C"`?EHN/G>=;O/W\MOBX?%!??NRF[M1`@6D*,.(0\6% M`@4CO6F`,OZ>]D_4Z.?+R*MG[F?2.MGO<=_LM MSNK.,G$*@MXLC9J:N=WP$!AVE'S+@.!(]A62_TQRL:`AU?&ZJUNIZ\7J\[MZ MN;@]5F"4:B(EUD!A@45*-.A?^F620V3Q?J.KA8A;Z8-32>_5!??5SQ(:VV/W MQSJ3+RM$)*?+%_O#,?Z.#D]GOUO77ZKU]NE=T^':UX+4/Q\77]H,=U>R'DBH M54$%D(JV]9`+*/%@/\NLSD(',QIYZ>7X@?C>TZND\[7;/!Z\=7Q"(QQ\,TF[ M"'<[@?/$'$7G3+&-J%YP\C/1P/!QU9&[K*4^GK7*GX:Z\91"1B5@)*=9G@D) MFGE?;_H_Y)UM<]PVDL>_"M]=MDJ[11`@";XD0"*;*B=VV;G;>S=%:VB+=])0 M.QS9J_OT!W)(SD@6)V@\<)"[JJW=.,FRNW_`_-%X:N0H!#W.:,.>8U6\_!/] M_&SP;(85VFI:N#9HBS)X<\6',12P79!!F]`]44"K(;7N^J@MW3LK;4]BEI=I M*/(R3T1*2$C*>#*=1D2I4H1->W[HGMY#%U9X&RJ?(]0.E.\Z[V,H@-/1/@WL MOFN?3DBJVJ>-RUS[WLTWU1C&(DX*G)(2AV%$LW"LBRPM]SN05J1/W=Q5E<_@ MTJ\-TH:BYP:RU4FO$M]U%>^=PKU;B\A]USN-B%3E3A>6Q@I@N3LTA^=_--OZ M8_VMWO5/6/Y:_5>[YT_=H7V0LM&_FO;8WQC1B)7#!>)CD5-`?-@-?P9\5UPV,001]%,(;1YXI#(,$<2?^WYEB",1CC M546'#0I=7/Q<"[?R MJ/'2^K`2D1=15A:8I"7G&4$I$11-EDJA5CC2X/..-?VU8&NM;^I04U-:Q\!@ MPCGY<9TERA]17%`T`VZ>")1)!*VU3@2][%@]2%5[86^$T%&6:923)4DPF&WF61'0-JIN[^97FQX M1>8-J34"Z,.U!6W?6PL]"**AI>PAT],$2<&CHBCCI$R2,D4TC_'T^8A'ZD^. M`[[I6#E[3[2$`8)%02\=$8%)Y2HP``+I",J?6QM/4)9D40.;#XJHXW9KUEM` M;V_5CS);W8X6:!(6",>41PQQ+@UQQB<+!"?JKZ?`/NM8#4=G]%YS@O%1T$1W M:&"RN"(5R%M6SNAHOEFE3$GQ7:KS^):D3@^"#VJGZ7EKW`.@V\93&6?VU/7C M5S=M.PS+A@DNBQ#C"!YH_<;!E!2TSR4@F/JMS`:@@"X9Z6D@A)6:"KZ*<4D'=5'XH(3:OK<6^@)$ M#7]_[JK/^V:T$)=$E/VKZBSG+!.TE)GF9"%G@$5[V&<=*^'HC-9O'^JE34M.^%_$M*9\>!!]T3]/SUK@'@`Z]W1+BD?IH$F0>LX'^JIC\3OZHO4+A\%1$#YG7&"RMQH2@.0Y0Z,G>,J( MU.3N/+HEL=,BX(/4Z3G>FC8^<-?SA^NB+RY6O)M+"I0DI!''F%.1Q9G@B6#S MU#K)H@1RV^?'MI#=1_L1QG\J=D%XS__"U#WS-BJB=UJ M6&$*]\*MH/?K)CAYMK*V76)T0="LH/5$Q>S$TCKH>T"].CW4>:H"GZ?]Q86< MY%F425-A@EC*&,X2)!`MD.HKM3J?=IDCS-Y<[S&#-Y!<^,&8`/3D=V(40FNO M/VF7*QL?2^B&!Q*'-[OSW79^S_WDTK$.#J=96K(0I10E<1BF/(MF=WB!2KT2 M979]<#SVS_6LWG\))L>#X_.2@^N!]#V8G3][)]JX$)GEIE(3.1]:"2:$YP7' M)I]OCBUT,S91I=U$CLN-@1A?4%;7K>:)^CH/<[&4F$NLRBK.*MGQ;^M/=W5] M>->WA4RKAFL`E!1Q5$9Y$LH<"H4)S_-\LA='A$-D6MN(8QT>_0H&QX+),[VK M0OH@U41T%88PE=3$YT3_EO!<$#ACHIXHF'D6N9D&#QDL'<11Q+&B*<4DC M4C(D*)DLIKE0J@=DPJQ)T$@4 M5$D+CGIMQ#XQ.^5AXTXA*J(T"0N9C14H93PK4S:)8,22#('J(FI9<*Q&QXGH M^8P&MF5OB$]-@MR3@ZF/!C0WU1#?XG)!J(VAD&\KH!H`8G:.2B^K[?- M(?^ZKX?KV%.=B#(F*"EB+I,JFI41YRR>+.6"*2V0&7S>L;HC/@I4-69G1\.&UE&$%KK:M`Y/67 M77-HJOM^:6VT@ED>9US.8'$49E&>ASP.)RN)_$?*T@K_M&-9'1T:%J>U-$(# MEH*O()1*8FG3\$NB2;^D1\D$P#[ULKW0)4B&,K-5GV MC!>&6%C&B'(D;<4B'2HSSBDOD3FP>CT.G:\[%LR33_J"H$=-03:=`X,IY_58 M06IWN&:F6<(#S$ZQE,<;X2X)J1$:'[34+(#65B^!*.K']KFZ/SR_SG.SK!2< MT#3#/$M1SD@<\LE4FA*E!_I,ON]854>O#.>KNNP4E'4%;#!MO2XQ@+ZN0$Y/ M874(JFGLVR$OJ:PA(!]TUC2$UEY_`141J?T="WK/AA-IDV]Z537T,2HH[SH$8>+K!SQ( M>9)5(&J6*M&%J5BY9"GT)3TV9^6#)%N(HK7:@2#"+-K]Y[K:]_OVC_MF=]L\ M]IOXKRUSC$D4LSP28181AL,D8:-EG,E,7%FD[9AS+-AG3@:SE^;Z8PFU@I"O M3QDFZGX#!HC]^J#UA-\*<+5!0`G)TH!@EZC%SC,D/HZ-/C+KG/WHS^!=$@OYP234LG374("IN>K M\X&DXBXY:6;@(%Z*:?>K,!>S;5T9J*F,9XVA7$.$(85C=!PX#KG(>U2R&'RH>&`,!5#IXE)WIKNKJ>=GVM?GQR'V> M%S3C1`@D""51DH9T6BW`98Z43E+9M[J^!NE=T;'(64V:KH/86*^N7335UUW;'9K;;LKF4,)Q2),L+W!: MRO\5@D[68H[5]Y+T33C6M\FQX,PSK8F7`42%&>HZ_&#BY0,ZP.1U'81ZLUA- ME&K3V<7`E^:UYJ1\F.!:B**UVGU`AU/_U?YXZUIX\,>PVQV7^NI('5:QACE"2_#..88ORE!I/4_CLZZ% M[NB,YK./(#XJ4N<,#5#KUJ,">@S3%1W=QS!5*:D^AGD6WZ+@:4'P0O'T/&^- M>P!$\]Z5OWW*/XX&1)C%41H1'@E6,$ZR?B]Y-)`3JOX0$NBKCA7OZ(O63QL& M1T'OG'&!R=UJ2`!BYPR-GM8I(U*3NO/HEI1.BX`/0J?G>&O:^!"9*Y[VU6%Z M44EPGL0E*R@7,16HC%@R57+$5*:1RC('^JICF3OZHO6;AL%1D#EG7&`RMQH2 M@,PY0Z,G<\J(U&3N/+HEF=,BX(/,Z3G>FC8^2.::?7U[$/?M]^EX8"1X*@I$ M:$YPF*=%FDU5/>0?U9XUTONR:[F;_='[?8-!J2T9`Z5L;#T0"76+2E$$( M+D4I?!7EHASJTO!"$K6=;VUT"%"IMVI?_T=33R9"5!1,)ID9)0DC*!9T-D&X MH.I'FH'?=7U`9O1&KTH9$)&")#JD`Q/$5<%`ZK:Y`Z19L$T=E&*AMA<1+LF@ M)@S`71?HPRY*])V< M2%2E^8:\.6L03\XCVH^K==R3S:J0_[QONV[#\@@5(HVC-(U#S!#+Q72SA#`D M0(]H:1EPK(:G'^!^=NPF^-J[9E:%7!&?FL@Y)P<3M+=4ZR;X^3*T-:J0#RY< MT"8CCI[HD%D,ETN0ZP!1FY;^]M0G?.V7Q^JYS]6[0RO_.-BMMQLJPB))2<$* MGC/,,X18,1D,PY`J3U*-K#A6FJ-O_4-ODW?!H0T^U\'D(&2F9H9384*[&DF8 M\G@$$3#Y70VFWE38`*K:U/A2_$L392O,?)@VVPFDM=V=(.+]H=XW[;:1^>EN M>.GUJ;J?;&]BEA1906.9A=(DC"FB=#JL0V@8Q"Z.>7&OB5)/J"Z$O*;4-6CX(M94X6LO="%0$K=EW MAX=FUSP\/8R&-C3$.(E(F6:"BI2E$0JS>3A@`E#R3./CSN?NTJ5@]&GZ!8`J M;>D`4Y!AUZR@L_5K8(*4'W.,2[/8&`R;8EFQ'T-=DE43*C[(J9'_K:7N`5P" M?>-1[%^E@G]ICJ]`=A_V+_XL_ZV>X?:7W;=:NB@=BS:T*%*$4I[W5=[+B"(> MS_EWGF$!63!=P9W5EE?/5PI?!'$3R##^>OZW@BF0X!0)<#%VC8946[KUK`UM M+/1:;3XGR\+FT"\L(J_8HIXL.:\9<7NUGP\LU1[=.NT:/9RY<=MVAZJK;MN' MQW8GG6B_3.4LJ]VV/=S5?:'+5KI7'S9ES%@2(CF(%4E1H!B7V>P>X['Z9:05 M?;K*IMQY,#=!'TY0=4$5S!'U*YAS(=A^=WV(*CB&=1/(P&!9[WI-K#2G\+)U M=<>3_R<-"YH%>=G`NI.GU1M:=0)FB_+RO&WU=O1CNK=^V.UU?SYFYVM^DY9" M4F8XSD,FI[&Q[*>NJP^_5KOJZUBVL#MT_:)8&)>\B%"6 M2+-)$I_.[80L)*#3S#H&7)]<[GT*3DX%@U?0\\E:Y-3DQ#DTF*!`>;DY4?P& MDTNGATT0>J(H9C&\/A5L#D3QA)X4KY-V]<\WO?_2_[T-P025")4IBEB2)(2@ M>*JT1[*(*LF*F07'NC*\)R9G'J?,,?BIV07#+6:9.OX%=*9,FZ+"&L`J`&$: MXP<[R%F\-1AJOJK1OZ@Q\I0SDF`GW3H#^S?C8W@+H2\>P3-%Y<.\U#R(UF;O MT7C96?Z2ZG9WK`HHIZ?[^EN]>ZJ[9O=8RWZT.VP2.1R@C(99'*(\R_*H_XC,TE!A&ZP/(X?UF-YXM-HR,+5QY>>G_KF]0UUO M_RG_2@KP_?/+XS7W[?=-5*(,R?^0,N6BH#2+YU=:XT1DZN>ZK5AS/**(N^;KW29E>1%3Q$7,BA27)$8TF2S'21'9&R*4S/DP1O2.6A4R M-=`V1@GKC!T,$U?":W.@L([9X4AQ&;>EH:(WHCU6@&C^*08+6$2@T4(#EMIP M\"JR\6 MF1IRO?,PN1?('\?^?(E6>Q70@HR*\"V<;;>/WY+BC];!:M[T6 M5$U_7V^;P_P\_"@NO'&EN M7S6$\_^E/S;:;5".0H3"N"11Q$N24$[(Y!--L/J] M?]>..!Y6YI1O*F$9//4!R#\>(PBJ*83@2[L//H]!_%L7?!["&$Y+]X'\\+,% ME19TW9H*8Y-/#:F9MO_?;D-("4F/VE*SS*2S-AUN]E>/C_>-_.BA#:J'XX,D MVZ=ZM-'??K`^"!LVR=(0O59+^S"`KQ9K>X6?$FA>V#X\-$-]H=];Z=^W9EL+ MV76;W=?B:2__^_VN_KO\L^S"OW^7_]+SMGJ6#GZN^QWZV_I8&'1#RS+.(EK& M@C!,N4"8T#DKB=-(;0%M/7^<+ZWE@Q`,Y4"JW7-PUQ<'Z7_^1Y78?NM]'15" M:X!8I]549J&^-1=LN`>TD\EXODYS0>:TOC6;WLANT'SF,V$+"!`(YUF:S5GDL/=OI(M M,QQ:J?]5[V^;KA]JJ^VV=ZJZGQ=-;>\DJL^-;#6)%_,>:\%W>C7,#<9*=)$T"25I%",L<#)?&FGH*72=,2B.<=CT%Q3 M:CRP:D'^+&%6&&_6)PP;=/R%"SIYO39D.Q6]IJHN^6E0:0YW8W$7X[%!B M'`)^VO4XT!YDZB2;NFMD/SDN2#Q6S9!RC?60^IWG_HOWF)X<)2C"8O3U95=+UOK70:\&7MYF&T]''XP8QK]QLN M"D0884G$,A*'91Z?,EQ$N)*6&!MQK"J_[)I#(W6E.;H8?#FZ-4B)EHR84U5( M*]<""I,6#UE";VBOP%0_=VR4^0;?[YK;N^![U0T)9[/KS\`:9Y07""WED3:@ M^I`]6HGCATO;5L`H9XJG9?/WWW?UEE7W_6K&I[M*=KM-C%`4\2(MLI`Q@C`7 MZ7Q[D&0X@^2-1H:!V:(95+7<<36>4+G71NDDM[R$ MZ4*F:86N)WFGG5A:!]T/DI.6_WQJ#L_-;+8;3'7M_?;X5QO*(H22`D=(SJ%I MQ%'!IKM]"8G+5#DQ-;;D6*V._@4G!V^"HV-![V/PT_$/H.4Y<[@*^>FJ7&&J MY2520)JZ*EJ]7-48L5HZ^DQGK7_V<%4YJVT8:3#.4)RD5/"(% ME2GL=#PB[9FE$5"&97`\F3("\ MX@BZC+H63]VKIOI<5>]^7B"PE#;:P>9#SF@IDM9ZGS(H3?:INJ_??SF__]G_ MG4_U[=.^.30R8Q49R?BKZ-W-`CUW(BF1TKVC1.IV@3W^4 M+,EN=[?,XA]9=POL)MET7%4_2H^+Q2+9^-:\4(._/SY4^Q_KYO\]N6QQ;)G] M,.@EHS<;`>A7A$/QO9]C=DW(D:36RWC,)-?U$]O(L6:.!?3"TV.%8!&IN;]H M\O18?<>2)(_3'`]D1P34;N3!_/S8>A<<7??(6-VA<4]:#Z/BG;?7!^3FW#TZ MZ(B^P#'Z/\A@:(06)#82T[P:6BPW^[\OMX_E0A:($\ESDB2HX*+@F>B;26D1 MA1 M7"N>FHJCS:7?=OMRN=W\LUS_QW*S>U?5]?O=R8MZ$>%"RB1G*,HD+;#$1<8[ MLRP2*8'`R=:69T*=W`L:_X(?&@__TES1>^8DD%/6\NK!:DIE8<2R%-4+MZZH M-0(O5SK/A&#.PJG\/(Z0U:"?EM^;"]&.)R"I/&^]WAQWZ#:=F/5O7ZL=/QR4 M-RU<'W[:;)4WU4Y-P'F:$"0(XRDC>4Y%D8BT=X;17&HO%'GSP#/W.K^[PQJ; M2=9R<+WM2U;SJD?EOO>;'_HR!`!9&O$W3!JK3[,8(1@__Y\,#F!):Q:# M9+;:93U8UFW]IN*]M5#F?3#FL(;F/\AJRN<;.`,0Y.ZA MV.SKPR_E'X^;?;F^/UZ*@Q9Q$6*)DB)&3-(XBT4Z]`<250_-W86GFPL7+,S#@H1%S%!"8H2CF-.AW$(C+2K96?#, MH\ZO`+URVS5D_FNNH$;Q81+Q8`BZO6Z`NL`D^AENZ#?246]&_U;8;\W8K66: MPXS;MZIS3#UW0>O977`,HOF[4QC!,8[@XU/_ M#^KA7X#+`[Y'4;.$,*,!!)89)AD[/U4).]''*A<3#>=?<0Q^^T&RP/VDX^,,\G9#,QW7KZD+I;FST9HSP]T%J4-NQY)>Y?5QY_%9 M4W1O\9DC"T$C&A8HD9&(4R**0@[7!C%.)=4!!.:9OSY^K,L_'I59^:U=!?Q8'_;+U6'!$<\SDD=QAB3-F*1$H"SE-(F: MTW$*W5X>X\_W]T*=7`J./@6_]U[]]\19QEOJC"02UH+.)%>PCZ-R_*39O3D? MVCIAE(5YD8N0Q(QD-"$TH:2S)7"4:37J6QGP_.U^^>X$O[=NC;PW#K4S(HY[ MV>QH2AEAB*& M>)%TYM2?!6B?HZF-J?G2.*:^GY5KMHS15M$,,SX$M"2-EG:3T*83!P`9#1"8.N*C@5A8Z.P#@$%'6^)((&WP,K,P^1SKZ)K($&,6>OX$10"\SH M&YF<-(UK0>N;)6T`0AH!QX^&MLS1DF\*[@SRZ*,'KN@\Z6,0QSB`3(71Z\4_ M[<#Z4-WOJV^;==G=RR<>]^I_W^_*OZH_[\OUAS_5#SVMET]%M?]8+IM6U?*^ MW&^J]2)7;"Q8*$0FPS3FJOR]U3\'E9 M'Z^9;V]N7JZ_-9X&*HAR'ZQ4()O#Z19ZVQ9L%_*]\L9./S1S:.V>-N#J5F\! M^)!.]6"7'Y;?Q:9>;:OZ<5\.*UU4YED8%H5(2$ZQ^B_C*8T%0TD4(ISK'RMI M;L)G'T3C5:#<"DY^W6[I=D2DD>]<%]+.Y&O722@OSI9T)8_V^U242J?E=K#\ MQ5G0F3'`12N7[@H`6)P_+0YJ*_KLK=4F42[7H/ MD:F@@HN8Q`*I!$*$H>R-"9*`#FTQL^"[%-'Y8KC6:R::9N7!NU[`LH.N5'X* M#:^I,59EL%)O)ERQ#.*RON!`$GV>=#9^V]5?R]7F85.NNU4;2@I<)((F)(PY M22@C:=$;S-("UDYB;&4BKMP%9ZX9+^F::ZF)FDED-,,-5$$_]'E+H#$"68LZ M%PK9!W))(D?2&%PQ4K>W![R67IW56R5.D"C2."68)[197QZF?,H-T!UZ;BU[ MIM:9LW?]+1IO3C/,UVPE6`P&M-[D>`\\7G&C(.5J9\C$L,R&GI^#> MO!G%O83P^K#\_K72[KX5NX_5OHT M-;,">5W/'3*I$G>N@9EHJ!^PMNY1...Z>N=3\$/GU5]N55-_+HY./=U0SMGP MR3*,M^KH5K*`+FA:59]VS6TJRFAGK59>[,ME7=:_E/7CMCE9M+GC+G_<[Q4B MCZMDZJ?OJ[H]7+Y>,"DPBZ.0%)QBQI*4$]Q[QT@$ZNR;R"7/>>!Y%.T;VL=Q M%_21!$,DQTLHNUB"8S#M/QK",;@8:HIAU2/G#$<4!MK)!M/;A53V\H^@?.+Q MG0GYIX[ZE5NP)A?=IM?A0_G]D"D!_[%(\SR,"D:*-"(%DR%%87:T*1%.8#M2 MK`QYKP7T^1GXW'H[_8R;1?Q(YZ1;I'$M:'V;0;_(H!.L800N[TQ8YR:6ZRTC MI@)I<^G]X7.Y?[=9?MQLV\/A7C/-I8R%Q!0E'*$()['(.],DQ#@)(7AR8<\S MI5H7@W?5[M./'\K]E^#,6R"TG(BKQZZI=84AK)/TY-Y,2*:AV@C07&H^$ZXY M#:GR]XA"+UW;-(VONW5]OWQJ.EZ.?=4J^_OU\W)?+J("AX*D69A2SB+)L6"B MM9K*C$<9@144+8UYKRL._@5?CPX&?SPN]PJ4VZ?@A\TN$-5VN]RKOU6O;.OR MU+6S<0%'7DA'RL_D7705S>6-7BY%,GX#FYO$1+E2#UJY%LNGGZK=X3/?K?^K M7.X7.8TD)3S&`F,>HI"$+.I="!/8MEB7=CWG'2_>R[M@W=S$M^[<#7YHG!]Y M&?T+KY>+W$IS6$YRDON^E[N]^+#W],;0&Q$-0$`7TL\4ATY"N\)&=_)I@S); MUIOZ_0-?K1HL;W:?%H5,!.%I$N4)ZF$K27`/]TS]%J'FF.2 M[]4/E=T=)'?!?;7=K)Z`J#.03@]H?E6#86L0[.3-+6=0+Z09@9.YC#-!D$4` ME:LG"GQ]ZJY6[]*Z?:^.;]5IME6PF$N4\ES-K$A,&,JZ?4C*IL)8#KL_U<*0 M9\C<[S>[U>;KMFQ?G&>>&J+&3E8]ZDRF*`Q`K\H7_-[]>CL2C7&OJC.!]+LPZO+]@ZP/FR\J`:L7<8@PYRA,:(I#%N(TC?!@)=*[4=7P MHWUW1=3M'1&#/V;ODQ,--5L7_,D';$%PHIR?_H)G&HWU"9B).1/:F'I_N6YO M(X(V47X9+L"K+QD6YHABFH0%(VD:*E.2)D/F11*M"RTBL1Z"))(;1Z!7A9@"BMZ4:@9(#?6<"*!>15,X?/FCAO/QX MN#25Q0-6M(UU M\U/1?BG.6.7:0LJ9\,8JA,M*M+4<@-3H6[E[+'\Y=D^^-LO+"_7I,L*XB#*: MTC`,LV&6%T=4ZRYU=]8\TZ=S,#CST"&,'(BMFR9-J3,T6W(DL:>LZ8IRH\F3 M*]5GPC2'`;U(I=Q*I7=&)5_]\;C9E^M?JJ?E]O!TO$KQ!6@E5G-0CL-(9*ED MC#`<]X:+G&;:9U`ZL>:9=[V/0>=D=TFI!>L<"CW.NMMH#&/=K.5=5ZO'+_VJ MZ\QD?N;;M'+KG9"JH\@K7Q7NU9S#":=N`ZI\/7C`U/BGY?]4^_RQ/E1?%%B/ M1B]-1TPRG$DJ\SC&(LJE".E@&B-0OB]Z[9AEUI5[/OS/*AC5T&\F'7:H^DXS8:4B5OX<4>GALM2\WGW;'C9'*WGZY MJY>K=D\DWZW;/V[;5_T%>QG+$QZ%>1HEN4PRE!7AJ?")8*NS_KSPC,7.\:#W M//AKN?ZTV7TR!*/'T=##Y3P&`@;1%V-P[G6[WG7N]WP0:ZSU"'C]C]],<#Q! MH)?GZ$XD+7QO^8L"2H9B$67*5$(IHB')4-3;8R(%I:;&1CR#][0[VF&5UEQ1 M/;I.(B8,GK8Z^MUIK@\^:VEGPC7[.-[:76XG#*#S^,O7??FYW-6;;^71^.L) M+4H(1D6&I4QC(7.$"RQ[^P11T/X&9T9]SZ+/_>S.8'3(+W?:Z_'L)K+#^.9. M<4_=RWH*CI#/^2#,A(3NXWK1X>Q%.&U2_ES^>=H(BB]Z7C`D.IA M*+RP%2KI"&.]C5FJZWO=%JXKXNU02^[8D^Z_-\[9@2 MS(L"$RS5M#T-11:K!^]X3$E*PH0G!03`?CSP3>&VF_RBA?QPT4(.)*ZGH=## M[NU'`<;>UM^[]LAV]4OK\]EPG+D]DY.6C/0=`;'?\9H)C3T'64WY"IC>'?;^ MH=CLEKO59KGM#^D<[E%,XXA*ED9)HG+RG)!4%((76:[^6.19HMO%[<26OU=] M<*_9[S8X.)R>>[M[0W5T&WF%GXU,872;.T&?"Z%#%YAB M<^,(T/NWB&$B`IP-^799U^\??CVHQ*"]"##)69*D64R2B.(P0RQAG4$2(D9! M\R1S*[YK^8T_S7=SZY'EK9]P"8$`\:H>L"0/$\XO3RYUT4&+L99SHXQY(&\! MQU(:_57&,SO=?7^"9QF-B$@3E0#E<4Y".E@*L8"=:@3_^(EI8W;]IXELFDN! M?A6S(\QM;OI\*4W4WFG<06FA7PSH8A- M!&\E):9B:%.$UW5YJ+O+A8:2C,RRD,LBX@D2"<89"E'8&TN2D$)`8F;!=T[2 MW>VU;)W[=R!$#$73XXA_O6`H.?IS-UR'=K/B[:O"C!#%3LB90,4RB,KELP6= MZ"SKYNCIYA?YQ^/FVW+;K)7S0[[<[Y\VNT]_7VX?RP4G<8PH$G%1)`57IC.& M>^-,`'LIG5CTC1[E7;OPN6I^4Y[\G#K'UQ%K+.UW*O9,7C?'05U.#CQ(IO]- M_VVYV39%U:+:_ZHL_UJN'O?':VW*CX?3GSHZ+-(XBVFF9B@I%45"LHR'Z.1& M!EHP<6W;]TSC<[4_')M#-J=KQ:?^NH-I-O9%Z$G]F;RSWL*[_/+T*J/^>WQL M0JM/70X_EX?>)DE3+)G`2(T`BU?6!GR_(:>MPNUE_5N-ZOF MKNVNQ:MJVD"@2;V5KIJY_522`E/\SJVS+JR[0'DV)/U3HV]$IC'.N5!W+E!S M$LLEP=P)!#@-]*%4!IHKBX^SC[/[],ZLXS!EJ4Q5IL-B$G,>QBGIK%/!".A" M84(S M(9OKJ%X<0^I!-/V-44TSJIKBM9VIKV(62QR'19[CG.0J#21A)/JLD$9)#*IW MV%OSS+ACT_U^\`RZH\E>33VV32LD#&M=PWSK6IO<=IV4NT]S2=>NJC?".'?* MSP1O#@.ZW(#D6"IMJ-WORZ_+S5I^_]I,L?HN^V>UY$46YY+22!;*@[AIKF=9 MW)LN&&SIV84]SV#K7#Q--H/5LQ4E(.B<**R'NJG%A<&NU[5S[VR#T,4RU,2( MTU!M!'(N-9\)YIR&5/E[1&V6PQ#\#4XH?V:?6C^B1VR@$H9K'T[%+I7S\A!X:A9N_O:+`FIU&O!$<))1!E)$HHC1(N$B=YF@E)0 MQ=W*D/>,Y^A;^Y5<]H[=!;MRY/7P(*=NEC.1DM#TYNC67=`ZUFHI3UK^/*:E MI[SF;9U&$QH'\LX$1&YB>9'".!/(0>WI9Z5$A\@H17%&(Y$(3E(A:1$-;80L M2I+03?D)8'"2"M1IFG:J1:FO]VU_!H2SNA1$:=O2E">1_56G3@[/ID!U;E86FWU:3<]>>W9RP+?;ZD_%OO*&I!N7$++6:*;] M3.CF*IIK:XLV(FD3[:SZ=68L3:4(U4P7,<(+Q"B58=8;PY*!VC/-+'CFU['L M:X0K0\7T*.5?+!B5V49`8Z=C#/AC&40E"GEJJF[G1X&G9Z(8%85N`(8Q3'/)4**61@ M22FV@-@\VES$?';K=; M5%>R$5(Y5WTF+',?U^6YG'Z$,^'AY5[7$.&X2`B-.AW^;(L9B`0&9KP#*%A5]G7HUN&^_&@ MNFE.SOQ+!IRL]6IU'MUZ[]US8<;FP\VX&SQE1`;=Q,H!V8.*ULKZ4\ MTT/G=7G&N6,IZ7S08QO(2_HXD08*H.'"QI-!F64Y8J%,$,EDA`N+7NISG446FLZ+13:!O,XB:VE, M&H!>`6`F4HGC2(1%'F9M9>6><&5FJJ8>DZ82$ M8>DM#>=RK``H7W(C\DPXY2B8M_M[K"72/\>Y.6SL0[G_DBUW_V@[)OENW790 M=I/'199%B.(\B24)<425]80-AFD$.AO%WIIG;C6^!5OEF&'9R(&<>M":5DD8 MN,X.L&N\.VO//O;#WU^3UL]YT-<4&Z&7.[5G0C"'`5T>'NU8*OT#7ZO=MW)_ MV#2MWF?FA@.F$I:Q4&"4R)`0D>88]XM]2?CMY]_R%,YT4VBJK M1[0)187AS$9//V?GCBHU@C%'$L^$8:ZB>7&[O4.1+)H&%C**8BG2HI"%S*D, MD]BSW2E.2QB(E*@?#>1IS@G)ZHE<,N^O+TM:$:="N M_=HVF])92PI.?[RKZ2S_N=E^CRMJZ>5`5CK/A%+.PGD["W(@$VRWV?F9F6<[ M4>C_LGNENRN@6``$E7S2:V98=XOQ?D\^$.%A"'^2ES/=_UD>,ZAX:7Z_M, M>I-CRY\70:,7QHBX) MG#@(_80_,F4)0_&P^B>"KCCC6JL[\>YS)^E'&.D_O&^1'HKN]AAQ[T]5-D7Y-2_7HD@(0^3&'@X"/_7Y M+R1-#D4Z'HY7//O?5O)=`?V25+Z`4U$*[=>#N.[FJU-YX(-HUH#HI\D;L&<= MN]AX'>_S0KXA(Z%\UV@U98_"/;AGMQQ9)T^R*VWTCNEF@J7AG M>]Y=0%J;%PW8O1!.F8CDN_MU#9FC#(+6]B#K/M\RE@R10"TU7X#';@2>A#/S#^1\'@D?>SZ[O^<=U!:!SY3A. M]R?>1M@W]]6N^'>^^5]05L-/B[H6:T3;L_SV3=WPW_#DHG[2NGH]R`'.=A6H MD>WH_N?._5;0%?C8NCC]\>FOK;F`KC%&+H19HT+X_CCTD78H]5>J\J0<+XC# M&/(6FY>@.,)I0,)AS5L4.K'B;(7BPZU/3P@]$G!R_;-T@H%[Y8=N"R48H"L8 M!9=Q!;(&?.8O4/YPRPMPG2L@/IGV7[%\W?\4MC_UK@!_SF.^;HJG?/NL/&FB M6I6RLR06:U%U6J2MP`7P[;4I[W0@M?Q;"-GT];_151QAA/S>I,VF$.(`T>N[+]FW5>S%$8E] MG/JA'\>\VTFCX>Q0[/A(]>)FHV7;IM11[G"7UJE@_NT)Q>K;*,WZ+TFR&:U7 M)-R)Z]V4]PNMPU;,#T+N3X?3CKGFZ;=CJCAZ"8R6ZF8IP+05WO<;.BW:*`W8 MF[S)BC+?)-FNY/VJ^D16?Z;?*DA2ESA)%'@0AQ`SSX=I7W+J,;6K5@T49QFC M@T*0]Q(5B6G"4#E(3NRE&A/\G"H?K%%%S>*AL]>?F^ M<[J3ED9-LS99.?L,I=+,I+2G"\'/F`C>G8E4-,/8(=&KA,1)[,"`!"%V0A*F MR!]ZPBED5.FVT]&%3;UFL1V!-X"B\2[+@6E2@]4P]?9)T`L[_EEN6>0X:Q=" M*W/Q*![SK&B4RGVLF_VZN=Y]SG=/Q3HGWPJQNBQP`H*A0PEB'F8$NRXE#$*/ MN1`%@>(]K.H%6%]-T6KJS[#O=-7@+R'MPGHD@_[)+H*P;)WJ*@@=UVQ=M?J= M,Q<708PPJCC5$E3`MUOJ7AE4/O%^X\@-*J1^G*75X-6,GA4EZ M*!#'D09F-$J9AS6=.$W:Z'BIA!S+-AKASKL.VB3/]P:]CY\1IBZ+06,">1M$ MHZUYET:/FVVQ^I/^UJX*6@4D$?<(IB&-B(M]E#HD&AX>(2:U^U+MB98I\R<% M?W5*9)&B:,AE?-CS0@T5UFW85.N]V)'1WE(Z@QTORC=KRRML;'V.D!/PF\E`-APNQ3P&:$]FH MAU%M.^70>C[V<[`UX-82\&LBC,KL2Z2":'+SD;#^^0A[(7*=*(V2"#M1Q"@. MA^>S"$O=)*W\4-MKRH04+6@H.2,!65NFJ%%U(C\4J&G+%SU,ROHC1\63V,YA M4"?\)7!/2WVS=,D]J4D#]J;;9 MUFK1^YB5S)&AFRU?%/$VE24J@+-EC2;A9"V21-Q)=&<9I^/`(B"G);P:6_E* MF'L2!VOL;JKG;-L\WQ1?[YN^M)AY843%IE`DID.2%(D=#5UI?A)(W7`RL@C; M`.R$@5X9:*7I??SZ+LK`<1(#%4FY!.]4*#J)AYI(U?12DK#G(C^+V]%6+8*] MXZ.HC+X_*E3^A3^_?[P;1#`)O`A2EU(?^BA$"24IA`QCBMU0&L,*S[3,7:%$ M"Q4JMDAPU9(C:B"=Q`P%4%HR18^,DN;(@?`8V3GR:<2^!-3IR*[&5;D*S'ZM M_NZ?3L.0,B\B#L1)2(C+B!N)I],PI3&.I&X15GRD991Q(5H?KX(G$B"S8X<: MQR9P0H%B=AS1@YB<,W(,.\1U#F'J@2^!8!JJJU&UK<*O+[NL7-_G<$`DIOS) M:>*[,<4>@F$88][>$[QT.#OE&V2*S[5,LEX-@%I?L:I'$E"S:(\:V:9U1@%R M%AW2(YV*4W*\>QGB.>AI&K$$\NE*K\:_!QH,=/LB($I8XL:$,C])Q*J?D%!> M1!Q#RE`@=\J(SG,G8J`[YDN7]DB>@3;LT6/@-,ZH,]"&0^,8*..4$@-=*0:J M&K$@!BI+?X.!>N'+,3#.ZOO'[%F\$G?5[I'7_WU6YQ4/IAT3W(DQP15V*/*C M$`>($B]$*<78ZT<#B1\FCC09C91FF9="(^A%`JX2##+%&K%>*&B5JM#"C,\2 M=)W<8C7F+ME=!4)/[K(>MTVX+<=S&4/.4=ZHF4M@O]F`*EOOG4J>2(MO^68H M)6ORK,X><_[2\3?R*R^_SK9YO?*).(HT2KR`(2>%T(4PI"0)W1#'(?7D\X21 MTBSGB5;C\2/B*D%6@PPIC!B MMURJD''D7*HPZN824H79@"I;+Y[2ZJNRW&?;ON0^63UDWXJ'_<,JC'$08S>@ M$0MP56*^WP+?7BKD`O3VD9T1@K)7+`5"ZJ MH7\I!JJLQ)K(2,VU6+J&2B[&.A_\V>58!OQ:`KZ-Q%$9?I%48/WI[2Z$!QD, M4QS!.`Q#BEV:>(\DP#R!;6I,/NO8%(8I M@'@"X_08K&&@''W?CO@<>$?ZLP3FC@VA,O>Z*)Z1!*6PJ'(),)2.Q-,E&-[U(1+ZZ^2*EIQ5V#3 MR^MZG1^*$GSJ^BD7SI$V;^]E*$_MK.)8B3"UE04^]J8.RH"0-O&12A=,>@-+ M)JU=R+%*1D*IS+]Y*@W#FQ,>#N/,S2XKZVPM\MZZJIMZQ9R4IL3%49C$O'06 MN\FP^YZ@T)5?^VJD-,OHNCG-VL>9E!.9H-6ITB(RX[)$@W)R@]4(MEQO%=J> MDWNLUQ(=[[5E5^9?M=^_Z)^^S%)=$U MJ>O]PZ/X44V?^_,`2;GYYS[CJIH\?Y&Z2`)9$(2$$8;3P*,^2J)#2YN$B4JS MU[X:RQE&!/#S$`$XA'`%3H(`M\^@#Z,]/_,0B'2;;ZZ:E&MA+ZL2U;+8-/5G MYTCXL;9?:-E/5Z4+:?]/&/#K4^/A_&H2.TQO2,1@^5,,E72]^E/1 M5^!$-AATN.FYBL&\7QE)FJ17N>!OA[WR1EPP5T__VMFW44UU4FWQXKH90\B#2Q(BC" MB2LNJ@R8CZ$70'0B)E+BLAT%ELD\B`:#:M`)O@(W^6.U:XKR:_\3_B^>JNU3 MWLVW]P$!$1$80N*MPS8H16A;JCHY;,]?:VK@GKC"K#!=R_,+5+=;APOANN4@ MJRD_"]T6=W??U*_Y4[Z%7ZKV5R1V%M5WG'R]!H^$+`F0SZ(P(#"`3NP=QH?< MU%$:AC%:L&62'^0`\>Z`K=`(H+@JLOLMN@*9#IW-FJ_8EI[:=]U&]%5_^]T5 M^/7H>_=;!`Z"9\*MBILR;6>3E;(0N-J)[5QKV;R!HU"*>@WPM08GP:'K.\@+ M'>A2F@04LUX#=5-?ZB@-*P7/@5)T1"DTB%)]\_51.HGOIE"*CBB%BT3I.3<5 M43JZ4A:,TO&Q2:#4D(&2BXU/]I_TZ^VR-=>RRS_XGA$(;:7';_83#6L`AW4*:VD'>.DQ'*1J4Q4X]U"_%-9CCR1CYIK MDC7]E%R8?#[VLZN3#=BUA-4>1N*H#+]'ZM>\KO-\4Z<\M+C:;O-V.]5 MD]LV'_@=AIP'A-9;S+^ICO0"M7=<^!*=_E^J4S6*[80CNXW2J\ M`EPC_[9!I[*?._\TF#TY&V7@;H5"+*#PA:(G>QQ%%1W M68=^5@T>2;U.&SB*FY5TKYV2)IRVQ8LDFWXT%XDVTJ11)/M8UWM>(N/=/H99 MXG@8.5[(`@S]H407IXI=,.UB9B)8T:HS3"]99_7)9<%4,]3JA"V`6)T015HI MVKI@4JE&(D$I+7-&$>IZW]1-5FZ*\NN*Q*&/$H2CV!%72V$*C*RUU7+\*)Y\$0NS%)P\AS(A9;9U$NT,IQFQ6XYN4SNM M1KC>Y`6.HDGX=H%V)EU?"/&,AE39>TGUR?==%]=W8.3'-(2,P@@SE@8I.109 M0J4.YYAR)B2=V0&S4>8J\\VJKV.X-OSRV*4?RGEFC;1'GU5] M1Q?!V(E1$-,`,3=-$?'8H;@T"8-1G)(L8PY&C1X2TS94DTT6O!S/I:MYAL+. MF*,")$4[EPHCU3#>`Y&6+?H0.NV>^E$2^9Y'@H2P((C$!4[I4&9,Y$Y*,U+0 M'#@R,^HUSE]-,-FRU@2=YAOMNF23"J=TW%TJK+1B>8]8^@:I;VXB=9TW=7\H MP>:ZO,G7^]V.ETRSNJC_**O;.M\]=?M;'_<-_VON5+$MVC7'7_)O#>7^_/^* MA-!/`^I3!R4NC,+`C:).9A#!B"J1;FIMEN%XNE^GBV@X1V0#^.=]"`JT45V! MT[BZDUW!R\C`7U_:OQ,1@C9$V2LL9ZM].0XON>+5T#UOG=O=SV6F M@X7DF-G"/[=Q;)9JD,YDG]?W^6:_S:_O7@DFY>;7(KOE0IHB/RN__:Q.1/I1 MX%)((^B'+*1NX(1H$$E=/U;)8],JLYS%AF#$;H>[XW'NXD]%F?'ZSGC5E'6S M:W#A!'>[`^YN16"*R6KB"I9+5^;L2A""?_#T]&U=>R M:!O5M\_],15_%\U]48+F/F__5=?DOB_R':_L^V>5/<93U/OE%+7$*M=/2O^M M;86-YPNK=;W]Z4NM?;G][^.KX(V6Q]25NX3=]%.&6\WS#:GV=`O^+M\5ZZQL MR+H]NYNW9SY5VV+-A1U+CV.8.A`%D<,(13@@OA>VI6,O]>,`*G5AS11INW6P M?WC(=L\"$2>"P5$Q&"2K=CT-.2[9IYS>;,6\?-EMNF`W3I'G(B]P_[+=B;>0US^:[N'IXW.7WXDSMI_QCN:X>M&M%!^SYOKNR_9MQ5C8>@X,7)QF*8.0HGK MAI2Z.'!8)(8L5X_YKJ@VGYMLU\@A=`Z5*@AX'9`T#?XH=WFV;9=$?LV*L@8? MMCR.O/Y)#`YE0S@_WU6[G\6U\Z`^1'0%;O.O15EV(X+\H6O5BVMFJ7HYBB^] MOM60?Q(-:,,!+^(!74#@@PCIIRM`OJ_V8V#@&-D5X+&)?,VCFSA36*B?"VEE MSK=A(3EH5@NJY7R<=K);W/TC_K/XGG^X>?VQY,K^R8$L_K8]ERBK[]-M]?YU%:063I,$O59-MP7M@%+J5'C`T;93^],?V M!FC..[RY$!AARA@*:))@2B*/>=A'E'J1Y_E!ZA"T>LIWMY7L`/QTNE10<1K" M!.-%BNWE">M2KDV\S$I4:_<:'?RY;0.:H45KK"8N)(;I:WLA*6.&P*NY/S2# M:8;Q]M=3VR:N_V_/07GWS)M)I.X:P(?\A[PHR40(33,*(A1=B+_<0[=GA(Q(P!7[I`RTR7'TTP M"'1YM\Q#%AS$]] M=I`:LH#U@[))N9EO_'>BQZ!'?!ZS=D:W\A])G5@@G6 M;ZA5Q\+6;S@X=B$FU$A7CSV0^A;HIUEU=/R[]+:C1\!=3_X_+OL MR_!CX7`J4V:9?U>K,FOS[R2$#)&`EXB9PSS^6Y<.,IB?));@)UW^!!A3F7O_ M$5AF8>)=MI9^++ZHAS=RXEW-1OE-;>)L:]$>N[[K"B7EY@TIY+9N=MFZ66&" M2.32V($>HJ$30NBE)*5!2*"#PS"2W6MEN%B+FZX&I6(XYLTAF[\&E9-ONE(S M\=+N*TO5L9!OVEIXK_=C6;51^IOFS#@"9!4E#@L<@E",4T0<+V`8]H5`&""E MHP'5GFQYI%H,D1:M&L61:$5_Y(AFSQHU7@E77HPE`](TN^)VW[3'`S65N->" MOZ(3L^J%/1=(I&?C0CBC*;XR\299F/OZU+:)^<]Y5[W.6=[]>J"7$U"6AM1S M>7LD\%B*4@?WRA"B@=(Y[Q/(L4RCKMV_?M%`*/KO<-O-Z93=G$YS:4YGMLHR M-[$V83U9G':;KUDWWN.1\W.&*G`A4)XR8HVY/:-FC\;_<5CVEVHKABN&,:GK M\F00?U?4_*_87ASHUND_=%/#!%,_2!P8!DG(')<%$![TIDCIDJ+91%I.%=V8 MG]B(]O)\I:)\RKO)D7:7VCNS@,:SB?VZ'Y=C%E7MQC//R81(']Z++8KB(H*3 MQ=Q=E*`+$W1Q+G#1R-@JTTADD[TE"T]OT_D@F?0FKA@C/:&;?+W-ZKH]8T>< M4W>"*+BL($1D#.6M^22'.2L&&B9P@GJ].=U3N0/\!)+FR7%OUSWUJ'>8Y3JO02YN(DTM0M(LC@N"61&G M)68,,`2R`2D`L9--#X_P/`?S2UP(]=F8KA)6B[:CSU3558KJ\C+ISY>CTFTE MJ^R4MRX1^/0T!P/:&2G/C3%3+NH)^A$JPXS#0C2Q/^=YADJ"LP$JI#E%JWWU M59Y"_#Q7,LH,II+B%9WB/?-H_O3#4S%<+`MEV"7FR#]Y[`;+9IY,FC[`C-.+ M[>,MUV37&P*?\V:AP&E^R45SS%B5AXLDQR4L&08Y@1F#")`>6)XE.'6547*# MQG,FZ9]%7TPDRFW3_@2"Y-AAYT5?]*AV6_0%"B9HS$L$$4P0+W+$P&`[@05R MI2?*!F=)/M=NCK#^M&5)5!OA)QC<^CZ9E"71(TQYB+Y@]JP*LN(3(04K4I#C M-"MSQD>31&C-]#9V/`](]L(@U%PX6K&HM@"&$ MGKE@/A`9<^)*[;YC:HI6N3[(NNK'C]7AT[>F(YV?7Y/5ZI@`,814I+``"4U@ M]_Q:20L@F(U8)+[(QUK2S[C M^"I#$U)DSVH@0N3`D=IUA],4(;X[;II(_>%0?;B5&M@(8)O@^;-J"PVP^G@Z MMDB^K(_5]N/ZL3U",EXV$0(F`@F04Q+S#),,T+)#17B6IU1QG'E&X6\PGH$/ ME_T'Z%&//6K!WW0C];<6?S0XL-R-,3O")\;V3"T9B`#,Y6V]R'#Q)27T$M59 MX4B&L4`-``$1Q2D@)60#+%X"K8M@OK%XCHT^G1H0O[78GHB*9GSDO44HB7WTYO=LW$\F#M/>/_?J^/ISD M@1B)5[XGO@()$Q2F`I`X)JD@D#)YF)R5B#(.`3`X/6)O=)ZS(!)G=`8JS[V- M4*,!Z]Q"\!9W4T/=&>^A#&9W#ET/5\=4O3D@OV_O=JL_UH^RV=_7I^KX1W7_ MI3ITOZZ@H""-@>`P2Q)2IJS$O*W]EJ1QGA&E#)*=!<\14H,KDL"B%EGT5X?J MO\8?%",E2Q:GXY_Y"-2+:L+@;EMOVK'2SFH!9/OKX\@?(W[OC*H&``<1RE-`B9R#F92$&R+@`0F=IO"1.SY/");++ MXA>#<_VSW6?WY*KN>3[])OKR&+WVK;^DHZH2&0+GJL_`_R3=0F^J,VU%/Q65 M_5$\$<2'T+"!A/]!4'%=U3D$3"YFNO?K^XK7]^O=?@4(S(!\Z)U24K`XPM$N&]4>9U1P,]\::NP`=5! M2ZF)/TIZ:$R4^FF<^^]W]6-5M5LO'[Y+M>W7"P42!12B+(I,I'$#H.,YK!$T=Q[$F M-1!-OVH7E\=WQ^%!MXQ7%.&_B+``RQ'E1XI@WJ#H4"8U% MH74LQZUISZK4;N>>X=Y$(^`GF[P=YJ@#O<#NKCJA;VSU>FB90$:K+^]>V`3V M1N)<&Q'DOMVN3LL2T3*G@J:\9%DN<0W@<%%J/0(T#Z(Y$SWG8GE1]61S8?-T MUC_E]V^EXQ?Y]U%4&W86?8+/+2IFYT![;VBSI,@,E&:[/O; M--!LW4!FB9F==KL18$2YSD.O\O.-P?[Y6;+?EH=#?6#UX5!MVJS1>+X<$H$@ M!`S)RHPE0`3$>7OTD*`<`5JH*HQ+FQZ%9(09]3BC]7X;M4BC"ZC+7?;0(7)* M$WRT1RA#WXMOSQ]P]46@^NNMFV_5]D'6@7YF>;_]>-C5AZYNW;G`CUR;]H]4 M?I;WGE=9ENM.'!LS$OE:!UHZ]F M>5G_Z\*3Z*_6%]UTUQR-J:;5@;6CGH+/U(1^7O2U)GY"\6=LU4#F@3D]OGX* M>&ZRU;=&%?$<+P#1QXL_]/]QO^V"U/9L"J(<<40(+IIP51#$DHR,\QLG6K/( M(@!]IQO.J-N725Z*)PU.(B[3EHJ[NZ$WH^;"P+H%_6P1>V!Y:G=YR48-9%99 MEH/K/>WE&T0][7!&(^K#%?+^/!#CN*19PD#&(>"XF?L@'TS'"#&M1+4#>PO/ M"\9G#EU0K9C8F9EEM[*]V.'#MUF;2MXXY#P0577JTG6JQCE=7J/MWW?[ZEWS MXW%5I'DN;S4E*[TT63#P]LNTX<-9OQ4"T?"9G'83"IA0KZW]7$_'38&_<$(A1 MS(LTXRDN3`OM5'V"C<3@]26S4"& MG[4;M=M.IE,#XS\>JFI?G=9W__*],=<,UO[T)*)9T7R?"PA*@2$5">"#K0QB MI02CE0'/`4X+*ZI.40,LZI$9E7`P)G!:<&;C3D]MEJ=-H_#%'/29U;TPI%&M M^L4K;K^@PTY8"J'VA;4/M<-NHR._9/,_#[M#M3WLOGX;#1$!RYBPDI.L3"F& M"43E8*B,2Z*LO49?]YV!ZS%%'2@C\3!C34%PO1.F>SAJ*:XT5-8[9V82J\^= MFKJ^Y.YKTFI%30BZ:N=`[:J7:%\#_%'M'ZKS:3#*!"1)B3@E."\AQ@"(P4Y: MY*7>#4#-CWO6TP&/]ET_78[4%LA>Z=%3SP'*+`"DYAK283>IWT+1(C9Z9',+1!/:)B2!S.^0A$'0_37TF!#@MIZ[-V^&6'R.G%O M(^$BC7F6(,Y1@1@2*(.##0!YK+P4T_VP9U$8X`RJH+.BT.9(8>'EDQ[=?/J, MS&@LLWPR9+;"4F=*;65UY>%KBRI3(D)83QECKQWT!,T`Z??=IMH?J^,@MQC# M/"U31$E>%K1$*`9L,%,(II25,OVV9S4B> M:#9=-"DSHY=5<4J*639EH12*0NI$F9Q`1KL^[E=2)9J.JS_=_KTZK.6%V_+O M[ZV>C#F9'*`8"Q0+)&#"4`X@249!`4BKO(FY%<\*,`*+JAZ9I@I8\*1:C'EY[IG?]!*"F*%ESJB9- M<]*I)U"73#[%-BC6S"KU!E436N6*Y$`4RYD[M9^^:!H^=>04 M@`3#E)2_:S&9!DPZC&F&2I[(,@V2 M^N/;OTA`$Q7M_(9'9TY4`B,#!@,1&"L77@N&C.E0%I+W];Y^:JU7KC'^PJ*0 M3R(F))>5+T6<"9"->^0<:)6#L+?F.11J`/Y67Z_-;J)]-5%&T!>O:N(S+Z5Z M4G2);52C'MZORRW=WJ1L0JGOC(Y/MS[;G+E4=]^E8=^BC)1+N,^%-3*]_4Z>G3 M&4VO3C?1^RFV/%UM>T;)A/[8$!B(XEBY\.PZFRT=&JK2#;%A94<2E`)YLQ2Q M3,"8-29',SA&?'A-7553]+ZN-"B>/IMNJ"C56XD+-VRIZH<'FNS.\BR3V+DB M8E(QS"@+1BT,X3]3"AL:U-/*Z]W^*!=LU?'#OOQ;QCX/N^,WJ5`?;N4K!"M> MH)RF&!)1,$(HYQD:@QXNJ%95)'MKOD^_M-BB>A\]12<+>DI\N M9.\]A_$VFY:Y"Z=$.LQ9A)*H,$E0*',:B#PY<$0U(:%)C6;!&"F$W2,1LL+\ M0V.\S^_6^R.M;NM#U?V_S^N_J^,?NWU]V)T>AW"%[+=/OU+^ST/SSW]4IV_U M]KSZ.:X*FB:E7.U`0'F6$I@F^>`";>(<'8$+";=GR>Q'^)?6GSYG$IVD1]H+ MGG`XTRHX%`9DGPNUBUVPX>V@P=7H[.O0!SH/HLZ%Z,*'FV$Z:)FXD1'M8=W( MX&Z_/CQV%L;+FWIASF108]O"C1?'H2TMZFOHZG1Q[`"!9H4.&4@19CDA"4CS\89\ M"8566*GW9<^!7P/FS8-$?A9UERQ,+>2,V`ID#!B"OUZP65"@7M7Y^KF^87Z/$8J-AH.O&& MTIA08BPS7#[&6VU7%#&>0B*W<),DHSE"YSWA0:2J3+9J!:I.W&&VID1HNR'OUG)2M-5EORHSJL MOU;O'V3%R0^WK>GCAX?3\;3>;QL\8_A%L@0QF/$<`8(33F*4TO&P"2WF.-.K#RV$T'-[K`.\K? MKL[.M):0P1WCS)9_8P9Q90%>8F5-,I\8%(I5N?:H\] M55,4QSB[8UXDORF*$XSD&>()PD#%,*"YB(3#"LFG&SLN%O M!)X?1&W"EU8'6V3+I<^F>)H8;T[H#62JGW46)Q!C$)0*4`$@R`I*8-:.]1\(H1E"K1(][\W,$(K?M M`&Q/]Y^O;ZU'K+HWWSRT@9KB+4R_G@[*S>F6_0%N].4Q^D4BCG;[7Z,1='1& MO6#5'VUFIP]G^FJF0/34IX?/CWGZ)5-9>R\>EO]<_UE)JG9WU9-CJ)]K7:RL M8"7+\E@T\T*&14&*G/98>9D*K<3:(@`]Z_>%3]&IC@Z#5_+&\G@CKV[_M)%B M\_U";%[2^G_5%/ME&EUM.@B^O?4FC*NF'AV299>>EJN4__S33"T^6FEB\EFT M4P0R/2W+01W0*-6=XN[KPVGW?^T%O@^W8K=?-V#W7UE]/!U7.$T82E@>IRBA MA&68,S'8C/,4:$U5-H9\3SD7V.0:OFFQ'U7S-U_DK%.?&BV1=?2:#]]'=_5: M_I?;ZB#59B/1Z\XO5HPKSA-SD:VI]U<\C\`B-DVD'YF>(&E*;EUP&XIL.O'E M6O[<$:3VDB;[UG2R:K>_7>\./]9W#U5]NQ[>`._>\>R>`E^!.$.PX)1F(DEB M4O""IKUQP=)2_8E-9Q9]YT):G$V(%$FD40M5#KSU^&+]\&)O"U?G`4IWI$]+ MVG)\:V[#_`Q4:SP"N@CE9J^#.J->[?%0569>F$/\,!O"0ZU`F97-GT? MEKJ`>1,]B?#:9V\&J&_44O9+NUK4O`3C>I.,([*]A-.*[$U$UJ[Y#R3(=NY6 M[;?;&I2XE2F-#_M/Z[OJP^UE'9^R%+A`6=-C(,P!CF&*,:5I7")8IHSG0U'L MSWHU;DW-*0W,IU6R/^LKHD0XI"WEP9P&IHQ&+H#JOJ-FP[":]'EGU>S]-`LF MO14,?H6F"5US06X@6N;$E1?*`[NA1_V]-/DD1I>-71&>,\;BF$-!2%X0WHCB M((LH3ZE>X7Z=+QO(D9X2_7NU;==%U>UM)3/*U;XZMM6W99VVW==]5/V]Z=9. M;9'"]49;FK2(5),BYPR:/9O6/IKR;HF*4!<$3(B*"4V!B(@1].LWT8S=5S_1 MV!>RJ+:LOI>EUKJL"2RS&!`&($E9BA`J<5(.UK*$"9TUGJ$)STNZ]@#I;U\D M+'ET>\1E^/:'*8]J^L^ZIHFJ[)')$CI@/1 M*W?^/,L*.25*I\;RH6H$DU?=[Q>G6MCZ^^ZTOAN/M%#0K.G*HH0X3^3-/-8L M]08$L!!:D91#L[/LR1[E=M7Z>*Q.W6"\VZV_[.Z,#BRZ9%Q-[A8B6T_X!I#1 M+P/,7R7GYZ."/=3ES@FJTS@AB![:(A!I].'9\UK:?LBSD$NRV=0/^]/QSVI3 M[7ZLO]Q5*X!CS$LD[3`$&*%I3%K;$*3-6I<9I-&=V)TGGWX&U-_HN=MMY#*T M#V/:YVVM)=.$=5.Q],6T2YD<,$9GD(NKXW/>M'31@O9@%='&IS>UT)HP"Q7\ M>*B^KW?;(8H=G@K?;]O$'VD#IQ4#"8!%BD7!,IS`F.:<]6A046#D1!>=()E' M*7NH%Z]^;QX:S/M3'VE:JZ2;5C'5S?E:PJ62#HW2PVT;I]M=(&\TRDRRJD*K MEM`Z;:=@I=>MEV^*L0=2+>3YO;P5<9X76"\;K?*"(TYPU\3/, M!^L9X`M8M['`6C9@P;9SB]L>HTN]D2?'$=.HP0\R7R]'*:-NP' M*X)V7KV=R[0GS4$>\^/Z40KPY\-Z6ZW*G*`")1P02!''2&`.1^N\T"I^X,9'VO0/E+%.IQZMMKM(;I6ZSE3W,FZ@%NKCNO<2>4<[2B/Y@=<_.*^6\ MI05I=KHGUX*_GS=T5Q!@2A*3NBC==L3.E/62I,_9)1>CL"+.7N8OC1;W< MK@J*69Y@C#C+"PX$8&B(,#$FB7V,9VC7L^B],DZ?'+O[Z"X&-"7?4A,]\^Y$ M&O4HGU<;G_-G(I$6K1"Z4MJXIBJ8UO39Y@7?-R1U"2I*B@$& M,1/#[@TN@"@MST.:&_:LG%W2ZJ[>?_VMJ['E,&RTH=LJ5>B?:8<)PS/8H.+) MUXG43Q[:M4>PJNG"-[5$H@L"/50]7S76*>8TR46.<$(0*,40\6((<[(ZU:?U MG9IJ.C2KI9DC0N7A_%ZU_*VW4N=O$Z^FGPMQKJ>>!J7-@ZUG/J&='MHB$.7T MX9EQW7)-\FQ5LRNH\$I968%0R@M",AYG*:OQ6Q M&Z`Z%U"K-K`2TKGH=RJH(^@@"GKK,ZNOL2Z:*6RM=>*AFN:Z(U.M`NW'II=_ M:T+E^O9I.4*6F_B,PI`$/.`DAHG?'_M$D!"LG\"1\SS M'!@<2.65I,JT,Q:221DWJ[3;AS5'[]<2M]6<7QS:7N&`8T*YBR@E0>1Q%@:' M>3)C$5.[3S*Z.8VAJI]/C;P_,I[;8;/.:4C5R[1ZS=N5H`/WZK+(3$IWB:T! M$C>:Z(5IVWA[+HB:(:+TU4S(Z%-6[9X_BUZYP\4F$5]]DC^R"B$*W(#B(/+# M&*$@"+C3(2`.=956W0PV:WNV>&8\]F!O0`/WIKD>>T`\5O-&>$!3_:8A?[P. MZO(^C2I>9%%%'\>[8JE*:<"RMS33%'D6]BY6'O61Y_DB'>6!FQ"/X*B?2U(4 MT=C`CJ].LU/M^.[;1?)I-RO>)MWT)H51OJUO3BQV1\+(3L1@7RQ$,6U8IKWS MH$C>\'SS9,9^^U!6NZ]9]2)722^U6 M;&>3IVM8H('6'A^4X%031WTJ!^:)D["HF!;J$6@G`[S$S[6$;S2G"U$K`X:\ M3.<,43,V>SL\_GEF']:'L<\(0I[KHB1F,'!YV",)7.H9.'DRIOF)3Y[<'9[" M-9W,C?+!J*1N*OJ-)G?'-XD7?/+D"K/J^9X)-RU$26U:."S_,T>FSA[HE^RI MVT'X=$>/CYA_KKJJ8BKI8>F&[>LNT>0 MK5EQUE8UUQ\E!O/E]D_X`4-X/DVH`?Q.6PGVJQK%B*Q M]NR[O#=M@TBM:?9)XTTV'8110D.'0A1QW^%NDF#4-QD'3'NBK=K.I%/MW4,& M\KK>BSAW7D1O0#'YZ[-7V!LXA=3E?"GCTH0I5Z:1X^A13F8^W$CO-(A.2_8/@K3@Y/#:"'3'\;:6^#2S%"U. MU1(2:V2.RST$C1(7Z($!>IU&JTG&&8X&Y!-CF%V*1)DPY4*6,)X>U9/^?4JR M6:?;;?DDSR_7(NZ5=[OTKU45L\2QK72Z8C.WQ=PVHY/I3"U&> MIA%SC[V()C(C?A*9;['+TRW8Y-M]\USJ_DG\LV[RIEI^+O[`^B17;@]X'AV6 MU3^;N[UPC=0ST<:&2Y9UM\&,2>>O.ABD:W"B+.;$A]#7S+KZ2C:^"'NA[Z#( M\WG@$$(1/:PR>C#@&E<=M-O2R).U'HAZ.DGTVA.^>I6V]$D=EB;;)5(KJ&B1 M9R4_OD3.E>1X-)\+R8S'VU$:[FCZT_9<[H<4FWI%8@?%"#%(&2<,.YBP_I@U M99&O^!B(3@O6I^G-/N*FQP/D`RWZ<_/AQ"G/R(Q@V\U;F M;R&Z,LJ$RS-M33HLG"99T0B%/J(413XA.*$N<7L$C'MA9.`LL$ZS4YT%/JG^ M]+E#)$;9MWYX9+$G1HR<%!GLBX4HH@W+M$^&*)(W6#]E M\[C8R/_)>QO?TZT4[L]9E9>;E]7]5BQQ8MX<2\'00TX4^!'I,7@)9"H*:K3A M"30T[S#][&0AFI`W^[2:C=&457;51G'+R&J#^F7J@G2'?B6W>=%(3,C MN=@MU\N;9A8QHE^PJ3R4=;VQZ#&L;=2@P3N.,L.C%N(@=B&"U(&>3[@?QH<; MK2S!B'6C-BD&+E69:55]S/8`S8S83#XB?O>?/$Z'>N!=C=/!1FF-4S7*!H_3 MV_W3TS9K]F:W$@'?EG_^6MR5U6.S5WLX0<]8P&'$.8H=1!-9:CQ)^N9IXD.5 M\Y:FVK1\M.(49CM.Y:TA,4LY(%6MA\9`Z:U:8B/S#<2*+$"$Y`SG?_ M9R![5Z30-/\+$4/C9I5VNZWZNS''%VKRS>_9;H7E,S3,XXD7^)0[(>=Q=XL< MNC`)0L77853_O&69:\:=W#]K[HGD[0M.S:$8]2=@E)D;IF2625,3K1=O7.6; M&_#[Y(?N7S-R18A&T+<0S1ECP>LW5L:1H:`D8C1F]4XVLPH2Y@:$>P1BAAT& M'13@OHTDB!2?YE/XPQ.K1XM,63E4F!JJ&99(4E6+%D:C%).+Q)&"J_*@P=1B MA$$'^RM)T"9@L!@T#SG=YO=%?I>OTV(GWW020^=KE1:UW"HNBV::U]RRJ_-- M\W!)6?R2?\\*N(*A0,5#%`0ACB.4D`3Z/28Q(U0JV&`5B&6Q:9],.P$/.O3@ M!/X-:`SH[L<=30"-#8K*9-=MPY1L,1Y34SZKSK*BEV.(OJ*OD_AO(7H\C:WE M#`-$4>]_RPO98)5M\AU/U_+1OF=:/C[F.SFSY5F&'\M]L5L11D*$/)1`!R(O M\GG@'9J'R"$JTFZJ3!^FS7-0KB;# MIMBVHK@#Z;LBKJ8=L!`=-6Y6:;??:NP.RG6]3JF/I1N+S9G#6BROU]NRWE?9 M8?$OI@YT(I=0B/P(!1&/Y6L(+:X8R:='A\NF=3!3[E-L#O#J]BF#XF.[=3'^ M8*I]IPW3W$7Y2TV,#WL<-X=D^%C25FX'GZV!=C1AONV0L:2_L64\B3\7HNW3 MV7MFHWE"H@='@^3Q:5L^9]F7;-M%H2U42VQ_:Q:L&!$W0B[6WQ M32R?;_)U11_-<;T0`31H4&FK6VKO]327/?O6>((9AB0133$8P##T/=*WYG." M]'9]E)JP+%:_CMWQ4>-+=>_'&E7:NT`-HKEDZ#PQ@_:&M)A+B?M$( M4@9+R^'.YXOF$AJ',?(3B&G(DC!@4>!US6$/,:53*;IM6!:7'A9XTJHIHE M6YX=DZ?0]2AES`F=A%'*,2(H7(E"FK#EW*L042:H9U)D&B>/'<1#X)`C#.,&4>,CM&T38#U2J/>BWHB1+ MZJ4=OLI?F2?.*XV@\00N9/`8,.1\8!]-S?`KB.N';+/?9I_NOF3?LV*?D>=_ MI/]35G1?[\I'$1K)\Y?LJ:SD5M5M=M^^EBLG0U^SOW9DVSQ`X7&/.XS[L1-` MS!.1;#`4L!#&F#EQHK0_-`$&)1@+ MTJ+7]ZRG)IL MA1OIW^KL7WO18/*]:?70H.\@@AT_1"'"G/E)Y"5>TV#D.QX-E7;3]%NQ?IJK M!P9:9&+4#QGOIKDDH]W9?6Q%K:`^F",=HYJRUFJ&>H" M_*2?G^+7KCGB!S\:L*3<5(_T09FI97\N1;,JK\6WF/BTN&]K)WY- M_UJ)6!62)$"!BV),_(3X(>NAR@^5]RHFQFI@A?V4!?M69Q/F!W-`5U'E@P3_TPTX\7QG&9"F==^7[C^)0IV! MH+6PJV![(ZNSS+&98]9-;^T`S=0I%A*D9J7@W%[3K.XP&,J.&)D`\UV$V>\7 M0;HN92P,DY`3'#@A2F+7[4&ZOJ,TNYD6V9SAZUA,4*0[][8BEE$_FHI5<[G0 M9I1Z$9U.#'M/X4G!,Z,"DXT>\&Y"DA7CE8.1/1HO+1B%, M>-:A;*+V]@A5>_G8K!-4%XUGXU]_J;@[6]E@;I;UVR^;KN"^-P`GWB!3B."8N9"`(PADU[ M&&+QK[/ZGE7?RL'W[W2;41G=IX@&#W)Z\FQZ\YSM#?@L$L1U_I1N`4G%SZXS M\&F_JW=BU(O$<>J+9A>(NS)J1W.]D'$YWHZ7=\W,$#.\"-2AWI0A:9VN/!+[K)`$A`>>$^0Z/(C=N!WC,/(\,/3QHME%[P?4$9_M8VRG2950$ M4F'RRGBTXY&%#%)+QKTL[&.10K/#^1BP(133*"_A)/`)IBC&@8]Z%#`(E&H: M&V[:\I3EZM!6K<1)ZK=!/&'@K+"ON[R&`KV5W5GUZW1?LP85T&XVH:*U]S_F%O['AN$.Q* MT$('I]AO0(=^ON15F^@K^FO?>0N1X@D,??VP^R34VA/H541A"$,>NMQ'"7-I M[`W%\CZLM&)EOW_I*4J<1^UJ,>Z$+XI,G`0P4[6/P\EM/604VG3+4#VFE M6N_)@E,LR;91;TPFUTO7:)/:/-A#[U63AQLX5HL5J1RLP?_,\OL'J?5"CM+[ M3"1]W[+JT]VM5([Z9$GZ$`NXCWG(&70=+W)9XKJ^[_8X$A]1-0DVWKQU!699 M43[FQ?7$V,I05N7JRDBV1OM"!K(]^\J)^J^E84S2.E^O$B^A(868(\()<[$# MH[`'$42!XKZ;V;:M#^#F!!'XLP/],6U1M[E2_59F]4W:T/XL^)"+$-_\UD\+ M58*&<0,RH.:Y=Z8!BL9I"H`.A3EX>5!S M?H=TR59/DXMVNRK_M=^T"UFNP)[:LH(.BA,>!P!7`@/FN[QXV M$CSLQVI/N5B'8SM:;#;YKBWQW,K!.M^O]MJT-4MX= MUO63S[?#9I^S^7%80%F8"]7"QPGXPX)_Z\53_'(MH5G"E;$3700&$$A MKQ?8#@YCO&0P,DSDH`G#`OW!H=*FDS(M2XP)EUTP-B`8<.Y[B@8FS-4)!<9H M-AP'TNWVTY/,>^4)TG^F,CZ)T(2PX\0XAC0*(N3X"7&"Z#"SB6.E@YDV<5C6 M_W$:(TP"G4W->>[>*BN10M./)J.$?1=.&2'4O3=C=#A+_>C(,,ZA[RHJC#15 M*R*8H%>C9H.,/B_N(X M$W5M`=\$OPM10#.V7*Q\,)J@-S7L:;/-5[=9)9)EX66WN=G_\GD'BMV0810X M<<@C%D80H;Y%-W8'+5H8:&9*_1(!XUF6:?N>;O>MA.V+]%$^@B'+O&WR>BWO MP[<52*5-0!K5ED48*&@F>+\N9Q-3KB]F[X3M3;ENZB$T.QE+8?T'4,./#Z;? M]MNT:JCM[KT*/[2!N=V^D>Z0[PWO\KM\W?SQ&R`&U6-]`^ZR="=^0WRT+K?; M5'Q5S`&J[%_[O,W+VI2^+<&4%W=E]=CN_139.JMK6?5?S`I2<)?F%7@2?Z=' M_S/X^B`^`_)88K,,F)XLZ(+=0RIZ0)7?YX7([9[[!C?B@Z=N[T'TF$S^7`%V M?V9;,>,0R>'N0<"YVTDH=;UO:I24%;BO,HF[^^$'F9,(E%M0/LG;@M+V]?.Z M[9SRNY*&W?,-R._`MA2(JI\'!UK9'9KPZ<2>TP3/MSO(F=!IL%?-'#A-6E(: M'W)*0?,0I5^4AY,E?:^!H0EWG.2).`(N\X!C./X@Q:`["*8,-3F'7*0 MM=#'J[PUMPP)MTOPB'XD?D?.4(G&2W"*7J`VZ)R!@4F3JXLQRS;WBPAGUHTL MI^S.*D'P'^FS[$3GFHOEAKOG^0ZC'@\\3X;?OCF(X:!S4F/;6.:<41@DAVR@ MKJ=CZ!X0OB9B>I*IXCPD*X2EB$#"@T&;1!:;GW,^*.1AA)9;XJ>!$GC`X M#URD$\Q,`2=RAH7YGXI31L_^U..17,3+4`5][UR7B3BXN, M[B03[Q/QLN#9MVHO4CH!,3J[,NNY/F,>12Y#B/JNA^/XL#(;N(,>KI@#US)G MEKU54A.B5A.4C@G,[VZ%R+I`3T\RLWW_3M:(W`MT]OB0/J'3U1(`,VR_E1E, M[-,EI0Q3FWXNEYB%?M4DH\]ZNZ17Y+QOX1$)CQM&U.<)"5T6.K&/HQZ/[Y%! M]>2M@YA[1FTSAEAPF5)6,*^W#,^ZWYFCM"+[O`ZS-#.?.F`KD_AV=+;GEV6% M8HMVGH^[MHD=7G2MK]K*R^HVW6;'FW._5&5=?WGQ3.SOV6X5Q=3W$2(^#UU( M*&[YU(.)H/>9OG-LW\82+N[>;]J&=4% M^61,S%I^+S(1X6Y.IQ=O.WRZ.&:%?M6H-V\?6'*,G)F9(1%U"SV:`$&EHDR6(,P2%W^4M6\70J/62P:V/&4K5!EWDEK8 MT2)^(6'FC><4+/OBW75;\6RN)X?O'JO*XR@Y!PIX,G*R!\2 M*6B@&DWV%#@WD-S9H=O"&L(@MJ?/\`[\Z69TZ@Y8B/:9MDHE8],E;;`J]@U] M*FA:/_!M^:<49@$E:^JV"E1%UFZ`(L=G7B*F[3A).`UX&/NX!Y!@[*H(H[E6 M)SCXT8_,L@#_U]ZU[;:M8]%?T6,'<`'=*(F/I"1V"K1-T!;G/!0#0[65U#BN MU+&5GG:^?DC*LN4D=D2)-R?GI1?GHK4O7&MODB(96H?!Y0TQ&\5'@&<.A2Q( MD1(#,(PES?A>C"BENET)5P[VXAFZE!\)2QA3@6&UZB0>74T>H!P^8P\.T\2# M44Q(ZN<)RCV2(7\_TQE@H0YW^M,LF$;\6"[JVXKOR:(?MO/'H^O)T5X7+25U M.'QL%7GL7TJ4_2_IY\0GG3:H=)SJ<$LX4*)!)PM&.:X2X+ROS6%T=V\D?RR: M=AEH>5W2A*V:XK:<^QYQ*>.B)`$>#-,H2E'+NLA%O@]2L6O:)3Y89%B.NJ.= MG]%]`#MS.K@.PSMK=Q$LG0-D[8-TJ"_/CE;I`;%FV,JW[,'X5>2\D0,Y/1S; M?[A2YR.;E?/F+O1<'++;G'.`(2)I',(.`$C\?,HXGO)<_<.XAW;6O^R*`S8Z MAL_XP%,/.#F!YKALY?M^S8]=6S>^,DL<<^TF.LCP),T(;'^BZ M*`N[)X8P(6)=Q^C'*&XW>CYOW[&;.1T\A^%S7K$_12\0G.+6H6V%%H^*]A/W MJ.[(E4:IK>^AP5PVRJU6DM1'TOG1DVHYQIR4`9 MA[V6D$VC;PD[7%V26 M?8TQ'E9GV!E>L;+D061W=\X_'=G[E],/BZSBN](F!N(,C>L/MB4:8,#PDU>V MZ77]66>LP0!TCXRC82>PRWB.ZBJ907O= M%KQO*[:ZP%;J.8M\:1$*E[Q3G#JPB-7D3\&RE*$ZIO&!?E1#Q*>==(Y/);C6 M%EJ486&UA>8U6BQ: MZ\IVMGK1R/][MVI^]W9J7K%;N3Y_*ZJK'_QM+%)O;LH5O\[KSW)U^ZTIEXCV MP<5M^8;^\H:M'I%BM>&+&W,O)'D4$A`2/Z,&>E'@NJUUT,VR84+;]]AUC M?R@;MI#1B[_(U0,JHG9>K8U&:N0FO!8L>S6JQ70X69Q?+,`A.@QR]_4=:-.1 M$+C[P7!$QEWY,#XRDV\#%O?7([6`:L_;<*F#2O-J/0FLJ_7_<,>FL7<;%K;] M@]"YAL]]C'+?S5`(_)ADV,U];R_;B!`R_\$UXU-3;!K%+?U4J"+<<-\JL7YH MZZ`C2N#X9@XNUOQF\:_E[:JJF.!2$6V?Y+RB=-+^K.@V=7.A5]PBZXRW]J:W M-6Z_'>31C+F4]O6)0*EH2&7EQJ6WF-+\(*MIE!L8]?JW:V6O[IIM4U1+2LJM M!7.8^5F$4D11HB`@7IZ%>0<40"_5*'RC,>I1/-X9[J?I[A/;0?:*QA;E&Q]T MQ9*G)=+:M6Z?&SV[ND2Y%(T[%1D5XC8Y"RY=U:8[0):<20J%01W+PLC+PBS( M/.!Z*21^DJ(.:)0GT4['\FII2L6>0BBN8ITQ2C2LK):BZO4/E8T.^K.ELL$. M4$YE8J$P067W5I?R7^5FL=J6UYO5HIP3@(E'$I3&*?1P&'L>V#.Q!Z+<:*$^ M";F)\OW!PGH'V>&8!U7S6;U>%YLM^ZCE1H.%_;34T5[N:\L72YJ`)]+MI$66+8K)-J2`'C`"`<`3^&"0@PQ'OX2>H;[$4FX=;? MH8C(],.&142@_R%:+:GSPHAVL%L,$:U8V"S8H?^!G3VTI>;LFKK03V,21!E* M2`)8=Q>GZ7Z=!0108UE"KXH=[1AC78Y8Z&PBV:=?#DZ]%*S#;JYSCT<.LTR.)%Y\@R%U\OC,Q0LW_&A-0M-MU^&4L_6UJPW M0?K"S@,9G@AFJPYY>?IR"A*)/M-?J\@.N`5ES'&O^[2!0>H2Y/DX0#%.7.Q# MY!ZVTU++;9S-G6Z5J>G>H45,?Q;8XFI%>K*9+EE,YIFM=475[X()H4% M<]/R$O?9%S+*'&=H=EMVZ"TH:03*->SF81XAZ*=Y#-G.8Q^"_7N.680MG!F? M;I3)2?,1LS+/:8/O"VI]AV;ALU<,%3ZSL?45"[CYL[\0`F$0XS3$*?!@#`@. MX0ZO%T+B:N/^J4!UO)_1;C8Z>^[7Q2]Y6GC0T]#07SJ)2O.#KH.>Q`)C05'\ M!V?Q_9Z6Q`U\+X-)$">Q%T1QXD&TQT]IVXYI/$'0BF?I]$VAM'8/V95G>1:9 MGI]3F$"V3K\-SQV[U% M_=L/,B\%Z;X\<7WBV2COTZUZMOH_L_%"(NDY:5>QH#<=+Z6:>'&+>8))84%9 M(B]Q7UC=(M%QA@H;V:'7,$E;[RQY8&GO^AU4+?-?/U8;_DNW\S2.PB`C6>YE M?A2'`W%AXHTLJNN&!%2)>L+"C/KTJL#I;Z1M@ZA/(##-7[QK5S>KP@D](-$2)]E/52U MMNYPLA70_&Y3LP52%C^'9G&S*1:-L`!*\_9`\3+A:$'AZ?GX`/*HA?WRF:]. M,[0.A_L?W8(QT(WGR%YV)&PA:NEVW2=9-8Z319!OJT\-[<78OZ]NR*HJJL6J M6%_7VQ6C[7V+=H")89)FD9_$:1!E>4+;-IAW,`,HE4>E8]-(MSRQ62G)2L4; M-@/UDV'=[JEX3\%L&BNE"EFO5VS#X7*_=>73M[*4S=#RPRV%R(U&6CK?LTU& MG3G\SM[.(*>SJ#]U;KT\B`9GO(HH2X/+$!MUYHMIDN(PR)*N_.:F7#17%9]] M9!W,IOQ&FQC^38OZ>_FNWF[YT.II+`)NCJ";N"ZBW4B21+%_T%B22Q0O!>@T MRA<%[93<`O:_Y8'G5L<\Q[[O2+SVF<.5KC65:^"9[SKRSNYGY,J>BE21(GR& MLT2V],V^A0FPF6(GTH'B,F?\E`,%L`W M=P5_A;J\^KI>W;83:>^+7ZOO=]_S7S_J[=VFG,,TP3AWPR1.8`)2[.$DX(]. M(H*#`(E(FHSG*1:ISW5#Z^@UNP'>^=%.26[YOG^F1,N[=K:Q4[#;SA[-O#+` MCV>80F84+!G[4DVJU27MP/'Y8[E>S=-B^XVLZ[__72YOR^W[DA\8AI,DR*+< MSV,_Q!&.W"Q,VP<%KN_A:,AH'/_;%8\]ALEAH)P6E?.EQ75&MF6Y[7RQI<=C M8L6206I_;'?1J?JLK=_H?Z_K#@_PC!((#=?E7Z=N94Y5\+J`I M?@GVYF8".JP]MSZ68J)SJBM_PT/;=MT?CT/[5)?>M?3L"SL;9PZU4G-)K2)0 M9VIPHWEA2=%NU@>U10-5LH*MB^UV=;,JEX3Z'"UH@72W9M.BE&;?5DU]&B\D M?HP(07F>9B%Q`<0Y[O"Z'I2J8LI`*E:R-\>$-P=1R-1(6,<%DPTZ.:CE MN*HW.OL)\X[^BW[8?43_8"\_T$_^#U!+`P04````"`!I@&1'CE'VO@.6```1 M7`<`%0`<`'!D;&DM,C`Q-3`Y,S!?<')E+GAM;%54"0`#EG(Z5I9R.E9U>`L` M`00E#@``!#D!``#L75ESXSB2?M^(_0_>FF>728(7.J9V`@?1XPA7V6-7S@1/G2`8H`I7+U2W>98B:^3'Q()$[^]6\/T^SHGI=5 M6N2?/M@?K0]'/!\5XS2_^?3AV]4QNB*GIQ_^]K___5]__9_CXW_CR[,C6HQF M4Y[71Z3D2_7XT*8OIT;^*\O?T/CD^7D@=S?^5I?GOO\C_ M7"<5/WJHTE^JT2V?)F?%**F;XF_K^NZ7DY/OW[]_?+@NLX]%>7/B6!8X64JM M?4/^==R^=BP?'=O.,;`_/E3C#T?"R+QJRE8HI'W]X%&KMDW]_/KMJ[#Q.\ZI.\A'_(+QQ=#3W1UED_))/CN3_OUV>OM!R-\X^ MCHKIB?SM!(U&Y8R/S]+D.LW2.N65*+Q1<5ORR:V)'CAOGY!960J>?$VNLUW0*BHE?R6YY5PQ*F(BE-^5E0J M2+NH&0YX=U;TT#J<63*ZCF<9/Y_@))/QM3J?*(IJ=80V',.Y3KGI=5>FP0B2 M5+ M5)%TBZB_*_'"%1_-RJ9S782PJUO.:Y(E595.TGF:KLX:@\6:=LP.#;VK+M,F M/#55\9;X:;W3-=BX:V&FG:`>)A15Z`!<3*?IHB'D8Q$V:S'8%H-NA2&=@JA9 M@&Q6STK^.R1DWE(`:]':IHJ*V=2MB3N1IK4D'Y$$;JMLNH M*>V02$35+V*LQ$?%K*SF`Z07_=Q%F8IH>Y=D7;M1727H-;K51O5&C"L<]*M)&X`Z*L)LF`-:MJD17)6=V12!;*9@YN*ZI-0J9` M=0T5'728@GS!2_E'2S?AGGE1BR**T@K)1R!0HEN:)&$8EV6E>U67C MFVKQ^QC52Y%S.1";E6+(=8.3*E7LA,R5:,H=9X+$&?B6%]<5+^]EHSS-[V:U M'(4*S%GZ;.EFM_KODF3]57_8;$8,IE:KV2@J@.@$7)TYM\ON]M]/AW/KX1[7LKMHU2 MQF`]J]U7+T0/H]LDO^%R7:%,1G5UGF^=!5V'4TF MHN&>3Z@8+]TW$)[U5Z?YYLG7^9J3ZJQS'P<=`.`!*F,;ZRFOQ,\2.:K:!1JI M1'6T/%3YQERE&.059#5`G)/D:_*P'=&*5_4"Z!B%MDOJA7=1%O>IW'4FJN;9 MX\Y@E?3HA?XR96T#B?AIB45&CIEH$]\JP;)O5S*HS.JB?&1\S$N9_R\$Y(Z[ MSA:;+-ZLH[[EY3P'_`\?BQW28EWP9MK8`),!W=IBIO!.JS!W)V9B1:'DTS&6V;WW>UH)/: M_1FVM;'UU6O"-+60M45,!S"YOB/Z+IXVTU_"$7F3B/RA22@$`#P3J1/??D)LBY@Y8!U=W$V+#MBR!N>YR59L M;U_5"Z"KK[9*ZH7W[)^=`:Z5U0M1+8*N%=`%IHT('8Y.;Y,S"&T7VJFK,0A\ MW?-^=JAI-6A6!Q)OE=8`\Z+D=TDZ;GN[Q8EXM9"I(FL88D=V[Z#*L`&;?NMO MD[IVPV:JL5Y=@Q:XQ1TOZT>Y%>&/67HGI]NW`UPO8PA29X8KJS`$>-6SW;%O MUV;(#%7&;I/4`.\?LZ2L>9D]+K=NT*1.E`\L*(J;!]J1RKMI,V_&EI^U&->I M#/,FJS6&3DHT@+ZJB]'O.&F6VJ=R9[G2%K3-4L9@H?&XV70B%SZ66]XN^4U2 MRDG7\UEY?B>?5-$#+T=II=7,&I=\5!=E-3\?M_RIEW>TEV_.51@12%X3^KN( M-#H:2N_BC#E"K4M4D=4!<79=\3]F(OF,[E6V.J][WP"4KB%?35P+T)9:3ZO; M:#0J9LU=!1=%EJK7L/]E\3B^2!Z;:"YO"92PDJQ"UU5S+J`%E4E7?/H@RH\5 MI&(4!9@YD(5N8$&"(]^Q/-^C@0T1=5%`7]J:R>OFB[+UJEEC%UU9M8#?HG]Y M'WA:C;)"'B+[*NH!"R"_;W#$CAICP"!$5NAA&+JN31B)W*!UDA_B4,E)S\F' MRM%148YY^>F#_>%(_#+?7'PVA[RFT8`Y'^LW020I1V\H_%)P\<;)77.[UO'H M-LV6:R'RLP,&^%+LP_7"SF6+/UG9Y/5'`[5+ZG_L*.$#8D74\RP'NC;T`L(\ M&V,`?1M#X$.TQRC13@I>\N:2[;=?/-A@\E;9V(N$B81X#O)MYMLH=.R@-3SP M?/P3M7QE#A1FG?RLC9ME5GN3T\(IV^FT6B!F$:+(QI&PC=J>'00NP*UY+L-^ M'PXY/P>'M'AV,.(L;TU79LX:B3@B,("^&]F(!#0*/!IZ8&$@`CX-^E`'_!S4 MT>/:P;BSR"8NRF+"JZI9UF9"R`R$%HV7YL&CI]".7]'(32 MZN&A(U0G+JTW$ELNA)[G8B\(8(0(!K[3&NDCUQLVP7XSU:6;1KJJ?'5HZNW? M0<;/W3_PI39X?KM`(I_$BB5N&"'OHB8.$(Y`P#"CP`]\AT2.X\\G+KP(.J$: MLR]0L(&^("2]?C`/7 MMFQ+-"6&0X1L&P06:TT275CT,T<`Y>HN-+JX8V98\=''F^+^9,Q32197_D-R MQ'W&$?$H;J[2F%]LBA[2:@5!5KP5>[Z+,;3"0(R41#[B6S:A"^CB6:1&^,-G M1]^**W1YT%#ES_'08IJD^9J:?_Y*;`=^Z%,*;40I!0YU?(I;T!3ZY)U4>Z_Z M*K3X;K!QX)+:5R.>)V5:K(D"&]^/*40NH+8=PM!S`X!=WW);XR+@J:TL_3B3 MXSWC@4Y?#D>4!<9O>77'1^DDY>.U@6.K3,Q\9%&`+199D>/+!H!;EX4VH^]E M@*&IIE_S1I-;AP\R8NS!3\4_E2+,\N78M1W+00&&HC5ASX?8MU!KEL.\7CLW M#G`!17=XV=610TY&*B7@:S^IBL:_S>8?*_W"Z_/)U^1A\S2F[M)B2H/`LH@# M8,"8Y3@1`$'KV##PP:`=X-V:O94_Y*!I_[5U:,V`S%\2STASIW!UF@O+?A7Q M7_XJOVGR\D+A^37/^AI&O_)C'"!L>PPR&]DA<.V0X:AUOH_@L*OA/V-3&;3^ M#JWQZ&L&2X=X@%%L.X12`AU,4.1%RZ0+$*M7[.^\*/\S$GK'FAAV\;Y'OX7Y MI)#7:FXBK;8RXA!B2AT?1Q'$*'2I"ST'8S=T7<]G%AIV2\`]+Z^+]S#WNZ_Z M.0B2/WU@HOK'+,G2R6.:WZ!JWKTH1.3>NF/'#4,Q?H(88#&V%B-A+R!M9(#8 M[C5A[1_."/)@*&VB5@Z"RCW9NC2=(=N!+`AQ@!WH$B]RG[HJ%-)>A`S^)*0N MQQ]:^GK`4R".X_J01,2U(4&4>LRC[&F%Q%<[@[:&T>%N:?#3Z=@[\:=`_MC, M#O_`%-]_Q1U:B_C!9T,L2(`-$?:<`#DN9)Y%G87SH1?8O79.PC];S>%6Y:&U M(P,3(RBPJ8-\83ND%G7%/T&[Y`VI%_7;0V3]2>XA:N5@MAFNN@#E1]PKR,(0 M$Y\1,>SQ01BXD/ANL\L3N=!%@=I95%-+_.U.SBYUHK+AN*?FV`_LP!$5Z`/+ ML8@/F!?BUFEAX/2:8CV@[0)F"?5F%\&0=6(^CLB^>7E,<)[R5CBYOUDPMJ'GAR1$ODC4/4Q%#^&"^>[P"(>$J76F0YK<[5(/ M91TQ83Z,`H)0Z`,"+,@LVVH=05W4:Z_9`<4"W;1XLSG$C+\';N<;[S9\#\T> MN18ET'+E41"$;&8[U%YZ/R#[3!=>G\E&4WDWS.OO'BJ3L@/%-FB)1;X4^0!Y#G4<)((;L`*W=805PEY3\0>Y>7D0MNGS^,!=RO(^ M3E+DHO7+*P+D]YXK5I3S)W4JS&N^O?A>.YW`M;''Y'((HC1T;>C`!03;;JK^G5S M[^W9X7J4%U"WG&]Y^W(-"C#"YNY"2$N:!7KW2`2:BY(+.K2X?),F4/?)]D M0E;>070JTLGY8OP>)RPE+('E-;KM2>1FP1@2Q"('BH\+!3&^:"A)^X'C(#G!H^4$88#GZEW?ND[XXP[?C!?D*['F^(H%80;XMDC'U9$"TBQIBFEXO[[GC>9H$G3MK?3-ZKST3``%P703D*JI#H(4HFN<) M\CI'C-6.J1K?I[.V6K9>]Z6J(X8L!'9DLR#T(M$BH(T9;!V!K7[+(S]>/Z1, MB_6[;;3Z>[#NI_FDVE=19G4^D2/NQ\LW3ZTJ:H@]:J%`A$0[\NW0 M=X!-8=@Z`%BDUT&"`R2<`6840SC^D)BW=:Y664=,0D81MD%(7'F&V`40+AMX M&"'VSMBGG1O=N;>3XP=CW^K^X#.?7O--&Q`VB<4X%.,(T7O@D$61:UDX#%%K M:F0ICGK?%<>Z\WG%[%JJROME)3XQ9Z`/;112ZS(N<4'X,<)E5A$ZO5/\` M8Y?Y5-^D^X<[L;C^]/*T*&LYQ4:*:K?I]A<:Y#=??(LR[#J.7!0.$5PL!B$` MJ6^]MT^"&F*'\I1['^?OC7VR=WAFPM-9J68!X>6LK\I-35KTQY9E!7;H`,MG MU,,$!`!:K?.8#7L-4W_0R*F?N4-4S<'S6JYDF.3U"_VQX[M.9`>AW!`>(1"X MH;]TGA.%O2Z&/L`T]+!YW:=J%'B]YF#VZET=:_S#*Y:DY3^3;/;L\-H*EFK2 M'(?8"2R+4IOX#I8U0!>;RH03?!#V.GUX@%]@-,O/_53*GJ<.44V2LI3WH35F M=%^A?"D?6X!9(!(C!==BEHM#7]C?&A_:/NS#R(.ZKW'8F&G"^0@<3Q(`E=FP+$H$.:2@A=>>)*+3+O;[KODH^*?)1F:5/5N]SULI/J&&%/ MT->U;ZXBXCK''&*8B\PA#9SX['$(*`-[GI1!*ABA^H[:# MHEC0E%"1B6'/Q8CX$'FNW[K$]KSWMJ1NB"]O/UEKK@[V&C$.YV#%7@)(`#P4 M^$'@!$C>_6$SVXWF->4S%SEJ)U3-..3765(F>%./(\O(#YV(/,\&K4F82OL M=2WW`?81>JMY\V?/N[EVN`U06CZ$;)-`WEU@62@,(Q@Q\2>9&PNL5TUR7WZ(6W+5:G%EDQM<1H(DG1$E?CQ MX^'9>(X0^-IJQ62N=.M&R-U@'5_(F&6QV7R\W17G:BMH7HX)PG`AI*98$(:` M3J%YUTP29RUL+C=+`467G2:XY&+1:RVQ?*7 M'Q84A$@0QK$0#!'(O."VF:K(O"$_6S4[FRX]0GKY#>`_5S^*Y?;'NOIZ]V9A MX]K>Y[\6IG`S@#Q;95KF:;X8%(2#4C M5MA4><0Q3X[!&D[B$7R5ZFVVI!@`VNDL\K9\.CTP((PQ98#C*`RIQLY2U!RO MW$J>=0MEM@IM-I-Z!74T#CU3MUM1Y\WG@Y3.1J$+(,?*0\Z8`[J9''(\R\G, MKY8Q?6`YLK5SULP)5'"NE:/&(^B$3E>SGF0EU5E!]NX*Z^#VS0A!]HZ0CL:( M9Z[%>("^[M#9(M[>]A4!6LBU1P0A2*F2+NX-?-P4\F7[]E]>,1Z450.!/@7O MVF=VO#\H`(BH3W>X%#0`:.\M;FP&3IW+NO,TPZA\_\O_/K_RH!X]/GIH^MT^ M,OKS@,`$B!(962*X]813[FV3?,`UY5?,I(L7^IW`:!:P8]^Y?(W#:>J\/298 MR[SS49ZSB)7"#C'89/MSS#VZLDR-8=C3"[9C$^B/^F;U+54G[$"@UV-2#,9` M#IR`6#N"/#).-I.$+.\6S@Q]Q<,1*!O;*5Q`G:30R7%!6^D0)19X$VU/!P`T M1X.#0Y45T9RAMCT`D?K$=[Q[%W>K]?9+N?ZFB_J?.X=H5!!W#M+#<7R"4&?' M!JT)9,@(ZC!`A,69"WZ<-"-9>3TS]$\/0*J^,1XONWI5/Y;K;94@!*]0KPA!Z`3I9_<(109Z6/*J$S MS`'H3!,!%L;BK#!K=W?UX#[*`7B3#>H4LN?#JOZ:Q&?+(^W,R"`EEM1*'(4N M,I(J#`U[VAPT2]V>M[TVC-^H7[S'C:`]3[-M'49[;M33^)OR[CA10&36"=;9SA^C MS/D(9UA?:(]8;>&"P.T)Z`#RVDJ*%3#$:P0X8HVG3#B;5\-VAG;^P$7'>H)Y MS.L6^^79??JY:]-O/!TLPI(+1)%F'D-G'1!'":[0U85C^UCBUW.-%%1R8:[._!B!*)J3CA2I(]O:(P*PT0CC,(,"IF$VJD7.8H$2675UCMOXYTP^R8T98F[9P M.ZLA4CXNTEU9;ZK'9SH#=WA0,,4(9*CWEU)@(<.K8?@`$ M4'1M=SF&H-J@B(]&P3]35C?5*47[_.#`G(_0.L$( ME!Q*2RCTAVE[8J_N7O,`1.L=Y`F-MTY&6Q``>B:D)(P*S97!%#:(>81T5L[1 M#!U'?2[T65.M([BSR=O.R-<.3AEG`&2*<0FXXA[11@OPT.IKN]T$)]ZAOH9 MNR;K'_!IA^E=N:UNBN65=Q-0&B"LC?'(>F,8XYCM>T4H(J5'[6YC#CS]CMT$ M@*"`,A-_2:KCB2H-TB7`KD1!'K:*-^7.\^?K$+B7TJUY_OBI/= M.MN](%C//<3"28FH0!`K=N@KFW8:A-=VO6]0\VD0R"=BW.Y3-^IA>[=:5_\J M%ZV9]G)@0$X#;3"2VGA#K&;6DN,&([1=0^U?4%(-S[!,J"=EUA^;S4-G5NT' M!$]!M`ZJUHE1@0*8&K]S:#44TEK/O#I.E,.L M4W&&U>[&(E8FSM,1ZJR&]*V.,$O>-9C<7$[TZDBS"> MCD3M%*M3PP(53E!"%'/*,B:H<]PW4S4*9WD8Y.].I\N!GBCUX@C/YN-M:IKF MEZO_V_Q5%P^+:OLDK2;-OCA^5K>LBU?#`G!."6@HA`((1!E"AFF-)4:>>\-X M*^;/*]L".Q"U*66M1)1XZI5THIF2E":KCNJ<(Q19RWLZRZ(;I+]8EH4T`,8) M:J\1)!HZHAEL)JDI,V$N6^G661;=8/UEHJ!48F%PLN.U5UIX"IQNIL6-R#)5YAR]ZDF\7`KD M:/Q(C=SBN?MIO7JLHB*H?_RU2740/]Z7ZR+=85FYH`SP`D)CE,+6 M*T.Q:;:6,59>6U+/D,O]FED7XSSB+>'_>=CL:V]\6?U9WJSJFVK7R>?IT[^L M^A-R0_RX8*1QA@OHTVG`O%12--!:1WR6%C_O$'Y_8G`&"S,>Y[^MUMOJ7[NE M/KK!ZJ]FM3G=J^7$L,`(,A09`0E%6AG.K/'-5*$@6<'9&8K1:>GRDKO]+4P+ M#K[3N-#<%?77LJIOBVK]F$)\J]OBYG\?JKAFZS8]#=N.#P!RBJ75FGN$H))6 M:G*8D#S]+5K:FX17N?E8N^$FH=J<[<_26SYCU/G M]MFQ@5DBB&!<84H4(89:CIM)6RZRNIG-\!">!2V'6IW1*&G+N*XWU7Z]GTEQ M52]25X$R_?ET'^"6;PC&2X0U-58Y(("$B&M[!$#@K/-YADEYLZ+G,<JMQ, M@'VL/Q?+\N/M'_5C><#VC,1\9U1PSC-)>?QY&`O`(":,I2KTCF)'C,T*4[7/ MY)-[,M;EUQ3Y_/)[<;*_Y1F-A[MR/GNL3O#NV5-!66&,@=!BKY20RL;MU&PH M*DA6M*)],M_///M]*';Y2HP7X$A9&KK8)4%\NR_KS6Z53P4YWAP0L.,0*`.P M(H902AU#KID>1WDMV&>8W#_/B&U9 M/9[)EFLS/$2%EUE'TS0-!49%Q7>?BX$!B5I+5H7@]I[LL8V3(;AQEG[9Z$]( MO$_K\KZH%HW<=]^3ZE%&F;]3>\\VOK_LA<$`!+`D<=,;SA"&6EAS@(=*R;*\ MC.V=W[\%.0=8CPGINFN*]+3/SG=`:_N*H)QVPB-A/;?0"<,])0T$J0/<.([O M$8WL2=C8"_A3:I5ITSPI-=W%XULO"`X3HC"&WE*KA8G'!1;-]"V@6;'`]E[M MWT(<]H#_#-3$0UNX+^MB<9FB^/P%P0E%)446**RI9=0SBX_3M_+:BFA/JB-F M`#\M[UXTE^_*NA?#`P9,*\0(D\QK8&#$@#93=\QG%<:D&\M99XIQE@`!K?F%Y,`I_5OG*&WN[IE+X^X)_AE91>KJ*$"(%F5B/A M!65(4>!\NV`$%@X&_M0#T98`Z1B2G.K,(0.NB,R6-BLK-49YOJ/P)T>X1Y/@A4_ M=A'T2.KGE(]_7CPD1,JS[N26;P@8(T>L@5Q33[V6T)'&G9ZN^&=I?_M=#)!^Y<$#AE%U"@J")>,44H].,"@ M@ MOX.X[/I"=VIQ=BS@T(>?^,3+`H$R=2%A&"'FI(4TU:\[P$*1R'SQ$$:I5E,GK;155U)^;1K1SM[1Z56`::HNTTA8P39T`TC1N M2:,Y&2GG?FJEKQ?2O.]P&6(I)K*$CQ_?X10'`FHE* M:K,X]^OXE@?A7&^HCR[\]N5"4A>`U('^7$6L$Z."4YX(J#SDUD(!B9'^.%'@ M<%;MTUFFQ4\@U/)Q[R/"U4C5Q4VQ7*[NTUIMZG*[NMT6W\\'O$Z-#I)+I"V7 ME"JH4NU$*HZ304YFY3C-,)(_`H6&0W^2H[#A_L?;OQ?K=7&Z),OI@<$X:A'4 M</D$"B6.8$,(') M;G*&F2-R&-*1O+HS":P.0;&>D)]"X:H2./6BI:+5/!UT:@;-F(7&>FT5B!9+ M$[(S5I"1&JI=O8)U(=XS=*+UXCP+1C!.F#%,$*V5,TBC!@;K,<^J7=8][7RJ MF,`0I!ML$4;C8OI\52_2;RF6]E@LTR;Z5*ZKU>)EYO0)-G9Y3;`.2+^#6T', M@*#D4`PD0H$=S$H;F6&,:A`G[H"`3\P]%;?4>OTC[IY=V]7.I'LQ/A@NH1;$ M(,&(4!IQ<"A1F38>9UD1T<[2[WZW0)$1Z^VU<"X/[RLC&U14(LA@:K=$M"=< M'K,0K%,L2[1UOENS)YNK&QWO/OYU76U_[`(,5\>[;M"/QKO/#_?WRQTDQ;*! MY(_Z=K7^5CQOX'F">2W?$*RE'@KO6=1ZC4MWVYQK`#".Y-U:`//SA@S32G$0 ML,>\U?IT_[9:G"[$_?KAH-*-7(N]PY08#[CW\I"Y`A%TM%V#T5\GJMG[:K^^ MGIJ'\(C$B6B7FVWZS).4>7HL4&>C#>.QABH:UQ8"1E4S%4=%UKWZ&88CAR?+ MQ=B.1I/=[>K/U=>ZNJUNBGJ;+EI'*+ZLBWI3[+*$=X?Q+EJ_B2;Q>@?-WZK' MLH8G:)7SV@!Y!"MJEI1R)05SVD'20!75@9&J>5T-#4=(-'Z&M-C?+U>9A7;:P"G)?O6L)'%5C;6"T MTQD57AY:`D?(),LK`P'GJ.L-99J.N`K/B/N?__%J`>)F^>?^W][\I\.;7H%Z MOUC^>U13]^L0A?HB%0U=).F^6E:+%",Z0K=)4O];?/%=?"9*_+U^^VF'_UVY MC>?%G^C1'&R?S6*1[W4.PO\//"?$,LI9SQ[U6%'#F)$(-F(B`:ZLD,1_>#[=( M\SR__ZJ+AZA?EXO?\>B6"BF!=53#"-(<<`B)5UXSKB"0O&5RQ,"@?#F3P_;S M@\$C[0AVD8R*$Y@*W2'23`E[=75.W*%6_&5H(`?E\>)-S5=^OBGK(HHI];TZ ME4?TYO.!IO^D9U8!@[F@GEMQF!PDQ&;%,>=,H8Y+^QY#,K`^O7U`2J7GH01(41=&Y5;=\'8!"GSYH-!J-AI=0"=-.TZ]YTQ&L_1N9(C[W+OZQEH6I&F?8!1F(H%8HB)98`O&X M$DND98`-V;7MR+RT!;+/#-?]:V&GDUCW[3+E$41//KK4.A"#F`!="8-%VF.` M0V;%A?V6%)"OOD4OQAP%N/L:-UN'LQMK[`G2/YXA82%(RRA$^!@$$I#>P4:( M%3W=C1P=-WO7S-4)W3:\5J+18_"U_,E,>FVY\"@N*5X"HB`PKB`.).F$?8#. M79^DO'!0MJ4*KSY+"M$^YO[DL%W7_<8)$R3 MY-_,A-`:>VMBV[SKXME MWGYB-/J-S&EC0MR?*A?_Q:B0/KA2K89#THVSYM[2Q6_X#'0B7%)G5R=^\^.: M3CRHIC^6L>@+:R.E/>U>=$O=7OA?07 M]Y<._EKFA`.J0UQ2`93DW@A9`DNMLDF/0M4TX)!ZVX0Z7HA.HD`SW`._H#I6E+=?27W_YVV#4( M>*)7%E<2;8W13C.D!)->.:@$-2')/#9WE_NL#7'1.'MWD`\@A6TP66O;@51# MJW$2=:1'ACD&S20PH14%ZA4.;)-&:+#AP=4SM\/*0F,^+I:*4W`\+IM`7K;ODI7_Z=GDLT.-<\$`H2<05Y1 M+5T@<8T+I6A&RJ1C_P$2I:UBWQ9H3(6R;Y:LXN*V&^WJ;*K9T3Y97)JX,)\H8+$HAG4D[BA\@7](4?9@UR:C6H,Z1(L3_6N?Y/(]^U=]^Q'D0U_/W M^>.7?'F`":>:9]Q*'4TI!(I\$-0&@J":-C2MJM-P29"BMT7GJ+8GP>XUI^GV M$<_3##C4-C.!^BB?!R,]LX(2RGTY4(]]TN75`9ZT=JS^#B"]F513RBT2`G&A MK`))'!>^$@L[GG04.4"F=.1=)`/9&S\^YC_S^;K6>T.OFV;6!6J(YV"-4)Y& MZ5"UBC*MDFK5#W`125'JF]K-25#VQX[M8]&[X9[BQHN&&4/1C\*:,L.EYTKY M("NS2DE:@OH`F=%>G:]YD0)C>W^B+)VT/*KG0\TR`H'A2'L.P#5W/'!964=$ M(2E$,<"U(5G+'8#88\F?^R*(N#H_]5^US$110,8S;HWRVGK.,7*E0#JXGEY4 MOQU6=(-C[PY##4X#S?3Q]E\5HRVR"+8C?\$?<[TS"RQ1?$G6[QAC9D2Q,M*8&'33,T` M/"PGJV^;[/=SKR"?;9O!IHKRP0U03MC+(#D%7@0;-);V`.,TER. M35U#?7V7J(TKE!5/3G("F!#-&-824:CRM!!22<]]#C#Q]')\Z@KB'M>TTOG? MO?X>1[Z.@]_M#A;SU?:2Y+/'/-[/YIN7E$I+'#>=+[]2O%/T]/M]_O2]R!@O ME_=3.[L>1Y%IRX@OG`J*+$AF*".J5(2-"TD*UYL_FWQ+.\;A:JGGZ1)%VTUK MF\_SK[-:[PR][)%)IE0(G".B'06N3!"ZREVQ*FD#T?PJU"WM.KM!=.#EP#B* M_@9UB''AE#$$,54=/G@:1OM,:`=!B00<>R.%GRSGT7(6;Y9^^CZI]>;%L2X9 M0SYZIMX)JQ009EE`%>^EQ3V_<'Q+EJ0C2*_&&CM9S>X;4&;3/D,>HD1<(J>! MAV!(7%XKX8Q)VCP.,'25KN0SK&F#ZM4H`[.'];-K8S5(L^N16>Z`45/$60B1 M5G&^#[0H*<:6=7QQVK3#M3?B_#LO\J/SJ?D9G?MO^5_K(D_Z[NMFZ*N[]=/J M:3(O:K'56+F:?BHSDG!')2B.C"!@,&>VBND9F70#8=VX% M;/2=S&D$FXJ`DGGJ0M`&5ZAKQM)>!1L>[RY'EI:L;*.%:U-R9\;?R-*^ ME*$(!`&)-EF$T0XPJM@^!#VZIV:O3 MR2BJ&RU/^GMUNF<\6*"J2$FB6D#<06M7.2G:B;0]PY"?5T]?DB^`;R]E*.*D M>)I]>>(K8T_\Y]3.?N'VF?2:!,0,&"*$:0MY@)*`474E5 M\^O\_0XP[7]:OO[O5\D18;$,^9?E>K+\':FG-DT@?YK,'K;_'L&TYA;BGCG^ M"U%D`B=6J^U#>-HZ`%R/]9<3\=T\CG-=IX#,@=:9X%)*ZZQ4WGJGA=?CT!(T$"X16LRJHFI[S[80?NC0LR6A>B21_ M31[/&Y9C73)/O0J@",,8`\-4R?T\8"2,S;2D*/DD7UI#VKZ6P)OMPNGR1$>: M9\Y'P;$P5&@6&(,XPE`.%Y$PMOM\Z6I;=`YJ;Y;COR?+66$D/TZ>SOFMKYMF M#CGKBR+J'+`D5@&BLA1)JC"V:@-=+BV)6%Z%'F>7E+>-,\+B[L]YZBBG2A@' MT<>J6,]@;`4/VZOU!#]:07DEU^-C/LT??Q2*VI8<;^2O'NJ<@3716,:%F!$= MW7T*'BH$&>-)1F:`]SLOY[]V@.Y`2-70MSW5F/;/&H4:C_3(O#8>`[*HD!&T$<\)B]'[7_'T?>.N<&Z_17_^H]L[JN]6J_5D?I^[Q>K@+;LZW3+@7@9B5-#@ M/%$T<.*KX1,YMN=;NZ+)!;#MS0J]'79Q^K98SY\^+//'V?KQA/DYVS>+]MM+ M@X.7DC,?C7I$M8J&*Y-$J,'O[=/M3M<`7W-M:[:,9=%ZZJ"X09:"T&"YV-5. MC()IH<:]8;O(BM40TNLGLGQ:/SY.EK_OOHX]?R5H(0D":BVV&!OF@+'H.#C/ MK1&4U./Z4/-7@#*]N:_M492.6LV*?*J-<+:X?CE"US-%Q37R5YHA>E/Y*UI" M\=ZD*FH]L>)DGC!3BA:7MC\A?Z6V=NODKS3#\^;R5S!B(DA!-87H^R"IQ>;A MOHUXUL#8MK5I*JZ7O](,TIO)7_%,6"HIBI\/0BNGI72E6"+^7Z/>V:89EF0T M;S)_Q4I,$*74"%2\`H4IH15:2.BD:E@#-"TI2JZ;O](,TJOGKQ0U!8-206GF M+'/.T4#+X<:_&ML+*.EJJY._T@S4F\A?D4@@A1D3JLC\Y`AM"@5N12**)9W8 M##[&E;:T)&)Y,_DKFCNA.0<612$$I`A.EF*!&]TA<7NUGL]?:0;E0%(-TO-7 M*/9:X\"%M,8'AH0A?">VTX(D^:^##X=VZ;]V@.Y`2-5-_HJ#Z.8!""T-"T$& MZUTH17=.CC$\UQ49VN2O-(/[!O-7HB@&=)!,!>(THQ+C,M#IJ-))(9D;R5_I MQE"UA?1*G/FO^61[6)E/RS/*VNPYT#=#Q`5+64"F")<7=9A=-0N!(M2/77I9 M+?_SU8X!:U/@)*72<>ZQGDEU%GCF\/A5RRQXCC`NPI<&D(C_I9@M!;(*CZU$ M7=>,28/S2L8G3.YS\]C(YNR[9,H$L-XP5SS1"L"LT.7NQ"DDQO9ZW45/*%O# MVG^ZP=LZ&>\G1;R*/TLQN/W<@N(^LW/*@L$R.K-,%4&[3=*'_P6E,$=>6R>L<1#70"M*$1TR]8*0+ M82^YE\@:)"DW@!E4$\0;GO3DPD"W#9=94]I".LJ;6MT+&&1>1-(@5\]#M M(;`]Q;VN'KZHS82V-[6:X3RXFUH4"ZLHBA//&,RLD220:OB$CJT<=%P8C6$=`BATT_Y7#!5.6L;58%S?>1FU\VM/D M`MB.))A*O90V($9(W$LB0'$CR4JAD7/COA*8;G>Z!OB&@JG*^\U#(483QX!3 M`6PO&(6D'(3FP=3%T^3AIIB3#FG_P=2_)LME_,+/?"Q!4\.U`:.*>N+"@9?! M\>V+.HH%RFK>=AUJT%1@BQUW1($@QI*@*&*E<`&KI(W*0%W*%!77>8ZM$:(W M$S05&'MAXIY.&"*#1YQ84T&DT@Y4!TJ4UIH]'S1MAN9-!DTY%M)H)B2+FR' MNTW=D&8$.=8_-I_SY>,_ M%Y/YWTZSXU6SN%_W<:7C*`Z1>F\T`J:K]8[YI!,.,782I('97M?O8]?OQ5^7 M`SBM\R/-,^L44\8)[ZFB%ENK%2F'*R#M12DY=MUW`^H5+C."-K@HK0G,D!#_ M!QA7L1>3>(](C5WKB6BV5W>YODSW"\R9+!: MG;1KT&.G0&>X7C45#[Q6`@OE!(K2$VRL$>50K;)IU]C1V#G0!::]!14_3N;? MSM4NKMID0$!)'@3#"'`4A:&]09/`_H1\N[:G$VU![)<)9X/+SUIEGL1_I%72 M8^)M9+7UE44S3"2YB`,,+;?0X"$.M`*O-Q;8N'@5=9//$N%EPTPZ98DN8N-, M1LM77(FI(!':C.V8H94F%QTB>(/)VD21(#7B5O,@[:80=Q4Y110GU0P>?#BZ MRZ/MMI#VQIGV93AU49@]&"6$%I:&0+RO!*)ZY'6E6^CU3!G.9G`FQ!>+E+_[ MN->91:0WN'^;_4._F]U&\.)B0%_?$_>3^.T8(?5C.YO>S'Y.'^'<% M$EN^KP[?^VCWH8P5H?A`*#&FN(FEL;3[)#4G_Y0L[%:$NC3:"2&R<@C;,K// M!_IA,IM^.!$J.]LS,XQ0(9@+`B$MI$*,5!Z@!CKN@]5$RG0.;X]I^]/U?3[= MD_GNZZOU=Y=/?L+_J?V-+'J'7H#5+EB+$-8ZZ/T),TLK-SWX`]ETS^A20/>X M#]OJ)\SFU36IOR\7J],[L2-],D?BWA10W'6`D83;$%"UCA.EDR*\@S_936=3 M5\#V=W%M^C_KU5,A_.KSPDRGLT)GDX?"PKZ;N\F/670$_?^N9T^_W>+QQV(> M&[Z9(">(UL7GLR`E`@3$$BHU%I2!5]7F6(NDO=_@3YS3.7D%';1WQXJ3D>G= MEX?9MZVF'C;JS*>?%^74^CSY95:K_/CUW`:?R!!R%J`0"?OB8`91Y:L0G0Q) MF\3!'VLG.FB7P_E*,_WT5(@2GHF8 M`N:K&PF.AB1?;?!'Z%VLKA="^DJ$Z_J1*\:B,:9`%!-QOFGFGYT4V#CI>CJ> M?_G*U0TS+!WC7HGU;`^SG'V+'NA#\;?;[3,^0ZR3?3.I+&B'0#@1*`W:QT6[ M%!H<3;NE^@>$W[M&."$!,/[F=,?E97Y?Z&#ZM)A47N&/Z!7.YO=;K_!H=F"3 MCV3"2>:80J`58C1@('O1M$E,&AI[)/Z24'?-HNE.#T^3^(G)E]E#W%(TH]"A M+V36:^>#T`@[`7%BP+,H7S2Y27F'>.R!]XOAG$:>O7S/-IKO9_/9X_IQ;R@_ M+&?W^],[1-+;=.. M*C+9(\GI^-\O((F4[5@415`D)<_T0__FV( M1+4[1A.9%J)T[:[Y03`_!\%F/S;36Y2K>7'_?&YO6W@);\LHP<89#RBSG.OP M)<']4NR#]9M$L"OVRP^'^02\#.[N+K^)EUJ)CH8WWI,I2"0@RH9MWPFB"!.B MMH"I!VGU']Z%*_]\:(]$O6I MBPQ\!Y[ZYS'I-UPD&A\MX] MKP09%N]Y>=MIX6OSW@QJ+)&2!GI!#4!0`6_V$7$LS6?V[IS]YT5_,*K^NBQO M\OQVY0-\[6_1&T9E5`+A!8)"GY(6I_5Y>&-'Z0[?[ M/ONZB.?G_(]=PNAFPU>K_5'STUT=&7=H@^WVMLQ;X6+Q10&EH,($VXG7]CE@ M+JT)X!5[^8?#?*0MU<^"``\G74_NAV26T^B.%I(8(+B%2'"P_X9(DO\?7;'_ MOV=@QS^.[:V8SU&/B3;G]AT9QQ9:J*#U``!DC;&N3I^6#*2QZXIO!\Z-=$(( MV&-,>_QT]_?\]C[,XC':*`&;]3P_'/)U>$@6#&,G&#>24LB]ML[@&AC#25+S M*'3MGO[^@.VWB$D,K#V8EW'@^4Q!QK`U`C!.A-+$"5S',,;+]R0F7+M+OB=4 MTY>%+U^#\*L8H?KP4!9?UN7--U.&E2J_U4]O3;+^LV.+1^<79T8)!PE"D`LN MK;(!VOKF5,.TFGCHBEWMH\`_BJU?-;'Y=+'WH&7O5=X1PKPVYW3\ML],-OO)PJ4'_5JMG]1!KQ1DDN,O%7$ M:B6\WE,6#WHGK_`Q`)[@W9ZNO,5)Q758%`U[5$3CHR3PV,+,D_)861$.&E$*`*+0/ M].?:IG`%3[XD7:K3LF=X4^HZQ#3<*-)=?I`-+Q[*!+<8$0V`,,(#H)WDMLXI MHBXIP`5?N[LZ!+V?\KB9OM_&K:;%J,S@[2` M2`DI/,4P'/:>U5Z6*"U*#[\#WW3_&`^>-_^AN"D?\M]F/W9Y_CHO\KMY\TU' MX\C,.B2%\DI+`8E`B%F[KX6#=5*6'WX7+ND^\4V)(Z[36//5I^)4/V3+X5E8 M>S%FR%GKE3>(..)K@Q,HD+8&7;N#^CP@#[8(_6TV+U8?R]4J3M[]6,^+^\?Y MZFL$9MNIMF$9.CHVPP[AL,#BV/O,(T6)-'4\-)`VK;!B>X?W!>>#]HUQ/RE7 M00'AH'Y?;'+`RN)8[;P60S,GJ",0*&*5EX0[*LP>()U6LA=?NPN[?X#3>.)J M8VZU+M=?&]H\O/5P1BD%`C@-N`'$*:B$\'MK0+5KN'N("U?L8.X-TL&VGXWG M<1.?U+#/[!_*/!:8(R\UX=`A!"'7^S*UV*=M*%<<>YT,Y7!6T?S[_#8O;E<[ MBV[K*?PU7VZFWF04-0[,K/%:(:8A\Q)C13QV=:P2D2CIT@J_!Y=NG_`.N+Z4 MRW5L=:3+Y;+\,YR>FNX]WW@Z\S%_.O=F_Z":*P5?XE&/=;5%^'SGYY?'B8+9]>%"';_(7- MU[/YXN7T\A_K\%GDM_\UT!W8S]WKC]QXO='NGF&"F;(80(>U)T!@M76J*Z"0 M,.U"TH8(WMP4IV\=IKDM9>\(0%HK2YCTBFO@G;>5<,Z!:VO^D:KBQG#,+HB. M%.=[I%70SP]GC$O'E%<2,J0YY=(#5(DEK;_N!O4G:K:1)1W0'(DD^PY:K:GR MK.D65,0@`:6ES"!,B<9:5R)RE%:`??*$.4W)C7SI#&EWKT0/O>>\4HALBX>@ M8#-Q#VW]K7C-DRR(R6N_B\J.MYX[#=($GU37KJ-<`6BD,I1S$@N%RG#4K2:H M*$@*[IC\[6RJSA/13%+WLT;7QW7^\\,999C!6,!,<&.0)9SOZL7&C3&L=$GN M@G>@^&1(NVO_=8_S(XO]@<P!8:")U\PYJJ6*Z;.R`H$*E)9` M^/X(UQ_44^);CX7Z!,=@$W+DS]G% MT'*O,##4$!%6:AO^D%>F7V?IQ.5\_V=F;R5K' M!V4:":>L$\1Z0*P$(!Y;*WM$BB27SN2-N[[7G`1D1R)06@TIIAW!$2S'J>+2 M,L3J4Z)!-NF`=')TZN4?D#HC.T+DT*SX%MT:JTU2T3JO`J!:Q1$=&)MYX!00 M3`11O12:<*QJ3[AG,.DNZ8("7+N2J6^`!V-52P*]$$6K@(1D2""K.2`&<(#K M(YR024O/1=4_Z,J6!#1'C#W;79U=5=R9ACK\CPEL`"/8R5J#4EG.W(7'G2G@ M!3=<0@.,$M0SSBOAG%=I;8*FN::GJ+A-W-E)B%Y,W)GQ(AR+L=/2"&"X\'SG M<0QB2K6P!4@++B#TUG/&(*"@$E'A MQ+:Z4V=-!TVW]6F=ANM(U.F[^;<"QG"LD-"0Q08]RAI:[]&)>3?MEZ`)U'KH MAT[I$$_:JP4HB3>2T1,CO/2($(,J41A*2[ZYH!O@KEQ)P')$G]:K+(!K<6M1 MPX`G`'MC!-J-GC;JW3T+Q(MQ8E"`&' M*>&60*6YXU)7(DIIAXUR'<6MU5K);=U:IT$Z:CHEE)X)9Z%Q&(8)$P!W#8O# M5"&'27V3)J_]+BH[GDYY&J07Z.4B&`H*>%A*A5#$VV!:UP(&:8<-4[[D+:8K MI!?IY8H]6#2FX6O25EI+")2PAHS#I+9+EY5-T5;7;?UKM9* M?QV+VQ^TO=FC1WEQ?%#&8ELB&Q8I(+D7E@O(6#7UL"7!8;;Y2V-%[\`F<*(F M9I7_NVOC\*GH1I>.[\N,\P@$,]\`I%V`32%0"PQ`6@/@B1X!>F/2,)AW)]GS M*.UV-#H$I,1$(P)L`9[BG'\2*I)AS-.T@WZ1/,<^R)*;ZB>9;TYG26=7I9Y M'RNU>"R`=A#'QGH&UJ)ZFG22F6B*XP`K36^`IW.KO+N9+9=/\^+^^VSQF,^* MV\>]^5QU@"B+G\HOG4:Z?GXE8Q@1:[%AR#)F",)*UGI`-.U"<*(=/?IFXRB: MZ(.F\]U'E&\_HKMRF2*%&)3;!.*N$VT2S+_@EX M;MC/[Z:QY*L.13JO_N9$'FFY^9[W^FP1?3 M>FP6+"5+&)(&:2(UPR!^T9LP+ZMCV'.R6V:5W_SEOOS^U]M\'CTR)/Y'%)0\ M<\2$/\HV*,YW>G]#I)^>R;RV0'&C&,;"4B:LX:*:.H#N6H*(SJ#+LA](3_21 MMV7"Q_Q^MMA^5`<"AMYX*C/">HX<\=8#J!FPT,%ZZB(M^WU";$C06=D7>&?2 M^W8^!T-_7C^2.8;"$1EYC"2@EAF)N:LF[4Q:1]*):;RSOEY_Z=VP.ZO"GVV< M'QO".)H'9!(33KPF`,7(200$4*02*.;U7XEGM9_/OS<FQS/*I#`<4@>Y%5I3;HBM.8UQ6C>V]T*/GM`]ZX9BRH>'LOBR+F^^;1H, MKCX]KE<1BGEQW[B]-`W,H)>`,8*UP\!+AB%PJ!)0"I44$W)8GY<>*9">=TD) MU:&;&9DPA'[OEPV;SPOGHQ1TTX3Q33%2C@7S#@CZW,4)VDIM1-J/CT$ M/5*0/2LY_I4O%O\HRC^++_EL51;Y[8?5ZO'-;,JC8[)PY@;.<0XAI80++Y&H M/8P.BZ2@53@A1_L0A.D'XS/[U7[-E_/RMMF;\N:SF>/,8D&`I58I:H3`=N\7 M0CZMP-R[\;SV@>V9*;+W\_CP)X>.)P>>SC1'$FKB`--,8^)@U;4QB$*\2*/) MN_/(IJ$["%&V3&Y/E6?/9Y92CP`6E@@SXF8>'755-N]J]_>W:ET/^51\SF\>E\MY<:]GJ_GH)=W.L00(8Q%U MVBH?ZW])R3'9Y1()IT7+)O!G%E>M5ODZ=D'Y.)_]/E]L@DXJ=3W3T:9-2K%\ MH;)C1>%Z^XV,>Z`DTHY`))1FU$!`*B`!O[IRL_V0ZM#2,K`V!BNR4`NHG^K_ M_/L\7X8)?'WZF'_/%T=*T[5[0<:T!U!Z3!$R0!CH$$.5^(2H-%?)A,DX'&\. M,;=/O0Q/RQ>;Y$]R'*V&=])[,D`\%4K$?K$`08:I M`?OAB?BA^.-QO=J@`@\6X&LQ*L,("^X,-HB$G<@B9KVI!*6*7>U*V"\+#G$M M&?!1F84Z,6LW*@.<:&VE\E!0Q"$UDM)*4`CEM76E&(]9W0`?E5FX$[-VHS+' M6/A\$'`"`T:D,G*_!5A(KZU\_'C,Z@;X&-;"YF!K%K/5JKV!\'),1C5%X0AK MPY?B&$!8FET+F2`DIGJ@%A;OTR9(4L7P?-M"]@9(&U3^MRA_7^7+[Q&]%\3C#%Y; MK]3Q:5*>02V#L<[]^W&^?OH2L=IM34=8]_:`C!,9N\,YA[U`5@E<]7X.XAF/ MDE@W_>U]?-;UHI:QMOI.IZ./+8K=]_H[F=,2&VX5=\!#*8,!@.N=S#B==,_90^FU[`G_[M2H;_YW@A\I773@\8R%@W,X/B!,%-&4"ZX(K)T0 MS@]4)O\]T:4?30RVOYK9ZFM`(?XK'@R^SQ8OG%K[2_.&O;/U.S)'E,5"A@-+ M.%T(Q(C@M6=4`7DM-8?Z(4(Y#,J#44U]G\T7<9?WY?)+F/W^"-K`K<.#,D*8 M=H`QI1R65FLG57T`1@(GU5F=T-IV%C+U!NMP[-D(?MK"='!,AATSP602W`CL M*&'PV2?B(4L*J#_]@%ZN9XL+XDY/J`YG0Y;+?'Y?;'-8;YY,66P`V,AQ&J%. M?%.F`0=>@6D@ M0FG9L!->>I*(=98[\R[ZN-"H)&XTMI`Y1!B6R$'/!:B$#&;/U<;G#LF/UG%) MIRGC/W%)':Z7(2562`T=`=`*RZQRKH(8R#138Q\C(Z+:FQ?L63:AQ/_MN-0)X`O;PC^>'G&4 M^DN9X<1P3#6DX>BO+&!`U("&92")L=/W-8][0!U%A=V=@>;KK+C/Y\5=F/^F MI5UY-[OY]^,\S'WY/-IEZZ_Y7"X6=^7RS]GR]@TZI[TP(UQ+1K0"W%JMC'), MBIW(5BB7E.PQP75V-,:4_\_>E76WC2/K?S0'^_*(M9-STW%.G)YYY%$D.M9M M6?01I71[?OT%9)%>HH4F*(KF[8?)N!.`!K[Z@"H44%47D-9%P\+_,U_?_@)C M^1+'EZ!O1;+]3)-=NZ-?E2DK`/"$2N,%]>7S6IZ.RF/OH@[QZ_+=#CA8068 M-9!S*8,Q#'R];WF5]%!E^`\#QK!PVLKR/2Z3WHTT[3PR`5%"M1::!6B)K"!5 M!B55DGCS8X?[*LOQ/TOD_++L;7E\F3P\YI,H5E]6Q33/9Z4/0@D_SS;3]?SG M3@Y'6-_P"QF#E`AE%:&84(L8M$!5`#COQU)@:6A$/H]X+I$]YF=>KK=3<55A MU=O)VDP6T\UBLLX_Y^NGU?8E7VT+D_V"[A_+53Y9S/^;SZ+%5T:3+R\?'1/! M]MOWR"J^XYPO-_GL6Z'S#_EBINZ*S;+1BYR!#3D3,%`%!Z5,+5;&":-5[4:) MF:C&>K%UE@[F7#3-F-8A%ME#@$M`QZ[6RU90X-V,)G.M6O$6'D/9G!S[: M`U>KZ[`]S:?YB?<3^YIG$#+`E(1`*V2)M$IBO)L:AB@MNFF`;&DKV-<&6CJ4 M?;,DJJ3=:$\_%3O8)Z-,:TV-]QJ$7R>!A\[7DY1IY=\'R)]G33*J[6]S M;7Y?W.6S@_EX?FV4$>X$DI1QK`F51#.`334T1N38LDAT(*.B(RS;B_G?^KB$ MJW_/6#"H,;=!*PJ%)44>[`S0,""!;)(O=X"GBXZ%VQ+&]G+]8QG,\%4Y7S\4 M-[_/PV1_3);')7VX1P:0IS;\X0T%'`#*#5/UE"D=6^*ACF7?&;#MV:"^?E3V MN/B?-=BG9>? MBLDR(K$+_%W^^)I/\_G69ZD?GG[^%H9XPDN0\MD,4(4 M;U9\[_W8DQUY$WJ$O#=VOASI28?#ON:9#'/Q`4AKD+3&(<15=]I=ZZ[V>YLO):EZ<4&M[VV<"6LNA$XPQ8+Q1GNKJ?D"%9924F62`9^". M]%476/9'E-T8_UB6]_ET?C//9R>UT<$^&86`<0@( M=""=H@L@VTOW4_'7<>'6#3+-N;9$*`"EXTIAJ["(0]+<:R/%V`J==2S;MCCV M;QULDR%R- M-,_'>=)$^+5QYAT(DY(0L:@:K66H?FRB'&OXEN@=Z8MT^;Y.6YV*:7O5\6T5 M3MFW^>&ZK'M:95CJL.=Y1['1DB`85D-\'AZ5'`@*;VP&0HIXBJY03!;QX3*6 M>UIE$#GKL%':4N?B#2]7<8+&0&T10_V&W+X[$;=#L7\KX5.#'!R_-@[,]1X; M:!7!T&D`K"35Q8!2,"TAP0"OV[JV"]H"F9#,8E+>WC_&5MP4J_M=&%QQ\SR5 MP:&-H4G?3`*-J."2!7U'./):RMJ:IMPEU1D8H$9($65Q7FS;D\3/_WY*;A'F M-RDG]_EJ&B7R(XRIG"SVQMPV[IM1Q8$QPA%F$0BG8`PAU\IQS*7AFHRE&$77 M)#D#M@DW%\OE9K+8C69'W;O)W_.[S=W!FXO#7;)@\C`C,=/",HPILE0'&\A3 MY1DQGB918LA^Z$1*=`=I>R9\>9,6V=\Z(]!"[J6`AG.N)=:.U'N;0&QL,?5= MR;\3-"\1%AECD&.\2KSO_1JP.&)W'NF5$2$P1"IL>)X*(I2S'M:VN9"C-4#; MTZ9[5-OO',^K!58VSSHZIM9X+576`KN3)B--=BIV@_# M<9+?S:GE[+?- M)!8;R?.&.U'RMS/EH&6,*ZNL#&I84^1$O3$KGI0;@X^2D)?"_J*I7LKK?%G. MU_.?\_6#6DX6#^6\M'DY7E'-K-`:91[M!G,N`DQQ0@PD%0`MHQ M+:L;(HT]3;L?'Z>GNP><$UR=S]SM.X=;E0S\H+_S<)=,"N0`DDZ&5<*X)I:+ M*HQ2`PZ3@H7@B+W>W6&:<)-:W-W-MYFTOA7AY/ES/LO]9ENF-)Q2PY]7R_Q# M^.\PI&]_A48/L\F#+U;?\W@RG<;46O/B<(6`#KZ=(4R]!-0KCQ$(.I\)4Z\) M"9Q.(M>(7>H7`+\W';@-K'H*`9Z]4>5YVDU3+!;YUO5[=?-J#D?8T_`+F9&4Z[!I:^^P M\4AC)U@`(":&H4CBM%>CX_32GQ?B9QSK,\WB]?0VGVT6^=5-_<]7-_N228;9 M76^^_V^8[+>B;AHST/Y8SI^*(K^-BQT>Z9\@QK`U7FB),L,42/TT?43BV MA\;=4.%PA=BN@.[_\*X?ZA\_S/-5&,#MX]FP>:WB(Q_(D')<8Z:4Q`1*(+W$ MOIH^H8G&S8!YU@DE#O.M.\@O>RWWZSR:UQQN\IU,6"N%M]QH"QAA3'@G*S`T M-V.KI-DU19I33TZP@Z&<#3HE6GFI:/Q`C*8@XX[ZR"K)LJL&JTR M[98%Q]]3)0!^468=#@YJT"OCUB'!`"?2"\*\D):X:J**I-5!'Z"[^W+,:@=X M;\P:8F8N&Z_B)0**,P<=80@^014LZ;$%'9S5M.M1$+UQMHM\75SP6!298ZE$ M6-$*>E5O]%#[L6G6?FC0)%_7VX!O?^OSGWRQ*(-HWI*PZUB?#''$O6<2,FR\ MXU197@\<6#"V`V>:\(KSH-J>#A\>MO7E3J2@?MDJ"R:@19!39C6QT`O/@*WM M@,#]D2FB[D2>A&-"I%NW.?H48L$V$YY"$*.SK`LX5,.VTB7IB`'>^7`[QG[XX> MYX`WX[&F:*6H\,)HJ0&.\OP<`@FJ8F-"D8F8#O!SO MC@7I8+:7^?],%GGQEAWA8(<,"Y!4@YXI&67'C`:G(;Y<=6SN:L#JYD M>"_$FL^3N].NJT-=,JRL<_&I(L%0.`*`$[45S9A)>X\\/`:E"/DH7UI#VE[C M7(>3<5Z&OT=;9]QQ;;.W<>:%)=:PL,EZ3(DEE!%>#Y6DI0(?O/3;B*SH&-*$ MT\@F_WWR$/_^Q,'C5;N,41E4:PR*]@Q)#90$M6;54(ZM7$FW,D]$L[VX??Y] MM9FLXJ\6#9;[@>99W.H"RYQR[> M7<]-%D_9BR>/&30^-<@!FOKI#(?EPJU0DCBK#QL6?CUIS,#8#CG] MD>3HD2A=$OT]7GH,.3D=L/&R8<:@IS8<$ZE2T#B(=%C*M4.9NB1__0!MZ8L1 M*PGV?D,M8]Q2?!;S*N;O<[&<;E81Y"/L:O:!#&O!.8)1]W MD_HR>3@1_OF\68:P!(S0,(NPYKQPB./Z3EX#-[;PIR1I[MM]VN'8WSY3A"-O MOKJ+1X-Z"1W;:?:US[@,,%@II9*,.1A.SK!6RI*FN2T'J)VZ)$D7@%XH.\#6 M55*^',I[#^I7`#D)L903C(<$HQ-!IHY)2L0!#")MTL#OD(V`4M+R.#'BRY8I7/?RS- MUITV??B0SWZ$)70Y(\[FJ_G/,(6?^=/-1,1Y-S`UW:9M#V@_";6!C9?PUVND*75S/-F\7^#`:N),DSY;(:]Y1P;AB"@BFABW.ZH$N`B M#"=M,@,T[GIAUB_W=KW)YU(;T+/\@1C#XFL`\*5T+D::SORT4U2!!;P@,:XW^I539Y\EJM1W_/UKH%P,( M0NFT@M`H(1U"TC#S:(O(6/"+#4(+/9O6;Y/Y,E9PT95LO^:++47*V_F]?OBX M#%3(GY('Q_&&?]0/^S[V=5[^>2KQ:G^#B.\H,`1`2V.@%`99)'DE"HO20IE' MIBL;L[:)V3X$:5Y`_39%X&2,99L/9@`PA;S1T%G&+!%!8^`*'LI@6N&%=T+V M"Q,O>6VT$&1O/-\SW),AGP?[9)`#&W-F`,^5PE@R0FI,N5%)-?]&P=:W4:$X M#^[#V$0_-8@0:?:!#'&-G>8."4N\LE:%$UPU?>%XTH.Q]W*V>4>;9%O!]<;; M:J!72S,I;V/NEXAIF$I^]LJT\G6-=Z7/ZB6<2@\U,,5= M&.]MK&8=/QE;_^-D>GU64T\!MPKI@F3 MVECC434UA-5XB=).P`?YTAK2]J\37QCO)U+2[&N;:2&PC<%Q82/53#-@2;U* M$-3-+FS>H^S;"*OH%LT+;!)O\R8]6?X04B>I@HRS:)]K1*6K)L;"J6"TYZ&N M=$E;*(?AA-P5^OQO/ONXO%K?YJL]YQ17.0Z^Q)P3Q;+I$;R[7Y?Y<"IE!%LC MP@^$8"-5#2UV(WZIV()=;_%$]B./P5!],2G+^VOS*1'7'FOG#.6>$"E=KJV6J!,HOR@-^;S4[XGF8S$8VH]=$I* MS#R%'ALMM"*UBO0TJ:C.FT-1?N:K[\6[I&(W$[T"LB)`+`)DXZK2FO'#/`5 M"$*H9HZ_]Y/(KDN&G0ODR[OB3T43V+P,_QPW;E6^/+3]XUE_[5EE#!G)@47A M-,RQT,C;^AZ;0-HLS-A4AYXJ16@$#$I"+/UVU''Q^M`>Z.D&QC?+3&]`'TJ MY=*H:NFQ;IFTQA/K6?@?U5X)C&"-G]=I!40&39\4L1_D4C+`O7%I9[54UDKX MS[\FJ]GI0N!'NF6.:P\(U]82Y0P$O*JQ$Z8*G1OO5I0B]M=96+H#^-U=&$LG M$#$`28V,TYH19$']/);"L27YZEZ5):#YKBZ,&03`8`^5$E9+8#61HD9*BO$^ MQ6PGX"87QF^#M/V%L=NLBEFQ6$Q6U_EBL=O>JOT3_@M1=OP2N6G_3##NO(<: M:!_F$BO%FGI"").QI95,$VIQ?H3/2!F>2)E=_TQJ3#D2B@DC2=B&'8.N?FD, MT^I4#%K_G)TR[1`^(V5D(F5D]>#"0.$%U-QZ',X+A`)?/T[G&/9[ZS`JRK1# M^'R482"-,E7_#.*PA5(@@%:Q.A1C:)>G-X:5691DO`SZ$N'3?+^E80"``@D`@1"/ON:-8I--:P+6LQ=]`GR4O`^P>WIN\G`GP%659.JFUT1)3 M+2FB=I-`4A&&H<^Z`S)H:Z:M`,RY4%Y`1K;B704:/TW6!6PD+OLF!@JE@##2 MC"B$%DD@7!V+`,!E7>T>M+=]!L M%VSJN:N-D(#9J)Z5!J9^7ZG)V^B:^^OR4>@6Q?>4X_'EJF2O!]A?*9&KXN8_ MOI<__W.V^%FLUDD>\?;?21+Q$TE\_.[3[;],/)S,U>V!?I$G9@0+L$?$.$:U M9PY3"EU-F``B*_XSZ.WO?$%J%])+)7-=NL_(`!.Q)(W\U$IYYBR6!'BJD*( M6OI+7G'>9=[M)?!UO1F./R(H)`B12'JGHY7O.:1(53#$;[R%[(C6)>9@5X96 M>=&;(71B_>\6=7F%#]_J+G$?R]4LB<.NIG^^U+[VDX*6(BIW)+C!S#I!H)4U MQ[#\_U*SW0MWQRP;RCNP+59R\.I6R@L_HZ].2Y\5E*+`J>A8`:`(MD*PJI-+ M4BQY;L2@S;[!O`>=,ZU[P_)QH5\F_US2CJP7\2H[\T`_2+W>._X@)VTS"I+,;60*)]"ZQ5Q%HNLFYT#E)P6N/S2PFL!UA[]E<Y7>-SA_?]5SHCI'`EHOJ<1("88E$[4ZCW",K71V^_JI M2[A[E+WM:MT_=ZD]G2X6Q;=9([/P^8R`(E&1*JN5Q`(RCYEF]KZJU4>U MC([X?\CYR8*[-WGZ>[&L*RO%16]7NXI4+(O)JEA]*E;W\W5JGACQW#9B^UA$ M;9U&5V'*8TJNG0\(W%G$*0'8*X8X%U)A5,'',6D6A;@>[=>%77\13G3OP/]5 MK!_1BFO]_".B>SF_W4V6BXC?JEI)`Z?]T)1`N:%6"P24D>G&!,/F,4XBG:84 M-3N:Z8?,)C&W@W,"C)0:#R#&VA,L`=((5X1*,+KKY_D,+[M!]@)OZF`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`ZI^IH@/$JZVQG@*94 M9_JD+81[/$*,!N7L9EU,-TL^*4)[QP>I%-&64&$01`Y2YI2IX8KOS,C\R,[$ MIPUT+Q3>?]^H\-W>&0$+("R2T"&NF3/41S]\2V#\WV69SP,4G^Y.@\Z%M,?D MEL7/8KF>19+3RH_FM3P;&;PTQG"GL/!(1[F'F%5GJ@C*D1\`G<'7W]):T4>5N MX="P8=&EZS&BVY:N3M&^E@CIP>)WK3X_$.>H=B)U?K#.<)%PJ\!CTF4IP@&: MZFV+ZB68<(D4[R??T)/5[$8MIC:1'4W+]/,Q97Y;E8Y<($B7NSR%EEKRV"!9 M>FTH;I;MV@V9-1M2'1WU,T*^J:531AF[+1<;(_]'.8_OWFK+G`8XG/W,P%/5 M(*$UYQ()[)$2VQM,$2B!1Q>FSA>8\C+(][;CO9J@-L4R"`,YY)XC3YBSR$B@ M;`4*(+C?),`^;L)>7B!?B7E_IR#%[/N/],)$-DR^%W_=I\#'AV^/9N.'^_5J M/5E,4XFTT^KQM8\*GBC/O4V5YP6R#B%"4`6)(RRK7=FK#:JK%,..(1^<%&X, MJA9$&NU/:7F] M^!UZ4M`:4!H!3Z7!N706TMW;B*D=FUG8D;0TD\F6F-#?,>/+W(T3JF_O^."5 M-A$_K!1D0&+!G`"UU2%M5KK"`,-K_4A8&U!?3(Y.^Q,'9@2C#1+""LVDL1XZ MX)&H"%2*CRWK[S*R=![8%SIZ/.="/19",:X5%%)"&Z'R$%>$>="PS,?U=/9K MW>3*Q[2_L'[J[/0E?N:I5.6GXP*BPBM,O>),4J\)XSM'F3DXMH*F6?Q\&6+/ M`+(WJ:BVS&*:XOW%8K5ETC+U_]H4*],/NS$?)P^;BWB)LAUYB^G'^631*(6X MBX\+7!@*O+/42Z*10(8B7[^\'F5YC@.4T3/EZF79R\MSXDJ3!`4U-M*ID',` M>B,,IK`BDG,]MDJ]EQ64QHF%K^/*E2460@*QAU3Z2)YD2%$E3$6<)2;KL'N` MCN.@1*X-CEQ-00H`"3<.1'<9:HR$D4K7;Y'D,FLK':"@M6GN9:-YE04I.*6: M8VSB[ZAT@91,L#K.$O\>V6:8P^2F!2E>!^G%+T^G$@"0`X$<,)0J8Z)FK98+ MF1F;]9W/MB:7IU\'ZD7+7\5]U4GAL39"(XZ@$ZS>5P&361&"P6\9N?QO`]*L MDC3;$@XGJ]$\&QB>=$*1(XH MF/(\I=&*IO(03M:!=1"55:^']%?(^&Q(K_!:$Q"I7)<1TA*NL>#2@-J@9G*$ MW2V[\BG.A;0WF=G4\D\KG;XSFUC@[TU_OU8U+>[X[[$[_^B'CE/SQ` MP$2J326)II#:E"%?IY]B1<86N*B%51G2!@ILY+G!K_)]R6G;4!_@4M8&QOH@DVIV[QD11REPAI, MK+.<"8"U?$P4B2YZ_-XE^^+L6ISO38G;W7P[H]/]JYX8',(*:1M=&40L,-1& MF"J0K!C="6F^L!QL5M\E[CUH@A33^E3<%+.?::%QW1_6/XKE^W+Q_4NQO-W] MY(+*XUKC_K>0$I[Q%&CD;O%UA-XV)K@(1J"-#UJ(,L&2G[!WQ(>F`P M+;GRU8+BCC&GB))("D\`@_JQ^!'T4%C8S"+NVE)0-S?I(O^CB&V$+3+'SQ:3 MQ4W<=G9DG MS.-ZB\\_BF+]/O$Y,?-X_LJA*4$02Y%#B@%@%`3,**4J$BDB65=9!RA5G4M" MV0GN%Q6MDQDOAR<%BI#!7G",G4#1WX9>D(I,KOS8:G#EL[N!_)P%;7\%(IX; M,">S./>.#]`BSH"-+YV%7!OIN*[PBM9@7BSW2N3FM6Q^6>BA!5S[NW#34!GK MAR>*N<']G(S'!D(-M%!Q86!$GQGAMQT>(E14C>X&:M\[8X^\Z3&#_>E*&S32 M_'UXT-1*P0QS7#G+%504R(HTK//RUP>H^?H1@]_RU+.!WR-3UP-Z'OV7V6@. M)&J9B.IL7;?7/)ZHM7=P$(X2R"PUT103TB%C-*V6JKP>6SG\5IC?&ISG<_[= M8K:>3>9)9QSG^F\#`]:*2A/-<8R`1$H!0T&U1!9_-+(3V/8XG@OE^=Q6TRAJ M$>DF#-\W-FC@*(P;15PK]9PI@4RMD$C44"-+QVR/YRV@>3[;/Y4/D_GZH:%^ MWS\Z2.F\(8)+;"2'2A,*3+58SDF6)3_`R@WML;X5/,]G?CKPF$>9VY0KB;@5 MJQ/\/S@A"*N#9F$6@+THR[5^7R:S%9IOC(W7(6 MW8*[%"QI*!&-)@>#,4%4*^3C'D8T!HSI+2E81L66(QU\S-+1!;P9^B(MY$>Q M_E6>4!,OQ@6K$#,VM>S"A$AK/:B=%0PDS+(-Q)CYGXED;X$9DV(,Q3+"LWY( M5U-.Q`WW#0^<`J:0UA0ZQ;FG@N+*TL48P68UPZ_':>@['M@"YCW&^>ZVW=]J MT^CE\AL$_QH^(RAEA33$>^B)((AQ(*J-%CL%QY8BF"<(OT7ZND'Y_$WJW\5\ MOHI\L+/)]T6Y6L]N3EPE/C@A6,@,!H))93%W\6_O1;5D:O#X,D):YV79`VBQ M/,'TIX,"=Q1#Q8P#5!EN##2DUH7>@;$9(EUS/0/;\]G^WOWU67TZSO6G8T)T MG2CBB!CDM=6&I.9!U<(4$6.[3=XQTS.@S:DIL)RL)Z=*">S&!&\,HTY;8:+! MXZ%#FE6F-!8BK\GE(..6G?(\`]H,GL^6Q_SX#V?_Q\GR\ET]OWV\]UL<3@7[M#0H!G&5L4-23MJ MH./.@)W;(T!6S>E!!B8[E8)\A,\7A'_%^2G_@XQ+=LK^+'#/Y_Q_3>9%F6)G#9)BCT\(T-M4LUA1QP"QUB2/=+OD MZ*30+'4@WYP\M(5S1O)2A.&_9\4)V^#YJ`"@M3J:JU(0I@FD7M1;%S%>Y-W8 M`&]."K+0O4R"M%I,-V'XG=R^;U!SJNDC@@/$4V@<J8V.T;'K1"T'H>W6Y.`=90*U\=$Q(-\^J<#3!RW3[+ MC^?@G@/R^;O88X.A\MO=8Q&KU;J,7V[6LK=;T\DY07@0]U]BM35*8R,AU/7V M"T">US/`L'9GTM$VTAEN<#*\I[-(Z&)SD_=^,J_6<]`=/CPE4,VLM(+J31D? M*J`0E>E.!$!T9!'P;@6D/:`SS3=8YZX0H'U6H'2`%DNW\I`/<&^FR![;[,\HRM]FCSA+4<0FY42I1V2$!#:_6J9%Z[\@$&\#LWK*:W)2W=^4B+JS\5N5,3A;3,E5\F6WJPBV*(XJPK4\( M+KJX+'HRFEMF+:38R1H4;?+Z20_PL*%K_7DAOES*`_QKKXP>'AP`<1)3!73< M36A\:P@G59R&6,.S+O3UD4Q_=_XKXCN_.&Y6SLO?QV2H"9S`W)0PO@K^L7&6R$DK6_`4>9E5A@* MOJ4P=E>0=R@[/V;??YPM/&ERX%I9&OU/3[7EV!$*!:M(H?S8D/#HQ&_.JJ*7OF$X!2BWI%H_D/GB-;`/'E;(,AK M:OOJ&/?/8OFUO%:!ZQ;ZC"RUYV6>/D<^I9CZ3H4>3%P[-3$8S`P`'$<2D/-Q M;Y;$5R1@GIG+]N8BSVWCG7'>OQ7A3]M$@[\7TU2)_S:N+]+]<5#%M?#L()RC$@E'/=%8&`\Q$?5;27F>)_CJD/95[Z&78LIP4A[* MU;K#G(?33P]6((IM=+&5(%@X#`2H@8,$9E5;@V\I%'\YIK1F*S;7HR?F!8N) M9QAA)3DWT50AC*(Z\,?S4KS0FPO5MPQW3A!DB13X7`HI,'D M((GES`O&(Q,@Q=AC5L?\K'!Y==S?7)2^"\Q[VSRW)U3NG[MBL3H6_7@^,'AI M2=S]H]\$L"-.1^.T/G60`&;E\?T?>]?6W#:.K/_+^0&SN%^JS@NNNU.5&:@MA>I; MX6]B6'YZN_WV3].;;ZOEUC+<&Y5_>4AFX@5R331#6A(*G*(/2A(2DP:+MQF4 M;X73O>F3!POKZN]Y/JF[N,1^Q'NTR[YA&84PN,.66PFTCMSRO(XH$XF3JKVA MMQ2_[X#;O0&KG-W'Q72\MY%@_5!&N:1(2!54**!&Y4J$SV;;U*;YS/&O#-.$2Z4`AY$,[^*(S"&:)H;_I8BZ&VR M.>6<)FBXN\#%"-UX$Z%&=3';&:O9.R@+,^<2*L:%-XA8X6D=U6>0I_6O0F\I M/[MU7I\E^^"/45E9X=%I4/S-'_EXO9BNIGO-Y&->$UQ(HAP%7@F)$=)4^;J: M#XL9&DFP>XM1YPZY/T@@;O;UEN"X>5E&PO9OHRJG0?%B8:@TJ%Z?,.W^)WY+ M0>O>9'`^<\R/IHM_CV;K?1[?[D&9\U!AIPP6`OK`4J5M%7%EGH"D.W7X+46Y M6^=U;Y#Z,E_DH]GT__+)/T?3^8=BN;R:/U"Q;Z<],#(CR#LG#(=$.^:10[[N MZL&)E6D5I]]B_+M=AI]N__\V^A%3Y-5M)#^+U-28&@Q5Y)C8YCUPE8%)CAG)JD@%'YSH?2>Q-";9K/Y MU]6O\^5JL8XSMC%K_[HL4_(I#YM\D.K'S1T/N$?'-7Y'1CU`#@9G"G+':.R+ M5,>$.4,FZ2HI?HL1^*Y8WQO^'A+*(G],,5_%G@'S\7[_=<^HS%J+@'6.0\"" M=L?.@/-1>Q;8G,R+M"1N'CV?$:=5(X'Y<@=PMI+[F`-Y*`OT^K> MO:7H>YML[F\7FHV"GW#]YV@1;[I>+RF24NSP6XKYGT<@YT6P^Y$OQM/EYK2] M_F--RSZ;_J3W90HXQ!GG!BFJ`#-(X'IY*^Z33JCP6SPJZ$,,1V)TF8]_N2F^ M_V-S8!81BK>?(S;Q(VQN?OLHW%?-]"<"7@!ALX&9980!#X4CEDILO7=UYCU7 MS*554W]+9P"=\+LWU5=--G!DLP"NUJNRY-_+N:=-AF7>4@3?/(_/6!\,Z.'F=CIY!^>'#8,:2D6EC(F,/8<2(L9=1&[PTPW3`-OV_2/P<)Z/"E_SV)]GIT MIIRCUB$&A8*0($&MT17Q"*4U@!S@6F\3#D77W#[?8O\]:JS5]'MN\]5H.CME M[>\(6NSZQCU+N=&X6,(+"`&9$4%]!LV)K?`E:Q50#K!F)]4-B7CH[?)4Z)_W M!6`.#,L<]`@*'6S7`#_"#?-,5B1HDA:'&=!:;%F>16<IIJX`3TJ1 M'1HX6A-CT18_.X+"9CZ;/F,[Q+';Q`/3@AR2F#G'?=4>B&ET,Y59$!$TS)2AP.!3O1` M1TSNS=NOJU%>?9U-;S9E&K9)&>['76EK[G$'&HS.I,`F^)Z(,XV=-@Y252\2 MR$B_'=2Z+!G3/A2*KKG=&\S4>+Q8YY-/@7V_%_/Q>A$9N0=8+SZ?<2H$D@`X M@@6PABBJ8;TX'4PJPO9Z%%4ZD-K@[OD\R5V_/]VQ?!U!I6!=*`(,=E9(;[GG M"H-2/E):8!OV5#ZO.XH8-3I`#'(?+"VI%,&\(D$8E'3-8$#&9A="/<8G/8[- M@_))M5!*Z0!&C8%5BA'O:35U#T1:A;GA(*1=,>[Q28_CYT!\4@H],"[8VQHK M)TSPJF0]:6CLI00FDN2URR<]CG>#]4FMAYX+XJ"&P8;5'`F&*C*D(V_*)SU6 M#W3$Y%?F+#BFM.$<88HI8QAXH5A%'&$H[7KWV(MV2(8&PIYA@'GQPXR0VK>0PI2;HT.\"+/AVB MKCNN]W?);!H+1<\GRX^C^V@@'*GDF@S/&!4R&!LZ6*#20`H%\:(B'1F>E"@] MP%L_'0*N`W;WAK2G;&F$K]V#,HZ5AH('O\99"#`)S*R=$^QPDAH[_K90L1K- M7BNJ6F/R^>*XI7-SP4F`5!.@(&1.8\L1UY;";=87\\S&VVUG2P)\XAR6C75C M+NF+_F>3O,#37IC%[ADN.)_6`AA<3\*-!!6+@D.:UBSN5>XRC4'SM`QD'P+H M7E?\L0JSTJ-E/C'%;2RY7`X_GXYXD-#5]>,9?SM\ M7^9A.R_.O,?(4P^$5M!RICC0FY,_J2P7I%F$],PLTX\I:Z)D$M^<*WH\7]U77YYZN[$@[SR:<\ M<&\Z#G26OU=_CQ83-5X%%V!U?^[SZ:'J,BS"QD,,`E8Q&O8][3E07AM'A>=. M-%N67=M)#XA]3*&*MW!NRFX22WW_#-6E^'<=F+?^'9FFBE#/,`PK-QC_D""D M*D92#B[MXD5?L-MI:?4KK_XBZ.4,PW?N.+9_\;G,20V(!/&8TFOJ')/05,1( M#I,J@0P0?&=`P=/P>0+[>\/2Z8[,PBZ_+H,4L(41E)K M%GPD:@F@O&*M9:K?.S2]]#P\#5DO-28XKRSZ@WDT]AZ3&:?]6QZK8.Q#Z^Y1 M&060Z$"?LX8&^A"$E-:[$Z.7MI>?%RQ/D=N:7'H#H+N]FQ7W>?[(&SD(OYUC M,D@HUH1+PJT6A@LGN*^)Y/C24B<&!;ZVI-(;])ZXO`=A]^+S&:#*4`."JZ\< M(@HBJ>I=Q@&35DCN'7)[(=>&1(9C4>YBW(<]:8GMO3Q3%FD.-#(78_J'>9#1_JFX8"#X5L-U=F/G\;S3<;RM(7B^M\NEH'F/V9 MQ_HQ^40%SV)TD_\SWC"+A6^;5/D?Q@3#QN@=(YX2CVR0(&08;",Y$EBK+RVN MWR?@VUIKYQ3XZ3GN-A\O\D#*=+[IF#:J6GAQW9K2 MEL#`!#G\M;+=M1Y5W=MPH(M%LNN[,FE1<.N,"AQ5&'OH+'$54ZE,NPY_=%+X M^^KH7(+ORZ(14RUAT!*+;3#GH)$>":,JIC(GFN5=MI6ZOED6;C[9+HJ[\.,B MF,*E9_&^0EH6YFM<(4_0>:I]M`+%2Q<"37A$-):14'*DLKW')VR M_[[)G$FN[PNK=0'(P'*-J=(LV,124*REK@4@TMI/']TAY7V;.K^(A[_&#D;Q M?B_*FO?YI#NS[]@Y9"3`PV-FE?""1E."&U.[GA0GG2P>W?'E?0,[FV0O8'F5 ML93EK_./)8K.LKI^GD(F,=6<.8(],<1[*X41E0@(D$EE6@;8H.8BEU622"]@ M50UQTP*4>(`5]0Y@++`RRM1G"PJGQ3#@T;UXWJW#(4CYDI;:,+,.FD\O,]#$ M"M\0>"&IDX*18(=L12>!2ZMJ?'32P;M9.42I7\""_=DV&.:J/7*.&3;`*X@T M5ER+@$09R_U7(>74C@=#3-&[Q$7;K=`O8.5>SE:K@2..*8E,@%J,6"-)ZT-2 MR]*JP9Z8!?)N"P\6`,-?NP-,M%**$LRU(=I0*#GUFL@MBR&1/NVZV8FY).]K MK%>A#G_='-0I_RX5REGCHS]/(1,`(VBEP%QPB!D74*I:!$&)):VK`=91?(W+ MJ%N97MRR&J8]>>0<,XN?90O6W]=9G_M0[CW/"$:*E8H(H!;PGPUFW!ZL6 MOO!X1C0PWEB`*<>:"PM3^C-8G415,3,$0=`8Z"Q4PE-:;`'>7IM7Z@<&S.GG)C.\-4R:R)U\$ M;J[N8XG``_KLI<:QIDIX:8DW&-O54"PSM4?_< MK1?C;Z-EKFX6>1D2?CK]!DJIX3LR!J4R@`$.J#?A,XS7CK=,T!I>6F7C-"`\ MTT#=F[P+1X\E1<3\MDP/)LJ9CMK**W=U`FO%=>0B-8F*V7QD)'==C:&6'& M>)=TH7Z`BB5=A$5'K#T=%::XO9V67_NY^+@H8N-4OR[OV=OU(OQ[-<__%7X. M0OC\=WCH?C**;7R_YJ-%,/SRG6E?K;T[,\')]3P6F0R6(E72Z?!?I;@3&Y@. MWW5+Q-@9)'`Z%#_'+_V6P^)Z'GR,16WZ[X+7KNA$R+3$U608H"-A\.SYC&*&)3/$.V\9$5I;!FK"L.W5MJ! M02I7CS1SE_GXEYOB^S\VFV$T;GZ;_5KOFG_&T^NP>1XJ.M1L M8.:9D(AZA)TG@AF+(>:!3(VP80"A)/`,,8NX+?!TPMX^CH. M4]Y&O,(V^;&83"F\##$]=VBX8/92U M;HH@O'%\\=7UKV%`D-!T-'.+1;$H`P&;)*E!J`3S+>:5EGFA<7H/,S].21Q^ M38:5IQB#V*6&8`>H`E"4HE14T&`&G%-MU&U1GLU^/OD8K[-MW!DU^<]ZLS/% M)CQ!K+=- MY2."XLE;_+V MO.!YFFS2NGSZ.VBK^/''.)^/`DL.)>>^]'RF5'2&-<20<.(Y`,;+BCBL61+X MAACN/I_2;(/__8%K.\NR#D^5TU"B-Y<7L0706B:`X9192("!01ZU77],/D] M%#Y[-O-.6*RD($;!8#0J7(4'`V'2D0O-HTT2<=$N3WM,D9TO`]&34DPE^?=- M`OK[AF6>4^5BZAT2`%/,H5;U-@ZENS2#N0/XM,C>WI#T91EWTN5J&@/S^XR4 MGQ_,*(!(*0@$DPAP@*0DJ":'D$MK>M\!6I(8>H8+'LOF>F;WH"SPA\43+,^Q MC"40N6.U[26Q4!>62](!;EIC;F\8LOG757/PO/!T%I/`&=.&<^\T0AA*:"K" ME$))O3H&F$32`6K2N=JCROF>S]=YP'D1')/C+)R#8S/C`V6.(.2)9I(!`'2] M#U/"FIG_;34%?)50:IO'IV]Z:%?AO]IUB8]7)5W`:^;R;=7`\U M&)T1[CC2CCE#*;+$.`M833B"29KHZ.YNKPIK2-0?=R>_,.#="!<9+(HP3&FH/'@Q'F.;-#;`76@=0[(OW MO0'TU_DXK*K/HQ_-\;=K2&8TI);H0)U@##*`-205B=S*)$UW?$NP5XFOEGC; M8X3R-DCE6SY?3K_GF\D?NXZ( MU[W![??\[T=<613S\'%<'L`=;;H=^ZH,.1Y4MX$88H0D4H"YA\@N-&E-7MY& MY+QCG@_E,/7A[#K0>)1U(=H\.3+,K]>SSZ$M;@\=PW1MH]? M&?#"6NZAXX8;('P,69:7&)35N&'\I>O,]TH\'V=1CH]DU#R_??\K,FBQ=U0: M:)T4U!N*+:_9@-"E58YL`Q`[<]9;975O6];.6>O[!E7<&HS.I,1*6J@$D8C\ M?W=7T]0V#$3_DKZE/>JS/7#HM)UI;YH`'IHI-$P"S-!?7R6@E`!Q'$LX'E\X MA+5'^]Y:?K)V5\0Z;*3-CFM_%H^H[+2.L.;4^W4JJ:.`C%%`47@Z M8T5H!>!'4E*:QG[W^&-^V>RA95T0<[M8KCW\UEQM5H!'U)3VO7MT2&*N=,`8 M(9X4J$8D9/""TE.32C7":'\)Z4`LG&@K$`P?VN\/OT($IY,>FN!8JR$:?\LED_-G^1R<_%K[ZD`[YE%$YQ%S"JT/D$-F`!)61Z> M!IA:S\@*/"VJH=F?;)^$=CO/_RTB$\X2Y]+*S@OA)5::TSPH8DE1O^$1KG8J M4]P;R/[LNO0VNVDNVPG>,8I*((+B^_:5=-%8*8`HA!=AY9*BP>:X$*D11T]>C=<4@<56'V]<1 M4P!J04;TPVR5HK[]!;1C%#VV00ML&$FS)]%`C))Y:,BPHGEDA#JR)R^+2OCU MI_9SL[QH;@^2^\HLVC35"?"!!12X\I("XWEX7,NI:<@*])8AV)_@[X^KV?ER MWD[OCE'DG@5OF;)&6P-!^>1E'IHVDQ./%<@MP:]@B7]]?]/<_9T=6.'O6$6= M'*.@G+-8*0K$!9JU"G@*14_N"$LE*Y!;!&!_=G\NKF?S93NW+VVB"Z/6J9&=-M\]?O+6MPDUJ\:W!*( M;9N0FE5EC%UPP& MS8QSH)ER6N<4&"YPMT\B'YU:<>2,V.D`@.*;1T&3Z$(N,$`\O:2]`;?-'D+@ MRXHCQC=9U`BBO8D5`Y'0:19Y_L_ZS_ELU:1?_@%02P,$%`````@`:8!D1T1Z MHL)O&P``-TL!`!$`'`!P9&QI+3(P,34P.3,P+GAS9%54"0`#EG(Z5I9R.E9U M>`L``00E#@``!#D!``#L7>MOXSB2_W[`_0^\``?T`N>.G4=WIS&]"^O/Y)Z2Y1(RC72^!^#IPGY$,` M.6?X,>3HDC+_'"U@Z/$O>R'Y(X0>7F#D"BD$`LI9,A]YI`M$;^%/@I6T$%? M]IXX7WW>W__QX\?[E>N]=ZB_?S">'(]/#H5*0DD2?/8P^5[(^/+(O/>4+47. M\>&^_/P(`Y1D)Y20T-<3N)SM\_4*[8M,(Y$+,>RD=&:B(H&0%ULI(#FY/,V: M%_]X/_J8SXH;E,4DX)`XJ;(OE5!`CEEZTOQMYUH'F,% M+A<9$RGCB91Q\F$3&15K@I:R\[:7*4^U74%:5$Q"L;D`^A[<1HX\Y6U$N$UQ MNHFR@1QZ-V+9BA("6?)QRS(#Y+Q?TN=]AX:$L[7LH@YM^C8=7?+'*&/259J0 M,1$"*;9'K<3)$Z9_C3(V'05R$6XM2T(C?VPN`7IQGJP]3X5(_>KD;`K\,'E& M`6]M)#FR^/?F)D(@=I0KGK21)*.*?HXR!AWE"+#36HJ$1O[8@@1\Q=J+D!"I M7TU"0$(H5YQ46I*Z6F&RH'&22)0^_'/BR._1`JAX]7/L19NCVOT5HRO$.!;! M56X$H!@\,;3XLB?#\U$2BO_3@=Y[$0 MY/`@<@`L!GQ3QV$AEC+O`9GAV_V5=NRJBM<0I64DI61V]->#B?C? M>`Q&X!P'CD>#D"'Q1\P%Y-C\LE^F+;,-`^3.R%_5[W(MQ-1QEB;*4M.U)RRV M#CU=G)I4<[O:KZ:':W0PQ]*8A@P)\0.Z.^4.H)D4!8ZA41]8^N M:6")D!6GYM!$A&':T"1A#11O4&`.(N[@G>0_(*BO]TY=8Q?&S?WEP?A(&[[8 MXSOTI/:@RU4B-_30;'$*/;D,$,P6EJ3;-I/-13$;ELX1MS&L1$9`%R"14OYN MQ68P2@.<;7Q^"W[-@<#!6!\(M#&/'0T1SF#P=(Z?L8N(:P-;,;]A)N*CQMU+ M!B#EL-/5W=YK-Y(;QC(?-;ZY",;@?,L(S4/?AVP]6YQ1$N_PN1<=2G!)693" ML>@U;BEO,;&P80%FE"N.LHQR7*AT?EFQ0)4+%I2!7,E`%3U8@ZHY:]^FHS(, M93]J/%@9MQUV41=_A/@9>D*18$K<*[4(*?>VV:)13]_LPL;'=2XLQQ%`XH(< MSP&@7&5,GT6_(0U7=&ESD6&.G)"I:9DX")\_(<3//!@$>(&C-<]6?>EKE-S< MR8Z/-3.Z)J,`[U)Y1D*@D90(9"(E0Q*@A`)%J7:[_ZT%N%O\9,W.;`3Z>*K1 M"(8(JQG3+"`2N<2G^D:\'=!;EV>V"GW\U6@5^8A,9I89&KN+P7JT:+:*T$Q< MFB.V\7%=Q-:(]*[&<-3W<>R6B2L&&!R3)2*.W1Z()FK#%,2!+G[+V"F`"@P' M9-*JN`RYJ+`;49H?^K,5DHZ++*\1#-`=7"L2^TYX&\48QKX'NKZW"6OP+BH; MQ(6#M'2@B@=)^3O36#:>TXC#\-,QX'.;S9# MM[-.D[B("'+Q(Z`>=N5:1G[L:H>7D4D38,)]'HZ5"YV+JE3G"25>L]OSB]OY MQ;G\-9]=7YU/'\0?I]/KZ>W9!9A_O;AXF`]PE6OZ#LK]>4^(BW&]MQWP2BQ- M4!ZKMM<:2O"N6,[0%"40:34&T?#QTJ,_@F\$ABY6Q\*ZP6O@:D#XR+JQSA_$ M?VXN;@6ZLTMP-IU_!9?7L]\%UFEA`\P50*JKU-MIU.T*,1C!@74S+QG![.;N M_N*KR'?UVP6XNA5_7PQ-OP-XH*3A:VZ_,@:2E#[,?>DG9)7ID(63K@_'D4VZ[3/3O+KAM7*2AM1X>C4^,N&M2WB6"@%@2M64G MD05(8%K=D*/IJM0-]3B($<$"5*\(]W?G>?$9LY8A@%HJX.MHVZGK,9^.--@(\* ME=@?#-@7$>JRFM7,P8RE9@FK@N6P;%6!JK1INLL>[)8*`<>O?H&9$073+J7V-'CJB"F>B!)N/9(OZT M&<;="S1;0S4PK;&&3`CI\908("X,2$%`(@F0HH#)^+]EOCC'8$&%VK1WB@W4 M!L_X2><9:[`=W&.N=G,-+#A=_XKHDL'5$W:F#,'-VK$-:W.+K<:F=:CFVV@` M'M<@*Q'((G>W528/+$R)>T$XYNLKLJ#,MXV/&LF;$!RGZ_#I$P^YGX(=B/B! M',-=P^828O8;]$)T@Z"T<-MSO'JZYJ!U?*0)6B4CH#B!/*L!!U$)EYA`XF#H M79&`,V6V0?S=G?*49":W+X2,8;(\A0&V'\F_0J'-/>KX2!,#U5@`>)=*`G*B M)'E<`'F>5/3!$*0B`273[G:Y6F2OA7/R#K\1^A@@]BRCD"NR"KG<@B*JV<.Y M0]>=NX!699B-I;+`4F-K/OM?]]PACZ[@^ZOKO&9$3X7^BP*_D2,4$J MIQP#I)*"O*C%"WUVN/_6FD*'&-"*C]D:JD%@K34,46`->EG\=;%8B+AEMCA' M##^KNLJ-FZ](\]&6Z/RX[9FG#2WE+64V6V5UT%EKE?D`,U)%_LJ4*BW^&*;A]&-A`;5F9/-+%C'H8A7BQB<\?H,Y8W2XN> M(I?*@:#:E11X1WL@C-ED>D-E5(AY0 M\JE\W][/WX-43A`+FB>7L@X&J('_&V'1S/B?R!493A$11;'C M'(1N02YN=(1P=AFJ:)$M5/446%<7&B4;X"^ M)4`V(4=GUF;P*_,#6P%_]P+)"D36P7P=I6$]0W>H6(_=CH;VZE3U/7(05KN: M10M1+ZA>4[)\0,S/OEB!9,_,$.GHWA.-#H!G3%3+BMY[E26,N"@B]WGG1@OV MM=\A/.K,V]"Y?M2,,-H"/<14`OT96T*"_U2""'A.PP`3%-BTVCI*0Q/5C=CS MK!1J";,!#54-[1N>)2-#*].-XVNQ&IJ3!%!V-]$LK`U*N=R&B2[=,<6H;XOH M=[BB.[2.>F+#S);ND%`>AJ$1%+')_>R"3I7)$> MHL'_U>"F2]L(P@:&9C0U_DV/ICY]@#9?ZRU\6"VQP7?I]GG70;:C'NM_0\@X M8M[Z,KDF\1QRV.;14Q,'PS*9;JMKRA*D/(%DNLLOFAJJN;V#:\G0L(RCVQ9K M`^/@^>< M.M]/82"O/O/E^WU*)`NX:@@-2X>Z2_44IY%B!?*\!BC4CBO7547(<^7I+>[W M:`F9//DT"]EL)5."BQ?$'!RTZ'2W6YYA@>J#YKAR'?#@729$_NYZD(H!A!P@ M%@2DDNQN'ZR'LGWD9@BR:M"[1P%GV%'WOHGO4T=4$N;K#;%L MYFI&MO(4<#VR65%1)I`4-B!=Q$0=_XCO](-D+?[CBT0%S[.H)1F8?"-N?.A$ M4=]YD-BOKKQ&J69+J1Q8JK>42)3D^C\A#(BD2>PFD0:,YJ55`9AFX*JL3]9)=J31V' MAH1CLKRC'G;L]N);,C)LO=`WI\PUY6[^RIB#A/L`GJ[.SRB3\1]6=T$*`HX8 MAMX%8Y0IOV!_.\1VRS-L"CC03;A9FP+(I)"Y<2H'0%(0P-5P;&5N\M][=VW7[!V/QC\9?VR.<_!IPU<*0/7:@V_`S6UP$ M',O^T?T6H$7H78NFTF+ZY+5%,/<.U9FZ%K:3?W&A9@>3?#LDD0]$`@(EX="A MV*(>O[M]NKZ!_Z(L>:,[V';L85V@V:BJDR<=C2J61+XXKF1)7R@/=O@6*SLX M[:=2VK`S;&V4_VR"_?__R99?]E\"]S-9R':4T8@(,3_G-Y?3<]OD/^(V!X@T$=?]HI)V%-K)PEA(,;Q'/-0 M%O,KH^'JR][+(_/P9\R1OP>X$//+'J&$A/YGE_H0DROQ04J_!Z*,HHO'U'U0 M&=V0Q1M&]MO([#BA+RL=Q8<_JH]97=,@F,;TJ5ZMR;KH'J7(*5NR?`W5D7?_ M4L*KF/9V@.6D%,Z;(?>>KJ''U_=X^<2C:'3]@%[XJ4>=[YGT5GDWT(HG;%X# MCDAXIJ0NPZ+]UL?VE&Z7N::0E+30?^N#D?F4\?CV)WGY_2._"H)0/F-Y1@,Y MVQPK8,S6O97[E(@`@JW+RCQ&SVD*3=`CYANH*"H,>BQJ&2NXEE]]^(+]T$_5 M:\SR%JIA$G`H3X>U,L%G*"0KVUXIL8]-YUET\XB5Y2XF]E=N>4]A=@VA5HN: M+/W5*>](M!II,_11GQ?Z*RHWB6):#Z4^@PS]AM&/HMR5U!XX$/EG*'['TZ'D&8G80`@F!DX%,$T97Q$K1X2,[<$JJ:G"@`5EJY`)%0)$%W&$ MH(+1HJ;&O#U65L$CAL&B03W+!D47,(FZ@R)'*W_WDHQ^(S@KZ*O^7[6#]$IK4+ MUZ)??D20R>+O5'EI#6V'5Y\K*^W1XGNQD]9_Q["#IH'0P9$38DNU9(")@U?0 MRZJG(W4G-R!\P"KBMP4GH/J;Z9(A]:'>`,SYNH.;B/H*L5=1[))KKOG8!]]< M%$T]Z>Y>$8X8"KA\6K)&!VW&5S0R*Z'+XXL571:Z;=:^AZ+/B@H&(541F=6X()L-T$>4NA8_G M8OSC1Y_4G\C-*J`#Y09K2(K3-IIT^BXL"F;D+H[5W#/H>?$A6#D5GFEIF_U- M,.X6&9VC%?616XR(RHD]G$V+#@_)&94;42$.])IF;&TS]US/.I5Z+#UUE*.' MQ!7_%AT@SDZ=EU>A+?/V;^GY/$27Z)&%HMD>C"?')9QJ/O81K%!$GWH5RNF] ME%Y0P;+DA;0>2GWAE=>5"RD]&(+*J7O9%I_%0%)^B9QO0#TW^I7*;<[WFA[? M*L))=TOZD'U'',?C8U$-,E()L"^B%B;J+S>OC=/!2JKHADS>:!A>;X(AHRX5 M0K$Y\KS+:$93C,-4[LG[@^,/)0.US]_'!F>2_F-+;3_^U-J>M-3VY&?6]L.X MG;:Y_#^=M@ZIH+%S_)<4HRSLR&F45E6^3_";3] M71Z**L_0FS+]!'H%S1KU84=`O2[)]7[17>_E@5O]Y_Z-U5)9<^^]U.JCS_-F M2I65($N63F'XU%6;_R6Q7#Z!`72HOZ)$$-)%$J.*H;5:5\%J3S=!996WP[&W M$]N7F(FQ2;30$&_OR"I`]ZG'FKQD>Q+$P$.`LTI7B>@B@%XV,+/,V[=A26YI M>96LE$.YU2`RO%)W:IFYAYWKKTBV*.0\%36J)O=1=D\,:OF?I5F72FH/9C%^ M#:%:>$#N'\FMM<76_H273ZD"EIG[NXW%J(%'?UAK&^7MG;*U5OE5]DBKRJ;Y M:G(/6]1785DEL?,I?91XK7B4*[N2JP0T=E;9`*%.QF-BWR*?6_*[DS@K=^2S=AUX88;8G M:T:*ZY"9Z(UYWGH?5R(>BPZ0EZ7.DONW#%[4`?N%LY7Q3M:"/K59>M>^:UO( MWT6`3YM6QYLR]-#A7%_&ZWWL1;B!SGN0J MMGI#N.(OZC_WP&O$NT*GOMQB-EMD9X]EAQ1\6U$RY5R4%%U:A;`NSA3J@ M>";["<16D'&<]2+-6;KK)J?IEHAM')@F\N5NX$^NWC^C8FB&W-.U;M=FFE96 M=!-&;[[9)5*"+N)9'-&A/Z)H>K^L:&V>-X.TMH]7]]-<4[)47KI^#<^O,5)J7@4/^I!V[K+K>4$"\R)&$,JS M"E%KR"G0D*5O4R699O($C:!2_8E0:0-X5.^Y.3[)+%L4O.;G MXNX@=N]R;<0F9^_"V9RBU$'(#>[C_E>]R7(O,KFRW\I=F7!*&:,_!&2G#$'G M:;:0?5QFK!NSZ7$5&4YHO,V1C"T/8W1*E)Q!4XX^^(3TPH3D^+/K"$EI)*FH M3;K@\*6LC3%W[R#4**R[3:+VZ_]5=RV]#<(P^!_UT-YVV[3C'EKWO*80VD@L MJ0AHXM_/0-*`(0E#W>H=24ST?<3.TS9T9XY)Q#I,B.;^QFMF3Q5O_%58OCK" M?DWB)'7^:@(&MN5IU>:0%[+GV"'D<1AL&Q>[>%2M24)K[PY..ZA3)'LS*3D^ M\X0I9B`PUPB>%`3>6@K*YE1'R2[-%AB&N>718Z6;+7YYY>N-7G;N@=Z3FB76 MZTUC6A%9NM&]VZF1'!>2G9%<`FWC9"K3WJ[^095;$W=]79Z2B$V?HIZE)1JG MK8Z*'1+-S_8>9?PT>>G+Y*D_0V-<`X'U,O:Q]VDFW'6$NJ,OI])W0K:[<#WF M'A*E=SSFQ_W2]YZ(B\VCEI97A[J9:ZI=^U%^QY?;HE59PHJBAC;;S&-,IA70 M:3/T\M0FEU!R%#<05N^SM4K+ZIW_.>^L-E/%C[_,DB:(VOYPQ!HN+7V5!%:6 M\T;J?SD<6R>"U;`SQL4$'24:D#F`]'K;AP0(J-6+@FU[HJ06*>_D]P)V'V#@ M*%\ISMNTY$5J*V9_KS;1$0>.(B5'I13ZSV!26?.MBY%[9*">6F]@3NL(IZEZ M:IQB&K:9U+`-`0V+(2^_U"3V?CE%]+5FNT(@Z*B0(.Y7*5I_^;)6V;U(#F*/ M??*"$@09O=T,\?>>":)]YWD.9E[>"K:7"N`D:.D8$B#,)^1D&Y$AR.I#Y4P@ M3T94]H>HNQ]J:1@4/QD\?@-02P$"'@,4````"`!I@&1'G,IS957/`0#:HQ\` M$0`8```````!````I($`````<&1L:2TR,#$U,#DS,"YX;6Q55`4``Y9R.E9U M>`L``00E#@``!#D!``!02P$"'@,4````"`!I@&1'D*NPL<,A``"A9`$`%0`8 M```````!````I(&@SP$`<&1L:2TR,#$U,#DS,%]C86PN>&UL550%``.6O^O:@``JP0%`!4` M&````````0```*2!LO$!`'!D;&DM,C`Q-3`Y,S!?9&5F+GAM;%54!0`#EG(Z M5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`&F`9$?37Q[%7=(``,8R"P`5 M`!@```````$```"D@;!<`@!P9&QI+3(P,34P.3,P7VQA8BYX;6Q55`4``Y9R M.E9U>`L``00E#@``!#D!``!02P$"'@,4````"`!I@&1'CE'VO@.6```17`<` M%0`8```````!````I(%<+P,`<&1L:2TR,#$U,#DS,%]P&UL550%``.6 M'-D550%``.6 XML 48 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares
shares in Thousands

Sep. 30, 2015
^[1]
Dec. 31, 2014
^[2]

Preferred stock par value (in Dollars per Share) $ 0.01 $ 0.01

Preferred stock, shares authorized (in Shares) 10,000 10,000

Preferred stock, shares issued (in Shares) 0 0

Preferred stock, shares outstanding (in Shares) 0 0

Common stock par value (in Dollars per Share) $ 0.01 $ 0.01

Common stock, shares authorized (in Shares) 350,000 350,000

Common stock, shares issued (in Shares) 163,573 162,186

Common stock, shares outstanding (in Shares) 163,573 162,186

[1] unaudited

[2] Note 1

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 49 R59.htm IDEA: XBRL DOCUMENT v3.3.0.814

Cash Dividends (Narrative) (Detail)
3 Months Ended

Sep. 30, 2015

$ / shares

Stockholders' Equity Note [Abstract]

Dividends payable quarterly (in Dollars per Share) $ 0.15

Dividends payable, date declared (Date) Jan. 27, 2015

X

- Definition
The per share amount of a dividend declared, but not paid, as of the financial reporting date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DividendsPayableAmountPerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Date the dividend to be paid was declared, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

+ Details

Name: us-gaap_DividendsPayableDateDeclaredDayMonthAndYear

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 50 R35.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Narrative) (Detail) - USD ($)
3 Months Ended 9 Months Ended

Sep. 22, 2015

Sep. 30, 2015

Sep. 30, 2015

Sep. 30, 2014

Sep. 23, 2015

Sep. 18, 2015

Jul. 28, 2015

Dec. 31, 2014

Nov. 06, 2014

Jun. 26, 2014

Oct. 18, 2013

Apr. 18, 2013

Cash payment for purchase of royalty right $ 65,600,000

Royalty rights $ 384,572,000 ^[1] $ 384,572,000 ^[1] $ 259,244,000 ^[2]

Transfers from level 1 to level 2, amount 0 0 0

Transfers from level 2 to level 1, amount $ 0 0 0

Percentage of royalty acquired 75.00%

Financing receivable, gross $ 20,000,000

Proceeds from Collection of Notes Receivable $ 21,400,000 $ 20,600,000 $ 0

Depomed [Member]

Cash payment for purchase of royalty right $ 240,500,000

Purchase of royalty rights 241,300,000

Royalty right purchase transaction costs $ 800,000

Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 21.00% 21.00%

Fair Value Measurements, Sensitivity Analysis, Description Should these discount rates increase or decrease by 5%, the fair value of the asset could decrease by $18.3 million or increase by $23.2 million, respectively. A third-party expert was engaged to help management develop its original estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. We periodically assess the expected future cash flows and to the extent such payments are greater or less than our initial estimates, or the timing of such payments is materially different than our original estimates, we will adjust the estimated fair value of the asset. Certain manufacturers of generic equivalents to Glumetza will be permitted to enter the market starting in February and August 2016. Our current expected future cash flows anticipate a reduction in future cash flows of Glumetza as result of the generic competition in 2016. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $7.1 million or decrease by $7.7 million, respectively.

Royalty rights $ 178,200,000 $ 178,200,000 176,200,000

Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount $ 178,200,000 $ 178,200,000

VB [Member]

Purchase of royalty rights $ 15,500,000

Fair value inputs, discount rate (in Percent) 17.50%

Fair Value Measurements, Sensitivity Analysis, Description Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $2.4 million or increase by $3.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $0.8 million or decrease by $0.8 million, respectively.

Royalty rights $ 16,900,000 $ 16,900,000 16,100,000

Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount $ 16,900,000 $ 16,900,000

University of Michigan [Member]

Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 12.80% 12.80%

Fair Value Measurements, Sensitivity Analysis, Description Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $11.1 million or increase by $14.5 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.6 million or decrease by $3.6 million, respectively.

Royalty rights $ 71,600,000 $ 71,600,000 66,900,000

Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount $ 71,600,000 $ 71,600,000

ARIAD [Member]

Annual royalty payment, maximum $ 20,000,000

Purchase of royalty rights 100,000,000

Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 10.00% 10.00%

Fair Value Measurements, Sensitivity Analysis, Description Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $15.1 million or increase by $20.0 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $2.5 million or decrease by $2.5 million, respectively.

Royalty rights $ 49,900,000 $ 49,900,000 0

Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount $ 49,900,000 $ 49,900,000

ARIAD [Member] | Tranche 1 [Member]

Purchase of royalty rights 50,000,000

ARIAD [Member] | Tranche 3 [Member]

Cash payment for purchase of royalty right $ 100,000,000

ARIAD [Member] | High [Member]

Fixed royalty rate as a percentage of sales 7.50%

ARIAD [Member] | Low [Member]

Fixed royalty rate as a percentage of sales 2.50%

AcelRx [Member]

Purchase of royalty rights $ 65,000,000

Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 13.40% 13.40%

Fair Value Measurements, Sensitivity Analysis, Description Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $18.4 million or increase by $29.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.3 million or decrease by $3.3 million, respectively

Royalty rights $ 65,300,000 $ 65,300,000 0

Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount $ 65,300,000 $ 65,300,000

Percentage of royalty acquired 75.00%

Avinger Royalty Right [Member]

Fixed royalty rate as a percentage of sales 0.90% 1.80%

Long-Duration Contracts, Assumptions by Product and Guarantee, Discount Rate 15.00% 15.00%

Fair Value Measurements, Sensitivity Analysis, Description Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5.0%, the fair value of this asset could decrease by $158,000 or increase by $179,000, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $137,000 or decrease by $137,000, respectively.

Royalty rights $ 2,700,000 $ 2,700,000 $ 0

Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount $ 2,700,000 $ 2,700,000

[1] unaudited

[2] Note 1

X

- Definition
Annual royalty payment, maximum
+ References
No definition available.
+ Details

Name: pdli_Annualroyaltypaymentmaximum

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Cash payment for purchase of royalty right
+ References
No definition available.
+ Details

Name: pdli_Cashpaymentforpurchaseofroyaltyright

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Fixed royalty rate as a percentage of sales
+ References
No definition available.
+ Details

Name: pdli_Fixedroyaltyrateasapercentageofsales

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of royalty acquired
+ References
No definition available.
+ Details

Name: pdli_Percentageofroyaltyacquired

Namespace Prefix: pdli_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Purchase of royalty right
+ References
No definition available.
+ Details

Name: pdli_Purchaseofroyaltyright

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Royalty right purchase transaction costs
+ References
No definition available.
+ Details

Name: pdli_Royaltyrightpurchasetransactioncosts

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Royalty rights
+ References
No definition available.
+ Details

Name: pdli_Royaltyrights

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of transfers of financial instruments classified in shareholders' equity measured on a recurring basis out of level 1 of the fair value hierarchy into level 2.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueEquityLevel1ToLevel2TransfersAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of transfers of financial instruments classified in shareholders' equity measured on a recurring basis out of level 2 of the fair value hierarchy into level 1.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueEquityLevel2ToLevel1TransfersAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value. For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (bbb)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInputsDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of the sensitivity of the fair value measurements to changes in unobservable inputs and the inter-relationships between those inputs as well as how those inter-relationships might magnify or mitigate the effect of changes in the unobservable inputs on the fair value measurements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (g)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementsSensitivityAnalysisDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage discount rate used to calculate present value of an expected stream of future payments, which is included in the calculation of the amount of the specified guaranteed benefit obligation as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 80

-Section 50

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=6484115&loc=d3e19393-158473

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 40

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6482852&loc=d3e14931-158439

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 20

-Section 55

-Paragraph 15

-Subparagraph (f)

-URI http://asc.fasb.org/extlink&oid=6588021&loc=d3e7104-158389

+ Details

Name: us-gaap_LongDurationContractsAssumptionsByProductAndGuaranteeDiscountRate

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount representing an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. Excludes amounts related to receivables held-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.10(3))

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

+ Details

Name: us-gaap_NotesReceivableGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromCollectionOfNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The reporting entity's maximum amount of exposure to loss as a result of its involvement with the Variable Interest Entity (VIE).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph b

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5728-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=52262685&loc=d3e5747-111685

+ Details

Name: us-gaap_VariableInterestEntityEntityMaximumLossExposureAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_ProductOrServiceAxis=pdli_DepomedMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=pdli_VBMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=pdli_UniversityofMichiganMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=pdli_ARIADMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=pdli_Tranche1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=pdli_Tranche3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=pdli_HighMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementScenarioAxis=pdli_LowMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=pdli_AcelRxMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ProductOrServiceAxis=pdli_AvingerRoyaltyRightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 51 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814

Subsequent Events
9 Months Ended

Sep. 30, 2015

Subsequent Events [Abstract]

Subsequent Events [Text Block]
15. Subsequent Event

CareView

On October 7, 2015, PDL and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. On this date, PDL also funded the first tranche of $20.0 million, net of fees, upon attainment of the modified first tranche milestone relating to the placement of CareView Systems. The additional $20.0 million in the form of a second tranche continues to be available upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA, to be accomplished no later than June 30, 2017 under the terms of the amended credit agreement.

In connection with the amendment of the credit agreement, PDL and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant's exercise price from $0.45 to $0.40 per share.

Paradigm Spine

On October 27, 2015, PDL and Paradigm Spine entered into an amendment to the Paradigm Spine Credit Agreement to provide additional term loan commitments of up to $7.0 million payable in two tranches of $4.0 million and $3.0 million, of which the first tranche was drawn on the closing date of the amendment, net of fees, and the second tranche is to be funded at the option of Paradigm Spine prior to June 30, 2016.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 52 R36.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Royalty rights $ 384,572 ^[1] $ 259,244 ^[2]

Financial assets:

Assets, Fair Value 532,104 487,415

Foreign Currency Contract, Asset, Fair Value Disclosure 4,597 4,069

Warrants and Rights Outstanding 1,258

Money Market Funds [Member]

Financial assets:

Cash and Cash Equivalents, Fair Value 139,850 221,792

Equity Securities [Member]

Financial assets:

Available for Sale Securities, Fair Value 1,827 2,310

Fair Value Level 1 [Member]

Financial assets:

Assets, Fair Value 139,850 221,792

Foreign Currency Contract, Asset, Fair Value Disclosure 0 0

Fair Value Level 1 [Member] | Money Market Funds [Member]

Financial assets:

Cash and Cash Equivalents, Fair Value 139,850 221,792

Fair Value Level 1 [Member] | Equity Securities [Member]

Financial assets:

Available for Sale Securities, Fair Value 0 0

Fair Value Level 2 [Member]

Financial assets:

Assets, Fair Value 7,682 6,379

Foreign Currency Contract, Asset, Fair Value Disclosure 4,597 4,069

Warrants and Rights Outstanding 1,258

Fair Value Level 2 [Member] | Money Market Funds [Member]

Financial assets:

Cash and Cash Equivalents, Fair Value 0 0

Fair Value Level 2 [Member] | Equity Securities [Member]

Financial assets:

Available for Sale Securities, Fair Value 1,827 2,310

Fair Value Level 3 [Member]

Fair Value Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]

Royalty rights 384,572 259,244

Financial assets:

Assets, Fair Value $ 384,572 $ 259,244

[1] unaudited

[2] Note 1

X

- Definition
Financial assets:
+ References
No definition available.
+ Details

Name: pdli_FinancialAssetsAbstract

Namespace Prefix: pdli_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Royalty rights
+ References
No definition available.
+ Details

Name: pdli_Royaltyrights

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_AssetsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 5

-Subparagraph (aa)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562

+ Details

Name: us-gaap_AvailableForSaleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.
+ References
No definition available.
+ Details

Name: us-gaap_ForeignCurrencyContractAssetFairValueDisclosure

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(i))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_WarrantsAndRightsOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 53 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies (Tables)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Schedule of Revenue by Major Customers

Three Months Ended September 30,

Nine Months Ended September 30,
Licensee

Product Name

2015

2014

2015

2014
Genentech

Avastin

32
%

24
%

28
%

25
%

Herceptin

32
%

24
%

28
%

25
%

Xolair

10
%

6
%

8
%

6
%

Biogen

Tysabri^®

11
%

10
%

10
%

9
%

Depomed

Glumetza^®

(10
)%

14
%

—
%

13
%

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 54 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 55 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
$ in Thousands
9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Cash flows from operating activities

Net income $ 232,221 $ 267,173

Adjustments to reconcile net income to net cash provided by operating activities:

Amortization of convertible notes and term loan offering costs 9,744 13,473

Change in fair value of acquired royalty rights (19,298) (72,992)

Losses on Extinguishment of Debt 0 (6,143)

Depreciation, Amortization and Accretion, Net 29 (144)

Gain (Loss) on Sale of Investments (580) 0

Hedge ineffectiveness on foreign exchange contracts 0 (5)

Stock-based compensation expense 1,348 1,026

Deferred income taxes 9,143 (6,493)

Changes in assets and liabilities:

Receivables from licensees and other (294) 50

Prepaid and other current assets (4,434) 1,959

Accrued interest on notes receivable (3,076) (8,367)

Other assets 35 (29)

Accounts payable 103 792

Accrued liabilities (861) 3,325

Increase (Decrease) in Income Taxes Payable (3,293) 6,494

Other long-term liabilities 10,599 10,834

Net cash provided by operating activities 231,386 223,239

Cash flows from investing activities

Proceeds from Sale of Available-for-sale Securities, Equity 1,124 0

Purchase of royalty rights 115,000 15,500

Payments for (Proceeds from) Productive Assets 8,970 81,717

Purchase of notes receivable (8,976) (215,000)

Proceeds from Collection of Notes Receivable 20,600 0

Payments to Acquire Property, Plant, and Equipment 9 49

Net cash used in investing activities (93,291) (148,832)

Proceeds from Short-term Debt 100,000 0

Cash flows from financing activities

Repurchase of Convertible Notes 177,387 29,906

Proceeds from the issuance of Convertible Notes, net 0 300,000

Payment of debt issuance costs (607) (9,287)

Purchase of purchased call options, net of tax 0 (30,951)

Proceeds from Issuance of Warrants 0 11,427

Repayments of Notes Payable (50,000) (56,250)

Cash dividends paid (73,623) (72,135)

Net cash provided by/(used in) financing activities (201,617) 112,898

Net increase/(decrease) in cash and cash equivalents (63,522) 187,305

Cash and cash equivalents at beginning of the period ^[1] 291,377

Cash and cash equivalents at end of period ^[2],[3] 227,855

Supplemental cash flow information

Cash paid for income taxes 125,000 134,000

Cash paid for interest 16,045 15,217

Other Significant Noncash Transaction, Value of Consideration Given 9,794 157,591

Line of Credit Facility, Commitment Fee Amount $ (1,258) $ 0

[1] Note 1

[2] unaudited

[3] unaudited

X

- Definition
Change in fair value of acquired royalty rights
+ References
No definition available.
+ Details

Name: pdli_Changeinfairvalueofacquiredroyaltyrights

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Purchase of Call Options to reduce the potential dilution upon conversion of convertible notes net of taxes.
+ References
No definition available.
+ Details

Name: pdli_Purchaseofpurchasedcalloptionsnetoftax

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Purchase of royalty rights
+ References
No definition available.
+ Details

Name: pdli_Purchaseofroyaltyrights

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 8

-Article 9

+ Details

Name: us-gaap_AmortizationOfFinancingCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 230

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of deferred income tax expense (benefit) and income tax credits.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 20

-Section 55

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=32706628&loc=d3e11374-113907

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DeferredIncomeTaxesAndTaxCredits

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_DepreciationAmortizationAndAccretionNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_GainLossOnSaleOfInvestments

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 50

-Section 40

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629

+ Details

Name: us-gaap_GainsLossesOnExtinguishmentOfDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayableTrade

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period of amounts due within one year (or one business cycle) from note holders for outstanding loans.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInNotesReceivableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.
+ References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The amount of cash paid for interest during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of the fee for available but unused credit capacity under the credit facility.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(b),22(b))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LineOfCreditFacilityCommitmentFeeAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Reflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.4)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

+ Details

Name: us-gaap_OtherIncome

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The value of the noncash (or part noncash) consideration given (for example, liability, equity) in a transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of a transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4313-108586

+ Details

Name: us-gaap_OtherSignificantNoncashTransactionValueOfConsiderationGiven1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsForProceedsFromProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to reacquire preferred stock originally issued and identified as a security that can be exchanged for another type of financial security. This repurchased stock is held in treasury.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_PaymentsForRepurchaseOfConvertiblePreferredStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDebtIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_PaymentsOfDividends

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsToAcquireNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 13

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585

+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

+ Details

Name: us-gaap_ProceedsFromCollectionOfNotesReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

+ Details

Name: us-gaap_ProceedsFromConvertibleDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the sale of equity securities classified as available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26853-111562

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 12

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3179-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromShortTermDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow for a borrowing supported by a written promise to pay an obligation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 15

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3291-108585

+ Details

Name: us-gaap_RepaymentsOfNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 56 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Net income $ 69,459 $ 102,235 $ 232,221 $ 267,173

Other comprehensive income (loss), net of tax

Change in fair value of investments in available-for-sale securities, net of tax 634 (258) 445 (1,554)

Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax 406 0 406 0

Total change in unrealized gains (losses) on investments in available-for-sale securities, net of tax 228 ^[1] (258) ^[1] 39 (1,554)

Unrealized gains (losses) on cash flow hedges (57) 1,974 4,306 2,305

Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax (1,495) 989 (3,903) 3,744

Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Net of Tax (1,552) ^[2] 2,963 ^[2] 403 6,049

Total other comprehensive income (loss), net of tax (1,324) 2,705 442 4,495

Comprehensive income $ 68,135 $ 104,940 $ 232,663 $ 271,668

[1] Net of tax of $123 and ($139) for the three months ended September 30, 2015 and 2014, respectively, and $21 and ($837) for the nine months ended September 30, 2015 and 2014, respectively.

[2] Net of tax of ($836) and $1,595 for the three months ended September 30, 2015 and 2014, respectively, and $217 and $3,257 for the

X

- Definition
Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831223

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e557-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

+ Details

Name: us-gaap_ComprehensiveIncomeNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=51831255

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=51831270

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 19

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax and reclassification adjustments of other comprehensive income (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669625-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 55

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=51821188&loc=d3e1436-108581

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-Subparagraph c

-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 57 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814

Other Long-Term Liabilities
9 Months Ended

Sep. 30, 2015

Other Liabilities Disclosure [Abstract]

Other Long-Term Liabilities
10. Other Long-Term Liabilities

September 30,

December 31,

2015

2014
(In thousands)

Accrued lease liability

$
10,700

$
10,700

Long-term incentive accrual

2,446

578

Uncertain tax positions

35,035

26,356

Dividend payable

293

68

Total

$
48,474

$
37,702

In connection with the Spin-Off, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. Should Facet default under its lease obligations, we could be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of September 30, 2015, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $70.5 million. If Facet were to default, we could also be responsible for lease-related costs including utilities, property taxes and common area maintenance that may be as much as the actual lease payments. We have recorded a liability of $10.7 million on our Condensed Consolidated Balance Sheets as of September 30, 2015, and December 31, 2014, related to this guarantee.

X

- References
No definition available.
+ Details

Name: us-gaap_OtherLiabilitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for other liabilities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 58 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814

Document And Entity Information - shares
9 Months Ended

Sep. 30, 2015

Oct. 26, 2015

Entity Information [Line Items]

Entity Registrant Name PDL BIOPHARMA, INC.

Document Type 10-Q

Current Fiscal Year End Date --12-31

Entity Common Stock, Shares Outstanding 163,575,319

Amendment Flag false

Entity Central Index Key 0000882104

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Filer Category Large Accelerated Filer

Entity Well-known Seasoned Issuer Yes

Document Period End Date Sep. 30, 2015

Document Fiscal Year Focus 2015

Document Fiscal Period Focus Q3

X

- Definition
If the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: dei_EntityInformationLineItems

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
No definition available.
+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
No definition available.
+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

XML 59 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-Based Compensation
9 Months Ended

Sep. 30, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation
11. Stock-Based Compensation

The Company grants stock options and restricted stock awards pursuant to a stockholder approved stock-based incentive plan. This incentive plan is described in further detail in Note 13, Stock-Based Compensation, of Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, as amended.

The following table summarizes the Company’s stock option and restricted stock award activity during the nine months ended September 30, 2015:

Stock Options

Restricted Stock Awards
(In thousands except per share amounts)

Shares Available for Grant

Number of Shares Outstanding

Weighted Average Exercise Price

Number of Shares Outstanding

Weighted Average Grant-date Fair Value Per Share
Balance at December 31, 2014

4,166

58

$
5.41

277

$
8.39

Granted

(522
)

—

522

6.40

Shares released

—

—

(46
)

8.58

Forfeited or canceled

40

—

(40
)

6.46

Balance at September 30, 2015

3,684

58

$
5.41

713

$
7.36

X

- Definition
The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 40

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 50

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51659978&loc=d3e25284-112666

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 14

+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 60 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Statement of Comprehensive Income [Abstract]

Unrealized gains (losses) on available-for-sale securities, tax $ 123 $ (139) $ 21 $ (837)

Unrealized gains (losses) on cash flow hedges, tax $ (836) $ 1,595 $ 217 $ 3,257

X

- Definition
Amount of tax expense (benefit), before reclassification adjustments, related to increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 10A

-Subparagraph (e,f)

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669646-108580

+ Details

Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814

Foreign Currency Hedging
9 Months Ended

Sep. 30, 2015

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Foreign Currency Hedging
5. Foreign Currency Hedging

We designate the foreign currency exchange contracts used to hedge our royalty revenues based on underlying Euro-denominated sales as cash flow hedges. Euro forward contracts are presented on a net basis on our Condensed Consolidated Balance Sheets as we have entered into a netting arrangement with the counterparty. As of September 30, 2015, and December 31, 2014, all outstanding Euro forward contracts were classified as cash flow hedges.

In October 2014, we entered into a series of Euro forward contracts covering the quarters in which our licensees' sales occurred through December 2015.

The notional amounts, Euro exchange rates and fair values of our Euro forward contracts designated as cash flow hedges were as follows:

Euro Forward Contracts

September 30, 2015

December 31, 2014

(In thousands)

(In thousands)
Currency

Settlement Price
($ per Euro)

Type

Notional Amount

Fair Value

Notional Amount

Fair Value
Euro

1.256

Sell Euro

$
—

$
—

$
6,000

$
241

Euro

1.257

Sell Euro

—

—

15,750

728

Euro

1.259

Sell Euro

—

—

16,125

752

Euro

1.260

Sell Euro

33,000

4,597

33,000

1,468

Euro

1.270

Sell Euro

—

—

7,000

377

Euro

1.281

Sell Euro

—

—

8,000

503

Total

$
33,000

$
4,597

$
85,875

$
4,069

The location and fair values of our Euro contracts in our Condensed Consolidated Balance Sheets were as follows:

Cash Flow Hedge

Location

September 30,
2015

December 31,
2014
(In thousands)

Euro contracts

Prepaid and other current assets

$
4,597

$
3,352

Euro contracts

Other assets

$
—

$
717

The effect of our derivative instruments in our Condensed Consolidated Statements of Income and our Condensed Consolidated Statements of Comprehensive Income was as follows:

Three Months Ended

Nine Months Ended

September 30,

September 30,

2015

2014

2015

2014
(In thousands)

Net gain (loss) recognized in OCI, net of tax ⁽¹⁾

$
(57
)

$
1,974

$
4,306

$
2,305

Gain (loss) reclassified from accumulated OCI into royalty revenue, net of tax ⁽²⁾

$
1,495

$
(989
)

$
3,903

$
(3,744
)
Net gain (loss) recognized in interest and other income, net - cash flow hedges ⁽³⁾

$
—

$
2

$
—

$
5

_______________________________
(1) Change in the fair value of cash flow hedges, net of tax.
(2) Effective portion classified as royalty revenue.
(3) Ineffectiveness from excess hedge was approximately zero and ($2) for the three months ended September 30, 2015 and 2014, respectively, and zero and ($5) for the nine months ended September 30, 2015 and 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6441202&loc=d3e80720-113993

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41620-113959

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4B

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624163-113959

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579240-113959

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4D

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624177-113959

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80784-113994

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41641-113959

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5579245-113959

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4H

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624258-113959

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=35736893&loc=d3e80748-113994

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708775-113959

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5708773-113959

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4A

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 1B

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5580258-113959

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4E

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624181-113959

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 25

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6886632&loc=d3e76258-113986

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56946850&loc=d3e41638-113959

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(n))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 62 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814

Cash Equivalents and Investments
9 Months Ended

Sep. 30, 2015

Cash and Cash Equivalents [Abstract]

Cash Equivalents and Investments
4. Cash Equivalents and Short-Term Investments

As of September 30, 2015, and December 31, 2014, we had invested our excess cash balances primarily in money market funds, and a corporate equity security. Our securities are classified as available-for-sale and are carried at estimated fair value, with unrealized gains and losses reported in "Accumulated other comprehensive income" in stockholders’ equity, net of estimated taxes. See Note 3 for fair value measurement information. The cost of securities sold is based on the specific identification method. To date, we have not experienced credit losses on investments in these instruments, and we do not require collateral for our investment activities.

Summary of Cash and Available-For-Sale Securities

Adjusted Cost

Unrealized Gains

Unrealized Losses

Estimated Fair Value

Cash and Cash Equivalents

Short-Term Investments
(In thousands)

September 30, 2015

Cash

$
88,005

$
—

$
—

$
88,005

$
88,005

$
—

Money market funds

139,850

—

—

139,850

139,850

—

Corporate securities

1,206

621

—

1,827

—

1,827

Total

$
229,061

$
621

$
—

$
229,682

$
227,855

$
1,827

December 31, 2014

Cash

$
69,585

$
—

$
—

$
69,585

$
69,585

$
—

Money market funds

221,792

—

—

221,792

221,792

—

Corporate securities

1,750

560

—

2,310

—

2,310

Total

$
293,127

$
560

$
—

$
293,687

$
291,377

$
2,310

For the three and nine months ended September 30, 2015, recognized realized gains of available-for-sale securities was $580,000. There were no gains or losses on sales of available-for-sale securities recognized for the three and nine months ended September 31, 2014.

The unrealized gains on investments included in "Other comprehensive income (loss), net of tax" was approximately $404,000 and $364,000 as of September 30, 2015, and December 31, 2014, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).
+ References
No definition available.
+ Details

Name: us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 63 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814

Summary of Significant Accounting Policies (Policies)
9 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Basis of Presentation, Policy
Basis of Presentation

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with GAAP for interim financial information. The financial statements include all adjustments (consisting only of normal recurring adjustments), that management of PDL believes are necessary for a fair presentation of the periods presented. These interim financial results are not necessarily indicative of results expected for the full fiscal year or for any subsequent interim period.

The accompanying unaudited Condensed Consolidated Financial Statements and related financial information should be read in conjunction with our audited Consolidated Financial Statements and the related notes thereto for the year ended December 31, 2014, included in our Annual Report on Form 10-K, as amended, filed with the SEC. The Condensed Consolidated Balance Sheet at December 31, 2014, has been derived from the audited Consolidated Financial Statements at that date, but does not include all disclosures required by GAAP.

Principles of Consolidation, Policy
Principles of Consolidation

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of PDL and its wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated in consolidation. Our accompanying unaudited Condensed Consolidated Financial Statements are prepared in accordance with GAAP and the rules and regulations of the SEC.

Use of Estimates, Policy [Policy Text Block]

Management Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Notes Receivable and Other Long-Term Receivables, Policy
Notes Receivable and Other Long-Term Receivables

We account for our notes receivable at both amortized cost, net of unamortized origination fees, if any, and as dependent on collateral when the loan for which repayment is expected to be provided solely by the underlying collateral. For loans accounted for at their amortized cost, related fees and costs are recorded net of any amounts reimbursed. Interest is accreted or accrued to "Interest revenue" using the interest method. When and if supplemental royalties are received from certain of these notes and other long-term receivables, an adjustment to the estimated effective interest rate is affected prospectively.

We evaluate the collectability of both interest and principal for each note receivable and loan to determine whether it is impaired. A note receivable or loan is considered to be impaired when, based on current information and events, we determine it is probable that we will be unable to collect amounts due according to the existing contractual terms. When a note receivable or loan is considered to be impaired, the amount of loss is calculated by comparing the carrying value of the financial asset to the value determined by discounting the expected future cash flows at the loan's effective interest rate or to the estimated fair value of the underlying collateral, less costs to sell, if the loan is collateralized and we expect repayment to be provided solely by the collateral. Impairment assessments require significant judgments and are based on significant assumptions related to the borrower's credit risk, financial performance, expected sales, and estimated fair value of the collateral.

Debt, Policy [Policy Text Block]
Convertible Notes

We issued our Series 2012 Notes, May 2015 Notes and February 2018 Notes with a net share settlement feature, meaning that upon any conversion, the principal amount will be settled in cash and the remaining amount, if any, will be settled in shares of our common stock. In accordance with accounting guidance for convertible debt instruments that may be settled in cash or other assets upon conversion, we separated the principal balance between the fair value of the liability component and the common stock conversion feature using a market interest rate for a similar nonconvertible instrument at the date of issuance.

Revenue Recognition, Policy [Policy Text Block]
Queen et al. Royalty Revenues

Under our Queen Patent license agreements, we receive royalty payments based upon our licensees’ net sales of covered products. Generally, under these agreements we receive royalty reports from our licensees approximately one quarter in arrears, that is, generally in the second month of the quarter after the licensee has sold the royalty-bearing product. We recognize royalty revenues when we can reliably estimate such amounts and collectability is reasonably assured. As such, we generally recognize royalty revenues in the quarter reported to us by our licensees, that is, royalty revenues are generally recognized one quarter following the quarter in which sales by our licensees occurred. Under this accounting policy, the royalty revenues we report are not based upon our estimates and such royalty revenues are typically reported in the same period in which we receive payment from our licensees.

We also received annual maintenance fees from licensees of our Queen et al. patents prior to patent expiry as well as periodic milestone payments. We have no performance obligations with respect to such fees. Maintenance fees were recognized as they became due and when payment was reasonably assured. Total annual maintenance and milestone payments in each of the last several years have been less than 1% of total revenue.

Acquired Royalty Rights [Policy Text Block]
Royalty Rights - At Fair Value

Currently, we have elected to account for our investments in royalty rights at fair value with changes in fair value presented in earnings. The fair value of the investments in royalty rights is determined by using a discounted cash flow analysis related to the expected future cash flows to be received. These assets are classified as Level 3 assets within the fair value hierarchy as our valuation estimates utilize significant unobservable inputs, including estimates as to the probability and timing of future sales of the related products. Transaction-related fees and costs are expensed as incurred.

The changes in the estimated fair value from investments in royalty rights along with cash receipts each reporting period are presented together on our Condensed Consolidated Statements of Income as a component of revenue under the caption, “Royalty rights - change in fair value.”

Customer Concentration, Policy
Customer Concentration

The percentage of total revenue recognized, which individually accounted for 10% or more of our total revenues, was as follows:

Three Months Ended September 30,

Nine Months Ended September 30,
Licensee

Product Name

2015

2014

2015

2014
Genentech

Avastin

32
%

24
%

28
%

25
%

Herceptin

32
%

24
%

28
%

25
%

Xolair

10
%

6
%

8
%

6
%

Biogen

Tysabri^®

11
%

10
%

10
%

9
%

Depomed

Glumetza^®

(10
)%

14
%

—
%

13
%

Foreign Currency Hedging, Policy
Foreign Currency Hedging

We enter into foreign currency hedges to manage exposures arising in the normal course of business and not for speculative purposes.

We hedge certain Euro-denominated currency exposures related to royalties associated with our licensees’ product sales with Euro forward contracts. In general, these contracts are intended to offset the underlying Euro market risk in our royalty revenues. The last of these contracts expires in the first quarter of 2016. We designate foreign currency exchange contracts used to hedge royalty revenues based on underlying Euro-denominated licensee product sales as cash flow hedges.

At the inception of each hedging relationship and on a quarterly basis, we assess the hedge effectiveness. The fair value of the Euro contracts is estimated using pricing models with readily observable inputs from actively quoted markets and is disclosed on a gross basis. The aggregate unrealized gains or losses, net of tax, on the effective component of the hedge is recorded in stockholders’ equity as "Accumulated other comprehensive income." Realized gains or losses on cash flow hedges are recognized as an adjustment to royalty revenue in the same period that the hedged transaction impacts earnings as royalty revenue. Any gain or loss on the ineffective portion of our hedge contracts is reported in "Interest and other income, net" in the period the ineffectiveness occurs.

Income Tax, Policy [Policy Text Block]
Income Taxes

The provision for income taxes is determined using the asset and liability approach. Tax laws require items to be included in tax filings at different times than the items are reflected in the financial statements. A current liability is recognized for the estimated taxes payable for the current year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes are adjusted for enacted changes in tax rates and tax laws. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized.

The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such positions are then measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement.

Comprehensive Income, Policy [Policy Text Block]
Comprehensive Income

Comprehensive income comprises net income adjusted for other comprehensive income (loss), using the specific identification method, which includes the changes in unrealized gains and losses on cash flow hedges and changes in unrealized gains and losses on our investments in available-for-sale securities, all net of tax, which are excluded from our net income.

New Accounting Pronouncements, Policy [Policy Text Block]
Recently Issued Accounting Pronouncements

In April 2015, the FASB issued ASU 2015-03 – Simplifying the Presentation of Debt Issuance Costs, which requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. This ASU requires retrospective adoption and will be effective for the Company beginning in the first quarter of 2016. The adoption of this ASU is not expected to have a significant impact on the Company's consolidated financial position or results of operations.

X

- Definition
Acquired Royalty Rights [Policy Text Block]
+ References
No definition available.
+ Details

Name: pdli_AcquiredRoyaltyRightsPolicyTextBlock

Namespace Prefix: pdli_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccounting

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for comprehensive income.
+ References
No definition available.
+ Details

Name: us-gaap_ComprehensiveIncomePolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.3A-02)

-URI http://asc.fasb.org/extlink&oid=27015204&loc=d3e355033-122828

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph k

-Article 1

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02, 03

-Article 3A

+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

+ Details

Name: us-gaap_DebtPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 30

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 830

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895

+ Details

Name: us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32840-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 30

-Section 05

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6423966&loc=d3e40913-109327

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 954

-SubTopic 740

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 17

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32809-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32247-109318

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e32280-109318

+ Details

Name: us-gaap_IncomeTaxPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 20

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 18

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 42

-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6327-108592

+ Details

Name: us-gaap_MajorCustomersPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6378556&loc=d3e10133-111534

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e4975-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3-5

-Article 5

+ Details

Name: us-gaap_ReceivablesPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18823-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18780-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=51655414&loc=d3e18726-107790

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.B.Q1)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section B

-Paragraph Question 1

+ Details

Name: us-gaap_RevenueRecognitionPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6061-108592

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6143-108592

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6132-108592

+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 64 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814

Cash Dividends
9 Months Ended

Sep. 30, 2015

Stockholders' Equity Note [Abstract]

Cash Dividends
12. Cash Dividends

On January 27, 2015, our board of directors declared that the regular quarterly dividends to be paid to our stockholders in 2015 will be $0.15 per share of common stock, payable on March 12, June 12, September 11 and December 11 of 2015 to stockholders of record on March 5, June 5, September 4 and December 4 of 2015, the record dates for each of the dividend payments, respectively.

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityNoteAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814

Commitments and Contingencies
9 Months Ended

Sep. 30, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies
. Commitments and Contingencies

Legal Proceedings

From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity.

PDL BioPharma, Inc. v Merck Sharp & Dohme, Corp.

On October 28, 2015, the Company filed a Complaint against Merck Sharp & Dohme, Corp (“Merck”) for patent infringement. In the Complaint, the Company alleges that manufacture and sales of certain of Merck’s Keytruda product infringes one or more claims of the Company’s '761 Patent. The Company has requested judgment that Merck has infringed the ‘761 Patent, an award of damages due to the infringement, a finding that such infringement was willful and deliberate and trebling of damages therefore, and a declaration that the case is exceptional and warrants an award of attorney’s fees and costs. Although the ‘761 Patent expired on December 2, 2014, the Company believes that Merck infringed the patent through, e.g., manufacture and/or sale of Keytruda prior to the expiration of the ‘761 Patent.

Wellstat Litigation

On September 4, 2015, PDL filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics’ Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, PDL filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics’ Guarantors assets. At a hearing on September 24, 2015, regarding the Company’s request for a temporary restraining order, the court ordered that the Company’s request for attachment and for summary judgment would be heard at a hearing on November 5, 2015. Although the court denied the Company’s request for a temporary restraining order at the hearing on September 24, it ordered that assets of the Wellstat Diagnostics Guarantors should be held in status quo ante and only used in the normal course of business pending the outcome of the hearing.

On October 22, 2015, the Wellstat Diagnostics Guarantors filed a complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect.

Lease Guarantee

In connection with the Spin-Off, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. Should Facet default under its lease obligations, we could be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of September 30, 2015, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $70.5 million. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie. If AbbVie were to default, we could also be responsible for lease-related costs including utilities, property taxes and common area maintenance, which may be as much as the actual lease payments.

We have recorded a liability of $10.7 million on our Condensed Consolidated Balance Sheets as of September 30, 2015, and December 31, 2014, related to this guarantee. In future periods, we may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 460

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 440

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 66 R60.htm IDEA: XBRL DOCUMENT v3.3.0.814

Income Taxes (Narrative) (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Investments, Owned, Federal Income Tax Note [Line Items]

Income Tax Expense $ 40,895 $ 47,361 $ 135,208 $ 144,083

Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions $ 2,400 $ 7,000

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-Subparagraph (a),(b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Income Tax Expense (or Benefit)

-URI http://asc.fasb.org/extlink&oid=6515339

+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_InvestmentsOwnedFederalIncomeTaxNoteLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15A

-Subparagraph (a)(2)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=SL6600010-109319

+ Details

Name: us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 67 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814

Notes Receivable and Other Long-term Receivables
9 Months Ended

Sep. 30, 2015

Receivables [Abstract]

Notes and Other Long-term Receivables
6. Notes Receivable and Other Long-Term Receivables

Notes receivable and other long-term receivables included the following significant agreements:

Wellstat Diagnostics Note Receivable and Credit Agreement

In March 2012, the Company executed a $7.5 million two-year senior secured note receivable with the holders of the equity interests in Wellstat Diagnostics. In addition to bearing interest at 10% per annum, the note receivable gave PDL certain rights to negotiate for certain future financing transactions. In August 2012, PDL and Wellstat Diagnostics amended the note receivable, providing a senior secured note receivable of $10.0 million, bearing interest at 12% per annum, to replace the original $7.5 million note receivable. This $10.0 million note receivable was repaid on November 2, 2012, using the proceeds of the $40.0 million credit facility entered into with the Company on the same date.

On November 2, 2012, the Company and Wellstat Diagnostics entered into a $40.0 million credit agreement pursuant to which the Company was to accrue quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, PDL was to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics' net revenues, generated by the sale, distribution or other use of Wellstat Diagnostics' products, if any, commencing upon the commercialization of its products.

In January 2013, the Company was informed that, as of December 31, 2012, Wellstat Diagnostics had used funds contrary to the terms of the credit agreement and breached Sections 2.1.2 and 7 of the credit agreement. PDL sent Wellstat Diagnostics a notice of default on January 22, 2013, and accelerated the amounts owed under the credit agreement. In connection with the notice of default, PDL exercised one of its available remedies and transferred approximately $8.1 million of available cash from a bank account of Wellstat Diagnostics to PDL and applied the funds to amounts due under the credit agreement. On February 28, 2013, the parties entered into a forbearance agreement whereby PDL agreed to refrain from exercising additional remedies for 120 days while Wellstat Diagnostics raised funds to capitalize the business and the parties attempted to negotiate a revised credit agreement. PDL agreed to provide up to $7.9 million to Wellstat Diagnostics to fund the business for the 120-day forbearance period under the terms of the forbearance agreement. Following the conclusion of the forbearance period that ended on June 28, 2013, the Company agreed to forbear its exercise of remedies for additional periods of time to allow the owners and affiliates of Wellstat Diagnostics to complete a pending financing transaction. During such forbearance period, the Company provided approximately $1.3 million to Wellstat Diagnostics to fund ongoing operations of the business. During the year ended December 31, 2013, approximately $8.7 million was advanced pursuant to the forbearance agreement.

On August 15, 2013, the owners and affiliates of Wellstat Diagnostics completed a financing transaction to fulfill Wellstat Diagnostics' obligations under the forbearance agreement. On August 15, 2013, the Company entered into an amended and restated credit agreement with Wellstat Diagnostics. The Company determined that the new agreement should be accounted for as a modification of the existing agreement.

Except as otherwise described here, the material terms of the amended and restated credit agreement are substantially the same as those of the original credit agreement, including quarterly interest payments at the rate of 5% per annum (payable in cash or in kind). In addition, PDL was to continue to receive quarterly royalty payments based on a low double-digit royalty rate of Wellstat Diagnostics' net revenues. However, pursuant to the amended and restated credit agreement: (i) the principal amount was reset to approximately $44.1 million, which was comprised of approximately $33.7 million original loan principal and interest, $1.3 million term loan principal and interest and $9.1 million forbearance principal and interest; (ii) the specified internal rates of return increased; (iii) the default interest rate was increased; (iv) Wellstat Diagnostics' obligation to provide certain financial information increased in frequency to monthly; (v) internal financial controls were strengthened by requiring Wellstat Diagnostics to maintain an independent, third-party financial professional with control over fund disbursements; (vi) the Company waived the existing events of default; and (vii) the owners and affiliates of Wellstat Diagnostics were required to contribute additional capital to Wellstat Diagnostics upon the sale of an affiliate entity. The amended and restated credit agreement had an ultimate maturity date of December 31, 2021 (but has subsequently been accelerated as described below).

When the principal amount was reset, a $2.5 million reduction of the carrying value was recorded as a financing cost as a component of "Interest and other income, net". The new carrying value is lower as a function of the variable nature of the internal rate of return to be realized by the Company based on when the note was to be repaid. The internal rate of return calculation, although increased, was reset when the credit agreement was amended and restated.

In June of 2014, the Company received information from Wellstat Diagnostics that showed that it was generally unable to pay its debts as they became due. This constituted an event of default under the amended and restated credit agreement. Wellstat Diagnostics entered into a transaction involving another lender, pursuant to which Wellstat Diagnostics obtained additional short-term funding for its operations. At the same time, the Company entered into the first amendment to amended and restated credit agreement with Wellstat Diagnostics. The material terms of the amendment included the following: (1) Wellstat Diagnostics acknowledged that an event of default had occurred; (2) the Company agreed to forbear from immediately enforcing its rights for up to 60 days, so long as the other lender provided agreed levels of interim funding to Wellstat Diagnostics; and (3) the Company obtained specified additional information rights with regard to Wellstat Diagnostics’ financial matters and investment banking activities.

On August 5, 2014, the Company received notice that the short-term funding being provided pursuant to the agreement with the other lender entered into during June 2014, was being terminated. Wellstat Diagnostics remained in default because it was still unable to pay its debts as they became due. Accordingly, the Company delivered the Wellstat Diagnostics Borrower Notice. The Wellstat Diagnostics Borrower Notice accelerated all obligations under the amended and restated credit agreement and demanded immediate payment in full in an amount equal to approximately $53.9 million, (which amount, in accordance with the terms of the amended and restated credit agreement, included an amount that, together with interest and royalty payments already made to the Company, would generate a specified internal rate of return to the Company), plus accruing fees, costs and interest, and demanded that Wellstat Diagnostics protect and preserve all collateral securing its obligations. On August 7, 2014, the Company delivered the Wellstat Diagnostics Guarantor Notice. The Wellstat Diagnostics Guarantor Notice included a demand that the guarantors remit payment to the Company in the amount of the outstanding obligations. The guarantors include certain affiliates and related companies of Wellstat Diagnostics, including Wellstat Therapeutics and Wellstat Diagnostics’ stockholders.

On September 24, 2014, the Company filed the Wellstat Diagnostics Petition, which was granted on the same day. The order granting the Wellstat Diagnostics Petition authorizes the receiver to take immediate possession of the physical assets of Wellstat Diagnostics, with the purpose of holding, protecting, insuring, managing and preserving the business of Wellstat Diagnostics and the value of the Company’s collateral. Wellstat Diagnostics has remained in operation during the period of the receivership with incremental additional funding from the Company. The Company continues to assess its options with respect to collecting on the loan, including determining whether and when it will foreclose on the collateral and proceed with a sale of Wellstat Diagnostics’ assets, whether providing further capital to the receiver to fund Wellstat Diagnostics’ operations for a period of time prior to sale will best position Wellstat Diagnostics’ assets for sale, and assessing the value of the guarantees obtained by the Company from Wellstat Diagnostics’ guarantors, including Wellstat Diagnostics’ stockholders and Wellstat Therapeutics.

On November 4, 2014, the Company entered into the third amendment to the amended and restated credit agreement with Wellstat Diagnostics. The amendment provides that additional funding, if any, to be made by the Company is conditioned upon the agreement by Wellstat Diagnostics to make certain operational changes within Wellstat Diagnostics, which the Company believes will allow the receiver to more efficiently optimize the value of the collateral.

During the second quarter of 2015, the receiver initiated a process for a public sale of the assets of Wellstat Diagnostics and retained the investment banking firm of Duff & Phelps to organize and manage the sale process. The receiver filed a "Motion For Approval of Sale Procedures" with the Circuit Court for Montgomery County, Maryland, which is the court having jurisdiction over the receivership and a hearing was held on July 22, 2015 at which time arguments were heard from interested parties regarding the sale procedures. No significant substantive disagreements between the parties regarding the sale procedures remained after the hearing and a decision approving the receiver’s sale procedures is expected shortly. The sale process is ongoing and Duff & Phelps is actively contacting and holding discussions with interested third parties who may be willing to bid on the assets. In addition, depending on the nature and value of the bids received from third parties, it is possible that PDL will credit bid for the assets at a value corresponding to some portion of the outstanding amount due under the amended and restated credit agreement. We anticipate that the sale process will be completed during the fourth quarter of 2015.

On September 4, 2015, PDL filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, PDL filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics Guarantors' assets. At a hearing on September 24, 2015, regarding the Company’s request for a temporary restraining order, the court ordered that the Company’s request for attachment and for summary judgment would be heard at a hearing on November 5, 2015. Although the court denied the Company’s request for a temporary restraining order at the hearing on September 24, it ordered that assets of the Wellstat Diagnostics Guarantors should be held in status quo ante and only used in the normal course of business pending the outcome of the hearing.

On October 22, 2015, the Wellstat Diagnostics Guarantors filed a complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect.

Through the period ended September 30, 2015, PDL has advanced to Wellstat Diagnostics $11.1 million to fund the ongoing operations of the business and other associated costs. This funding has been expensed as incurred.

Effective April 1, 2014, and as a result of the event of default, we determined the loan to be impaired and we ceased to accrue interest revenue. At that time and as of September 30, 2015 it has been determined that an allowance on the carrying value of the note was not necessary as the Company believes the value of the collateral securing Wellstat Diagnostics’ obligations exceeds the carrying value of the asset and is sufficient to enable the Company to recover the current carrying value of $50.2 million. There can be no assurance that this will be true in the event of the Company’s foreclosure on the collateral, nor can there be any assurance of the timing in realizing value from such collateral, whether from the sale process currently underway or a subsequent monetization event if PDL makes a successful credit bid for the assets.

Hyperion Agreement

On January 27, 2012, PDL and Hyperion entered into an agreement whereby Hyperion sold to PDL the royalty streams due from SDK related to a certain patent license agreement between Hyperion and SDK dated December 31, 2008. The agreement assigned the patent license agreement royalty stream accruing from January 1, 2012, through December 31, 2013, to PDL in exchange for the lump sum payment to Hyperion of $2.3 million. In exchange for the lump sum payment, PDL was to receive two equal payments of $1.2 million on both March 5, 2013 and 2014. The first payment of $1.2 million was paid on March 5, 2013, but Hyperion has not made the payment that was due on March 5, 2014. The Company completed an impairment analysis as of September 30, 2015. Effective with this date and as a result of the event of default, we ceased to accrue interest revenue. As of September 30, 2015, the estimated fair value of the collateral was determined to be in excess of the carrying value. There can be no assurance that this will be true in the event of the Company's foreclosure on the collateral, nor can there be any assurance of realizing value from such collateral. Hyperion is considering other sources of financing and strategic alternatives, including selling the company.

AxoGen Note Receivable and AxoGen Royalty Agreement

In October 2012, PDL entered into the AxoGen Royalty Agreement with AxoGen pursuant to which the Company would receive specified royalties on AxoGen’s net revenues (as defined in the AxoGen Royalty Agreement) generated by the sale, distribution or other use of AxoGen’s products. The AxoGen Royalty Agreement had an eight-year term and provided PDL with royalties of 9.95% based on AxoGen's net revenues, subject to agreed-upon guaranteed quarterly minimum payments of approximately $1.3 million to $2.5 million, which were to begin in the fourth quarter of 2014, and the right to require AxoGen to repurchase the royalties under the AxoGen Royalty Agreement at the end of the fourth year. AxoGen was granted certain rights to call the contract in years five through eight. The total consideration PDL paid to AxoGen for the royalty rights was $20.8 million, including an interim funding of $1.8 million in August 2012. AxoGen was required to use a portion of the proceeds from the AxoGen Royalty Agreement to pay the outstanding balance under its existing credit facility. The royalty rights were secured by the cash and accounts receivable of AxoGen.

On August 14, 2013, PDL purchased 1,166,666 shares of registered common stock of AxoGen (AXGN) at $3.00 per share, totaling $3.5 million. On December 22, 2014, PDL sold these shares at $3.03 per share, totaling approximately $3.5 million.

On November 13, 2014, the Company agreed to terminate the AxoGen Royalty Agreement in consideration for a payment of $30.3 million in cash, which was the sum of the outstanding principal, interest and embedded derivative.

Subsequent to the pay-off, the Company acquired 643,382 shares of registered common stock of AxoGen for approximately $1.7 million at a public offering price of $2.72 per share. The shares are classified as available for sale securities and recorded as short-term investments on the Condensed Consolidated Balance Sheets. On September 15, 2015, PDL sold 200,000 shares at $5.62 per share, totaling approximately $1.1 million. As of September 30, 2015, the remaining shares were valued at $1.8 million, which resulted in an unrealized gain of $0.6 million and is recorded in "Other comprehensive income (loss), net of tax."

Avinger Credit and Royalty Agreement

On April 18, 2013, PDL entered into the Avinger Credit and Royalty Agreement, under which we made available to Avinger up to $40.0 million to be used by Avinger in connection with the commercialization of its lumivascular catheter devices and the development of Avinger's lumivascular atherectomy device. Of the $40.0 million initially available to Avinger, we funded an initial $20.0 million, net of fees, at the close of the transaction. Outstanding borrowings under the initial loan bore interest at a stated rate of 12% per annum.

On September 22, 2015, Avinger elected as per the voluntary prepayment provision under the Avinger Credit and Royalty Agreement to prepay the notes receivable in whole for a payment of $21.4 million in cash, which was the sum of the outstanding principal, interest and a prepayment fee.

Under the terms of the Avinger Credit and Royalty Agreement, the Company will receive a low, single-digit royalty on Avinger's net revenues until April 2018. Avinger repaid the note receivable prior to its maturity date in April 2018, which resulted in the royalty on Avinger's net revenues being reduced by 50% and subject to certain minimum payments from the prepayment date until April 2018. PDL has accounted for the royalty rights in accordance with the fair value option (see Note 3).

LENSAR Credit Agreement

On October 1, 2013, PDL entered into a credit agreement with LENSAR, under which PDL made available to LENSAR up to $60.0 million to be used by LENSAR in connection with the commercialization of its currently marketed LENSAR™ Laser System. Of the $60.0 million available to LENSAR, an initial $40.0 million, net of fees, was funded by the Company at the close of the transaction. The additional $20.0 million in the form of a second tranche is no longer available to LENSAR under the terms of the credit agreement. Outstanding borrowings under the loans bear interest at the rate of 15.5% per annum, payable quarterly in arrears.

Principal repayment will commence on the thirteenth interest payment date or December 31, 2016. The principal amount outstanding at the commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on October 1, 2018. LENSAR may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The loans are secured by all of the assets of LENSAR.

On May 12, 2015, PDL entered into a forbearance agreement with LENSAR under which PDL agreed to refrain from exercising certain remedies available to it resulting from the failure of LENSAR to comply with a liquidity covenant and make interest payments due under the credit agreement. Under the forbearance agreement, PDL has agreed to provide LENSAR with up to an aggregate of $8.5 million in weekly increments through the period ending September 30, 2015 plus employee retention amounts of approximately $0.5 million in the form of additional loans subject to LENSAR meeting certain milestones related to LENSAR obtaining additional capital to fund the business or selling itself and repaying outstanding amounts under the credit agreement. As of September 30, 2015, PDL has funded an additional $9.0 million of principal under the forbearance agreement. In exchange for the forbearance, LENSAR agreed to additional reporting covenants, the engagement of a chief restructuring officer and an increase on the interest rate to 18.5%, applicable to all outstanding amounts under the credit agreement. On September 30, 2015, PDL agreed to extend the forbearance agreement until October 9, 2015 and provide for up to an additional $0.8 million in funding while LENSAR negotiated a potential sale of its assets. On October 9, 2015, the forbearance agreement expired, but PDL has agreed to fund LENSAR's operations while LENSAR continues to negotiate a potential sale of its assets.

The Company completed an impairment analysis as of September 30, 2015. Effective April 1, 2015 and as a result of the forbearance, we determined the loan to be impaired and we ceased to accrue interest revenue.

Durata Credit Agreement

On October 31, 2013, PDL entered into a credit agreement with Durata, under which the Company made available to Durata up to $70.0 million. Of the $70.0 million available to Durata, an initial $25.0 million (tranche one), net of fees, was funded by the Company at the close of the transaction. On May 27, 2014, the Company funded Durata an additional $15.0 million (tranche two) as a result of Durata's marketing approval of dalbavancin in the United States, which occurred on May 23, 2014, and was the milestone needed to receive the tranche two funding. Until the occurrence of the tranche two milestone, outstanding borrowings under tranche one bore interest at the rate of 14.0% per annum, payable quarterly in arrears. Upon occurrence of the tranche two milestone, the interest rate of the loans decreased to 12.75%.

On November 17, 2014, the Company received a payment of approximately $42.7 million constituting repayment in full of the outstanding principal amount of loans plus accrued interest and fees under the credit agreement. The repayment was made in connection with the acquisition of Durata by Actavis plc.

Direct Flow Medical Credit Agreement

On November 5, 2013, PDL entered into a credit agreement with Direct Flow Medical, under which PDL agreed to provide up to $50.0 million to Direct Flow Medical. Of the $50.0 million available to Direct Flow Medical, an initial $35.0 million (tranche one), net of fees, was funded by the Company at the close of the transaction. Pursuant to the original terms of the credit agreement the Company agreed to provide Direct Flow Medical an additional $15.0 million tranche, net of fees, upon the attainment of a specified revenue milestone to be accomplished no later than December 31, 2014 (the tranche two milestone). Until the occurrence of the tranche two milestone, outstanding borrowings under tranche one bore interest at the rate of 15.5% per annum, payable quarterly in arrears.

On November 10, 2014, PDL and Direct Flow Medical agreed to an amendment to the credit agreement to permit Direct Flow Medical to borrow the $15.0 million second tranche upon receipt by Direct Flow Medical of a specified minimum amount of proceeds from an equity offering prior to December 31, 2014. In exchange, the parties amended the credit agreement to provide for additional fees associated with certain liquidity events, such as a change of control or the consummation of an initial public offering, and granted PDL certain board of director observation rights. On November 19, 2014, upon Direct Flow Medical satisfying the amended tranche two milestone, the Company funded the $15.0 million second tranche to Direct Flow Medical, net of fees. Upon occurrence of the borrowing of the second tranche, the interest rate applicable to all loans under the credit agreement was decreased to 13.5% per annum, payable quarterly in arrears.

Principal repayment will commence on the twelfth interest payment date, September 30, 2016. The principal amount outstanding at commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on November 5, 2018. Direct Flow Medical may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The obligations under the credit agreement are secured by a pledge of substantially all of the assets of Direct Flow Medical and any of its subsidiaries.

Paradigm Spine Credit Agreement

On February 14, 2014, the Company entered into the Paradigm Spine Credit Agreement, under which it made available to Paradigm Spine up to $75.0 million to be used by Paradigm Spine to refinance its existing credit facility and expand its domestic commercial operations. Of the $75.0 million available to Paradigm Spine, an initial $50.0 million, net of fees, was funded by the Company at the close of the transaction. The second and third tranches of up to an additional $25.0 million in the aggregate, net of fees, are no longer available under the terms of the Paradigm Spine Credit Agreement. Borrowings under the credit agreement bear interest at the rate of 13.0% per annum, payable quarterly in arrears.

Principal repayment will commence on the twelfth interest payment date, December 31, 2016. The principal amount outstanding at commencement of repayment will be repaid in equal installments until final maturity of the loans. The loans will mature on February 14, 2019. Paradigm Spine may elect to prepay the loans at any time, subject to a prepayment penalty that decreases over the life of the loans. The obligations under the Paradigm Spine Credit Agreement are secured by a pledge of substantially all of the assets of Paradigm Spine and its domestic subsidiaries and, initially, certain assets of Paradigm Spine’s German subsidiaries.

On October 27, 2015, PDL and Paradigm Spine entered into an amendment to the Paradigm Spine Credit Agreement to provide additional term loan commitments of up to $7.0 million payable in two tranches of $4.0 million and $3.0 million, of which the first tranche was drawn on the closing date of the amendment, net of fees, and the second tranche is to be funded at the option of Paradigm Spine prior to June 30, 2016.

kaléo Note Purchase Agreement

On April 1, 2014, PDL entered into a note purchase agreement with Accel 300, a wholly-owned subsidiary of kaléo, pursuant to which the Company acquired $150.0 million of secured notes due 2029. The secured notes were issued pursuant to an indenture between Accel 300 and U.S. Bank, National Association, as trustee, and are secured by the kaléo Revenue Interests, and a pledge of kaléo’s equity ownership in Accel 300.

The secured notes bear interest at 13% per annum, paid quarterly in arrears on principal outstanding. The principal balance of the secured notes is repaid to the extent that the kaléo Revenue Interests exceed the quarterly interest payment, as limited by a quarterly payment cap. The final maturity of the secured notes is June 2029. kaléo may redeem the secured notes at any time, subject to a redemption premium.

As of September 30, 2015, the Company determined that its royalty purchase interest in Accel 300 represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Accel 300 that most significantly impact Accel 300's economic performance and is not the primary beneficiary of Accel 300; therefore, Accel 300 is not subject to consolidation by the Company.

On October 28, 2015, Sanofi US initiated a voluntary nationwide recall of all Auvi-Q^® units effectively immediately. Sanofi is the exclusive licensee of kaléo for the manufacturing and commercialization of Auvi-Q. While Sanofi has not identified the reason for the recall, press reports indicate that a small number of units have failed to activate or delivered inadequate doses of epinephrine. It is not known at this time when Sanofi will reintroduce Auvi-Q in the U.S.

As part of our financing transaction, kaléo was required to establish an interest reserve account of $20 million from the $150 million provided by PDL. The purpose of this interest reserve account is to cover any possible shortfalls in interest payments owed to PDL. As of this date, despite the recall of Auvi-Q, it is projected that the interest reserve account alone is sufficient to cover possible interest shortfalls until at least through the first quarter of 2016. PDL will monitor the recall situation and how it may impact the ability of kaléo to meet its obligations under the Notes, but at this point it has been determined that there is no impairment.

CareView Credit Agreement

On June 26, 2015, PDL entered into a credit agreement with CareView, under which the Company made available to CareView up to $40.0 million in two tranches of $20.0 million each. Under the terms of the credit agreement, the first tranche of $20.0 million was to be funded by the Company upon CareView’s attainment of a specified milestone relating to the placement of CareView Systems^®, to be accomplished no later than October 31, 2015. The Company expects to fund CareView an additional $20.0 million upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA (as defined in the credit agreement), to be accomplished no later than June 30, 2017. Outstanding borrowings under the credit agreement will bear interest at the rate of 13.5% per annum and are payable quarterly in arrears.

As part of the transaction, the Company received a warrant to purchase approximately 4.4 million shares of common stock of CareView at the exercise price of $0.45 per share. We have accounted for the warrant as derivative asset with an offsetting credit as debt discount. At each reporting period the warrant is marked to market for changes in fair value.

On October 7, 2015, PDL and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. On this date, PDL also funded the first tranche of $20.0 million, net of fees, upon attainment of the modified first tranche milestone relating to the placement of CareView Systems. The additional $20.0 million in the form of a second tranche continues to be available upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA, to be accomplished no later than June 30, 2017 under the terms of the amended credit agreement.

In connection with the amendment of the credit agreement, PDL and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant's exercise price from $0.45 to $0.40 per share. At September 30, 2015, we determined an estimated fair value of the warrant of approximately $1.3 million.

For carrying value and fair value measurement information related to our notes receivable and other long-term receivables, see Note 3.

X

- Definition
The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5066-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3,4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5162-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 7

-Article 9

+ Details

Name: us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ReceivablesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 68 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814

Accrued Liabilities
9 Months Ended

Sep. 30, 2015

Payables and Accruals [Abstract]

Accrued Liabilities
. Accrued Liabilities

September 30,
2015

December 31,
2014
(In thousands)

Compensation

$
3,588

$
1,332

Interest

2,000

6,210

Dividend payable

24,735

90

Legal

1,139

296

Other

1,249

948

Total

$
32,711

$
8,876

X

- Definition
The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a),20,24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_PayablesAndAccrualsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 69 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes
9 Months Ended

Sep. 30, 2015

Debt Disclosure [Abstract]

Convertible and Non-Recourse Notes
. Convertible Notes and Term Loans

Principal Balance Outstanding

Carrying Value

September 30,

September 30,

December 31,
Description

Maturity Date

2015

2015

2014
(In thousands)

Convertible Notes

Series 2012 Notes

February 15, 2015

$
—

$
—

$
22,261

May 2015 Notes

May 1, 2015

$
—

—

153,235

February 2018 Notes

February 1, 2018

$
300,000

281,581

276,228

March 2015 Term Loan

February 15, 2016

$
50,000

49,842

—

Total

$
331,423

$
451,724

As of September 30, 2015, PDL was in compliance with all applicable debt covenants, and embedded features of all debt agreements were evaluated and did not need to be accounted for separately.

Series 2012 Notes

In January 2012, we exchanged $169.0 million aggregate principal of Series 2012 Notes for an identical principal amount of our then existing February 2015 Notes, plus a cash payment of $5.00 for each $1,000 principal amount tendered, totaling approximately $845,000. The cash incentive payment was allocated to deferred issue costs of $765,000, additional paid-in capital of $52,000 and deferred tax assets of $28,000. The deferred issue costs will be recognized over the life of the Series 2012 Notes as interest expense. In February 2012, we entered into separate privately negotiated exchange agreements under which we exchanged an additional $10.0 million aggregate principal amount of the Series 2012 Notes for an identical principal amount of our then existing February 2015 Notes. In August 2013, the Company entered into a separate privately negotiated exchange agreement under which it retired the final $1.0 million aggregate principal amount of the Company's outstanding February 2015 Notes. Pursuant to the exchange agreement, the holder of the February 2015 Notes received $1.0 million aggregate principal amount of the Company's Series 2012 Notes. Immediately following the exchange, no principal amount of the February 2015 Notes remained outstanding and $180.0 million principal amount of the Series 2012 Notes was outstanding.

On February 6, 2014, the Company entered into exchange and purchase agreements with certain holders of approximately $131.7 million aggregate principal amount of outstanding Series 2012 Notes. The exchange agreement provided for the issuance by the Company of shares of common stock and a cash payment for the Series 2012 Notes being exchanged, and the purchase agreement provided for a cash payment for the Series 2012 Notes being repurchased. The total consideration given was approximately $191.8 million. The Company issued to the participating holders of the February 2015 Notes a total of approximately 20.3 million shares of its common stock with a fair value of approximately $157.6 million and made an aggregate cash payment of approximately $34.2 million pursuant to the exchange and purchase agreements. Of the $34.2 million cash payment, $2.5 million is attributable to an inducement fee, $1.8 million is attributable to interest accrued through the date of settlement and $29.9 million is attributable to the repurchase of the Series 2012 Notes. It was determined that the exchange and purchase agreement represented an extinguishment of the related notes. As a result, a loss on extinguishment of $6.1 million was recorded. The $6.1 million loss on extinguishment included the derecognition of the original issuance discount of $5.8 million and a $0.3 million charge resulting from the difference of the face value of the notes and the fair value of the notes. Immediately following the exchange, $48.3 million principal amount of the Series 2012 Notes was outstanding with approximately $2.1 million of remaining original issuance discount to be amortized over the remaining life of the Series 2012 Notes.

On October 20, 2014, the Company entered into a privately negotiated exchange agreement under which it retired approximately $26.0 million in principal of the outstanding Series 2012 Notes. The exchange agreement provided for the issuance, by the Company, of shares of common stock and a cash payment for the Series 2012 Notes being exchanged. The Company issued approximately 1.8 million shares of its common stock and made a cash payment of approximately $26.2 million. Immediately following the exchange, $22.3 million principal amount of the Series 2012 Notes was outstanding with approximately $0.1 million of remaining original issuance discount to be amortized over the remaining life of the Series 2012 Notes.

The Series 2012 Notes were due February 15, 2015, and bore interest at a rate of 2.875% per annum, payable semi-annually in arrears on February 15 and August 15 of each year. On February 17, 2015, the Company completed the retirement of the remaining $22.3 million of aggregate principal of its Series 2012 notes at their stated maturity for $22.3 million, plus approximately 1.34 million shares of its common stock.

The principal amount, carrying value and unamortized discount of our Series 2012 Notes were as follows:

(In thousands)

September 30, 2015

December 31, 2014
Principal amount of the Series 2012 Notes

$
—

$
22,337

Unamortized discount of liability component

—

(76
)
Total

$
—

$
22,261

Interest expense for our Series 2012 Notes on our Condensed Consolidated Statements of Income was as follows:

Three Months Ended

Nine Months Ended

September 30,

September 30,
(In thousands)

2015

2014

2015

2014
Contractual coupon interest

$
—

$
347

$
80

$
1,455

Amortization of debt issuance costs

—

64

13

996

Amortization of debt discount

—

404

76

1,783

Total

$
—

$
815

$
169

$
4,234

May 2015 Notes

On May 16, 2011, we issued $155.3 million in aggregate principal amount, at par, of our May 2015 Notes in an underwritten public offering, for net proceeds of $149.7 million. Our May 2015 Notes were due May 1, 2015, and we paid interest at 3.75% on our May 2015 Notes semiannually in arrears on May 1 and November 1 of each year, beginning November 1, 2011. Proceeds from our May 2015 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem a portion of our Series 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders had the option to require PDL to redeem the May 2015 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

On May 1, 2015, the Company completed the retirement of the remaining $155.1 million of aggregate principal of its May 2015 Notes at their stated maturity for $155.1 million, plus approximately 5.2 million shares of its common stock for the excess conversion value.

The carrying value and unamortized discount of our May 2015 Notes were as follows:

(In thousands)

September 30, 2015

December 31, 2014
Principal amount of the May 2015 Notes

$
—

$
155,050

Unamortized discount of liability component

—

(1,815
)
Total

$
—

$
153,235

Interest expense for our May 2015 Notes on our Condensed Consolidated Statements of Income was as follows:

Three Months Ended

Nine Months Ended

September 30,

September 30,
(In thousands)

2015

2014

2015

2014
Contractual coupon interest

$
—

$
1,455

$
1,938

$
4,366

Amortization of debt issuance costs

—

320

435

952

Amortization of debt discount

—

1,308

1,815

3,852

Total

$
—

$
3,083

$
4,188

$
9,170

Purchased Call Options and Warrants

In connection with the issuance of our May 2015 Notes, we entered into purchased call option transactions with two hedge counterparties. We paid an aggregate amount of $20.8 million, plus legal fees, for the purchased call options with terms substantially similar to the embedded conversion options in our May 2015 Notes. We exercised the purchased call options upon conversion of our May 2015 Notes on May 1, 2015, which required the hedge counterparties to deliver shares to the Company. The hedge counterparties delivered to us approximately 5.2 million of PDL common shares, which was the amount equal to the shares required to be delivered by us to the note holders for the excess conversion value.

In addition, we sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive up to 27.5 million shares of common stock underlying our May 2015 Notes. We received an aggregate amount of $10.9 million for the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates through the 120 scheduled trading days beginning on July 30, 2015 and ending on January 20, 2016. If the VWAP of our common stock, as defined in the warrant agreement, exceeds the strike price of the warrants on the date of conversion, we will deliver to the warrant counterparties shares of our common stock equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.

The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of our May 2015 Notes. The strike price is approximately $6.40, subject to further adjustment upon certain events including dividend payments, for the warrants.

Because the share price was above $5.44, but below $6.40, upon conversion of our May 2015 Notes, the purchased call options offset the share dilution, and the Company received shares on exercise of the purchased call options equal to the shares that the Company delivered to the note holders. If the share price is above $6.40, upon exercise of the warrants, the Company will deliver shares to the counterparties in an amount equal to the excess of the share price over $6.40. For example, a 10% increase in the share price above $6.40 would result in the issuance of 2.1 million incremental shares upon exercise of the warrants. If our share price continues to increase, additional dilution would occur.

While the purchased call options reduced the potential equity dilution upon conversion of our May 2015 Notes, prior to the conversion or exercise, our May 2015 Notes and the warrants had a dilutive effect on the Company’s earnings per share to the extent that the price of the Company’s common stock during a given measurement period exceeds the respective exercise prices of those instruments. As of September 30, 2015, and December 31, 2014, there were no related warrants exercised.

The warrants are considered indexed to PDL stock, require net-share settlement and met all criteria for equity classification at inception and at September 30, 2015, and December 31, 2014. The purchased call options cost, including legal fees, of $20.8 million, less deferred taxes of $7.2 million, and the $10.9 million received for the warrant issuance, was recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the warrants continue to meet all criteria for equity classification.

February 2018 Notes

On February 12, 2014, we issued $300.0 million in aggregate principal amount, at par, of our February 2018 Notes in an underwritten public offering, for net proceeds of $290.2 million. Our February 2018 Notes are due February 1, 2018, and we pay interest at 4.0% on our February 2018 Notes semiannually in arrears on February 1 and August 1 of each year, beginning August 1, 2014. A portion of the proceeds from our February 2018 Notes, net of amounts used for purchased call option transactions and provided by the warrant transactions described below, were used to redeem $131.7 million of our Series 2012 Notes. Upon the occurrence of a fundamental change, as defined in the indenture, holders have the option to require PDL to redeem the February 2018 Notes at a purchase price equal to 100% of the principal, plus accrued interest.

Our February 2018 Notes are convertible under any of the following circumstances:

•
During any fiscal quarter ending after the quarter ended June 30, 2014, if the last reported sale price of our common stock for at least 20 trading days in a period of 30 consecutive trading days ending on the last trading day of the immediately preceding fiscal quarter exceeds 130% of the conversion price for the notes on the last day of such preceding fiscal quarter;
•
During the five business-day period immediately after any five consecutive trading-day period, which we refer to as the measurement period, in which the trading price per $1,000 principal amount of notes for each trading day of that measurement period was less than 98% of the product of the last reported sale price of our common stock and the conversion rate for the notes for each such day;
•
Upon the occurrence of specified corporate events as described further in the indenture; or
•
At any time on or after August 1, 2017.

The initial conversion rate for the February 2018 Notes is 109.1048 shares of the Company's common stock per $1,000 principal amount of February 2018 Notes, which is equivalent to an initial conversion price of approximately $9.17 per share of common stock, subject to adjustments upon the occurrence of certain specified events as set forth in the indenture. Upon conversion, the Company will be required to pay cash and, if applicable, deliver shares of the Company's common stock as described in the indenture.

In accordance with the accounting guidance for convertible debt instruments that may be settled in cash or other assets on conversion, we were required to separately account for the liability component of the instrument in a manner that reflects the market interest rate for a similar nonconvertible instrument at the date of issuance. As a result, we separated the principal balance of our February 2018 Notes between the fair value of the debt component and the fair value of the common stock conversion feature. Using an assumed borrowing rate of 7.0%, which represents the estimated market interest rate for a similar nonconvertible instrument available to us on the date of issuance, we recorded a total debt discount of $29.7 million, allocated $19.3 million to additional paid-in capital and allocated $10.4 million to deferred tax liability. The discount is being amortized to interest expense over the term of our February 2018 Notes and increases interest expense during the term of our February 2018 Notes from the 4.0% cash coupon interest rate to an effective interest rate of 6.9%. As of September 30, 2015, the remaining discount amortization period is 2.3 years.

The carrying value and unamortized discount of our February 2018 Notes were as follows:

(In thousands)

September 30, 2015

December 31, 2014
Principal amount of the February 2018 Notes

$
300,000

$
300,000

Unamortized discount of liability component

(18,419
)

(23,772
)
Total

$
281,581

$
276,228

Interest expense for our February 2018 Notes on our Condensed Consolidated Statements of Income was as follows:

Three Months Ended

Nine Months Ended

September 30,

September 30,
(In thousands)

2015

2014

2015

2014
Contractual coupon interest

$
3,000

$
3,000

$
9,000

$
7,633

Amortization of debt issuance costs

510

536

1,599

1,358

Amortization of debt discount

1,830

1,688

5,353

4,238

Total

$
5,340

$
5,224

$
15,952

$
13,229

As of September 30, 2015, our February 2018 Notes are not convertible. At September 30, 2015, the if-converted value of our February 2018 Notes did not exceed the principal amount.

Purchased Call Options and Warrants

In connection with the issuance of our February 2018 Notes, we entered into purchased call option transactions with two hedge counterparties. We paid an aggregate amount of $31.0 million for the purchased call options with terms substantially similar to the embedded conversion options in our February 2018 Notes. The purchased call options cover, subject to anti-dilution and certain other customary adjustments substantially similar to those in our February 2018 Notes, approximately 32.7 million shares of our common stock. We may exercise the purchased call options upon conversion of our February 2018 Notes and require the hedge counterparty to deliver shares to the Company in an amount equal to the shares required to be delivered by the Company to the note holder for the excess conversion value. The purchased call options expire on February 1, 2018, or the last day any of our February 2018 Notes remain outstanding.

In addition, we sold to the hedge counterparties warrants exercisable, on a cashless basis, for the sale of rights to receive shares of common stock that will initially underlie our February 2018 Notes at a strike price of $10.3610 per share, which represents a premium of approximately 30% over the last reported sale price of the Company's common stock of $7.97 on February 6, 2014. The warrant transactions could have a dilutive effect to the extent that the market price of the Company's common stock exceeds the applicable strike price of the warrants on the date of conversion. We received an aggregate amount of $11.4 million for the sale from the two counterparties. The warrant counterparties may exercise the warrants on their specified expiration dates that occur over a period of time. If the VWAP of our common stock, as defined in the warrant agreement, exceeds the strike price of the warrants, we will deliver to the warrant counterparties shares equal to the spread between the VWAP on the date of exercise or expiration and the strike price. If the VWAP is less than the strike price, neither party is obligated to deliver anything to the other.

The purchased call option transactions and warrant sales effectively serve to reduce the potential dilution associated with conversion of our February 2018 Notes. The strike price is subject to further adjustment in the event that future quarterly dividends exceed $0.15 per share.

The purchased call options and warrants are considered indexed to PDL stock, require net-share settlement, and met all criteria for equity classification at inception and at September 30, 2015. The purchased call options cost of $31.0 million, less deferred taxes of $10.8 million, and the $11.4 million received for the warrants, was recorded as adjustments to additional paid-in capital. Subsequent changes in fair value will not be recognized as long as the purchased call options and warrants continue to meet all criteria for equity classification.

March 2015 Term Loan

On March 30, 2015, PDL entered into a credit agreement among the Company, the lenders party thereto and the Royal Bank of Canada, as administrative agent. The credit agreement consists of a term loan of $100.0 million.

The interest rates per annum applicable to amounts outstanding under the term loan are, at the Company’s option, either (a) the alternate base rate (as defined in the credit agreement) plus 0.75%, or (b) the adjusted Eurodollar rate (as defined in the credit agreement) plus 1.75% per annum. As of September 30, 2015, the interest rate, based upon the adjusted Eurodollar rate, was 2.09%. Interest payments under the credit agreement are due on the interest payment dates specified in the credit agreement.

The term loan requires amortization in the form of scheduled principal payments on June 15, September 15 and December 15 of 2015, with the remaining outstanding balance due on February 15, 2016.

Any future material domestic subsidiaries of the Company are required to guarantee the obligations of the Company under the credit agreement, except as otherwise provided by the credit agreement. The Company’s obligations under the credit agreement are secured by a lien on a substantial portion of its assets.

The credit agreement contains affirmative and negative covenants that the Company believes are usual and customary for a senior secured credit agreement. The credit agreement also requires compliance with certain financial covenants, including a maximum total leverage ratio, a debt service coverage ratio and a minimum liquidity covenant, in each case calculated as set forth in the credit agreement and compliance with which may be necessary to take certain corporate actions.

The credit agreement contains events of default that the Company believes are usual and customary for a senior secured credit agreement.

October 2013 Term Loan

On October 28, 2013, PDL entered into a credit agreement among the Company, the lenders party thereto and the Royal Bank of Canada, as administrative agent. The October 2013 Term Loan amount was for $75 million, with a term of one year.

The interest rates per annum applicable to amounts outstanding under the October 2013 Term Loan were, at the Company’s option, either (a) the base rate plus 1.00%, or (b) the Eurodollar rate plus 2.00% per annum. As of the final payment date, the interest rate was 2.22%. This principal balance and outstanding interest was paid in full on October 28, 2014.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for long-term debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LongTermDebtTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 70 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814

Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Numerator

Income used to compute net income per diluted share $ 69,459 $ 102,235 $ 232,221 $ 267,173

Denominator

Total weighted-average shares used to compute net income per basic share (in Shares) 163,560 160,268 163,314 157,274

Diluted (in Shares) 163,742 166,894 163,899 165,141

Basic (in Dollars per Share) $ 0.42 $ 0.64 $ 1.42 $ 1.70

Net income per diluted share (in Dollars per Share) $ 0.42 $ 0.61 $ 1.42 $ 1.62

Debt Instrument [Line Items]

Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 0 0 403 0

February 2018 Notes [Member]

Debt Instrument [Line Items]

Assumed conversion of debt notes (in Shares) 0 0 0 0

Series 2012 Notes [Member]

Debt Instrument [Line Items]

Assumed conversion of debt notes (in Shares) 0 2,247 33 3,301

May 2015 Notes [Member]

Debt Instrument [Line Items]

Assumed conversion of debt notes (in Shares) 0 4,261 0 4,431

Stock Options [Member]

Debt Instrument [Line Items]

Additional shares included in the calculation of diluted EPS (in Shares) 15 22 18 22

Restricted Stock [Member]

Debt Instrument [Line Items]

Additional shares included in the calculation of diluted EPS (in Shares) 167 96 131 113

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 55

-Paragraph 52

-URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-04.23)

-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.21)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 18

-Article 7

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 20

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 21

-Article 9

+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 23

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1757-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Treasury Stock Method

-URI http://asc.fasb.org/extlink&oid=6527216

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Call Option

-URI http://asc.fasb.org/extlink&oid=6506649

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Warrant

-URI http://asc.fasb.org/extlink&oid=6528364

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 40

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1930-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 28A

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1500-109256

+ Details

Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Net Income or Loss Available to Common Stockholders plus adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1377-109256

+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 45

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Weighted-Average Number of Common Shares Outstanding

-URI http://asc.fasb.org/extlink&oid=6528421

+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_February2018NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_Series2012NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_DueMay2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 71 R51.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes (Interest Expense for the Series 2012 Notes) (Detail) - Series 2012 Notes [Member] - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Debt Instrument [Line Items]

Contractual coupon interest $ 0 $ 347 $ 80 $ 1,455

Amortization of debt issuance costs 0 64 13 996

Amortization of debt discount 0 404 76 1,783

Total $ 0 $ 815 $ 169 $ 4,234

X

- Definition
Amortization of debt issuance costs
+ References
No definition available.
+ Details

Name: pdli_AmortizationOfDebtIssuanceCosts

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_AmortizationOfDebtDiscountPremium

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense for debt.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.8)

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph 8

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name: us-gaap_InterestExpenseDebtExcludingAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_Series2012NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 72 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814

Accumulated Other Comprehensive Income (Loss)
9 Months Ended

Sep. 30, 2015

Accumulated Other Comprehensive Income (Loss) [Abstract]

Accumulated Other Comprehensive Income (Loss)
14. Accumulated Other Comprehensive Income

Comprehensive income is comprised of net income and other comprehensive income (loss). We include unrealized net gains (losses) on investments held in our available-for-sale securities and unrealized gains (losses) on our cash flow hedges in other comprehensive income (loss), and present the amounts net of tax. Our other comprehensive income (loss) is included in our Condensed Consolidated Statements of Comprehensive Income.

The balance of accumulated other comprehensive income, net of tax, was as follows:

Unrealized gains (losses) on available-for-sale securities

Unrealized gains on cash flow hedges

Total Accumulated Other Comprehensive Income
(In thousands)

Beginning Balance at December 31, 2014

$
364

$
2,585

$
2,949

Activity for the nine months ended September 30, 2015

39

403

442

Ending Balance at September 30, 2015

$
403

$
2,988

$
3,391

X

- Definition
Accumulated Other Comprehensive Income (Loss) [Abstract]
+ References
No definition available.
+ Details

Name: pdli_AccumulatedOtherComprehensiveIncomeLossAbstract

Namespace Prefix: pdli_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 1A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 12

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 17

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Reclassification Adjustments

-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Name: us-gaap_ComprehensiveIncomeNoteTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 73 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements (Tables)
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the nine months ended September 30, 2015:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)

Royalty Rights - At Fair Value
Beginning Balance at December 31, 2014

$
259,244

Total net change in fair value for the period

Change in fair value of royalty rights - at fair value
$
19,298

Proceeds from royalty rights - at fair value
$
(8,970
)

Total net change in fair value for the period

10,328

Purchases, issues, sales, and settlements

Purchases

115,000

Ending Balance at September 30, 2015

$
384,572

Schedule of fair value of financial instruments measured on recurring basis

September 30, 2015

December 31, 2014

Level 1

Level 2

Level 3

Total

Level 1

Level 2

Level 3

Total
(In thousands)

Financial assets:

Money market funds

$
139,850

$
—

$
—

$
139,850

$
221,792

$
—

$
—

$
221,792

Corporate securities

—

1,827

—

1,827

—

2,310

—

2,310

Foreign currency hedge contracts

—

4,597

—

4,597

—

4,069

—

4,069

Warrants

—

1,258

—

1,258

—

—

—

—

Royalty rights - at fair value

—

—

384,572

384,572

—

—

259,244

259,244

Total

$
139,850

$
7,682

$
384,572

$
532,104

$
221,792

$
6,379

$
259,244

$
487,415

Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy
The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:

September 30, 2015

December 31, 2014

Carrying Value

Fair Value
Level 2

Fair Value
Level 3

Carrying Value

Fair Value
Level 2

Fair Value
Level 3
(In thousands)

Assets:

Wellstat Diagnostics note receivable

$
50,191

$
—

$
50,191

$
50,191

$
—

$
50,191

Hyperion note receivable

1,200

—

1,200

1,200

—

1,200

Avinger note receivable

—

—

—

20,611

—

20,760

LENSAR note receivable

50,266

—

50,266

39,668

—

40,451

Direct Flow Medical note receivable

51,772

—

52,052

50,397

—

49,940

Paradigm Spine note receivable

49,909

—

51,071

49,571

—

50,125

kaléo note receivable

151,496

—

151,476

151,574

—

151,073

Total¹

$
354,834

$
—

$
356,256

$
363,212

$
—

$
363,740

Liabilities:

Series 2012 Notes

$
—

$
—

$
—

$
22,261

$
33,506

$
—

May 2015 Notes

—

—

—

153,235

205,534

—

February 2018 Notes

281,581

262,313

—

276,228

289,665

—

March 2015 Term Loan

49,842

50,000

—

—

—

—

Total

$
331,423

$
312,313

$
—

$
451,724

$
528,705

$
—

X

- Definition
Schedule of fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy
+ References
No definition available.
+ Details

Name: pdli_ScheduleOfAssetsAndLiabilitiesNotRecordedAtFairValueTableTextBlock

Namespace Prefix: pdli_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19279-110258

+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19190-110258

+ Details

Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 74 R49.htm IDEA: XBRL DOCUMENT v3.3.0.814

Convertible Notes (Summary of Convertible Notes) (Detail)
1 Months Ended 3 Months Ended 9 Months Ended

Feb. 11, 2014

Jan. 31, 2012

USD ($)

Sep. 30, 2015

USD ($)

$ / shares

Sep. 30, 2015

USD ($)

$ / shares

May. 01, 2015

USD ($)

Feb. 17, 2015

USD ($)

Dec. 31, 2014

USD ($)

Feb. 12, 2014

USD ($)

$ / shares

Feb. 06, 2014

USD ($)

Aug. 01, 2013

USD ($)

Debt Instrument [Line Items]

Principal amount a $5 incentive cash payment per each to convert debt $ 1,000

Term loan payable ^[1] 49,842,000 $ 49,842,000 $ 0

Convertible Notes Payable, Carrying Value 331,423,000 $ 331,423,000 451,724,000

Series 2012 Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 2.875%

Convertible Notes, Maturity Date (Date) Feb. 15, 2015

Convertible Notes, Principal Balance Outstanding 0 $ 0 $ 22,300,000 22,337,000 $ 48,300,000 $ 180,000,000

Convertible Notes Payable, Carrying Value $ 0 $ 0 22,261,000

May 2015 Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 3.75% 3.75%

Convertible notes, conversion price (in Dollars per Share) | $ / shares $ 5.44 $ 5.44

Convertible Notes, Maturity Date (Date) May 01, 2015

Convertible Notes, Principal Balance Outstanding $ 0 $ 0 $ 155,100,000 155,050,000

Convertible Notes Payable, Carrying Value 0 0 153,235,000

February 2015 Notes [Member]

Debt Instrument [Line Items]

Principal amount a $5 incentive cash payment per each to convert debt $ 1,000

Convertible Notes, Principal Balance Outstanding 0 $ 0

February 2018 Notes [Member]

Debt Instrument [Line Items]

Debt Instrument, Interest Rate, Stated Percentage 4.00%

Debt Instrument, Convertible, Conversion Ratio 109.1048

Convertible notes, conversion price (in Dollars per Share) | $ / shares $ 9.17

Convertible Notes, Maturity Date (Date) Feb. 01, 2018

Convertible Notes, Principal Balance Outstanding 300,000,000 $ 300,000,000 300,000,000 $ 300,000,000

Convertible Notes Payable, Carrying Value 281,581,000 $ 281,581,000 $ 276,228,000

Term Loan. [Member]

Debt Instrument [Line Items]

Convertible Notes, Maturity Date (Date) Feb. 15, 2016

Convertible Notes, Principal Balance Outstanding 50,000,000 $ 50,000,000

Convertible Notes Payable, Carrying Value $ 49,842,000 $ 49,842,000

[1] unaudited

X

- Definition
The amount of principal tendered which a $5.00 cash payment is made per each to convert the Series 2012 notes to February 2015 notes.
+ References
No definition available.
+ Details

Name: pdli_PrincipalAmountIncentiveFeePaidPer

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The price per share of the conversion feature embedded in the debt instrument.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 470

-SubTopic 20

-Section 50

-Paragraph 5

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionPrice1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Conversion Rate

-URI http://asc.fasb.org/extlink&oid=6509012

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(5))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 7

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644

+ Details

Name: us-gaap_DebtInstrumentConvertibleConversionRatio1

Namespace Prefix: us-gaap_

Data Type: xbrli:pureItemType

Balance Type: na

Period Type: duration

X

- Definition
Face (par) amount of debt instrument at time of issuance.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 55

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 835

-SubTopic 30

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399

+ Details

Name: us-gaap_DebtInstrumentFaceAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Contractual interest rate for funds borrowed, under the debt agreement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentInterestRateStatedPercentage

Namespace Prefix: us-gaap_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DebtInstrumentLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22(a)(2))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_DebtInstrumentMaturityDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.16)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 13, 16

-Article 9

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19, 20, 22

-Article 5

+ Details

Name: us-gaap_NotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount at the balance sheet date of borrowings from a bank, not elsewhere enumerated in the taxonomy, with a maturity within one year (or within one operating cycle if longer) from the date of borrowing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ShortTermBankLoansAndNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_Series2012NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_DueMay2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_DueFebruary2015Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_February2018NotesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_DebtInstrumentAxis=pdli_TermLoan.Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 75 R41.htm IDEA: XBRL DOCUMENT v3.3.0.814

Foreign Currency Hedging (Narrative) (Detail) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Derivative Instrument Gain Loss [Line Items]

Gain (Loss) on Cash Flow Hedge Ineffectiveness, Net $ 0 $ (2) $ 0 $ (5)

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsGainLossLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net gain (loss) recognized in earnings during the reporting period representing the amount of the cash flow hedges' ineffectiveness.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 815

-SubTopic 10

-Section 50

-Paragraph 4C

-Subparagraph (d)(1)

-URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5624171-113959

+ Details

Name: us-gaap_GainLossOnCashFlowHedgeIneffectivenessNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 76 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands

Sep. 30, 2015

Dec. 31, 2014

Current assets:

Cash and cash equivalents $ 227,855 ^[1],[2] $ 291,377 ^[3]

Short-term investments 1,827 ^[1] 2,310 ^[3]

Receivables from licensees and other 594 ^[1] 300 ^[3]

Deferred tax assets 0 ^[1] 375 ^[3]

Notes receivable 67,246 ^[1] 57,597 ^[3]

Prepaid and other current assets 9,166 ^[1] 3,938 ^[3]

Total current assets 306,688 ^[1] 355,897 ^[3]

Property and equipment, net 42 ^[1] 62 ^[3]

Royalty rights 384,572 ^[1] 259,244 ^[3]

Notes and other receivables, long-term 286,160 ^[1] 305,615 ^[3]

Long-term deferred tax assets 36,499 ^[1] 33,799 ^[3]

Other assets 6,640 ^[1] 7,733 ^[3]

Total assets 1,020,601 ^[1] 962,350 ^[3]

Current liabilities:

Accounts payable 421 ^[1] 318 ^[3]

Accrued liabilities 32,711 ^[1] 8,876 ^[3]

Accrued Income Taxes, Current 0 ^[1] 3,293 ^[3]

Deferred Tax Liabilities 11,615 0

Term loan payable ^[1] 49,842 0

Convertible Notes Payable, Current 0 ^[1] 175,496 ^[3]

Total current liabilities 94,589 ^[1] 187,983 ^[3]

Convertible notes payable 281,581 ^[1] 276,228 ^[3]

Other long-term liabilities 48,474 ^[1] 37,702 ^[3]

Total liabilities $ 424,644 ^[1] $ 501,913 ^[3]

Commitments and contingencies (Note 8) ^[1] ^[3]

Stockholders' deficit:

Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding $ 0 ^[1] $ 0 ^[3]

Common stock, par value $0.01 per share, 350,000 shares authorized; 163,573 and 162,186 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively 1,636 ^[1] 1,622 ^[3]

Additional paid-in capital (118,540) ^[1] (119,874) ^[3]

Accumulated other comprehensive income 3,391 ^[1] 2,949 ^[3]

Retained earnings 709,470 ^[1] 575,740 ^[3]

Total stockholders' equity 595,957 ^[1] 460,437 ^[3]

Total liabilities and stockholders' equity $ 1,020,601 ^[1] $ 962,350 ^[3]

[1] unaudited

[2] unaudited

[3] Note 1

X

- Definition
Royalty rights
+ References
No definition available.
+ Details

Name: pdli_Royaltyrights

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3-4)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 3

-Subparagraph a(1)

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 4

-Article 5

+ Details

Name: us-gaap_AccountsReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Article 9

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 15

-Subparagraph b(1)

-Article 7

+ Details

Name: us-gaap_AccruedIncomeTaxesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14

-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 14A

-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669686-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 12

-Article 7

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.9)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of investments in debt securities classified as available-for-sale, expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 25

-Paragraph 1

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 320

-SubTopic 10

-Section 45

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26626-111562

+ Details

Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3044-108585

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.(a),19)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 450

-SubTopic 20

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 942

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.9-03.17)

-URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.25)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommitmentsAndContingencies

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.22)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleLongTermNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.20)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ConvertibleNotesPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, netted by jurisdiction and classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_DeferredTaxAssetsLiabilitiesNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31928-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

+ Details

Name: us-gaap_DeferredTaxAssetsNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, netted by jurisdiction and classified as current.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31958-109318

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31917-109318

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=37586315&loc=d3e31931-109318

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

+ Details

Name: us-gaap_DeferredTaxLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 25

-Article 7

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.21)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
An amount representing an agreement for an unconditional promise by the maker to pay the Company (holder) a definite sum of money within one year from the balance sheet date (or the normal operating cycle, whichever is longer), net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section 45

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=28367877&loc=d3e4531-111522

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.3)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

+ Details

Name: us-gaap_NotesAndLoansReceivableNetCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date more than one year from the balance sheet date, net of any write-downs taken for collection uncertainty on the part of the holder. Such amount may include accrued interest receivable in accordance with the terms of the debt. The debt also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among a myriad of other features and characteristics. This amount does not include amounts related to receivables held-for-sale.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_NotesAndLoansReceivableNetNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.17)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherAssetsNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.24)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_OtherLiabilitiesNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29

-Article 5

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 8

-Article 5

+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.13)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 360

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 13

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 8

-Article 7

+ Details

Name: us-gaap_PropertyPlantAndEquipmentNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.31(a)(3))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying amount at the balance sheet date of borrowings from a bank, not elsewhere enumerated in the taxonomy, with a maturity within one year (or within one operating cycle if longer) from the date of borrowing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 210

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-03.16)

-URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_ShortTermBankLoansAndNotesPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 77 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements
9 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements
3. Fair Value Measurements

The fair value of our financial instruments are estimates of the amounts that would be received if we were to sell an asset or pay to transfer a liability in an orderly transaction between market participants at the measurement date or exit price. The assets and liabilities are categorized and disclosed in one of the following three categories:

Level 1 – based on quoted market prices in active markets for identical assets and liabilities;

Level 2 – based on quoted market prices for similar assets and liabilities, using observable market-based inputs or unobservable market-based inputs corroborated by market data; and

Level 3 – based on unobservable inputs using management’s best estimate and assumptions when inputs are unavailable.

The following tables present the fair value of our financial instruments measured at fair value on a recurring basis by level within the valuation hierarchy.

September 30, 2015

December 31, 2014

Level 1

Level 2

Level 3

Total

Level 1

Level 2

Level 3

Total
(In thousands)

Financial assets:

Money market funds

$
139,850

$
—

$
—

$
139,850

$
221,792

$
—

$
—

$
221,792

Corporate securities

—

1,827

—

1,827

—

2,310

—

2,310

Foreign currency hedge contracts

—

4,597

—

4,597

—

4,069

—

4,069

Warrants

—

1,258

—

1,258

—

—

—

—

Royalty rights - at fair value

—

—

384,572

384,572

—

—

259,244

259,244

Total

$
139,850

$
7,682

$
384,572

$
532,104

$
221,792

$
6,379

$
259,244

$
487,415

There have been no transfers between levels during each of the three-month periods ended September 30, 2015, and December 31, 2014. The Company recognizes transfers between levels on the date of the event or change in circumstances that caused the transfer.

Corporate Securities

Corporate securities consist primarily of U.S. corporate equity holdings. The fair value of corporate securities is estimated using recently executed transactions or market quoted prices, where observable. Independent pricing sources are also used for valuation.

Royalty Rights - At Fair Value

Depomed Royalty Agreement

On October 18, 2013, PDL entered into the Depomed Royalty Agreement, whereby the Company acquired the rights to receive royalties and milestones payable on sales of Type 2 diabetes products licensed by Depomed in exchange for a $240.5 million cash payment. Total arrangement consideration was $241.3 million, which was comprised of the $240.5 million cash payment to Depomed and $0.8 million in transaction costs.

The rights acquired include Depomed’s royalty and milestone payments accruing from and after October 1, 2013: (a) from Santarus (which was subsequently acquired by Salix, which itself was recently acquired by Valeant Pharmaceuticals) with respect to sales of Glumetza (metformin HCL extended-release tablets) in the United States; (b) from Merck with respect to sales of Janumet^® XR (sitagliptin and metformin HCL extended-release tablets); (c) from Janssen Pharmaceutica with respect to potential future development milestones and sales of its investigational fixed-dose combination of Invokana^® (canagliflozin) and extended-release metformin tablets; (d) from Boehringer Ingelheim with respect to potential future development milestones and sales of the investigational fixed-dose combinations of drugs and extended-release metformin subject to Depomed’s license agreement with Boehringer Ingelheim; and (e) from LG Life Sciences and Valeant Pharmaceuticals for sales of extended-release metformin tablets in Korea and Canada, respectively.

Under the terms of the Depomed Royalty Agreement, the Company will receive all royalty and milestone payments due under license agreements between Depomed and its licensees until the Company has received payments equal to two times the cash payment it made to Depomed, after which all net payments received by Depomed will be shared evenly between the Company and Depomed.

The Depomed Royalty Agreement terminates on the third anniversary following the date upon which the later of the following occurs: (a) October 25, 2021, or (b) at such time as no royalty payments remain payable under any license agreement and each of the license agreements has expired by its terms.

As of September 30, 2015, and December 31, 2014, the Company determined that its royalty purchase interest in Depo DR Sub represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of Depo DR Sub that most significantly impact Depo DR Sub's economic performance and is not the primary beneficiary of Depo DR Sub; therefore, Depo DR Sub is not subject to consolidation by the Company.

The asset acquired represents a single unit of accounting. The fair value of the asset acquired was determined by using a discounted cash flow analysis related to the expected future cash flows to be generated by each licensed product. This asset is classified as a Level 3 asset within the fair value hierarchy, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future commercialization for products not yet approved by the FDA or other regulatory agencies. The discounted cash flows are based upon expected royalties from sales of licensed products over a eight-year period. The discount rates utilized range from approximately 21% to 25%. Significant judgment is required in selecting appropriate discount rates. At September 30, 2015, an evaluation was performed to assess those rates and general market conditions potentially affecting the fair market value. Should these discount rates increase or decrease by 5%, the fair value of the asset could decrease by $18.3 million or increase by $23.2 million, respectively. A third-party expert was engaged to help management develop its original estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from those estimates. We periodically assess the expected future cash flows and to the extent such payments are greater or less than our initial estimates, or the timing of such payments is materially different than our original estimates, we will adjust the estimated fair value of the asset. Certain manufacturers of generic equivalents to Glumetza will be permitted to enter the market starting in February and August 2016. Our current expected future cash flows anticipate a reduction in future cash flows of Glumetza as result of the generic competition in 2016. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $7.1 million or decrease by $7.7 million, respectively.

When PDL acquired the Depomed royalties, Glumetza was marketed by Santarus. In January 2014, Salix acquired Santarus and assumed responsibility for commercializing Glumetza, which was generally perceived to be a positive development because of Salix's larger sales force and track record in the successful commercialization of therapies. In late 2014, Salix made a number of disclosures relating to an excess of supply at the distribution level of Glumetza and other drugs that it commercialized, the practices leading to this excess of supply which were under review by Salix's audit committee in relation to the related accounting practices. Because of these disclosures and PDL's lack of direct access to information as to the levels of inventory of Glumetza in the distribution channels, PDL reviewed of all public statements by Salix, publicly available historical third-party prescription data, analyst reports and other relevant data sources. PDL also engaged a third-party expert to specifically assess estimated inventory levels of Glumetza in the distribution channel and to ascertain the potential effects those inventory levels may have on expected future cash flows. We have received no royalties from Glumetza sales in 2015. Salix was acquired by Valeant Pharmaceuticals in early April 2015. On June 18, 2015, Valeant Pharmaceuticals implemented a price increase on Glumetza and implemented an additional price increase on July 31, 2015. As of September 30, 2015, our discounted cash flow analysis reflects our expectations as to the amount and timing of future cash flows up to the valuation date. We will monitor whether the acquisition or price increase by Valeant Pharmaceuticals has any effect on sales of Glumetza and thus royalties on such sales paid to PDL. Due to the uncertainty around Valeant's marketing and pricing strategy, as well as the near-term generic competition, we may be unable to fully assess the impact of the acquisition or price increase on sales of Glumetza and thus royalties on such sales paid to PDL. PDL expects to exercise its royalty audit right for Glumetza in the near future.

As of September 30, 2015, and December 31, 2014, the carrying value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was approximately $178.2 million and $176.2 million, respectively. As of September 30, 2015, the maximum loss exposure was $178.2 million.

VB Royalty Agreement

On June 26, 2014, PDL entered into the VB Royalty Agreement, whereby VB conveyed to the Company the right to receive royalties payable on sales of a spinal implant that has received pre-market approval from the FDA, in exchange for a $15.5 million cash payment, less fees.

The acquired royalties include royalty amounts accruing from and after April 1, 2014. Under the terms of the VB Royalty Agreement, the Company will receive all royalty payments due to VB pursuant to certain technology transfer agreements between VB and Paradigm Spine until the Company has received payments equal to two and three tenths times the cash payment made to VB, after which all rights to receive royalties will be returned to VB. VB may repurchase the royalty right at any time on or before June 26, 2018, for a specified amount. The acting chief executive officer of Paradigm Spine is one of the owners of VB. The Paradigm Spine Credit Agreement and the VB Royalty Agreement were negotiated separately.

The fair value of the VB Royalty Agreement royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a nine-year period. The discount rate utilized was approximately 17.5%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $2.4 million or increase by $3.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $0.8 million or decrease by $0.8 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. At each reporting period, an evaluation is performed to assess those estimates, discount rates utilized and general market conditions affecting fair market value.

As of September 30, 2015, and December 31, 2014, the carrying value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was $16.9 million and $16.1 million, respectively. As of September 30, 2015, the maximum loss exposure was $16.9 million.

University of Michigan Royalty Agreement

On November 6, 2014, PDL acquired a portion of all royalty payments of U-M’s worldwide royalty interest in Cerdelga (Eliglustat) for $65.6 million. Under the terms of the Michigan Royalty Agreement, PDL will receive 75% of all royalty payments due under U-M’s license agreement with Genzyme until expiration of the licensed patents, excluding any patent term extension. Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme. Cerdelga was approved in the United States on August 19, 2014, in the European Union on January 22, 2015, and in Japan on March 25, 2015. In addition, marketing applications for Cerdelga are under review by other regulatory authorities.

The fair value of the royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a seven-year period. The discount rate utilized was approximately 12.8%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $11.1 million or increase by $14.5 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.6 million or decrease by $3.6 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of September 30, 2015, and December 31, 2014, the fair value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was $71.6 million and $66.9 million. As of September 30, 2015, the maximum loss exposure was $71.6 million.

ARIAD Royalty Agreement

On July 28, 2015, PDL entered into the ARIAD Royalty Agreement, whereby the Company acquired the rights to receive royalties payable from ARIAD's net revenues generated by the sale, distribution or other use of Iclusig^® (ponatinib), a cancer medicine for the treatment of adult patients with chronic myeloid leukemia, in exchange for up to $200.0 million in cash payments. The purchase price of $100.0 million is payable in two tranches of $50.0 million each, with the first tranche funded on the closing date and the second tranche to be funded on the 12-month anniversary of the closing date. The ARIAD Royalty Agreement provides ARIAD with an option to draw up to an additional $100.0 million in up to two draws at any time between the six- and 12-month anniversaries of the closing date. ARIAD may repurchase the royalty rights at any time for a specified amount. Upon the occurrence of certain events, PDL has the right to require ARIAD to repurchase the royalty rights for a specified amount. Under the ARIAD Royalty Agreement, the Company has the right to a make-whole payment from ARIAD if the Company does not receive payments equal to or greater than the amounts funded on or prior to the fifth anniversary of each of the respective fundings. In such case, ARIAD will pay to the Company the difference between the amounts paid to such date by ARIAD (excluding any delinquent fee payments) and the amounts funded by the Company. PDL has elected the fair value option to account for the hybrid instrument in its entirety. Any embedded derivative shall not be separated from the host contract.

Under the terms of the ARIAD Royalty Agreement, the Company will receive royalty payments at a royalty rate ranging from 2.5% to 7.5% of Iclusig revenue until the first to occur of (i) repurchase of the royalty rights by ARIAD or (ii) December 31, 2033. The annual royalty payments shall not exceed $20.0 million is any fiscal year for the years ended December 31, 2015 through December 31, 2018. If Iclusig revenue does not meet certain agreed-upon projections on an annual basis, PDL is entitled to certain royalty payments from net revenue of another ARIAD product, brigatinib, up to the amount of the shortfall from the projections for the applicable year.

The asset acquired pursuant to the ARIAD Royalty Agreement represents a single unit of accounting. The fair value of the royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a seven-year period. The discount rate utilized was approximately 10.0%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $15.1 million or increase by $20.0 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $2.5 million or decrease by $2.5 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of September 30, 2015, and December 31, 2014, the fair value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was $49.9 million and zero. As of September 30, 2015, the maximum loss exposure was $49.9 million.

AcelRx Royalty Agreement

On September 18, 2015, PDL entered into the AcelRx Royalty Agreement with ARPI LLC, a wholly owned subsidiary of AcelRx, whereby the Company acquired the rights to receive a portion of the royalties and certain milestone payments on sales of Zalviso^™ (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by AcelRx's commercial partner, Grünenthal, in exchange for a $65.0 million cash payment. Under the terms of the AcelRx Royalty Agreement, the Company will receive 75% of all royalty payments and 80% of the first four commercial milestone payments due under AcelRx's license agreement with Grünenthal until the earlier to occur of (i) receipt by the Company of payments equal to three times the cash payments made to AcelRx and (ii) the expiration of the licensed patents.

As of September 30, 2015, and December 31, 2014, the Company determined that its royalty rights under the agreement with ARPI LLC represented a variable interest in a variable interest entity. However, the Company does not have the power to direct the activities of ARPI LLC that most significantly impact ARPI LLC's economic performance and is not the primary beneficiary of ARPI LLC; therefore, ARPI LLC is not subject to consolidation by the Company.

The fair value of the royalty right at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a sixteen-year period. The discount rate utilized was approximately 13.4%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5%, the fair value of this asset could decrease by $18.4 million or increase by $29.2 million, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $3.3 million or decrease by $3.3 million, respectively. A third-party expert is engaged to assist management with the development of its estimate of the expected future cash flows, when deemed necessary. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of September 30, 2015, and December 31, 2014, the fair value of the asset acquired as reported in our Condensed Consolidated Balance Sheets was $65.3 million and zero. As of September 30, 2015, the maximum loss exposure was $65.3 million.

Avinger Credit and Royalty Agreement

On April 18, 2013, PDL entered into the Avinger Credit and Royalty Agreement, under which we made available to Avinger up to $40.0 million (of which only $20.0 million was funded) to be used by Avinger in connection with the commercialization of its lumivascular catheter devices and the development of Avinger's lumivascular atherectomy device. On September 22, 2015, Avinger elected to prepay the note receivable in whole for a payment of $21.4 million in cash (see Note 6).

Under the terms of the Avinger Credit and Royalty Agreement, the Company is entitled to receive royalties at a rate of 1.8% on Avinger's net revenues. As Avinger repaid the note receivable prior to its maturity date in April 2018, the royalty rate was reduced to 0.9% and will be subject to certain minimum payments from the prepayment date until April 2018. PDL has accounted for the royalty rights in accordance with the fair value option. The fair value of the royalty rights at September 30, 2015, was determined by using a discounted cash flow analysis related to the expected future cash flows to be received. This asset is classified as a Level 3 asset, as our valuation utilized significant unobservable inputs, including estimates as to the probability and timing of future sales of the licensed product. The discounted cash flow was based upon expected royalties from sales of licensed product over a three-year period. The discount rate utilized was approximately 15.0%. Significant judgment is required in selecting the appropriate discount rate. Should this discount rate increase or decrease by 5.0%, the fair value of this asset could decrease by $158,000 or increase by $179,000, respectively. Should the expected royalties increase or decrease by 5%, the fair value of the asset could increase by $137,000 or decrease by $137,000, respectively. Management considered the contractual minimum payments when developing its estimate of the expected future cash flows. The fair value of the asset is subject to variation should those cash flows vary significantly from our estimates. An evaluation of those estimates, discount rates utilized and general market conditions affecting fair market value is performed in each reporting period.

As of September 30, 2015, and December 31, 2014, the fair value of the royalty asset as reported in our Condensed Consolidated Balance Sheets was $2.7 million and zero. As of September 30, 2015, the maximum loss exposure was $2.7 million.

The following tables summarize the changes in Level 3 assets and the gains and losses included in earnings for the nine months ended September 30, 2015:

Fair Value Measurements Using Significant Unobservable Inputs (Level 3)

(in thousands)

Royalty Rights - At Fair Value
Beginning Balance at December 31, 2014

$
259,244

Total net change in fair value for the period

Change in fair value of royalty rights - at fair value
$
19,298

Proceeds from royalty rights - at fair value
$
(8,970
)

Total net change in fair value for the period

10,328

Purchases, issues, sales, and settlements

Purchases

115,000

Ending Balance at September 30, 2015

$
384,572

The changes in the estimated fair value included in earnings for each period are presented in "Royalty rights - change in fair value" as follows:

Three Months Ended

Nine Months Ended

September 30,

September 30,
(in thousands)

2015

2014

2015

2014

Total change in fair value for the period included in earnings for assets held at the end of the reporting period

$
(4,280
)

$
26,787

$
19,298

$
72,992

Foreign Currency Hedge Contracts

The fair value of the foreign currency hedge contracts is estimated based on pricing models using readily observable inputs from actively quoted markets and are disclosed on a gross basis.

Warrants

Warrants consist primarily of purchased call options to buy U.S. corporate equity holdings and derivative assets acquired as part of note receivable investments. The fair value of the warrants is estimated using recently quoted market prices and the Black-Scholes model.

The following tables present the fair value of assets and liabilities not subject to fair value recognition by level within the valuation hierarchy:

September 30, 2015

December 31, 2014

Carrying Value

Fair Value
Level 2

Fair Value
Level 3

Carrying Value

Fair Value
Level 2

Fair Value
Level 3
(In thousands)

Assets:

Wellstat Diagnostics note receivable

$
50,191

$
—

$
50,191

$
50,191

$
—

$
50,191

Hyperion note receivable

1,200

—

1,200

1,200

—

1,200

Avinger note receivable

—

—

—

20,611

—

20,760

LENSAR note receivable

50,266

—

50,266

39,668

—

40,451

Direct Flow Medical note receivable

51,772

—

52,052

50,397

—

49,940

Paradigm Spine note receivable

49,909

—

51,071

49,571

—

50,125

kaléo note receivable

151,496

—

151,476

151,574

—

151,073

Total¹

$
354,834

$
—

$
356,256

$
363,212

$
—

$
363,740

Liabilities:

Series 2012 Notes

$
—

$
—

$
—

$
22,261

$
33,506

$
—

May 2015 Notes

—

—

—

153,235

205,534

—

February 2018 Notes

281,581

262,313

—

276,228

289,665

—

March 2015 Term Loan

49,842

50,000

—

—

—

—

Total

$
331,423

$
312,313

$
—

$
451,724

$
528,705

$
—

___________________
¹ The carrying amount of notes receivable excludes the debt discount of $1.4 million arisen from the CareView transaction (Note 6).

As of September 30, 2015 and December 31, 2014, the estimated fair values of our Paradigm Spine note receivable, kaléo note receivable, Hyperion note receivable, Avinger note receivable and Direct Flow Medical note receivable, were determined using one or more discounted cash flow models, incorporating expected payments and the interest rate extended on the notes receivable, with fixed interest rates and incorporating expected payments for notes receivable with a variable rate of return. In some instances the carrying values of certain notes receivable differed from their estimated fair market values. This is generally the result of discount rates used when performing a discounted cash flow for fair value valuation purposes.

When deemed necessary we engage a third-party valuation expert to assist in evaluating our investments and the related inputs needed for us to estimate the fair value of certain investments. We determined our notes receivable assets are Level 3 assets as our valuations utilized significant unobservable inputs, including estimates of future revenues, discount rates, expectations about settlement, terminal values and required yield. To provide support for the estimated fair value measurements, we considered forward-looking performance related to the investment and current measures associated with high yield indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in similar sectors.

The Wellstat Diagnostics Note Receivable and Credit Agreement, as amended and restated, is secured by all assets and equity interests in Wellstat Diagnostics. The estimated fair value of the collateral was determined by using an asset approach related to the underlying collateral and was adjusted to consider estimated costs to sell the assets.

The loans under the credit agreement with LENSAR are secured by substantially all of the assets of LENSAR. The estimated fair value of the collateral was determined by using an asset approach related to the underlying collateral and was adjusted to consider estimated costs to sell the assets.

On September 30, 2015, the carrying values of several of our notes receivable differed from their fair value. This is the result of discount rates used when performing a discounted cash flow for fair value valuation purposes. We determined these notes receivable to be Level 3 assets, as our valuations utilized significant unobservable inputs, estimates of future revenues, expectations about settlement and required yield. To provide support for the fair value measurements, we considered forward-looking performance, and current measures associated with high yield and published indices, and reviewed the terms and yields of notes placed by specialty finance and venture firms both across industries and in a similar sector.

The fair values of our convertible notes were determined using quoted market pricing or dealer quotes.

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 30

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 21

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 16

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 825

-SubTopic 10

-Section 50

-Paragraph 10

-URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611

+ Details

Name: us-gaap_FairValueDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 78 R58.htm IDEA: XBRL DOCUMENT v3.3.0.814

Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail)
shares in Thousands
9 Months Ended

Sep. 30, 2015

$ / shares

shares

Share Based Compensation Arrangment By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period (46)

Stock-Based Incentive Plan [Member]

Share Based Compensation Arrangment By Share Based Payment Award [Line Items]

Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures (522)

Shares Available for Grant, Balance beginning of period (in Shares) 4,166

Shares Available for Grant, Balance end of period (in Shares) 3,684

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period 0

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations 40

Stock Options [Member]

Share Based Compensation Arrangment By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares

Stock Options, Number of Shares, Balance at beginning of period (in Shares) 58

Stock Options, Number of Shares, Balance at end of period (in Shares) 58

Stock Options, Weighted Average Exercise Price, Balance at beginning of period (in Dollars per Share) | $ / shares $ 5.41

Stock Options, Weighted Average Exercise Price, Balance at end of period (in Dollars per Share) | $ / shares 5.41

Restricted Stock [Member]

Share Based Compensation Arrangment By Share Based Payment Award [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | $ / shares $ 6.46

Restricted Stock Award, Number of Shares, Balance at beginning of period (in Shares) 277

Restricted Stock Awards, Number of Shares Granted (in Shares) 522

Restricted Stock Awards, Number of Shares, Balance at end of period (in Shares) 713

Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at beginning of period (in Dollars per Share) | $ / shares $ 8.39

Restricted Stock Awards, Weighted Average Grant-date Fair Value, Granted (in Dollars per Share) | $ / shares 6.40

Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at end of period (in Dollars per Share) | $ / shares 7.36

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value | $ / shares $ 8.58

Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations (40)

X

- Definition
Decrease in shares available for grant from shares granted.
+ References
No definition available.
+ Details

Name: pdli_Decreaseinsharesavailableforgrantfromsharesgranted

Namespace Prefix: pdli_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(3)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(1)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)(iii)(2)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares under non-option equity instrument agreements that were either cancelled or expired.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(iv)(3)-(4)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)-(ii)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 718

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)(i)

-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 79 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814

Cash Equivalents and Investments (Tables)
9 Months Ended

Sep. 30, 2015

Cash and Cash Equivalents [Abstract]

Summary of cash and available-for-sale securities
Summary of Cash and Available-For-Sale Securities

Adjusted Cost

Unrealized Gains

Unrealized Losses

Estimated Fair Value

Cash and Cash Equivalents

Short-Term Investments
(In thousands)

September 30, 2015

Cash

$
88,005

$
—

$
—

$
88,005

$
88,005

$
—

Money market funds

139,850

—

—

139,850

139,850

—

Corporate securities

1,206

621

—

1,827

—

1,827

Total

$
229,061

$
621

$
—

$
229,682

$
227,855

$
1,827

December 31, 2014

Cash

$
69,585

$
—

$
—

$
69,585

$
69,585

$
—

Money market funds

221,792

—

—

221,792

221,792

—

Corporate securities

1,750

560

—

2,310

—

2,310

Total

$
293,127

$
560

$
—

$
293,687

$
291,377

$
2,310

X

- References
No definition available.
+ Details

Name: us-gaap_CashAndCashEquivalentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.
+ References
No definition available.
+ Details

Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 310 312 1 true 82 0 false 4 false false R1.htm 0001000 - Document - Document And Entity Information Sheet http://www.pdl.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1001000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfIncomeUnaudited CONDENSED CONSOLIDATED STATEMENTS OF INCOME (Unaudited) Statements 2 false false R3.htm 1002000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeUnaudited CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited) Statements 3 false false R4.htm 1002501 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParentheticals CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parentheticals) Statements 4 false false R5.htm 1003000 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://www.pdl.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 5 false false R6.htm 1003501 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Sheet http://www.pdl.com/role/CondensedConsolidatedBalanceSheetsParentheticals CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) Statements 6 false false R7.htm 1004000 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://www.pdl.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 7 false false R8.htm 2102100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pdl.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2103100 - Disclosure - Net Income per Share Sheet http://www.pdl.com/role/NetIncomePerShare Net Income per Share Notes 9 false false R10.htm 2104100 - Disclosure - Fair Value Measurements Sheet http://www.pdl.com/role/FairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 2105100 - Disclosure - Cash Equivalents and Investments Sheet http://www.pdl.com/role/CashEquivalentsAndInvestments Cash Equivalents and Investments Notes 11 false false R12.htm 2106100 - Disclosure - Foreign Currency Hedging Sheet http://www.pdl.com/role/ForeignCurrencyHedging Foreign Currency Hedging Notes 12 false false R13.htm 2107100 - Disclosure - Notes Receivable and Other Long-term Receivables Notes http://www.pdl.com/role/NotesReceivableAndOtherLongTermReceivables Notes Receivable and Other Long-term Receivables Notes 13 false false R14.htm 2111100 - Disclosure - Accrued Liabilities Sheet http://www.pdl.com/role/AccruedLiabilities Accrued Liabilities Notes 14 false false R15.htm 2112100 - Disclosure - Commitments and Contingencies Sheet http://www.pdl.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 2113100 - Disclosure - Convertible Notes Notes http://www.pdl.com/role/ConvertibleNotes Convertible Notes Notes 16 false false R17.htm 2115100 - Disclosure - Other Long-Term Liabilities Sheet http://www.pdl.com/role/OtherLongTermLiabilities Other Long-Term Liabilities Notes 17 false false R18.htm 2116100 - Disclosure - Stock-Based Compensation Sheet http://www.pdl.com/role/StockBasedCompensation Stock-Based Compensation Notes 18 false false R19.htm 2117100 - Disclosure - Cash Dividends Sheet http://www.pdl.com/role/CashDividends Cash Dividends Notes 19 false false R20.htm 2119100 - Disclosure - Income Taxes Sheet http://www.pdl.com/role/IncomeTaxes Income Taxes Notes 20 false false R21.htm 2120100 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.pdl.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 21 false false R22.htm 2122100 - Disclosure - Subsequent Events Sheet http://www.pdl.com/role/SubsequentEvents Subsequent Events Notes 22 false false R23.htm 2202201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.pdl.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.pdl.com/role/SummaryOfSignificantAccountingPolicies 23 false false R24.htm 2302302 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.pdl.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.pdl.com/role/SummaryOfSignificantAccountingPolicies 24 false false R25.htm 2303301 - Disclosure - Net Income per Share (Tables) Sheet http://www.pdl.com/role/NetIncomePerShareTables Net Income per Share (Tables) Tables http://www.pdl.com/role/NetIncomePerShare 25 false false R26.htm 2304301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.pdl.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.pdl.com/role/FairValueMeasurements 26 false false R27.htm 2305301 - Disclosure - Cash Equivalents and Investments (Tables) Sheet http://www.pdl.com/role/CashEquivalentsAndInvestmentsTables Cash Equivalents and Investments (Tables) Tables http://www.pdl.com/role/CashEquivalentsAndInvestments 27 false false R28.htm 2306301 - Disclosure - Foreign Currency Hedging (Tables) Sheet http://www.pdl.com/role/ForeignCurrencyHedgingTables Foreign Currency Hedging (Tables) Tables http://www.pdl.com/role/ForeignCurrencyHedging 28 false false R29.htm 2313301 - Disclosure - Convertible Notes (Tables) Notes http://www.pdl.com/role/ConvertibleNotesTables Convertible Notes (Tables) Tables http://www.pdl.com/role/ConvertibleNotes 29 false false R30.htm 2315301 - Disclosure - Other Long-Term Liabilities (Tables) Sheet http://www.pdl.com/role/OtherLongTermLiabilitiesTables Other Long-Term Liabilities (Tables) Tables http://www.pdl.com/role/OtherLongTermLiabilities 30 false false R31.htm 2320301 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.pdl.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.pdl.com/role/AccumulatedOtherComprehensiveIncomeLoss 31 false false R32.htm 2402405 - Disclosure - Summary of Significant Accounting Policies (Schedule of Revenue by Major Customers) (Details) Sheet http://www.pdl.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfRevenueByMajorCustomersDetails Summary of Significant Accounting Policies (Schedule of Revenue by Major Customers) (Details) Details http://www.pdl.com/role/SummaryOfSignificantAccountingPoliciesTables 32 false false R33.htm 2403402 - Disclosure - Net Income per Share (Narrative) (Detail) Sheet http://www.pdl.com/role/NetIncomePerShareNarrativeDetail Net Income per Share (Narrative) (Detail) Details http://www.pdl.com/role/NetIncomePerShareTables 33 false false R34.htm 2403403 - Disclosure - Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) Sheet http://www.pdl.com/role/NetIncomePerShareNetIncomePerBasicAndDilutedShareDetail Net Income per Share (Net Income Per Basic and Diluted Share) (Detail) Details http://www.pdl.com/role/NetIncomePerShareTables 34 false false R35.htm 2404402 - Disclosure - Fair Value Measurements (Narrative) (Detail) Sheet http://www.pdl.com/role/FairValueMeasurementsNarrativeDetail Fair Value Measurements (Narrative) (Detail) Details http://www.pdl.com/role/FairValueMeasurementsTables 35 false false R36.htm 2404403 - Disclosure - Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) Sheet http://www.pdl.com/role/FairValueMeasurementsFinancialInstrumentsMeasuredAtFairValueOnRecurringBasisDetail Fair Value Measurements (Financial Instruments Measured at Fair Value on a Recurring Basis) (Detail) Details http://www.pdl.com/role/FairValueMeasurementsTables 36 false false R37.htm 2404404 - Disclosure - Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) Sheet http://www.pdl.com/role/FairValueMeasurementsScheduleOfFairValueOfAssetsAndLiabilitiesNotSubjectToFairValueRecognitionDetail Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) Details http://www.pdl.com/role/FairValueMeasurementsTables 37 false false R38.htm 2404405 - Disclosure - Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) Sheet http://www.pdl.com/role/FairValueMeasurementsLevel3UnobservableInputReconciliationDetails Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) Details 38 false false R39.htm 2405402 - Disclosure - Cash Equivalents and Investments (Narrative) (Detail) Sheet http://www.pdl.com/role/CashEquivalentsAndInvestmentsNarrativeDetail Cash Equivalents and Investments (Narrative) (Detail) Details http://www.pdl.com/role/CashEquivalentsAndInvestmentsTables 39 false false R40.htm 2405403 - Disclosure - Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) Sheet http://www.pdl.com/role/CashEquivalentsAndInvestmentsSummaryOfCashAndAvailableForSaleSecuritiesDetail Cash Equivalents and Investments (Summary of Cash and Available-For-Sale Securities) (Detail) Details http://www.pdl.com/role/CashEquivalentsAndInvestmentsTables 40 false false R41.htm 2406402 - Disclosure - Foreign Currency Hedging (Narrative) (Detail) Sheet http://www.pdl.com/role/ForeignCurrencyHedgingNarrativeDetail Foreign Currency Hedging (Narrative) (Detail) Details http://www.pdl.com/role/ForeignCurrencyHedgingTables 41 false false R42.htm 2406403 - Disclosure - Foreign Currency Hedging (Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges) (Detail) Sheet http://www.pdl.com/role/ForeignCurrencyHedgingScheduleOfForeignCurrencyExchangeContractsDesignatedAsCashFlowHedgesDetail Foreign Currency Hedging (Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges) (Detail) Details http://www.pdl.com/role/ForeignCurrencyHedgingTables 42 false false R43.htm 2406404 - Disclosure - Foreign Currency Hedging (Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet) (Detail) Sheet http://www.pdl.com/role/ForeignCurrencyHedgingFairValueOfForeignCurrencyExchangeContractsOnCondensedConsolidatedBalanceSheetDetail Foreign Currency Hedging (Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet) (Detail) Details http://www.pdl.com/role/ForeignCurrencyHedgingTables 43 false false R44.htm 2406405 - Disclosure - Foreign Currency Hedging (Schedule of Effect of Derivative Instruments in Consolidated Statements of Income and Consolidated Statements of Comprehensive Income) (Detail) Sheet http://www.pdl.com/role/ForeignCurrencyHedgingScheduleOfEffectOfDerivativeInstrumentsInConsolidatedStatementsOfIncomeAndConsolidatedStatementsOfComprehensiveIncomeDetail Foreign Currency Hedging (Schedule of Effect of Derivative Instruments in Consolidated Statements of Income and Consolidated Statements of Comprehensive Income) (Detail) Details http://www.pdl.com/role/ForeignCurrencyHedgingTables 44 false false R45.htm 2407401 - Disclosure - Notes Receivable and Other Long-term Receivables (Narrative) (Detail) Notes http://www.pdl.com/role/NotesReceivableAndOtherLongTermReceivablesNarrativeDetail Notes Receivable and Other Long-term Receivables (Narrative) (Detail) Details http://www.pdl.com/role/NotesReceivableAndOtherLongTermReceivables 45 false false R46.htm 2411404 - Disclosure - Accrued Liabilities (Accrued Liabilities) (Detail) Sheet http://www.pdl.com/role/AccruedLiabilitiesAccruedLiabilitiesDetail Accrued Liabilities (Accrued Liabilities) (Detail) Details http://www.pdl.com/role/AccruedLiabilities 46 false false R47.htm 2412402 - Disclosure - Commitments and Contingencies (Narrative) (Detail) Sheet http://www.pdl.com/role/CommitmentsAndContingenciesNarrativeDetail Commitments and Contingencies (Narrative) (Detail) Details http://www.pdl.com/role/CommitmentsAndContingencies 47 false false R48.htm 2413402 - Disclosure - Convertible Notes (Narrative) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesNarrativeDetail Convertible Notes (Narrative) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 48 false false R49.htm 2413403 - Disclosure - Convertible Notes (Summary of Convertible Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesSummaryOfConvertibleNotesDetail Convertible Notes (Summary of Convertible Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 49 false false R50.htm 2413404 - Disclosure - Convertible Notes (Summary of Series 2012 Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesSummaryOfSeries2012NotesDetail Convertible Notes (Summary of Series 2012 Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 50 false false R51.htm 2413405 - Disclosure - Convertible Notes (Interest Expense for the Series 2012 Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesInterestExpenseForSeries2012NotesDetail Convertible Notes (Interest Expense for the Series 2012 Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 51 false false R52.htm 2413406 - Disclosure - Convertible Notes (Summary of May 2015 Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesSummaryOfMay2015NotesDetail Convertible Notes (Summary of May 2015 Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 52 false false R53.htm 2413407 - Disclosure - Convertible Notes (Interest Expense for the May 2015 Notes) (Detail) Notes http://www.pdl.com/role/ConvertibleNotesInterestExpenseForMay2015NotesDetail Convertible Notes (Interest Expense for the May 2015 Notes) (Detail) Details http://www.pdl.com/role/ConvertibleNotesTables 53 false false R54.htm 2413408 - Disclosure - Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesSummaryOfFebruary2018NotesDetailDetails Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) Details 54 false false R55.htm 2413409 - Disclosure - Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) Notes http://www.pdl.com/role/ConvertibleNotesConvertibleNotesInterestExpenseForFebruary2018NotesDetailDetails Convertible Notes Convertible Notes (Interest Expense for February 2018 Notes) (Detail) (Details) Details 55 false false R56.htm 2415402 - Disclosure - Other Long-Term Liabilities (Narrative) (Detail) Sheet http://www.pdl.com/role/OtherLongTermLiabilitiesNarrativeDetail Other Long-Term Liabilities (Narrative) (Detail) Details http://www.pdl.com/role/OtherLongTermLiabilitiesTables 56 false false R57.htm 2415403 - Disclosure - Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) Sheet http://www.pdl.com/role/OtherLongTermLiabilitiesOtherLongTermLiabilitiesDetail Other Long-Term Liabilities (Other Long-Term Liabilities) (Detail) Details http://www.pdl.com/role/OtherLongTermLiabilitiesTables 57 false false R58.htm 2416405 - Disclosure - Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) Sheet http://www.pdl.com/role/StockBasedCompensationSummaryOfStockOptionAndRestrictedStockAwardActivityDetail Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) Details http://www.pdl.com/role/StockBasedCompensation 58 false false R59.htm 2417402 - Disclosure - Cash Dividends (Narrative) (Detail) Sheet http://www.pdl.com/role/CashDividendsNarrativeDetail Cash Dividends (Narrative) (Detail) Details http://www.pdl.com/role/CashDividends 59 false false R60.htm 2419402 - Disclosure - Income Taxes (Narrative) (Detail) Sheet http://www.pdl.com/role/IncomeTaxesNarrativeDetail Income Taxes (Narrative) (Detail) Details http://www.pdl.com/role/IncomeTaxes 60 false false R61.htm 2420403 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) Sheet http://www.pdl.com/role/AccumulatedOtherComprehensiveIncomeLossScheduleOfBalancesOfAccumulatedOtherComprehensiveIncomeLossDetail Accumulated Other Comprehensive Income (Loss) (Schedule of Balances of Accumulated Other Comprehensive Income (Loss)) (Detail) Details http://www.pdl.com/role/AccumulatedOtherComprehensiveIncomeLossTables 61 false false R62.htm 2422401 - Disclosure - Subsequent Events (Narrative) (Detail) Sheet http://www.pdl.com/role/SubsequentEventsNarrativeDetail Subsequent Events (Narrative) (Detail) Details http://www.pdl.com/role/SubsequentEvents 62 false false All Reports Book All Reports In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 2, 4, 5 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)'', column(s) 1, 2, 3, 4 are contained in other reports, so were removed by flow through suppression. pdli-20150930.xml pdli-20150930_cal.xml pdli-20150930_def.xml pdli-20150930_lab.xml pdli-20150930_pre.xml pdli-20150930.xsd true true XML 81 R38.htm IDEA: XBRL DOCUMENT v3.3.0.814

Fair Value Measurements Level 3 Unobservable Input Reconciliation (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended

Sep. 30, 2015

Sep. 30, 2014

Sep. 30, 2015

Sep. 30, 2014

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]

Change in fair value of acquired royalty rights $ 19,298

Beginning balance 259,244

Gains (losses) included in earnings 10,328

Purchases 115,000

Ending balance $ 384,572 384,572

Payments for (Proceeds from) Productive Assets (8,970) $ (81,717)

Fair Value, Investments, Entities that Calculate Net Asset Value Per Share, Unobservable Input, Unrealized Gains (Losses), Changes in Assets and Liabilities, Continued to be Held, Amount $ (4,280) $ 26,787 $ 19,298 $ 72,992

X

- Definition
Change in fair value of acquired royalty rights, Level 3 Rollforward
+ References
No definition available.
+ Details

Name: pdli_ChangeinfairvalueofacquiredroyaltyrightsLevel3Rollforward

Namespace Prefix: pdli_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The portion (amount) of unrealized gains and losses recognized as changes in net assets during the period and attributable to alternative investments continued to be held at period end. These gains or losses are attributable to certain investments for which net asset value per share is calculated for purposes of measuring fair value and which are subject to unobservable inputs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph d

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueInvestmentsEntitiesThatCalculateNetAssetValuePerShareUnobservableInputUnrealizedGainsLossesChangesInAssetsAndLiabilitiesContinuedToBeHeldAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of gain (loss) recognized in the income statement for financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(1)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)(2)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 820

-SubTopic 10

-Section 50

-Paragraph 2

-Subparagraph (c)

-URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258

+ Details

Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The net cash outflow or inflow from purchases, sales and disposals of property, plant and equipment and other productive assets, including intangibles.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Investing Activities

-URI http://asc.fasb.org/extlink&oid=6516133

+ Details

Name: us-gaap_PaymentsForProceedsFromProductiveAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 82 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814

Income Taxes
9 Months Ended

Sep. 30, 2015

Income Tax Disclosure [Abstract]

Income Taxes
13. Income Taxes

Income tax expense for the three months ended September 30, 2015 and 2014, was $40.9 million and $47.4 million, respectively, and for the nine months ended September 30, 2015 and 2014, was $135.2 million and $144.1 million, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes.

The uncertain tax positions increased during the three and nine months ended September 30, 2015, by $2.4 million and $7.0 million, respectively, resulting from an increase in tax uncertainties and estimated tax liabilities.

In general, our income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 1996 forward. In May 2012, PDL received a “no-change” letter from the IRS upon completion of an examination of the Company's 2008 federal tax return. We are currently under income tax examination in the state of California for tax years 2009 and 2010. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, we do not anticipate any material change to the amount of our unrecognized tax benefit over the next 12 months.

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeTaxDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

Cash Equivalents and Investments (Narrative) (Detail) - USD ($)	3 Months Ended			9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014	Sep. 30, 2014	Sep. 30, 2015
Cash and Cash Equivalents [Abstract]
Gains (losses) on sales of available-for-sale securities	$ 580,000		$ 0
Unrealized Gain (Loss) on Investments		$ 364,000		$ 404,000

Convertible Notes Convertible Notes (Summary of February 2018 Notes) (Detail) (Details) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Feb. 12, 2014
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount	$ (1,400)
February 2018 Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Unamortized Discount	(18,419)	$ (23,772)	$ (29,700)
Convertible notes	281,581	276,228	300,000
Debt Instrument, Face Amount	$ 300,000	$ 300,000	$ 300,000

Convertible Notes (Narrative) (Detail) $ / shares in Units, shares in Millions							1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	May. 02, 2015 shares	Feb. 18, 2015 shares	Oct. 20, 2014 USD ($) shares	Feb. 11, 2014 USD ($)	Feb. 05, 2014 USD ($) shares	May. 16, 2011 USD ($)	Jan. 31, 2013 USD ($)	Jan. 31, 2012 USD ($)	Sep. 30, 2015 USD ($) $ / shares shares	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) $ / shares shares	Sep. 30, 2014 USD ($)	Dec. 31, 2014 USD ($)	May. 01, 2015 USD ($)	Mar. 30, 2015 USD ($)	Feb. 17, 2015 USD ($)	Nov. 24, 2014 USD ($)	Feb. 12, 2014 USD ($) $ / shares	Feb. 07, 2014 USD ($)	Feb. 06, 2014 USD ($) $ / shares	Oct. 28, 2013 USD ($)	Aug. 01, 2013 USD ($)	Feb. 29, 2012 USD ($)
Debt Instrument [Line Items]
Principal amount a $5 incentive cash payment per each to convert debt									$ 1,000
Unamortized discount of liability component									(1,400,000)		$ (1,400,000)
Debt Conversion, Original Debt, Amount			$ 26,000,000
Net proceeds from the issuance of convertible notes											0	$ 300,000,000
Proceeds from Issuance of Warrants											0	11,427,000
Gain on conversion of convertible notes									$ 0	$ 0	$ 0	$ 6,143,000
Share Price \| $ / shares																				$ 7.97
Dividends Payable, Amount Per Share \| $ / shares									$ 0.15		$ 0.15
Warrants [Member]
Debt Instrument [Line Items]
Convertible notes, conversion price (in Dollars per Share) \| $ / shares									$ 6.40		$ 6.40
Number of shares of common stock covered by the purchased call options purchased (in Shares) \| shares									27.5		27.5
Proceeds from Issuance of Warrants							$ 10,900,000		$ 10,900,000
Debt conversion, shares issued (in Shares) \| shares									2.1
February 2015 Notes [Member]
Debt Instrument [Line Items]
Convertible notes								$ 169,000,000														$ 1,000,000
Incentive fee per each $1,000 principal amount tendered to convert debt								5.00
Principal amount a $5 incentive cash payment per each to convert debt								1,000
Debt Instrument, Face Amount									$ 0		$ 0
February 2018 Notes [Member]
Debt Instrument [Line Items]
Convertible notes									281,581,000		281,581,000		$ 276,228,000					$ 300,000,000
Debt instrument, interest rate (in Percent)																		4.00%
Unamortized discount of liability component									$ (18,419,000)		(18,419,000)		$ (23,772,000)					$ (29,700,000)
Debt discount recorded to additional paid in capital																		19,300,000
Debt discount recorded to deferred tax liability																		$ 10,400,000
Minimum conversion price percent for note conversion (in Percent)									130.00%
Maximum percent of common stock closing price and conversion rate to convert note (in Percent)									98.00%
Debt Instrument, Interest Rate, Effective Percentage																		6.90%
Convertible notes, conversion price (in Dollars per Share) \| $ / shares																		$ 9.17
Estimated market interest rate for similar nonconvertible instrument																		7.00%
Debt instrument, convertible, remaining amortization period (in Duration)													2 years 4 months 5 days
Net proceeds from the issuance of convertible notes				$ 290,200,000
Debt Instrument, Face Amount									$ 300,000,000		$ 300,000,000		$ 300,000,000					$ 300,000,000
Conversion Rate per $1,000 Principal Amount (in Ratio)				109.1048
February 2018 Note Warrant [Member]
Debt Instrument [Line Items]
Convertible notes, conversion price (in Dollars per Share) \| $ / shares									$ 10.3610		$ 10.3610
Proceeds from Issuance of Warrants					$ 11,400,000
February 2018 Note Purchase Call Option [Member]
Debt Instrument [Line Items]
Number of hedge counterparties (in Counterparties)									2		2
Purchased call options cost				$ 31,000,000
Number of shares of common stock covered by the purchased call options purchased (in Shares) \| shares									32.7		32.7
Deferred taxes included in purchased call options cost				$ 10,800,000
Term Loan. [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount									$ 50,000,000		$ 50,000,000
Short-term Debt																					$ 75,000,000
Term Loan. [Member] \| Base Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate (in Percent)									2.22%		2.22%										1.00%
March 2015 Term Loan [Member]
Debt Instrument [Line Items]
Short-term Debt															$ 100,000,000
March 2015 Term Loan [Member] \| Base Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate (in Percent)									2.09%		2.09%				0.75%
May 2015 Notes [Member]
Debt Instrument [Line Items]
Convertible notes						$ 155,300,000
Debt instrument, interest rate (in Percent)									3.75%		3.75%
Unamortized discount of liability component									$ 0		$ 0		(1,815,000)
Convertible notes, conversion price (in Dollars per Share) \| $ / shares									$ 5.44		$ 5.44
Net proceeds from the issuance of convertible notes						$ 149,700,000
Convertible notes repurchase price as a percentage of principal (in Percent)						100.00%
Debt Instrument, Face Amount									$ 0		$ 0		155,050,000	$ 155,100,000
Debt conversion, shares issued (in Shares) \| shares	5.2
Purchased Call Options [Member]
Debt Instrument [Line Items]
Purchased call options cost									20,800,000
Deferred taxes included in purchased call options cost									7,200,000
Series 2012 Notes [Member]
Debt Instrument [Line Items]
Convertible notes																$ 22,300,000	$ 26,000,000		$ 131,700,000	$ 131,700,000			$ 10,000,000
Total consideration given for convertible note exchange																				191,800,000
Induced conversion of convertible debt expense								845,000
Deferred issue costs, incentive payment allocated								765,000
Adjustments to additional paid in capital, equity component of convertible debt								52,000
Noted obligation allocated to deferred tax assets								$ 28,000
Debt instrument, interest rate (in Percent)								2.875%
Unamortized discount of liability component			$ (100,000)						0		0		(76,000)					$ (2,100,000)
Debt Instrument, Face Amount									$ 0		$ 0		$ 22,337,000			$ 22,300,000				48,300,000		$ 180,000,000
Debt conversion, shares issued (in Shares) \| shares		1.3	1.8		20.3
Debt Conversion, Converted Instrument, Amount					$ 157,600,000
Cash paid to exchange convertible note			$ 26,200,000																	34,200,000
Inducement fee																				2,500,000
Interest Payable																				1,800,000
Deferred Income Tax Expense (Benefit)					$ 29,900,000
Debt discount, derecognition on exchange																				5,800,000
Debt Exchange cost other																				$ 300,000

Net Income per Share (Narrative) (Detail) - USD ($) $ in Thousands					3 Months Ended		9 Months Ended
	May. 02, 2015	Feb. 18, 2015	Oct. 20, 2014	Feb. 05, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	May. 01, 2015	Feb. 17, 2015	Dec. 31, 2014	Nov. 24, 2014	Feb. 12, 2014	Feb. 07, 2014	Feb. 06, 2014	Aug. 01, 2013	Feb. 29, 2012	Jan. 31, 2012
Warrants [Member]
Debt Instrument [Line Items]
Antidilutive securities excluded from computation of earnings per share (in Shares)						22,200,000
Stock Options [Member]
Debt Instrument [Line Items]
Antidilutive securities excluded from computation of earnings per share (in Shares)					42,000	4,000	39,000	4,000
Restricted Stock [Member]
Debt Instrument [Line Items]
Antidilutive securities excluded from computation of earnings per share (in Shares)					475,000	0	437,000	0
February 2015 Notes [Member]
Debt Instrument [Line Items]
Convertible notes																$ 1,000		$ 169,000
Series 2012 Notes [Member]
Debt Instrument [Line Items]
Convertible notes										$ 22,300		$ 26,000		$ 131,700	$ 131,700		$ 10,000
Debt Conversion, Converted Instrument, Shares Issued		1,300,000	1,800,000	20,300,000
May 2015 Notes [Member] [Member]
Debt Instrument [Line Items]
Convertible notes									$ 155,100
May 2015 Notes [Member] [Member] \| Warrants [Member]
Debt Instrument [Line Items]
Antidilutive securities excluded from computation of earnings per share (in Shares)					18,100,000		0	22,200,000
May 2015 Notes [Member] [Member] \| Purchased Call Options [Member]
Debt Instrument [Line Items]
Antidilutive securities excluded from computation of earnings per share (in Shares)					0	26,100,000	0	26,100,000
February 2018 Notes [Member]
Debt Instrument [Line Items]
Convertible notes					$ 281,581		$ 281,581				$ 276,228		$ 300,000
February 2018 Notes [Member] \| Warrants [Member]
Debt Instrument [Line Items]
Antidilutive securities excluded from computation of earnings per share (in Shares)					29,000,000
February 2018 Notes [Member] \| Purchased Call Options [Member]
Debt Instrument [Line Items]
Antidilutive securities excluded from computation of earnings per share (in Shares)					32,700,000
Series 2012 Notes [Member]
Debt Instrument [Line Items]
Debt Conversion, Converted Instrument, Shares Issued	5,200,000

Foreign Currency Hedging (Schedule of Foreign Currency Exchange Contracts Designated as Cash Flow Hedges) (Detail) $ in Thousands	Sep. 30, 2015 USD ($)	Dec. 31, 2014 USD ($)
Derivative [Line Items]
Fair Value	$ (4,597)	$ (4,069)
Derivative, Notional Amount	$ 33,000	85,875
Eurodollar Sell Forward Contract 1.256 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	1.256
Fair Value	$ 0	241
Derivative, Notional Amount	$ 0	6,000
Eurodollar Sell Forward Contract 1.257 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	1.257
Fair Value	$ 0	728
Derivative, Notional Amount	$ 0	15,750
Eurodollar Sell Forward Contract 1.259 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	1.259
Fair Value	$ 0	752
Derivative, Notional Amount	$ 0	16,125
Eurodollar Sell Forward Contract 1.260 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	1.260
Fair Value	$ 4,597	1,468
Derivative, Notional Amount	$ 33,000	33,000
Eurodollar Sell Forward Contract 1.270 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	1.270
Fair Value	$ 0
Derivative, Notional Amount	$ 0
Eurodollar Sell Forward Contract 1.281 [Member]
Derivative [Line Items]
Derivative, Forward Exchange Rate	1.281
Fair Value	$ 0
Derivative, Notional Amount	$ 0
Euro Forward Contracts [Member] \| Eurodollar Sell Forward Contract 1.270 [Member]
Derivative [Line Items]
Fair Value		(377)
Derivative, Notional Amount		7,000
Euro Forward Contracts [Member] \| Eurodollar Sell Forward Contract 1.281 [Member]
Derivative [Line Items]
Fair Value		(503)
Derivative, Notional Amount		$ 8,000

Fair Value Measurements (Schedule of Fair Value of Assets and Liabilities not Subject to Fair Value Recognition) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014	Oct. 20, 2014	Feb. 12, 2014
Fair Value by Balance Sheet Grouping [Line Items]
Debt Instrument, Unamortized Discount	$ 1,400
Assets
Notes receivable, Carrying Value	354,834	$ 363,212
Liabilities:
Convertible Notes Payable, Carrying Value	331,423	451,724
Series 2012 Notes [Member]
Fair Value by Balance Sheet Grouping [Line Items]
Debt Instrument, Unamortized Discount	0	76	$ 100	$ 2,100
Liabilities:
Convertible Notes Payable, Carrying Value	0	22,261
May 2015 Notes [Member]
Fair Value by Balance Sheet Grouping [Line Items]
Debt Instrument, Unamortized Discount	0	1,815
Liabilities:
Convertible Notes Payable, Carrying Value	0	153,235
February 2018 Notes [Member]
Fair Value by Balance Sheet Grouping [Line Items]
Debt Instrument, Unamortized Discount	18,419	23,772		$ 29,700
Liabilities:
Convertible Notes Payable, Carrying Value	281,581	276,228
Term Loan. [Member]
Liabilities:
Convertible Notes Payable, Carrying Value	49,842
Wellstat Note Receivable [Member]
Assets
Notes receivable, Carrying Value	50,191	50,191
Hyperion [Member]
Assets
Notes receivable, Carrying Value	1,200	1,200
Avinger Note Receivable [Member]
Assets
Notes receivable, Carrying Value	0	20,611
LENSAR Note Receivable [Member]
Assets
Notes receivable, Carrying Value	50,266	39,668
Direct Flow Medical Note Receivable [Member]
Assets
Notes receivable, Carrying Value	51,772	50,397
Paradigm Spine [Member]
Assets
Notes receivable, Carrying Value	49,909	49,571
kaleo Note Receivable [Member]
Assets
Notes receivable, Carrying Value	151,496	151,574
Fair Value Level 2 [Member]
Liabilities:
Notes payable, Fair Value	312,313	528,705
Fair Value Level 2 [Member] \| Series 2012 Notes [Member]
Liabilities:
Notes payable, Fair Value		33,506
Fair Value Level 2 [Member] \| May 2015 Notes [Member]
Liabilities:
Notes payable, Fair Value		205,534
Fair Value Level 2 [Member] \| February 2018 Notes [Member]
Liabilities:
Notes payable, Fair Value	262,313	289,665
Fair Value Level 2 [Member] \| Term Loan. [Member]
Liabilities:
Notes payable, Fair Value	50,000
Fair Value Level 2 [Member] \| Hyperion [Member]
Assets
Notes receivable, Fair Value	0	0
Fair Value Level 2 [Member] \| LENSAR Note Receivable [Member]
Assets
Notes receivable, Fair Value	0	0
Fair Value Level 2 [Member] \| Direct Flow Medical Note Receivable [Member]
Assets
Notes receivable, Fair Value	0	0
Fair Value Level 2 [Member] \| Paradigm Spine [Member]
Assets
Notes receivable, Fair Value	0	0
Fair Value Level 2 [Member] \| kaleo Note Receivable [Member]
Assets
Notes receivable, Fair Value	0	0
Fair Value Level 3 [Member]
Assets
Notes receivable, Fair Value	356,256	363,740
Fair Value Level 3 [Member] \| Wellstat Note Receivable [Member]
Assets
Notes receivable, Fair Value	50,191	50,191
Fair Value Level 3 [Member] \| Hyperion [Member]
Assets
Notes receivable, Fair Value	1,200	1,200
Fair Value Level 3 [Member] \| Avinger Note Receivable [Member]
Assets
Notes receivable, Fair Value	0	20,760
Fair Value Level 3 [Member] \| LENSAR Note Receivable [Member]
Assets
Notes receivable, Fair Value	50,266	40,451
Fair Value Level 3 [Member] \| Direct Flow Medical Note Receivable [Member]
Assets
Notes receivable, Fair Value	52,052	49,940
Fair Value Level 3 [Member] \| Paradigm Spine [Member]
Assets
Notes receivable, Fair Value	51,071	50,125
Fair Value Level 3 [Member] \| kaleo Note Receivable [Member]
Assets
Notes receivable, Fair Value	$ 151,476	$ 151,073

Commitments and Contingencies (Narrative) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Total lease payments for the duration of the guarantee	$ 70,500
Accrued lease liability	$ 10,700	$ 10,700

Subsequent Events (Narrative) (Detail) - USD ($) $ / shares in Units, $ in Millions	Oct. 27, 2015	Oct. 07, 2015	Oct. 06, 2015	Oct. 28, 2015	Sep. 15, 2015
Subsequent Event [Line Items]
Price per share of investment sold					$ 5.62
Investment Warrants, Exercise Price		$ 0.40	$ 0.45
Subsequent Event [Member]
Subsequent Event [Line Items]
Amount company has agreed to advance under credit agreement	$ 7.0
Tranche 1 of note receivable		$ 20.0		$ 4.0
Tranche 2 of note receivable		$ 20.0		$ 3.0

Foreign Currency Hedging (Fair Value of Foreign Currency Exchange Contracts on Condensed Consolidated Balance Sheet) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Asset, Current	$ 4,597	$ 3,352
Derivative Asset, Noncurrent	$ 0	$ 717

Other Long-Term Liabilities (Narrative) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Dec. 31, 2014
Schedule of Other Liabilities [Line Items]
Guarantor Obligations, Maximum Exposure, Undiscounted	$ 70,500
Accrued lease liability	$ 10,700	$ 10,700

Cash Dividends (Narrative) (Detail)	3 Months Ended
Cash Dividends (Narrative) (Detail)	Sep. 30, 2015 $ / shares
Stockholders' Equity Note [Abstract]
Dividends payable quarterly (in Dollars per Share)	$ 0.15
Dividends payable, date declared (Date)	Jan. 27, 2015

Subsequent Events	9 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	15. Subsequent Event CareView On October 7, 2015, PDL and CareView entered into an amendment of the credit agreement to modify certain definitions related to the first and second tranche milestones. On this date, PDL also funded the first tranche of $20.0 million, net of fees, upon attainment of the modified first tranche milestone relating to the placement of CareView Systems. The additional $20.0 million in the form of a second tranche continues to be available upon CareView’s attainment of specified milestones relating to the placement of CareView Systems and Consolidated EBITDA, to be accomplished no later than June 30, 2017 under the terms of the amended credit agreement. In connection with the amendment of the credit agreement, PDL and CareView also agreed to amend the warrant to purchase common stock agreement by reducing the warrant's exercise price from $0.45 to $0.40 per share. Paradigm Spine On October 27, 2015, PDL and Paradigm Spine entered into an amendment to the Paradigm Spine Credit Agreement to provide additional term loan commitments of up to $7.0 million payable in two tranches of $4.0 million and $3.0 million, of which the first tranche was drawn on the closing date of the amendment, net of fees, and the second tranche is to be funded at the option of Paradigm Spine prior to June 30, 2016.

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2015	Oct. 26, 2015
Entity Information [Line Items]
Entity Registrant Name	PDL BIOPHARMA, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		163,575,319
Amendment Flag	false
Entity Central Index Key	0000882104
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Large Accelerated Filer
Entity Well-known Seasoned Issuer	Yes
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q3

Cash Dividends	9 Months Ended
Cash Dividends	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Cash Dividends	12. Cash Dividends On January 27, 2015, our board of directors declared that the regular quarterly dividends to be paid to our stockholders in 2015 will be $0.15 per share of common stock, payable on March 12, June 12, September 11 and December 11 of 2015 to stockholders of record on March 5, June 5, September 4 and December 4 of 2015, the record dates for each of the dividend payments, respectively.

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	. Commitments and Contingencies Legal Proceedings From time to time, we are involved in lawsuits, arbitrations, claims, investigations and proceedings, consisting of intellectual property, commercial, employment and other matters, which arise in the ordinary course of business. We make provisions for liabilities when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Such provisions are reviewed at least quarterly and adjusted to reflect the impact of settlement negotiations, judicial and administrative rulings, advice of legal counsel, and other information and events pertaining to a particular case. Litigation is inherently unpredictable. If any unfavorable ruling were to occur in any specific period, there exists the possibility of a material adverse impact on the results of our operations of that period and on our cash flows and liquidity. PDL BioPharma, Inc. v Merck Sharp & Dohme, Corp. On October 28, 2015, the Company filed a Complaint against Merck Sharp & Dohme, Corp (“Merck”) for patent infringement. In the Complaint, the Company alleges that manufacture and sales of certain of Merck’s Keytruda product infringes one or more claims of the Company’s '761 Patent. The Company has requested judgment that Merck has infringed the ‘761 Patent, an award of damages due to the infringement, a finding that such infringement was willful and deliberate and trebling of damages therefore, and a declaration that the case is exceptional and warrants an award of attorney’s fees and costs. Although the ‘761 Patent expired on December 2, 2014, the Company believes that Merck infringed the patent through, e.g., manufacture and/or sale of Keytruda prior to the expiration of the ‘761 Patent. Wellstat Litigation On September 4, 2015, PDL filed in the Supreme Court of New York a motion for summary judgment in lieu of complaint which requested that the court enter judgment against Wellstat Diagnostics’ Guarantors for the total amount due on the Wellstat Diagnostics debt, plus all costs and expenses including lawyers’ fees incurred by the Company in enforcement of the related guarantees. On September 23, 2015, PDL filed in the same court an ex parte application for a temporary restraining order and order of attachment of the Wellstat Diagnostics’ Guarantors assets. At a hearing on September 24, 2015, regarding the Company’s request for a temporary restraining order, the court ordered that the Company’s request for attachment and for summary judgment would be heard at a hearing on November 5, 2015. Although the court denied the Company’s request for a temporary restraining order at the hearing on September 24, it ordered that assets of the Wellstat Diagnostics Guarantors should be held in status quo ante and only used in the normal course of business pending the outcome of the hearing. On October 22, 2015, the Wellstat Diagnostics Guarantors filed a complaint against the Company in the Supreme Court of New York seeking a declaratory judgment that certain contractual arrangements entered into between the parties subsequent to Wellstat Diagnostics’ default, and which relate to a split of proceeds in the event that the Wellstat Diagnostics Guarantors voluntarily monetize any assets that are the Company’s collateral, is of no force or effect. Lease Guarantee In connection with the Spin-Off, we entered into amendments to the leases for our former facilities in Redwood City, California, under which Facet was added as a co-tenant, and a Co-Tenancy Agreement, under which Facet agreed to indemnify us for all matters related to the leases attributable to the period after the Spin-Off date. Should Facet default under its lease obligations, we could be held liable by the landlord as a co-tenant and, thus, we have in substance guaranteed the payments under the lease agreements for the Redwood City facilities. As of September 30, 2015, the total lease payments for the duration of the guarantee, which runs through December 2021, are approximately $70.5 million. In April 2010, Abbott Laboratories acquired Facet and later renamed the entity AbbVie. If AbbVie were to default, we could also be responsible for lease-related costs including utilities, property taxes and common area maintenance, which may be as much as the actual lease payments. We have recorded a liability of $10.7 million on our Condensed Consolidated Balance Sheets as of September 30, 2015, and December 31, 2014, related to this guarantee. In future periods, we may adjust this liability for any changes in the ultimate outcome of this matter that are both probable and estimable.

Income Taxes (Narrative) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Income Taxes (Narrative) (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Investments, Owned, Federal Income Tax Note [Line Items]
Income Tax Expense	$ 40,895	$ 47,361	$ 135,208	$ 144,083
Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions	$ 2,400		$ 7,000

Stock-Based Compensation (Summary of Stock Option and Restricted Stock Award Activity) (Detail) shares in Thousands	9 Months Ended
	Sep. 30, 2015 $ / shares shares
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	(46)
Stock-Based Incentive Plan [Member]
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures	(522)
Shares Available for Grant, Balance beginning of period (in Shares)	4,166
Shares Available for Grant, Balance end of period (in Shares)	3,684
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	0
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations	40
Stock Options [Member]
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value \| $ / shares
Stock Options, Number of Shares, Balance at beginning of period (in Shares)	58
Stock Options, Number of Shares, Balance at end of period (in Shares)	58
Stock Options, Weighted Average Exercise Price, Balance at beginning of period (in Dollars per Share) \| $ / shares	$ 5.41
Stock Options, Weighted Average Exercise Price, Balance at end of period (in Dollars per Share) \| $ / shares	5.41
Restricted Stock [Member]
Share Based Compensation Arrangment By Share Based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value \| $ / shares	$ 6.46
Restricted Stock Award, Number of Shares, Balance at beginning of period (in Shares)	277
Restricted Stock Awards, Number of Shares Granted (in Shares)	522
Restricted Stock Awards, Number of Shares, Balance at end of period (in Shares)	713
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at beginning of period (in Dollars per Share) \| $ / shares	$ 8.39
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Granted (in Dollars per Share) \| $ / shares	6.40
Restricted Stock Awards, Weighted Average Grant-date Fair Value, Balance at end of period (in Dollars per Share) \| $ / shares	7.36
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value \| $ / shares	$ 8.58
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations	(40)

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes Income tax expense for the three months ended September 30, 2015 and 2014, was $40.9 million and $47.4 million, respectively, and for the nine months ended September 30, 2015 and 2014, was $135.2 million and $144.1 million, respectively, which resulted primarily from applying the federal statutory income tax rate to income before income taxes. The uncertain tax positions increased during the three and nine months ended September 30, 2015, by $2.4 million and $7.0 million, respectively, resulting from an increase in tax uncertainties and estimated tax liabilities. In general, our income tax returns are subject to examination by U.S. federal, state and local tax authorities for tax years 1996 forward. In May 2012, PDL received a “no-change” letter from the IRS upon completion of an examination of the Company's 2008 federal tax return. We are currently under income tax examination in the state of California for tax years 2009 and 2010. Although the timing of the resolution of income tax examinations is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ materially from the amounts accrued for each year, we do not anticipate any material change to the amount of our unrecognized tax benefit over the next 12 months.